Nanogen - Die Zahlen - 500 Beiträge pro Seite
eröffnet am 31.01.02 20:35:16 von
neuester Beitrag 05.05.05 14:27:09 von
neuester Beitrag 05.05.05 14:27:09 von
Beiträge: 406
ID: 543.893
ID: 543.893
Aufrufe heute: 0
Gesamt: 39.488
Gesamt: 39.488
Aktive User: 0
ISIN: US6300751095 · WKN: 911841
Werte aus der Branche Nanotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,1600 | +8,41 | |
| 33,50 | +8,24 | |
| 80,38 | +1,97 | |
| 1,1500 | +0,88 | |
| 33,89 | +0,47 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3270 | 0,00 | |
| 0,5150 | 0,00 | |
| 2,7650 | 0,00 | |
| 1,5100 | -2,58 | |
| 0,8580 | -10,93 |
Feedback
Nanogen Earnings Conference Call (Q4 2001)
Scheduled to start Thu, Jan 31, 2002, 4:30 pm Eastern
Scheduled to start Thu, Jan 31, 2002, 4:30 pm Eastern
Thursday January 31, 4:02 pm Eastern Time
Press Release
SOURCE: Nanogen, Inc.
Nanogen Reports 2001 Fourth Quarter and Year-End
Results; Record Product Revenues Achieved for Year
SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) today announced its financial results for
the fourth quarter and year ended December 31, 2001.
Product revenues for the fourth quarter of 2001 were $691,000, over three times the total of $210,000 for the same period in 2000.
During the current quarter, Nanogen sold five (5) NanoChip® Molecular Biology Workstations; three sales were included in
product revenues and the remaining revenue was deferred due to the structure of two of the transactions. In addition, the
Company entered into sixteen (16) non-title transfer transactions under new Development Site Agreements during the quarter.
Total revenues for the quarter ended December 31, 2001 were $2.3 million compared to $3.0 million for the same period in 2000.
The decline in total revenues was due to an anticipated decrease in revenues earned in connection with sponsored research
programs as the Company`s revenue base transitions from primarily sponsored research revenues to product revenues.
For the year ended December 31, 2001, product revenues were $2.2 million, as compared to $919,000 for the year ended
December 31, 2000. Total revenues remained unchanged from the prior year and were $11.2 million. During the year ended
December 31, 2001, 20% of revenues came from product revenues as compared to 8% of revenues for the same period in 2000.
This shift in the revenue base for the Company was anticipated and was due to both a decrease in revenues earned in connection
with sponsored research programs as well as an increase in product revenues.
The Company`s cash, cash equivalents and short-term investment balance at December 31, 2001 was $67.5 million. Total
operating expenses for the fourth quarter of 2001 were $10.6 million, as compared to $10.5 million for the same period in 2000.
For the year ended December 31, 2001, total operating expenses, excluding charges totaling $6.3 million related to the defense and
settlement of a patent litigation matter, were $41.8 million compared to $34.8 million for the same period in 2000. The increase in
operating expenses for the year ended December 31, 2001, as compared to the same period in 2000, was primarily due to
increased sales and marketing expenses as the Company expanded its sales and marketing organization.
The reported net loss for the quarter ended December 31, 2001 was $7.5 million, or $0.35 per share compared to a net loss of $5.9
million, or $0.29 per share for the same period in 2000. For the year ended December 31, 2001, inclusive of the defense and
settlement charges noted above of $6.3 million, the Company reported a net loss of $32.5 million or $1.54 per share. For the year
ended December 31, 2001, excluding the defense and settlement charges noted above of $6.3 million, the Company reported a net
loss of $26.2 million or $1.24 per share, compared to a net loss of $18.3 million or $0.92 per share for the same period in 2000.
``In 2001, we focused on a number of strategic initiatives, all with the end goal of accelerating Nanogen`s entry into molecular
diagnostics. We have introduced our first five gene-based research protocols, a major step toward achieving our goal,`` said
Howard C. Birndorf, Executive Chairman and Co-Founder of Nanogen. ``Additionally, we realized record product revenues in
2001, a result of expanding our installed base of instruments and increasing the adoption of Nanogen`s NanoChip® System through
Development Site Agreements. We are pleased with our progress in 2001, bringing us closer to our planned entry into the
molecular diagnostics market, which has been a primary goal of the Company since its inception.``
The following summarizes the highlights of Nanogen`s progress for 2001:
-- Internally validated the Company`s first five DNA-based research
protocols for use on the NanoChip(R) Molecular Biology Workstation,
meeting an objective set by the Company in July 2001.
-- Ended 2001 with an installed base of sixty-one instruments. This
falls within the range the Company projected in July 2001.
-- Converted the first two of our existing Development Site Agreements
into sales transactions, validating this sales model.
-- Strengthened the intellectual property position for our core
technology by the issuance of twenty new U.S. patents and seven
foreign patents in 2001, bringing our total number of issued patents
to sixty-two.
-- Resolved the Company`s litigation with Motorola, Genometrix and MIT on
favorable terms without providing access to Nanogen`s own technology.
To its knowledge, Nanogen remains the only current provider of
commercially available electronic-aided hybridization products.
-- Formed Nanogen Recognomics GmbH, a joint venture with Aventis to
research and develop new technological advances for the NanoChip(R)
System while still focusing on the Company`s near-term goal of entry
into molecular diagnostics.
-- Appointed Randy White as CEO and Jerry Wills as CFO to round out
Nanogen`s senior management team.
``We are excited and optimistic about our progress during 2001 and believe that Nanogen can play a future role in the growing
molecular diagnostics marketplace,`` said Randy White, Chief Executive Officer of Nanogen. ``Within this market, there exist a
number of attractive commercial opportunities for which we believe Nanogen`s technology platform may be ideally suited. They
exist both in the research setting, where scientists demand an open and flexible platform, and in high volume laboratories, which
additionally require optimal speed and accuracy. We are clearly focused on two simple and primary objectives: first, to continue to
increase the installed base of our instruments; and second, to expand our menu by developing internally validated protocols and
converting existing research protocols into Analyte Specific Reagents which may allow Nanogen to increase its overall margins.
These two objectives will complement each other and act as the key drivers of our planned product sales growth.``
Webcast of Conference Call
Nanogen management will hold a conference call to discuss fourth quarter and year-end 2001 financial results today at 4:30 p.m.
Eastern Time. A live webcast is available via Nanogen`s website at http://www.nanogen.com . A telephone replay of the
conference call will be available approximately two hours following the call until 11:59 p.m. Eastern Time on February 4, 2002 and
can be accessed at 800-642-1687 (domestic) or 706-645-9291 (international), passcode ID #3015483. The webcast will also be
archived on Nanogen`s website through February 14, 2002.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and
flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is
seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop
applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four
associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron
overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The
NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please
visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to
differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can
be successfully commercialized, whether products under development can be successfully developed and commercialized, whether
results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of
the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in
developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests
utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results``
and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or
obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
December 31, December 31,
2001 2000
ASSETS
Current assets:
Cash and cash equivalents $10,455 $55,330
Short-term investments 57,069 39,759
Receivables, net 4,469 1,322
Inventory 4,688 2,289
Other current assets 2,384 1,689
Total current assets 79,065 100,389
Property and equipment, net 5,386 5,373
Acquired technology rights, net 4,183 5,179
Restricted cash 299 164
Other assets 1,158 63
$90,091 $111,168
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $1,051 $1,223
Accrued liabilities 4,916 4,095
Deferred revenue 522 360
Current portion of capital lease
obligations 1,060 2,011
Total current liabilities 7,549 7,689
Capital lease obligations, less current
portion 1,755 1,565
Other long term liabilities 1,675 500
Total long term liabilities 3,430 2065
Minority interest in consolidated
subsidiary 4,183 --
Stockholders` equity:
Convertible preferred stock,
$.001 par value, 5,000,000 shares
authorized; no shares issued and
outstanding at December 31, 2001
and 2000 -- --
Common stock, $.001 par value,
50,000,000 shares authorized;
21,616,172 and 20,913,151 shares
issued and outstanding at
December 31, 2001 and 2000,
respectively 22 21
Additional paid-in capital 198,387 193,459
Accumulated other comprehensive income 1,253 270
Deferred compensation (336) (325)
Notes receivable from officers (984) (1,099)
Accumulated deficit (123,413) (90,912)
Total stockholders` equity 74,929 101,414
$90,091 $111,168
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
Three months ended Twelve months ended
December 31, December 31,
2001 2000 2001 2000
(unaudited)
Revenues:
Sales $691 $210 $2,245 $919
Sponsored research 1,228 2,325 7,457 8,457
Contract and grant
revenue 376 486 1,467 1,856
Total revenues 2,295 3,021 11,169 11,232
Operating expenses:
Cost of sales 479 149 1,606 599
Research and
development 4,025 4,703 17,563 18,905
Selling, general and
administrative 6,224 5,616 22,610 15,267
Litigation and
settlement of
patent matter (110) -- 6,322 --
Total operating
expenses 10,618 10,468 48,101 34,771
Loss from operations (8,323) (7,447) (36,932) (23,539)
Interest income, net 857 1,535 4,294 5,257
Other income 14 -- 137 --
Net loss $ (7,452) $ (5,912) $ (32,501) $ (18,282)
Net loss per share -
basic and diluted $(0.35) $(0.29) $(1.54) $(0.92)
Number of shares used
in computing net loss
per share - basic and
diluted 21,532 20,505 21,091 19,944
SOURCE: Nanogen, Inc.
Press Release
SOURCE: Nanogen, Inc.
Nanogen Reports 2001 Fourth Quarter and Year-End
Results; Record Product Revenues Achieved for Year
SAN DIEGO, Jan. 31 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) today announced its financial results for
the fourth quarter and year ended December 31, 2001.
Product revenues for the fourth quarter of 2001 were $691,000, over three times the total of $210,000 for the same period in 2000.
During the current quarter, Nanogen sold five (5) NanoChip® Molecular Biology Workstations; three sales were included in
product revenues and the remaining revenue was deferred due to the structure of two of the transactions. In addition, the
Company entered into sixteen (16) non-title transfer transactions under new Development Site Agreements during the quarter.
Total revenues for the quarter ended December 31, 2001 were $2.3 million compared to $3.0 million for the same period in 2000.
The decline in total revenues was due to an anticipated decrease in revenues earned in connection with sponsored research
programs as the Company`s revenue base transitions from primarily sponsored research revenues to product revenues.
For the year ended December 31, 2001, product revenues were $2.2 million, as compared to $919,000 for the year ended
December 31, 2000. Total revenues remained unchanged from the prior year and were $11.2 million. During the year ended
December 31, 2001, 20% of revenues came from product revenues as compared to 8% of revenues for the same period in 2000.
This shift in the revenue base for the Company was anticipated and was due to both a decrease in revenues earned in connection
with sponsored research programs as well as an increase in product revenues.
The Company`s cash, cash equivalents and short-term investment balance at December 31, 2001 was $67.5 million. Total
operating expenses for the fourth quarter of 2001 were $10.6 million, as compared to $10.5 million for the same period in 2000.
For the year ended December 31, 2001, total operating expenses, excluding charges totaling $6.3 million related to the defense and
settlement of a patent litigation matter, were $41.8 million compared to $34.8 million for the same period in 2000. The increase in
operating expenses for the year ended December 31, 2001, as compared to the same period in 2000, was primarily due to
increased sales and marketing expenses as the Company expanded its sales and marketing organization.
The reported net loss for the quarter ended December 31, 2001 was $7.5 million, or $0.35 per share compared to a net loss of $5.9
million, or $0.29 per share for the same period in 2000. For the year ended December 31, 2001, inclusive of the defense and
settlement charges noted above of $6.3 million, the Company reported a net loss of $32.5 million or $1.54 per share. For the year
ended December 31, 2001, excluding the defense and settlement charges noted above of $6.3 million, the Company reported a net
loss of $26.2 million or $1.24 per share, compared to a net loss of $18.3 million or $0.92 per share for the same period in 2000.
``In 2001, we focused on a number of strategic initiatives, all with the end goal of accelerating Nanogen`s entry into molecular
diagnostics. We have introduced our first five gene-based research protocols, a major step toward achieving our goal,`` said
Howard C. Birndorf, Executive Chairman and Co-Founder of Nanogen. ``Additionally, we realized record product revenues in
2001, a result of expanding our installed base of instruments and increasing the adoption of Nanogen`s NanoChip® System through
Development Site Agreements. We are pleased with our progress in 2001, bringing us closer to our planned entry into the
molecular diagnostics market, which has been a primary goal of the Company since its inception.``
The following summarizes the highlights of Nanogen`s progress for 2001:
-- Internally validated the Company`s first five DNA-based research
protocols for use on the NanoChip(R) Molecular Biology Workstation,
meeting an objective set by the Company in July 2001.
-- Ended 2001 with an installed base of sixty-one instruments. This
falls within the range the Company projected in July 2001.
-- Converted the first two of our existing Development Site Agreements
into sales transactions, validating this sales model.
-- Strengthened the intellectual property position for our core
technology by the issuance of twenty new U.S. patents and seven
foreign patents in 2001, bringing our total number of issued patents
to sixty-two.
-- Resolved the Company`s litigation with Motorola, Genometrix and MIT on
favorable terms without providing access to Nanogen`s own technology.
To its knowledge, Nanogen remains the only current provider of
commercially available electronic-aided hybridization products.
-- Formed Nanogen Recognomics GmbH, a joint venture with Aventis to
research and develop new technological advances for the NanoChip(R)
System while still focusing on the Company`s near-term goal of entry
into molecular diagnostics.
-- Appointed Randy White as CEO and Jerry Wills as CFO to round out
Nanogen`s senior management team.
``We are excited and optimistic about our progress during 2001 and believe that Nanogen can play a future role in the growing
molecular diagnostics marketplace,`` said Randy White, Chief Executive Officer of Nanogen. ``Within this market, there exist a
number of attractive commercial opportunities for which we believe Nanogen`s technology platform may be ideally suited. They
exist both in the research setting, where scientists demand an open and flexible platform, and in high volume laboratories, which
additionally require optimal speed and accuracy. We are clearly focused on two simple and primary objectives: first, to continue to
increase the installed base of our instruments; and second, to expand our menu by developing internally validated protocols and
converting existing research protocols into Analyte Specific Reagents which may allow Nanogen to increase its overall margins.
These two objectives will complement each other and act as the key drivers of our planned product sales growth.``
Webcast of Conference Call
Nanogen management will hold a conference call to discuss fourth quarter and year-end 2001 financial results today at 4:30 p.m.
Eastern Time. A live webcast is available via Nanogen`s website at http://www.nanogen.com . A telephone replay of the
conference call will be available approximately two hours following the call until 11:59 p.m. Eastern Time on February 4, 2002 and
can be accessed at 800-642-1687 (domestic) or 706-645-9291 (international), passcode ID #3015483. The webcast will also be
archived on Nanogen`s website through February 14, 2002.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and
flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is
seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop
applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four
associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron
overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The
NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please
visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to
differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can
be successfully commercialized, whether products under development can be successfully developed and commercialized, whether
results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of
the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in
developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests
utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results``
and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or
obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
December 31, December 31,
2001 2000
ASSETS
Current assets:
Cash and cash equivalents $10,455 $55,330
Short-term investments 57,069 39,759
Receivables, net 4,469 1,322
Inventory 4,688 2,289
Other current assets 2,384 1,689
Total current assets 79,065 100,389
Property and equipment, net 5,386 5,373
Acquired technology rights, net 4,183 5,179
Restricted cash 299 164
Other assets 1,158 63
$90,091 $111,168
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $1,051 $1,223
Accrued liabilities 4,916 4,095
Deferred revenue 522 360
Current portion of capital lease
obligations 1,060 2,011
Total current liabilities 7,549 7,689
Capital lease obligations, less current
portion 1,755 1,565
Other long term liabilities 1,675 500
Total long term liabilities 3,430 2065
Minority interest in consolidated
subsidiary 4,183 --
Stockholders` equity:
Convertible preferred stock,
$.001 par value, 5,000,000 shares
authorized; no shares issued and
outstanding at December 31, 2001
and 2000 -- --
Common stock, $.001 par value,
50,000,000 shares authorized;
21,616,172 and 20,913,151 shares
issued and outstanding at
December 31, 2001 and 2000,
respectively 22 21
Additional paid-in capital 198,387 193,459
Accumulated other comprehensive income 1,253 270
Deferred compensation (336) (325)
Notes receivable from officers (984) (1,099)
Accumulated deficit (123,413) (90,912)
Total stockholders` equity 74,929 101,414
$90,091 $111,168
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
Three months ended Twelve months ended
December 31, December 31,
2001 2000 2001 2000
(unaudited)
Revenues:
Sales $691 $210 $2,245 $919
Sponsored research 1,228 2,325 7,457 8,457
Contract and grant
revenue 376 486 1,467 1,856
Total revenues 2,295 3,021 11,169 11,232
Operating expenses:
Cost of sales 479 149 1,606 599
Research and
development 4,025 4,703 17,563 18,905
Selling, general and
administrative 6,224 5,616 22,610 15,267
Litigation and
settlement of
patent matter (110) -- 6,322 --
Total operating
expenses 10,618 10,468 48,101 34,771
Loss from operations (8,323) (7,447) (36,932) (23,539)
Interest income, net 857 1,535 4,294 5,257
Other income 14 -- 137 --
Net loss $ (7,452) $ (5,912) $ (32,501) $ (18,282)
Net loss per share -
basic and diluted $(0.35) $(0.29) $(1.54) $(0.92)
Number of shares used
in computing net loss
per share - basic and
diluted 21,532 20,505 21,091 19,944
SOURCE: Nanogen, Inc.
Tuesday February 5, 8:08 am Eastern Time
Press Release
SOURCE: Gentris Corporation; Nanogen, Inc.
Gentris and Nanogen Enter Into Development Site
Collaboration
The Companies Will Collaborate to Develop and Commercialize Assay Products In the Pharmacogenomic Space For the Drug Development Industry
RESEARCH TRIANGLE PARK, N.C. and SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Gentris Corporation, a clinical pharmacogenomics testing and diagnostic products company, and Nanogen, Inc. (Nasdaq: NGEN - news), today announced they have entered into a Development Site Collaboration. Under the terms of the Agreement, Nanogen will provide its NanoChip® Molecular Biology Workstation to Gentris as part of the joint development effort, which it will use in combination with its current applications, to develop one or more commercially viable, SNP assays. These assays may be used by clinical research laboratories to test for genetic markers in order to predict drug response during clinical development studies. Nanogen will have exclusive commercialization rights to assays developed under the Agreement and will provide Gentris with certain payments resulting from the sale of such products.
``The NanoChip® is an open platform ideally suited for researchers who require the flexibility of a user-friendly, customizable chip to design in-house applications,`` said Michael Murphy, Chief Executive Officer of Gentris. ``We believe this technology will add significant value to our services and products by allowing us to further develop accurate, reliable and cost-effective assays. Gentris and Nanogen will initially target clinical research customers for assays resulting from the Agreement, which we will seek to develop as turnkey, `off the shelf` solutions. Eventually, with the proper approval from the FDA, we would like to target customers in the clinical diagnostic market.``
``We believe Gentris` expertise and experience in developing clinically relevant pharmacogenomic products will help Nanogen develop and commercialize important new tests using our technology and allow us to enter the clinical pharmacogenomic market,`` said Randy White, Chief Executive Officer of Nanogen. ``Gentris is a new and exciting company in the pharmacogenomic clinical application industry. Development site agreements, such as this one, help expand our pipeline of future NanoChip® applications as we continue our pursuit of near-term opportunities in molecular diagnostics.``
About Gentris Corporation:
Gentris Corporation is engaged in the development and rapid commercialization of innovative proprietary clinical pharmacogenomic products and services. The company provides global pharmaceutical research organizations with turnkey pharmacogenomic solutions to improve the efficiency and predictability of drug development. The ultimate benefit to these organizations is to shorten drug development cycles, improve new drug approval rates, and allow drugs that might have otherwise been abandoned advance towards final approval and be prescribed to a targeted subset of the population. In the near future, the company will develop specialized, high quality, reliable diagnostic products, which will provide physicians and their patient`s access to pharmacogenomic testing, as personalized medicine becomes the new standard of medical practice. For additional information, please visit Gentris` website at www.gentris.com.
About Nanogen:
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether Nanogen`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by customers or partners can be identically replicated, whether Development Sites will result in future sales of Nanogen`s NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen and Gentris disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Gentris Corporation; Nanogen, Inc.
Press Release
SOURCE: Gentris Corporation; Nanogen, Inc.
Gentris and Nanogen Enter Into Development Site
Collaboration
The Companies Will Collaborate to Develop and Commercialize Assay Products In the Pharmacogenomic Space For the Drug Development Industry
RESEARCH TRIANGLE PARK, N.C. and SAN DIEGO, Feb. 5 /PRNewswire-FirstCall/ -- Gentris Corporation, a clinical pharmacogenomics testing and diagnostic products company, and Nanogen, Inc. (Nasdaq: NGEN - news), today announced they have entered into a Development Site Collaboration. Under the terms of the Agreement, Nanogen will provide its NanoChip® Molecular Biology Workstation to Gentris as part of the joint development effort, which it will use in combination with its current applications, to develop one or more commercially viable, SNP assays. These assays may be used by clinical research laboratories to test for genetic markers in order to predict drug response during clinical development studies. Nanogen will have exclusive commercialization rights to assays developed under the Agreement and will provide Gentris with certain payments resulting from the sale of such products.
``The NanoChip® is an open platform ideally suited for researchers who require the flexibility of a user-friendly, customizable chip to design in-house applications,`` said Michael Murphy, Chief Executive Officer of Gentris. ``We believe this technology will add significant value to our services and products by allowing us to further develop accurate, reliable and cost-effective assays. Gentris and Nanogen will initially target clinical research customers for assays resulting from the Agreement, which we will seek to develop as turnkey, `off the shelf` solutions. Eventually, with the proper approval from the FDA, we would like to target customers in the clinical diagnostic market.``
``We believe Gentris` expertise and experience in developing clinically relevant pharmacogenomic products will help Nanogen develop and commercialize important new tests using our technology and allow us to enter the clinical pharmacogenomic market,`` said Randy White, Chief Executive Officer of Nanogen. ``Gentris is a new and exciting company in the pharmacogenomic clinical application industry. Development site agreements, such as this one, help expand our pipeline of future NanoChip® applications as we continue our pursuit of near-term opportunities in molecular diagnostics.``
About Gentris Corporation:
Gentris Corporation is engaged in the development and rapid commercialization of innovative proprietary clinical pharmacogenomic products and services. The company provides global pharmaceutical research organizations with turnkey pharmacogenomic solutions to improve the efficiency and predictability of drug development. The ultimate benefit to these organizations is to shorten drug development cycles, improve new drug approval rates, and allow drugs that might have otherwise been abandoned advance towards final approval and be prescribed to a targeted subset of the population. In the near future, the company will develop specialized, high quality, reliable diagnostic products, which will provide physicians and their patient`s access to pharmacogenomic testing, as personalized medicine becomes the new standard of medical practice. For additional information, please visit Gentris` website at www.gentris.com.
About Nanogen:
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether Nanogen`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by customers or partners can be identically replicated, whether Development Sites will result in future sales of Nanogen`s NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen and Gentris disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Gentris Corporation; Nanogen, Inc.
Wednesday February 6, 8:04 pm Eastern Time
Press Release
SOURCE: Nanogen, Inc.
Nanogen Announces Management Changes
SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced the following management changes today:
Ira Marks has joined Nanogen and has been appointed Vice President of Business Development. He will lead the implementation and execution of Nanogen`s business development strategy to continue its pursuit of the molecular diagnostics market.
``We are delighted to welcome Ira as the newest addition to our growing molecular diagnostics team and look forward to his contributions. Ira brings a remarkable breadth of experience in clinical diagnostics to Nanogen,`` said Randy White, Chief Executive Officer of Nanogen. ``Esoteric testing, which includes molecular diagnostics, is one of the fastest growing markets within the diagnostics field. With over 25 years experience in the clinical diagnostics arena, Ira has a strong sense of new and emerging market opportunities and how to strategically capture value from Nanogen`s technology platform, which we believe is ideally suited for simplifying the often complex, difficult to perform molecular diagnostic tests.``
Prior to joining Nanogen, Mr. Marks served as President of the Raichem Division of Hemagen Diagnostics, a company focused on biochemistry and immunoassays for hospitals, reference laboratories, and veterinarians` and doctors` offices. From 1982 through 1995, Mr. Marks held various senior level positions with Bio-Rad Laboratories, a company focused on the clinical laboratory market with a highly diverse product offering. Mr. Marks holds a Masters Degree from City University of New York.
In other news, Nanogen also announced that Vera P. Pardee, Esq., Vice President, General Counsel and Secretary, has resigned her position and that Randy Berholtz, Esq. will assume the role of acting General Counsel and Secretary. Mr. Berholtz has over 11 years of legal experience and has been with Nanogen since February 2000.
``I would like to thank Vera for her leadership and numerous other contributions she has made to our Legal Department and to Nanogen,`` said Howard C. Birndorf, Executive Chairman and Co-founder of Nanogen. ``Among her many accomplishments, Vera`s extensive experience in trial litigation proved to be invaluable in the Company`s litigation settlement with Motorola, Genometrix and MIT last year. We appreciate Vera`s many significant contributions to Nanogen and wish her well in her future endeavors.``
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
Press Release
SOURCE: Nanogen, Inc.
Nanogen Announces Management Changes
SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced the following management changes today:
Ira Marks has joined Nanogen and has been appointed Vice President of Business Development. He will lead the implementation and execution of Nanogen`s business development strategy to continue its pursuit of the molecular diagnostics market.
``We are delighted to welcome Ira as the newest addition to our growing molecular diagnostics team and look forward to his contributions. Ira brings a remarkable breadth of experience in clinical diagnostics to Nanogen,`` said Randy White, Chief Executive Officer of Nanogen. ``Esoteric testing, which includes molecular diagnostics, is one of the fastest growing markets within the diagnostics field. With over 25 years experience in the clinical diagnostics arena, Ira has a strong sense of new and emerging market opportunities and how to strategically capture value from Nanogen`s technology platform, which we believe is ideally suited for simplifying the often complex, difficult to perform molecular diagnostic tests.``
Prior to joining Nanogen, Mr. Marks served as President of the Raichem Division of Hemagen Diagnostics, a company focused on biochemistry and immunoassays for hospitals, reference laboratories, and veterinarians` and doctors` offices. From 1982 through 1995, Mr. Marks held various senior level positions with Bio-Rad Laboratories, a company focused on the clinical laboratory market with a highly diverse product offering. Mr. Marks holds a Masters Degree from City University of New York.
In other news, Nanogen also announced that Vera P. Pardee, Esq., Vice President, General Counsel and Secretary, has resigned her position and that Randy Berholtz, Esq. will assume the role of acting General Counsel and Secretary. Mr. Berholtz has over 11 years of legal experience and has been with Nanogen since February 2000.
``I would like to thank Vera for her leadership and numerous other contributions she has made to our Legal Department and to Nanogen,`` said Howard C. Birndorf, Executive Chairman and Co-founder of Nanogen. ``Among her many accomplishments, Vera`s extensive experience in trial litigation proved to be invaluable in the Company`s litigation settlement with Motorola, Genometrix and MIT last year. We appreciate Vera`s many significant contributions to Nanogen and wish her well in her future endeavors.``
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
Nanogen to Present at Lehman Brothers Global Healthcare Conference On February 28
SAN DIEGO, Feb 21, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that the Company will be presenting at the 5th Annual Lehman Brothers Global Healthcare Conference on Thursday, February 28, 2002 at 11:15 a.m. Eastern Time. Gerard A. Wills, Chief Financial Officer of Nanogen, will provide a corporate overview and discuss the Company`s strategy for pursuing market share in the molecular diagnostics research and development market.
Nanogen invites you to listen to Mr. Wills` presentation by calling into the phone numbers listed below:
Live (domestic): 1-800-553-3587
Live (international): 1-303-713-7920
Replay (domestic): 1-800-625-5288
Replay (international): 1-303-804-1855
ID# 1561251
The audio replay will be available until March 8, 2002.
You can also access a live webcast via Nanogen`s website at www.nanogen.com under the "Investor/News" section. The presentation will be archived on Nanogen`s site for 90 days.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether regulatory clearances or approvals will be obtained, whether patented inventions can be successfully incorporated into commercial products, whether Nanogen will be successful in developing FDA-approved molecular diagnostic tests utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X01584203
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Media Relations, Tom Baker of Susan E. Atkins &
Associates, +1-858-860-0266, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Feb 21, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that the Company will be presenting at the 5th Annual Lehman Brothers Global Healthcare Conference on Thursday, February 28, 2002 at 11:15 a.m. Eastern Time. Gerard A. Wills, Chief Financial Officer of Nanogen, will provide a corporate overview and discuss the Company`s strategy for pursuing market share in the molecular diagnostics research and development market.
Nanogen invites you to listen to Mr. Wills` presentation by calling into the phone numbers listed below:
Live (domestic): 1-800-553-3587
Live (international): 1-303-713-7920
Replay (domestic): 1-800-625-5288
Replay (international): 1-303-804-1855
ID# 1561251
The audio replay will be available until March 8, 2002.
You can also access a live webcast via Nanogen`s website at www.nanogen.com under the "Investor/News" section. The presentation will be archived on Nanogen`s site for 90 days.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether regulatory clearances or approvals will be obtained, whether patented inventions can be successfully incorporated into commercial products, whether Nanogen will be successful in developing FDA-approved molecular diagnostic tests utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X01584203
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Media Relations, Tom Baker of Susan E. Atkins &
Associates, +1-858-860-0266, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Trading Spotlight
Friday February 22, 12:12 pm Eastern Time
Press Release
SOURCE: Nanogen, Inc.
Nanogen CEO Randy White Testifies on Biowarfare Detection Before The House Armed Services Committee
SAN DIEGO, Feb. 22 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today that CEO Randy White, Ph.D., testified yesterday before the House of Representatives Armed Services Committee meeting in San Diego, California, addressing biowarfare detection. The Committee, which was chaired by Rep. Duncan Hunter (El Cajon), met to hear testimony from local government and business leaders concerning the identification of near-term practical solutions to improve the United States` homeland defense and preparedness. Dr. White was invited to speak at the meeting on behalf of San Diego`s biotechnology companies by Joseph Panetta, President of San Diego`s BIOCOM, the local biotechnology trade organization. Currently there are three biodefense funding related spending bills being considered by Congress, ``The Public Health Security and Bioterrorism Response Act of 2001 (HR 3448)``, ``Bioterrorism Preparedness Act of 2001 (S. 1765)``, and ``Bill S. 1764``.
``The biotechnology community stands ready to answer the need for rapid detection and testing,`` said Randy White. ``The DUST (Dual Use Science & Technology) and DARPA (Defense Advanced Research Projects Agency) grants have fueled many prototype defense technologies. However, the funding proposed by these bills will be important for continued support of these technologies and ensuring that they can be converted from prototypes into commercial instruments. To date, Nanogen has been awarded over $11 million in grants from government agencies, which has resulted in the development of technologies such as a prototype biowarfare detection device. In addition, Nanogen has also successfully performed multiplex analysis for six microorganisms simultaneously in a single homogeneous sample and has most recently completed an internal validation of a multiplex analysis for anthrax and smallpox. A contracted external validation is in process.``
The samples Nanogen used to validate the detection of pathogens at Nanogen were cloned DNA containing portions of Bacillus anthracis and Vaccinia virus, a smallpox simulant. Nanogen has not performed such tests using any live microorganisms associated with these biological agents, and does not store or handle such organisms at its facilities.
Nanogen`s DUST/DARPA funding has been directed toward developing a single-step portable sample-to-answer detection device. Current DNA testing is a three-step process: extraction of genomic DNA from a sample source; an amplification step; and finally a detection system. The Company believes that its current instrument is capable of detecting Anthrax, Smallpox, Yersinia pestis, Botulinum toxin and many other pathogens using the three-step process. The single-step process, although more applicable to field use, may, if successfully developed by the Company, eventually become part of a new Nanogen instrument.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether regulatory clearances or approvals will be obtained, whether patented inventions can be successfully incorporated into commercial products, whether Nanogen will be successful in developing FDA-approved molecular diagnostic tests utilizing the NanoChip® System, whether the NanoChip® System can be developed into a product capable of detecting Anthrax, Smallpox, Yersina pestis, Botulinum toxins and other pathogens in a three-step or single-step process, whether such products can be successfully commercialized, whether Nanogen will be awarded additional grants from the government, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
Press Release
SOURCE: Nanogen, Inc.
Nanogen CEO Randy White Testifies on Biowarfare Detection Before The House Armed Services Committee
SAN DIEGO, Feb. 22 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today that CEO Randy White, Ph.D., testified yesterday before the House of Representatives Armed Services Committee meeting in San Diego, California, addressing biowarfare detection. The Committee, which was chaired by Rep. Duncan Hunter (El Cajon), met to hear testimony from local government and business leaders concerning the identification of near-term practical solutions to improve the United States` homeland defense and preparedness. Dr. White was invited to speak at the meeting on behalf of San Diego`s biotechnology companies by Joseph Panetta, President of San Diego`s BIOCOM, the local biotechnology trade organization. Currently there are three biodefense funding related spending bills being considered by Congress, ``The Public Health Security and Bioterrorism Response Act of 2001 (HR 3448)``, ``Bioterrorism Preparedness Act of 2001 (S. 1765)``, and ``Bill S. 1764``.
``The biotechnology community stands ready to answer the need for rapid detection and testing,`` said Randy White. ``The DUST (Dual Use Science & Technology) and DARPA (Defense Advanced Research Projects Agency) grants have fueled many prototype defense technologies. However, the funding proposed by these bills will be important for continued support of these technologies and ensuring that they can be converted from prototypes into commercial instruments. To date, Nanogen has been awarded over $11 million in grants from government agencies, which has resulted in the development of technologies such as a prototype biowarfare detection device. In addition, Nanogen has also successfully performed multiplex analysis for six microorganisms simultaneously in a single homogeneous sample and has most recently completed an internal validation of a multiplex analysis for anthrax and smallpox. A contracted external validation is in process.``
The samples Nanogen used to validate the detection of pathogens at Nanogen were cloned DNA containing portions of Bacillus anthracis and Vaccinia virus, a smallpox simulant. Nanogen has not performed such tests using any live microorganisms associated with these biological agents, and does not store or handle such organisms at its facilities.
Nanogen`s DUST/DARPA funding has been directed toward developing a single-step portable sample-to-answer detection device. Current DNA testing is a three-step process: extraction of genomic DNA from a sample source; an amplification step; and finally a detection system. The Company believes that its current instrument is capable of detecting Anthrax, Smallpox, Yersinia pestis, Botulinum toxin and many other pathogens using the three-step process. The single-step process, although more applicable to field use, may, if successfully developed by the Company, eventually become part of a new Nanogen instrument.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether regulatory clearances or approvals will be obtained, whether patented inventions can be successfully incorporated into commercial products, whether Nanogen will be successful in developing FDA-approved molecular diagnostic tests utilizing the NanoChip® System, whether the NanoChip® System can be developed into a product capable of detecting Anthrax, Smallpox, Yersina pestis, Botulinum toxins and other pathogens in a three-step or single-step process, whether such products can be successfully commercialized, whether Nanogen will be awarded additional grants from the government, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
A HANDHELD DISEASE DETECTOR
COULD BE DEVELOPED IN 3 YEARS
By Elizabeth Gardner
Small Times Correspondent
CHICAGO, Feb. 25, 2002 – Wouldn’t it be great if your doctor could figure out within a few minutes not only what kind of infection you have, but also which antibiotics are still effective against it? Within the next few years, a nanoscale technology developed by a team at Northwestern University may yield a handheld device that does just that, and potentially much more.
Writing in the February 22 issue of Science, researchers from Northwestern’s Institute for Nanotechnology describe a new method of DNA detection that uses gold nanoparticle probes and microarrays of electrodes. It’s 10 times more sensitive (causing fewer false negatives) and 100,000 times more selective (causing far fewer false positives) than current methods.
The nanoprobes are coated with a synthesized string of nucleotides that complement one end of a target sequence in the sample being analyzed, so they can “grab” it if it’s there. Another set of nucleotides, complementing the other end of the target, is attached to a surface between two electrodes. If the target sequence is present in the sample, it attaches to both the nanoprobes and the sequences on the surface between the electrodes, so that the nanoprobes are anchored to the surface like a cluster of little balloons. When they’re treated with a silver solution, they create a bridge between the electrodes and produce a charge.
The technology could theoretically be used to detect any disease or condition with a unique genomic fingerprint. For example, it could differentiate between various antibiotic-resistant strains of strep, or detect cancerous cells, or quickly identify HIV or biological weapons agents like anthrax. A single chip could contain electrode pairs to test for thousands of biological targets at once. And because an electrical charge is either present or absent, there’s no ambiguity in the results.
The head of the research team is Chad Mirkin, director of the institute and co-founder of Nanosphere Inc., Northbrook, Ill., which is licensed to begin commercial development of the technology. “Nanotechnology can be used to get better results in all categories that are important in DNA detection – sensitivity, selectivity, cost, ease of use and speed,” he said. “The electrical DNA detection method that we have invented excels in all of these areas and has a good chance to become a truly disruptive technology.”
Nanosphere is already developing DNA detection systems based on an earlier method invented by Mirkin’s team, also using gold nanoprobes, that causes a color change in a solution when a particular DNA sequence is detected. The first of those products is scheduled to be in beta testing by the end of the year.
Vijaya Vasista, Nanosphere’s chief operating officer, says the new method described in the Science paper will be better suited to developing a handheld device that can be used in physicians’ offices, at a hospital bedside or on the battlefield. She estimates that such a device could be ready for testing and approval by the U.S. Food and Drug Administration in as little as three years. The company is planning to hire a regulatory specialist this year to shepherd its products through the intricate and rigorous process. Vasista anticipates that the company’s products will be marketed first in Europe, where approvals come more quickly.
The first hurdle in developing the electrode-based detector will be to create a simple process for preparing the DNA samples for testing, Vasista says. For example, blood samples must now be prepared by separating out the white blood cells (the only ones that contain DNA), and then treating them to isolate the genetic material. “We need a miniature way to do that,” she said.
Using figures from several industry analysts, including Merrill Lynch, Salomon Smith Barney and Credit Suisse First Boston, Nanosphere estimates this year’s total genomics market opportunity at about $4.3 billion, mostly in clinical research laboratory expenditures and in-vitro diagnostics. The company projects that the market will grow to more than $7 billion by 2005.
If Nanosphere’s technology yields a device that fulfills its promise technically, it’s likely to find an eager market, said analyst Raylene Ballard of ECRI, Plymouth Meeting, Pa., a nonprofit organization that evaluates medical technology for health care providers. “These kinds of applications have a direct relation to quality of care,” she said. “There’s an obvious benefit in being able to get a result on the spot instead of waiting for two days.”
Whether potential popularity translates into financial success will depend on a number of factors beyond Nanosphere’s control, Ballard added. “They have to be able to manufacture it fairly cheaply, and the government and insurance companies have to be willing to reimburse providers for its use. And you have to convince the medical community to use it, which is sometimes a slow process. But I don’t think it will be that hard to do if the device clearly works.”
“If it delivers as advertised, it would be a really worthwhile thing,” said James Holman, senior vice president of medical affairs at Carilion Health System, a network of 10 hospitals headquartered in Roanoke, Va. “For an infectious disease, response time is critical.” Carilion routinely evaluates new technologies based on whether they’re an improvement over what’s already being used, and whether they’re the best use of scarce dollars.
ECRI’s Ballard says many companies, including Nanogen Inc. in San Diego and Cepheid in Sunnyvale, Calif., are working on miniaturized DNA analysis. Cepheid announced in January that it had shipped field-ready DNA test kits for anthrax, botulism, plague, and tularemia to the U.S. Army Medical Research Institute of Infectious Diseases.
Larger diagnostics companies like Roche, Bayer and Johnson & Johnson are also likely working toward the same goal, Ballard added. “They don’t like to talk about R&D until they’re ready to announce a product,” she said. “But they also may let some small company do the research and then swoop down and buy it. That’s very common in diagnostics.”
COULD BE DEVELOPED IN 3 YEARS
By Elizabeth Gardner
Small Times Correspondent
CHICAGO, Feb. 25, 2002 – Wouldn’t it be great if your doctor could figure out within a few minutes not only what kind of infection you have, but also which antibiotics are still effective against it? Within the next few years, a nanoscale technology developed by a team at Northwestern University may yield a handheld device that does just that, and potentially much more.
Writing in the February 22 issue of Science, researchers from Northwestern’s Institute for Nanotechnology describe a new method of DNA detection that uses gold nanoparticle probes and microarrays of electrodes. It’s 10 times more sensitive (causing fewer false negatives) and 100,000 times more selective (causing far fewer false positives) than current methods.
The nanoprobes are coated with a synthesized string of nucleotides that complement one end of a target sequence in the sample being analyzed, so they can “grab” it if it’s there. Another set of nucleotides, complementing the other end of the target, is attached to a surface between two electrodes. If the target sequence is present in the sample, it attaches to both the nanoprobes and the sequences on the surface between the electrodes, so that the nanoprobes are anchored to the surface like a cluster of little balloons. When they’re treated with a silver solution, they create a bridge between the electrodes and produce a charge.
The technology could theoretically be used to detect any disease or condition with a unique genomic fingerprint. For example, it could differentiate between various antibiotic-resistant strains of strep, or detect cancerous cells, or quickly identify HIV or biological weapons agents like anthrax. A single chip could contain electrode pairs to test for thousands of biological targets at once. And because an electrical charge is either present or absent, there’s no ambiguity in the results.
The head of the research team is Chad Mirkin, director of the institute and co-founder of Nanosphere Inc., Northbrook, Ill., which is licensed to begin commercial development of the technology. “Nanotechnology can be used to get better results in all categories that are important in DNA detection – sensitivity, selectivity, cost, ease of use and speed,” he said. “The electrical DNA detection method that we have invented excels in all of these areas and has a good chance to become a truly disruptive technology.”
Nanosphere is already developing DNA detection systems based on an earlier method invented by Mirkin’s team, also using gold nanoprobes, that causes a color change in a solution when a particular DNA sequence is detected. The first of those products is scheduled to be in beta testing by the end of the year.
Vijaya Vasista, Nanosphere’s chief operating officer, says the new method described in the Science paper will be better suited to developing a handheld device that can be used in physicians’ offices, at a hospital bedside or on the battlefield. She estimates that such a device could be ready for testing and approval by the U.S. Food and Drug Administration in as little as three years. The company is planning to hire a regulatory specialist this year to shepherd its products through the intricate and rigorous process. Vasista anticipates that the company’s products will be marketed first in Europe, where approvals come more quickly.
The first hurdle in developing the electrode-based detector will be to create a simple process for preparing the DNA samples for testing, Vasista says. For example, blood samples must now be prepared by separating out the white blood cells (the only ones that contain DNA), and then treating them to isolate the genetic material. “We need a miniature way to do that,” she said.
Using figures from several industry analysts, including Merrill Lynch, Salomon Smith Barney and Credit Suisse First Boston, Nanosphere estimates this year’s total genomics market opportunity at about $4.3 billion, mostly in clinical research laboratory expenditures and in-vitro diagnostics. The company projects that the market will grow to more than $7 billion by 2005.
If Nanosphere’s technology yields a device that fulfills its promise technically, it’s likely to find an eager market, said analyst Raylene Ballard of ECRI, Plymouth Meeting, Pa., a nonprofit organization that evaluates medical technology for health care providers. “These kinds of applications have a direct relation to quality of care,” she said. “There’s an obvious benefit in being able to get a result on the spot instead of waiting for two days.”
Whether potential popularity translates into financial success will depend on a number of factors beyond Nanosphere’s control, Ballard added. “They have to be able to manufacture it fairly cheaply, and the government and insurance companies have to be willing to reimburse providers for its use. And you have to convince the medical community to use it, which is sometimes a slow process. But I don’t think it will be that hard to do if the device clearly works.”
“If it delivers as advertised, it would be a really worthwhile thing,” said James Holman, senior vice president of medical affairs at Carilion Health System, a network of 10 hospitals headquartered in Roanoke, Va. “For an infectious disease, response time is critical.” Carilion routinely evaluates new technologies based on whether they’re an improvement over what’s already being used, and whether they’re the best use of scarce dollars.
ECRI’s Ballard says many companies, including Nanogen Inc. in San Diego and Cepheid in Sunnyvale, Calif., are working on miniaturized DNA analysis. Cepheid announced in January that it had shipped field-ready DNA test kits for anthrax, botulism, plague, and tularemia to the U.S. Army Medical Research Institute of Infectious Diseases.
Larger diagnostics companies like Roche, Bayer and Johnson & Johnson are also likely working toward the same goal, Ballard added. “They don’t like to talk about R&D until they’re ready to announce a product,” she said. “But they also may let some small company do the research and then swoop down and buy it. That’s very common in diagnostics.”
Press Release
SOURCE: Nanogen, Inc.
Nanogen and ARUP Laboratories Begin Gene-Based Assay Development Collaboration
SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) today announced it has recently installed a NanoChip® Molecular Biology Workstation at Associated Regional and University Pathologists (ARUP) Laboratories, a full-service reference laboratory owned by the University of Utah, to develop novel gene-based assays. Under this Development Site Agreement entered into in December, Nanogen has provided one of its NanoChip® Molecular Biology Workstations to ARUP in exchange for certain commercialization rights to assays developed by ARUP under the collaboration. The collaboration may eventually lead to the development of molecular diagnostic test protocols to be performed on the NanoChip® Cartridge and the NanoChip® Molecular Biology Workstation.
``We are very excited to be working with ARUP, a recognized leader in esoteric testing,`` said Randy White, Chief Executive Officer of Nanogen. ``Their commitment to developing novel gene-based assays under our Development Site Agreement may provide an important source of new content for our cartridges and may play a vital role in expanding our menu of customer applications.``
``This Agreement is representative of our view that molecular diagnostics is an emerging, untapped market within esoteric testing, and by partnering with Nanogen we now have access to one of the leading molecular analysis technologies,`` said Ronald L. Weiss, M.D., Senior Vice President of ARUP. ``With this Agreement we have the opportunity to closely evaluate the NanoChip® System as a flexible, universal platform that may be able to develop, automate, and simplify the process of conducting often-complex gene-based assays.``
Nanogen`s Development Site Program was established to actively collaborate with selected customers in strategically important market segments (including clinical research, the research divisions of reference diagnostic laboratories and genomics, pharmaceutical, biotechnology and agrochemical companies) in their development of assays on the Nanogen platform. Under these Agreements, collaborating companies and institutions provide expertise and/or intellectual property in exchange for preferential access to Nanogen`s technology. After the conclusion of the program, the collaborating institutions may purchase the NanoChip® Molecular Biology Workstation and NanoChip® Cartridges for use in their operations.
ARUP Laboratories
ARUP Laboratories, based in Salt Lake City, Utah, was formed in 1984 as an independent, full-service reference laboratory by the Department of Pathology at the University of Utah Health Sciences Center (UUHSC). ARUP`s market focus is to perform esoteric testing that supplements the testing available in local communities. ARUP does not compete with its clients, and thus, does not market to physician offices directly. ARUP offers a comprehensive test menu of more than 2,000 tests and test combinations. Quality, service, and technological advancement are key areas of emphasis. ARUP Laboratories and its more than 1300 employees dedicate themselves to assisting clients with cost-effective testing through continuity of care, utilization management, and outcomes management. For more information please visit ARUP`s web site at www.aruplab.com
Nanogen, Inc.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
SOURCE: Nanogen, Inc.
Nanogen and ARUP Laboratories Begin Gene-Based Assay Development Collaboration
SAN DIEGO, Feb. 26 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) today announced it has recently installed a NanoChip® Molecular Biology Workstation at Associated Regional and University Pathologists (ARUP) Laboratories, a full-service reference laboratory owned by the University of Utah, to develop novel gene-based assays. Under this Development Site Agreement entered into in December, Nanogen has provided one of its NanoChip® Molecular Biology Workstations to ARUP in exchange for certain commercialization rights to assays developed by ARUP under the collaboration. The collaboration may eventually lead to the development of molecular diagnostic test protocols to be performed on the NanoChip® Cartridge and the NanoChip® Molecular Biology Workstation.
``We are very excited to be working with ARUP, a recognized leader in esoteric testing,`` said Randy White, Chief Executive Officer of Nanogen. ``Their commitment to developing novel gene-based assays under our Development Site Agreement may provide an important source of new content for our cartridges and may play a vital role in expanding our menu of customer applications.``
``This Agreement is representative of our view that molecular diagnostics is an emerging, untapped market within esoteric testing, and by partnering with Nanogen we now have access to one of the leading molecular analysis technologies,`` said Ronald L. Weiss, M.D., Senior Vice President of ARUP. ``With this Agreement we have the opportunity to closely evaluate the NanoChip® System as a flexible, universal platform that may be able to develop, automate, and simplify the process of conducting often-complex gene-based assays.``
Nanogen`s Development Site Program was established to actively collaborate with selected customers in strategically important market segments (including clinical research, the research divisions of reference diagnostic laboratories and genomics, pharmaceutical, biotechnology and agrochemical companies) in their development of assays on the Nanogen platform. Under these Agreements, collaborating companies and institutions provide expertise and/or intellectual property in exchange for preferential access to Nanogen`s technology. After the conclusion of the program, the collaborating institutions may purchase the NanoChip® Molecular Biology Workstation and NanoChip® Cartridges for use in their operations.
ARUP Laboratories
ARUP Laboratories, based in Salt Lake City, Utah, was formed in 1984 as an independent, full-service reference laboratory by the Department of Pathology at the University of Utah Health Sciences Center (UUHSC). ARUP`s market focus is to perform esoteric testing that supplements the testing available in local communities. ARUP does not compete with its clients, and thus, does not market to physician offices directly. ARUP offers a comprehensive test menu of more than 2,000 tests and test combinations. Quality, service, and technological advancement are key areas of emphasis. ARUP Laboratories and its more than 1300 employees dedicate themselves to assisting clients with cost-effective testing through continuity of care, utilization management, and outcomes management. For more information please visit ARUP`s web site at www.aruplab.com
Nanogen, Inc.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
Today`s Lehman Presentation Notes
NGEN PRESENTATION 2/28/02
Overview Market:
Two molecular markets. High through-put and diagnostics. Not competing in the first and no clear leader in the second. Goal is to be the leading provider of molecular diagnostics tests. $1B market now that is expected to expand to $3 to 5 billion in five years. Think of all the money being poured into gene research and trials. Diagnostic molecular testing breakthrough at FDA before therapeutics, because the latter have a longer time line. Genetic testing and therapy is the future of medicine. Quest Diagnostics, a leading CLIA lab, expects 25% annual growth of molecular testing. Lab testing expenses are only 3-4% of health care. Molecular is the fastest growing lab test segment. Eventually, will shift from detection and treatment to prevention.
Types of tests:
1 Pre-disposition testing. Healthy people can confirm genetic defect. E.g. Hereditary breast and cervical cancer.
2. Screening. Cystic fibrosis. Prostate. Cancer subset.
3. Viruses. Profile and design better treatment.
4. Pharmacogenomics. Customize treatment.
5. Diagnostics and Prognosis. Common today.
Dynamics.
CF is first molecular based test recommended for nationwide screening. 1 in 31 carry CF mutation. National College of OBGYNs says screen all women contemplating pregnancy. CF only occurs in babies that receive mutation from both parents. 25% chance of passing it on if both are carriers. In 2002, NGEN will launch a 25 mutation CF screen. The CF testing market is now only $35 million annually. But the nationwide recommendation is expected to cause a significant increase because that recommendation establishes the standard of care. (Think of lawsuits against doctors who faile to screen by parents giving birth to CF babies.) Capturing the market in one protocol will cause other NGEN protocols to sell.
First product. Razor and blade. $160,000 with 30% margin. Cartridge $500 with 75-80% margin. Discount to $150 to research market.
2002 Goals:
1. Increase the installed base of workstations to increase blades. Expect another 55-60 instruments. 2001 had 61 in field, majority in research. Now targeting clinical reference labs.
Sales Methods: a. Development site agreements. No revenue recognized. Assist in installed base. Ultimately sales possible.
b. Direct sales. Cash. Rental. Reagent rental. Flexible.
2. Increase breadth of menu in protocols.
Now have 5 DNA based protocols. 4 are aimed at cardiovascular. One for excess iron storage. Certified labs will adopt and use.
2002 goal: 10 new protocols including the CF multiplex protocol.
Customers evaluated 47 new protocols. Open architecture.
The more protocols, the more blades.
3. Increase depth of menu. Each protocol.
In 2002, will convert to analyte specific reagents. ASRs. Will also sell ASR reagent sets. Expect ASR facility compliance approval by end of Q1.
Need FDA approval for tests to expand beyond CLIA approved labs.
Amplification (PCR is the standard now) is actually making DNA copies. Royalty charges are very expensive for PCR. Nanogen (SDA) will take 45 minutes vs. 2 hours for PCR. Then with on-chip amplification, NGEN will go from three steps to two. Operational advantage.
4. Will either add to sales force, enter distribution agreements, or strike a new partner collaboration.
Randy White’s lab was recently acquired by Quest Diagnostics, the leading CLIA lab.
$67 million in cash 12/31/01.
NGEN PRESENTATION 2/28/02
Overview Market:
Two molecular markets. High through-put and diagnostics. Not competing in the first and no clear leader in the second. Goal is to be the leading provider of molecular diagnostics tests. $1B market now that is expected to expand to $3 to 5 billion in five years. Think of all the money being poured into gene research and trials. Diagnostic molecular testing breakthrough at FDA before therapeutics, because the latter have a longer time line. Genetic testing and therapy is the future of medicine. Quest Diagnostics, a leading CLIA lab, expects 25% annual growth of molecular testing. Lab testing expenses are only 3-4% of health care. Molecular is the fastest growing lab test segment. Eventually, will shift from detection and treatment to prevention.
Types of tests:
1 Pre-disposition testing. Healthy people can confirm genetic defect. E.g. Hereditary breast and cervical cancer.
2. Screening. Cystic fibrosis. Prostate. Cancer subset.
3. Viruses. Profile and design better treatment.
4. Pharmacogenomics. Customize treatment.
5. Diagnostics and Prognosis. Common today.
Dynamics.
CF is first molecular based test recommended for nationwide screening. 1 in 31 carry CF mutation. National College of OBGYNs says screen all women contemplating pregnancy. CF only occurs in babies that receive mutation from both parents. 25% chance of passing it on if both are carriers. In 2002, NGEN will launch a 25 mutation CF screen. The CF testing market is now only $35 million annually. But the nationwide recommendation is expected to cause a significant increase because that recommendation establishes the standard of care. (Think of lawsuits against doctors who faile to screen by parents giving birth to CF babies.) Capturing the market in one protocol will cause other NGEN protocols to sell.
First product. Razor and blade. $160,000 with 30% margin. Cartridge $500 with 75-80% margin. Discount to $150 to research market.
2002 Goals:
1. Increase the installed base of workstations to increase blades. Expect another 55-60 instruments. 2001 had 61 in field, majority in research. Now targeting clinical reference labs.
Sales Methods: a. Development site agreements. No revenue recognized. Assist in installed base. Ultimately sales possible.
b. Direct sales. Cash. Rental. Reagent rental. Flexible.
2. Increase breadth of menu in protocols.
Now have 5 DNA based protocols. 4 are aimed at cardiovascular. One for excess iron storage. Certified labs will adopt and use.
2002 goal: 10 new protocols including the CF multiplex protocol.
Customers evaluated 47 new protocols. Open architecture.
The more protocols, the more blades.
3. Increase depth of menu. Each protocol.
In 2002, will convert to analyte specific reagents. ASRs. Will also sell ASR reagent sets. Expect ASR facility compliance approval by end of Q1.
Need FDA approval for tests to expand beyond CLIA approved labs.
Amplification (PCR is the standard now) is actually making DNA copies. Royalty charges are very expensive for PCR. Nanogen (SDA) will take 45 minutes vs. 2 hours for PCR. Then with on-chip amplification, NGEN will go from three steps to two. Operational advantage.
4. Will either add to sales force, enter distribution agreements, or strike a new partner collaboration.
Randy White’s lab was recently acquired by Quest Diagnostics, the leading CLIA lab.
$67 million in cash 12/31/01.
Monday March 18, 7:00 am Eastern Time
Press Release
SOURCE: Nanogen, Inc.
Nanogen to Present at Banc of America Securities Genomics and Diagnostics Conference on March 20
SAN DIEGO, March 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today that the Company will be presenting at the Banc of America Securities Genomics and Diagnostics Conference on Wednesday, March 20, 2002 at 3:30 p.m. Eastern Time. Dr. Randy White, Chief Executive Officer of Nanogen, will discuss the Company`s strategy for becoming a leading provider of molecular diagnostics.
Nanogen invites you to access Dr. White`s audio and slide presentation via live webcast on the investor relations section of Nanogen`s corporate website, at www.nanogen.com under the Investor/News section. The presentation will be archived on the Company`s website until April 5, 2002 at 6:00 p.m. Eastern Time.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully further commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
Press Release
SOURCE: Nanogen, Inc.
Nanogen to Present at Banc of America Securities Genomics and Diagnostics Conference on March 20
SAN DIEGO, March 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) announced today that the Company will be presenting at the Banc of America Securities Genomics and Diagnostics Conference on Wednesday, March 20, 2002 at 3:30 p.m. Eastern Time. Dr. Randy White, Chief Executive Officer of Nanogen, will discuss the Company`s strategy for becoming a leading provider of molecular diagnostics.
Nanogen invites you to access Dr. White`s audio and slide presentation via live webcast on the investor relations section of Nanogen`s corporate website, at www.nanogen.com under the Investor/News section. The presentation will be archived on the Company`s website until April 5, 2002 at 6:00 p.m. Eastern Time.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed and internally validated five research protocols, four associated with cardiovascular disease and one associated with Hereditary Hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully further commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip® System, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
http://www.immune-therapy.de/Abstracts/Windhab.htm
Dr. N. Windhab, Nanogen Recognomics GmbH Frankfurt
A real Bio-Molecular Workstation, application platform in the Genomic Medicine era
Genomic Medicine is now a self-sustaining reality positioned in an overwhelming visionary research and development phase such as new strategies in Immune Therapy. Nucleic Acid Diagnostics- sometimes misleadingly called ‘Molecular Diagnostics’- will profit from the convergence of knowledge generated in genome research and its trend towards individualized approaches in prediction, prevention and therapy .
Robust new technology is mandatory even – or especially - for approaches with a given (targeted) set of genes encoding e.g. signal cascades or markers that are already identified. This converges therapeutic research into a “cure-diagnostic-package”. Surprisingly enough, high density chip-technology focuses on large sets of genes or variants rather than on the analysis of multiple allotypes, genomes or differentiating cell lines, because comparative multiple sample application on the same chip is hampered by all passive array-tests. In contrats to this case study examples will highlight Nanogen’s high accuracy Biomolecular Workstation platform with versatile benchtop technology such as SNP-Detection, STR and Gene Expression analysis (the latter not commercially available yet) on active semiconductor DNA chips. Nanogen Recognomics – the new Nanogen Joint-Venture with Aventis R&T will also present first workstation-derived data from new applications for massive parallel SNP-discovery, and its visionary Epitope-Chip technology.
Dr. N. Windhab, Nanogen Recognomics GmbH Frankfurt
A real Bio-Molecular Workstation, application platform in the Genomic Medicine era
Genomic Medicine is now a self-sustaining reality positioned in an overwhelming visionary research and development phase such as new strategies in Immune Therapy. Nucleic Acid Diagnostics- sometimes misleadingly called ‘Molecular Diagnostics’- will profit from the convergence of knowledge generated in genome research and its trend towards individualized approaches in prediction, prevention and therapy .
Robust new technology is mandatory even – or especially - for approaches with a given (targeted) set of genes encoding e.g. signal cascades or markers that are already identified. This converges therapeutic research into a “cure-diagnostic-package”. Surprisingly enough, high density chip-technology focuses on large sets of genes or variants rather than on the analysis of multiple allotypes, genomes or differentiating cell lines, because comparative multiple sample application on the same chip is hampered by all passive array-tests. In contrats to this case study examples will highlight Nanogen’s high accuracy Biomolecular Workstation platform with versatile benchtop technology such as SNP-Detection, STR and Gene Expression analysis (the latter not commercially available yet) on active semiconductor DNA chips. Nanogen Recognomics – the new Nanogen Joint-Venture with Aventis R&T will also present first workstation-derived data from new applications for massive parallel SNP-discovery, and its visionary Epitope-Chip technology.
LOL! Das liest sich wie ein Werbeprospekt! Nur hohle Phrasen für die Investoren!
In den USA müsst es nach dieser News wohl wieder aufwärts gehen::
Nanogen Introduces Factor V Leiden Analyte Specific Reagent; Company Achieves Key Milestone in Execution of Business Plan
SAN DIEGO, Mar 20, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today the introduction of its first Analyte Specific Reagent (ASR), designed for the detection of Factor V Leiden, a gene mutation associated with cardiovascular disease and the pathology of thrombosis. The introduction of the ASR is an important step in the Company`s strategy to build its consumable revenue base. The Company has put in place policies and procedures that will enable it to meet the Quality System Regulations, or QSRs, in its facilities. QSR Compliance is a regulatory requirement of the FDA that is intended to ensure the quality of medical devices and related products.
Nanogen`s Factor V Leiden ASR determines if the Factor V Leiden gene is present in a blood sample by detecting the presence of a certain characteristic gene polymorphism. The ASR consists of active reagents that CLIA-certified high complexity laboratories can use in their tests to detect this mutation.
"Testing for Factor V Leiden, one of the most common inherited links to the pathology of thrombosis, can provide a physician with important information relating to risk assessment and prevention," said Howard C. Birndorf, Executive Chairman and Co-Founder of Nanogen. "Our ASR for Factor V Leiden will now offer CLIA-certified high complexity laboratories a more complete solution than our "home brew" protocol currently provided. Because the Factor V ASR can be used on the NanoChip(R) Molecular Biology Workstation, this makes the NanoChip(R) System an even more competitive platform in the fast growing market of molecular diagnostics."
Factor V Leiden is the most common hereditary blood coagulation disorder present in three to seven percent of the population in Europe and the United States. Individuals who are carriers of Factor V Leiden have an increased risk of thrombosis, a clot that hinders the passage of blood through the vessels potentially causing heart attacks, strokes and other related illnesses.
"The introduction of our first ASR and achieving QSR compliance meets a major business objective we set out to achieve this quarter. We will continue to expand both the breadth and depth of our menu with the launch of additional protocols and ASRs, which we believe will create a significant opportunity to increase consumable product revenues related to the use of our NanoChip(R) platform," said Randy White, Chief Executive Officer of Nanogen. "Moving forward, our strategy is to continue down the regulatory pathway to reach our ultimate goal of offering FDA-cleared or approved products on a case-by-case basis to a wide range of customers, including clinical reference laboratories."
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X44471843
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Susan E. Atkins &
Associates, +1-858-527-3493, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Nanogen Introduces Factor V Leiden Analyte Specific Reagent; Company Achieves Key Milestone in Execution of Business Plan
SAN DIEGO, Mar 20, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today the introduction of its first Analyte Specific Reagent (ASR), designed for the detection of Factor V Leiden, a gene mutation associated with cardiovascular disease and the pathology of thrombosis. The introduction of the ASR is an important step in the Company`s strategy to build its consumable revenue base. The Company has put in place policies and procedures that will enable it to meet the Quality System Regulations, or QSRs, in its facilities. QSR Compliance is a regulatory requirement of the FDA that is intended to ensure the quality of medical devices and related products.
Nanogen`s Factor V Leiden ASR determines if the Factor V Leiden gene is present in a blood sample by detecting the presence of a certain characteristic gene polymorphism. The ASR consists of active reagents that CLIA-certified high complexity laboratories can use in their tests to detect this mutation.
"Testing for Factor V Leiden, one of the most common inherited links to the pathology of thrombosis, can provide a physician with important information relating to risk assessment and prevention," said Howard C. Birndorf, Executive Chairman and Co-Founder of Nanogen. "Our ASR for Factor V Leiden will now offer CLIA-certified high complexity laboratories a more complete solution than our "home brew" protocol currently provided. Because the Factor V ASR can be used on the NanoChip(R) Molecular Biology Workstation, this makes the NanoChip(R) System an even more competitive platform in the fast growing market of molecular diagnostics."
Factor V Leiden is the most common hereditary blood coagulation disorder present in three to seven percent of the population in Europe and the United States. Individuals who are carriers of Factor V Leiden have an increased risk of thrombosis, a clot that hinders the passage of blood through the vessels potentially causing heart attacks, strokes and other related illnesses.
"The introduction of our first ASR and achieving QSR compliance meets a major business objective we set out to achieve this quarter. We will continue to expand both the breadth and depth of our menu with the launch of additional protocols and ASRs, which we believe will create a significant opportunity to increase consumable product revenues related to the use of our NanoChip(R) platform," said Randy White, Chief Executive Officer of Nanogen. "Moving forward, our strategy is to continue down the regulatory pathway to reach our ultimate goal of offering FDA-cleared or approved products on a case-by-case basis to a wide range of customers, including clinical reference laboratories."
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000, as amended, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X44471843
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Susan E. Atkins &
Associates, +1-858-527-3493, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Für alle die es interessiert mal in deutsch zur Aufhellung (wg.: In den USA müsst es nach dieser News wohl wieder aufwärts gehen gepostet von tst 89.)
Durch den Defekt im Faktor V (5) [FV Leiden/APC Resistenz] der Gerinnungskaskade ist F. V nicht mehr durch Protein C spaltbar, reichert sich an, verschiebt so das Gleichgewicht der Gerinnungsbalance in Richtung Koagulation. Der Defekt kommt in der Mitteleuropäischen Bevölkerung zu ca. 5% vor und ist in der Tat ein wesentlicher Co – Risikofaktor bei der Thromboseentstehung die, nicht erkannt, über eine Lungenembolie tötlich ausgehen kann. Mann schätzt das in 25-35 % der Thrombosen die APC Resistenz eine Rolle spielt. Entdeckt wurde der Defekt 1993 von Dahlbäck – einem Schweden. Seitdem wurden eine Menge Tests auf den Markt gebracht und etabliert welche den Defekt zuverlässig nachweisen. Die Vorteile von Nanogen liegen mir nicht ganz so auf der Hand.
Durch den Defekt im Faktor V (5) [FV Leiden/APC Resistenz] der Gerinnungskaskade ist F. V nicht mehr durch Protein C spaltbar, reichert sich an, verschiebt so das Gleichgewicht der Gerinnungsbalance in Richtung Koagulation. Der Defekt kommt in der Mitteleuropäischen Bevölkerung zu ca. 5% vor und ist in der Tat ein wesentlicher Co – Risikofaktor bei der Thromboseentstehung die, nicht erkannt, über eine Lungenembolie tötlich ausgehen kann. Mann schätzt das in 25-35 % der Thrombosen die APC Resistenz eine Rolle spielt. Entdeckt wurde der Defekt 1993 von Dahlbäck – einem Schweden. Seitdem wurden eine Menge Tests auf den Markt gebracht und etabliert welche den Defekt zuverlässig nachweisen. Die Vorteile von Nanogen liegen mir nicht ganz so auf der Hand.
Nanogen ist aus Charttechnicher Sicht sicher ein Buy
auch ist Nanogen ein total unterbewerteter Titel ich
werde in den nächsten Tagen einsteigen.
TST89 bitte mal Post anschauen hier bei W-O
auch ist Nanogen ein total unterbewerteter Titel ich
werde in den nächsten Tagen einsteigen.
TST89 bitte mal Post anschauen hier bei W-O
Indikatoren drehen 
Interessanter Jahresabschlußbericht (finanziell 
)
http://media.corporate-ir.net/media_files/NSD/ngen/reports/1…
)http://media.corporate-ir.net/media_files/NSD/ngen/reports/1…
Na bitte passte doch leider mit einem Tag Verzögerung
ich gelobe Besserung
ich gelobe Besserung
Nanogen Selected to Present at the Future Leaders in the Biotech Industry
Conference on April 11
SAN DIEGO, April 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN)
announced today that the Company will present at the Future Leaders in the Biotech
Industry Conference, hosted by BioCentury Publications and Thomson
Financial/Carson, on Thursday, April 11, 2002 at 3:50 p.m. Eastern Time at the
Millennium Broadway Hotel & Conference Center, New York. Dr. Randy White, CEO of
Nanogen, will provide a corporate overview and discuss the Company`s strategy for
pursuing market share in the molecular diagnostics research and development market,
an emerging and fast-growing field in clinical diagnostics.
The slide presentation will be available via Nanogen`s website at www.nanogen.com
under the "Investor/News" section on the day of the event. The presentation will also be
archived on Nanogen`s site for 90 days.
Future Leaders in the Biotech Industry Conference is a collaborative gathering of the
corporate and investment communities. The conference showcases companies best
positioned to provide market leadership in uncertain times and offers the Wall Street
community the best opportunity to review -- in a single day -- the leading prospects in
the "BioCentury." For more information on the conference or to register, please visit the
conference site at http://www.biocentury.com/conf.htm .
Nanogen`s goal is to become the leading provider of electronic microarray technology
with the required accuracy, simplicity and flexibility necessary to bridge the gap
between the research and clinical setting in genomics-based diagnostics. The
Company is seeking to establish the NanoChip(R) System as the standard platform for
the detection of genetic mutations and to develop applications for future clinical use. To
date, the Company has developed one ASR for the detection of Factor V Leiden, and
internally validated five research protocols, four associated with cardiovascular disease
and one associated with hereditary hemochromatosis, the most common form of iron
overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to
scientists and genomics laboratories. The NanoChip(R) System is intended for
laboratory use only. For additional information please visit Nanogen`s web site at
www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those set forth in
the forward-looking statements, including whether the Company`s NanoChip(R) System
can be successfully commercialized, whether products under development can be
successfully developed and commercialized, whether results reported by our
customers or partners can be identically replicated, whether regulatory clearances or
approvals will be obtained, whether patented inventions can be successfully
incorporated into commercial products, whether Nanogen will be successful in
developing FDA-approved molecular diagnostic tests utilizing the NanoChip(R) System,
and other risks and uncertainties discussed under the caption "Factors That May
Affect Results" and elsewhere in the Company`s Form 10-K for the year ended
December 31, 2001 filed with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. The Company disclaims
any intent or obligation to update these forward-looking statements.
Tell Us What You Think -- Click Here
http://tbutton.prnewswire.com/prn/11690X48528413
SOURCE Nanogen, Inc.
-0- 04/08/2002
/CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Susan E. Atkins & Associates,
+1-858-527-3493, for Nanogen, Inc./
/Web site: http://www.biocentury.com/conf.htm
Conference on April 11
SAN DIEGO, April 8 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN)
announced today that the Company will present at the Future Leaders in the Biotech
Industry Conference, hosted by BioCentury Publications and Thomson
Financial/Carson, on Thursday, April 11, 2002 at 3:50 p.m. Eastern Time at the
Millennium Broadway Hotel & Conference Center, New York. Dr. Randy White, CEO of
Nanogen, will provide a corporate overview and discuss the Company`s strategy for
pursuing market share in the molecular diagnostics research and development market,
an emerging and fast-growing field in clinical diagnostics.
The slide presentation will be available via Nanogen`s website at www.nanogen.com
under the "Investor/News" section on the day of the event. The presentation will also be
archived on Nanogen`s site for 90 days.
Future Leaders in the Biotech Industry Conference is a collaborative gathering of the
corporate and investment communities. The conference showcases companies best
positioned to provide market leadership in uncertain times and offers the Wall Street
community the best opportunity to review -- in a single day -- the leading prospects in
the "BioCentury." For more information on the conference or to register, please visit the
conference site at http://www.biocentury.com/conf.htm .
Nanogen`s goal is to become the leading provider of electronic microarray technology
with the required accuracy, simplicity and flexibility necessary to bridge the gap
between the research and clinical setting in genomics-based diagnostics. The
Company is seeking to establish the NanoChip(R) System as the standard platform for
the detection of genetic mutations and to develop applications for future clinical use. To
date, the Company has developed one ASR for the detection of Factor V Leiden, and
internally validated five research protocols, four associated with cardiovascular disease
and one associated with hereditary hemochromatosis, the most common form of iron
overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to
scientists and genomics laboratories. The NanoChip(R) System is intended for
laboratory use only. For additional information please visit Nanogen`s web site at
www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and
uncertainties that could cause actual results to differ materially from those set forth in
the forward-looking statements, including whether the Company`s NanoChip(R) System
can be successfully commercialized, whether products under development can be
successfully developed and commercialized, whether results reported by our
customers or partners can be identically replicated, whether regulatory clearances or
approvals will be obtained, whether patented inventions can be successfully
incorporated into commercial products, whether Nanogen will be successful in
developing FDA-approved molecular diagnostic tests utilizing the NanoChip(R) System,
and other risks and uncertainties discussed under the caption "Factors That May
Affect Results" and elsewhere in the Company`s Form 10-K for the year ended
December 31, 2001 filed with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. The Company disclaims
any intent or obligation to update these forward-looking statements.
Tell Us What You Think -- Click Here
http://tbutton.prnewswire.com/prn/11690X48528413
SOURCE Nanogen, Inc.
-0- 04/08/2002
/CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Susan E. Atkins & Associates,
+1-858-527-3493, for Nanogen, Inc./
/Web site: http://www.biocentury.com/conf.htm
Monday April 22, 8:34 am Eastern Time
Press Release
SOURCE: Genetic Technologies; Nanogen
Nanogen and Genetic Technologies Enter License Agreement For Non-Coding DNA Analysis
SAN DIEGO, and MELBOURNE, Australia, April 22 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) and Genetic Technologies Limited (ASX: GTG; OTC: GNTLF), today announced a non-exclusive limited license agreement for non-coding DNA analysis patents held by Genetic Technologies. The license, which covers applications in genetic research and human diagnostics, was granted to Nanogen in exchange for an upfront payment in the form of cash and securities. Other terms of the deal were not disclosed. Genetic Technologies is a biotechnology company that holds several US and international patents in three leading areas of genetics: non-coding sequence analysis, genomic mapping, and fetal cell recovery.
``This is another example of Nanogen accessing rights which help ensure full freedom to operate in our selected markets. This IP is added to Nanogen`s own proprietary and exclusive technology to help form a unique and powerful product offering,`` said Randy White, Chief Executive Officer of Nanogen.
``Granting this license to Nanogen, following other recent licenses from our intellectual property portfolio, confirms the strength and commercial value of Genetic Technologies` United States and international patents, which span a broad range of emerging genetic strategies,`` said Dr. Mervyn Jacobson, Executive Chairman of Genetic Technologies. ``This is our second license agreement in the last two weeks and we expect more announcements to follow in coming months. Our patents have a wide range of diagnostic and mapping applications and we are pleased that they are now generating so much interest in the US biotechnology market.``
About Nanogen
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at http://www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
About Genetic Technologies
Genetic Technologies is an Australian biotechnology company that holds several US and international patents in three leading areas of genetics: non-coding sequence/intron DNA analysis, non-coding sequence genomic mapping, and fetal cell recovery. The non-coding patents cover most genes in most species. Genetic Technologies operates the largest DNA laboratory in Australia for paternity testing. The Company is also pursuing research in the treatment of AIDS and in the control of parasites in livestock using gene-based strategies, and is also developing genetic markers in various animal and plant species.
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company`s Securities and Exchange Commission filings under ``Risk Factors,`` including risks relating to license agreements; dependence on third parties; future capital needs.
SOURCE: Genetic Technologies; Nanogen
Press Release
SOURCE: Genetic Technologies; Nanogen
Nanogen and Genetic Technologies Enter License Agreement For Non-Coding DNA Analysis
SAN DIEGO, and MELBOURNE, Australia, April 22 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) and Genetic Technologies Limited (ASX: GTG; OTC: GNTLF), today announced a non-exclusive limited license agreement for non-coding DNA analysis patents held by Genetic Technologies. The license, which covers applications in genetic research and human diagnostics, was granted to Nanogen in exchange for an upfront payment in the form of cash and securities. Other terms of the deal were not disclosed. Genetic Technologies is a biotechnology company that holds several US and international patents in three leading areas of genetics: non-coding sequence analysis, genomic mapping, and fetal cell recovery.
``This is another example of Nanogen accessing rights which help ensure full freedom to operate in our selected markets. This IP is added to Nanogen`s own proprietary and exclusive technology to help form a unique and powerful product offering,`` said Randy White, Chief Executive Officer of Nanogen.
``Granting this license to Nanogen, following other recent licenses from our intellectual property portfolio, confirms the strength and commercial value of Genetic Technologies` United States and international patents, which span a broad range of emerging genetic strategies,`` said Dr. Mervyn Jacobson, Executive Chairman of Genetic Technologies. ``This is our second license agreement in the last two weeks and we expect more announcements to follow in coming months. Our patents have a wide range of diagnostic and mapping applications and we are pleased that they are now generating so much interest in the US biotechnology market.``
About Nanogen
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at http://www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
About Genetic Technologies
Genetic Technologies is an Australian biotechnology company that holds several US and international patents in three leading areas of genetics: non-coding sequence/intron DNA analysis, non-coding sequence genomic mapping, and fetal cell recovery. The non-coding patents cover most genes in most species. Genetic Technologies operates the largest DNA laboratory in Australia for paternity testing. The Company is also pursuing research in the treatment of AIDS and in the control of parasites in livestock using gene-based strategies, and is also developing genetic markers in various animal and plant species.
Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in the Company`s Securities and Exchange Commission filings under ``Risk Factors,`` including risks relating to license agreements; dependence on third parties; future capital needs.
SOURCE: Genetic Technologies; Nanogen
Tuesday April 23, 8:03 am Eastern Time
Press Release
SOURCE: Nanogen, Inc.
Nanogen to Hold Conference Call on 2002 First Quarter Financial Results
SAN DIEGO, Calif.--(BUSINESS WIRE)--April 23, 2002--Nanogen, Inc. (Nasdaq:NGEN - news) will hold a conference call on Tuesday, April 30, 2002 at 4:30 p.m. Eastern Time to discuss 2001 year-end and fourth quarter financial results. The earnings release will be issued at close of market April 30, 2002
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived until May 5, 2002. A digital recording will be available two hours after the completion of the conference from April 30, 2002 to May 5, 2002, which may be accessed via telephone at (800) 642-7687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 3905172, will be required to listen to the playback.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Nanogen, Inc.
Gerard A. Wills, 858/410-4605
gwills@nanogen.com
or
Media:
Susan E. Atkins & Associates
Tom Baker, 858/860-0266 Ext. 126
tbaker@nanogen.com
Press Release
SOURCE: Nanogen, Inc.
Nanogen to Hold Conference Call on 2002 First Quarter Financial Results
SAN DIEGO, Calif.--(BUSINESS WIRE)--April 23, 2002--Nanogen, Inc. (Nasdaq:NGEN - news) will hold a conference call on Tuesday, April 30, 2002 at 4:30 p.m. Eastern Time to discuss 2001 year-end and fourth quarter financial results. The earnings release will be issued at close of market April 30, 2002
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived until May 5, 2002. A digital recording will be available two hours after the completion of the conference from April 30, 2002 to May 5, 2002, which may be accessed via telephone at (800) 642-7687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 3905172, will be required to listen to the playback.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption ``Factors That May Affect Results`` and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Nanogen, Inc.
Gerard A. Wills, 858/410-4605
gwills@nanogen.com
or
Media:
Susan E. Atkins & Associates
Tom Baker, 858/860-0266 Ext. 126
tbaker@nanogen.com
Nanogen Appoints Unilab CEO Robert E. Whalen to Board of Directors
SAN DIEGO, Apr 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today the appointment of Robert E. Whalen to the Company`s Board of Directors. Mr. Whalen brings to Nanogen over 23 years of senior executive management experience in the clinical laboratory and healthcare fields, where he is currently serving as President, Chief Executive Officer and Director of Unilab, California`s largest provider of clinical laboratory services.
"We welcome Bob and look forward to the strategic guidance he will offer Nanogen in its entry into the molecular diagnostics market," said Howard C. Birndorf, Chairman of the Board and Executive Chairman of Nanogen. "His experience at the executive level of clinical laboratories and understanding of the industry`s technological demands for sustained growth will be a valuable asset to our organization`s efforts to offer a state-of-the-art gene-based testing platform. Bob`s appointment is part of a continuing process to bring broad diagnostics expertise to Nanogen."
Prior to Unilab, Mr. Whalen served as Executive Vice President and Chief Operating Officer of Scripps Clinic, a 320-physician multi-specialty medical group located in Southern California. Mr. Whalen held various senior level positions with National Health Laboratories, and following the merger with Roche Biomedical Laboratories, he served as Executive Vice President of Laboratory Corporation of America.
In other news, Nanogen announced that Cam L. Garner, Chairman of the Board of Xcel Pharmaceuticals, will not seek re-election to its Board of Directors but will complete his current term which expires in June. Mr. Birndorf commented, "Cam came on our Board in September 1997 and helped us take the Company through its initial public offering in 1998. He has been a great asset in helping the Company transition from a research and development company to one that is highly focused on molecular diagnostics today. During Cam`s five years on the Board, his knowledge, expertise and assistance to the Company were invaluable. We appreciate Cam`s many significant contributions to Nanogen and wish him well in his future endeavors."
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X87788931
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President and CFO of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Atkins & Associates,
+1-858-527-3493, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Apr 30, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today the appointment of Robert E. Whalen to the Company`s Board of Directors. Mr. Whalen brings to Nanogen over 23 years of senior executive management experience in the clinical laboratory and healthcare fields, where he is currently serving as President, Chief Executive Officer and Director of Unilab, California`s largest provider of clinical laboratory services.
"We welcome Bob and look forward to the strategic guidance he will offer Nanogen in its entry into the molecular diagnostics market," said Howard C. Birndorf, Chairman of the Board and Executive Chairman of Nanogen. "His experience at the executive level of clinical laboratories and understanding of the industry`s technological demands for sustained growth will be a valuable asset to our organization`s efforts to offer a state-of-the-art gene-based testing platform. Bob`s appointment is part of a continuing process to bring broad diagnostics expertise to Nanogen."
Prior to Unilab, Mr. Whalen served as Executive Vice President and Chief Operating Officer of Scripps Clinic, a 320-physician multi-specialty medical group located in Southern California. Mr. Whalen held various senior level positions with National Health Laboratories, and following the merger with Roche Biomedical Laboratories, he served as Executive Vice President of Laboratory Corporation of America.
In other news, Nanogen announced that Cam L. Garner, Chairman of the Board of Xcel Pharmaceuticals, will not seek re-election to its Board of Directors but will complete his current term which expires in June. Mr. Birndorf commented, "Cam came on our Board in September 1997 and helped us take the Company through its initial public offering in 1998. He has been a great asset in helping the Company transition from a research and development company to one that is highly focused on molecular diagnostics today. During Cam`s five years on the Board, his knowledge, expertise and assistance to the Company were invaluable. We appreciate Cam`s many significant contributions to Nanogen and wish him well in his future endeavors."
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X87788931
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President and CFO of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Atkins & Associates,
+1-858-527-3493, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Tuesday April 30, 4:00 pm Eastern Time
Press Release
SOURCE: Nanogen, Inc.
Nanogen Reports 2002 First Quarter Results; Product Revenues Triple Over Prior Year
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) today announced its financial results for the first quarter ended March 31, 2002.
Product revenues for the first quarter were $812,000, more than three times the total for the first quarter of 2001 of $229,000. During the current quarter, seven NanoChip® Molecular Biology Workstations were sold and four additional non-title transfer transactions were initiated. Two of the seven units sold during the current quarter were Nanogen`s first systems sold in Japan by Hitachi Instruments. Nanogen recognizes a royalty on the sale of instruments in Japan that is included under product revenues. Total revenues for the first quarter ended March 31, 2002 were $1.5 million compared to $2.9 million for the same period in 2001. The decline in total revenues was due to an anticipated decrease in revenues earned in connection with sponsored research programs as the Company`s revenue base continues its transition from primarily sponsored research revenues to product revenues. Notably, the Company continued to increase its percentage of product driven revenues, as 53% of total revenues for the current quarter came from product revenues, compared to 30% for the fourth quarter of 2001 and 8% for the first quarter of 2001. Product revenue recognized during the first quarter ended March 31, 2002 primarily included sales of the Company`s NanoChip® Molecular Biology Workstation.
The Company`s cash, cash equivalents and short-term investment balance at March 31, 2002 was $59.5 million. Total operating expenses for the first quarter of 2002 were $9.8 million, as compared to $10.5 million for the same period in 2001 and $10.6 million for the three months ended December 31, 2001. The Company`s reported net loss for the quarter ended March 31, 2002 was $7.5 million or $0.35 per share, compared to a net loss of $6.3 million or $0.30 per share, for the same period in 2001.
"This quarter we achieved an important milestone by introducing the Company`s first Analyte Specific Reagent (ASR), designed for the detection of Factor V Leiden that can be used on the NanoChip® System," said Howard C. Birndorf, Chairman of the Board and Executive Chairman of Nanogen. "This was accomplished by putting in place policies and procedures that enable us to meet the Quality System Regulations, or QSRs, in our facilities. These are regulatory requirements of the FDA that are intended to ensure the quality of medical devices and related products. We are now positioned to expand our current product offerings to include ASRs for CLIA-approved laboratories. This capability is important to our strategy as it increases the potential for revenue capture for every assay performed on the NanoChip® System."
"We are encouraged by our continued shift toward product revenues," said Randy White, Chief Executive Officer of Nanogen. "As importantly, we are expanding our global reach, having placed 11 systems across Europe, Japan, Mexico and the United States, and realizing our first workstation sales through Hitachi in Japan. On the technology front, we have continued our progress toward launching an ASR for cystic fibrosis, as well as offering SDA amplification, a cost-effective alternative for DNA amplification, both of which we believe will create more value for our system and customers."
Webcast of Conference Call
Nanogen management will host a conference call to discuss the first quarter financial results today at 4:30 p.m. Eastern Time. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com . A telephone replay will be available approximately two hours following the conference call until 11:59 p.m. Eastern Time on May 2, 2002, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants, passcode ID #3905172. The webcast will also be archived on Nanogen`s website through May 14, 2002.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether regulatory clearances or approvals will be obtained, whether patented inventions can be successfully incorporated into commercial products, whether Nanogen will be successful in developing FDA-approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
March 31, December 31,
2002 2001
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $7,126 $10,455
Short-term investments 52,393 57,069
Receivables, net 2,285 4,380
Inventories, net 5,879 4,688
Other current assets 1,656 2,473
Total current assets 69,339 79,065
Property and equipment, net 4,914 5,386
Acquired technology rights, net 4,327 4,183
Other assets, net 1,147 1,158
Restricted cash 299 299
$80,026 $90,091
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $835 $1,051
Accrued liabilities 3,953 4,916
Deferred revenue 458 522
Current portion of capital lease obligations 963 1,060
Total current liabilities 6,209 7,549
Capital lease obligations, less current portion 1,433 1,755
Other long-term liabilities 1,659 1,675
Total long-term liabilities 3,092 3,430
Minority interest in consolidated subsidiary 3,401 4,183
Stockholders` equity:
Convertible preferred stock, $.001 par value,
5,000,000 shares authorized; no shares issued and
outstanding at March 31, 2002 and December 31, 2001 -- --
Common stock, $.001 par value, 50,000,000 shares
authorized; 21,653,015 and 21,616,172 shares
issued and outstanding at March 31, 2002 and
December 31, 2001, respectively 22 22
Additional paid-in capital 198,563 198,387
Accumulated other comprehensive income 901 1,253
Deferred compensation (219) (336)
Notes receivable from officers (998) (984)
Accumulated deficit (130,945) (123,413)
Total stockholders` equity 67,324 74,929
$80,026 $90,091
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended March 31,
2002 2001
Revenues:
Sales $812 $229
Sponsored research 313 2,346
Contract and grant 408 364
Total revenues 1,533 2,939
Operating expenses:
Cost of sales 557 170
Research and development 4,280 4,786
Selling, general and administrative 4,972 4,784
Litigation and settlement of patent matter -- 798
Total operating expenses 9,809 10,538
Loss from operations (8,276) (7,599)
Interest income, net 729 1,320
Other income 15 --
Net loss $(7,532) $(6,279)
Net loss per share - basic and diluted $(0.35) $(0.30)
Number of shares used in computing net loss per
share - basic and diluted 21,620 20,655
SOURCE: Nanogen, Inc.
Press Release
SOURCE: Nanogen, Inc.
Nanogen Reports 2002 First Quarter Results; Product Revenues Triple Over Prior Year
SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - news) today announced its financial results for the first quarter ended March 31, 2002.
Product revenues for the first quarter were $812,000, more than three times the total for the first quarter of 2001 of $229,000. During the current quarter, seven NanoChip® Molecular Biology Workstations were sold and four additional non-title transfer transactions were initiated. Two of the seven units sold during the current quarter were Nanogen`s first systems sold in Japan by Hitachi Instruments. Nanogen recognizes a royalty on the sale of instruments in Japan that is included under product revenues. Total revenues for the first quarter ended March 31, 2002 were $1.5 million compared to $2.9 million for the same period in 2001. The decline in total revenues was due to an anticipated decrease in revenues earned in connection with sponsored research programs as the Company`s revenue base continues its transition from primarily sponsored research revenues to product revenues. Notably, the Company continued to increase its percentage of product driven revenues, as 53% of total revenues for the current quarter came from product revenues, compared to 30% for the fourth quarter of 2001 and 8% for the first quarter of 2001. Product revenue recognized during the first quarter ended March 31, 2002 primarily included sales of the Company`s NanoChip® Molecular Biology Workstation.
The Company`s cash, cash equivalents and short-term investment balance at March 31, 2002 was $59.5 million. Total operating expenses for the first quarter of 2002 were $9.8 million, as compared to $10.5 million for the same period in 2001 and $10.6 million for the three months ended December 31, 2001. The Company`s reported net loss for the quarter ended March 31, 2002 was $7.5 million or $0.35 per share, compared to a net loss of $6.3 million or $0.30 per share, for the same period in 2001.
"This quarter we achieved an important milestone by introducing the Company`s first Analyte Specific Reagent (ASR), designed for the detection of Factor V Leiden that can be used on the NanoChip® System," said Howard C. Birndorf, Chairman of the Board and Executive Chairman of Nanogen. "This was accomplished by putting in place policies and procedures that enable us to meet the Quality System Regulations, or QSRs, in our facilities. These are regulatory requirements of the FDA that are intended to ensure the quality of medical devices and related products. We are now positioned to expand our current product offerings to include ASRs for CLIA-approved laboratories. This capability is important to our strategy as it increases the potential for revenue capture for every assay performed on the NanoChip® System."
"We are encouraged by our continued shift toward product revenues," said Randy White, Chief Executive Officer of Nanogen. "As importantly, we are expanding our global reach, having placed 11 systems across Europe, Japan, Mexico and the United States, and realizing our first workstation sales through Hitachi in Japan. On the technology front, we have continued our progress toward launching an ASR for cystic fibrosis, as well as offering SDA amplification, a cost-effective alternative for DNA amplification, both of which we believe will create more value for our system and customers."
Webcast of Conference Call
Nanogen management will host a conference call to discuss the first quarter financial results today at 4:30 p.m. Eastern Time. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com . A telephone replay will be available approximately two hours following the conference call until 11:59 p.m. Eastern Time on May 2, 2002, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants, passcode ID #3905172. The webcast will also be archived on Nanogen`s website through May 14, 2002.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether regulatory clearances or approvals will be obtained, whether patented inventions can be successfully incorporated into commercial products, whether Nanogen will be successful in developing FDA-approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
March 31, December 31,
2002 2001
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $7,126 $10,455
Short-term investments 52,393 57,069
Receivables, net 2,285 4,380
Inventories, net 5,879 4,688
Other current assets 1,656 2,473
Total current assets 69,339 79,065
Property and equipment, net 4,914 5,386
Acquired technology rights, net 4,327 4,183
Other assets, net 1,147 1,158
Restricted cash 299 299
$80,026 $90,091
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $835 $1,051
Accrued liabilities 3,953 4,916
Deferred revenue 458 522
Current portion of capital lease obligations 963 1,060
Total current liabilities 6,209 7,549
Capital lease obligations, less current portion 1,433 1,755
Other long-term liabilities 1,659 1,675
Total long-term liabilities 3,092 3,430
Minority interest in consolidated subsidiary 3,401 4,183
Stockholders` equity:
Convertible preferred stock, $.001 par value,
5,000,000 shares authorized; no shares issued and
outstanding at March 31, 2002 and December 31, 2001 -- --
Common stock, $.001 par value, 50,000,000 shares
authorized; 21,653,015 and 21,616,172 shares
issued and outstanding at March 31, 2002 and
December 31, 2001, respectively 22 22
Additional paid-in capital 198,563 198,387
Accumulated other comprehensive income 901 1,253
Deferred compensation (219) (336)
Notes receivable from officers (998) (984)
Accumulated deficit (130,945) (123,413)
Total stockholders` equity 67,324 74,929
$80,026 $90,091
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended March 31,
2002 2001
Revenues:
Sales $812 $229
Sponsored research 313 2,346
Contract and grant 408 364
Total revenues 1,533 2,939
Operating expenses:
Cost of sales 557 170
Research and development 4,280 4,786
Selling, general and administrative 4,972 4,784
Litigation and settlement of patent matter -- 798
Total operating expenses 9,809 10,538
Loss from operations (8,276) (7,599)
Interest income, net 729 1,320
Other income 15 --
Net loss $(7,532) $(6,279)
Net loss per share - basic and diluted $(0.35) $(0.30)
Number of shares used in computing net loss per
share - basic and diluted 21,620 20,655
SOURCE: Nanogen, Inc.
Nanogen Announces Appointment of Senior Vice President of Operations
SAN DIEGO, May 8, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Veteran of Diagnostics Industry to Lead Product Development and Manufacturing -
Nanogen, Inc. (Nasdaq: NGEN) announced the appointment of David Macdonald as Senior Vice President of Operations. Mr. Macdonald brings to Nanogen over 22 years of relevant diagnostic product experience, having served as President and COO of Nichols Institute Diagnostics, a division of Quest Diagnostics, and most recently as President and CEO of both Progeny Systems and Medical Electronic Systems. Under Mr. Macdonald`s leadership, both Progeny Systems and Medical Electronics Systems achieved profitability and positive cash flow in eighteen months. Reporting to Dr. Randy White, Chief Executive Officer of Nanogen, Mr. Macdonald will be responsible for leading the product development, manufacturing and operations teams.
"We are excited to bring on David as a key member of the Nanogen management team and look forward to his executive leadership and guidance as we expand out product offerings," said Dr. Randy White, Chief Executive Officer of Nanogen. "David`s expertise in developing and marketing diagnostic products will be extremely valuable as we prepare to launch our cystic fibrosis Analyte Specific Reagent (ASR) as well as other products to further expand our menu and increase our potential consumable revenue capture. We believe this will put us one step closer to becoming a leader in the emerging and fast growing molecular diagnostics market."
Prior to his positions at Progeny Systems and Medical Electronics Systems, Mr. Macdonald served as President and Chief Operating Officer of Nichols Institute Diagnostics, where he assisted in the transition of the company from manually performed diagnostic tests to fully automated diagnostic systems. From 1988 to 1992, he was Director of Operations for Behring Diagnostics, where he helped develop and launch the Opus line of diagnostic systems for use in hospital and reference laboratories. Mr. Macdonald holds a B.S. degree in Business Administration from Northwestern University and an MBA from Babson College.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X07063171
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker of Atkins + Associates, +1-858-527-3493, Media
Relations for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, May 8, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Veteran of Diagnostics Industry to Lead Product Development and Manufacturing -
Nanogen, Inc. (Nasdaq: NGEN) announced the appointment of David Macdonald as Senior Vice President of Operations. Mr. Macdonald brings to Nanogen over 22 years of relevant diagnostic product experience, having served as President and COO of Nichols Institute Diagnostics, a division of Quest Diagnostics, and most recently as President and CEO of both Progeny Systems and Medical Electronic Systems. Under Mr. Macdonald`s leadership, both Progeny Systems and Medical Electronics Systems achieved profitability and positive cash flow in eighteen months. Reporting to Dr. Randy White, Chief Executive Officer of Nanogen, Mr. Macdonald will be responsible for leading the product development, manufacturing and operations teams.
"We are excited to bring on David as a key member of the Nanogen management team and look forward to his executive leadership and guidance as we expand out product offerings," said Dr. Randy White, Chief Executive Officer of Nanogen. "David`s expertise in developing and marketing diagnostic products will be extremely valuable as we prepare to launch our cystic fibrosis Analyte Specific Reagent (ASR) as well as other products to further expand our menu and increase our potential consumable revenue capture. We believe this will put us one step closer to becoming a leader in the emerging and fast growing molecular diagnostics market."
Prior to his positions at Progeny Systems and Medical Electronics Systems, Mr. Macdonald served as President and Chief Operating Officer of Nichols Institute Diagnostics, where he assisted in the transition of the company from manually performed diagnostic tests to fully automated diagnostic systems. From 1988 to 1992, he was Director of Operations for Behring Diagnostics, where he helped develop and launch the Opus line of diagnostic systems for use in hospital and reference laboratories. Mr. Macdonald holds a B.S. degree in Business Administration from Northwestern University and an MBA from Babson College.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X07063171
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker of Atkins + Associates, +1-858-527-3493, Media
Relations for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Nanogen to Present at BIO 2002 International Convention And Exhibition on June 10
SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that the Company will participate in the Investor Forum at the 16th Annual BIO 2002 International Convention and Exhibition and will present on Monday, June 10, 2002 at 8:30 AM Eastern Time. Gerard A. Wills, Chief Financial Officer of Nanogen, will provide a brief corporate overview and discuss the Company`s strategy for becoming a leading provider of molecular diagnostic tests.
Nanogen invites you to access Mr. Wills` audio and slide presentation via live webcast on Nanogen`s corporate website at www.nanogen.com under the Investor/News section. The presentation will be archived on the Company`s website for 90 days.
In addition, Mr. Wills will participate in a panel session titled "Attracting Financing in Good and Bad Times" on Monday, June 10 from 10:30 AM to 12:00 PM. Mr. Wills will discuss current fundraising options in today`s bear market, including several types of private placements. For more information on the conference, you can visit BIO`s website at http://www.bio2002.org /.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X67315888
SOURCE Nanogen, Inc.
-0- 06/03/2002
/CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc., +1-858-410-4605; or Tom Baker, Media Relations of Atkins + Associates, +1-858-527-3493, for Nanogen, Inc./
/Web site: http://www.nanogen.com
SAN DIEGO, June 3 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that the Company will participate in the Investor Forum at the 16th Annual BIO 2002 International Convention and Exhibition and will present on Monday, June 10, 2002 at 8:30 AM Eastern Time. Gerard A. Wills, Chief Financial Officer of Nanogen, will provide a brief corporate overview and discuss the Company`s strategy for becoming a leading provider of molecular diagnostic tests.
Nanogen invites you to access Mr. Wills` audio and slide presentation via live webcast on Nanogen`s corporate website at www.nanogen.com under the Investor/News section. The presentation will be archived on the Company`s website for 90 days.
In addition, Mr. Wills will participate in a panel session titled "Attracting Financing in Good and Bad Times" on Monday, June 10 from 10:30 AM to 12:00 PM. Mr. Wills will discuss current fundraising options in today`s bear market, including several types of private placements. For more information on the conference, you can visit BIO`s website at http://www.bio2002.org /.
Nanogen`s goal is to become the leading provider of electronic microarray technology with the required accuracy, simplicity and flexibility necessary to bridge the gap between the research and clinical setting in genomics-based diagnostics. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X67315888
SOURCE Nanogen, Inc.
-0- 06/03/2002
/CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc., +1-858-410-4605; or Tom Baker, Media Relations of Atkins + Associates, +1-858-527-3493, for Nanogen, Inc./
/Web site: http://www.nanogen.com
Nanogen Expands Genetic Content Patent Portfolio
SAN DIEGO, Jun 4, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Announces Issuance of Patent for Method of Detection for Hereditary Hemochromatosis -
Nanogen, Inc. (Nasdaq: NGEN) announced today the issuance of U.S Patent No. 6,355,425 (the "`425 patent") entitled "Mutations Associated with Iron Disorders" relating to methods for the detection of certain mutations linked to Hereditary Hemochromatosis ("HH"). HH is a genetically inherited disease that results in excess storage of iron, principally in the liver and bone joints. Nanogen has had an exclusive license to the `425 patent from Billups-Rothenberg, Inc. and Dr. Barry E. Rothenberg since 1998.
The `425 patent addresses identification and detection of mutations in the HFE gene, which is critical to diagnosing HH. Under this patent, Nanogen has exclusive rights to S65c, one of the three common mutations in the HFE gene. The three combined mutations are present in approximately 94% of HH cases identified in the United States. In 2001, Nanogen developed a protocol for S65c and plans to introduce a consumable Analyte Specific Reagent ("ASR") for this and possibly other HH mutations by the end of 2002.
"HH is one of the most common genetic diseases in Caucasian populations, yet because the disease is asymptomatic until fully expressed, it remains both underdiagnosed and often misdiagnosed," said Dr. Randy White, Chief Executive Officer of Nanogen. "The claims of the `425 patent will allow us to continue development of diagnostics in this area, with an objective of providing a more cost-effective and accurate means of detection. Early detection and treatment for HH can potentially lead to improved patient care and lowered healthcare costs."
Dr. White continued, "We anticipate the introduction of an HH ASR later this year. The introduction of clinically-valuable reagent sets is an important step in our business plan, moving us closer to our key objectives of increasing workstation placements and consumable revenues."
Iron plays an essential role in normal growth and development, but in elevated concentrations, iron is toxic to many of the body`s vital organs. Without proper treatment, the excess iron storage associated with HH can lead to a number of common diseases including hepatitis, cancer, diabetes, heart disease and AIDS. If caught early, however, HH is easily treated with regular blood donations. The disorder affects about 1 in every 300 Caucasians and 1 in 9 is a carrier of the HFE gene. Diagnosis of HH in patients with clinical symptoms is usually based on the measurement of iron levels in serum or tissue. However, with the discovery of the HFE gene in 1996, DNA testing can be a valuable tool in determining the prognosis for HH.
Nanogen`s goal is to become a leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X37751105
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Atkins & Associates,
+1-858-527-3493, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Jun 4, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Announces Issuance of Patent for Method of Detection for Hereditary Hemochromatosis -
Nanogen, Inc. (Nasdaq: NGEN) announced today the issuance of U.S Patent No. 6,355,425 (the "`425 patent") entitled "Mutations Associated with Iron Disorders" relating to methods for the detection of certain mutations linked to Hereditary Hemochromatosis ("HH"). HH is a genetically inherited disease that results in excess storage of iron, principally in the liver and bone joints. Nanogen has had an exclusive license to the `425 patent from Billups-Rothenberg, Inc. and Dr. Barry E. Rothenberg since 1998.
The `425 patent addresses identification and detection of mutations in the HFE gene, which is critical to diagnosing HH. Under this patent, Nanogen has exclusive rights to S65c, one of the three common mutations in the HFE gene. The three combined mutations are present in approximately 94% of HH cases identified in the United States. In 2001, Nanogen developed a protocol for S65c and plans to introduce a consumable Analyte Specific Reagent ("ASR") for this and possibly other HH mutations by the end of 2002.
"HH is one of the most common genetic diseases in Caucasian populations, yet because the disease is asymptomatic until fully expressed, it remains both underdiagnosed and often misdiagnosed," said Dr. Randy White, Chief Executive Officer of Nanogen. "The claims of the `425 patent will allow us to continue development of diagnostics in this area, with an objective of providing a more cost-effective and accurate means of detection. Early detection and treatment for HH can potentially lead to improved patient care and lowered healthcare costs."
Dr. White continued, "We anticipate the introduction of an HH ASR later this year. The introduction of clinically-valuable reagent sets is an important step in our business plan, moving us closer to our key objectives of increasing workstation placements and consumable revenues."
Iron plays an essential role in normal growth and development, but in elevated concentrations, iron is toxic to many of the body`s vital organs. Without proper treatment, the excess iron storage associated with HH can lead to a number of common diseases including hepatitis, cancer, diabetes, heart disease and AIDS. If caught early, however, HH is easily treated with regular blood donations. The disorder affects about 1 in every 300 Caucasians and 1 in 9 is a carrier of the HFE gene. Diagnosis of HH in patients with clinical symptoms is usually based on the measurement of iron levels in serum or tissue. However, with the discovery of the HFE gene in 1996, DNA testing can be a valuable tool in determining the prognosis for HH.
Nanogen`s goal is to become a leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X37751105
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Atkins & Associates,
+1-858-527-3493, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Hier nochmal die News ohne Link:
Nanogen and Centers For Disease Control and Prevention Begin Gene-Based E. coli Assay Development Collaboration
SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced it has entered into a Development Site Agreement with the Centers for Disease Control and Prevention (CDC) and will shortly begin installation of a NanoChip(R) Molecular Biology Workstation at the CDC`s Foodborne and Diarrheal Diseases Branch in Atlanta, Georgia. Under this Agreement, Drs. Balasubra Swaminathan and Nancy Strockbine of the CDC will be principal investigators and will seek to develop methods for simultaneously detecting specific strains of diarrheal Escherichia coli (E. coli) and other pathogens on the NanoChip(R) System. In exchange, Nanogen will receive certain licensing and commercialization rights to the assays developed by the CDC. Additionally, the collaboration may eventually lead to the development by Nanogen of certain molecular diagnostic test protocols and other products to be performed on the NanoChip(R) System.
"We look forward to working with the CDC in this very important area of infectious diseases," said Dr. Randy White, Chief Executive Officer of Nanogen. "Our platform, we believe, offers our customers the versatility and accuracy needed to develop new ways of detection of multiple pathogens, such as E. coli, anthrax and smallpox. Furthermore, we will continue to enter collaborations such as this, which enable the use of our platform in various markets while complementing our core focus on human diagnostics."
Nanogen`s Development Site Program was established to actively collaborate with selected customers in strategically important market segments (including clinical research, the research divisions of reference diagnostic laboratories and genomics, pharmaceutical, biotechnology and agrochemical companies) in their development of assays on the Nanogen platform. Under these agreements, collaborating companies and institutions provide expertise and certain rights to intellectual property in exchange for preferential access to Nanogen`s technology. After the conclusion of the program, the collaborating institutions may purchase the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridges for use in their operations.
Centers for Disease Control and Prevention
The Centers for Disease Control and Prevention (CDC) protects people`s health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national and international organizations.
Reference to the Centers for Disease Control and Prevention does not imply governmental endorsement of Nanogen products or services.
Nanogen, Inc.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip(R) System and NanoChip(R) Cartridges, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X15869354
SOURCE Nanogen, Inc.
-0- 06/06/2002
/CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc., +1-858-410-4605; or Tom Baker, Media Relations of Atkins + Associates, +1-858-527-3493, for Nanogen, Inc./
Nanogen and Centers For Disease Control and Prevention Begin Gene-Based E. coli Assay Development Collaboration
SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced it has entered into a Development Site Agreement with the Centers for Disease Control and Prevention (CDC) and will shortly begin installation of a NanoChip(R) Molecular Biology Workstation at the CDC`s Foodborne and Diarrheal Diseases Branch in Atlanta, Georgia. Under this Agreement, Drs. Balasubra Swaminathan and Nancy Strockbine of the CDC will be principal investigators and will seek to develop methods for simultaneously detecting specific strains of diarrheal Escherichia coli (E. coli) and other pathogens on the NanoChip(R) System. In exchange, Nanogen will receive certain licensing and commercialization rights to the assays developed by the CDC. Additionally, the collaboration may eventually lead to the development by Nanogen of certain molecular diagnostic test protocols and other products to be performed on the NanoChip(R) System.
"We look forward to working with the CDC in this very important area of infectious diseases," said Dr. Randy White, Chief Executive Officer of Nanogen. "Our platform, we believe, offers our customers the versatility and accuracy needed to develop new ways of detection of multiple pathogens, such as E. coli, anthrax and smallpox. Furthermore, we will continue to enter collaborations such as this, which enable the use of our platform in various markets while complementing our core focus on human diagnostics."
Nanogen`s Development Site Program was established to actively collaborate with selected customers in strategically important market segments (including clinical research, the research divisions of reference diagnostic laboratories and genomics, pharmaceutical, biotechnology and agrochemical companies) in their development of assays on the Nanogen platform. Under these agreements, collaborating companies and institutions provide expertise and certain rights to intellectual property in exchange for preferential access to Nanogen`s technology. After the conclusion of the program, the collaborating institutions may purchase the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridges for use in their operations.
Centers for Disease Control and Prevention
The Centers for Disease Control and Prevention (CDC) protects people`s health and safety by preventing and controlling diseases and injuries; enhances health decisions by providing credible information on critical health issues; and promotes healthy living through strong partnerships with local, national and international organizations.
Reference to the Centers for Disease Control and Prevention does not imply governmental endorsement of Nanogen products or services.
Nanogen, Inc.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip(R) System and NanoChip(R) Cartridges, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X15869354
SOURCE Nanogen, Inc.
-0- 06/06/2002
/CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc., +1-858-410-4605; or Tom Baker, Media Relations of Atkins + Associates, +1-858-527-3493, for Nanogen, Inc./
Nanogen and NASA Enter Into Collaboration Agreement
SAN DIEGO, Jun 12, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Collaboration Seeks to Expand Breadth of Nanogen`s Molecular Diagnostic Products -
Nanogen, Inc. (Nasdaq: NGEN) announced today that it has entered into a collaboration agreement with the National Aeronautics and Space Administration (NASA) Ames Research Center (ARC). Under the collaboration, Nanogen has provided one of its NanoChip(R) Molecular Biology Workstations to NASA in exchange for certain commercialization rights to intellectual property and assays developed by NASA. Scientists in NASA`s Fundamental Biology Program will use the Nanogen platform to develop and validate protocols for specific Single Nucleotide Polymorphism (SNP) and Short Tandem Repeat (STR) analyses related to NASA`s mission requirements. The collaboration may eventually lead to the development and optimization of novel gene-based assays on the NanoChip(R) Molecular Biology Workstation for commercialization by Nanogen. Also, scientists in NASA`s Center for Nanotechnology will evaluate Nanogen`s NanoChip(R) technology for the potential development of certain biosensors for astrobiology and biomedical applications.
"Nanogen is pleased to enter into this agreement with NASA, one of the nation`s leading research and technology organizations, as part of our ongoing efforts to expand the breadth and depth of our product offerings," said Dr. Randy White, Chief Executive Officer of Nanogen. "Our Advanced Technologies Group has been involved in research and development designed to further the expansion of our core microelectronic platform by creating innovative designs for future bioassay systems. We believe that important collaborations such as this one with NASA, will help us expand opportunities in our core area of focus, the molecular diagnostics market, by strengthening the open-platform capabilities of the NanoChip(R) System."
"The collaboration between NASA and Nanogen is representative of our view that we must explore exciting new technologies, such as the NanoChip(R) System, to achieve NASA`s core mission," said John Hines, Technology Development Manager, NASA Fundamental Biology Program. "We believe that Nanogen possesses a unique technology capable of facilitating our efforts in two main areas: the analysis of certain SNPs and STRs to monitor the health and well-being of astronauts and other NASA personnel; and the functionalization of carbon nanotubes for biosensor applications."
NASA
NASA is an independent United States government agency. Ames Research Center was the second of NASA`s ten field centers, founded in December 20, 1939, as an aeronautics research laboratory and named for National Advisory Committee for Aeronautics (NACA) chairperson Dr. Joseph S. Ames. With over 3,500 research personnel and a $700 million annual budget, Ames plays a critical role in all NASA missions supporting the nation`s aeronautics and space programs. In fact, as the agency`s `center of excellence` for information technology, Ames conducts the enabling, leading-edge research and development that makes those missions possible. Ames is also NASA`s lead center for astrobiology, conducting research on the origin, evolution, distribution and destiny of life in the universe.
Reference to NASA does not imply governmental endorsement of Nanogen products or services.
Nanogen, Inc.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether intellectual property, inventions or products may be created under any of Nanogen`s collaborations, whether patents and other intellectual property will become commercial products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip(R) System and NanoChip(R) Cartridges, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, and ASRs, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X65519292
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Atkins + Associates,
+1-858-527-3493, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Jun 12, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Collaboration Seeks to Expand Breadth of Nanogen`s Molecular Diagnostic Products -
Nanogen, Inc. (Nasdaq: NGEN) announced today that it has entered into a collaboration agreement with the National Aeronautics and Space Administration (NASA) Ames Research Center (ARC). Under the collaboration, Nanogen has provided one of its NanoChip(R) Molecular Biology Workstations to NASA in exchange for certain commercialization rights to intellectual property and assays developed by NASA. Scientists in NASA`s Fundamental Biology Program will use the Nanogen platform to develop and validate protocols for specific Single Nucleotide Polymorphism (SNP) and Short Tandem Repeat (STR) analyses related to NASA`s mission requirements. The collaboration may eventually lead to the development and optimization of novel gene-based assays on the NanoChip(R) Molecular Biology Workstation for commercialization by Nanogen. Also, scientists in NASA`s Center for Nanotechnology will evaluate Nanogen`s NanoChip(R) technology for the potential development of certain biosensors for astrobiology and biomedical applications.
"Nanogen is pleased to enter into this agreement with NASA, one of the nation`s leading research and technology organizations, as part of our ongoing efforts to expand the breadth and depth of our product offerings," said Dr. Randy White, Chief Executive Officer of Nanogen. "Our Advanced Technologies Group has been involved in research and development designed to further the expansion of our core microelectronic platform by creating innovative designs for future bioassay systems. We believe that important collaborations such as this one with NASA, will help us expand opportunities in our core area of focus, the molecular diagnostics market, by strengthening the open-platform capabilities of the NanoChip(R) System."
"The collaboration between NASA and Nanogen is representative of our view that we must explore exciting new technologies, such as the NanoChip(R) System, to achieve NASA`s core mission," said John Hines, Technology Development Manager, NASA Fundamental Biology Program. "We believe that Nanogen possesses a unique technology capable of facilitating our efforts in two main areas: the analysis of certain SNPs and STRs to monitor the health and well-being of astronauts and other NASA personnel; and the functionalization of carbon nanotubes for biosensor applications."
NASA
NASA is an independent United States government agency. Ames Research Center was the second of NASA`s ten field centers, founded in December 20, 1939, as an aeronautics research laboratory and named for National Advisory Committee for Aeronautics (NACA) chairperson Dr. Joseph S. Ames. With over 3,500 research personnel and a $700 million annual budget, Ames plays a critical role in all NASA missions supporting the nation`s aeronautics and space programs. In fact, as the agency`s `center of excellence` for information technology, Ames conducts the enabling, leading-edge research and development that makes those missions possible. Ames is also NASA`s lead center for astrobiology, conducting research on the origin, evolution, distribution and destiny of life in the universe.
Reference to NASA does not imply governmental endorsement of Nanogen products or services.
Nanogen, Inc.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether intellectual property, inventions or products may be created under any of Nanogen`s collaborations, whether patents and other intellectual property will become commercial products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip(R) System and NanoChip(R) Cartridges, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, and ASRs, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X65519292
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Tom Baker, Media Relations of Atkins + Associates,
+1-858-527-3493, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Monday June 17, 7:01 am Eastern Time
Press Release
SOURCE: Nanogen, Inc.
Nanogen Reports on Its Annual Stockholders` Meeting; Company Announces Additions to Management Team
SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) today reported highlights from its annual stockholders` meeting held today in San Diego, California. Howard C. Birndorf, Nanogen`s Executive Chairman and Chairman of the Board, presided over the business section of the meeting at which the stockholders elected two directors for a three-year term. In addition, the stockholders approved a proposal to amend the 1997 Stock Incentive Plan to increase the aggregate shares reserved for issuance and a proposal to adopt Nanogen`s 2002 Stock Bonus Plan. Lastly, the stockholders ratified the selection of Ernst & Young LLP as Nanogen`s independent auditors for the fiscal year ending December 31, 2002.
"We are extremely pleased with our progress to date in capitalizing on the commercial opportunity of molecular diagnostics," said Dr. Randy White, Chief Executive Officer of Nanogen. "We have been successful in bringing on senior management with combined experience in diagnostics of over 125 years, adding senior management to our worldwide sales force, further developing our commercial products in the form of protocols and Analyte Specific Reagents (ASRs) and by making further technological improvements to our NanoChip® platform."
During the meeting, Nanogen reviewed its anticipated milestones for 2002. To summarize, the Company reiterated its plans to achieve its initial customer launch of a cystic fibrosis ASR by the end of the second quarter as previously announced; add 10 new ASRs before year-end, one of which will be a 3-SNP assay for hereditary hemochromatosis; and continue pursuing government contracts for biowarfare applications.
The Company also provided an update on its recent board and management additions, all of which support the shift toward commercialization of molecular diagnostics. As mentioned above, Robert E. Whalen, Chief Executive Officer of Unilab, was formally elected to the board and Mr. Birndorf was re-elected to his position as Chairman. Additionally, Joseph G. Turgeon has been appointed as Vice President of Operations and Mary Holland has joined the Company as Senior Director of Worldwide Corporate Accounts.
Mr. Turgeon brings to Nanogen over 23 years of relevant diagnostic systems experience. Prior to Nanogen, he served as Vice President of Operations at Progeny Systems and Medical Electronics Systems in San Diego as well as Director of Operations at the Nichols Institute, a wholly owned subsidiary of Quest Diagnostics. Mr. Turgeon will be responsible for managing the facilities, materials and reagent production groups and for product support activities of the operations group.
Ms. Holland brings 19 years of experience in the diagnostics industry. She has held senior level roles in sales, business development and corporate accounts with Third Wave Technologies for seven years and was a co-founder of Oncogenetics, Inc., a genetics and cancer diagnostics research laboratory. She has also served in commercial roles for Diagnostic Products Corporation, Genetrix, Inc. and Vivigen, Inc.
In other news, the Company reported that Dr. Regina Herzlinger has stepped down from her position on the Company`s board of directors. "We thank Regina for her contribution and strategic guidance while on the Nanogen board and wish her well in her future endeavors," said Mr. Birndorf.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether intellectual property, inventions or products may be created under any of Nanogen`s collaborations, whether patents and other intellectual property will become commercial products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip® System and NanoChip® Cartridges, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, and ASRs, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
Press Release
SOURCE: Nanogen, Inc.
Nanogen Reports on Its Annual Stockholders` Meeting; Company Announces Additions to Management Team
SAN DIEGO, June 17 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) today reported highlights from its annual stockholders` meeting held today in San Diego, California. Howard C. Birndorf, Nanogen`s Executive Chairman and Chairman of the Board, presided over the business section of the meeting at which the stockholders elected two directors for a three-year term. In addition, the stockholders approved a proposal to amend the 1997 Stock Incentive Plan to increase the aggregate shares reserved for issuance and a proposal to adopt Nanogen`s 2002 Stock Bonus Plan. Lastly, the stockholders ratified the selection of Ernst & Young LLP as Nanogen`s independent auditors for the fiscal year ending December 31, 2002.
"We are extremely pleased with our progress to date in capitalizing on the commercial opportunity of molecular diagnostics," said Dr. Randy White, Chief Executive Officer of Nanogen. "We have been successful in bringing on senior management with combined experience in diagnostics of over 125 years, adding senior management to our worldwide sales force, further developing our commercial products in the form of protocols and Analyte Specific Reagents (ASRs) and by making further technological improvements to our NanoChip® platform."
During the meeting, Nanogen reviewed its anticipated milestones for 2002. To summarize, the Company reiterated its plans to achieve its initial customer launch of a cystic fibrosis ASR by the end of the second quarter as previously announced; add 10 new ASRs before year-end, one of which will be a 3-SNP assay for hereditary hemochromatosis; and continue pursuing government contracts for biowarfare applications.
The Company also provided an update on its recent board and management additions, all of which support the shift toward commercialization of molecular diagnostics. As mentioned above, Robert E. Whalen, Chief Executive Officer of Unilab, was formally elected to the board and Mr. Birndorf was re-elected to his position as Chairman. Additionally, Joseph G. Turgeon has been appointed as Vice President of Operations and Mary Holland has joined the Company as Senior Director of Worldwide Corporate Accounts.
Mr. Turgeon brings to Nanogen over 23 years of relevant diagnostic systems experience. Prior to Nanogen, he served as Vice President of Operations at Progeny Systems and Medical Electronics Systems in San Diego as well as Director of Operations at the Nichols Institute, a wholly owned subsidiary of Quest Diagnostics. Mr. Turgeon will be responsible for managing the facilities, materials and reagent production groups and for product support activities of the operations group.
Ms. Holland brings 19 years of experience in the diagnostics industry. She has held senior level roles in sales, business development and corporate accounts with Third Wave Technologies for seven years and was a co-founder of Oncogenetics, Inc., a genetics and cancer diagnostics research laboratory. She has also served in commercial roles for Diagnostic Products Corporation, Genetrix, Inc. and Vivigen, Inc.
In other news, the Company reported that Dr. Regina Herzlinger has stepped down from her position on the Company`s board of directors. "We thank Regina for her contribution and strategic guidance while on the Nanogen board and wish her well in her future endeavors," said Mr. Birndorf.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed one ASR for the detection of Factor V Leiden, and internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether intellectual property, inventions or products may be created under any of Nanogen`s collaborations, whether patents and other intellectual property will become commercial products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip® System and NanoChip® Cartridges, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, and ASRs, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE: Nanogen, Inc.
Nanogen Introduces Cystic Fibrosis Analyte Specific Reagents
SAN DIEGO, Jun 27, 2002 /PRNewswire-FirstCall via COMTEX/ --
- The Company`s ASRs Are Capable of Performing Analysis of 25 Alleles of the CFTR Gene on A Microarray -
Nanogen, Inc. (Nasdaq: NGEN) announced today the initial release of Analyte Specific Reagents (ASRs), designed for the detection of the 25 gene mutations most commonly associated with cystic fibrosis (CF), to its first customer site for evaluation. Additional customer evaluations of the CF ASRs are scheduled prior to general release. Nanogen`s CF ASRs can be performed on the NanoChip(R) Molecular Biology Workstation, the first microarray capable of performing such an analysis of the CFTR gene. The format of the Company`s CF ASRs corresponds to the recommendations made in 2001 by the American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG). Both ACMG and ACOG recommend that all women contemplating pregnancy should be offered a CFTR screen by their physicians.
"Introducing the CF ASRs is an important strategic milestone we set, as it represents an opportunity for the Company to build its consumable revenue base in the future," said Dr. Randy White, Chief Executive Officer of Nanogen. "In less than nine months, we have delivered on our promise to design what is thought to be one of the most complex genetic assays being performed today, into highly accurate, cost-effective and simple-to-use ASRs. We have been advised by customers that the market for CF testing in the U.S. has grown substantially in the last year and that the market appears to continue to grow in response to the new ACMG and ACOG guidelines. The introduction of this product clearly demonstrates the strength of our NanoChip(R) platform and marks a turning point for Nanogen as a true leader in the development of molecular diagnostic tests and products."
CF is one of the most common genetic disorders in Caucasian populations of European descent, carried by about 1 in 29 Caucasians. CF is characterized by pulmonary and gastrointestinal symptoms of varying severity, but most CF cases are associated with substantial illness and shortened lifespan and require lifelong medical care. The Nanogen CF ASRs will offer an automated, multiplexed method to detect the 25 mutations most commonly associated with the CFTR gene. They may be used by CLIA-approved laboratories to screen and genotype individuals for mutations in the CFTR gene. CF is an autosomal recessive genetic disorder. To express the disease, a child must inherit two copies of the defective gene, one from each parent. Many people carry a single cystic fibrosis mutation and do not experience any significant health problems as a result. Couples who are both carriers have a one in four chance of having a child with CF.
"We believe we are well positioned to enter the CF testing market with the NanoChip(R) System due to several competitive factors favoring its adoption," said Howard T. Birndorf, Executive Chairman and Chairman of the Board of Directors of Nanogen. "First, the diagnostics industry has historically adopted platform consolidation, an attribute the NanoChip(R) Workstation can offer in the market of gene-based testing. Second, the Workstation`s flexibility will allow customers to easily add mutations to the CF ASRs for research purposes, to accommodate broad ethnic populations and perform analyses for other diseases and conditions in addition to CF. Third, the NanoChip(R) System offers the highest throughput of available methods today, and is capable of running up to 180 samples per workshift. We view this as a critical advantage following the ACMG and ACOG recommendations and their likely impact on the increases in demand."
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the genetics testing market for cystic fibrosis will eventually reach the projected sales levels described herein, whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X77477788
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, VP and CFO of Nanogen, Inc., +1-858-518-3529;
or Tom Baker of Atkins + Associates, +1-858-527-3493, Media Relations for
Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Jun 27, 2002 /PRNewswire-FirstCall via COMTEX/ --
- The Company`s ASRs Are Capable of Performing Analysis of 25 Alleles of the CFTR Gene on A Microarray -
Nanogen, Inc. (Nasdaq: NGEN) announced today the initial release of Analyte Specific Reagents (ASRs), designed for the detection of the 25 gene mutations most commonly associated with cystic fibrosis (CF), to its first customer site for evaluation. Additional customer evaluations of the CF ASRs are scheduled prior to general release. Nanogen`s CF ASRs can be performed on the NanoChip(R) Molecular Biology Workstation, the first microarray capable of performing such an analysis of the CFTR gene. The format of the Company`s CF ASRs corresponds to the recommendations made in 2001 by the American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG). Both ACMG and ACOG recommend that all women contemplating pregnancy should be offered a CFTR screen by their physicians.
"Introducing the CF ASRs is an important strategic milestone we set, as it represents an opportunity for the Company to build its consumable revenue base in the future," said Dr. Randy White, Chief Executive Officer of Nanogen. "In less than nine months, we have delivered on our promise to design what is thought to be one of the most complex genetic assays being performed today, into highly accurate, cost-effective and simple-to-use ASRs. We have been advised by customers that the market for CF testing in the U.S. has grown substantially in the last year and that the market appears to continue to grow in response to the new ACMG and ACOG guidelines. The introduction of this product clearly demonstrates the strength of our NanoChip(R) platform and marks a turning point for Nanogen as a true leader in the development of molecular diagnostic tests and products."
CF is one of the most common genetic disorders in Caucasian populations of European descent, carried by about 1 in 29 Caucasians. CF is characterized by pulmonary and gastrointestinal symptoms of varying severity, but most CF cases are associated with substantial illness and shortened lifespan and require lifelong medical care. The Nanogen CF ASRs will offer an automated, multiplexed method to detect the 25 mutations most commonly associated with the CFTR gene. They may be used by CLIA-approved laboratories to screen and genotype individuals for mutations in the CFTR gene. CF is an autosomal recessive genetic disorder. To express the disease, a child must inherit two copies of the defective gene, one from each parent. Many people carry a single cystic fibrosis mutation and do not experience any significant health problems as a result. Couples who are both carriers have a one in four chance of having a child with CF.
"We believe we are well positioned to enter the CF testing market with the NanoChip(R) System due to several competitive factors favoring its adoption," said Howard T. Birndorf, Executive Chairman and Chairman of the Board of Directors of Nanogen. "First, the diagnostics industry has historically adopted platform consolidation, an attribute the NanoChip(R) Workstation can offer in the market of gene-based testing. Second, the Workstation`s flexibility will allow customers to easily add mutations to the CF ASRs for research purposes, to accommodate broad ethnic populations and perform analyses for other diseases and conditions in addition to CF. Third, the NanoChip(R) System offers the highest throughput of available methods today, and is capable of running up to 180 samples per workshift. We view this as a critical advantage following the ACMG and ACOG recommendations and their likely impact on the increases in demand."
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the genetics testing market for cystic fibrosis will eventually reach the projected sales levels described herein, whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X77477788
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, VP and CFO of Nanogen, Inc., +1-858-518-3529;
or Tom Baker of Atkins + Associates, +1-858-527-3493, Media Relations for
Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Leicht verspätet....werde mich bessern
Wednesday July 24, 3:32 pm Eastern Time
Press Release
SOURCE: Nanogen Inc.
CORRECTED: Nanogen to Hold Conference Call on 2002 Second Quarter Financial Results
SAN DIEGO--(BUSINESS WIRE)--July 24, 2002--Nanogen, Inc. (Nasdaq:NGEN - News) will hold a conference call on Wednesday July 31, 2002 at 4:30 p.m. EST to discuss 2002 second quarter financial results. The earnings release will be issued at close of market July 31, 2002.
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived until August 14, 2002. A digital recording of the call will also be available two hours after the completion of the conference from July 31, 2002 to August 2, 2002, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 12650, will be required to listen to the playback.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Nanogen, Inc.
Gerard A. Wills, 858/410-4605
gwills@nanogen.com
or
Susan E. Atkins & Associates
Tom Baker, 858/527-3493 (Media)
tbaker@nanogen.com
Wednesday July 24, 3:32 pm Eastern Time
Press Release
SOURCE: Nanogen Inc.
CORRECTED: Nanogen to Hold Conference Call on 2002 Second Quarter Financial Results
SAN DIEGO--(BUSINESS WIRE)--July 24, 2002--Nanogen, Inc. (Nasdaq:NGEN - News) will hold a conference call on Wednesday July 31, 2002 at 4:30 p.m. EST to discuss 2002 second quarter financial results. The earnings release will be issued at close of market July 31, 2002.
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived until August 14, 2002. A digital recording of the call will also be available two hours after the completion of the conference from July 31, 2002 to August 2, 2002, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 12650, will be required to listen to the playback.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip® System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
Nanogen, Inc.
Gerard A. Wills, 858/410-4605
gwills@nanogen.com
or
Susan E. Atkins & Associates
Tom Baker, 858/527-3493 (Media)
tbaker@nanogen.com
Nucleic Acids Res 2002 Jul 15;30
Rapid parallel mutation scanning of gene fragments using a microelectronic protein-DNA chip format.
Behrensdorf HA, Pignot M, Windhab N, Kappel A.
Nanogen Recognomics GmbH, Industriepark Hoechst, Building G830, 65926 Frankfurt am Main, Germany.
We have developed a method for the de novo discovery of genetic variations, including single nucleotide polymorphisms and mutations, on microelectronic chip devices. The method combines the features of electronically controlled DNA hybridisation on open-format microarrays, with mutation detection by a fluorescence-labelled mismatch- binding protein. Electronic addressing of DNA strands to distinct test sites of the chip allows parallel analysis of several individuals, as demonstrated for mutations in different exons of the p53 gene. This microelectronic chip-based mutation discovery assay may substitute for time-consuming sequencing studies and will complement existing technologies in genomic research.
Rapid parallel mutation scanning of gene fragments using a microelectronic protein-DNA chip format.
Behrensdorf HA, Pignot M, Windhab N, Kappel A.
Nanogen Recognomics GmbH, Industriepark Hoechst, Building G830, 65926 Frankfurt am Main, Germany.
We have developed a method for the de novo discovery of genetic variations, including single nucleotide polymorphisms and mutations, on microelectronic chip devices. The method combines the features of electronically controlled DNA hybridisation on open-format microarrays, with mutation detection by a fluorescence-labelled mismatch- binding protein. Electronic addressing of DNA strands to distinct test sites of the chip allows parallel analysis of several individuals, as demonstrated for mutations in different exons of the p53 gene. This microelectronic chip-based mutation discovery assay may substitute for time-consuming sequencing studies and will complement existing technologies in genomic research.
Nanogen Reports 2002 Second Quarter Results
SAN DIEGO, Jul 31, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Records Highest Quarterly Product Revenues in Company`s History -
Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the second quarter ended June 30, 2002.
Product revenues for the second quarter were $1.1 million, more than three times the total for the second quarter of 2001 of $302,000. During the second quarter, the Company recognized revenue from the sale of eight NanoChip(R) Molecular Biology Workstations (including three sales converted from former development site customers). One additional development site was converted into a reagent rental, which represents the Company`s second transaction under its reagent rental program. Nanogen entered into three additional non-title transfer transactions during the quarter. Product revenues for the six months ended June 30, 2002 were $1.9 million compared to $531,000 for the first six months of 2001, also more than three times the prior year year-to-date total. Total revenues for the second quarter and six months ended June 30, 2002 were $2.0 million and $3.5 million, respectively, as compared to $2.7 million and $5.7 million for the same periods in the prior year. These declines in total revenues were due to anticipated decreases in revenues earned in connection with sponsored research programs as the Company`s revenue base continues its transition from primarily sponsored research revenues to product revenues. Notably, the Company continued to increase its percentage of product-driven revenues, as 57% of total revenues for the second quarter came from product revenues, compared to 11% for the second quarter of 2001. Product revenue recognized during the second quarter ended June 30, 2002 was primarily derived from sales of the Company`s NanoChip(R) Molecular Biology Workstation.
The Company`s cash, cash equivalents and short-term investments balance at June 30, 2002 was $51.7 million. Total operating expenses for the second quarter and six months ended June 30, 2002 were $11.2 million and $21.0 million, respectively, as compared to $15.6 million and $26.1 million for the same periods in the prior year. The prior year amounts included charges related to a prior patent litigation and settlement amounting to $5.5 million for the quarter and $6.3 million for the six months ended June 30, 2001. The increase in operating expenses in 2002 as compared to 2001, excluding the litigation and settlement charges, relates primarily to an increase in cost of sales in conjunction with our growing product revenues.
The Company`s net loss for the quarter ended June 30, 2002 was $8.5 million or $0.39 per share, compared to a net loss of $11.8 million or $0.56 per share (or, excluding the Motorola litigation matter, $6.2 million or $0.30 per share), for the same period in 2001. For the six months ended June 30, 2002, the Company`s reported net loss was $16.1 million or $0.74 per share, compared to a net loss of $18.0 million or $0.87 per share (or, $11.7 million or $0.56 per share absent the Motorola litigation matter), for the same period in 2001.
"We are very pleased that for the second quarter in a row we have more than tripled our product revenues as compared to the same quarter in the previous year and continue to convert our development sites into sales in both the United States and in Europe," said Howard C. Birndorf, Nanogen`s Chairman of the Board and Executive Chairman. "As we have stated, we believe that as more customers use our NanoChip(R) System the more they realize the importance of its competitive advantages, notably its efficiency, high accuracy and open architecture. We believe that our platform will continue to increase in popularity as we develop additional molecular diagnostic Analyte Specific Reagents ("ASRs") and eventually test kits for use on our NanoChip(R) System," he continued.
"As part of our platformation(TM) efforts, we have reached an important milestone this quarter in releasing our second Analyte Specific Reagent for the detection of the 25 mutations of the CFTR gene most commonly associated with cystic fibrosis, to our first customer site for evaluation," said Dr. Randy White, Nanogen`s Chief Executive Officer. "This moves Nanogen one step closer to a wider customer launch. Since the American College of Medical Genetics ("ACMG") and the American College of Obstetricians and Gynecologists ("ACOG") recommended last year that all women contemplating pregnancy should be offered a CFTR screen by their physicians, we have been informed by several reference laboratories that there has been a dramatic increase in referral orders for this test. We believe that the launch of our ASR for CF will have an important impact on placements of the NanoChip(R) System and on corresponding consumable sales."
Dr. White continued, "In addition, we have made progress in expanding our menu of other ASRs to be performed on the NanoChip(R) system by securing rights to all three of the most important mutations associated with a genetically inherited excess iron disorder, hereditary hemochromatosis ("HH"). At the end of the first quarter, a patent was issued for one of the mutations associated with HH for which Nanogen had already acquired exclusive rights. Additionally, in the second quarter, we entered into a license agreement with Bio-Rad Laboratories to the other two mutations, in effect making Nanogen the only current company with rights to develop and sell a three mutation ASR for HH. During the remainder of this year, we expect to further expand the menu of ASRs to be used on our System."
Webcast of Conference Call
Nanogen management will host a live conference call and listen-only Webcast today to discuss the second quarter financial results and update the Company`s earnings guidance for 2002 today at 4:30 p.m. Eastern Time. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com. A telephone replay will be available approximately two hours following the conference call until 11:59 p.m. Eastern Time on August 2, 2002, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants. The conference ID is 12650 and it will be required to listen to the playback. The webcast will also be archived on Nanogen`s website through August 14, 2002.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue with continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
June 30, December 31,
2002 2001
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $11,089 $10,455
Short-term investments 40,638 57,069
Receivables, net 2,189 4,380
Inventories, net 5,220 4,688
Other current assets 2,266 2,473
Total current assets 61,402 79,065
Property and equipment, net 5,391 5,386
Acquired technology rights, net 5,365 4,183
Other assets, net 1,030 1,158
Restricted cash 114 299
$73,302 $90,091
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $1,073 $1,051
Accrued liabilities 5,056 4,916
Deferred revenue 353 522
Current portion of capital lease obligations 890 1,060
Total current liabilities 7,372 7,549
Capital lease obligations, less current portion 1,256 1,755
Other long-term liabilities 1,662 1,675
Total long-term liabilities 2,918 3,430
Minority interest in consolidated subsidiary 2,990 4,183
Stockholders` equity:
Convertible preferred stock, $.001 par value,
5,000,000 shares authorized; no shares issued
and outstanding at June 30, 2002 and
December 31, 2001 -- --
Common stock, $.001 par value, 50,000,000 shares
authorized; 21,942,999 and 21,616,172 shares
issued and outstanding at June 30, 2002 and
December 31, 2001, respectively 22 22
Additional paid-in capital 199,380 198,387
Accumulated other comprehensive income 1,252 1,253
Deferred compensation (153) (336)
Notes receivable from officers (1,013) (984)
Accumulated deficit (139,466) (123,413)
Total stockholders` equity 60,022 74,929
$73,302 $90,091
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended June 30, Six months ended June 30,
2002 2001 2002 2001
Revenues:
Sales $1,104 $302 $1,916 $531
Sponsored research 313 2,055 626 4,401
Contract and grant 534 358 942 723
Total revenues 1,951 2,715 3,484 5,655
Operating expenses:
Cost of sales 836 230 1,393 400
Research and
development 4,575 4,414 8,855 9,199
Selling, general and
administrative 5,744 5,406 10,716 10,192
Litigation and
settlement of patent
matter -- 5,511 -- 6,309
Total operating
expenses 11,155 15,561 20,964 26,100
Loss from operations (9,204) (12,846) (17,480) (20,445)
Interest income, net 556 1,092 1,285 2,418
Other income (loss) 127 4 142 (2)
Net loss $(8,521) $(11,750) $(16,053) $(18,029)
Net loss per share -
basic and diluted $(0.39) $(0.56) $(0.74) $(0.87)
Number of shares used
in computing net loss
per share -
basic and diluted 21,650 20,847 21,635 20,802
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X34704280
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc., +1-858-410-4605; or Tom Baker, Media Relations of Atkins + Associates, +1-858-527-3493, for Nanogen, Inc. URL: http://www.nanogen.com http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Jul 31, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Records Highest Quarterly Product Revenues in Company`s History -
Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the second quarter ended June 30, 2002.
Product revenues for the second quarter were $1.1 million, more than three times the total for the second quarter of 2001 of $302,000. During the second quarter, the Company recognized revenue from the sale of eight NanoChip(R) Molecular Biology Workstations (including three sales converted from former development site customers). One additional development site was converted into a reagent rental, which represents the Company`s second transaction under its reagent rental program. Nanogen entered into three additional non-title transfer transactions during the quarter. Product revenues for the six months ended June 30, 2002 were $1.9 million compared to $531,000 for the first six months of 2001, also more than three times the prior year year-to-date total. Total revenues for the second quarter and six months ended June 30, 2002 were $2.0 million and $3.5 million, respectively, as compared to $2.7 million and $5.7 million for the same periods in the prior year. These declines in total revenues were due to anticipated decreases in revenues earned in connection with sponsored research programs as the Company`s revenue base continues its transition from primarily sponsored research revenues to product revenues. Notably, the Company continued to increase its percentage of product-driven revenues, as 57% of total revenues for the second quarter came from product revenues, compared to 11% for the second quarter of 2001. Product revenue recognized during the second quarter ended June 30, 2002 was primarily derived from sales of the Company`s NanoChip(R) Molecular Biology Workstation.
The Company`s cash, cash equivalents and short-term investments balance at June 30, 2002 was $51.7 million. Total operating expenses for the second quarter and six months ended June 30, 2002 were $11.2 million and $21.0 million, respectively, as compared to $15.6 million and $26.1 million for the same periods in the prior year. The prior year amounts included charges related to a prior patent litigation and settlement amounting to $5.5 million for the quarter and $6.3 million for the six months ended June 30, 2001. The increase in operating expenses in 2002 as compared to 2001, excluding the litigation and settlement charges, relates primarily to an increase in cost of sales in conjunction with our growing product revenues.
The Company`s net loss for the quarter ended June 30, 2002 was $8.5 million or $0.39 per share, compared to a net loss of $11.8 million or $0.56 per share (or, excluding the Motorola litigation matter, $6.2 million or $0.30 per share), for the same period in 2001. For the six months ended June 30, 2002, the Company`s reported net loss was $16.1 million or $0.74 per share, compared to a net loss of $18.0 million or $0.87 per share (or, $11.7 million or $0.56 per share absent the Motorola litigation matter), for the same period in 2001.
"We are very pleased that for the second quarter in a row we have more than tripled our product revenues as compared to the same quarter in the previous year and continue to convert our development sites into sales in both the United States and in Europe," said Howard C. Birndorf, Nanogen`s Chairman of the Board and Executive Chairman. "As we have stated, we believe that as more customers use our NanoChip(R) System the more they realize the importance of its competitive advantages, notably its efficiency, high accuracy and open architecture. We believe that our platform will continue to increase in popularity as we develop additional molecular diagnostic Analyte Specific Reagents ("ASRs") and eventually test kits for use on our NanoChip(R) System," he continued.
"As part of our platformation(TM) efforts, we have reached an important milestone this quarter in releasing our second Analyte Specific Reagent for the detection of the 25 mutations of the CFTR gene most commonly associated with cystic fibrosis, to our first customer site for evaluation," said Dr. Randy White, Nanogen`s Chief Executive Officer. "This moves Nanogen one step closer to a wider customer launch. Since the American College of Medical Genetics ("ACMG") and the American College of Obstetricians and Gynecologists ("ACOG") recommended last year that all women contemplating pregnancy should be offered a CFTR screen by their physicians, we have been informed by several reference laboratories that there has been a dramatic increase in referral orders for this test. We believe that the launch of our ASR for CF will have an important impact on placements of the NanoChip(R) System and on corresponding consumable sales."
Dr. White continued, "In addition, we have made progress in expanding our menu of other ASRs to be performed on the NanoChip(R) system by securing rights to all three of the most important mutations associated with a genetically inherited excess iron disorder, hereditary hemochromatosis ("HH"). At the end of the first quarter, a patent was issued for one of the mutations associated with HH for which Nanogen had already acquired exclusive rights. Additionally, in the second quarter, we entered into a license agreement with Bio-Rad Laboratories to the other two mutations, in effect making Nanogen the only current company with rights to develop and sell a three mutation ASR for HH. During the remainder of this year, we expect to further expand the menu of ASRs to be used on our System."
Webcast of Conference Call
Nanogen management will host a live conference call and listen-only Webcast today to discuss the second quarter financial results and update the Company`s earnings guidance for 2002 today at 4:30 p.m. Eastern Time. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com. A telephone replay will be available approximately two hours following the conference call until 11:59 p.m. Eastern Time on August 2, 2002, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants. The conference ID is 12650 and it will be required to listen to the playback. The webcast will also be archived on Nanogen`s website through August 14, 2002.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue with continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
June 30, December 31,
2002 2001
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $11,089 $10,455
Short-term investments 40,638 57,069
Receivables, net 2,189 4,380
Inventories, net 5,220 4,688
Other current assets 2,266 2,473
Total current assets 61,402 79,065
Property and equipment, net 5,391 5,386
Acquired technology rights, net 5,365 4,183
Other assets, net 1,030 1,158
Restricted cash 114 299
$73,302 $90,091
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $1,073 $1,051
Accrued liabilities 5,056 4,916
Deferred revenue 353 522
Current portion of capital lease obligations 890 1,060
Total current liabilities 7,372 7,549
Capital lease obligations, less current portion 1,256 1,755
Other long-term liabilities 1,662 1,675
Total long-term liabilities 2,918 3,430
Minority interest in consolidated subsidiary 2,990 4,183
Stockholders` equity:
Convertible preferred stock, $.001 par value,
5,000,000 shares authorized; no shares issued
and outstanding at June 30, 2002 and
December 31, 2001 -- --
Common stock, $.001 par value, 50,000,000 shares
authorized; 21,942,999 and 21,616,172 shares
issued and outstanding at June 30, 2002 and
December 31, 2001, respectively 22 22
Additional paid-in capital 199,380 198,387
Accumulated other comprehensive income 1,252 1,253
Deferred compensation (153) (336)
Notes receivable from officers (1,013) (984)
Accumulated deficit (139,466) (123,413)
Total stockholders` equity 60,022 74,929
$73,302 $90,091
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended June 30, Six months ended June 30,
2002 2001 2002 2001
Revenues:
Sales $1,104 $302 $1,916 $531
Sponsored research 313 2,055 626 4,401
Contract and grant 534 358 942 723
Total revenues 1,951 2,715 3,484 5,655
Operating expenses:
Cost of sales 836 230 1,393 400
Research and
development 4,575 4,414 8,855 9,199
Selling, general and
administrative 5,744 5,406 10,716 10,192
Litigation and
settlement of patent
matter -- 5,511 -- 6,309
Total operating
expenses 11,155 15,561 20,964 26,100
Loss from operations (9,204) (12,846) (17,480) (20,445)
Interest income, net 556 1,092 1,285 2,418
Other income (loss) 127 4 142 (2)
Net loss $(8,521) $(11,750) $(16,053) $(18,029)
Net loss per share -
basic and diluted $(0.39) $(0.56) $(0.74) $(0.87)
Number of shares used
in computing net loss
per share -
basic and diluted 21,650 20,847 21,635 20,802
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X34704280
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc., +1-858-410-4605; or Tom Baker, Media Relations of Atkins + Associates, +1-858-527-3493, for Nanogen, Inc. URL: http://www.nanogen.com http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Adviser Soapbox
Beware Of Nano Pretenders
Josh Wolfe, Forbes/Wolfe Nanotech Report, 08.01.02, 7:00 AM ET
NEW YORK - As tech and telecom stocks continue to languish, investors and media commentators are looking for the next big thing. Nanotechnology fits the bill.
Sign up for Forbes` Free Investment Guru Weekly e-mail.
It`s not surprising to see everyone jumping aboard the nanotech bandwagon. You saw the action in one of my top picks, Veeco Instruments (nasdaq: VECO - news - people ), after Merrill Lynch put the semiconductor equipment maker on its tech stock buy list. It soared 11% in three days.
However, with all the amazing discoveries nanotechnology promises, out of the woodwork comes the hype. Remember in the `80s PC boom, when a slew of companies changed their names to incorporate the phrase "tech" and, more recently, the addition of "dot-com" to brighten up boring corporate logos? Make way for the new "nano" companies:
1) Nanometrics (nasdaq: NANO - news - people )
Great name, but where`s the nano? The Milpitas, Calif.-based company was founded in 1975 and went public in 1984. It makes equipment for the semiconductor industry and provides tools at the microscale (remember, 1,000 times larger than nano) that are used in process and quality control. Don`t let the product line--with names like NanoSpec 9000--fool you. They are merely improved versions of products the company first launched over two decades ago. But no nanotech is involved. Nanometrics has a $220 million market cap despite a mature and cyclical business with lousy recent results. It lost $1.5 million on sales of $8 million in the first quarter, down over 40% from the same period in 2001. If you still think it might be a good long-term nanotech play, don`t just take my word for it. Chief Financial Officer Paul Nolan passed on this clear message to me: "Our company has nothing to do with nanotechnology." At least in Nanometrics` case, it`s had the name for two decades.
2) Nanogen (nasdaq: NGEN - news - people )
Another great name! But, still no nano. Based in the biotech valley of San Diego, the company creates gene chips also known as microarrays, which are used to do genetic research and diagnostics. Its core product, the NanoChip, measures about 0.7cm square, with an array measuring 2mm square. The individual features are 80 microns, or 80,000 nanometers, a far cry from the generally accepted realm of nanotech that is below 100nm. The distance between each array site is 200 microns--or 200,000nm--which makes a Grand Canyon of a difference. Nanogen sells a complete system, consisting of the NanoChip Cartridge, which is placed into the NanoChip Molecular Biology Workstation. The Workstation has a machine that reads the chip and a computer with hardware and software that allows researchers to generate meaningful genetic data.
Nanogen`s stock took a nosedive right before the attacks of Sept. 11 and then sharply recovered amid general public concern over anthrax threats and general investor enthusiasm over tools that might be able to do quick diagnostics. Investors who drove the stock higher on this basis overlooked company statements saying the Nanogen system is intended for research use only and not for use in diagnostic procedures. Last year, revenue fell 1% to $11.2 million, with a net loss of $32.5 million, a drop of nearly 80%.
In general, the gene-chip players are faced with a very competitive landscape: fickle biotech investors, unsure which "-omics" is worthy of their capital, and researchers inundated with a flood of genomics data. It`s like trying to use a straw to sip water being shot through a fire hose. Unless Nanogen acquires a startup working in nanofluidics, which helps it offer a chip system that could perform at least ten times more quickly, accurately or cheaply, I`d caution you to not be mislead by its name.
3) NanoPierce Technologies
This one is traded on the OTC bulletin board. It has nearly doubled since January. My advice: Stay far, far away from this one. In April 2001, the company initiated a lawsuit claiming a slew of promoters were fraudulently manipulating the price of its stock.
The company operates out of Germany, but has corporate offices in Denver, Colo. Denver has been a hot bed for penny-stock hustlers for three decades. It is not surprising that the junk-stock crowd is latching on to nanotechnology. NanoPierce was originally incorporated in 1996 as Sunlight Systems and was also known as Mendell-Denver. The company currently has negative cash flow from operations, and the bulk of its revenue was from a German division--which sells consulting services and software. Revenue was $103,000 for the 12 months ending last December, yet its stock, at a price of $1.05, has a market cap of over $55 million.
NanoPierce has nothing to do with nanotechnology. Its technology revolves around what it calls NCS, NanoPierce Connection System. At its essence, NCS creates electronic connections between the microscale and the macroscale on circuitboards. It hopes to apply the process to smart-card applications.
4) Altair Nanotechnologies (nasdaq: ALTI - news - people )
The company was first known as Altair International; then in August 2001, it changed to Altair Nanotechnologies. It also rebranded its wholly owned subsidiary Altair Technologies as Altair Nanomaterials. The firm`s name has had more alterations than Oprah`s clothes!
So what else has changed besides the name? Altair Chief Executive Bill Long says it now aims to be the No. 1 supplier of nanomaterials worldwide. It doesn`t deal with carbon nanotubes or buckyballs, but instead makes products like metal oxides that are used in sunscreens, paints and catalysts. The company was originally a shell company. Here is how the shell game worked in the `80s: A group would acquire a controlling interest in the stock of a publicly traded shell and then merge an operating company into it. Presto: a quick and easy public offering. Then if the new company had an exciting story--like nanotechnology--you could pump up the stock and then dump the shares.
In the case of Altair, its first business was developing the largest titanium ore body in Camden, Tenn. The idea was to take the titanium and turn it into pigment used in paints and coatings. Two years ago, Altair acquired a pigment process from BHP Broken Hill Proprietary, for about $9.5 million. Altair realized that it couldn`t compete in the international pigment market, where firms in Australia and the U.K. were more established. Altair also realized that while pigments could sell on average for $1 a pound, nanoparticles--depending on what metal oxide--could sell from $8 to $60 a pound.
Now it is trying to produce nanoparticles of lithium titanate, which is used in rechargeable-battery applications. Long, 54, admits he knows little about the rechargeable-battery market, but is happy to report that there is a $6 billion potential. Now Altair is converting the recently acquired plant to nanoparticles. Revenue for 2001 totaled a whopping $43,000; the company is burning through cash at a rate of $640,000 per month and has lost nearly $14 million over the past two years. Its $23 million market cap is ridiculous. This mining-cum-specialty-materials firm has an uphill battle to garner market share against a host of competitors producing metal oxides. Just say no to this nano-come-lately.
5) Nanophase Technologies (nasdaq: NANX - news - people )
What about this Romeoville, Ill.-based company with a market cap of $87 million? Ah, finally a company that is indeed operating at the nanoscale. It makes metal-oxide particles and could be considered one of the few pure-play nanotechnology companies. It has a strong patent position, with 38 issued and applied that cover its production processes of making nanoparticles. Its plant has a capacity of 1 million pounds, and it is aggressively driving down manufacturing costs and increasing production capacity. In 1999, it took one operator for each reactor; today Nanophase is able to have one operator for four reactors. Founded in 1989 as a spinoff from Argonne National Labs, it went public in 1997 at $8 a share and is currently selling at around $6.
In 1999, it began rebuilding and restaffing, bringing on current CEO Joseph Cross to expand its client base. BASF (nyse: BF - news - people ) is its single-largest client, accounting for over 50% of last year`s $4 million in revenue. Cross believes that with the ability to produce 120 different types of nanoparticles, mostly metal-oxides, and two shifts running five days a week, the company can continue to scale its process. Nanophase needs three to four times the current revenue base to break-even by late 2003, but Cross is optimistic. "Its undoubtedly the strongest opportunity that we`ve seen in multiple markets." The biggest markets are in personal health care, nanoparticles used for antimicrobial applications. This one is no nanoimposter, but I`d consider the uphill battle for significant revenue.
Excerpted from the May issue of Forbes/Wolfe Nanotechnology Report
Beware Of Nano Pretenders
Josh Wolfe, Forbes/Wolfe Nanotech Report, 08.01.02, 7:00 AM ET
NEW YORK - As tech and telecom stocks continue to languish, investors and media commentators are looking for the next big thing. Nanotechnology fits the bill.
Sign up for Forbes` Free Investment Guru Weekly e-mail.
It`s not surprising to see everyone jumping aboard the nanotech bandwagon. You saw the action in one of my top picks, Veeco Instruments (nasdaq: VECO - news - people ), after Merrill Lynch put the semiconductor equipment maker on its tech stock buy list. It soared 11% in three days.
However, with all the amazing discoveries nanotechnology promises, out of the woodwork comes the hype. Remember in the `80s PC boom, when a slew of companies changed their names to incorporate the phrase "tech" and, more recently, the addition of "dot-com" to brighten up boring corporate logos? Make way for the new "nano" companies:
1) Nanometrics (nasdaq: NANO - news - people )
Great name, but where`s the nano? The Milpitas, Calif.-based company was founded in 1975 and went public in 1984. It makes equipment for the semiconductor industry and provides tools at the microscale (remember, 1,000 times larger than nano) that are used in process and quality control. Don`t let the product line--with names like NanoSpec 9000--fool you. They are merely improved versions of products the company first launched over two decades ago. But no nanotech is involved. Nanometrics has a $220 million market cap despite a mature and cyclical business with lousy recent results. It lost $1.5 million on sales of $8 million in the first quarter, down over 40% from the same period in 2001. If you still think it might be a good long-term nanotech play, don`t just take my word for it. Chief Financial Officer Paul Nolan passed on this clear message to me: "Our company has nothing to do with nanotechnology." At least in Nanometrics` case, it`s had the name for two decades.
2) Nanogen (nasdaq: NGEN - news - people )
Another great name! But, still no nano. Based in the biotech valley of San Diego, the company creates gene chips also known as microarrays, which are used to do genetic research and diagnostics. Its core product, the NanoChip, measures about 0.7cm square, with an array measuring 2mm square. The individual features are 80 microns, or 80,000 nanometers, a far cry from the generally accepted realm of nanotech that is below 100nm. The distance between each array site is 200 microns--or 200,000nm--which makes a Grand Canyon of a difference. Nanogen sells a complete system, consisting of the NanoChip Cartridge, which is placed into the NanoChip Molecular Biology Workstation. The Workstation has a machine that reads the chip and a computer with hardware and software that allows researchers to generate meaningful genetic data.
Nanogen`s stock took a nosedive right before the attacks of Sept. 11 and then sharply recovered amid general public concern over anthrax threats and general investor enthusiasm over tools that might be able to do quick diagnostics. Investors who drove the stock higher on this basis overlooked company statements saying the Nanogen system is intended for research use only and not for use in diagnostic procedures. Last year, revenue fell 1% to $11.2 million, with a net loss of $32.5 million, a drop of nearly 80%.
In general, the gene-chip players are faced with a very competitive landscape: fickle biotech investors, unsure which "-omics" is worthy of their capital, and researchers inundated with a flood of genomics data. It`s like trying to use a straw to sip water being shot through a fire hose. Unless Nanogen acquires a startup working in nanofluidics, which helps it offer a chip system that could perform at least ten times more quickly, accurately or cheaply, I`d caution you to not be mislead by its name.
3) NanoPierce Technologies
This one is traded on the OTC bulletin board. It has nearly doubled since January. My advice: Stay far, far away from this one. In April 2001, the company initiated a lawsuit claiming a slew of promoters were fraudulently manipulating the price of its stock.
The company operates out of Germany, but has corporate offices in Denver, Colo. Denver has been a hot bed for penny-stock hustlers for three decades. It is not surprising that the junk-stock crowd is latching on to nanotechnology. NanoPierce was originally incorporated in 1996 as Sunlight Systems and was also known as Mendell-Denver. The company currently has negative cash flow from operations, and the bulk of its revenue was from a German division--which sells consulting services and software. Revenue was $103,000 for the 12 months ending last December, yet its stock, at a price of $1.05, has a market cap of over $55 million.
NanoPierce has nothing to do with nanotechnology. Its technology revolves around what it calls NCS, NanoPierce Connection System. At its essence, NCS creates electronic connections between the microscale and the macroscale on circuitboards. It hopes to apply the process to smart-card applications.
4) Altair Nanotechnologies (nasdaq: ALTI - news - people )
The company was first known as Altair International; then in August 2001, it changed to Altair Nanotechnologies. It also rebranded its wholly owned subsidiary Altair Technologies as Altair Nanomaterials. The firm`s name has had more alterations than Oprah`s clothes!
So what else has changed besides the name? Altair Chief Executive Bill Long says it now aims to be the No. 1 supplier of nanomaterials worldwide. It doesn`t deal with carbon nanotubes or buckyballs, but instead makes products like metal oxides that are used in sunscreens, paints and catalysts. The company was originally a shell company. Here is how the shell game worked in the `80s: A group would acquire a controlling interest in the stock of a publicly traded shell and then merge an operating company into it. Presto: a quick and easy public offering. Then if the new company had an exciting story--like nanotechnology--you could pump up the stock and then dump the shares.
In the case of Altair, its first business was developing the largest titanium ore body in Camden, Tenn. The idea was to take the titanium and turn it into pigment used in paints and coatings. Two years ago, Altair acquired a pigment process from BHP Broken Hill Proprietary, for about $9.5 million. Altair realized that it couldn`t compete in the international pigment market, where firms in Australia and the U.K. were more established. Altair also realized that while pigments could sell on average for $1 a pound, nanoparticles--depending on what metal oxide--could sell from $8 to $60 a pound.
Now it is trying to produce nanoparticles of lithium titanate, which is used in rechargeable-battery applications. Long, 54, admits he knows little about the rechargeable-battery market, but is happy to report that there is a $6 billion potential. Now Altair is converting the recently acquired plant to nanoparticles. Revenue for 2001 totaled a whopping $43,000; the company is burning through cash at a rate of $640,000 per month and has lost nearly $14 million over the past two years. Its $23 million market cap is ridiculous. This mining-cum-specialty-materials firm has an uphill battle to garner market share against a host of competitors producing metal oxides. Just say no to this nano-come-lately.
5) Nanophase Technologies (nasdaq: NANX - news - people )
What about this Romeoville, Ill.-based company with a market cap of $87 million? Ah, finally a company that is indeed operating at the nanoscale. It makes metal-oxide particles and could be considered one of the few pure-play nanotechnology companies. It has a strong patent position, with 38 issued and applied that cover its production processes of making nanoparticles. Its plant has a capacity of 1 million pounds, and it is aggressively driving down manufacturing costs and increasing production capacity. In 1999, it took one operator for each reactor; today Nanophase is able to have one operator for four reactors. Founded in 1989 as a spinoff from Argonne National Labs, it went public in 1997 at $8 a share and is currently selling at around $6.
In 1999, it began rebuilding and restaffing, bringing on current CEO Joseph Cross to expand its client base. BASF (nyse: BF - news - people ) is its single-largest client, accounting for over 50% of last year`s $4 million in revenue. Cross believes that with the ability to produce 120 different types of nanoparticles, mostly metal-oxides, and two shifts running five days a week, the company can continue to scale its process. Nanophase needs three to four times the current revenue base to break-even by late 2003, but Cross is optimistic. "Its undoubtedly the strongest opportunity that we`ve seen in multiple markets." The biggest markets are in personal health care, nanoparticles used for antimicrobial applications. This one is no nanoimposter, but I`d consider the uphill battle for significant revenue.
Excerpted from the May issue of Forbes/Wolfe Nanotechnology Report
Forbes Newsletter Watch
Will Biotech Boom Again?
John Dobosz, 08.06.02, 4:10 PM ET
Have biotech stocks finally bottomed? The American Stock Exchange Biotechnology Index is still down more than 40% since the first of the year, but it has rallied an impressive 25% off of its low point in mid-July. Most newsletters aren`t predicting an extended bull run in biotech yet, but they do point to a number of screaming bargains among the stocks.
Sign up for Forbes` Free Investment Guru Weekly e-mail.
Matt Berry, associate analyst at John McCamant`s Medical Technology Stock Letter, says much of the malaise in the current market is fallout from the ImClone (nasdaq: IMCL - news - people ) fiasco. Biotech has always relied on partnerships with big pharmaceutical firms to share costs associated with Food and Drug Administration approval and eventually with marketing and distribution of approved drugs. Now, most big companies don`t want anything to do with biotech firms. Indeed, new drug development partnering virtually evaporated in 2002.
Nonetheless, Berry says that most companies are "making solid progress" in development and clinical trials and that Big Pharma, with pipelines running dry and blockbuster drugs coming off-patent, needs biotech partners more than ever. Plus, many biotech companies accumulated substantial cash positions during the last biotech boom, in 1999, and have enough to sustain themselves for "two or three years."
"This group is going to lead the next advance," predicts Berry, who points out that many companies are trading at a discount to their cash reserves and have blockbuster products in the pipeline. Among the bargain stocks, Berry says, is Cell Genesys (nasdaq: CEGE - news - people ), which has a number of products in late stage-three trials, including a vaccine for non-small cell lung cancer. Icos (nasdaq: ICOS - news - people ) has developed an impotence drug, Cialis, that could compete with Viagra but has yet to be approved by the FDA. The Medicines Co. (nasdaq: MDCO - news - people ), NPS Pharmaceuticals (nasdaq: NPSP - news - people ) and Amylin (nasdaq: AMLN - news - people ) are all companies that look attractive to Berry.
"A lot of companies that are going to do very well are very cheap," says Dr. Scott Gottlieb, editor of the Gilder Biotech Report. He agrees that valuations are attractive but believes that any broad biotech advance would require a change in leadership at the FDA, which has been slow to approve new products. Another catalyst that could move the group higher, says Gottlieb, could come from scientific symposiums held in late fall. It`s at these meetings that many companies make big announcements about new product development. Gottlieb says "bottom-fishing" institutional investors led last month`s rally, and he doubts that it`s sustainable.
One company that Gottlieb says holds a lot of promise is Vertex Pharmaceuticals (nasdaq: VRTX - news - people ). Vertex is working on treatments for arthritis and other inflammatory conditions, as well as one drug already approved to treat HIV. Gottlieb also likes the valuations and prospects for Sequenom (nasdaq: SQNM - news - people ), Nanogen (nasdaq: NGEN - news - people ) and, more speculatively, CuraGen (nasdaq: CRGN - news - people ). As for a long-term play, Gottlieb is a big fan of Isis Pharmaceuticals (nasdaq: ISIS - news - people ), the leader in "antisense" drugs that fight disease at the genetic level.
David Kliff, editor of Diabetic Investor, thinks that Generex Biotech (nasdaq: GNBT - news - people ) is a big bargain at about $2 a share. Kliff says the company has "the best technology for alternative delivery of insulin," which is by mouth. Kliff also likes Neurocrine Biosciences (nasdaq: NBIX - news - people ), which develops drugs to treat diabetes and other disorders.
For mutual fund investors, John Bonnanzio at Eric Kobren`s FundsNet Insight has a "buy" rating on the Fidelity Select Biotech Fund (nasdaq: FBIOX - news - people ), as well as the PIMCO RCM Biotech Fund (nasdaq: RABTX - news - people ).
Will Biotech Boom Again?
John Dobosz, 08.06.02, 4:10 PM ET
Have biotech stocks finally bottomed? The American Stock Exchange Biotechnology Index is still down more than 40% since the first of the year, but it has rallied an impressive 25% off of its low point in mid-July. Most newsletters aren`t predicting an extended bull run in biotech yet, but they do point to a number of screaming bargains among the stocks.
Sign up for Forbes` Free Investment Guru Weekly e-mail.
Matt Berry, associate analyst at John McCamant`s Medical Technology Stock Letter, says much of the malaise in the current market is fallout from the ImClone (nasdaq: IMCL - news - people ) fiasco. Biotech has always relied on partnerships with big pharmaceutical firms to share costs associated with Food and Drug Administration approval and eventually with marketing and distribution of approved drugs. Now, most big companies don`t want anything to do with biotech firms. Indeed, new drug development partnering virtually evaporated in 2002.
Nonetheless, Berry says that most companies are "making solid progress" in development and clinical trials and that Big Pharma, with pipelines running dry and blockbuster drugs coming off-patent, needs biotech partners more than ever. Plus, many biotech companies accumulated substantial cash positions during the last biotech boom, in 1999, and have enough to sustain themselves for "two or three years."
"This group is going to lead the next advance," predicts Berry, who points out that many companies are trading at a discount to their cash reserves and have blockbuster products in the pipeline. Among the bargain stocks, Berry says, is Cell Genesys (nasdaq: CEGE - news - people ), which has a number of products in late stage-three trials, including a vaccine for non-small cell lung cancer. Icos (nasdaq: ICOS - news - people ) has developed an impotence drug, Cialis, that could compete with Viagra but has yet to be approved by the FDA. The Medicines Co. (nasdaq: MDCO - news - people ), NPS Pharmaceuticals (nasdaq: NPSP - news - people ) and Amylin (nasdaq: AMLN - news - people ) are all companies that look attractive to Berry.
"A lot of companies that are going to do very well are very cheap," says Dr. Scott Gottlieb, editor of the Gilder Biotech Report. He agrees that valuations are attractive but believes that any broad biotech advance would require a change in leadership at the FDA, which has been slow to approve new products. Another catalyst that could move the group higher, says Gottlieb, could come from scientific symposiums held in late fall. It`s at these meetings that many companies make big announcements about new product development. Gottlieb says "bottom-fishing" institutional investors led last month`s rally, and he doubts that it`s sustainable.
One company that Gottlieb says holds a lot of promise is Vertex Pharmaceuticals (nasdaq: VRTX - news - people ). Vertex is working on treatments for arthritis and other inflammatory conditions, as well as one drug already approved to treat HIV. Gottlieb also likes the valuations and prospects for Sequenom (nasdaq: SQNM - news - people ), Nanogen (nasdaq: NGEN - news - people ) and, more speculatively, CuraGen (nasdaq: CRGN - news - people ). As for a long-term play, Gottlieb is a big fan of Isis Pharmaceuticals (nasdaq: ISIS - news - people ), the leader in "antisense" drugs that fight disease at the genetic level.
David Kliff, editor of Diabetic Investor, thinks that Generex Biotech (nasdaq: GNBT - news - people ) is a big bargain at about $2 a share. Kliff says the company has "the best technology for alternative delivery of insulin," which is by mouth. Kliff also likes Neurocrine Biosciences (nasdaq: NBIX - news - people ), which develops drugs to treat diabetes and other disorders.
For mutual fund investors, John Bonnanzio at Eric Kobren`s FundsNet Insight has a "buy" rating on the Fidelity Select Biotech Fund (nasdaq: FBIOX - news - people ), as well as the PIMCO RCM Biotech Fund (nasdaq: RABTX - news - people ).
Nanogen Reports Favorable Ruling in Its Litigation Against CombiMatrix Corp. and Dr. Donald Montgomery
SAN DIEGO, Aug 7, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced a recent favorable ruling in its litigation with CombiMatrix Corp. and Dr. Donald Montgomery.
In November 2000, Nanogen filed a complaint in the United States District Court for the Southern District of California against CombiMatrix and Dr. Montgomery, a former employee of Nanogen, who is affiliated with CombiMatrix. Nanogen`s complaint alleges that Dr. Montgomery misappropriated Nanogen technology after he left Nanogen by disclosing trade secrets to CombiMatrix and by filing patent applications on those trade secrets in his name. Nanogen`s complaint seeks a correction of inventorship on U.S. Patents No. 6,093,302, 6,280,595 and related patents or applications, assignment of rights in those patents or applications to Nanogen, an injunction preventing disclosure of trade secrets and damages for trade secret misappropriation. Nanogen`s claims also include breach of written contract relating to a settlement agreement entered into between Nanogen and Dr. Montgomery in February 1996, inducing breach of a written contract, breach of the implied covenant of good faith and fair dealing, intentional interference with prospective economic advantage and unfair competition. In June 2002, the court permitted Nanogen to amend its complaint to include an additional claim against Dr. Montgomery for fraudulent inducement to enter into the settlement agreement.
On July 30, 2002, the court denied a partial summary judgment motion made by CombiMatrix and Dr. Montgomery relating to certain Nanogen claims. In their motion for summary judgment, CombiMatrix and Dr. Montgomery argued that certain trade secrets that Nanogen contends Dr. Montgomery misappropriated were not delineated in the prior settlement agreement between Dr. Montgomery and Nanogen, and as a result, Nanogen was precluded from bringing its claims.
The court, however, disagreed with CombiMatrix`s and Dr. Montgomery`s interpretation of the settlement agreement. The court ruled that the settlement agreement, in which Dr. Montgomery agreed not to misappropriate any of Nanogen`s trade secrets, was not limited to the specific trade secrets mentioned therein. The court also rejected CombiMatrix`s and Dr. Montgomery`s contention that the settlement agreement released Dr. Montgomery from all claims except for those arising out of that agreement.
Since the court has disagreed with CombiMatrix`s and Dr. Montgomery`s interpretation of the settlement agreement, Nanogen now can focus its efforts on proving its trade secret misappropriation claims. Although there can be no assurance in such a litigation that Nanogen will ultimately prevail at trial, Nanogen believes that this recent ruling will assist the Company in its litigation efforts to receive full rights to the technology that incorporates the `302 and `595 patents and related intellectual property and be compensated fully for the economic and other losses it has suffered relating to the actions of Dr. Montgomery and CombiMatrix. Discovery is currently ongoing in this lawsuit and trial is scheduled for November 2002.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether Nanogen will prevail in its litigation against CombiMatrix and Dr. Montgomery and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X37174328
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO, +1-858-410-4605, or
William Franzblau, Vice President, Legal Affairs, +1-858-410-4604, both of
Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Aug 7, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced a recent favorable ruling in its litigation with CombiMatrix Corp. and Dr. Donald Montgomery.
In November 2000, Nanogen filed a complaint in the United States District Court for the Southern District of California against CombiMatrix and Dr. Montgomery, a former employee of Nanogen, who is affiliated with CombiMatrix. Nanogen`s complaint alleges that Dr. Montgomery misappropriated Nanogen technology after he left Nanogen by disclosing trade secrets to CombiMatrix and by filing patent applications on those trade secrets in his name. Nanogen`s complaint seeks a correction of inventorship on U.S. Patents No. 6,093,302, 6,280,595 and related patents or applications, assignment of rights in those patents or applications to Nanogen, an injunction preventing disclosure of trade secrets and damages for trade secret misappropriation. Nanogen`s claims also include breach of written contract relating to a settlement agreement entered into between Nanogen and Dr. Montgomery in February 1996, inducing breach of a written contract, breach of the implied covenant of good faith and fair dealing, intentional interference with prospective economic advantage and unfair competition. In June 2002, the court permitted Nanogen to amend its complaint to include an additional claim against Dr. Montgomery for fraudulent inducement to enter into the settlement agreement.
On July 30, 2002, the court denied a partial summary judgment motion made by CombiMatrix and Dr. Montgomery relating to certain Nanogen claims. In their motion for summary judgment, CombiMatrix and Dr. Montgomery argued that certain trade secrets that Nanogen contends Dr. Montgomery misappropriated were not delineated in the prior settlement agreement between Dr. Montgomery and Nanogen, and as a result, Nanogen was precluded from bringing its claims.
The court, however, disagreed with CombiMatrix`s and Dr. Montgomery`s interpretation of the settlement agreement. The court ruled that the settlement agreement, in which Dr. Montgomery agreed not to misappropriate any of Nanogen`s trade secrets, was not limited to the specific trade secrets mentioned therein. The court also rejected CombiMatrix`s and Dr. Montgomery`s contention that the settlement agreement released Dr. Montgomery from all claims except for those arising out of that agreement.
Since the court has disagreed with CombiMatrix`s and Dr. Montgomery`s interpretation of the settlement agreement, Nanogen now can focus its efforts on proving its trade secret misappropriation claims. Although there can be no assurance in such a litigation that Nanogen will ultimately prevail at trial, Nanogen believes that this recent ruling will assist the Company in its litigation efforts to receive full rights to the technology that incorporates the `302 and `595 patents and related intellectual property and be compensated fully for the economic and other losses it has suffered relating to the actions of Dr. Montgomery and CombiMatrix. Discovery is currently ongoing in this lawsuit and trial is scheduled for November 2002.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether Nanogen will prevail in its litigation against CombiMatrix and Dr. Montgomery and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X37174328
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO, +1-858-410-4605, or
William Franzblau, Vice President, Legal Affairs, +1-858-410-4604, both of
Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
www.GenomeWeb.com
Susceptibility Tests Will Generate One-Third of Genomic-Diagnostics Revenue
By a GenomeWeb staff reporter
NEW YORK, Aug. 14 - Testing for disease susceptibility will account for one-third of the total genomic-diagnostic revenues this year, according to a report released today.
The report, by health-care research firm Decision Resources, shows that revenues from sales of assays for disease-susceptibility testing, prognostics, and monitoring are projected to reach $115 million in 2002 from an estimated $71 million collected last year. If fulfilled, this forecast means that these applications will account for about 90 percent of the total genomic-diagnostics market.
Companies that currently occupy the genomics-diagnostics space include Affymetrix, Cepheid, DNA Sciences, Myriad Genetics, Nanogen, and Third Wave Technologies.
Still, "there aren`t many [of these] products on the market right now," Karen O`Connor, an analyst with Decision Resources, told GenomeWeb. "These estimates have ... been based on products that have not come out to market yet."
Susceptibility Tests Will Generate One-Third of Genomic-Diagnostics Revenue
By a GenomeWeb staff reporter
NEW YORK, Aug. 14 - Testing for disease susceptibility will account for one-third of the total genomic-diagnostic revenues this year, according to a report released today.
The report, by health-care research firm Decision Resources, shows that revenues from sales of assays for disease-susceptibility testing, prognostics, and monitoring are projected to reach $115 million in 2002 from an estimated $71 million collected last year. If fulfilled, this forecast means that these applications will account for about 90 percent of the total genomic-diagnostics market.
Companies that currently occupy the genomics-diagnostics space include Affymetrix, Cepheid, DNA Sciences, Myriad Genetics, Nanogen, and Third Wave Technologies.
Still, "there aren`t many [of these] products on the market right now," Karen O`Connor, an analyst with Decision Resources, told GenomeWeb. "These estimates have ... been based on products that have not come out to market yet."
Nanogen Launches New Website to Reflect Focus on Molecular Diagnostics
SAN DIEGO, Sep 10, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today the launch of a newly improved website - www.nanogen.com - reflecting its customer-driven focus on providing molecular diagnostic tools for the gene-based testing market. This launch comes as part of a strategic initiative to provide partners, potential customers and investors with the most up-to-date information on Nanogen`s products and services, latest news and events, and technology advancements.
"As we continue to make progress toward our goal of becoming a leading supplier of molecular diagnostic tests, we feel it is important to provide an accurate and timely resource to our various audiences, representing the commitment to our customers as well as our existing and potential investors," said Dr. Randy White, Chief Executive Officer of Nanogen. "Reflecting the forward momentum we`ve sustained, the website embraces new technology and offers unique ways to educate our online audience about Nanogen and its people."
The Nanogen website includes improved navigation, detailed descriptions of products and services, and multi-media features.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com ( http://www.nanogen.com/ ).
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc., +1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates, +1-858-527-3494, for Nanogen, Inc.
SAN DIEGO, Sep 10, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today the launch of a newly improved website - www.nanogen.com - reflecting its customer-driven focus on providing molecular diagnostic tools for the gene-based testing market. This launch comes as part of a strategic initiative to provide partners, potential customers and investors with the most up-to-date information on Nanogen`s products and services, latest news and events, and technology advancements.
"As we continue to make progress toward our goal of becoming a leading supplier of molecular diagnostic tests, we feel it is important to provide an accurate and timely resource to our various audiences, representing the commitment to our customers as well as our existing and potential investors," said Dr. Randy White, Chief Executive Officer of Nanogen. "Reflecting the forward momentum we`ve sustained, the website embraces new technology and offers unique ways to educate our online audience about Nanogen and its people."
The Nanogen website includes improved navigation, detailed descriptions of products and services, and multi-media features.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com ( http://www.nanogen.com/ ).
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc., +1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates, +1-858-527-3494, for Nanogen, Inc.
Nanogen Settles Litigation With CombiMatrix and Dr. Donald Montgomery
SAN DIEGO, Oct 1, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Nanogen to Receive $1 Million, Royalties and Equity Stake -
Nanogen, Inc. (Nasdaq: NGEN) announced today the settlement of its pending litigation with CombiMatrix Corporation, Acacia Research Corporation`s (Nasdaq: ACRI) majority-owned subsidiary, and Dr. Donald Montgomery.
Under the agreement, Nanogen will receive cash payments totaling $1 million, seventeen and one-half percent (17.5%) of the outstanding shares of CombiMatrix common stock, and royalty payments of twelve and one-half percent (12.5%) on sales of products developed by either CombiMatrix or its affiliates that incorporate the disputed technology. Additionally, the settlement agreement provides for certain minimum annual royalty payments and that the equity interest in CombiMatrix will be non-dilutive under certain circumstances for a period of up to three years. Also, as part of the settlement agreement, Nanogen, CombiMatrix and Dr. Montgomery have agreed to drop their claims and counterclaims.
"We are extremely pleased with the terms of the settlement agreement with CombiMatrix and Dr. Montgomery," commented Howard C. Birndorf, Executive Chairman and Chairman of the Board of Nanogen. "We believe this is a clear win for Nanogen. We have developed a valuable portfolio of intellectual property that we intend to protect. It is important to note that as part of this settlement, Nanogen did not out-license any technology fundamental to our core product line. The cash payment of $1 million will compensate us for the litigation costs incurred in protecting our rights to the disputed technology, while the equity and royalty payments ensure that Nanogen will participate in any benefit resulting from CombiMatrix`s further development and commercialization of this technology. By reaching a settlement, we gain an additional benefit of avoiding further legal costs, thereby helping us to meet our stated objective of reducing Nanogen`s operating expenses."
In November 2000, Nanogen filed a complaint in the United States District Court for the Southern District of California against CombiMatrix and Dr. Montgomery, a former employee of Nanogen, who is affiliated with CombiMatrix. Nanogen`s complaint alleged that Dr. Montgomery misappropriated Nanogen technology after he left Nanogen by disclosing trade secrets to CombiMatrix and by filing patent applications on those trade secrets in his name. Nanogen`s complaint sought a correction of inventorship on U.S. Patents No. 6,093,302, 6,280,595 and related patents or applications, assignment of rights in those patents or applications to Nanogen, an injunction preventing disclosure of trade secrets and damages for trade secret misappropriation. Nanogen`s claims also included breach of written contract relating to a settlement agreement entered into between Nanogen and Dr. Montgomery in February 1996, inducing breach of a written contract, breach of the implied covenant of good faith and fair dealing, intentional interference with prospective economic advantage and unfair competition. In June 2002, the court permitted Nanogen to amend its complaint to include an additional claim against Dr. Montgomery for fraudulent inducement to enter into the settlement agreement.
About Nanogen, Inc.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X74716691
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer, +1-858-410-4605, or
William Franzblau, Esq., Vice President, Legal Affairs, +1-858-410-4604, both
of Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Oct 1, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Nanogen to Receive $1 Million, Royalties and Equity Stake -
Nanogen, Inc. (Nasdaq: NGEN) announced today the settlement of its pending litigation with CombiMatrix Corporation, Acacia Research Corporation`s (Nasdaq: ACRI) majority-owned subsidiary, and Dr. Donald Montgomery.
Under the agreement, Nanogen will receive cash payments totaling $1 million, seventeen and one-half percent (17.5%) of the outstanding shares of CombiMatrix common stock, and royalty payments of twelve and one-half percent (12.5%) on sales of products developed by either CombiMatrix or its affiliates that incorporate the disputed technology. Additionally, the settlement agreement provides for certain minimum annual royalty payments and that the equity interest in CombiMatrix will be non-dilutive under certain circumstances for a period of up to three years. Also, as part of the settlement agreement, Nanogen, CombiMatrix and Dr. Montgomery have agreed to drop their claims and counterclaims.
"We are extremely pleased with the terms of the settlement agreement with CombiMatrix and Dr. Montgomery," commented Howard C. Birndorf, Executive Chairman and Chairman of the Board of Nanogen. "We believe this is a clear win for Nanogen. We have developed a valuable portfolio of intellectual property that we intend to protect. It is important to note that as part of this settlement, Nanogen did not out-license any technology fundamental to our core product line. The cash payment of $1 million will compensate us for the litigation costs incurred in protecting our rights to the disputed technology, while the equity and royalty payments ensure that Nanogen will participate in any benefit resulting from CombiMatrix`s further development and commercialization of this technology. By reaching a settlement, we gain an additional benefit of avoiding further legal costs, thereby helping us to meet our stated objective of reducing Nanogen`s operating expenses."
In November 2000, Nanogen filed a complaint in the United States District Court for the Southern District of California against CombiMatrix and Dr. Montgomery, a former employee of Nanogen, who is affiliated with CombiMatrix. Nanogen`s complaint alleged that Dr. Montgomery misappropriated Nanogen technology after he left Nanogen by disclosing trade secrets to CombiMatrix and by filing patent applications on those trade secrets in his name. Nanogen`s complaint sought a correction of inventorship on U.S. Patents No. 6,093,302, 6,280,595 and related patents or applications, assignment of rights in those patents or applications to Nanogen, an injunction preventing disclosure of trade secrets and damages for trade secret misappropriation. Nanogen`s claims also included breach of written contract relating to a settlement agreement entered into between Nanogen and Dr. Montgomery in February 1996, inducing breach of a written contract, breach of the implied covenant of good faith and fair dealing, intentional interference with prospective economic advantage and unfair competition. In June 2002, the court permitted Nanogen to amend its complaint to include an additional claim against Dr. Montgomery for fraudulent inducement to enter into the settlement agreement.
About Nanogen, Inc.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X74716691
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer, +1-858-410-4605, or
William Franzblau, Esq., Vice President, Legal Affairs, +1-858-410-4604, both
of Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Bionomics and Nanogen in Epilepsy Diagnostic Deal
SAN DIEGO and ADELAIDE, Australia, Oct 01, 2002 /PRNewsire-FirstCall via Comtex/ -- Nanogen, Inc. (Nasdaq: NGEN) and Bionomics Limited (ASX: BNO) have announced a development collaboration and license agreement to develop a new generation diagnostic product for epilepsy. The development program will utilize Nanogen`s NanoChip(R) Molecular Biology Workstation, a gene-chip approach to the rapid and accurate detection of gene variations, and Bionomics` world-exclusive epilepsy gene discoveries.
The unique, open-architecture design of the Nanogen instrument will permit Bionomics researchers to define, select and build their own diagnostic tests. Any diagnostic related intellectual property resulting from this collaboration will be exclusively licensed to Nanogen. In return, Nanogen will provide Bionomics with research support and funding, including development and commercialization milestone payments and royalties.
Bionomics CEO and Managing Director, Dr. Deborah Rathjen, said the deal was another key business milestone for the Adelaide-based company. "This collaboration with Nanogen is very exciting because it combines epilepsy gene discoveries from Bionomics` proprietary ionX(TM) discovery platform with Nanogen`s cutting-edge NanoChip(R) technology. The collaboration specifically focuses on the development of the world`s first molecular diagnostic test for epilepsy. This test will enable the rapid and accurate selection of treatment paths for epilepsy patients, leading to safer and more effective treatment and management of this serious condition," Dr. Rathjen said.
"We are very pleased to have the opportunity to combine the power of Nanogen`s electronic microarray and Bionomics` world-class scientific team," said Dr. Randy White, Chief Executive Officer of Nanogen. "DNA diagnostics for epilepsy represents a very large market opportunity that Bionomics and Nanogen may be uniquely positioned to serve. Nanogen plans to incorporate all relevant epilepsy diagnostic tests that are developed as part of this relationship into our growing menu of genetic based tests."
In the US there are approximately two million diagnosed cases of epilepsy, with an additional 180,000 new cases of epilepsy diagnosed each year. Current diagnostic methods of epilepsy rely on experienced clinicians interpreting physical symptoms or real-time measures of brain electrical activity. The process of diagnosis can be extremely time intensive and carry high medical costs, with incorrect diagnosis leading to serious adverse effects and, in extreme cases, death.
About Bionomics Limited
Bionomics Limited is an Australian Stock Exchange (ASX) listed biotechnology company based in Adelaide, Australia. Bionomics combines its strong genomics-based research focus on the discovery of genes associated with serious medical conditions with validation and development efforts leading to new drugs, gene therapies and diagnostic applications. Bionomics focuses its research and development activities in breast cancer, epilepsy and angiogenesis (a critical process involved in serious diseases such as cancer, chronic inflammatory diseases and eye diseases). These diseases are in need of improved medical treatments and represent large markets for Bionomics- developed products. Importantly, Bionomics has exclusive access to clinical material and clinical insights, which in combination with its platform of core technologies, diverse set of skills and expertise and strategic academic and commercial collaborations, positions Bionomics as a world leader in the fields of rapid disease gene and drug discovery, therapeutic and diagnostic product development.
Bionomics leverages its gene discoveries in epilepsy with the Bionomics-developed ionX(TM) discovery platform, a novel platform for the discovery and development of new and more effective treatments for epilepsy and other CNS disorders. The global CNS market is the second largest sector of the pharmaceuticals market, valued in 2001 at US$52 billion and projected to grow to US$77 billion by 2007. For more information about Bionomics, visit www.bionomics.com.au .
About Nanogen Inc.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X56396261
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Dr. Deborah Rathjen, CEO & Managing Director of Bionomics
Limited, (011) 61-8-8354-6101
URL: http://www.prnewswire.com
http://www.bionomics.com.a
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO and ADELAIDE, Australia, Oct 01, 2002 /PRNewsire-FirstCall via Comtex/ -- Nanogen, Inc. (Nasdaq: NGEN) and Bionomics Limited (ASX: BNO) have announced a development collaboration and license agreement to develop a new generation diagnostic product for epilepsy. The development program will utilize Nanogen`s NanoChip(R) Molecular Biology Workstation, a gene-chip approach to the rapid and accurate detection of gene variations, and Bionomics` world-exclusive epilepsy gene discoveries.
The unique, open-architecture design of the Nanogen instrument will permit Bionomics researchers to define, select and build their own diagnostic tests. Any diagnostic related intellectual property resulting from this collaboration will be exclusively licensed to Nanogen. In return, Nanogen will provide Bionomics with research support and funding, including development and commercialization milestone payments and royalties.
Bionomics CEO and Managing Director, Dr. Deborah Rathjen, said the deal was another key business milestone for the Adelaide-based company. "This collaboration with Nanogen is very exciting because it combines epilepsy gene discoveries from Bionomics` proprietary ionX(TM) discovery platform with Nanogen`s cutting-edge NanoChip(R) technology. The collaboration specifically focuses on the development of the world`s first molecular diagnostic test for epilepsy. This test will enable the rapid and accurate selection of treatment paths for epilepsy patients, leading to safer and more effective treatment and management of this serious condition," Dr. Rathjen said.
"We are very pleased to have the opportunity to combine the power of Nanogen`s electronic microarray and Bionomics` world-class scientific team," said Dr. Randy White, Chief Executive Officer of Nanogen. "DNA diagnostics for epilepsy represents a very large market opportunity that Bionomics and Nanogen may be uniquely positioned to serve. Nanogen plans to incorporate all relevant epilepsy diagnostic tests that are developed as part of this relationship into our growing menu of genetic based tests."
In the US there are approximately two million diagnosed cases of epilepsy, with an additional 180,000 new cases of epilepsy diagnosed each year. Current diagnostic methods of epilepsy rely on experienced clinicians interpreting physical symptoms or real-time measures of brain electrical activity. The process of diagnosis can be extremely time intensive and carry high medical costs, with incorrect diagnosis leading to serious adverse effects and, in extreme cases, death.
About Bionomics Limited
Bionomics Limited is an Australian Stock Exchange (ASX) listed biotechnology company based in Adelaide, Australia. Bionomics combines its strong genomics-based research focus on the discovery of genes associated with serious medical conditions with validation and development efforts leading to new drugs, gene therapies and diagnostic applications. Bionomics focuses its research and development activities in breast cancer, epilepsy and angiogenesis (a critical process involved in serious diseases such as cancer, chronic inflammatory diseases and eye diseases). These diseases are in need of improved medical treatments and represent large markets for Bionomics- developed products. Importantly, Bionomics has exclusive access to clinical material and clinical insights, which in combination with its platform of core technologies, diverse set of skills and expertise and strategic academic and commercial collaborations, positions Bionomics as a world leader in the fields of rapid disease gene and drug discovery, therapeutic and diagnostic product development.
Bionomics leverages its gene discoveries in epilepsy with the Bionomics-developed ionX(TM) discovery platform, a novel platform for the discovery and development of new and more effective treatments for epilepsy and other CNS disorders. The global CNS market is the second largest sector of the pharmaceuticals market, valued in 2001 at US$52 billion and projected to grow to US$77 billion by 2007. For more information about Bionomics, visit www.bionomics.com.au .
About Nanogen Inc.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X56396261
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Dr. Deborah Rathjen, CEO & Managing Director of Bionomics
Limited, (011) 61-8-8354-6101
URL: http://www.prnewswire.com
http://www.bionomics.com.a
Copyright (C) 2002 PR Newswire. All rights reserved.
Hi tst89,
sind wir die letzen beiden dt. Nanogen-Aktionäre ???
Habe vor kurzem die IR angemailt und (in Englisch)
Informationen und eine Stellungnahme zum Kursverlauf
angefordert - und bis heute keine Antwort erhalten
Weist du außer den Koop-Adhocs noch andere u.U. erfreuliche
News ???
RK (allein mit ngen
)
sind wir die letzen beiden dt. Nanogen-Aktionäre ???
Habe vor kurzem die IR angemailt und (in Englisch)
Informationen und eine Stellungnahme zum Kursverlauf
angefordert - und bis heute keine Antwort erhalten
Weist du außer den Koop-Adhocs noch andere u.U. erfreuliche
News ???RK (allein mit ngen
)
Hi Realkamikaze!
ich glaube nicht dass wir die letzten NGEN-Aktionäre sind.
Glaube eher dass wir die einzigen sind die sich bei diesem Umfeld trauen ein paar Zeilen zu schreiben.
Leider habe ich auch keine anderen Infos außer die Pressemitteilungen und andere Ami-Boards.
Wie siehst Du NGEN auf längere Sicht hin?
Meine Meinung ist klar oder??
Viele Grüße
tst
ich glaube nicht dass wir die letzten NGEN-Aktionäre sind.
Glaube eher dass wir die einzigen sind die sich bei diesem Umfeld trauen ein paar Zeilen zu schreiben.
Leider habe ich auch keine anderen Infos außer die Pressemitteilungen und andere Ami-Boards.
Wie siehst Du NGEN auf längere Sicht hin?
Meine Meinung ist klar oder??
Viele Grüße
tst
Nein, ich denke ihr seid nicht die einzigen nur schneller mit dem posten............. ;-)))
Acacia Research Unit Settles Litigation With Nanogen
SAN DIEGO -(Dow Jones)- Acacia Research Corp.`s (ACRI) CombiMatrix Corp. unit settled a lawsuit filed by Nanogen Inc. (NGEN) and agreed to pay the microelectronics technology maker $1 million in cash to cover litigation costs and issue 4 million common shares, or 17.5% of its unit`s stock.
In a press release Tuesday, Acacia said it also will make royalty payments of 12.5% to the San Diego-based company on sales of products developed by either CombiMatrix or its affiliates that use the disputed technology.
Separately, Nanogen confirmed the settlement and said its new equity interest in CombiMatrix will be non-dilutive under certain circumstances for up to three years.
The almost two-year-old lawsuit began when Nanogen filed a complaint against CombiMatrix and Donald Montgomery, a former employee of Nanogen who is affiliated with CombiMatrix. The suit alleged Montgomery took Nanogen`s technology after he left the company, disclosed the trade secrets to CombiMatrix and filed a patent application related to that information under his name. The claims also alleged Montgomery breached several contracts and agreements with the company.
As part of the settlement, Nanogen, CombiMatrix and Montgomery all agreed to drop their claims and counterclaims.
Acacia Research Unit Settles Litigation With Nanogen
SAN DIEGO -(Dow Jones)- Acacia Research Corp.`s (ACRI) CombiMatrix Corp. unit settled a lawsuit filed by Nanogen Inc. (NGEN) and agreed to pay the microelectronics technology maker $1 million in cash to cover litigation costs and issue 4 million common shares, or 17.5% of its unit`s stock.
In a press release Tuesday, Acacia said it also will make royalty payments of 12.5% to the San Diego-based company on sales of products developed by either CombiMatrix or its affiliates that use the disputed technology.
Separately, Nanogen confirmed the settlement and said its new equity interest in CombiMatrix will be non-dilutive under certain circumstances for up to three years.
The almost two-year-old lawsuit began when Nanogen filed a complaint against CombiMatrix and Donald Montgomery, a former employee of Nanogen who is affiliated with CombiMatrix. The suit alleged Montgomery took Nanogen`s technology after he left the company, disclosed the trade secrets to CombiMatrix and filed a patent application related to that information under his name. The claims also alleged Montgomery breached several contracts and agreements with the company.
As part of the settlement, Nanogen, CombiMatrix and Montgomery all agreed to drop their claims and counterclaims.
Nanogen to Present at UBS Warburg Global Life Sciences Conference on October 8
SAN DIEGO, Oct 2, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that the Company will be presenting at the UBS Warburg Global Life Sciences Conference on Tuesday, October 8, 2001 at 1:30 p.m. ET. Mr. Howard Birndorf and Dr. Randy White, Nanogen`s Executive Chairman and Chief Executive Officer respectively, will provide a corporate overview and discuss the Company`s strategy for pursuing a leadership position in the molecular diagnostics market.
An audio webcast of the presentation will be available online through Nanogen`s website at www.nanogen.com and will be archived until November 10, 2002. Slides used will also be available on Nanogen`s website.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X11792867
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605, or Pam Lord, Media Relations of Susan E. Atkins & Associates,
+1-858-527-3494, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Oct 2, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that the Company will be presenting at the UBS Warburg Global Life Sciences Conference on Tuesday, October 8, 2001 at 1:30 p.m. ET. Mr. Howard Birndorf and Dr. Randy White, Nanogen`s Executive Chairman and Chief Executive Officer respectively, will provide a corporate overview and discuss the Company`s strategy for pursuing a leadership position in the molecular diagnostics market.
An audio webcast of the presentation will be available online through Nanogen`s website at www.nanogen.com and will be archived until November 10, 2002. Slides used will also be available on Nanogen`s website.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X11792867
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605, or Pam Lord, Media Relations of Susan E. Atkins & Associates,
+1-858-527-3494, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
So jetzt steht der NGEN-Thread wieder oben
Hi zusammen,.................
bin natürlich bullish,...........
nee, jetzt mal im Ernst:
Ngen hat einen Haufen guter Produkte in der Pipeline,
so z.B. den Chip-Schnelltest für den Polizeieinsatz,
verbrennt allerdings einen Haufen Cash und generiert
dabei zu wenig Umsatz. Eine Verdopplung des Umsatzes halte
ich bei gegenwärtigem Umfeld für unwahrscheinlich.
Bleiben also (bei gegenwärtiger Lage) noch 6 Quartale,
danach braucht ngen entweder mehr Cash (Kapitalerhöhung),
doppelten Umsatz, oder 
.
Einziger Lichtblick sind die vielen Patente, so dass es
eigentlich auch Interessenten für eine Übernahme geben
müsste - leider kaufen die Großen zunehmend aus der Inso-
Masse, anstatt die Aktionäre mit zu beteiligen. Hoffen wir
also auf ein besseres wirtschaftliches Umfeld oder einen
Investor, oder auf Bush Junior und sein AntiTerror-Paket,
dass ja Ngen auch die letzte Rally bis € 12,xx beschert hat.
Auch eure Meinung würde mich interessieren !!!!
Es grüßt
RK ( 1800 St. zu über € 10,00 )
bin natürlich bullish,
...........nee, jetzt mal im Ernst:
Ngen hat einen Haufen guter Produkte in der Pipeline,
so z.B. den Chip-Schnelltest für den Polizeieinsatz,
verbrennt allerdings einen Haufen Cash und generiert
dabei zu wenig Umsatz. Eine Verdopplung des Umsatzes halte
ich bei gegenwärtigem Umfeld für unwahrscheinlich.
Bleiben also (bei gegenwärtiger Lage) noch 6 Quartale,
danach braucht ngen entweder mehr Cash (Kapitalerhöhung),
doppelten Umsatz, oder
.Einziger Lichtblick sind die vielen Patente, so dass es
eigentlich auch Interessenten für eine Übernahme geben
müsste - leider kaufen die Großen zunehmend aus der Inso-
Masse, anstatt die Aktionäre mit zu beteiligen. Hoffen wir
also auf ein besseres wirtschaftliches Umfeld oder einen
Investor, oder auf Bush Junior und sein AntiTerror-Paket,
dass ja Ngen auch die letzte Rally bis € 12,xx beschert hat.
Auch eure Meinung würde mich interessieren !!!!
Es grüßt
RK ( 1800 St. zu über € 10,00
)
Haaallloooooooooooooooo
RK (allein leidend )
RK (allein leidend
)
Hier die Präsentation bei UBS Warburg:
http://media.corporate-ir.net/media_files/NSD/NGEN/presentat…
http://media.corporate-ir.net/media_files/NSD/NGEN/presentat…
Hi RK!
Ebenfalls bullish, was sonst?!
Ich finde NGEN hat für eine Bio-Tech Firma ziemlich viel
Cash und deswegen haben sie noch genügend Zeit um ihre
vielversprechenden Produkte und extrem viele Patente´zu Kohle zu machen.
Und so böse es ist aber die könnten von dem Cowboy der die Staaten regiert ebenfalls profitieren.
Grüße
tst
Ebenfalls bullish, was sonst?!
Ich finde NGEN hat für eine Bio-Tech Firma ziemlich viel
Cash und deswegen haben sie noch genügend Zeit um ihre
vielversprechenden Produkte und extrem viele Patente´zu Kohle zu machen.
Und so böse es ist aber die könnten von dem Cowboy der die Staaten regiert ebenfalls profitieren.
Grüße
tst
Nanogen Announces Placement of NanoChip(R) Molecular Biology Workstations at Top Clinical Laboratories
SAN DIEGO, Oct 9, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Update on Product Development Provided at UBS Warburg Conference -
Nanogen, Inc. (Nasdaq: NGEN) announced yesterday during its presentation at the UBS Warburg Global Life Sciences Conference in New York City that it has placed 10 NanoChip(R) Molecular Biology Workstations during the third quarter, including four at major clinical reference laboratories nationwide. To date, the Company has placed five systems at clinical reference laboratories. In addition, Nanogen converted two additional Development Site Agreement (DSA) customers to sales transactions in the third quarter, further confirming its business strategy of placing and converting DSAs at key customer sites. This brings the total number of placements for 2002 to 28 and DSA conversions to six.
Of the four systems placed at clinical laboratories during the third quarter, two were placed in top 10 national clinical reference laboratories while the remaining two systems were installed at leading regional clinical laboratories.
"We`re pleased to be working with several of the top clinical reference laboratories in the country. It is evident that the development of our cystic fibrosis Analyte Specific Reagent (ASR) is driving demand for our NanoChip(R) platform. The expansion of our customer base to include commercial clinical laboratories is validation that our system is meeting customers` demands for flexibility and operational simplicity combined with favorable throughput," said Dr. Randy White, Chief Executive Officer of Nanogen. "We believe that adoption of our system in clinical laboratories will continue to increase as we expand our menu to include another eight ASRs by year end, putting Nanogen among the top companies marketing molecular diagnostic products."
At the conference in New York, White also elaborated on Nanogen`s expanding menu offerings, which now include a license to Apolipoprotein-E with a medical claim for Alzheimer`s disease. White also stated that two laboratories are currently testing Nanogen`s 3-SNP (Single Nucleotide Polymorphism) multiplex ASR for the simultaneous detection of the most common mutations associated with Hereditary Hemachromatosis (HH). HH is an iron overload disease and one of the most common genetic disorders in the world. Nanogen`s ASR is expected to be the first 3-SNP ASR for HH to reach the diagnostic market.
The NanoChip(R) Molecular Biology Workstation is an automated multi-purpose instrument that facilitates detection of known genetic sequences, such as in the analysis of SNPs and Short Tandem Repeats (STRs) using the NanoChip(R) Electronic Microarray. The unique, open-architecture design permits researchers to define, select and build their own test panels or select from Nanogen-developed ASRs.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip(R) System and NanoChip(R) Cartridges, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X56139325
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates,
+1-858-527-3494, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Oct 9, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Update on Product Development Provided at UBS Warburg Conference -
Nanogen, Inc. (Nasdaq: NGEN) announced yesterday during its presentation at the UBS Warburg Global Life Sciences Conference in New York City that it has placed 10 NanoChip(R) Molecular Biology Workstations during the third quarter, including four at major clinical reference laboratories nationwide. To date, the Company has placed five systems at clinical reference laboratories. In addition, Nanogen converted two additional Development Site Agreement (DSA) customers to sales transactions in the third quarter, further confirming its business strategy of placing and converting DSAs at key customer sites. This brings the total number of placements for 2002 to 28 and DSA conversions to six.
Of the four systems placed at clinical laboratories during the third quarter, two were placed in top 10 national clinical reference laboratories while the remaining two systems were installed at leading regional clinical laboratories.
"We`re pleased to be working with several of the top clinical reference laboratories in the country. It is evident that the development of our cystic fibrosis Analyte Specific Reagent (ASR) is driving demand for our NanoChip(R) platform. The expansion of our customer base to include commercial clinical laboratories is validation that our system is meeting customers` demands for flexibility and operational simplicity combined with favorable throughput," said Dr. Randy White, Chief Executive Officer of Nanogen. "We believe that adoption of our system in clinical laboratories will continue to increase as we expand our menu to include another eight ASRs by year end, putting Nanogen among the top companies marketing molecular diagnostic products."
At the conference in New York, White also elaborated on Nanogen`s expanding menu offerings, which now include a license to Apolipoprotein-E with a medical claim for Alzheimer`s disease. White also stated that two laboratories are currently testing Nanogen`s 3-SNP (Single Nucleotide Polymorphism) multiplex ASR for the simultaneous detection of the most common mutations associated with Hereditary Hemachromatosis (HH). HH is an iron overload disease and one of the most common genetic disorders in the world. Nanogen`s ASR is expected to be the first 3-SNP ASR for HH to reach the diagnostic market.
The NanoChip(R) Molecular Biology Workstation is an automated multi-purpose instrument that facilitates detection of known genetic sequences, such as in the analysis of SNPs and Short Tandem Repeats (STRs) using the NanoChip(R) Electronic Microarray. The unique, open-architecture design permits researchers to define, select and build their own test panels or select from Nanogen-developed ASRs.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether Development Sites will result in future sales of the NanoChip(R) System and NanoChip(R) Cartridges, whether regulatory clearances or approvals will be obtained, whether Nanogen will be successful in developing additional protocols, whether Nanogen will be successful in developing FDA approved molecular diagnostic tests utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001, filed with the securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X56139325
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates,
+1-858-527-3494, for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Die nächsten Events wo NGEN vertreten ist:
DATE EVENT TITLE
10/08/02 - 10/10/02 MedExpo
10/15/02 - 10/20/02 American Society of Human Genetics
10/17/02 - 10/18/02 Provincial Laboratory for Public...
10/25/02 - 10/26/02 DNA Chip Seminar
11/04/02 - 11/08/02 Het instrument
11/14/02 - 11/17/02 AACC San Diego Conference
11/14/02 - 11/18/02 Association for Molecular Pathology
11/20/02 - 11/23/02 Medica
DATE EVENT TITLE
10/08/02 - 10/10/02 MedExpo
10/15/02 - 10/20/02 American Society of Human Genetics
10/17/02 - 10/18/02 Provincial Laboratory for Public...
10/25/02 - 10/26/02 DNA Chip Seminar
11/04/02 - 11/08/02 Het instrument
11/14/02 - 11/17/02 AACC San Diego Conference
11/14/02 - 11/18/02 Association for Molecular Pathology
11/20/02 - 11/23/02 Medica
Ein ganz netter und interessanter Link:
http://partners.thomsoninvest.net/thestreet/cgi-bin/info_dis…
http://partners.thomsoninvest.net/thestreet/cgi-bin/info_dis…
Und ein neues Patent vom 22.10.
Nanogen » Investor News » Patents » Patent Details
U.S. Patent No. 6,468,742 – “Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip”
October 22, 2002
Inventors:
Michael I. Nerenberg
David M. Canter
Ray R. Radtkey
Ling Wang
James P. O`Connell
Ronald G. Sosnowski
Abstract:
Methods are provided for the analysis and determination of the nature of single nucleic acid polymorphisms (SNPs) in a genetic target. In one method of this invention, the nature of the SNPs in the genetic target is determined by the steps of providing a plurality of hybridization complexes arrayed on a plurality of test sites on an electronically bioactive microchip, where the hybridization complex includes at least a nucleic acid target containing a SNP, a stabilizer probe having a sequence complementary to the target sequence and/or reporter probe, and a reporter probe having a selected sequence complementary to either the stabilizer or the same target sequence strand wherein a selected sequence of the reporter includes either a wild type nucleotide or a nucleotide corresponding to the SNP of the target. In accordance with the invention, the stabilizer, reporter and target amplicons are hybridized using electronic assistance of the microchip system such that base-stacking energies are utilized in discerning among other identifying indicators, the presence of wild type or polymorphism sequence. Applications include disease diagnostics, such as for the identification of polymorphisms in structural genes, regulatory regions, antibiotic or chemotherapeutic resistance conferring regions, or for SNPs associated with speciation or used for determination of genetic linkage.
Nanogen » Investor News » Patents » Patent Details
U.S. Patent No. 6,468,742 – “Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip”
October 22, 2002
Inventors:
Michael I. Nerenberg
David M. Canter
Ray R. Radtkey
Ling Wang
James P. O`Connell
Ronald G. Sosnowski
Abstract:
Methods are provided for the analysis and determination of the nature of single nucleic acid polymorphisms (SNPs) in a genetic target. In one method of this invention, the nature of the SNPs in the genetic target is determined by the steps of providing a plurality of hybridization complexes arrayed on a plurality of test sites on an electronically bioactive microchip, where the hybridization complex includes at least a nucleic acid target containing a SNP, a stabilizer probe having a sequence complementary to the target sequence and/or reporter probe, and a reporter probe having a selected sequence complementary to either the stabilizer or the same target sequence strand wherein a selected sequence of the reporter includes either a wild type nucleotide or a nucleotide corresponding to the SNP of the target. In accordance with the invention, the stabilizer, reporter and target amplicons are hybridized using electronic assistance of the microchip system such that base-stacking energies are utilized in discerning among other identifying indicators, the presence of wild type or polymorphism sequence. Applications include disease diagnostics, such as for the identification of polymorphisms in structural genes, regulatory regions, antibiotic or chemotherapeutic resistance conferring regions, or for SNPs associated with speciation or used for determination of genetic linkage.
Die 38-Tages-Linie sollte mal endlich überschritten werden:
Sollte dies ein gutes Omen für NGEN sein???
Aventis übertrifft Ergebnisprognose Dienstag, 29.10.02, 11:27
Der Pharmakonzern Aventis SA konnte seinen Umsatz in den ersten neun Monaten um 11,5 Prozent auf 13,033 Mrd. Euro steigern. Das EBITDA verbesserte sich um 20,0 Prozent auf 3,292 Mrd. Euro.
Im dritten Quartal kletterte das EBITDA um 15,0 Prozent auf 1,182 Mrd. Euro. Der Nettogewinn erhöhte sich um 21,0 Prozent auf 560,0 Mio. Euro oder 71 Cents je Aktie, während Analysten durchschnittlich nur mit einem Ergebnis von 68 Cents gerechnet hatten. Ursache des Gewinnanstiegs seien niedrigere Zins- und Steueraufwendungen.
Mit diesen Zahlen liege das Unternehmen zudem im Plan für das Ergebnisziel im Gesamtjahr. Aventis will in 2002 das Ergebnis je Aktie um 25,0 bis 30,0 Prozent steigern und ein Umsatzwachstum von 11,0 oder 12,0 Prozent erzielen.
Aventis übertrifft Ergebnisprognose Dienstag, 29.10.02, 11:27
Der Pharmakonzern Aventis SA konnte seinen Umsatz in den ersten neun Monaten um 11,5 Prozent auf 13,033 Mrd. Euro steigern. Das EBITDA verbesserte sich um 20,0 Prozent auf 3,292 Mrd. Euro.
Im dritten Quartal kletterte das EBITDA um 15,0 Prozent auf 1,182 Mrd. Euro. Der Nettogewinn erhöhte sich um 21,0 Prozent auf 560,0 Mio. Euro oder 71 Cents je Aktie, während Analysten durchschnittlich nur mit einem Ergebnis von 68 Cents gerechnet hatten. Ursache des Gewinnanstiegs seien niedrigere Zins- und Steueraufwendungen.
Mit diesen Zahlen liege das Unternehmen zudem im Plan für das Ergebnisziel im Gesamtjahr. Aventis will in 2002 das Ergebnis je Aktie um 25,0 bis 30,0 Prozent steigern und ein Umsatzwachstum von 11,0 oder 12,0 Prozent erzielen.
Press Release Source: DNAPrint genomics, Inc.
DNAPrint Enters Into Development Site Agreement With Nanogen to Develop DNA Chip Based Tests
Tuesday October 29, 10:15 am ET
SARASOTA, Fla.--(BUSINESS WIRE)--Oct. 29, 2002--DNAPrint genomics, Inc. (OTCBB
NAP - News; "DNAPrint" or the "Company") announced today that it has entered into a Development Site Agreement to develop DNA chip-based tests with San Diego-based Nanogen, Inc. (Nasdaq:NGEN - News).
The Agreement calls for DNAPrint to develop NanoChip® versions of its proprietary genomics tests. DNAPrint`s tests are complex because they involve the simultaneous reading of large sets of genetic markers or positions per sample, and the NanoChip® Molecular Biology Workstation platform is well suited for this type of test.
DNAPrint intends to first validate the performance of the tests on the NanoChip® platform, and if successful, both companies would then co-market the new tests for clinical and field application. Nanogen would receive a royalty on each NanoChip®-based test sold. The Agreement provides DNAPrint with a non-exclusive license to perform certain pharmacogenomics, recreational and forensics genomics testing services on the NanoChip® platform. Other terms of the agreement were not disclosed.
The Agreement is the second that DNAPrint has signed for helping it graduate tests from its pipeline to market. Earlier this year, the Company signed an agreement with Denmark-based Exiqon, enabling the Company to use Locked-Nucleic Acid (LNA) technology in order to increase the specificity of synthetic DNA oligonucleotides used in its tests.
About DNAPrint genomics, Inc.:
DNAPrint genomics Inc. is a personalized medicine company founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
--------------------------------------------------------------------------------
Contact:
DNAPrint genomics, Inc., Sarasota
Carrie Castillo, 941/366-3400
castillo@dnaprint.com
--------------------------------------------------------------------------------
Source: DNAPrint genomics, Inc.
DNAPrint Enters Into Development Site Agreement With Nanogen to Develop DNA Chip Based Tests
Tuesday October 29, 10:15 am ET
SARASOTA, Fla.--(BUSINESS WIRE)--Oct. 29, 2002--DNAPrint genomics, Inc. (OTCBB
NAP - News; "DNAPrint" or the "Company") announced today that it has entered into a Development Site Agreement to develop DNA chip-based tests with San Diego-based Nanogen, Inc. (Nasdaq:NGEN - News). The Agreement calls for DNAPrint to develop NanoChip® versions of its proprietary genomics tests. DNAPrint`s tests are complex because they involve the simultaneous reading of large sets of genetic markers or positions per sample, and the NanoChip® Molecular Biology Workstation platform is well suited for this type of test.
DNAPrint intends to first validate the performance of the tests on the NanoChip® platform, and if successful, both companies would then co-market the new tests for clinical and field application. Nanogen would receive a royalty on each NanoChip®-based test sold. The Agreement provides DNAPrint with a non-exclusive license to perform certain pharmacogenomics, recreational and forensics genomics testing services on the NanoChip® platform. Other terms of the agreement were not disclosed.
The Agreement is the second that DNAPrint has signed for helping it graduate tests from its pipeline to market. Earlier this year, the Company signed an agreement with Denmark-based Exiqon, enabling the Company to use Locked-Nucleic Acid (LNA) technology in order to increase the specificity of synthetic DNA oligonucleotides used in its tests.
About DNAPrint genomics, Inc.:
DNAPrint genomics Inc. is a personalized medicine company founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com.
All statements in this press release that are not historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
--------------------------------------------------------------------------------
Contact:
DNAPrint genomics, Inc., Sarasota
Carrie Castillo, 941/366-3400
castillo@dnaprint.com
--------------------------------------------------------------------------------
Source: DNAPrint genomics, Inc.
Nanogen To Host Conference Call On 2002 Third Quarter Financial Results Monday, November 4, At 4:30 PM ET, 1:30 PM PT
SAN DIEGO, Oct 29, 2002 (BUSINESS WIRE) -- Nanogen, Inc. (Nasdaq:NGEN) will host a conference call on Monday, November 4, 2002 at 4:30 p.m. ET to discuss 2002 third quarter financial results. The earnings press release will be issued at close of market November 4, 2002.
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived until November 18, 2002. A digital recording of the call will also be available two hours after the completion of the conference call on November 4, 2002 until midnight on November 6, 2002, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 17321, will be required to listen to the playback.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Nanogen, Inc. Gerard A. Wills, 858/410-4605 gwills@nanogen.com or Atkins & Associates Pam Lord, 858/527-3494 plord@irpr.com URL: http://www.businesswire.com Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.
SAN DIEGO, Oct 29, 2002 (BUSINESS WIRE) -- Nanogen, Inc. (Nasdaq:NGEN) will host a conference call on Monday, November 4, 2002 at 4:30 p.m. ET to discuss 2002 third quarter financial results. The earnings press release will be issued at close of market November 4, 2002.
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived until November 18, 2002. A digital recording of the call will also be available two hours after the completion of the conference call on November 4, 2002 until midnight on November 6, 2002, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 17321, will be required to listen to the playback.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Nanogen, Inc. Gerard A. Wills, 858/410-4605 gwills@nanogen.com or Atkins & Associates Pam Lord, 858/527-3494 plord@irpr.com URL: http://www.businesswire.com Today`s News On The Net - Business Wire`s full file on the Internet with Hyperlinks to your home page.
Copyright (C) 2002 Business Wire. All rights reserved.
Clin Chem 2002 Nov;48(11):1873-82 Links
Multiplexed, targeted gene expression profiling and genetic analysis on electronic microarrays.
Weidenhammer EM, Kahl BF, Wang L, Wang L, Duhon M, Jackson JA, Slater M, Xu X.
Department of Research and Development, Nanogen, Inc., 10398 Pacific Center Ct., San Diego, CA 92121.
BACKGROUND: Electronic microarrays comprise independent microelectrode test sites that can be electronically biased positive or negative, or left neutral, to move and concentrate charged molecules such as DNA and RNA to one or more test sites. We developed a protocol for multiplexed gene expression profiling of mRNA targets that uses electronic field-facilitated hybridization on electronic microarrays. METHODS: A multiplexed, T7 RNA polymerase-mediated amplification method was used for expression profiling of target mRNAs from total cellular RNA; targets were detected by hybridization to sequence-specific capture oligonucleotides on electronic microarrays. Activation of individual test sites on the electronic microarray was used to target hybridization to designated subsets of sites and allow comparisons of target concentrations in different samples. We used multiplexed amplification and electronic field-facilitated hybridization to analyze expression of a model set of 10 target genes in the U937 cell line during lipopolysaccharide-mediated differentiation. Performance of multiple genetic analyses (single-nucleotide polymorphism detection, gene expression profiling, and splicing isoform detection) on a single electronic microarray was demonstrated using the ApoE and ApoER2 genes as a model system. RESULTS: Targets were detected after a 2-min hybridization reaction. With noncomplementary capture probes, no signal was detectable. Twofold changes in target concentration were detectable throughout the ( approximately 64-fold) range of concentrations tested. Levels of 10 targets were analyzed side by side across seven time points. By confining electronic activation to subsets of test sites, polymorphism detection, expression profiling, and splicing isoform analysis were performed on a single electronic microarray. CONCLUSIONS: Microelectronic array technology provides specific target detection and quantification with advantages over currently available methodologies for targeted gene expression profiling and combinatorial genomics testing.
PMID: 12406971 [PubMed - in process]
Multiplexed, targeted gene expression profiling and genetic analysis on electronic microarrays.
Weidenhammer EM, Kahl BF, Wang L, Wang L, Duhon M, Jackson JA, Slater M, Xu X.
Department of Research and Development, Nanogen, Inc., 10398 Pacific Center Ct., San Diego, CA 92121.
BACKGROUND: Electronic microarrays comprise independent microelectrode test sites that can be electronically biased positive or negative, or left neutral, to move and concentrate charged molecules such as DNA and RNA to one or more test sites. We developed a protocol for multiplexed gene expression profiling of mRNA targets that uses electronic field-facilitated hybridization on electronic microarrays. METHODS: A multiplexed, T7 RNA polymerase-mediated amplification method was used for expression profiling of target mRNAs from total cellular RNA; targets were detected by hybridization to sequence-specific capture oligonucleotides on electronic microarrays. Activation of individual test sites on the electronic microarray was used to target hybridization to designated subsets of sites and allow comparisons of target concentrations in different samples. We used multiplexed amplification and electronic field-facilitated hybridization to analyze expression of a model set of 10 target genes in the U937 cell line during lipopolysaccharide-mediated differentiation. Performance of multiple genetic analyses (single-nucleotide polymorphism detection, gene expression profiling, and splicing isoform detection) on a single electronic microarray was demonstrated using the ApoE and ApoER2 genes as a model system. RESULTS: Targets were detected after a 2-min hybridization reaction. With noncomplementary capture probes, no signal was detectable. Twofold changes in target concentration were detectable throughout the ( approximately 64-fold) range of concentrations tested. Levels of 10 targets were analyzed side by side across seven time points. By confining electronic activation to subsets of test sites, polymorphism detection, expression profiling, and splicing isoform analysis were performed on a single electronic microarray. CONCLUSIONS: Microelectronic array technology provides specific target detection and quantification with advantages over currently available methodologies for targeted gene expression profiling and combinatorial genomics testing.
PMID: 12406971 [PubMed - in process]
Keine fundamentalen News aber ein netter Link
http://www.nexus.edu.au/ozprojects/nanogen/nc20201.htm
http://www.nexus.edu.au/ozprojects/nanogen/nc20201.htm
Nucleic Acids Res 2002 Nov 1;30(21):4793-802 Related Articles, Links
Hydrazide oligonucleotides: new chemical modification for chip array attachment and conjugation.
Raddatz S, Mueller-Ibeler J, Kluge J, Wass L, Burdinski G, Havens JR, Onofrey TJ, Wang D, Schweitzer M.
Nanogen Recognomics GmbH, Industriepark Hochst G830, 65926 Frankfurt am Main, Germany and. Nanogen Inc., 10398 Pacific Center Court, San Diego, CA 92121, USA.
We report the synthesis of new phosphoramidite building blocks and their use for the modification of oligonucleotides with hydrazides. The reaction of these hydrazide oligonucleotides with active esters and aldehydes is demonstrated for solution conjugation and immobilization. Compared with the established amino modified oligonucleotides, hydrazides show enhanced reactivity at neutral and acidic buffer conditions. One method to introduce hydrazides is using amidites with preformed, protected hydrazides. A completely novel approach is the generation of the hydrazide functionality during the oligonucleotide cleavage and deprotection with hydrazine. Therefore, building blocks for the introduction of esters as hydrazide precursors are described. For the enhanced attachment on surfaces branched modifier amidites, which introduce up to four reactive groups to the oligonucleotide, are applied. The efficiency of branched hydrazide oligonucleotides compared with standard amino modified oligonucleotides for the immobilization of DNA on active electronic Nanogen chips is demonstrated.
PMID: 12409470 [PubMed - in process]
Hydrazide oligonucleotides: new chemical modification for chip array attachment and conjugation.
Raddatz S, Mueller-Ibeler J, Kluge J, Wass L, Burdinski G, Havens JR, Onofrey TJ, Wang D, Schweitzer M.
Nanogen Recognomics GmbH, Industriepark Hochst G830, 65926 Frankfurt am Main, Germany and. Nanogen Inc., 10398 Pacific Center Court, San Diego, CA 92121, USA.
We report the synthesis of new phosphoramidite building blocks and their use for the modification of oligonucleotides with hydrazides. The reaction of these hydrazide oligonucleotides with active esters and aldehydes is demonstrated for solution conjugation and immobilization. Compared with the established amino modified oligonucleotides, hydrazides show enhanced reactivity at neutral and acidic buffer conditions. One method to introduce hydrazides is using amidites with preformed, protected hydrazides. A completely novel approach is the generation of the hydrazide functionality during the oligonucleotide cleavage and deprotection with hydrazine. Therefore, building blocks for the introduction of esters as hydrazide precursors are described. For the enhanced attachment on surfaces branched modifier amidites, which introduce up to four reactive groups to the oligonucleotide, are applied. The efficiency of branched hydrazide oligonucleotides compared with standard amino modified oligonucleotides for the immobilization of DNA on active electronic Nanogen chips is demonstrated.
PMID: 12409470 [PubMed - in process]
Nanogen Announces Stock Repurchase Program
SAN DIEGO, Nov 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced that its Board of Directors has authorized a stock repurchase program under which the Company may purchase up to an aggregate of ten percent (10%) of its outstanding Common Stock as of the date hereof from time-to-time. The Company`s Board of Directors believes that Nanogen`s stock is undervalued and represents an attractive investment opportunity and the Nanogen stock repurchase program is consistent with the Company`s objectives of making prudent investments with the Company`s cash resources.
Any purchases under the Nanogen stock repurchase program may be made from time-to-time in the open market or in privately negotiated transactions and may be initiated and discontinued at any time. As of October 29, 2002, Nanogen had approximately 21,941,398 shares of its Common Stock outstanding. Common Stock acquired through this program will be available for general corporate purposes. There are currently no specific plans for the shares that may be purchased under the program.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two analyte specific reagents for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Nanogen stock purchase program will be a good investment for the Company, whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue with continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X26214513
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Pam Lord of Atkins + Associates, +1-858-527-3494, Media
Relations for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Nov 4, 2002 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced that its Board of Directors has authorized a stock repurchase program under which the Company may purchase up to an aggregate of ten percent (10%) of its outstanding Common Stock as of the date hereof from time-to-time. The Company`s Board of Directors believes that Nanogen`s stock is undervalued and represents an attractive investment opportunity and the Nanogen stock repurchase program is consistent with the Company`s objectives of making prudent investments with the Company`s cash resources.
Any purchases under the Nanogen stock repurchase program may be made from time-to-time in the open market or in privately negotiated transactions and may be initiated and discontinued at any time. As of October 29, 2002, Nanogen had approximately 21,941,398 shares of its Common Stock outstanding. Common Stock acquired through this program will be available for general corporate purposes. There are currently no specific plans for the shares that may be purchased under the program.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two analyte specific reagents for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Nanogen stock purchase program will be a good investment for the Company, whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue with continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X26214513
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc.,
+1-858-410-4605; or Pam Lord of Atkins + Associates, +1-858-527-3494, Media
Relations for Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Nanogen Reports 2002 Third Quarter Financial Results
SAN DIEGO, Nov 4, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Company Closes Ten Commercial Transactions During the Quarter, Including Four With Major U.S. Clinical Diagnostic Laboratories -
Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the third quarter ended September 30, 2002.
During the third quarter, Nanogen closed its highest number of quarterly commercial transactions in the Company`s history, concluding 10 NanoChip(R) Molecular Biology Workstations transactions. These transactions included six sales transactions and four cost-per-reportable transactions. Two of the 10 transactions (one sale and one cost-per-reportable transaction) resulted from conversions of previous development site agreements that represent the Company`s fifth and sixth development site conversions to date. In addition, Nanogen entered into two new development site agreements during the third quarter 2002.
Product revenues for the third quarter of 2002 were $957,000, as compared to $1.0 million for the third quarter of 2001. Product revenues include revenues from the six sales transactions completed during the quarter, but no revenues related to the four cost-per-reportable transactions. As the Company has advised previously, the decrease in the third quarter product revenues from the previous year amount resulted primarily from the fact that Nanogen did not recognize revenue from the four cost-per-reportable transactions. The Company expects to recapture the value of the instruments placed under these agreements through a stream of future consumable products sold at a premium. Product revenues recognized during the third quarter ended September 30, 2002 also include revenue from the sale of cartridges and reagents shipped under other commercial agreements entered into earlier.
Product revenues for the nine months ended September 30, 2002 were $2.9 million compared to $1.6 million for the first nine months of 2001. Total revenues for the third quarter and nine months ended September 30, 2002 were $1.6 million and $5.0 million, respectively, as compared to $3.2 million and $8.9 million for the same periods in the prior year. These declines in total revenues were due primarily to anticipated decreases in revenues earned in connection with sponsored research programs as Nanogen`s revenue base continues its transition from primarily sponsored research revenues to product revenues. Notably, the Company continued to increase its percentage of product-driven revenues, as 62% of total revenues for the third quarter of 2002 came from product revenues, compared to 32% for the third quarter of 2001.
Nanogen`s operating expenses for the third quarter ended September 30, 2002 totaled $10.9 million compared to operating expenses of $11.9 million for the same period in 2001. For the nine months ended September 30, 2002, the Company`s reported operating expenses totaled $32.9 million, compared to operating expenses of $38.0 million for the same period in 2001. The prior year amounts included charges related to previous patent litigation and settlement matters with Motorola, CombiMatrix and Dr. Donald Montgomery. The increase in operating expenses in 2002 as compared to 2001, excluding the litigation and settlement charges, relates primarily to an increase in product development expenses.
Nanogen`s net loss for the third quarter ended September 30, 2002 was $8.2 million or $0.38 per share compared to a net loss of $7.0 million or $0.33 per share for the same period in 2001. For the nine months ended September 30, 2002, the Company`s reported net loss was $24.3 million or $1.12 per share compared to a net loss of $25.0 million or $1.20 per share for the same period in 2001. Nanogen`s cash, cash equivalents and short-term investments balance at September 30, 2002 was $46.4 million.
"We are very pleased to have surpassed our previous quarterly high for the number of commercial transactions closed involving our NanoChip(R) Systems," said Howard C. Birndorf, Nanogen`s Chairman of the Board and Executive Chairman. "We believe this demonstrates that Nanogen is making progress in its efforts to be the leading developer and producer of molecular diagnostic products in the nation. In addition, we are very pleased to have settled our litigation against CombiMatrix and Dr. Donald Montgomery. The settlement includes cash payments totaling $1.0 million, 17.5% of CombiMatrix`s outstanding common stock and a 12.5% royalty on the sale of products by CombiMatrix and its affiliates. It is important to note that, as part of the settlement, we did not relinquish rights to any of Nanogen`s core technology. Now we can focus our resources on our commercialization efforts and also benefit from those of CombiMatrix and its collaborators," he continued.
"As part of our mission to become the leading supplier of molecular diagnostic tests and in support of our commercialization strategy, we recently undertook a corporate reorganization to better align the skills of our workforce with our goals," said Dr. Randy White, Nanogen`s Chief Executive Officer. "This corporate reorganization resulted in a net reduction of approximately 10% of our personnel. A one-time severance charge of approximately $300,000 will be recognized in the fourth quarter 2002. The completed restructuring, along with the favorable impact of the settlement of the CombiMatrix litigation and other cost-cutting measures is expected to reduce Nanogen`s 2003 cash burn by approximately $5 million," Dr. White continued.
"We have also taken additional steps towards expanding our product menu of molecular tests," said Dr. White. "We have introduced our three single nucleotide polymorphism (SNP) hereditary hemochromotosis Analyte Specific Reagent (ASR) to two initial customer evaluation sites and expect to launch this ASR along with an ASR for Factor II and Factor V this upcoming quarter, among others. In addition, during the third quarter, we received a non-exclusive license from Athena Diagnostics for Apoliproprotein-E (APOE) SNPs relating to the detection of Alzheimer`s disease and entered into a worldwide exclusive joint development agreement with Bionomics to develop the world`s first molecular-based test for epilepsy. We believe that with all these accomplishments Nanogen is well-positioned to play a leading role in the molecular diagnostics industry."
Webcast of Conference Call
Nanogen management will host a live conference call today to discuss the third quarter financial results and update the Company`s earnings guidance for 2002 today at 4:30 p.m. Eastern Time. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com . A telephone replay will be available approximately two hours following the conference call until 11:00 p.m. Eastern Time on November 6, 2002, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants. The conference ID is 17321 and it will be required to listen to the playback. The webcast will also be archived on Nanogen`s website through November 18, 2002.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
September 30, December 31,
2002 2001
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $13,340 $10,455
Short-term investments 33,041 57,069
Receivables, net 1,396 4,380
Inventories, net 4,607 4,688
Other current assets 3,108 2,473
Total current assets 55,492 79,065
Property and equipment, net 5,220 5,386
Acquired technology rights, net 4,747 4,183
Other assets, net 908 1,158
Restricted cash 64 299
$66,431 $90,091
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $707 $1,051
Accrued liabilities 5,435 4,916
Deferred revenue 863 522
Current portion of capital lease obligations 842 1,060
Total current liabilities 7,847 7,549
Capital lease obligations, less current portion 1,322 1,755
Other long-term liabilities 3,037 1,675
Total long-term liabilities 4,359 3,430
Minority interest in consolidated subsidiary 2,339 4,183
Stockholders` equity:
Convertible preferred stock, $.001 par value,
5,000,000 shares authorized; no shares issued
and outstanding at September 30, 2002 and
December 31, 2001 -- --
Common stock, $.001 par value, 50,000,000 shares
authorized; 21,941,398 and 21,616,172 shares
issued and outstanding at September 30, 2002 and
December 31, 2001, respectively 22 22
Additional paid-in capital 199,534 198,387
Accumulated other comprehensive income 1,051 1,253
Deferred compensation (164) (336)
Notes receivable from officers (1,027) (984)
Accumulated deficit (147,530) (123,413)
Total stockholders` equity 51,886 74,929
$66,431 $90,091
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Nine months ended
September 30, September 30,
2002 2001 2002 2001
Revenues:
Product $957 $1,023 $2,873 $1,554
Sponsored research 354 1,828 980 6,229
Contract and grant 240 368 1,182 1,091
Total revenues 1,551 3,219 5,035 8,874
Operating expenses:
Cost of product sales 687 727 2,080 1,127
Research and
development 5,780 4,824 15,672 14,023
Selling, general
and administrative 5,428 6,054 15,346 15,982
Litigation and
settlement of patent
matter, net (963) 263 (165) 6,836
Total operating
expenses 10,932 11,868 32,933 37,968
Loss from operations (9,381) (8,649) (27,898) (29,094)
Interest income, net 488 1,019 1,834 3,437
Minority interest in
loss of consolidated
subsidiary 651 485 1,634 485
Other income 18 125 153 123
Net loss $ (8,224) $ (7,020) $ (24,277) $ (25,049)
Net loss per share -
basic and diluted $(0.38) $(0.33) $(1.12) $(1.20)
Number of shares used
in computing net loss
per share - basic and
diluted 21,923 21,206 21,732 20,898
Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X37853775
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc., +1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates, +1-858-527-3494, for Nanogen, Inc. URL: http://www.nanogen.com http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
SAN DIEGO, Nov 4, 2002 /PRNewswire-FirstCall via COMTEX/ --
- Company Closes Ten Commercial Transactions During the Quarter, Including Four With Major U.S. Clinical Diagnostic Laboratories -
Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the third quarter ended September 30, 2002.
During the third quarter, Nanogen closed its highest number of quarterly commercial transactions in the Company`s history, concluding 10 NanoChip(R) Molecular Biology Workstations transactions. These transactions included six sales transactions and four cost-per-reportable transactions. Two of the 10 transactions (one sale and one cost-per-reportable transaction) resulted from conversions of previous development site agreements that represent the Company`s fifth and sixth development site conversions to date. In addition, Nanogen entered into two new development site agreements during the third quarter 2002.
Product revenues for the third quarter of 2002 were $957,000, as compared to $1.0 million for the third quarter of 2001. Product revenues include revenues from the six sales transactions completed during the quarter, but no revenues related to the four cost-per-reportable transactions. As the Company has advised previously, the decrease in the third quarter product revenues from the previous year amount resulted primarily from the fact that Nanogen did not recognize revenue from the four cost-per-reportable transactions. The Company expects to recapture the value of the instruments placed under these agreements through a stream of future consumable products sold at a premium. Product revenues recognized during the third quarter ended September 30, 2002 also include revenue from the sale of cartridges and reagents shipped under other commercial agreements entered into earlier.
Product revenues for the nine months ended September 30, 2002 were $2.9 million compared to $1.6 million for the first nine months of 2001. Total revenues for the third quarter and nine months ended September 30, 2002 were $1.6 million and $5.0 million, respectively, as compared to $3.2 million and $8.9 million for the same periods in the prior year. These declines in total revenues were due primarily to anticipated decreases in revenues earned in connection with sponsored research programs as Nanogen`s revenue base continues its transition from primarily sponsored research revenues to product revenues. Notably, the Company continued to increase its percentage of product-driven revenues, as 62% of total revenues for the third quarter of 2002 came from product revenues, compared to 32% for the third quarter of 2001.
Nanogen`s operating expenses for the third quarter ended September 30, 2002 totaled $10.9 million compared to operating expenses of $11.9 million for the same period in 2001. For the nine months ended September 30, 2002, the Company`s reported operating expenses totaled $32.9 million, compared to operating expenses of $38.0 million for the same period in 2001. The prior year amounts included charges related to previous patent litigation and settlement matters with Motorola, CombiMatrix and Dr. Donald Montgomery. The increase in operating expenses in 2002 as compared to 2001, excluding the litigation and settlement charges, relates primarily to an increase in product development expenses.
Nanogen`s net loss for the third quarter ended September 30, 2002 was $8.2 million or $0.38 per share compared to a net loss of $7.0 million or $0.33 per share for the same period in 2001. For the nine months ended September 30, 2002, the Company`s reported net loss was $24.3 million or $1.12 per share compared to a net loss of $25.0 million or $1.20 per share for the same period in 2001. Nanogen`s cash, cash equivalents and short-term investments balance at September 30, 2002 was $46.4 million.
"We are very pleased to have surpassed our previous quarterly high for the number of commercial transactions closed involving our NanoChip(R) Systems," said Howard C. Birndorf, Nanogen`s Chairman of the Board and Executive Chairman. "We believe this demonstrates that Nanogen is making progress in its efforts to be the leading developer and producer of molecular diagnostic products in the nation. In addition, we are very pleased to have settled our litigation against CombiMatrix and Dr. Donald Montgomery. The settlement includes cash payments totaling $1.0 million, 17.5% of CombiMatrix`s outstanding common stock and a 12.5% royalty on the sale of products by CombiMatrix and its affiliates. It is important to note that, as part of the settlement, we did not relinquish rights to any of Nanogen`s core technology. Now we can focus our resources on our commercialization efforts and also benefit from those of CombiMatrix and its collaborators," he continued.
"As part of our mission to become the leading supplier of molecular diagnostic tests and in support of our commercialization strategy, we recently undertook a corporate reorganization to better align the skills of our workforce with our goals," said Dr. Randy White, Nanogen`s Chief Executive Officer. "This corporate reorganization resulted in a net reduction of approximately 10% of our personnel. A one-time severance charge of approximately $300,000 will be recognized in the fourth quarter 2002. The completed restructuring, along with the favorable impact of the settlement of the CombiMatrix litigation and other cost-cutting measures is expected to reduce Nanogen`s 2003 cash burn by approximately $5 million," Dr. White continued.
"We have also taken additional steps towards expanding our product menu of molecular tests," said Dr. White. "We have introduced our three single nucleotide polymorphism (SNP) hereditary hemochromotosis Analyte Specific Reagent (ASR) to two initial customer evaluation sites and expect to launch this ASR along with an ASR for Factor II and Factor V this upcoming quarter, among others. In addition, during the third quarter, we received a non-exclusive license from Athena Diagnostics for Apoliproprotein-E (APOE) SNPs relating to the detection of Alzheimer`s disease and entered into a worldwide exclusive joint development agreement with Bionomics to develop the world`s first molecular-based test for epilepsy. We believe that with all these accomplishments Nanogen is well-positioned to play a leading role in the molecular diagnostics industry."
Webcast of Conference Call
Nanogen management will host a live conference call today to discuss the third quarter financial results and update the Company`s earnings guidance for 2002 today at 4:30 p.m. Eastern Time. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com . A telephone replay will be available approximately two hours following the conference call until 11:00 p.m. Eastern Time on November 6, 2002, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants. The conference ID is 17321 and it will be required to listen to the playback. The webcast will also be archived on Nanogen`s website through November 18, 2002.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
September 30, December 31,
2002 2001
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $13,340 $10,455
Short-term investments 33,041 57,069
Receivables, net 1,396 4,380
Inventories, net 4,607 4,688
Other current assets 3,108 2,473
Total current assets 55,492 79,065
Property and equipment, net 5,220 5,386
Acquired technology rights, net 4,747 4,183
Other assets, net 908 1,158
Restricted cash 64 299
$66,431 $90,091
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $707 $1,051
Accrued liabilities 5,435 4,916
Deferred revenue 863 522
Current portion of capital lease obligations 842 1,060
Total current liabilities 7,847 7,549
Capital lease obligations, less current portion 1,322 1,755
Other long-term liabilities 3,037 1,675
Total long-term liabilities 4,359 3,430
Minority interest in consolidated subsidiary 2,339 4,183
Stockholders` equity:
Convertible preferred stock, $.001 par value,
5,000,000 shares authorized; no shares issued
and outstanding at September 30, 2002 and
December 31, 2001 -- --
Common stock, $.001 par value, 50,000,000 shares
authorized; 21,941,398 and 21,616,172 shares
issued and outstanding at September 30, 2002 and
December 31, 2001, respectively 22 22
Additional paid-in capital 199,534 198,387
Accumulated other comprehensive income 1,051 1,253
Deferred compensation (164) (336)
Notes receivable from officers (1,027) (984)
Accumulated deficit (147,530) (123,413)
Total stockholders` equity 51,886 74,929
$66,431 $90,091
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Nine months ended
September 30, September 30,
2002 2001 2002 2001
Revenues:
Product $957 $1,023 $2,873 $1,554
Sponsored research 354 1,828 980 6,229
Contract and grant 240 368 1,182 1,091
Total revenues 1,551 3,219 5,035 8,874
Operating expenses:
Cost of product sales 687 727 2,080 1,127
Research and
development 5,780 4,824 15,672 14,023
Selling, general
and administrative 5,428 6,054 15,346 15,982
Litigation and
settlement of patent
matter, net (963) 263 (165) 6,836
Total operating
expenses 10,932 11,868 32,933 37,968
Loss from operations (9,381) (8,649) (27,898) (29,094)
Interest income, net 488 1,019 1,834 3,437
Minority interest in
loss of consolidated
subsidiary 651 485 1,634 485
Other income 18 125 153 123
Net loss $ (8,224) $ (7,020) $ (24,277) $ (25,049)
Net loss per share -
basic and diluted $(0.38) $(0.33) $(1.12) $(1.20)
Number of shares used
in computing net loss
per share - basic and
diluted 21,923 21,206 21,732 20,898
Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X37853775
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO of Nanogen, Inc., +1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates, +1-858-527-3494, for Nanogen, Inc. URL: http://www.nanogen.com http://www.prnewswire.com
Copyright (C) 2002 PR Newswire. All rights reserved.
Nanogen To Present at the Wall Street Analyst Forum On November 12 in New York City
SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2002--Nanogen, Inc. (Nasdaq: NGEN) announced today that the Company will be presenting at the Wall Street Analyst Forum on Tuesday, November 12, 2002 at 11:00 a.m. Eastern Time at the Roosevelt Hotel in New York City. Mr. Gerard A. Wills, Nanogen`s Vice President and Chief Financial Officer, will provide a corporate overview and discuss the Company`s strategy for pursuing a leadership position in the molecular diagnostics market.
You can access a live webcast of the presentation via Nanogen`s website at www.nanogen.com under the "Investor/News" section. The slide presentation and audio replay will be archived on Nanogen`s site for 90 days. Analysts and portfolio managers who wish to attend the presentation should contact the Wall Street Analyst Forum at (802) 253-7596 to request additional information.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--30--bpm/cgo*
CONTACT: Nanogen, Inc.
Gerard A. Wills, 858/410-4605
gwills@nanogen.com
or
Atkins & Associates
Pam Lord (MR), 858/527-3494
plord@irpr.com
SAN DIEGO--(BUSINESS WIRE)--Nov. 7, 2002--Nanogen, Inc. (Nasdaq: NGEN) announced today that the Company will be presenting at the Wall Street Analyst Forum on Tuesday, November 12, 2002 at 11:00 a.m. Eastern Time at the Roosevelt Hotel in New York City. Mr. Gerard A. Wills, Nanogen`s Vice President and Chief Financial Officer, will provide a corporate overview and discuss the Company`s strategy for pursuing a leadership position in the molecular diagnostics market.
You can access a live webcast of the presentation via Nanogen`s website at www.nanogen.com under the "Investor/News" section. The slide presentation and audio replay will be archived on Nanogen`s site for 90 days. Analysts and portfolio managers who wish to attend the presentation should contact the Wall Street Analyst Forum at (802) 253-7596 to request additional information.
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--30--bpm/cgo*
CONTACT: Nanogen, Inc.
Gerard A. Wills, 858/410-4605
gwills@nanogen.com
or
Atkins & Associates
Pam Lord (MR), 858/527-3494
plord@irpr.com
Nur noch einen Tick und dann wären wir über der 100-Tages-Linie.....vielleicht klappts ja mal
Nanogen Announces Senior Management Changes
Bruce Huebner Named New President and Chief Operating Officer -
SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostic products, today announced that diagnostic veteran Bruce A. Huebner has been named as president and chief operating officer. Mr. Huebner has been a consultant to Nanogen since August 2002, prior to which he served approximately ten years at Gen-Probe, the past six years as its executive vice president and chief operating officer. While under Mr. Huebner`s direction, Gen-Probe`s annual revenues grew to over $130 million. Mr. Huebner brings to Nanogen over 28 years of diagnostic experience having served in various leadership roles at organizations such as Hybritech and Roche Diagnostics in addition to his most recent tenure at Gen-Probe.
"Bruce`s broad knowledge of the diagnostic industry, specifically in product development and marketing and selling products to clinical laboratories -- our primary growth market -- perfectly complements the skills of our existing management team," said Howard C. Birndorf, executive chairman. "His experience and leadership skills will be a positive influence on Nanogen in executing its strategy and establishing its leadership position in the molecular diagnostics market."
Nanogen also announced that it has regretfully accepted the resignation of its current president, Kieran T. Gallahue. Mr. Gallahue announced that he is leaving the company to pursue opportunities associated with an unrelated medical technologies firm. Mr. Gallahue supported the selection of his successor and at the company`s request, has agreed to remain with Nanogen through the end of the year.
"Kieran has played a critical role in Nanogen`s transition from a technology-focused company to a product and commercially oriented organization," said Birndorf. "He joined Nanogen prior to the company`s initial public offering and before the design and introduction of its first product -- the NanoChip(R) Molecular Biology Workstation. His experience, leadership and enthusiasm have been invaluable during this critical growth period as we have integrated market, product and commercial expertise within the organization."
In addition, Nanogen announced that Randy White, PhD. will leave both his positions as CEO and a member of the Board of Directors of Nanogen at the end of this year due to personal health reasons. Dr. White has served as chief executive officer of Nanogen since June 2001 and has been a director of the company since April 2001. Mr. Birndorf will now serve as Nanogen`s chief executive officer.
According to Birndorf, "Randy has been instrumental in Nanogen`s progress in focusing on the company`s primary growth market -- clinical reference laboratories. He built a team with significant diagnostic experience and has given the company valuable insights into key customers."
Birndorf continued, "I would like to thank both Randy and Kieran for the positive influence they have had on the company`s pursuit to become a leader in the diagnostics market. Their efforts will long be remembered and appreciated."
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.
Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X17621671
SOURCE Nanogen, Inc.
Bruce Huebner Named New President and Chief Operating Officer -
SAN DIEGO, Nov. 21 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostic products, today announced that diagnostic veteran Bruce A. Huebner has been named as president and chief operating officer. Mr. Huebner has been a consultant to Nanogen since August 2002, prior to which he served approximately ten years at Gen-Probe, the past six years as its executive vice president and chief operating officer. While under Mr. Huebner`s direction, Gen-Probe`s annual revenues grew to over $130 million. Mr. Huebner brings to Nanogen over 28 years of diagnostic experience having served in various leadership roles at organizations such as Hybritech and Roche Diagnostics in addition to his most recent tenure at Gen-Probe.
"Bruce`s broad knowledge of the diagnostic industry, specifically in product development and marketing and selling products to clinical laboratories -- our primary growth market -- perfectly complements the skills of our existing management team," said Howard C. Birndorf, executive chairman. "His experience and leadership skills will be a positive influence on Nanogen in executing its strategy and establishing its leadership position in the molecular diagnostics market."
Nanogen also announced that it has regretfully accepted the resignation of its current president, Kieran T. Gallahue. Mr. Gallahue announced that he is leaving the company to pursue opportunities associated with an unrelated medical technologies firm. Mr. Gallahue supported the selection of his successor and at the company`s request, has agreed to remain with Nanogen through the end of the year.
"Kieran has played a critical role in Nanogen`s transition from a technology-focused company to a product and commercially oriented organization," said Birndorf. "He joined Nanogen prior to the company`s initial public offering and before the design and introduction of its first product -- the NanoChip(R) Molecular Biology Workstation. His experience, leadership and enthusiasm have been invaluable during this critical growth period as we have integrated market, product and commercial expertise within the organization."
In addition, Nanogen announced that Randy White, PhD. will leave both his positions as CEO and a member of the Board of Directors of Nanogen at the end of this year due to personal health reasons. Dr. White has served as chief executive officer of Nanogen since June 2001 and has been a director of the company since April 2001. Mr. Birndorf will now serve as Nanogen`s chief executive officer.
According to Birndorf, "Randy has been instrumental in Nanogen`s progress in focusing on the company`s primary growth market -- clinical reference laboratories. He built a team with significant diagnostic experience and has given the company valuable insights into key customers."
Birndorf continued, "I would like to thank both Randy and Kieran for the positive influence they have had on the company`s pursuit to become a leader in the diagnostics market. Their efforts will long be remembered and appreciated."
Nanogen`s goal is to become the leading provider of molecular diagnostic products. The company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.
Make Your Opinion Count - Click Here
http://tbutton.prnewswire.com/prn/11690X17621671
SOURCE Nanogen, Inc.
Nanogen mit hübschen Umsätzen nach oben ...
Es war gut, unter 2 Euro wieder einzusteigen!
So - die erste Hürde wurde genommen...wenn wir noch nächste Woche die 2,26$ packen dann dürfte es nochmal einen schönen Ruck nach oben gehen
Psychiatr Genet 2002 Dec
Active microelectronic array system for DNA hybridization, genotyping and pharmacogenomic applications.
Sosnowski R, Heller MJ, Tu E, Forster AH, Radtkey R.
Microelectronic arrays have been developed for DNA hybridization analysis of point mutations, single nucleotide polymorphisms, short tandem repeats and gene expression. In addition to a variety of molecular biology and genomic research applications, such devices will also be used for infectious disease detection, genetic and cancer diagnostics, and pharmacogenomic applications. These microelectronic array devices are able to produce defined electric fields on their surfaces that allow charged molecules and other entities to be transported to or from any test site or micro-location on the planar surface of the device. These molecules and entities include DNA, RNA, proteins, enzymes, antibodies and cells. Electronic-based molecule addressing and hybridization can then be carried out, where the electric field is now used to greatly accelerate the hybridization reactions that occur on the selected test sites. When reversed, the electric field can be used to provide an additional parameter for improved hybridization. Special low-conductance buffers have been developed that provide for the rapid transport of the DNA molecules and facilitate the electronic hybridization reactions under conditions that do not support hybridization. Important to the device function is the permeation layer that overcoats the underlying microelectrodes. Generally composed of a porous hydrogel material impregnated with attachment chemistry, this permeation layer prevents the destruction of analytes at the active microelectrode surface, ameliorates the adverse effects of electrolysis products on the sensitive hybridization and affinity reactions, and serves as a support structure for attaching DNA probes and other molecules to the array. The microelectronic chip or array device is incorporated into a cartridge package (NanoChip trade mark cartridge) that provides the electronic, optical, and fluidic interfacing. A complete instrument system (NanoChip trade mark Molecular Biology Workstation) provides a chip loader, fluorescent reader, computer control interface and data display screen. The probe loader component allows DNA probes or target molecules (polymerase chain reactions amplicons, genomic DNA, RNA, etc.) to be selectively addressed to the array test sites, providing the end-user with `make your own chip` capabilities. The electronic hybridization can then be carried out and the chip analyzed using a fluorescent detector system. In addition to carrying out rapid, accurate and highly reliable genotyping (point mutations, single nucleotide polymorphisms, short tandem repeats), other future applications include gene expression analysis, or on-chip amplification, immunoassays and cell separation and selection. Smaller and more compact systems are also being designed for portable sample to answer and point of care diagnostics.
PMID: 12454523 [PubMed - in process]
Active microelectronic array system for DNA hybridization, genotyping and pharmacogenomic applications.
Sosnowski R, Heller MJ, Tu E, Forster AH, Radtkey R.
Microelectronic arrays have been developed for DNA hybridization analysis of point mutations, single nucleotide polymorphisms, short tandem repeats and gene expression. In addition to a variety of molecular biology and genomic research applications, such devices will also be used for infectious disease detection, genetic and cancer diagnostics, and pharmacogenomic applications. These microelectronic array devices are able to produce defined electric fields on their surfaces that allow charged molecules and other entities to be transported to or from any test site or micro-location on the planar surface of the device. These molecules and entities include DNA, RNA, proteins, enzymes, antibodies and cells. Electronic-based molecule addressing and hybridization can then be carried out, where the electric field is now used to greatly accelerate the hybridization reactions that occur on the selected test sites. When reversed, the electric field can be used to provide an additional parameter for improved hybridization. Special low-conductance buffers have been developed that provide for the rapid transport of the DNA molecules and facilitate the electronic hybridization reactions under conditions that do not support hybridization. Important to the device function is the permeation layer that overcoats the underlying microelectrodes. Generally composed of a porous hydrogel material impregnated with attachment chemistry, this permeation layer prevents the destruction of analytes at the active microelectrode surface, ameliorates the adverse effects of electrolysis products on the sensitive hybridization and affinity reactions, and serves as a support structure for attaching DNA probes and other molecules to the array. The microelectronic chip or array device is incorporated into a cartridge package (NanoChip trade mark cartridge) that provides the electronic, optical, and fluidic interfacing. A complete instrument system (NanoChip trade mark Molecular Biology Workstation) provides a chip loader, fluorescent reader, computer control interface and data display screen. The probe loader component allows DNA probes or target molecules (polymerase chain reactions amplicons, genomic DNA, RNA, etc.) to be selectively addressed to the array test sites, providing the end-user with `make your own chip` capabilities. The electronic hybridization can then be carried out and the chip analyzed using a fluorescent detector system. In addition to carrying out rapid, accurate and highly reliable genotyping (point mutations, single nucleotide polymorphisms, short tandem repeats), other future applications include gene expression analysis, or on-chip amplification, immunoassays and cell separation and selection. Smaller and more compact systems are also being designed for portable sample to answer and point of care diagnostics.
PMID: 12454523 [PubMed - in process]
Ein neues Patent:
United States Patent 6,488,832
Heller December 3, 2002
--------------------------------------------------------------------------------
Array based electrophoretic system for the analysis of multiple biological samples
Abstract
The present invention relates to an electrophoretic method to effect differential net migration, the extent of said migration being dependent on molecular size, of electrically charged macromolecules through a gel support in a single dimension, which method comprises subjecting electrically charged macromolecules applied to a gel support to an electric field oriented along a single axis within the gel for a time period sufficient to effect migration in the direction of the oriented field and form a separation pattern in order of the respective molecular weights of the macromolecules in a distance of about 0.5 to about 20 millimeters, said gel support comprising about 3 to about 40 percent acrylamide, said electric field being applied in an amount of about 5 to about 100 volts per millimeter of gel support along the axis length, and said gel support having a width perpendicular to said axis of about 0.1 to 1.5 millimeters.
--------------------------------------------------------------------------------
Inventors: Heller; Michael J. (Encinitas, CA)
Assignee: Nanogen, Inc. (San Diego, CA)
United States Patent 6,488,832
Heller December 3, 2002
--------------------------------------------------------------------------------
Array based electrophoretic system for the analysis of multiple biological samples
Abstract
The present invention relates to an electrophoretic method to effect differential net migration, the extent of said migration being dependent on molecular size, of electrically charged macromolecules through a gel support in a single dimension, which method comprises subjecting electrically charged macromolecules applied to a gel support to an electric field oriented along a single axis within the gel for a time period sufficient to effect migration in the direction of the oriented field and form a separation pattern in order of the respective molecular weights of the macromolecules in a distance of about 0.5 to about 20 millimeters, said gel support comprising about 3 to about 40 percent acrylamide, said electric field being applied in an amount of about 5 to about 100 volts per millimeter of gel support along the axis length, and said gel support having a width perpendicular to said axis of about 0.1 to 1.5 millimeters.
--------------------------------------------------------------------------------
Inventors: Heller; Michael J. (Encinitas, CA)
Assignee: Nanogen, Inc. (San Diego, CA)
Zwar nix mit NGEN - is aber trotzdem ein netter Artikel 
Source:
University At Buffalo
Date:
12/4/2002
University At Buffalo Engineer Develops Novel Method For Assembly Of Nanoparticles; Process May Lead To Manufacture Of Nanoscale Devices
BUFFALO, N.Y. -- A University at Buffalo engineer has developed a novel method for assembling nanoparticles into three-dimensional structures that one day may be used to produce new nanoscale tools and machines.
The work could be an important step in fulfilling the immense potential of nanotechnology because it gives scientists and engineers improved control and flexibility in the creation of materials for the manufacture of many nanoscale devices, according to Paschalis Alexandridis, associate professor of chemical engineering in UB`s School of Engineering and Applied Sciences.
Alexandridis and postdoctoral research associate Aristides Docoslis used non-uniform AC electric fields generated by microfabricated electrodes -- which create a motion known as dielectrophoresis -- to stack latex, silica or graphite microparticles into two- and three-dimensional structures of prescribed lengths and composition, held together by the electrical field.
The same process can be applied to nanoparticles, says Alexandridis, whose research is funded by a $100,000 Nanoscale Exploratory Research (NER) grant from the National Science Foundation, Division of Design, Manufacture and Industrial Innovation.
"This process enables you to guide particles to where you want them to go and then scale them up into ordered structures with desired electrical, optical or mechanical properties," explains Alexandridis. "You can use this process to create a well-defined object and assemble it on demand, which means these materials can actually be used to manufacture nanoscale tools or devices," he adds. "This may be particularly applicable for the manufacture of sensors and photonic devices."
Adaptability is an attractive feature of the process, Alexandridis says. The process can be used to direct and manipulate almost any particle, he explains, whether the particle has a net charge or not, or is suspended in an aqueous or non-aqueous medium. "Because of this flexibility, there`s no limit to the applications of this process," Alexandridis says. "That`s another advantage for the manufacturability of this method."
Focusing on the dielectrophoresis process, Alexandridis is developing models to predict how various particles, and combination of particles, will behave under the influence of different electrical fields, as a function of particle size and properties, electrode dimensions and pattern, and applied voltage and frequency. This information will help guide future nanomanufacturing applications, he says.
Alexandridis also is developing ways to glue particles together after the electrical field has assembled them. "The goal is to link the particles in a way that doesn`t change the properties of the structure, but which makes the structure permanent and resilient," he says. "After you glue the particles together you can switch off the electrical field and have a free-standing, ordered structure."
"Or you can change the field frequency so that you can remove selectively the unglued particles," he adds. Results from Alexandridis` and Docoslis` research were published recently in Electrophoresis (2002, 23, 2174-2183).
Nanotechnology is a potentially revolutionary and lucrative scientific industry, with experts predicting manufacture and commercialization of microscopic products benefiting the fields of electronics, medicine, supercomputing, energy and environmental cleanup.
--------------------------------------------------------------------------------
Note: This story has been adapted from a news release issued for journalists and other members of the public. If you wish to quote any part of this story, please credit University At Buffalo as the original source. You may also wish to include the following link in any citation:
http://www.sciencedaily.com/releases/2002/12/021204081355.ht…
Source:
University At Buffalo
Date:
12/4/2002
University At Buffalo Engineer Develops Novel Method For Assembly Of Nanoparticles; Process May Lead To Manufacture Of Nanoscale Devices
BUFFALO, N.Y. -- A University at Buffalo engineer has developed a novel method for assembling nanoparticles into three-dimensional structures that one day may be used to produce new nanoscale tools and machines.
The work could be an important step in fulfilling the immense potential of nanotechnology because it gives scientists and engineers improved control and flexibility in the creation of materials for the manufacture of many nanoscale devices, according to Paschalis Alexandridis, associate professor of chemical engineering in UB`s School of Engineering and Applied Sciences.
Alexandridis and postdoctoral research associate Aristides Docoslis used non-uniform AC electric fields generated by microfabricated electrodes -- which create a motion known as dielectrophoresis -- to stack latex, silica or graphite microparticles into two- and three-dimensional structures of prescribed lengths and composition, held together by the electrical field.
The same process can be applied to nanoparticles, says Alexandridis, whose research is funded by a $100,000 Nanoscale Exploratory Research (NER) grant from the National Science Foundation, Division of Design, Manufacture and Industrial Innovation.
"This process enables you to guide particles to where you want them to go and then scale them up into ordered structures with desired electrical, optical or mechanical properties," explains Alexandridis. "You can use this process to create a well-defined object and assemble it on demand, which means these materials can actually be used to manufacture nanoscale tools or devices," he adds. "This may be particularly applicable for the manufacture of sensors and photonic devices."
Adaptability is an attractive feature of the process, Alexandridis says. The process can be used to direct and manipulate almost any particle, he explains, whether the particle has a net charge or not, or is suspended in an aqueous or non-aqueous medium. "Because of this flexibility, there`s no limit to the applications of this process," Alexandridis says. "That`s another advantage for the manufacturability of this method."
Focusing on the dielectrophoresis process, Alexandridis is developing models to predict how various particles, and combination of particles, will behave under the influence of different electrical fields, as a function of particle size and properties, electrode dimensions and pattern, and applied voltage and frequency. This information will help guide future nanomanufacturing applications, he says.
Alexandridis also is developing ways to glue particles together after the electrical field has assembled them. "The goal is to link the particles in a way that doesn`t change the properties of the structure, but which makes the structure permanent and resilient," he says. "After you glue the particles together you can switch off the electrical field and have a free-standing, ordered structure."
"Or you can change the field frequency so that you can remove selectively the unglued particles," he adds. Results from Alexandridis` and Docoslis` research were published recently in Electrophoresis (2002, 23, 2174-2183).
Nanotechnology is a potentially revolutionary and lucrative scientific industry, with experts predicting manufacture and commercialization of microscopic products benefiting the fields of electronics, medicine, supercomputing, energy and environmental cleanup.
--------------------------------------------------------------------------------
Note: This story has been adapted from a news release issued for journalists and other members of the public. If you wish to quote any part of this story, please credit University At Buffalo as the original source. You may also wish to include the following link in any citation:
http://www.sciencedaily.com/releases/2002/12/021204081355.ht…
tja "dank" der letzten Tage sind wir unter allen Linien und Chart-technisch versagt wieder mal NGEN
Wollen wir mal hoffen dass bald News kommen die den Kurs in Bewegung bringen
Wollen wir mal hoffen dass bald News kommen die den Kurs in Bewegung bringen
11.12. / 13:09
Nanogen, Inc. , a leading provider of molecular diagnostic products, and Miami Children``s Hospital Research Institute, Inc., today announced the signing of a non-exclusive license agreement that includes three of the most common gene mutations associated with the diagnosis of Canavan disease. Canavan disease is a deadly genetic disorder that primarily strikes infants of eastern and central European Jewish (Ashkenazi) descent. The disorder attacks an infant``s brain and robs the baby of normal development, eventually resulting in premature death. About 90 percent of the American Jewish population is of Ashkenazi descent, from which one in 40 is a carrier of the Canavan gene. Financial terms of the license agreement were not disclosed.
"This agreement is a significant development in Nanogen``s effort to develop a panel of tests for the Ashkenazi Jewish population," said Howard C. Birndorf, Nanogen``s chairman of the board and chief executive officer. "Our NanoChip(R) System is a uniquely qualified testing platform that allows our customers to perform a wide variety of assays from the most simple to the highly complex."
There are a number of genetic disorders that are unusually common among the Ashkenazi Jewish population. While there is not an official comprehensive list, Canavan disease is joined by other disorders like cystic fibrosis, Gaucher disease and Tay-Sachs disease as common to this specific population.
Birndorf added, "Our molecular diagnostics platform, the NanoChip(R) System, provides our customers the versatility they need in order to test for many different gene mutations on a single platform. By obtaining important intellectual property rights to disease gene mutations like those associated with Canavan disease and potentially developing a panel of tests for populations like those of Ashkenazi decent, we will be able to attract more customers to our fast, flexible and economical diagnostic testing platform."
About Nanogen
Nanogen``s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen``s web site at http://www.nanogen.com/ .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company``s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company``s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Nanogen, Inc.
© PR Newswire
Nanogen, Inc. , a leading provider of molecular diagnostic products, and Miami Children``s Hospital Research Institute, Inc., today announced the signing of a non-exclusive license agreement that includes three of the most common gene mutations associated with the diagnosis of Canavan disease. Canavan disease is a deadly genetic disorder that primarily strikes infants of eastern and central European Jewish (Ashkenazi) descent. The disorder attacks an infant``s brain and robs the baby of normal development, eventually resulting in premature death. About 90 percent of the American Jewish population is of Ashkenazi descent, from which one in 40 is a carrier of the Canavan gene. Financial terms of the license agreement were not disclosed.
"This agreement is a significant development in Nanogen``s effort to develop a panel of tests for the Ashkenazi Jewish population," said Howard C. Birndorf, Nanogen``s chairman of the board and chief executive officer. "Our NanoChip(R) System is a uniquely qualified testing platform that allows our customers to perform a wide variety of assays from the most simple to the highly complex."
There are a number of genetic disorders that are unusually common among the Ashkenazi Jewish population. While there is not an official comprehensive list, Canavan disease is joined by other disorders like cystic fibrosis, Gaucher disease and Tay-Sachs disease as common to this specific population.
Birndorf added, "Our molecular diagnostics platform, the NanoChip(R) System, provides our customers the versatility they need in order to test for many different gene mutations on a single platform. By obtaining important intellectual property rights to disease gene mutations like those associated with Canavan disease and potentially developing a panel of tests for populations like those of Ashkenazi decent, we will be able to attract more customers to our fast, flexible and economical diagnostic testing platform."
About Nanogen
Nanogen``s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen``s web site at http://www.nanogen.com/ .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company``s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company``s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Nanogen, Inc.
© PR Newswire
Press Release Source: Nanogen, Inc.
Nanogen Licenses Rights to Apolipoprotein E (ApoE), A Common Marker Linked to Alzheimer`s Disease
Wednesday December 18, 7:01 am ET
SAN DIEGO, Dec. 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), a leading provider of molecular diagnostics, today announced the signing of a non-exclusive license agreement with Athena Diagnostics (Athena) that grants Nanogen a worldwide, non-exclusive license to certain patents and patent applications relating to methods of using Apolipoprotein E (ApoE) isoforms, or any nucleic acid sequence relating to a gene encoding such isoforms, associated with the detection, diagnosis and monitoring of Alzheimer`s disease. Financial terms of the license agreement were not disclosed.
"This agreement allows Nanogen to develop an Analyte Specific Reagent (ASR) and eventually an FDA-cleared kit for the detection of ApoE4, the main ApoE allele thought to be involved in the diagnosis of Alzheimer`s disease," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer.
Alzheimer`s disease (AD) is a progressive, degenerative disease of the brain and is the most common form of dementia. It affects the parts of the brain that control thought, memory and language. The Alzheimer`s Association has estimated that approximately 4 million Americans have AD, which costs the nation over $100 billion annually and an estimated 14 million Americans will develop AD by 2050. ApoE has been implicated as a specific risk factor for late-onset AD. AD usually begins after age 65 and the risk of AD increases with age. About 10% of men and women over 65 have AD and nearly 50% of those older than 85 have the disease. ApoE appears to play a role in the distribution of cholesterol for repairing nerve cells during development and after injury. Three variations of ApoE have been identified, known as ApoE2, ApoE3 and ApoE4. ApoE2 and ApoE3 seem to have protective qualities that help to maintain nerve-cell structure. ApoE4 does not have this protective capability and is considered to be a major inherited risk factor for AD. Studies have shown that having ApoE4 puts people at a higher risk of having AD, but does not necessarily ensure that they will develop the disease.
Birndorf added, "As research involving ApoE in other central nervous system diseases progresses, Nanogen may also be able to offer a single ApoE assay for such indications or in combination with other mutations. The NanoChip® Molecular Biology Workstation provides our customers the versatility they need in order to test for many different gene mutations on a single platform. By obtaining important intellectual property rights to disease gene mutations like those associated with Alzheimer`s disease, we will be able to attract more customers to our fast, versatile and economical diagnostic testing platform."
About Nanogen
Nanogen is a leading provider of molecular diagnostics. The Company is seeking to establish the NanoChip® Molecular Biology Workstation as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Nanogen Licenses Rights to Apolipoprotein E (ApoE), A Common Marker Linked to Alzheimer`s Disease
Wednesday December 18, 7:01 am ET
SAN DIEGO, Dec. 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), a leading provider of molecular diagnostics, today announced the signing of a non-exclusive license agreement with Athena Diagnostics (Athena) that grants Nanogen a worldwide, non-exclusive license to certain patents and patent applications relating to methods of using Apolipoprotein E (ApoE) isoforms, or any nucleic acid sequence relating to a gene encoding such isoforms, associated with the detection, diagnosis and monitoring of Alzheimer`s disease. Financial terms of the license agreement were not disclosed.
"This agreement allows Nanogen to develop an Analyte Specific Reagent (ASR) and eventually an FDA-cleared kit for the detection of ApoE4, the main ApoE allele thought to be involved in the diagnosis of Alzheimer`s disease," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer.
Alzheimer`s disease (AD) is a progressive, degenerative disease of the brain and is the most common form of dementia. It affects the parts of the brain that control thought, memory and language. The Alzheimer`s Association has estimated that approximately 4 million Americans have AD, which costs the nation over $100 billion annually and an estimated 14 million Americans will develop AD by 2050. ApoE has been implicated as a specific risk factor for late-onset AD. AD usually begins after age 65 and the risk of AD increases with age. About 10% of men and women over 65 have AD and nearly 50% of those older than 85 have the disease. ApoE appears to play a role in the distribution of cholesterol for repairing nerve cells during development and after injury. Three variations of ApoE have been identified, known as ApoE2, ApoE3 and ApoE4. ApoE2 and ApoE3 seem to have protective qualities that help to maintain nerve-cell structure. ApoE4 does not have this protective capability and is considered to be a major inherited risk factor for AD. Studies have shown that having ApoE4 puts people at a higher risk of having AD, but does not necessarily ensure that they will develop the disease.
Birndorf added, "As research involving ApoE in other central nervous system diseases progresses, Nanogen may also be able to offer a single ApoE assay for such indications or in combination with other mutations. The NanoChip® Molecular Biology Workstation provides our customers the versatility they need in order to test for many different gene mutations on a single platform. By obtaining important intellectual property rights to disease gene mutations like those associated with Alzheimer`s disease, we will be able to attract more customers to our fast, versatile and economical diagnostic testing platform."
About Nanogen
Nanogen is a leading provider of molecular diagnostics. The Company is seeking to establish the NanoChip® Molecular Biology Workstation as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Dow Jones Business News
Nanogen Says Litigation Settlement to Boost Income
Thursday December 19, 8:45 am ET
SAN DIEGO (Dow Jones)--Nanogen Inc. expects its litigation settlement with Acacia Research Corp.`s CombiMatrix Corp. unit and Donald Montgomery to add about $10.8 million to fourth quarter 2002 income.
In September, CombiMatrix agreed to pay Nanogen $1 million in cash to cover litigation costs and issue four million common shares, or 17.5% of its stock, to settle the lawsuit Nanogen brought against it nearly two years ago.
In a press release Thursday, Nanogen said it recognized the $1 million payment in the third quarter of 2002, but deferred recognition of the CombiMatrix shares until they began trading on Nasdaq Dec. 16. The shares were valued at the initial offering price of $2.70 per share
Nanogen Says Litigation Settlement to Boost Income
Thursday December 19, 8:45 am ET
SAN DIEGO (Dow Jones)--Nanogen Inc. expects its litigation settlement with Acacia Research Corp.`s CombiMatrix Corp. unit and Donald Montgomery to add about $10.8 million to fourth quarter 2002 income.
In September, CombiMatrix agreed to pay Nanogen $1 million in cash to cover litigation costs and issue four million common shares, or 17.5% of its stock, to settle the lawsuit Nanogen brought against it nearly two years ago.
In a press release Thursday, Nanogen said it recognized the $1 million payment in the third quarter of 2002, but deferred recognition of the CombiMatrix shares until they began trading on Nasdaq Dec. 16. The shares were valued at the initial offering price of $2.70 per share
Press Release Source: Nanogen, Inc.
Nanogen to Recognize $10.8 Million in Income As a Result of CombiMatrix Settlement
Thursday December 19, 7:01 am ET
SAN DIEGO, Dec. 19 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) announced today that it expects to include approximately $10.8 million in income in the fourth quarter of 2002 as a result of its settlement agreement with CombiMatrix Corporation, Acacia Research Corporation`s (Nasdaq: ACRI - News) majority-owned subsidiary, and Dr. Donald Montgomery. Under the settlement agreement finalized on September 30, 2002, Nanogen received seventeen and one-half percent (17.5%) of the outstanding shares of CombiMatrix common stock (4,016,346 shares). These shares are valued at the initial offering price of $2.70 per share. Nanogen deferred the recognition of the value of the shares received until CombiMatrix began trading on the Nasdaq stock market on December 16, 2002.
In addition to the ownership in CombiMatrix, Nanogen also will receive cash payments totaling $1 million (recognized in the third quarter of 2002), and royalty payments of twelve and one-half percent (12.5%) on sales of products developed by either CombiMatrix or its affiliates that incorporate the disputed technology.
About Nanogen
Nanogen is a leading provider of molecular diagnostics. The Company is seeking to establish the NanoChip® Molecular Biology Workstation as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Nanogen to Recognize $10.8 Million in Income As a Result of CombiMatrix Settlement
Thursday December 19, 7:01 am ET
SAN DIEGO, Dec. 19 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) announced today that it expects to include approximately $10.8 million in income in the fourth quarter of 2002 as a result of its settlement agreement with CombiMatrix Corporation, Acacia Research Corporation`s (Nasdaq: ACRI - News) majority-owned subsidiary, and Dr. Donald Montgomery. Under the settlement agreement finalized on September 30, 2002, Nanogen received seventeen and one-half percent (17.5%) of the outstanding shares of CombiMatrix common stock (4,016,346 shares). These shares are valued at the initial offering price of $2.70 per share. Nanogen deferred the recognition of the value of the shares received until CombiMatrix began trading on the Nasdaq stock market on December 16, 2002.
In addition to the ownership in CombiMatrix, Nanogen also will receive cash payments totaling $1 million (recognized in the third quarter of 2002), and royalty payments of twelve and one-half percent (12.5%) on sales of products developed by either CombiMatrix or its affiliates that incorporate the disputed technology.
About Nanogen
Nanogen is a leading provider of molecular diagnostics. The Company is seeking to establish the NanoChip® Molecular Biology Workstation as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed two ASRs for the detection of Factor V Leiden and the CFTR gene for cystic fibrosis, and has internally validated five research protocols, four associated with cardiovascular disease and one associated with hereditary hemochromatosis, the most common form of iron overload disease. Nanogen markets its NanoChip® Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Frohes Neues erstmal!
aus dem Ami-Board
http://www.eng.auburn.edu/~troppel/courses/6760spring2002/pr… ts/hicks_zengel_writ.doc
"As stated earlier, sales in the year 2003 is expected to be in the range of $350-750 million [6]. That range may be too small due to the fact that new breakthroughs could instantly create new products at any time. Both the medical field and the military have enormous resources for purchasing viable products in the bio-MEMS field, and they would receive political pressure to purchase any product that may prove cost efficient. With the increasing chance for either a terrorist biological or chemical attack, the military would be very interested in a device that could detect the early stages of adverse symptoms to personnel. Several companies have already invested in and are beginning to market bio-MEMS products, and those companies are Cepheid, Caliper Technologies, Nanogen, Aclara Biosciences, Orchid Biosciences, and Motorola [6].
Now that results are starting to show, funding for bio-MEMS related fields show continue to increase [9]. Since product development lags research funding, the true scope of the market will not be fully understood for quite some time"
aus dem Ami-Board
http://www.eng.auburn.edu/~troppel/courses/6760spring2002/pr… ts/hicks_zengel_writ.doc
"As stated earlier, sales in the year 2003 is expected to be in the range of $350-750 million [6]. That range may be too small due to the fact that new breakthroughs could instantly create new products at any time. Both the medical field and the military have enormous resources for purchasing viable products in the bio-MEMS field, and they would receive political pressure to purchase any product that may prove cost efficient. With the increasing chance for either a terrorist biological or chemical attack, the military would be very interested in a device that could detect the early stages of adverse symptoms to personnel. Several companies have already invested in and are beginning to market bio-MEMS products, and those companies are Cepheid, Caliper Technologies, Nanogen, Aclara Biosciences, Orchid Biosciences, and Motorola [6].
Now that results are starting to show, funding for bio-MEMS related fields show continue to increase [9]. Since product development lags research funding, the true scope of the market will not be fully understood for quite some time"
SAN DIEGO, Feb. 6 /PRNewswire-FirstCall/ -- Nanogen, Inc. today announced its financial results for the fourth quarter and year ended December 31, 2002.
During the fourth quarter, Nanogen entered into a record number of reagent rental and cost per test transactions by posting five new agreements, two of which were development site agreement conversions. In addition, the Company closed sales transactions for four instruments, as well as four new non- revenue placements. For the year, Nanogen completed commercial transactions for thirty-six reagent rentals and sales, of which eight were converted from development sites. The Company had an additional twelve development site agreements. This translates to a total of forty systems added to its installed base for the year.
Product revenues for the fourth quarter of 2002 were $511,000, as compared to $691,000 in revenue posted in the fourth quarter of 2001. Total revenues for the quarter were approximately $12.1 million which includes approximately $10.8 million in license revenue recognized as a result of the previously announced CombiMatrix settlement. Excluding the revenue recognized as a result of CombiMatrix, total revenues for the quarter were approximately $1.3 million. The overall decline in total revenues from the prior year has been anticipated and reported consistently over the past year as Nanogen``s revenue base continues to shift to potentially higher margin product revenues from the historical base of revenues derived from sponsored research, corporate alliances and government contracts. To that end, the Company continued to increase its percentage of product-driven revenues as thirty-nine (39%) percent of its revenues in the fourth quarter came from product revenues as compared to thirty percent (30%) of the revenues for the same period last year.
Product revenues for the year were $3.4 million, a fifty-one percent (51%) increase from $2.2 million for the year ended December 31, 2001. Total revenues were approximately $17.2 million as compared to last year``s figure of $11.2 million. Excluding the revenue recorded as a result of the CombiMatrix settlement, the total revenue for the year was $6.3 million.
Nanogen``s operating expenses for the fourth quarter ending December 31, 2002 totaled $10.9 million as compared to $11.1 million for the same period last year. The Company reported a year-to-date net loss of $22.2 million or $1.02 per share. Excluding the CombiMatrix settlement amounts of $10.8 million recognized in the fourth quarter and $1 million recognized in the third quarter, the net loss was $34.1 million or $1.57 per share in 2002. This compares with a net loss of $32.5 million or $1.54 per share for 2001. The Company``s consolidated cash and short-term investments balance at the end of the fourth quarter exceeded $52 million. This amount includes the stock that Nanogen received in its settlement with CombiMatrix which was valued at $14.6 million ($3.64 per share) at year end due to an increase in the stock price of CombiMatrix from the settlement date to year end.
Nanogen also announced that it completed beta-site testing of its set of Analyte Specific Reagents (ASRs) for the mutations in the CFTR gene, which are associated with the diagnosis of cystic fibrosis, and is commencing a controlled launch of the product to market. In addition, the Company announced the launch of the first and only 3-SNP ASR for the mutations in the HFE gene, which are associated with the diagnosis of hereditary hemachromotosis. It also announced the initiation of beta-site testing for its Assay Tool Box product, which is expected to be available for sale by the end of the month. Two other products began beta-site testing; a test for beta-Thalassemia to be sold only in Europe and a multiplex ASR for both Factor V and Factor II. Lastly, the Company stated it is internally validating a protocol for Canavan Disease and in March, expects to begin beta-site testing of an ASR for Apolipoprotein E (Apo-E), a genetic marker associated with the diagnosis of Alzheimer``s disease.
"This quarter was significant as the Company posted its highest number of reagent rental agreements for a quarter to date. Now with the launch of key products like CFTR and HFE, Nanogen is well positioned for success as its foundation for potential consumable revenue growth continues to thrive," said Howard C. Birndorf, Nanogen``s chairman of the board and chief executive officer. "The Nanogen technology offers our customers an open platform in which they can either use our newly available products or continue to develop their own tests. This gives Nanogen an important competitive advantage from all other companies offering molecular diagnostic testing tools and is a clear demonstration of our ability to offer both the simplest to the most complex of tests on a single platform," Mr. Birndorf added.
Nanogen management will hold a conference call to discuss fourth quarter and year-end 2002 financial results today at 4:30 p.m. Eastern Time. A live web cast is available via Nanogen``s website at http://www.nanogen.com/ . A telephone replay of the conference call will be available approximately two hours following the call until 11:59 p.m. Eastern Time on February 8, 2003 and can be accessed at 800-642-1687 (domestic) or 706-645-9291 (international), passcode ID #7737301.
About Nanogen
Nanogen``s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed three ASRs for the detection of mutations in the Factor V Leiden gene, the CFTR gene, which are associated with the diagnosis of cystic fibrosis, and the HFE gene, which are associated with the diagnosis of hereditary hemachromotosis. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen``s web site at http://www.nanogen.com/ .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company``s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company``s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.
NANOGEN, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share data) December 31, December 31, 2002 2001 (unaudited) ASSETS Current assets: Cash and cash equivalents $9,353 $10,455 Short-term investments 43,376 57,069 Receivables, net 1,754 4,380 Inventories, net 4,717 4,688 Other current assets 1,781 2,473 Total current assets 60,981 79,065 Property and equipment, net 4,982 5,386 Acquired technology rights, net 4,544 4,183 Other assets, net 789 1,158 Restricted cash 64 299 $71,360 $90,091 LIABILITIES AND STOCKHOLDERS`` EQUITY Current liabilities: Accounts payable $753 $1,051 Accrued liabilities 5,901 4,916 Deferred revenue 472 522 Current portion of capital lease obligations 805 1,060 Total current liabilities 7,931 7,549 Capital lease obligations, less current portion 1,134 1,755 Other long-term liabilities 3,085 1,675 Total long-term liabilities 4,219 3,430 Minority interest in consolidated subsidiary 1,817 4,183 Stockholders`` equity: Convertible preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2002 and December 31, 2001 -- -- Common stock, $.001 par value, 50,000,000 shares authorized; 21,981,115 and 21,616,172 shares issued and outstanding at December 31, 2002 and December 31, 2001, respectively 22 22 Additional paid-in capital 199,483 198,387 Accumulated other comprehensive income 4,926 1,253 Deferred compensation (156) (336) Notes receivable from officers (513) (984) Accumulated deficit (145,659) (123,413) Treasury stock, at cost (710) -- Total stockholders`` equity 57,393 74,929 $71,360 $90,091 NANOGEN, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Three months ended Twelve months ended December 31, December 31, 2002 2001 2002 2001 (unaudited) (unaudited) (unaudited) Revenues: Sales $511 $691 $3,384 $2,245 License fees 10,844 -- 10,844 -- Sponsored research 375 1,228 1,355 7,457 Contract and grant 414 376 1,596 1,467 Total revenues 12,144 2,295 17,179 11,169 Operating expenses: Cost of sales 386 479 2,466 1,606 Research and development 5,348 4,512 21,020 18,597 Selling, general and administrative 5,194 6,050 20,540 22,032 Litigation and settlement of patent matter -- 64 (165) 6,900 Total operating expenses 10,928 11,105 43,861 49,135 Income (loss) from operations 1,216 (8,810) (26,682) (37,966) Interest income, net 285 909 2,119 4,390 Minority interest in loss of consolidated subsidiary 522 421 2,156 907 Other income (loss) 8 28 161 168 Net Income (loss) $2,031 $(7,452) $(22,246) $(32,501) Net Income (loss) per share - basic and diluted $0.09 $(0.35) $(1.02) $(1.54) Number of shares used in computing net income (loss) per share - basic and diluted 21,697 21,532 21,722 21,091
Nanogen, Inc.
© PR Newswire
During the fourth quarter, Nanogen entered into a record number of reagent rental and cost per test transactions by posting five new agreements, two of which were development site agreement conversions. In addition, the Company closed sales transactions for four instruments, as well as four new non- revenue placements. For the year, Nanogen completed commercial transactions for thirty-six reagent rentals and sales, of which eight were converted from development sites. The Company had an additional twelve development site agreements. This translates to a total of forty systems added to its installed base for the year.
Product revenues for the fourth quarter of 2002 were $511,000, as compared to $691,000 in revenue posted in the fourth quarter of 2001. Total revenues for the quarter were approximately $12.1 million which includes approximately $10.8 million in license revenue recognized as a result of the previously announced CombiMatrix settlement. Excluding the revenue recognized as a result of CombiMatrix, total revenues for the quarter were approximately $1.3 million. The overall decline in total revenues from the prior year has been anticipated and reported consistently over the past year as Nanogen``s revenue base continues to shift to potentially higher margin product revenues from the historical base of revenues derived from sponsored research, corporate alliances and government contracts. To that end, the Company continued to increase its percentage of product-driven revenues as thirty-nine (39%) percent of its revenues in the fourth quarter came from product revenues as compared to thirty percent (30%) of the revenues for the same period last year.
Product revenues for the year were $3.4 million, a fifty-one percent (51%) increase from $2.2 million for the year ended December 31, 2001. Total revenues were approximately $17.2 million as compared to last year``s figure of $11.2 million. Excluding the revenue recorded as a result of the CombiMatrix settlement, the total revenue for the year was $6.3 million.
Nanogen``s operating expenses for the fourth quarter ending December 31, 2002 totaled $10.9 million as compared to $11.1 million for the same period last year. The Company reported a year-to-date net loss of $22.2 million or $1.02 per share. Excluding the CombiMatrix settlement amounts of $10.8 million recognized in the fourth quarter and $1 million recognized in the third quarter, the net loss was $34.1 million or $1.57 per share in 2002. This compares with a net loss of $32.5 million or $1.54 per share for 2001. The Company``s consolidated cash and short-term investments balance at the end of the fourth quarter exceeded $52 million. This amount includes the stock that Nanogen received in its settlement with CombiMatrix which was valued at $14.6 million ($3.64 per share) at year end due to an increase in the stock price of CombiMatrix from the settlement date to year end.
Nanogen also announced that it completed beta-site testing of its set of Analyte Specific Reagents (ASRs) for the mutations in the CFTR gene, which are associated with the diagnosis of cystic fibrosis, and is commencing a controlled launch of the product to market. In addition, the Company announced the launch of the first and only 3-SNP ASR for the mutations in the HFE gene, which are associated with the diagnosis of hereditary hemachromotosis. It also announced the initiation of beta-site testing for its Assay Tool Box product, which is expected to be available for sale by the end of the month. Two other products began beta-site testing; a test for beta-Thalassemia to be sold only in Europe and a multiplex ASR for both Factor V and Factor II. Lastly, the Company stated it is internally validating a protocol for Canavan Disease and in March, expects to begin beta-site testing of an ASR for Apolipoprotein E (Apo-E), a genetic marker associated with the diagnosis of Alzheimer``s disease.
"This quarter was significant as the Company posted its highest number of reagent rental agreements for a quarter to date. Now with the launch of key products like CFTR and HFE, Nanogen is well positioned for success as its foundation for potential consumable revenue growth continues to thrive," said Howard C. Birndorf, Nanogen``s chairman of the board and chief executive officer. "The Nanogen technology offers our customers an open platform in which they can either use our newly available products or continue to develop their own tests. This gives Nanogen an important competitive advantage from all other companies offering molecular diagnostic testing tools and is a clear demonstration of our ability to offer both the simplest to the most complex of tests on a single platform," Mr. Birndorf added.
Nanogen management will hold a conference call to discuss fourth quarter and year-end 2002 financial results today at 4:30 p.m. Eastern Time. A live web cast is available via Nanogen``s website at http://www.nanogen.com/ . A telephone replay of the conference call will be available approximately two hours following the call until 11:59 p.m. Eastern Time on February 8, 2003 and can be accessed at 800-642-1687 (domestic) or 706-645-9291 (international), passcode ID #7737301.
About Nanogen
Nanogen``s goal is to become the leading provider of molecular diagnostic products. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, the Company has developed three ASRs for the detection of mutations in the Factor V Leiden gene, the CFTR gene, which are associated with the diagnosis of cystic fibrosis, and the HFE gene, which are associated with the diagnosis of hereditary hemachromotosis. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen``s web site at http://www.nanogen.com/ .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company``s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company``s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.
NANOGEN, INC. CONSOLIDATED BALANCE SHEETS (in thousands, except share data) December 31, December 31, 2002 2001 (unaudited) ASSETS Current assets: Cash and cash equivalents $9,353 $10,455 Short-term investments 43,376 57,069 Receivables, net 1,754 4,380 Inventories, net 4,717 4,688 Other current assets 1,781 2,473 Total current assets 60,981 79,065 Property and equipment, net 4,982 5,386 Acquired technology rights, net 4,544 4,183 Other assets, net 789 1,158 Restricted cash 64 299 $71,360 $90,091 LIABILITIES AND STOCKHOLDERS`` EQUITY Current liabilities: Accounts payable $753 $1,051 Accrued liabilities 5,901 4,916 Deferred revenue 472 522 Current portion of capital lease obligations 805 1,060 Total current liabilities 7,931 7,549 Capital lease obligations, less current portion 1,134 1,755 Other long-term liabilities 3,085 1,675 Total long-term liabilities 4,219 3,430 Minority interest in consolidated subsidiary 1,817 4,183 Stockholders`` equity: Convertible preferred stock, $.001 par value, 5,000,000 shares authorized; no shares issued and outstanding at December 31, 2002 and December 31, 2001 -- -- Common stock, $.001 par value, 50,000,000 shares authorized; 21,981,115 and 21,616,172 shares issued and outstanding at December 31, 2002 and December 31, 2001, respectively 22 22 Additional paid-in capital 199,483 198,387 Accumulated other comprehensive income 4,926 1,253 Deferred compensation (156) (336) Notes receivable from officers (513) (984) Accumulated deficit (145,659) (123,413) Treasury stock, at cost (710) -- Total stockholders`` equity 57,393 74,929 $71,360 $90,091 NANOGEN, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) Three months ended Twelve months ended December 31, December 31, 2002 2001 2002 2001 (unaudited) (unaudited) (unaudited) Revenues: Sales $511 $691 $3,384 $2,245 License fees 10,844 -- 10,844 -- Sponsored research 375 1,228 1,355 7,457 Contract and grant 414 376 1,596 1,467 Total revenues 12,144 2,295 17,179 11,169 Operating expenses: Cost of sales 386 479 2,466 1,606 Research and development 5,348 4,512 21,020 18,597 Selling, general and administrative 5,194 6,050 20,540 22,032 Litigation and settlement of patent matter -- 64 (165) 6,900 Total operating expenses 10,928 11,105 43,861 49,135 Income (loss) from operations 1,216 (8,810) (26,682) (37,966) Interest income, net 285 909 2,119 4,390 Minority interest in loss of consolidated subsidiary 522 421 2,156 907 Other income (loss) 8 28 161 168 Net Income (loss) $2,031 $(7,452) $(22,246) $(32,501) Net Income (loss) per share - basic and diluted $0.09 $(0.35) $(1.02) $(1.54) Number of shares used in computing net income (loss) per share - basic and diluted 21,697 21,532 21,722 21,091
Nanogen, Inc.
© PR Newswire
NGEN kennt nur noch eine Richtung...
Sollte man jetzt einsteigen?
Newman8
Newman8
Nanogen Expands Molecular Diagnostic Product Menu
SAN DIEGO, Mar 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostic products, announced today that it has commercially released the first multiplex Analyte Specific Reagent (ASR), designed for the detection of Factor V Leiden and Factor II Prothrombin gene mutations associated with cardiovascular disease and the pathology of thrombosis. In addition, Nanogen released its Assay ToolBox(TM), a set of consumable products that allows customers to facilitate their own protocol and assay development on the NanoChip(R) platform. Recently, Nanogen launched ASRs for the detection of the CFTR gene for cystic fibrosis and the HFE gene for hereditary hemochromatosis.
The Factor V/ Factor II Prothrombin ASR consists of reagents, controls and analysis of the G1691A mutation on the Factor V (Leiden) gene and the G20210A mutation on the Prothrombin gene. High complexity CLIA certified laboratories may use the reagents to create and validate laboratory developed tests for detection of these mutations. Mutations in the Factor V gene (Factor V Leiden) and Factor II gene (Factor II, Prothrombin) are the most common causes of hereditary blood coagulation disorders that can lead to cardiovascular disease. The Factor V Leiden and Factor II Prothrombin mutations are present in three to seven percent of the population in the United States and two to three percent of the population in Europe. Carriers of the Factor II mutation have a three to eight-fold increased risk for blood clot formation, and the risk is significantly greater in those who also carry the Factor V Leiden mutation.
The Nanogen Assay ToolBox(TM) is a set of consumable reagents that enables users to define, select and build their own assays. This product complements the unique, open-architecture of the NanoChip(R) electronic microarray.
"Our aim is to deliver a solid testing platform with the broadest possible menu. Offering an ASR such as the market`s first multiplex ASR for Factor V/Factor II in addition to our Assay ToolBox(TM) continues to add to our menu of products. This, in addition to our ability to perform the simplest to the most complex of tests on a single platform, is a demonstration of what we call platformation," said Howard Birndorf, chairman of the board and chief executive officer of Nanogen.
Bruce Huebner, president and chief operating officer added, "The introduction of these products continues to demonstrate our ability to design, develop and market innovative molecular diagnostic products that meet or exceed our customers` needs of accuracy, speed, versatility and cost effectiveness. We will continue to expand the breadth of our menu with the launch of additional products in the upcoming months such as an ASR for ApoE, a mutation associated with the increased risk for Alzheimer`s disease. We believe these products will create a significant opportunity to increase consumable product revenues related to the use of our NanoChip(R) platform."
About Nanogen
Nanogen`s goal is to become a leading provider of molecular diagnostic products and services. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed four Analyte Specific Reagents (ASR) for the detection of Factor V Leiden, CFTR gene for cystic fibrosis, HFE gene for hereditary hemochromatosis and simultaneous detection of Factor V/Factor II Prothrombin. The Company has also internally validated a research protocol for MTHFR, a gene mutation associated with cardiovascular disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO, +1-858-410-4605, or
Robert Blodgett, Director of Investor Relations, +1-858-410-4651, both of
Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2003 PR Newswire. All rights reserved.
SAN DIEGO, Mar 6, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostic products, announced today that it has commercially released the first multiplex Analyte Specific Reagent (ASR), designed for the detection of Factor V Leiden and Factor II Prothrombin gene mutations associated with cardiovascular disease and the pathology of thrombosis. In addition, Nanogen released its Assay ToolBox(TM), a set of consumable products that allows customers to facilitate their own protocol and assay development on the NanoChip(R) platform. Recently, Nanogen launched ASRs for the detection of the CFTR gene for cystic fibrosis and the HFE gene for hereditary hemochromatosis.
The Factor V/ Factor II Prothrombin ASR consists of reagents, controls and analysis of the G1691A mutation on the Factor V (Leiden) gene and the G20210A mutation on the Prothrombin gene. High complexity CLIA certified laboratories may use the reagents to create and validate laboratory developed tests for detection of these mutations. Mutations in the Factor V gene (Factor V Leiden) and Factor II gene (Factor II, Prothrombin) are the most common causes of hereditary blood coagulation disorders that can lead to cardiovascular disease. The Factor V Leiden and Factor II Prothrombin mutations are present in three to seven percent of the population in the United States and two to three percent of the population in Europe. Carriers of the Factor II mutation have a three to eight-fold increased risk for blood clot formation, and the risk is significantly greater in those who also carry the Factor V Leiden mutation.
The Nanogen Assay ToolBox(TM) is a set of consumable reagents that enables users to define, select and build their own assays. This product complements the unique, open-architecture of the NanoChip(R) electronic microarray.
"Our aim is to deliver a solid testing platform with the broadest possible menu. Offering an ASR such as the market`s first multiplex ASR for Factor V/Factor II in addition to our Assay ToolBox(TM) continues to add to our menu of products. This, in addition to our ability to perform the simplest to the most complex of tests on a single platform, is a demonstration of what we call platformation," said Howard Birndorf, chairman of the board and chief executive officer of Nanogen.
Bruce Huebner, president and chief operating officer added, "The introduction of these products continues to demonstrate our ability to design, develop and market innovative molecular diagnostic products that meet or exceed our customers` needs of accuracy, speed, versatility and cost effectiveness. We will continue to expand the breadth of our menu with the launch of additional products in the upcoming months such as an ASR for ApoE, a mutation associated with the increased risk for Alzheimer`s disease. We believe these products will create a significant opportunity to increase consumable product revenues related to the use of our NanoChip(R) platform."
About Nanogen
Nanogen`s goal is to become a leading provider of molecular diagnostic products and services. The Company is seeking to establish the NanoChip(R) System as the standard platform for the detection of genetic mutations and to develop applications for future clinical use. To date, it has developed four Analyte Specific Reagents (ASR) for the detection of Factor V Leiden, CFTR gene for cystic fibrosis, HFE gene for hereditary hemochromatosis and simultaneous detection of Factor V/Factor II Prothrombin. The Company has also internally validated a research protocol for MTHFR, a gene mutation associated with cardiovascular disease. Nanogen markets its NanoChip(R) Molecular Biology Workstation to scientists and genomics laboratories. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2001 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof.
SOURCE Nanogen, Inc.
CONTACT: Gerard A. Wills, Vice President & CFO, +1-858-410-4605, or
Robert Blodgett, Director of Investor Relations, +1-858-410-4651, both of
Nanogen, Inc.
URL: http://www.nanogen.com
http://www.prnewswire.com
Copyright (C) 2003 PR Newswire. All rights reserved.
Hallo ihr beiden!
Leider kennt NGEN wirklich nur noch den Weg nach unten.
Hm..einsteigen.......
man kann denk ich bei NGEN überproportional viel gewinnen, aber dass muß jeder für sich wissen.
Ich finde gerade in solchen Krisensituationen war in der Vergangenheit auf eine Meldung von NGEN Verlaß.....vielleicht auch diesmal?
Lets see!
Leider kennt NGEN wirklich nur noch den Weg nach unten.
Hm..einsteigen.......
man kann denk ich bei NGEN überproportional viel gewinnen, aber dass muß jeder für sich wissen.
Ich finde gerade in solchen Krisensituationen war in der Vergangenheit auf eine Meldung von NGEN Verlaß.....vielleicht auch diesmal?
Lets see!
@tst89:
nicht nehr "nur nach unten"... +16% ist sehr erfreulich. Nur weiter so.
nicht nehr "nur nach unten"... +16% ist sehr erfreulich. Nur weiter so.
am 17.03.2003 ist eine Kostenpflichtige Analyse (19$) veröffentlicht worden,
ich vermute das die zur Kursexplosion von NGEN geführt hat.
Link: http://biz.yahoo.com/p/n/ngen.html
humm
ich vermute das die zur Kursexplosion von NGEN geführt hat.
Link: http://biz.yahoo.com/p/n/ngen.html
humm 
der letzte investierter Anleger in NGEN...
+15,5%...
+15,5%...
der letzte investierter Anleger in NGEN... (oder doch nicht )
+5,3%
wer hat Infos?
)+5,3%
wer hat Infos?
Atkins + Associates Hosts First Annual San Diego BioBusiness Investor Tour
SAN DIEGO, Mar 25, 2003 /PRNewswire via COMTEX/ -- Top institutional investors and analysts from across the country attended Atkins + Associates` First Annual San Diego BioBusiness Investor Tour this week to get up close and personal with some of the city`s best and brightest biotechnology and medical device companies. Participating companies included Avanir Pharmaceuticals (Amex: AVN), Corvas International (Nasdaq: CVAS), Diversa Corporation (Nasdaq: DVSA), Nanogen, Inc. (Nasdaq: NGEN), Quidel Corporation (Nasdaq: QDEL), Stressgen Biotechnologies (Toronto: SSB) and Vical, Inc. (Nasdaq: VICL).
Investors visited with seven different companies over two days to hear company presentations from all levels of management and to attend facility tours. In addition to on-site company visits, a cocktail reception was held at the prestigious Salk Institute, where company executives and investors had the opportunity to network and engage in a guided exploration of the campus. The event was sponsored by Nasdaq and PR Newswire and hosted by Atkins + Associates, the largest science-based agency on the West Coast providing public and investor relations services for bio-businesses.
"In spite of world turmoil, we have made a solid start in a worthwhile endeavor for San Diego biotechnology companies," said Susan E. Atkins, President & CEO of Atkins + Associates. "We hope to make the Investor Tour an annual event and we look forward to an even more successful tour in 2004."
Atkins + Associates
Founded in 1999, Atkins + Associates is the largest agency in the West providing strategic public and investor relations exclusively for bio- businesses. The agency`s targeted programs position clients in the minds of investors, venture capitalists, bankers, media, pharmaceutical partners, patients, healthcare professionals, and other important constituents. Helping clients achieve its business objectives such as an IPO, product launch, partnership agreement or additional financing is the goal of these strategic programs. Atkins + Associates` client roster currently spans all biotech categories: public, private, therapeutics, tools, and medical devices. For more information, call Carin Canale at 858-527-3498 or visit our web site at www.atkinsassociates.com
SOURCE Atkins + Associates
Carin Canale of Atkins + Associates, +1-858-527-3498,
ccanale@irpr.com
http://www.atkinsassociates.com
SAN DIEGO, Mar 25, 2003 /PRNewswire via COMTEX/ -- Top institutional investors and analysts from across the country attended Atkins + Associates` First Annual San Diego BioBusiness Investor Tour this week to get up close and personal with some of the city`s best and brightest biotechnology and medical device companies. Participating companies included Avanir Pharmaceuticals (Amex: AVN), Corvas International (Nasdaq: CVAS), Diversa Corporation (Nasdaq: DVSA), Nanogen, Inc. (Nasdaq: NGEN), Quidel Corporation (Nasdaq: QDEL), Stressgen Biotechnologies (Toronto: SSB) and Vical, Inc. (Nasdaq: VICL).
Investors visited with seven different companies over two days to hear company presentations from all levels of management and to attend facility tours. In addition to on-site company visits, a cocktail reception was held at the prestigious Salk Institute, where company executives and investors had the opportunity to network and engage in a guided exploration of the campus. The event was sponsored by Nasdaq and PR Newswire and hosted by Atkins + Associates, the largest science-based agency on the West Coast providing public and investor relations services for bio-businesses.
"In spite of world turmoil, we have made a solid start in a worthwhile endeavor for San Diego biotechnology companies," said Susan E. Atkins, President & CEO of Atkins + Associates. "We hope to make the Investor Tour an annual event and we look forward to an even more successful tour in 2004."
Atkins + Associates
Founded in 1999, Atkins + Associates is the largest agency in the West providing strategic public and investor relations exclusively for bio- businesses. The agency`s targeted programs position clients in the minds of investors, venture capitalists, bankers, media, pharmaceutical partners, patients, healthcare professionals, and other important constituents. Helping clients achieve its business objectives such as an IPO, product launch, partnership agreement or additional financing is the goal of these strategic programs. Atkins + Associates` client roster currently spans all biotech categories: public, private, therapeutics, tools, and medical devices. For more information, call Carin Canale at 858-527-3498 or visit our web site at www.atkinsassociates.com
SOURCE Atkins + Associates
Carin Canale of Atkins + Associates, +1-858-527-3498,
ccanale@irpr.com
http://www.atkinsassociates.com
Der Anbieter molecularer Diagnosetests Nanogen beabsichtigt 20% seiner Angestellten zu entlassen und seine Mitarbeiteranzahl somit auf 156 abzubauen. Diese Restrukturierung soll eine Kostenreduktion in Höhe von $5 Millionen für das Jahr 2003 zur Folge haben.
© BörseGo
© BörseGo
SAN DIEGO, April 10 /PRNewswire-FirstCall/ -- Nanogen, Inc. today announced that it has reorganized its workforce in order to effectively manage its resources dedicated to developing and marketing molecular diagnostic products. By eliminating full-time, contract and temporary positions, the Company is reducing its workforce by approximately 20%, retaining approximately 156 employees. The reduction in staff positions is across all functions of the Company. Nanogen expects that the reorganization measures, along with additional cost reductions, will result in a net savings in operating expenses of approximately $5 million in fiscal year 2003.
"Nanogen remains dedicated to its strategy to continue to place its NanoChip(R) Molecular Biology Workstations within clinical reference labs and increase sales of its consumable products -- including the three new products we announced today. Adjusting our cost structure will enable us to effectively manage our business in this weakened economy," said Howard C. Birndorf, Nanogen``s chairman of the board and chief executive officer.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer``s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen``s web site at http://www.nanogen.com/ .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company``s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company``s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Nanogen, Inc.
© PR Newswire
"Nanogen remains dedicated to its strategy to continue to place its NanoChip(R) Molecular Biology Workstations within clinical reference labs and increase sales of its consumable products -- including the three new products we announced today. Adjusting our cost structure will enable us to effectively manage our business in this weakened economy," said Howard C. Birndorf, Nanogen``s chairman of the board and chief executive officer.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer``s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen``s web site at http://www.nanogen.com/ .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company``s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company``s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Nanogen, Inc.
© PR Newswire
Nanogen Launches Three New Products for Detecting Genetic Mutations
SAN DIEGO, April 10 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostics, today announced the availability of three new products for the detection of certain genetic mutations often associated with Alzheimer`s disease, Canavan disease and beta thalassemia. Two of the products are Analyte Specific Reagents (ASR) that may be used by laboratories to create and validate tests for identifying mutations linked to Alzheimer`s and Canavan diseases. These products will be available to research laboratories and high complexity CLIA- certified clinical reference laboratories in the U.S. A research use only product for beta thalassemia has been launched in Europe, where the number of people with that genetic mutation is ten times more than in the U.S. Beta thalassemia is a disorder that affects the production of hemoglobin and causes anemia. All of the newly released products can be utilized on the NanoChip(R) Molecular Biology Workstation, Nanogen`s microarray platform.
"We continue to increase the breadth of our consumable product line, providing existing customers with a variety of high value reagents and attracting new customers who seek a versatile and economical testing platform in order to create, validate and broaden their own menu of tests," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer. "Nanogen will continue its strategy of obtaining important intellectual property rights to gene mutations associated with diseases in order to drive placements of the NanoChip(R) System and increase sales of consumables."
Nanogen`s ApoE ASRs consist of various reagents that may be used by laboratories to develop and validate a test for the detection of ApoE4, the main Apolipoprotein E allele associated with increased risk for Alzheimer`s disease. The Alzheimer`s Association estimates that approximately 14 million Americans will develop the disease by 2050.
Canavan disease is a genetic disorder that primarily strikes infants of eastern and central European Jewish (Ashkenazi) descent. Nanogen`s ASPA ASRs consist of various reagents that may be used by laboratories to develop and validate a test to detect whether a person carries mutations in the ASPA gene, which is associated with the diagnosis of Canavan disease. The disorder attacks an infant`s brain and robs the baby of normal development, eventually resulting in premature death. About 90 percent of the American Jewish population is of Ashkenazi descent, from which one in 40 is a carrier of the ASPA mutations.
Nanogen`s research use only product for beta thalassemia consists of various reagents that can be used to detect mutations of the HBB gene, which is most commonly associated with the diagnosis of beta thalassemia. Mutations in the HBB gene affect the production of hemoglobin, a protein in red blood cells that carries oxygen to the tissues of the body. People whose hemoglobin does not produce enough beta protein have beta thalassemia, which can cause life-threatening anemia in children, for which there is no cure. The frequency of this mutation in the general population is about one in 300. However, people with Mediterranean (including North African), Middle Eastern, or southeast Asian ancestry have a risk of about one in 30 for carrying this mutation, most likely related to the selective pressure from malaria. Beta thalassemia is an autosomal genetic disorder: if both parents have the HBB disease-causing mutation, each offspring has a one in four risk of being affected.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
-0- 04/10/2003
/CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates,
+1-858-527-3494, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
SAN DIEGO, April 10 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostics, today announced the availability of three new products for the detection of certain genetic mutations often associated with Alzheimer`s disease, Canavan disease and beta thalassemia. Two of the products are Analyte Specific Reagents (ASR) that may be used by laboratories to create and validate tests for identifying mutations linked to Alzheimer`s and Canavan diseases. These products will be available to research laboratories and high complexity CLIA- certified clinical reference laboratories in the U.S. A research use only product for beta thalassemia has been launched in Europe, where the number of people with that genetic mutation is ten times more than in the U.S. Beta thalassemia is a disorder that affects the production of hemoglobin and causes anemia. All of the newly released products can be utilized on the NanoChip(R) Molecular Biology Workstation, Nanogen`s microarray platform.
"We continue to increase the breadth of our consumable product line, providing existing customers with a variety of high value reagents and attracting new customers who seek a versatile and economical testing platform in order to create, validate and broaden their own menu of tests," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer. "Nanogen will continue its strategy of obtaining important intellectual property rights to gene mutations associated with diseases in order to drive placements of the NanoChip(R) System and increase sales of consumables."
Nanogen`s ApoE ASRs consist of various reagents that may be used by laboratories to develop and validate a test for the detection of ApoE4, the main Apolipoprotein E allele associated with increased risk for Alzheimer`s disease. The Alzheimer`s Association estimates that approximately 14 million Americans will develop the disease by 2050.
Canavan disease is a genetic disorder that primarily strikes infants of eastern and central European Jewish (Ashkenazi) descent. Nanogen`s ASPA ASRs consist of various reagents that may be used by laboratories to develop and validate a test to detect whether a person carries mutations in the ASPA gene, which is associated with the diagnosis of Canavan disease. The disorder attacks an infant`s brain and robs the baby of normal development, eventually resulting in premature death. About 90 percent of the American Jewish population is of Ashkenazi descent, from which one in 40 is a carrier of the ASPA mutations.
Nanogen`s research use only product for beta thalassemia consists of various reagents that can be used to detect mutations of the HBB gene, which is most commonly associated with the diagnosis of beta thalassemia. Mutations in the HBB gene affect the production of hemoglobin, a protein in red blood cells that carries oxygen to the tissues of the body. People whose hemoglobin does not produce enough beta protein have beta thalassemia, which can cause life-threatening anemia in children, for which there is no cure. The frequency of this mutation in the general population is about one in 300. However, people with Mediterranean (including North African), Middle Eastern, or southeast Asian ancestry have a risk of about one in 30 for carrying this mutation, most likely related to the selective pressure from malaria. Beta thalassemia is an autosomal genetic disorder: if both parents have the HBB disease-causing mutation, each offspring has a one in four risk of being affected.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
-0- 04/10/2003
/CONTACT: Gerard A. Wills, Chief Financial Officer of Nanogen, Inc.,
+1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates,
+1-858-527-3494, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
ups... +12,6%
Infos... nichts
Infos... nichts
...und mit dreifachen Umsatz als sonst...
Volume: 162,350
Avg Daily Volume: 50,000
Volume: 162,350
Avg Daily Volume: 50,000
hallo humm,
tja da ist aber sicher was im busch ;-)
vielleicht wissen wir danach mehr:
Nanogen, Inc. has added a News Release to its Investor Relations web site.
Title: Nanogen to Host Conference Call on 2003 First Quarter Financial Results
Date: 4/23/2003 7:02:00 AM
tja da ist aber sicher was im busch ;-)
vielleicht wissen wir danach mehr:
Nanogen, Inc. has added a News Release to its Investor Relations web site.
Title: Nanogen to Host Conference Call on 2003 First Quarter Financial Results
Date: 4/23/2003 7:02:00 AM
aus nem ami-board:
USAMRAA Cooperative Agreements—The Company received funding from two cooperative research agreements with the U.S. Army Medical Research Acquisition Activity. The first agreement, entered into in October 2000, is focused on developing technology to identify biological warfare compounds if used in combat against U.S. troops. The second cooperative agreement, entered into in October 2001, is to continue the development of miniaturized electronic devices for isolation and detection of biological warfare and infectious disease agents. In conjunction with the agreements, funding provided by the agency is matched dollar-for-dollar with Nanogen funds.
USAMRAA Cooperative Agreements—The Company received funding from two cooperative research agreements with the U.S. Army Medical Research Acquisition Activity. The first agreement, entered into in October 2000, is focused on developing technology to identify biological warfare compounds if used in combat against U.S. troops. The second cooperative agreement, entered into in October 2001, is to continue the development of miniaturized electronic devices for isolation and detection of biological warfare and infectious disease agents. In conjunction with the agreements, funding provided by the agency is matched dollar-for-dollar with Nanogen funds.
hallo tst89!
danke.
danke.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&d…
1: J Mol Diagn 2003 May;5(2):121-6 Related Articles
Rett syndrome is a neurodevelopmental disorder that affects females almost exclusively, and in which eight common point mutations on the X-linked MeCP2 gene are knows to cause over 70% of mutation-positive cases. We explored the use of a novel platform to detect the eight common mutations in Rett syndrome patients to expedite and simplify the process of identification of known genotypes. The Nanogen workstation consists of a two-color assay based on electric hybridization and thermal discrimination, all performed on an electronically active NanoChip. This genotyping platform was tested on 362 samples of a pre-determined genotype, which had been previously identified by a combination of DHPLC (denaturing high performance liquid chromatography) and direct sequencing. This genotyping technique proved to be rapid, facile, and displayed a specificity of 100% with 3% ambiguity. In addition, we present consecutive testing of seven mutations on a single pad of the NanoChip. This was accomplished by tagging down two amplimers together and serially hybridizing for seven different loci, allowing us to genotype samples for seven of the eight common Rett mutations on a single pad. This novel method displayed the same level of specificity and accuracy as the single amplimer reactions, and proved to be faster and more economical.
PMID: 12707377 [PubMed - in process]
1: J Mol Diagn 2003 May;5(2):121-6 Related Articles
Rett syndrome is a neurodevelopmental disorder that affects females almost exclusively, and in which eight common point mutations on the X-linked MeCP2 gene are knows to cause over 70% of mutation-positive cases. We explored the use of a novel platform to detect the eight common mutations in Rett syndrome patients to expedite and simplify the process of identification of known genotypes. The Nanogen workstation consists of a two-color assay based on electric hybridization and thermal discrimination, all performed on an electronically active NanoChip. This genotyping platform was tested on 362 samples of a pre-determined genotype, which had been previously identified by a combination of DHPLC (denaturing high performance liquid chromatography) and direct sequencing. This genotyping technique proved to be rapid, facile, and displayed a specificity of 100% with 3% ambiguity. In addition, we present consecutive testing of seven mutations on a single pad of the NanoChip. This was accomplished by tagging down two amplimers together and serially hybridizing for seven different loci, allowing us to genotype samples for seven of the eight common Rett mutations on a single pad. This novel method displayed the same level of specificity and accuracy as the single amplimer reactions, and proved to be faster and more economical.
PMID: 12707377 [PubMed - in process]
2 Tage alt.....
Nanogen to Host Conference Call on 2003 First Quarter Financial Results
April 23, 2003 07:07:00 AM ET
SAN DIEGO--(BUSINESS WIRE)--April 23, 2003--Nanogen, Inc. (Nasdaq:NGEN - news) will host a conference call on Wednesday, April 30, 2003 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2003 first quarter financial results. The earnings release will be issued at close of market April 30.
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived until May 7. A digital recording of the call will also be available two hours after the completion of the conference call on April 30 until midnight on May 2, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 9961044, will be required to listen to the playback.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Contact Information:
Nanogen, Inc.
Gerard A. Wills, VP and CFO
858/410-4605
gwills@nanogen.com
or
Media Contact:
Atkins + Associates
Pam Lord, Sr. Account Executive
858/527-3494
plord@irpr.com
© 2003 BusinessWire
Nanogen to Host Conference Call on 2003 First Quarter Financial Results
April 23, 2003 07:07:00 AM ET
SAN DIEGO--(BUSINESS WIRE)--April 23, 2003--Nanogen, Inc. (Nasdaq:NGEN - news) will host a conference call on Wednesday, April 30, 2003 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2003 first quarter financial results. The earnings release will be issued at close of market April 30.
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived until May 7. A digital recording of the call will also be available two hours after the completion of the conference call on April 30 until midnight on May 2, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 9961044, will be required to listen to the playback.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
Contact Information:
Nanogen, Inc.
Gerard A. Wills, VP and CFO
858/410-4605
gwills@nanogen.com
or
Media Contact:
Atkins + Associates
Pam Lord, Sr. Account Executive
858/527-3494
plord@irpr.com
© 2003 BusinessWire
Q1 2003 Nanogen, Inc. Earnings Release Apr. 30, 2003
Nanogen Reports 2003 First Quarter Results
- Seven New Molecular Diagnostic Products Launched Year-to-Date -
SAN DIEGO, Apr 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the first quarter ended March 31, 2003.
During the quarter, the Company entered into three commercial transactions for the NanoChip(R) Molecular Biology Workstation, which included two new reagent rental agreements, one of which was converted from a development site agreement. To date, Nanogen has released seven new products including five Analyte Specific Reagents (ASRs), one research use only product released in Europe, and Assay ToolBox(TM), a set of consumable reagents that allows customers to facilitate their own protocol and assay development on the NanoChip(R) platform.
Product revenues for the first quarter were $228,000 as compared to $812,000 for the first quarter last year. Product revenues for the first quarter of 2003 include revenues from the outright sale of one reader (a partial system) plus consumable revenues from the sale of cartridges and reagents shipped under reagent rental agreements entered into last year. Total revenues for the quarter ended March 31, 2003 were $1.2 million compared to $1.5 million for the same period in 2002.
Additionally, in the first quarter, to increase the Company`s operating cash reserves, Nanogen sold shares it held of CombiMatrix Corporation, Acacia Research Corporation`s majority-owned subsidiary, to generate $4.5 million in cash. Under a settlement entered into last year, Nanogen received 17.5% (approximately four million shares) of the outstanding common shares of CombiMatrix. These shares were originally valued at CombiMatrix` initial offering price of $2.70 per share in the fourth quarter of 2002. During the first quarter of 2003, Nanogen sold three million of these shares at $1.50 per share.
Nanogen`s cash, cash equivalents and short-term investment balance at March 31, 2003 was $36.9 million. Total operating expenses for the first quarter of 2003 were $9.1 million, as compared to $10.4 million for the same period in 2002. For the first quarter of 2003, the Company reported a net loss of $10.7 million, or $.50 per share, which includes a loss of $3.6 million on the sale of the CombiMatrix shares. This compares with a net loss of $7.5 million, or $.35 per share, for the prior year`s first quarter.
Nanogen remains committed to its strategy to develop and market molecular diagnostic products. Earlier this month, the Company reorganized its workforce in order to reduce its cost structure and more effectively manage its resources in this weakened economy. By eliminating full-time, contract and temporary positions across all functions of the Company, Nanogen reduced its workforce by approximately 20%. Nanogen expects that the measures taken will result in savings of approximately $5 million in operating expenses in fiscal year 2003, after charges of approximately $500,000 associated with the reorganization are recognized in the second quarter.
"Nanogen`s accomplishments during the first part of this year demonstrate the Company is capable of sustaining its momentum of commercializing products for a market that has very attractive growth potential," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer. "Our concept of platformation(TM) resonates with clinical diagnostic labs that demand a broad menu of high quality products that can be used on our versatile NanoChip(R) platform. As we continue to meet customers needs by increasing the breadth of the menu of products that we offer, we anticipate that our product revenues will increase throughout this fiscal year."
Webcast of Conference Call
Nanogen management will hold a conference call to discuss first quarter 2003 financial results today at 4:30 p.m. Eastern Time. A live webcast is available via Nanogen`s website at http://www.nanogen.com . A telephone replay of the conference call will be available approximately two hours following the call until 11:59 p.m. Eastern Time on May 2, 2003 and can be accessed at 800-642-1687 (domestic) or 706-645-9291 (international), passcode ID #9961044. The webcast will also be archived on Nanogen`s website for 90 days.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements, such as the ability to more effectively manage the Company`s resources and achieve anticipated cost savings in the future and the expectation for increasing product revenues during the remainder of 2003. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
March 31, December 31,
2003 2002
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $11,686 $9,353
Short-term investments 25,167 43,376
Receivables, net 1,406 1,754
Inventories, net 4,642 4,717
Other current assets 1,530 1,781
Total current assets 44,431 60,981
Property and equipment, net 4,855 4,982
Acquired technology rights, net 4,294 4,544
Other assets, net 505 789
Restricted cash 64 64
$54,149 $71,360
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $615 $753
Accrued liabilities 4,543 5,901
Deferred revenue 359 472
Current portion of capital lease obligations 825 805
Total current liabilities 6,342 7,931
Capital lease obligations, less current portion 923 1,134
Other long-term liabilities 3,088 3,085
Total long-term liabilities 4,011 4,219
Minority interest in consolidated subsidiary 1,269 1,817
Commitments and contingencies
Stockholders` equity:
Convertible preferred stock, $0.001 par value,
5,000,000 shares authorized at March 31, 2003
(unaudited) and December 31, 2002; no shares
issued and outstanding at March 31, 2003 and
December 31, 2002 -- --
Common stock, $0.001 par value, 50,000,000 shares
authorized at March 31, 2003 and December 31,
2002; 22,053,701 and 21,981,115 shares issued
and outstanding at March 31, 2003 (unaudited)
and December 31, 2002, respectively 22 22
Additional paid-in capital 199,591 199,483
Accumulated other comprehensive income 317 4,926
Deferred compensation (142) (156)
Notes receivable from officers -- (513)
Accumulated deficit (156,339) (145,659)
Treasury stock, at cost, 500,189 and
366,857 shares at March 31, 2003 (unaudited)
and December 31, 2002, respectively (922) (710)
Total stockholders` equity 42,527 57,393
$54,149 $71,360
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended March 31,
2003 2002
Revenues:
Product sales $228 $812
Sponsored research 375 313
Contract and grant 597 408
Total revenues 1,200 1,533
Operating expenses:
Cost of product sales 274 557
Research and development 4,710 4,863
Selling, general and administrative 4,066 4,602
Litigation and settlement of patent matter -- 370
Total operating expenses 9,050 10,392
Loss from operations (7,850) (8,859)
Interest income, net 195 760
Other income 27 6
Loss on sale of investments (3,600) --
Minority interest in loss of consolidated
subsidiary 548 561
Net loss $(10,680) $(7,532)
Net loss per share -
basic and diluted $(0.50) $(0.35)
Number of shares used in computing
net loss per share - basic and diluted 21,540 21,620
SOURCE Nanogen, Inc.
Gerard A. Wills, Vice President & CFO of Nanogen, Inc., +1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates, +1-858-527-3494, for Nanogen, Inc.
http://www.nanogen.com
- Seven New Molecular Diagnostic Products Launched Year-to-Date -
SAN DIEGO, Apr 30, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the first quarter ended March 31, 2003.
During the quarter, the Company entered into three commercial transactions for the NanoChip(R) Molecular Biology Workstation, which included two new reagent rental agreements, one of which was converted from a development site agreement. To date, Nanogen has released seven new products including five Analyte Specific Reagents (ASRs), one research use only product released in Europe, and Assay ToolBox(TM), a set of consumable reagents that allows customers to facilitate their own protocol and assay development on the NanoChip(R) platform.
Product revenues for the first quarter were $228,000 as compared to $812,000 for the first quarter last year. Product revenues for the first quarter of 2003 include revenues from the outright sale of one reader (a partial system) plus consumable revenues from the sale of cartridges and reagents shipped under reagent rental agreements entered into last year. Total revenues for the quarter ended March 31, 2003 were $1.2 million compared to $1.5 million for the same period in 2002.
Additionally, in the first quarter, to increase the Company`s operating cash reserves, Nanogen sold shares it held of CombiMatrix Corporation, Acacia Research Corporation`s majority-owned subsidiary, to generate $4.5 million in cash. Under a settlement entered into last year, Nanogen received 17.5% (approximately four million shares) of the outstanding common shares of CombiMatrix. These shares were originally valued at CombiMatrix` initial offering price of $2.70 per share in the fourth quarter of 2002. During the first quarter of 2003, Nanogen sold three million of these shares at $1.50 per share.
Nanogen`s cash, cash equivalents and short-term investment balance at March 31, 2003 was $36.9 million. Total operating expenses for the first quarter of 2003 were $9.1 million, as compared to $10.4 million for the same period in 2002. For the first quarter of 2003, the Company reported a net loss of $10.7 million, or $.50 per share, which includes a loss of $3.6 million on the sale of the CombiMatrix shares. This compares with a net loss of $7.5 million, or $.35 per share, for the prior year`s first quarter.
Nanogen remains committed to its strategy to develop and market molecular diagnostic products. Earlier this month, the Company reorganized its workforce in order to reduce its cost structure and more effectively manage its resources in this weakened economy. By eliminating full-time, contract and temporary positions across all functions of the Company, Nanogen reduced its workforce by approximately 20%. Nanogen expects that the measures taken will result in savings of approximately $5 million in operating expenses in fiscal year 2003, after charges of approximately $500,000 associated with the reorganization are recognized in the second quarter.
"Nanogen`s accomplishments during the first part of this year demonstrate the Company is capable of sustaining its momentum of commercializing products for a market that has very attractive growth potential," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer. "Our concept of platformation(TM) resonates with clinical diagnostic labs that demand a broad menu of high quality products that can be used on our versatile NanoChip(R) platform. As we continue to meet customers needs by increasing the breadth of the menu of products that we offer, we anticipate that our product revenues will increase throughout this fiscal year."
Webcast of Conference Call
Nanogen management will hold a conference call to discuss first quarter 2003 financial results today at 4:30 p.m. Eastern Time. A live webcast is available via Nanogen`s website at http://www.nanogen.com . A telephone replay of the conference call will be available approximately two hours following the call until 11:59 p.m. Eastern Time on May 2, 2003 and can be accessed at 800-642-1687 (domestic) or 706-645-9291 (international), passcode ID #9961044. The webcast will also be archived on Nanogen`s website for 90 days.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements, such as the ability to more effectively manage the Company`s resources and achieve anticipated cost savings in the future and the expectation for increasing product revenues during the remainder of 2003. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
March 31, December 31,
2003 2002
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $11,686 $9,353
Short-term investments 25,167 43,376
Receivables, net 1,406 1,754
Inventories, net 4,642 4,717
Other current assets 1,530 1,781
Total current assets 44,431 60,981
Property and equipment, net 4,855 4,982
Acquired technology rights, net 4,294 4,544
Other assets, net 505 789
Restricted cash 64 64
$54,149 $71,360
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $615 $753
Accrued liabilities 4,543 5,901
Deferred revenue 359 472
Current portion of capital lease obligations 825 805
Total current liabilities 6,342 7,931
Capital lease obligations, less current portion 923 1,134
Other long-term liabilities 3,088 3,085
Total long-term liabilities 4,011 4,219
Minority interest in consolidated subsidiary 1,269 1,817
Commitments and contingencies
Stockholders` equity:
Convertible preferred stock, $0.001 par value,
5,000,000 shares authorized at March 31, 2003
(unaudited) and December 31, 2002; no shares
issued and outstanding at March 31, 2003 and
December 31, 2002 -- --
Common stock, $0.001 par value, 50,000,000 shares
authorized at March 31, 2003 and December 31,
2002; 22,053,701 and 21,981,115 shares issued
and outstanding at March 31, 2003 (unaudited)
and December 31, 2002, respectively 22 22
Additional paid-in capital 199,591 199,483
Accumulated other comprehensive income 317 4,926
Deferred compensation (142) (156)
Notes receivable from officers -- (513)
Accumulated deficit (156,339) (145,659)
Treasury stock, at cost, 500,189 and
366,857 shares at March 31, 2003 (unaudited)
and December 31, 2002, respectively (922) (710)
Total stockholders` equity 42,527 57,393
$54,149 $71,360
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended March 31,
2003 2002
Revenues:
Product sales $228 $812
Sponsored research 375 313
Contract and grant 597 408
Total revenues 1,200 1,533
Operating expenses:
Cost of product sales 274 557
Research and development 4,710 4,863
Selling, general and administrative 4,066 4,602
Litigation and settlement of patent matter -- 370
Total operating expenses 9,050 10,392
Loss from operations (7,850) (8,859)
Interest income, net 195 760
Other income 27 6
Loss on sale of investments (3,600) --
Minority interest in loss of consolidated
subsidiary 548 561
Net loss $(10,680) $(7,532)
Net loss per share -
basic and diluted $(0.50) $(0.35)
Number of shares used in computing
net loss per share - basic and diluted 21,540 21,620
SOURCE Nanogen, Inc.
Gerard A. Wills, Vice President & CFO of Nanogen, Inc., +1-858-410-4605; or Pam Lord, Media Relations of Atkins + Associates, +1-858-527-3494, for Nanogen, Inc.
http://www.nanogen.com
Kurssprung in USA 
und ich habe verkauft...
@humm
die haben noch was gebracht?
Ich sitze dies aus und ich denke mit ein wenig Glück
steigen sie noch um einiges ;-)
die haben noch was gebracht?
Ich sitze dies aus und ich denke mit ein wenig Glück
steigen sie noch um einiges ;-)
@tst:
Ich bin ausgestiegen.
Gründe:
1. Der Dollarkurs grillt die Gewinne
2. Viel zu wenig Infos.
Ich bin ausgestiegen.
Gründe:
1. Der Dollarkurs grillt die Gewinne
2. Viel zu wenig Infos.
Nanogen Announces Senior Management Changes
SAN DIEGO, May 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostics, today announced David Ludvigson will join the management team as executive vice president. He will report to Howard Birndorf, chairman of the board and CEO, and will be responsible for corporate strategy, financial functions, and corporate development, including merger and acquisition activities. Mr. Ludvigson has been a member of Nanogen`s Board of Directors since 1996. Nanogen also announced Gerard A. Wills, vice president and CFO, will leave Nanogen to pursue other opportunities.
"I would like to thank Jerry for his service as CFO over the last two years and wish him success in his future activities," said Howard Birndorf, chairman and CEO.
"Nanogen is striving to accelerate growth and establish itself as a leader in the emerging molecular diagnostics field," continued Mr. Birndorf. "David`s working knowledge of Nanogen, together with his experience in developing and managing high growth businesses and in corporate development, will be important to our success."
Mr. Ludvigson has a broad range of management and financial experience in both biopharmaceutical and technology companies. In addition to his work as a board member at Nanogen, his biopharmaceutical experience includes Matrix Pharmaceuticals, Inc., and IDEC Pharmaceuticals. From 1998 to 2000, he was chief financial officer and then chief operating officer at Matrix Pharmaceuticals and was responsible for operations, finance and administration functions of this public company that focused on developing cancer therapeutics. From 1993 to 1996, he was vice president and CFO for IDEC during which time he helped conclude an alliance with Genentech for Rituxan(R), a cancer therapeutic, considered one of the most successful alliances in the biotech industry. In addition, he has held numerous executive management positions in high technology and software companies. Mr. Ludvigson recently joined the board of directors for Argonaut Technologies, a maker of instruments and chemistry consumables for drug discovery.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
Bruce A. Huebner, President & COO of Nanogen, Inc.,
+1-858-410-4600; or Pam Lord, Media Relations of Atkins + Associates,
+1-858-527-3494, for Nanogen, Inc.
http://www.nanogen.com
SAN DIEGO, May 21, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostics, today announced David Ludvigson will join the management team as executive vice president. He will report to Howard Birndorf, chairman of the board and CEO, and will be responsible for corporate strategy, financial functions, and corporate development, including merger and acquisition activities. Mr. Ludvigson has been a member of Nanogen`s Board of Directors since 1996. Nanogen also announced Gerard A. Wills, vice president and CFO, will leave Nanogen to pursue other opportunities.
"I would like to thank Jerry for his service as CFO over the last two years and wish him success in his future activities," said Howard Birndorf, chairman and CEO.
"Nanogen is striving to accelerate growth and establish itself as a leader in the emerging molecular diagnostics field," continued Mr. Birndorf. "David`s working knowledge of Nanogen, together with his experience in developing and managing high growth businesses and in corporate development, will be important to our success."
Mr. Ludvigson has a broad range of management and financial experience in both biopharmaceutical and technology companies. In addition to his work as a board member at Nanogen, his biopharmaceutical experience includes Matrix Pharmaceuticals, Inc., and IDEC Pharmaceuticals. From 1998 to 2000, he was chief financial officer and then chief operating officer at Matrix Pharmaceuticals and was responsible for operations, finance and administration functions of this public company that focused on developing cancer therapeutics. From 1993 to 1996, he was vice president and CFO for IDEC during which time he helped conclude an alliance with Genentech for Rituxan(R), a cancer therapeutic, considered one of the most successful alliances in the biotech industry. In addition, he has held numerous executive management positions in high technology and software companies. Mr. Ludvigson recently joined the board of directors for Argonaut Technologies, a maker of instruments and chemistry consumables for drug discovery.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
Bruce A. Huebner, President & COO of Nanogen, Inc.,
+1-858-410-4600; or Pam Lord, Media Relations of Atkins + Associates,
+1-858-527-3494, for Nanogen, Inc.
http://www.nanogen.com
@humm
Ja der Dollarkurs nervt mich in der Hinscht auch
Ich denke NGEN bringt zwar wenig News, aber ich gebe trotzdem die Hoffnung nicht auf. NGEN wird meiner Meinung nach wieder auf die Beine kommen.
Grüße
tst
Ja der Dollarkurs nervt mich in der Hinscht auch
Ich denke NGEN bringt zwar wenig News, aber ich gebe trotzdem die Hoffnung nicht auf. NGEN wird meiner Meinung nach wieder auf die Beine kommen.
Grüße
tst
Der Vollständigkeit halber
Nanogen Annual Meeting of Stockholders
Jun. 12, 2003 9:00 AM
Nanogen Annual Meeting of Stockholders
Jun. 12, 2003 9:00 AM
Dow Jones Business News
Nanogen Chief Financial Officer Wills Leaves Company
Wednesday May 21, 11:10 am ET
SAN DIEGO (Dow Jones)--Nanogen Inc. said Gerard A. Wills, chief financial officer for the past two years, left to pursue other opportunities.
Information on whether Nanogen named a replacement wasn`t immediately available.
In a press release Wednesday, the maker of molecular diagnostic products for the gene-based testing market said it named David Ludvigson executive vice president.
Ludvigson, a director since 1996, will be responsible for corporate strategy, financial functions and corporate development.
Nanogen`s shares traded recently at $1.82, down 13 cents, or 6.7%, on Nasdaq volume of 25,700 shares. Average daily volume is 90,599 shares.
Nanogen Chief Financial Officer Wills Leaves Company
Wednesday May 21, 11:10 am ET
SAN DIEGO (Dow Jones)--Nanogen Inc. said Gerard A. Wills, chief financial officer for the past two years, left to pursue other opportunities.
Information on whether Nanogen named a replacement wasn`t immediately available.
In a press release Wednesday, the maker of molecular diagnostic products for the gene-based testing market said it named David Ludvigson executive vice president.
Ludvigson, a director since 1996, will be responsible for corporate strategy, financial functions and corporate development.
Nanogen`s shares traded recently at $1.82, down 13 cents, or 6.7%, on Nasdaq volume of 25,700 shares. Average daily volume is 90,599 shares.
Press Release Source: Nanogen, Inc.
Nanogen Announces Issuance of Patent for Electronic Fabrication of Micro and nanoscale Devices
Wednesday May 28, 4:30 pm ET
SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) announced today that it has been issued U.S. Patent No. 6,569,382, "Methods and Apparatus for the Electronic, Homogeneous Assembly and Fabrication of Devices," by the U.S. Patent and Trademark Office. This patent relates to electronic fabrication of micro and nanoscale devices and is the first to issue in a series of applications filed to broaden Nanogen`s core proprietary technology. Nanogen has had five patents issued year-to-date, bringing the Company`s total number of issued patents to 52 in the United States.
ADVERTISEMENT
The new patent relates to methods to integrate micro and nanoscale components, such as light emitting diodes (LED) for displays, highly integrated biosensors and micromechanical devices, into higher order structures and devices. Using electroosmotic forces, component devices can be moved through a fluidic medium to a desired target location on a substrate or motherboard through electronic self-assembly fabrication. The heterogeneous assembly of microelectronic, microoptical and micromechanical components on an integrated silicon circuit illustrates the usefulness of these nanofabrication methods that go beyond lab-on-a-chip applications. These nanofabrication techniques could lead to faster, lower cost and more complex higher order devices and structures.
"One of the challenges to producing miniaturized products using nanoscale components will be the integration of these devices with existing microelectronic components. The electronic `pick and place` fabrication processes described in the patent facilitate the bringing together of micro and nanoscale components thereby helping solve scaling issues. By combining the best aspects of top-down and bottom-up fabrication through Nanogen`s proprietary electronic self assembly technology, nanoscale materials and components can be combined to form higher order devices," said Dr. Michael J. Heller, co-founder of Nanogen, one of the inventors, and currently a Professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
"We believe the technology described by Nanogen`s new patent could provide a key technological advantage for nanofabrication across many diverse applications of nanotechnology," said Howard Birndorf, Nanogen chairman and CEO. "The issuance of this patent is a product of our continuing efforts to increase and broaden our intellectual property portfolio."
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Source: Nanogen, Inc.
Nanogen Announces Issuance of Patent for Electronic Fabrication of Micro and nanoscale Devices
Wednesday May 28, 4:30 pm ET
SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) announced today that it has been issued U.S. Patent No. 6,569,382, "Methods and Apparatus for the Electronic, Homogeneous Assembly and Fabrication of Devices," by the U.S. Patent and Trademark Office. This patent relates to electronic fabrication of micro and nanoscale devices and is the first to issue in a series of applications filed to broaden Nanogen`s core proprietary technology. Nanogen has had five patents issued year-to-date, bringing the Company`s total number of issued patents to 52 in the United States.
ADVERTISEMENT
The new patent relates to methods to integrate micro and nanoscale components, such as light emitting diodes (LED) for displays, highly integrated biosensors and micromechanical devices, into higher order structures and devices. Using electroosmotic forces, component devices can be moved through a fluidic medium to a desired target location on a substrate or motherboard through electronic self-assembly fabrication. The heterogeneous assembly of microelectronic, microoptical and micromechanical components on an integrated silicon circuit illustrates the usefulness of these nanofabrication methods that go beyond lab-on-a-chip applications. These nanofabrication techniques could lead to faster, lower cost and more complex higher order devices and structures.
"One of the challenges to producing miniaturized products using nanoscale components will be the integration of these devices with existing microelectronic components. The electronic `pick and place` fabrication processes described in the patent facilitate the bringing together of micro and nanoscale components thereby helping solve scaling issues. By combining the best aspects of top-down and bottom-up fabrication through Nanogen`s proprietary electronic self assembly technology, nanoscale materials and components can be combined to form higher order devices," said Dr. Michael J. Heller, co-founder of Nanogen, one of the inventors, and currently a Professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
"We believe the technology described by Nanogen`s new patent could provide a key technological advantage for nanofabrication across many diverse applications of nanotechnology," said Howard Birndorf, Nanogen chairman and CEO. "The issuance of this patent is a product of our continuing efforts to increase and broaden our intellectual property portfolio."
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s web site at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Source: Nanogen, Inc.
die vorstellung ist dass maschinen sich selbst konstruieren, wobei der masstab kontinuierlich reduziert wird- zb.: man programmiert einen roboter eine eigene kopie im halben masstab anzufertigen. die kopierte maschine produziert wiederum eine halbgrossen roboter usw. bis man einen miniroboter im nanoscale masstab erzeugt hat (top down verfahren). heute existieren bereits nanowerkzeuge, mit denen man einzelne atome nach beliegen hin und herschieben kann. das öffnet tür und tor für maschinen, die legoartig atom für atom aufgebaut werden (bottom up verfahren). darüber hinaus gibt es das sog. self assembly prinzip: kleine strukturen, die sich spontan zu größeren verbänden organisieren. das prinzip funktioniert hervorragend bereits in der natur...man denke zb. an den tabakmosaikvirus der sich spontan zusammensetzt sobald die entsprechende nukleinsäure und die hüllproteine vorliegen.
ich bin davon überzeugt, dass es der nanotechnologie gelingen wird hier der natur die verfahrenstechnik abzuschauen und zu kopieren.
wann und wie das für nanofirmen wie nanogen nutzbar sein wird kann ich allerdings nicht sagen. aber einen haufen phantasie wird es mit sicherhiet erzeugen
ich bin davon überzeugt, dass es der nanotechnologie gelingen wird hier der natur die verfahrenstechnik abzuschauen und zu kopieren.
wann und wie das für nanofirmen wie nanogen nutzbar sein wird kann ich allerdings nicht sagen. aber einen haufen phantasie wird es mit sicherhiet erzeugen
2,50
3,49 $
Ladies & Gentlemen........hoffe es geht wieder stetig bergauf......
Ladies & Gentlemen........hoffe es geht wieder stetig bergauf......
Dow Jones Business News
Nanogen Shares Rally as Company Receives Another Patent
Thursday May 29, 12:05 pm ET
By Adam L. Freeman, Of Dow Jones Newswires
NEW YORK -- Nanogen Inc.`s stock surged Thursday, after the company secured another in a series of patents for technologies enabling the construction of micro, or nanoscale, devices.
The San Diego company, which develops molecular-scale diagnostic products for analyzing genetic information, said it has received up to five patents in the U.S. so far this year, bringing the total number to 52.
The new patent relates to methods to integrate micro and nanoscale components, such as light emitting diodes for displays, highly integrated biosensors and micromechanical devices, into higher order structures and devices, Nanogen said.
"We believe the technology described by Nanogen`s new patent could provide a key technological advantage for nanofabrication across many diverse applications of nanotechnology," Nanogen Chairman and Chief Executive Officer Howard Birndorf said Wednesday in a written statement. Nanotechnology refers to the direct manipulation of molecules and atoms to create new products.
In an effort to bolster its cash position, Nanogen this year sold off some noncore assets and shed its work force by more than 20%. In a filing with the Securities and Exchange Commission (News - Websites) at the end of March, the company said it has enough resources to continue operations for at least 18 months.
Near midday, shares of Nanogen were up 67 cents, or 33%, to $2.70 on Nasdaq volume of 754,000 shares, compared with average daily volume of 98,362.
-By Adam L. Freeman, Dow Jones Newswires; 201-938-5023; adam.freeman@dowjones.com
Nanogen Shares Rally as Company Receives Another Patent
Thursday May 29, 12:05 pm ET
By Adam L. Freeman, Of Dow Jones Newswires
NEW YORK -- Nanogen Inc.`s stock surged Thursday, after the company secured another in a series of patents for technologies enabling the construction of micro, or nanoscale, devices.
The San Diego company, which develops molecular-scale diagnostic products for analyzing genetic information, said it has received up to five patents in the U.S. so far this year, bringing the total number to 52.
The new patent relates to methods to integrate micro and nanoscale components, such as light emitting diodes for displays, highly integrated biosensors and micromechanical devices, into higher order structures and devices, Nanogen said.
"We believe the technology described by Nanogen`s new patent could provide a key technological advantage for nanofabrication across many diverse applications of nanotechnology," Nanogen Chairman and Chief Executive Officer Howard Birndorf said Wednesday in a written statement. Nanotechnology refers to the direct manipulation of molecules and atoms to create new products.
In an effort to bolster its cash position, Nanogen this year sold off some noncore assets and shed its work force by more than 20%. In a filing with the Securities and Exchange Commission (News - Websites) at the end of March, the company said it has enough resources to continue operations for at least 18 months.
Near midday, shares of Nanogen were up 67 cents, or 33%, to $2.70 on Nasdaq volume of 754,000 shares, compared with average daily volume of 98,362.
-By Adam L. Freeman, Dow Jones Newswires; 201-938-5023; adam.freeman@dowjones.com
2,85 euro! und weiter gehts
Habe letzte Woche zu 1,85€ gekauft!!! Hat die Aktie noch weiteres Potential oder sollte ich die Gewinne schnell mitnehmen?
@harryxoma
herzlichen Glückwunsch zu der super Performance.
Ich steh ja schon seit Jahren auf NGEN. Immer wieder
Verlaß drauf
Momentan würde ich sagen hat sie noch Potential nach oben, ist allerdings auch eine Frage des Gesamtmarktes. Sie wurde die letzte Zeit ohne Grund zu sehr in den Boden gestampft. Ich persönlich (meine eigene Meinung - nicht hängen falls es falsch ist), halte einen Wert von ca. 5-5,50$ für, zur Zeit, realistisch und fair.
Wer auf long setzt sollte sich mal den Chart der letzten 3 Jahre anschauen und weiß worauf ich im Insgeheimen spekuliere
herzlichen Glückwunsch zu der super Performance.
Ich steh ja schon seit Jahren auf NGEN. Immer wieder
Verlaß drauf
Momentan würde ich sagen hat sie noch Potential nach oben, ist allerdings auch eine Frage des Gesamtmarktes. Sie wurde die letzte Zeit ohne Grund zu sehr in den Boden gestampft. Ich persönlich (meine eigene Meinung - nicht hängen falls es falsch ist), halte einen Wert von ca. 5-5,50$ für, zur Zeit, realistisch und fair.
Wer auf long setzt sollte sich mal den Chart der letzten 3 Jahre anschauen und weiß worauf ich im Insgeheimen spekuliere
Danke tst89 für Deine Antwort.
Da Du Dich für Nanogen interessierst kennst du vielleicht auch deren Cash-Bestand bzw. Eigenkapitalquote?????
Dieser (diese) interessiert mich da ich wirklich gerne LONG investiert bleiben würde. Nur was nutzen gute Aussichten, wenn der Firma das Geld ausgeht?
Da Du Dich für Nanogen interessierst kennst du vielleicht auch deren Cash-Bestand bzw. Eigenkapitalquote?????
Dieser (diese) interessiert mich da ich wirklich gerne LONG investiert bleiben würde. Nur was nutzen gute Aussichten, wenn der Firma das Geld ausgeht?
Das wird schön , wenn Nanogen im Juni auf 5 euro steigt !
Und dann auf Dominika , Sankt Lucia , Martinik , Guadelup oder Dominica , Saint Lucia , Martinique , Guadeloupe :
Fotos : http://geocities.com/s1lucia 
Und dann auf Dominika , Sankt Lucia , Martinik , Guadelup oder Dominica , Saint Lucia , Martinique , Guadeloupe :
Fotos : http://geocities.com/s1lucia 
Der Hype ist doch vorprogrammiert
alle sind jetzt informiert
mfg jojo
Harris & Harris: Interessant (EurAmS)
Harris & Harris kennt an der Nasdaq zurzeit nur eine Richtung: nach oben. Die Venture-Capital-Gesellschaft hat sich auf Nanotechnologie spezialisiert. Einige Investoren haben hier den neuen Mega-Trend ausgemacht – vergleichbar mit dem Internet-Boom der 90er-Jahre. Da die Auswahl an Aktien hier noch sehr begrenzt ist, bezahlen Anleger derzeit mehr als das Doppelte des Portfolio-Wertes von umgerechnet zwei Euro, den Harris & Harris zum 31. März ausgewiesen hatte. Das ist nicht ganz so dumm, wie es aussieht: Dem inneren Wert des Beteiligungs-Portefeuilles hat nämlich auf die Sprünge geholfen, dass auch alle anderen Nanotech-Titel gestiegen sind. Die US-Gesellschaft, die sich demnächst in Tiny Technology Venture Capital umbenennen will, bietet eine gute Möglichkeit, mit breit gestreutem Risiko am Nano-Hype zu partizipieren.
Mutige spekulieren mit kleinen Summen auf eine Fortsetzung des Booms.
alle sind jetzt informiert
mfg jojo
Harris & Harris: Interessant (EurAmS)
Harris & Harris kennt an der Nasdaq zurzeit nur eine Richtung: nach oben. Die Venture-Capital-Gesellschaft hat sich auf Nanotechnologie spezialisiert. Einige Investoren haben hier den neuen Mega-Trend ausgemacht – vergleichbar mit dem Internet-Boom der 90er-Jahre. Da die Auswahl an Aktien hier noch sehr begrenzt ist, bezahlen Anleger derzeit mehr als das Doppelte des Portfolio-Wertes von umgerechnet zwei Euro, den Harris & Harris zum 31. März ausgewiesen hatte. Das ist nicht ganz so dumm, wie es aussieht: Dem inneren Wert des Beteiligungs-Portefeuilles hat nämlich auf die Sprünge geholfen, dass auch alle anderen Nanotech-Titel gestiegen sind. Die US-Gesellschaft, die sich demnächst in Tiny Technology Venture Capital umbenennen will, bietet eine gute Möglichkeit, mit breit gestreutem Risiko am Nano-Hype zu partizipieren.
Mutige spekulieren mit kleinen Summen auf eine Fortsetzung des Booms.
3,3 euro!
und jetzt schon bei 4.00Euro
geht es weiter? Was ist da los?
geht es weiter? Was ist da los?
4.4 euro!
was da los ist? ad hoc um ein fertigungspatent zum aufbau von nanostrukturen....nanotechnologie ist die schlüsseltechnologie der zukunft und nanogen ist eine der firmen.
und weiter gehts!!! dumdedumdedumm
was da los ist? ad hoc um ein fertigungspatent zum aufbau von nanostrukturen....nanotechnologie ist die schlüsseltechnologie der zukunft und nanogen ist eine der firmen.
und weiter gehts!!! dumdedumdedumm
was für ein KZ ist realistisch? Geht der Hype noch weiter, oder kann mann ab sofort mit einer Seitwärtsbewegung rechnen?
Ich habe leider keinerlei daten über die MK und Umsatz etc.
Gruss
Rico
Ich habe leider keinerlei daten über die MK und Umsatz etc.
Gruss
Rico
There it goes!
So macht NGEN wieder Spaß!
Aber nicht vergessen - falls ihr nicht long seid -
auch den schönsten Spaß mit Stopp-Loss abzusichern
@harryxoma
Zahlen vom 31.03.03
Cash 11,6 Mio. $
beschränkt verfügbares Cashvermögen 54,1 Mio $
Sprich die haben noch gut Luft die nächste Zeit.
@jojoba
klar nur fragt sich eben wie lange der hype anhält.
hast du nach calypte auch ngen??
So macht NGEN wieder Spaß!
Aber nicht vergessen - falls ihr nicht long seid -
auch den schönsten Spaß mit Stopp-Loss abzusichern
@harryxoma
Zahlen vom 31.03.03
Cash 11,6 Mio. $
beschränkt verfügbares Cashvermögen 54,1 Mio $
Sprich die haben noch gut Luft die nächste Zeit.
@jojoba
klar nur fragt sich eben wie lange der hype anhält.
hast du nach calypte auch ngen??
Dow Jones Business News
Nanogen Shares Rise Again Following Patent News Last Week
Monday June 2, 2:51 pm ET
By Amy Braunschweiger
NEW YORK -- Shares of Nanogen Inc. (NasdaqNM:NGEN - News) surged 42% to a 52-week high Monday, continuing a three-day rally ignited last week when the company secured another patent related to the nascent science of nanotechnology.
A series of promising reports on biotechnology and cancer treatment from the American Society of Clinical Oncology annual meeting also is contributing to the stock activity, a Nanogen official said.
"You have a couple of factors at work here," David Ludvigson, Nanogen`s executive vice president, said. "General investor attention is being brought to the market area."
Although Nanogen, of San Diego, isn`t directly involved in creating cancer therapeutics, the company is involved in the diagnostic aspects of the genetic structures of disease, he explained.
In midafternoon trading on the Nasdaq Stock Market (News - Websites), shares of Nanogen were up $1.04, or 30%, at $4.53. Earlier, the stock hit a 52-week high of $4.98, surpassing the previous high of $3.97 set on July 1, 2002.
Nanogen`s stock gained 27% Friday and 34% Thursday following the company`s announcement that it had gene-based testing market said it was granted a new patent entitled "Methods and Apparatus for the Electronic, Homogeneous Assembly and Fabrication of Devices."
The patent relates to methods to integrate micro and nanoscale components - such as light emitting diodes (LED) for displays, highly integrated biosensors and micromechanical devices - into higher order structures and devices.
The patent Nanogen received last week covers certain manufacturing techniques for nanodevices, Nanogen`s Mr. Ludvigson said.
"It`ll be the next step in the miniaturization of devices," he said about nanotechnology.
Nanogen doesn`t currently receive any revenue from nanotechnology, although it has received some government funding, according to the executive vice president. However, when revenue does start coming in, the company expects it in the form of licensing agreements and not from making products with the technology.
It will likely be three to five years before nanotechnology will be used in products sold to people and not just for research purposes, Mr. Ludvigson said.
"Licensing revenue could lead that by a short period of time," he believes, adding that he didn`t have an exact revenue forecast.
-By Amy Braunschweiger, Dow Jones Newswires; 201-938-2205; amy.braunschweiger@dowjones.com
Nanogen Shares Rise Again Following Patent News Last Week
Monday June 2, 2:51 pm ET
By Amy Braunschweiger
NEW YORK -- Shares of Nanogen Inc. (NasdaqNM:NGEN - News) surged 42% to a 52-week high Monday, continuing a three-day rally ignited last week when the company secured another patent related to the nascent science of nanotechnology.
A series of promising reports on biotechnology and cancer treatment from the American Society of Clinical Oncology annual meeting also is contributing to the stock activity, a Nanogen official said.
"You have a couple of factors at work here," David Ludvigson, Nanogen`s executive vice president, said. "General investor attention is being brought to the market area."
Although Nanogen, of San Diego, isn`t directly involved in creating cancer therapeutics, the company is involved in the diagnostic aspects of the genetic structures of disease, he explained.
In midafternoon trading on the Nasdaq Stock Market (News - Websites), shares of Nanogen were up $1.04, or 30%, at $4.53. Earlier, the stock hit a 52-week high of $4.98, surpassing the previous high of $3.97 set on July 1, 2002.
Nanogen`s stock gained 27% Friday and 34% Thursday following the company`s announcement that it had gene-based testing market said it was granted a new patent entitled "Methods and Apparatus for the Electronic, Homogeneous Assembly and Fabrication of Devices."
The patent relates to methods to integrate micro and nanoscale components - such as light emitting diodes (LED) for displays, highly integrated biosensors and micromechanical devices - into higher order structures and devices.
The patent Nanogen received last week covers certain manufacturing techniques for nanodevices, Nanogen`s Mr. Ludvigson said.
"It`ll be the next step in the miniaturization of devices," he said about nanotechnology.
Nanogen doesn`t currently receive any revenue from nanotechnology, although it has received some government funding, according to the executive vice president. However, when revenue does start coming in, the company expects it in the form of licensing agreements and not from making products with the technology.
It will likely be three to five years before nanotechnology will be used in products sold to people and not just for research purposes, Mr. Ludvigson said.
"Licensing revenue could lead that by a short period of time," he believes, adding that he didn`t have an exact revenue forecast.
-By Amy Braunschweiger, Dow Jones Newswires; 201-938-2205; amy.braunschweiger@dowjones.com
@rico
hier wichtige daten zu ngen:
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=NGEN&…
die frage nach dem kursziel lässt sich wie immer
schwer sagen und dies sind immer nur spekulationen.
ebenfalls spielt eine rolle ob du long oder short
gehen willst. wie ja wohl die meisten wissen bin ich
megalong
kurz dürften vielleicht 5-6$ drin sein, long sicherlich
ein mehrfaches
hier wichtige daten zu ngen:
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=NGEN&…
die frage nach dem kursziel lässt sich wie immer
schwer sagen und dies sind immer nur spekulationen.
ebenfalls spielt eine rolle ob du long oder short
gehen willst. wie ja wohl die meisten wissen bin ich
megalong
kurz dürften vielleicht 5-6$ drin sein, long sicherlich
ein mehrfaches
nanotechnologie steckt als zukunftstechnologie noch völlig in den kinderschuhen. sie wird anfänglich mit hoher wahrscheinlichkeit zu ähnlichen übertreibungen führen, wie wir sie 2000 am neuen markt hatten. auch nanogen wird sich wahrsch von der fundamentalen bewertung entkoppeln und man muss sich darauf vorbereiten wie man diesmal damit umgehen wird, das der kurs auf astronomische werte steigen wird...kurse von 200 oder 300 euro??? warum nicht. blase ist blase.
die herausforderung ist rechtzeitig von der rakete zu springen....
ich kann dir nicht sagen ob man bei 4,5 oder 6 mitnehmen soll. die chance, dass der kurs kurzfristig ins astronomische schiesst ist hoch. vielleicht teilgewinne absichern und rest laufen lassen?
die herausforderung ist rechtzeitig von der rakete zu springen....
ich kann dir nicht sagen ob man bei 4,5 oder 6 mitnehmen soll. die chance, dass der kurs kurzfristig ins astronomische schiesst ist hoch. vielleicht teilgewinne absichern und rest laufen lassen?
@tst89
danke für die Info, habe mich mal selbst auf der Nanogen Seite umgeschaut und finde nichts negatives. Wie vielleicht shon beschrieben wird es evtl einen super hype geben. Aber ich denke ich bleibe long, gewinne werden erst ab 60Euro realisiert
Naja, werd wohl nohmal zulegen und dann Teilgewinne machen, bis ich ´meinen Einsatz wieder drinn habe.
Danke und Gruss
Rico
danke für die Info, habe mich mal selbst auf der Nanogen Seite umgeschaut und finde nichts negatives. Wie vielleicht shon beschrieben wird es evtl einen super hype geben. Aber ich denke ich bleibe long, gewinne werden erst ab 60Euro realisiert
Naja, werd wohl nohmal zulegen und dann Teilgewinne machen, bis ich ´meinen Einsatz wieder drinn habe.
Danke und Gruss
Rico
naja heute ist wohl eher schwach das Anlegerinteresse. Da gehen die Shortys mit kleinen gewinnen nach Hause
gruss rico
gruss rico
Klar gehts mal wieder runter....
die Leute die nur mit NGEN kurz gezockt haben wurden, ja
auch ordentlich belohnt.
Kurse um 200-300 sind doch etwas zu utopisch denke ich, aber 120 hatten wir ja schon mal
grüße
tst
die Leute die nur mit NGEN kurz gezockt haben wurden, ja
auch ordentlich belohnt.
Kurse um 200-300 sind doch etwas zu utopisch denke ich, aber 120 hatten wir ja schon mal
grüße
tst
@tst89
wie wird der weitere Kursverlauf wohl werden? Können wir mit einigen Abschlägen in Amerika noch rechnen?
Würde mich über einen stätigen Anstieg freuen, als nur mal sporadische Ausbrüche.
Gruss
Rico
wie wird der weitere Kursverlauf wohl werden? Können wir mit einigen Abschlägen in Amerika noch rechnen?
Würde mich über einen stätigen Anstieg freuen, als nur mal sporadische Ausbrüche.
Gruss
Rico
ich schätze sie bricht heut aus auf 5 usd
brief wird bei 6.4 euro im xetra angeboten...
Es leidet nur unter Gewinnmitnahmen !
Und ich leide auch unter Gewinnmitnahmen -ich brauche dass Nanogen weiter steigt !
Und ich leide auch unter Gewinnmitnahmen -ich brauche dass Nanogen weiter steigt !
Ich habe eine Frage zu Nanogen bin damals bei 20€ eingestiegen,es war ja eine Weile sehr Ruhig um Nanogen .Aber wenn ich zur zeit das Handelsvolumen anschaue könnte mann meinen das wieder sehr viel Leben in nanogen kommt .Was meint ihr sehe ich die 20€ jemals wieder oder soll ich mich zu jetzigen zeitpunkt trennen ,lieber ein bischen wie v später nichts mehr .Und wo kann man etwas über Nanogen nachlesen ,weil wenn alles doch nicht so schlecht ist könnte ich ja noch nachkaufen.Vielen Dank ,und keine Spinner Bitte.
hi conir, der wert zeigt eine hohe volatilität...das ist typisch für werte, die man nicht richtig einschätzen kann. kann nach oben regelrecht explodieren, sowie zusammenbrechen. gestern an der nasdaq hat man allerdings gesehen, dass der wert erst abgestürzt, sich dann aber gut gefangen hat...
bei dem jetzigen preis stehen die chancen höher als die risiken.
bei dem jetzigen preis stehen die chancen höher als die risiken.
ich meine bei 2,50 eur,wieder einsteigen od. ???
aber ja warum nicht...der wert könnte locker wieder unter 1 usd fallen und innerhalb eineer woche auf 5 usd stehen... ideal zum zocken
@ricotec
Ein stetiger Anstieg ist keine Ausgangsbasis für einen langanhaltenden Kursanstieg
@speedy, vammi, conir
klar lohnt sich nachkaufen....der wert ist sicher gut für mehr als zocks (wobei er auch geeignet ist für zocks), aber ich sehe ngen trotzdem als long investition und baue nach und nach einen dicken bestand an aktien von ngen auf.
ich hoffe es wird sich lohnen (teilweise hat sichs ja schon
Ein stetiger Anstieg ist keine Ausgangsbasis für einen langanhaltenden Kursanstieg
@speedy, vammi, conir
klar lohnt sich nachkaufen....der wert ist sicher gut für mehr als zocks (wobei er auch geeignet ist für zocks), aber ich sehe ngen trotzdem als long investition und baue nach und nach einen dicken bestand an aktien von ngen auf.
ich hoffe es wird sich lohnen (teilweise hat sichs ja schon
langfristig finde ich den wert auch interessant, und das produkt und die präsentation auf biotech messen wirkt sexy (der chip sieht aus als wäre er direkt von apple designt worden...), das ist wichtig neben der performance. es gibt bereits einige zentren weltweit, die das gerät gekauft haben und entsprechend auch die reagenzien kaufen. allerdings muss man sagen dass die konversion von ausleihen der geräte richtung kaufen sehr langsam geschieht, so dass auch der reagenzien verkauf insgesamt träge wächst. in europa wird belegschaft abgebaut. das mahnt mich zur vorsicht.
fundamental war es lediglich eine adhoc über den erwerb eines patents zur herstellung miniaturisierter geräte mit nanotech methodik, die zum kurssprung geführt hat. ich glaube dass die euphorie bereits verpufft ist, und der wert sich in den nächsten tagen wieder hinlegt, zumal dieses patent weiter auslizenziert wird und nicht etwa kurzfristig zu einer bahnbrechenden veränderung der produktpipeline fürhren wird.
langfirstig interessant, kurzfristig mit hoher volatilität rechnen. es gibt für mich keinen grund mehr kurzfristig für einen weiteren anstieg. den wert kaufe ich erst nach wenn er wieder unter 1.5 is.
fundamental war es lediglich eine adhoc über den erwerb eines patents zur herstellung miniaturisierter geräte mit nanotech methodik, die zum kurssprung geführt hat. ich glaube dass die euphorie bereits verpufft ist, und der wert sich in den nächsten tagen wieder hinlegt, zumal dieses patent weiter auslizenziert wird und nicht etwa kurzfristig zu einer bahnbrechenden veränderung der produktpipeline fürhren wird.
langfirstig interessant, kurzfristig mit hoher volatilität rechnen. es gibt für mich keinen grund mehr kurzfristig für einen weiteren anstieg. den wert kaufe ich erst nach wenn er wieder unter 1.5 is.
ZU NANOGEN ICH WERDE SIE JETZT NICHT MEHR SO SCHNELL HERGEBEN ICH BIN SEHR ÜBERZEUGT DAS SIE DIESES JAHR NOCH DIE 10€ MARKE ÜBERSPRINEN WIRD: WARTET NUR MAL BIS DIE NEUE TESTREIHE ABGESCHLOSSEN IST.UND DIESES WIRD SEHR BALD GESCHEHEN .DANACH GIBT ES NUR NOCH EINE RICHTUNG UND ZWAR NACH OBEN .
@conir
es gibt nie immer nur eine richtung
aber ich denke ngen wird ein titel sein, bei dem
man froh sein kann wenn man den long hat.
wir werden hoffentlich alle reich beschenkt
werden
es gibt nie immer nur eine richtung
aber ich denke ngen wird ein titel sein, bei dem
man froh sein kann wenn man den long hat.
wir werden hoffentlich alle reich beschenkt
werden
Nanogen Appoints Board Directors at Annual Stockholders` Meeting
SAN DIEGO, Jun 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that David R. Schreiber was elected as a new Director and Stelios B. Papadopoulos was reelected to a second term during the Company`s annual stockholders` meeting, held yesterday in San Diego, California. Both board members will serve three-year terms. Mr. Papadopoulos has been a Nanogen Director since 1999.
Mr. Schreiber most recently served as Senior Vice President and Chief Financial Officer and was a director of Dianon Systems, Inc., a company acquired by the Laboratory Corporation of America. Dianon is a leading national provider of anatomic and molecular pathology testing services and genomic diagnostic services. Mr. Schreiber was also Vice President and General Manager of the Midwest Region for Corning Clinical Laboratories (now Quest Diagnostics) and earlier was Vice President, Finance and Administration at Unilab Corporation. He received an MBA and a B.S. in Finance with a minor in Economics from Northern Illinois University.
"David`s expertise in leading of one of the country`s largest, specialized pathology laboratories will enable him to provide Nanogen additional insight to the unique needs of esoteric labs and how our molecular diagnostic tools and system can continue to be integral to the growth of the genetic testing market," said Howard C. Birndorf, Chairman and CEO of Nanogen, Inc.
All other resolutions were also passed at yesterday`s stockholders` meeting. Following the formal meeting, in a presentation and question and answer session, management reiterated the Company`s financial objectives for the year.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
David Ludvigson, Executive Vice President of Nanogen,
+1-858-410-4600; or Pam Lord, Media Relations, of Atkins + Associates,
+1-858-527-3494, for Nanogen
http://www.nanogen.com
SAN DIEGO, Jun 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that David R. Schreiber was elected as a new Director and Stelios B. Papadopoulos was reelected to a second term during the Company`s annual stockholders` meeting, held yesterday in San Diego, California. Both board members will serve three-year terms. Mr. Papadopoulos has been a Nanogen Director since 1999.
Mr. Schreiber most recently served as Senior Vice President and Chief Financial Officer and was a director of Dianon Systems, Inc., a company acquired by the Laboratory Corporation of America. Dianon is a leading national provider of anatomic and molecular pathology testing services and genomic diagnostic services. Mr. Schreiber was also Vice President and General Manager of the Midwest Region for Corning Clinical Laboratories (now Quest Diagnostics) and earlier was Vice President, Finance and Administration at Unilab Corporation. He received an MBA and a B.S. in Finance with a minor in Economics from Northern Illinois University.
"David`s expertise in leading of one of the country`s largest, specialized pathology laboratories will enable him to provide Nanogen additional insight to the unique needs of esoteric labs and how our molecular diagnostic tools and system can continue to be integral to the growth of the genetic testing market," said Howard C. Birndorf, Chairman and CEO of Nanogen, Inc.
All other resolutions were also passed at yesterday`s stockholders` meeting. Following the formal meeting, in a presentation and question and answer session, management reiterated the Company`s financial objectives for the year.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
David Ludvigson, Executive Vice President of Nanogen,
+1-858-410-4600; or Pam Lord, Media Relations, of Atkins + Associates,
+1-858-527-3494, for Nanogen
http://www.nanogen.com
achtung, us eröffnet positiv, nanogen stürzt ab.
Machen sich gut im Cashburn-Depot ....
....
und weiter gehts abwärts...
übrigens, diese e-plus werbung ist ganz schön penetrant oder? als nächstes blockieren sie wohl die autobahnen mit LKW´s die ihr logo tragen...wäre vergleichbar. haben nix dazugelernt diese marketing strategen.
übrigens, diese e-plus werbung ist ganz schön penetrant oder? als nächstes blockieren sie wohl die autobahnen mit LKW´s die ihr logo tragen...wäre vergleichbar. haben nix dazugelernt diese marketing strategen.
hallo, gesell mich mal zu euch
#vammi, kannst du mir ne gute site nennen, wo ich den kurs in us kostenlos realtime sehe? besten dank im voraus! mit der werbung hast du recht, mittlerweile hat man 4 popups auf den weg zu einem thread..
#vammi, kannst du mir ne gute site nennen, wo ich den kurs in us kostenlos realtime sehe? besten dank im voraus! mit der werbung hast du recht, mittlerweile hat man 4 popups auf den weg zu einem thread..
hi mamers, muss ich passen, schau mir die zeitverzögerten kurse nur an...consors homepage gefällt mir am besten.
nanogen fällt jedenfalls weiter im nasdaq premarket....also auch hier mit deutliochen kursverlusten zu rechnnen...bald kommen die einkaufskurse zurück
nanogen fällt jedenfalls weiter im nasdaq premarket....also auch hier mit deutliochen kursverlusten zu rechnnen...bald kommen die einkaufskurse zurück
danke bei consors dat geht schon. der start war ja wohl
gar nicht so schlecht, nur ob nano das im heutigen marktumfeld halten kann?
egal, bin eh´ long und überzeugt von nanogen
gruss, mamers
bei consors dat geht schon. der start war ja wohlgar nicht so schlecht, nur ob nano das im heutigen marktumfeld halten kann?
egal, bin eh´ long und überzeugt von nanogen
gruss, mamers
Hallo,
http://www.usa-aktienprofi.de/ <= hier anklicken.. dann auf realtimekursen.. Kürzel von nanogen (NGN) geben.. siehe da du hast die realtime kurse(n)
gruß
sed
http://www.usa-aktienprofi.de/ <= hier anklicken.. dann auf realtimekursen.. Kürzel von nanogen (NGN) geben.. siehe da du hast die realtime kurse(n)
gruß
sed
#sed thx ;-)
schätze nanogen beruhigt sich wieder auf 1,5 euro im laufe dieser woche. dann aber einsteigen!!
warum bei 1,5 einsteigen ich warte bis sie unter 1 eur ist und warum sollen sie steigen ??? kommt was ???
Ich wüsste zur Zeit nix was die Aktie nach oben treiben
könnte....aber die besten News sind die unerwarteten.
Persönlich denke ich, dass wir uns auf ca. 2$ mal festpendeln und auf die nächsten News warten dürfen.
Grüße
tst
könnte....aber die besten News sind die unerwarteten.
Persönlich denke ich, dass wir uns auf ca. 2$ mal festpendeln und auf die nächsten News warten dürfen.
Grüße
tst
Kurz vor Ablauf des Quartals noch ein wenig
Aktie pushen
Schaut NGEN wieder ähnlich
Aktie pushen
Schaut NGEN wieder ähnlich
+21,94%
Insiderhandel......ob da was im Busch ist?
Insiderhandel......ob da was im Busch ist?
Hoffentlich ist jetzt Nanogen wieder wach !
Nanogen heute 2,40 € und 3,40 $.
Hoffentlich wird es bald wieder 4 € und 5 $ !
http://home.pages.at/stanollie
.
.
Nanogen heute 2,40 € und 3,40 $.
Hoffentlich wird es bald wieder 4 € und 5 $ !
http://home.pages.at/stanollie
.
.
United States Patent 6,589,742
Edman , et al. July 8, 2003
--------------------------------------------------------------------------------
Multiplex amplification and separation of nucleic acid sequences on a bioelectronic microchip using asymmetric structures
Abstract
A method for amplifying nucleic acids is provided wherein detection of amplified species is enhanced by the use of asymmetric amplification. Such amplification is made asymmetric by using divergent ratios of amplification primers or by using non-extending and/or non-cleavable amplification primers. Detection of the amplicons is improved because maintenance of single stranded species of amplicons during amplification facilitates their direct capture by immobilized probes without having to include denaturing steps.
--------------------------------------------------------------------------------
Inventors: Edman; Carl F. (San Diego, CA); Nerenberg; Michael I. (La Jolla, CA); Westin; Lorelei P. (La Mesa, CA); Carrino; John J. (San Diego, CA)
Assignee: Nanogen, Inc. (San Diego, CA)
Appl. No.: 954594
Edman , et al. July 8, 2003
--------------------------------------------------------------------------------
Multiplex amplification and separation of nucleic acid sequences on a bioelectronic microchip using asymmetric structures
Abstract
A method for amplifying nucleic acids is provided wherein detection of amplified species is enhanced by the use of asymmetric amplification. Such amplification is made asymmetric by using divergent ratios of amplification primers or by using non-extending and/or non-cleavable amplification primers. Detection of the amplicons is improved because maintenance of single stranded species of amplicons during amplification facilitates their direct capture by immobilized probes without having to include denaturing steps.
--------------------------------------------------------------------------------
Inventors: Edman; Carl F. (San Diego, CA); Nerenberg; Michael I. (La Jolla, CA); Westin; Lorelei P. (La Mesa, CA); Carrino; John J. (San Diego, CA)
Assignee: Nanogen, Inc. (San Diego, CA)
Appl. No.: 954594
Upcoming Events
Event Date(s)
Q2 2003 Nanogen Earnings Release
Event Date(s)
Q2 2003 Nanogen Earnings Release
Datum vergessen
31.07.2003
31.07.2003
#tst89 - thx - auf der HP haben die keinen kompletten Kalender, oder überseh ich den bloss?
ganz ordenlich gelaufen die ganzen letzten Tage vielleicht greift ngen heute die 4 $ an..
ganz ordenlich gelaufen die ganzen letzten Tage
vielleicht greift ngen heute die 4 $ an..
@mamers
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=NGEN&…
wie komplett dieser ist mmusst Du selber entscheiden ;-)
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=NGEN&…
wie komplett dieser ist mmusst Du selber entscheiden ;-)
Nanogen to Host Conference Call On 2003 Second Quarter Financial Results
SAN DIEGO--(BUSINESS WIRE)--July 24, 2003--Nanogen, Inc. (Nasdaq:NGEN - news) will host a conference call on Thursday, July 31, 2003 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2003 second quarter financial results. The earnings release will be issued at close of market on July 31.
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available two hours after the completion of the conference call on July 31 until midnight on August 2, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 1905968, will be required to listen to the playback.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Nanogen, Inc. David Ludvigson, 858-410-4600
dludvigson@nanogen.com
or
Media Contact:
Atkins + Associates
Pam Lord, 858-527-3494
plord@irpr.com
SOURCE: Nanogen, Inc.
SAN DIEGO--(BUSINESS WIRE)--July 24, 2003--Nanogen, Inc. (Nasdaq:NGEN - news) will host a conference call on Thursday, July 31, 2003 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2003 second quarter financial results. The earnings release will be issued at close of market on July 31.
Nanogen management will host the conference call. Audio of the management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available two hours after the completion of the conference call on July 31 until midnight on August 2, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 1905968, will be required to listen to the playback.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Nanogen, Inc. David Ludvigson, 858-410-4600
dludvigson@nanogen.com
or
Media Contact:
Atkins + Associates
Pam Lord, 858-527-3494
plord@irpr.com
SOURCE: Nanogen, Inc.
Event Details
Title: Q2 2003 Nanogen Earnings Release
Date: Thursday, July 31, 2003
Title: Q2 2003 Nanogen Earnings Conference Call
Date: Thursday, July 31, 2003
Time: 4:30 PM ET / 1:30 PM PT
Duration: 1 hour
Title: Q2 2003 Nanogen Earnings Release
Date: Thursday, July 31, 2003
Title: Q2 2003 Nanogen Earnings Conference Call
Date: Thursday, July 31, 2003
Time: 4:30 PM ET / 1:30 PM PT
Duration: 1 hour
Verdammt großer Insider-Handel in letzter Zeit....
...vielleicht wissen die ja mehr und kaufen
Hoffen wird mal....
allen ein schönes Wochenende...
...vielleicht wissen die ja mehr und kaufen
Hoffen wird mal....
allen ein schönes Wochenende...
Jepp, ende nächste woche wissen wir mehr..
hoffe auf einigermasse gute zahlen...
thx - tst für die schnellen info´s die du hier rein stellst!
schönes wochenende, mamers
hoffe auf einigermasse gute zahlen...
thx - tst für die schnellen info´s die du hier rein stellst!
schönes wochenende, mamers
@ mamers
gerne
@all
gibt schon wieder nen neuen Insiderhandel:
http://10kwizard.ccbn.com/fil_list.asp?TK=NGEN&CK=1030339&FG…
Gute Vorzeichen??
gruß
tst
gerne
@all
gibt schon wieder nen neuen Insiderhandel:
http://10kwizard.ccbn.com/fil_list.asp?TK=NGEN&CK=1030339&FG…
Gute Vorzeichen??
gruß
tst
Sehr interessanter Artikel:
http://www.smallcapmarketwatch.com/article.asp?Article_Id=64…
The Big View On Nanotechnology
June 17, 2003
We`ve been busy digging into over a dozen nanotechnology companies and what we found was that many were pretenders. The other problem we experienced was that the majority of the stocks ran up so much that it didn`t make sense for anyone to buy them at these inflated levels. What the SmallCap MarketWatch decided to do was filter all the nanotech companies we didn`t like and come up with a list of stocks that make for good potential trading alerts.
That does not mean these companies are good buys at current prices rather they are stocks to put on your nanotech watch list. The figure to the right are the nanotech companies that we felt our readers should pay attention to. We have the returns of each company since May 1 listed in the far right column. This was done to ensure that our readers understand these stocks are not cheap.
What would any industry be without an "incubator"? Harris & Harris (TINY) like its internet predecessors CMGI (CMGI) and Softbank is in the business of investing in nanotechnology companies. TINY has invested along side some of the most prestigious venture capital firms. Last April, the company invested $1.5 million in Nanosys which is considered by industry analysts to be the premier nanotechnology firm. Harris & Harris have a very extensive portfolio of companies which may someday create a windfall. However, considering the current market conditions for new issues the ability to value the TINY portfolio is difficult.
Publicly traded venture capital funds are valued according to how much their holdings are worth. The problem is without a public market to determine the true value of each portfolio company it is impossible to be precise. However, at $6.73 per share the stock is considerably higher than what Harris & Harris considers their portfolio Net Asset Value ($2.26 per share) to be. We included this stock in our basket because if the IPO window ever opens for nanotech stocks then the upside to TINY will be huge.
Flamel Technologies (FLML) has one of the prettiest charts we have ever seen. Too bad we didn`t discover the company until now. Flamel is a biopharmaceutical company engaged in the development of two polymer-based drug delivery platforms. The company`s Micropump® and Medusa® technologies are involved in fifteen different development programs with eight different collaborations of which five are in clinical phases. The company`s partners include Merck (MRK), GlaxoSmithKline (GSK), Biovail (BVF), and four other nondisclosed parties.
The science involved in Flamel is absolutely incredible. Currently patients take medication the usual "four times a day" but Flamel`s Micropump creates microparticles that prolong the delivery of drugs in the small intestine making it possible for once daily dosing. Imagine just one dose per day versus four with the same benefits. The large pharmaceuticals are in desperate need of this technology and for good reason. Patent expiration issues are forcing drug companies to innovate in hopes of protecting market share. Reintroducing the same drug with a new delivery mechanism is one of the ways to do this. Shares of Flamel closed at $12.05 per share and are up about 600% in the past twelve months. Wall Street coverage is virtually nonexistent because it is a French company that obviously does very little investment banking here in the states. Flamel stands to reap tremendous benefits from its partners off royalty payments once drugs start to receive FDA approval.
JMAR Technologies (JMAR) is included in the basket mainly because of valuation. Shares closed yesterday at $1.26 per share giving the company a $30.2 million dollar market cap. Sales for 2003 are expected to be in the range of $23 million and JMAR previously announced a $34.5 million dollar contract with the Department of Defense so there is a nice backlog of revenues.
The company is the originator of Collimated Plasma Lithography (CPL), a next generation lithography alternative designed to deliver affordable, sub-100 nanometer chip making capability in a compact format to the semiconductor industry. Its microelectronics division provides process integration and maintenance support for the U.S. Government`s Defense Microelectronics Activity semiconductor fabrication facility.
This past year JMAR unloaded a money losing division but has made up for the lost revenue by increase in contract funding for its CPL Program. If CPL continues to gain momentum then the company could be close to profitability in the near future.
Nanophase (NANX) engineers and manufactures nanocrystalline materials on a commercial scale (product list). The nanomaterials are currently used in sunscreens, personal care formulations, abrasion resistant floor coverings, and catalytic converters. The company is also developing several new emerging applications for nanocrystalline materials in multiple markets. Nanophase was included in the basket because the company expects revenues of $3 million in the first half 2003 and more in the second half of the year.
Revenue is important because it validates that the company has something that customers will pay for. Nanogen has passed the proof of concept stage and now needs to close large scale clients to win over investors. The stock closed yesterday at a hefty $5.34 per share equaling to a market cap of $81.1 million. Shares have gained 85.38% since May 1 and there are very few levels of support for the stock until the high two dollar level. Waiting for a pullback makes a lot of sense on this one.
Nanogen (NGEN) was a company that initially attracted us because it traded under its cash value of $1.71 per share ($36.9 million) for quite some time. Now at $3.54 the shares are considerably more expensive and subsequently much riskier. Cash burn is per quarter is approximately $8 million but management is already trimming costs and bringing the losses down. On the bright side, revenue has increased every year with 2002 bringing in $17.17 million.
The company is included on our nanotech basket because it has a large following and often trades well when the sector gets attention. In addition, the large cash coffer keeps the doors open for a long time. Nanogen hopes to establish its NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications.
Westaim (WEDX) was brought to our attention by quite a few Canadian readers. This company offers an indirect way to play nanotechnology because of its ownership in Nucryst Pharmaceutical Corp. Nucryst invented a nanocrystalline technology called Silcryst which is used in its wound dressing product called Acticoat. The company has deconstructed the structure of silver and rebuilt it with smaller crystals, which the body can absorb faster. Since its pure silver it also kills bacteria without damaging human tissue.
Our favorite stock in the nanotech basket has to be Westaim. The company is sitting on $95.7 million in cash and cash equivalents while the stock closed yesterday at $1.65 giving them a market cap of $128.8 million. Revenue for the most recent quarter ending March 31 was $16.66 million with Nucryst accounting for over 40%. Losses came in at $984,000 for the quarter but it`s possible for the company to reach breakeven very soon. If Nucryst was ever spun off it would probably be worth more than Westaim as a whole.
That concludes our edition on nanotechnology and as an added bonus we decided to list the support and resistance levels for the stocks in the basket. We look forward to reading your comments which may be sent to editor@smallcapmarketwatch.com.
http://www.smallcapmarketwatch.com/article.asp?Article_Id=64…
The Big View On Nanotechnology
June 17, 2003
We`ve been busy digging into over a dozen nanotechnology companies and what we found was that many were pretenders. The other problem we experienced was that the majority of the stocks ran up so much that it didn`t make sense for anyone to buy them at these inflated levels. What the SmallCap MarketWatch decided to do was filter all the nanotech companies we didn`t like and come up with a list of stocks that make for good potential trading alerts.
That does not mean these companies are good buys at current prices rather they are stocks to put on your nanotech watch list. The figure to the right are the nanotech companies that we felt our readers should pay attention to. We have the returns of each company since May 1 listed in the far right column. This was done to ensure that our readers understand these stocks are not cheap.
What would any industry be without an "incubator"? Harris & Harris (TINY) like its internet predecessors CMGI (CMGI) and Softbank is in the business of investing in nanotechnology companies. TINY has invested along side some of the most prestigious venture capital firms. Last April, the company invested $1.5 million in Nanosys which is considered by industry analysts to be the premier nanotechnology firm. Harris & Harris have a very extensive portfolio of companies which may someday create a windfall. However, considering the current market conditions for new issues the ability to value the TINY portfolio is difficult.
Publicly traded venture capital funds are valued according to how much their holdings are worth. The problem is without a public market to determine the true value of each portfolio company it is impossible to be precise. However, at $6.73 per share the stock is considerably higher than what Harris & Harris considers their portfolio Net Asset Value ($2.26 per share) to be. We included this stock in our basket because if the IPO window ever opens for nanotech stocks then the upside to TINY will be huge.
Flamel Technologies (FLML) has one of the prettiest charts we have ever seen. Too bad we didn`t discover the company until now. Flamel is a biopharmaceutical company engaged in the development of two polymer-based drug delivery platforms. The company`s Micropump® and Medusa® technologies are involved in fifteen different development programs with eight different collaborations of which five are in clinical phases. The company`s partners include Merck (MRK), GlaxoSmithKline (GSK), Biovail (BVF), and four other nondisclosed parties.
The science involved in Flamel is absolutely incredible. Currently patients take medication the usual "four times a day" but Flamel`s Micropump creates microparticles that prolong the delivery of drugs in the small intestine making it possible for once daily dosing. Imagine just one dose per day versus four with the same benefits. The large pharmaceuticals are in desperate need of this technology and for good reason. Patent expiration issues are forcing drug companies to innovate in hopes of protecting market share. Reintroducing the same drug with a new delivery mechanism is one of the ways to do this. Shares of Flamel closed at $12.05 per share and are up about 600% in the past twelve months. Wall Street coverage is virtually nonexistent because it is a French company that obviously does very little investment banking here in the states. Flamel stands to reap tremendous benefits from its partners off royalty payments once drugs start to receive FDA approval.
JMAR Technologies (JMAR) is included in the basket mainly because of valuation. Shares closed yesterday at $1.26 per share giving the company a $30.2 million dollar market cap. Sales for 2003 are expected to be in the range of $23 million and JMAR previously announced a $34.5 million dollar contract with the Department of Defense so there is a nice backlog of revenues.
The company is the originator of Collimated Plasma Lithography (CPL), a next generation lithography alternative designed to deliver affordable, sub-100 nanometer chip making capability in a compact format to the semiconductor industry. Its microelectronics division provides process integration and maintenance support for the U.S. Government`s Defense Microelectronics Activity semiconductor fabrication facility.
This past year JMAR unloaded a money losing division but has made up for the lost revenue by increase in contract funding for its CPL Program. If CPL continues to gain momentum then the company could be close to profitability in the near future.
Nanophase (NANX) engineers and manufactures nanocrystalline materials on a commercial scale (product list). The nanomaterials are currently used in sunscreens, personal care formulations, abrasion resistant floor coverings, and catalytic converters. The company is also developing several new emerging applications for nanocrystalline materials in multiple markets. Nanophase was included in the basket because the company expects revenues of $3 million in the first half 2003 and more in the second half of the year.
Revenue is important because it validates that the company has something that customers will pay for. Nanogen has passed the proof of concept stage and now needs to close large scale clients to win over investors. The stock closed yesterday at a hefty $5.34 per share equaling to a market cap of $81.1 million. Shares have gained 85.38% since May 1 and there are very few levels of support for the stock until the high two dollar level. Waiting for a pullback makes a lot of sense on this one.
Nanogen (NGEN) was a company that initially attracted us because it traded under its cash value of $1.71 per share ($36.9 million) for quite some time. Now at $3.54 the shares are considerably more expensive and subsequently much riskier. Cash burn is per quarter is approximately $8 million but management is already trimming costs and bringing the losses down. On the bright side, revenue has increased every year with 2002 bringing in $17.17 million.
The company is included on our nanotech basket because it has a large following and often trades well when the sector gets attention. In addition, the large cash coffer keeps the doors open for a long time. Nanogen hopes to establish its NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications.
Westaim (WEDX) was brought to our attention by quite a few Canadian readers. This company offers an indirect way to play nanotechnology because of its ownership in Nucryst Pharmaceutical Corp. Nucryst invented a nanocrystalline technology called Silcryst which is used in its wound dressing product called Acticoat. The company has deconstructed the structure of silver and rebuilt it with smaller crystals, which the body can absorb faster. Since its pure silver it also kills bacteria without damaging human tissue.
Our favorite stock in the nanotech basket has to be Westaim. The company is sitting on $95.7 million in cash and cash equivalents while the stock closed yesterday at $1.65 giving them a market cap of $128.8 million. Revenue for the most recent quarter ending March 31 was $16.66 million with Nucryst accounting for over 40%. Losses came in at $984,000 for the quarter but it`s possible for the company to reach breakeven very soon. If Nucryst was ever spun off it would probably be worth more than Westaim as a whole.
That concludes our edition on nanotechnology and as an added bonus we decided to list the support and resistance levels for the stocks in the basket. We look forward to reading your comments which may be sent to editor@smallcapmarketwatch.com.
Yeahh, thx a lot to tst89 für das obenhalten des NGEN-threads
MfG
Realkamikaze
MfG
Realkamikaze
Yeahh, thx a lot to tst89 für das obenhalten des NGEN-threads
MfG
Realkamikaze
MfG
Realkamikaze
hier die pressemeldung:
Nanogen Reports 2003 Second Quarter Results
SAN DIEGO, Jul 31, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the second quarter ended June 30, 2003.
Total revenues for the second quarter of 2003 were $1.7 million, an increase of 41% over the $1.2 million recorded in the first quarter of 2003 and 13% lower than the second quarter of the prior year. Product revenues for the second quarter of 2003 were $662,000, more than double the $228,000 recorded in the first quarter of 2003 and 40% lower than the second quarter of 2002. During the quarter, there were six commercial transactions for the NanoChip(R) Molecular Biology Workstation compared to three in the first quarter. Of the six transactions, four were instrument sales, one was a reagent rental agreement and one was a lease agreement. In addition, one instrument was installed as part of a product collaboration.
"Our product revenue results show improvement over the first quarter and we are starting to make good progress with our sales efforts to clinical laboratories," said Bruce Huebner, President and Chief Operating Officer of Nanogen. "During the quarter, we continued the controlled release of our CFTR analyte specific reagents. Eleven customers are currently evaluating and validating the product in their labs. While the customer validation process is taking longer than expected, we anticipate a significant increase in our consumable revenues once our customers begin offering tests utilizing the CFTR ASRs and other Nanogen ASR products."
The loss for the first quarter of 2003 was $6.9 million or $0.32 per share, an improvement of 19% from the loss of $8.5 million or $0.39 per share in the second quarter of 2002 and an improvement of 35% from the loss of $10.7 million or $0.50 per share in the first quarter of this year. The second quarter loss was approximately $200,000 or $0.01 per share better than the first quarter of 2003 after adjusting the first quarter results for the $3.6 million loss on the sale of CombiMatrix stock. The CombiMatrix stock was received during 2002 as part of a litigation settlement. Operating expenses for the second quarter of 2003 were $9.1 million, 21% lower than the $11.6 million incurred during the second quarter of 2002 and virtually identical to the first quarter of 2003 expense levels. Nanogen implemented a cost reduction initiative in April 2003, reducing the overall expense plan for this year by approximately $5.0 million. Approximately $500,000 of expenses associated with the cost reduction measures was incurred during the second quarter. The Company is continuing to review expense reduction opportunities.
The Company`s cash, cash equivalents and short-term investments balance at June 30, 2003 was $28.5 million.
In other developments, Nanogen and Hitachi are restructuring their collaborative business partnership. The companies have determined that their efforts will focus on the development and manufacture of a new clinical instrument and that the development collaboration agreement will be terminated, per provisions in the agreement. Nanogen and Hitachi are jointly responsible for development of the instrument. Hitachi is responsible for world-wide manufacturing and for distribution in Japan. Nanogen is responsible for development of assays and for marketing and sales except in Japan. Hitachi and Nanogen will also continue their collaboration on the current Molecular Biology Workstation and on instrument service.
"In the second quarter, we successfully implemented a significant cost reduction program and made solid progress on increasing product revenue," said Howard C. Birndorf, Chairman and Chief Executive Officer of Nanogen. "We will continue to investigate strategies to accelerate our growth and further strengthen our product and service offerings while reducing our operating costs."
Guidance for 2003
For 2003, product revenue is expected to be in the range of $4 to $6 million and between 35 and 45 placements of the NanoChip(R) Molecular Biology Workstation. This reduced product revenue estimate reflects lower than expected revenue in Europe, customer delays in the validation of ASRs and an increase in the estimated percentage of reagent rental contracts versus sale contracts. The expectation for contract and sponsored research revenues continues to be approximately $4 million. Sponsored research revenues from the Hitachi collaboration are expected to continue at their current level through the first quarter of 2004. Quarterly operating expenses for the second half of 2003 are expected to decline approximately 15% from second quarter levels as the cost benefit of Nanogen`s April cost reduction initiative is realized. The expense reduction efforts are expected to offset the effect of the reduced product revenue forecast and, therefore, the loss for 2003 is still expected to be between $27 million and $29 million. Cash, cash equivalents and short-term investments at the end of the year are expected to be approximately $20 million.
Webcast of the Conference Call
Nanogen management will host a conference call today to discuss the second quarter financial results at 4:30 p.m. Eastern Time. Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com . A telephone replay will be available approximately two hours following the conference call until 11:59 p.m. Eastern Time on August 2, 2003, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants. The conference ID is 1905968 and it will be required to listen to the playback. The webcast will also be archived on Nanogen`s website for 90 days.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Note Regarding Use of Non-GAAP Financial Information
To supplement our consolidated financial statements presented in accordance with GAAP, we used a non-GAAP adjustment to exclude the $3.6 million loss on the sale of CombiMatrix stock from the loss and loss per share information for the first quarter of 2003. We received shares of CombiMatrix stock during 2002 as part of a litigation settlement. Non-GAAP adjustments are provided to enhance the user`s overall understanding of current financial performance and prospects for the future. Specifically, we believe that the non-GAAP adjustment provides useful information to both management and investors by excluding certain losses that we believe are not indicative of our operating results, thereby permitting a more meaningful comparison between the loss and loss per share information for the first and second quarters of 2003. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.
Forward-Looking Statement
This press release contains forward-looking statements regarding future product revenues, contract and sponsored research revenues, estimates of operating expenses and estimates of future cash balances. These forward-looking statements are based upon current expectations and speak only as of the date hereof. Our actual results may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, the value of our investment in CombiMatrix securities, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
June 30, December 31,
2003 2002
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $5,635 $9,353
Short-term investments 22,845 43,376
Receivables, net 1,888 1,754
Inventories, net 5,066 4,717
Other current assets 2,358 1,781
Total current assets 37,792 60,981
Property and equipment, net 4,938 4,982
Acquired technology rights, net 4,040 4,544
Other assets, net 968 789
Restricted cash 64 64
$47,802 $71,360
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $214 $753
Accrued liabilities 4,618 5,901
Deferred revenue 343 472
Current portion of capital lease obligations 747 805
Total current liabilities 5,922 7,931
Capital lease obligations, less current
portion 885 1,134
Other long-term liabilities 3,090 3,085
Total long-term liabilities 3,975 4,219
Minority interest in consolidated subsidiary 712 1,817
Stockholders` equity:
Convertible preferred stock, $0.001 par
value, 5,000,000 shares authorized; no
shares issued and outstanding at
June 30, 2003 (unaudited) and
December 31, 2002 -- --
Common stock, $0.001 par value,
50,000,000 shares authorized;
22,161,509 and 21,981,115 shares issued
and outstanding at June 30, 2003
(unaudited) and December 31, 2002,
respectively 22 22
Additional paid-in capital 200,590 199,483
Accumulated other comprehensive income 872 4,926
Deferred compensation (137) (156)
Notes receivable from officers -- (513)
Accumulated deficit (163,232) (145,659)
Treasury stock, at cost, 500,189 and
366,857 shares at June 30, 2003
(unaudited) and December 31, 2002,
respectively (922) (710)
Total stockholders` equity 37,193 57,393
$47,802 $71,360
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Six months ended
June 30, June 30,
2003 2002 2003 2002
Revenues:
Product sales $662 $1,104 $890 $1,916
Sponsored research 375 313 750 626
Contracts and grant 657 534 1,254 942
Total revenues 1,694 1,951 2,894 3,484
Operating expenses:
Cost of product sales 524 836 798 1,393
Research and development 4,483 5,029 9,193 9,892
Selling, general and
administrative 4,130 5,316 8,196 9,918
Litigation and settlement
of patent matter -- 428 -- 798
Total operating expenses 9,137 11,609 18,187 22,001
Loss from operations (7,443) (9,658) (15,293) (18,517)
Interest income, net 113 586 308 1,346
Other income -- 129 27 135
Gain/(loss) on sale of
investments 32 -- (3,568) --
Loss on sale of fixed
assets (153) -- (153) --
Minority interest in loss
of consolidated subsidiary 558 422 1,106 983
Net loss $(6,893) $(8,521) $(17,573) $(16,053)
Net loss per share -
basic and diluted $(0.32) $(0.39) $(0.82) $(0.74)
Number of shares used
in computing net loss
per share - basic and
diluted 21,543 21,650 21,492 21,635
SOURCE Nanogen, Inc.
David Ludvigson, Executive Vice President of Nanogen, Inc.,
+1-858-410-4600, dludvigson@nanogen.com; or Pam Lord of Atkins + Associates,
+1-858-527-3494, plord@irpr.com, for Nanogen, Inc.
http://www.nanogen.com
Nanogen Reports 2003 Second Quarter Results
SAN DIEGO, Jul 31, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the second quarter ended June 30, 2003.
Total revenues for the second quarter of 2003 were $1.7 million, an increase of 41% over the $1.2 million recorded in the first quarter of 2003 and 13% lower than the second quarter of the prior year. Product revenues for the second quarter of 2003 were $662,000, more than double the $228,000 recorded in the first quarter of 2003 and 40% lower than the second quarter of 2002. During the quarter, there were six commercial transactions for the NanoChip(R) Molecular Biology Workstation compared to three in the first quarter. Of the six transactions, four were instrument sales, one was a reagent rental agreement and one was a lease agreement. In addition, one instrument was installed as part of a product collaboration.
"Our product revenue results show improvement over the first quarter and we are starting to make good progress with our sales efforts to clinical laboratories," said Bruce Huebner, President and Chief Operating Officer of Nanogen. "During the quarter, we continued the controlled release of our CFTR analyte specific reagents. Eleven customers are currently evaluating and validating the product in their labs. While the customer validation process is taking longer than expected, we anticipate a significant increase in our consumable revenues once our customers begin offering tests utilizing the CFTR ASRs and other Nanogen ASR products."
The loss for the first quarter of 2003 was $6.9 million or $0.32 per share, an improvement of 19% from the loss of $8.5 million or $0.39 per share in the second quarter of 2002 and an improvement of 35% from the loss of $10.7 million or $0.50 per share in the first quarter of this year. The second quarter loss was approximately $200,000 or $0.01 per share better than the first quarter of 2003 after adjusting the first quarter results for the $3.6 million loss on the sale of CombiMatrix stock. The CombiMatrix stock was received during 2002 as part of a litigation settlement. Operating expenses for the second quarter of 2003 were $9.1 million, 21% lower than the $11.6 million incurred during the second quarter of 2002 and virtually identical to the first quarter of 2003 expense levels. Nanogen implemented a cost reduction initiative in April 2003, reducing the overall expense plan for this year by approximately $5.0 million. Approximately $500,000 of expenses associated with the cost reduction measures was incurred during the second quarter. The Company is continuing to review expense reduction opportunities.
The Company`s cash, cash equivalents and short-term investments balance at June 30, 2003 was $28.5 million.
In other developments, Nanogen and Hitachi are restructuring their collaborative business partnership. The companies have determined that their efforts will focus on the development and manufacture of a new clinical instrument and that the development collaboration agreement will be terminated, per provisions in the agreement. Nanogen and Hitachi are jointly responsible for development of the instrument. Hitachi is responsible for world-wide manufacturing and for distribution in Japan. Nanogen is responsible for development of assays and for marketing and sales except in Japan. Hitachi and Nanogen will also continue their collaboration on the current Molecular Biology Workstation and on instrument service.
"In the second quarter, we successfully implemented a significant cost reduction program and made solid progress on increasing product revenue," said Howard C. Birndorf, Chairman and Chief Executive Officer of Nanogen. "We will continue to investigate strategies to accelerate our growth and further strengthen our product and service offerings while reducing our operating costs."
Guidance for 2003
For 2003, product revenue is expected to be in the range of $4 to $6 million and between 35 and 45 placements of the NanoChip(R) Molecular Biology Workstation. This reduced product revenue estimate reflects lower than expected revenue in Europe, customer delays in the validation of ASRs and an increase in the estimated percentage of reagent rental contracts versus sale contracts. The expectation for contract and sponsored research revenues continues to be approximately $4 million. Sponsored research revenues from the Hitachi collaboration are expected to continue at their current level through the first quarter of 2004. Quarterly operating expenses for the second half of 2003 are expected to decline approximately 15% from second quarter levels as the cost benefit of Nanogen`s April cost reduction initiative is realized. The expense reduction efforts are expected to offset the effect of the reduced product revenue forecast and, therefore, the loss for 2003 is still expected to be between $27 million and $29 million. Cash, cash equivalents and short-term investments at the end of the year are expected to be approximately $20 million.
Webcast of the Conference Call
Nanogen management will host a conference call today to discuss the second quarter financial results at 4:30 p.m. Eastern Time. Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com . A telephone replay will be available approximately two hours following the conference call until 11:59 p.m. Eastern Time on August 2, 2003, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants. The conference ID is 1905968 and it will be required to listen to the playback. The webcast will also be archived on Nanogen`s website for 90 days.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Note Regarding Use of Non-GAAP Financial Information
To supplement our consolidated financial statements presented in accordance with GAAP, we used a non-GAAP adjustment to exclude the $3.6 million loss on the sale of CombiMatrix stock from the loss and loss per share information for the first quarter of 2003. We received shares of CombiMatrix stock during 2002 as part of a litigation settlement. Non-GAAP adjustments are provided to enhance the user`s overall understanding of current financial performance and prospects for the future. Specifically, we believe that the non-GAAP adjustment provides useful information to both management and investors by excluding certain losses that we believe are not indicative of our operating results, thereby permitting a more meaningful comparison between the loss and loss per share information for the first and second quarters of 2003. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.
Forward-Looking Statement
This press release contains forward-looking statements regarding future product revenues, contract and sponsored research revenues, estimates of operating expenses and estimates of future cash balances. These forward-looking statements are based upon current expectations and speak only as of the date hereof. Our actual results may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, the value of our investment in CombiMatrix securities, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
June 30, December 31,
2003 2002
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $5,635 $9,353
Short-term investments 22,845 43,376
Receivables, net 1,888 1,754
Inventories, net 5,066 4,717
Other current assets 2,358 1,781
Total current assets 37,792 60,981
Property and equipment, net 4,938 4,982
Acquired technology rights, net 4,040 4,544
Other assets, net 968 789
Restricted cash 64 64
$47,802 $71,360
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $214 $753
Accrued liabilities 4,618 5,901
Deferred revenue 343 472
Current portion of capital lease obligations 747 805
Total current liabilities 5,922 7,931
Capital lease obligations, less current
portion 885 1,134
Other long-term liabilities 3,090 3,085
Total long-term liabilities 3,975 4,219
Minority interest in consolidated subsidiary 712 1,817
Stockholders` equity:
Convertible preferred stock, $0.001 par
value, 5,000,000 shares authorized; no
shares issued and outstanding at
June 30, 2003 (unaudited) and
December 31, 2002 -- --
Common stock, $0.001 par value,
50,000,000 shares authorized;
22,161,509 and 21,981,115 shares issued
and outstanding at June 30, 2003
(unaudited) and December 31, 2002,
respectively 22 22
Additional paid-in capital 200,590 199,483
Accumulated other comprehensive income 872 4,926
Deferred compensation (137) (156)
Notes receivable from officers -- (513)
Accumulated deficit (163,232) (145,659)
Treasury stock, at cost, 500,189 and
366,857 shares at June 30, 2003
(unaudited) and December 31, 2002,
respectively (922) (710)
Total stockholders` equity 37,193 57,393
$47,802 $71,360
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Six months ended
June 30, June 30,
2003 2002 2003 2002
Revenues:
Product sales $662 $1,104 $890 $1,916
Sponsored research 375 313 750 626
Contracts and grant 657 534 1,254 942
Total revenues 1,694 1,951 2,894 3,484
Operating expenses:
Cost of product sales 524 836 798 1,393
Research and development 4,483 5,029 9,193 9,892
Selling, general and
administrative 4,130 5,316 8,196 9,918
Litigation and settlement
of patent matter -- 428 -- 798
Total operating expenses 9,137 11,609 18,187 22,001
Loss from operations (7,443) (9,658) (15,293) (18,517)
Interest income, net 113 586 308 1,346
Other income -- 129 27 135
Gain/(loss) on sale of
investments 32 -- (3,568) --
Loss on sale of fixed
assets (153) -- (153) --
Minority interest in loss
of consolidated subsidiary 558 422 1,106 983
Net loss $(6,893) $(8,521) $(17,573) $(16,053)
Net loss per share -
basic and diluted $(0.32) $(0.39) $(0.82) $(0.74)
Number of shares used
in computing net loss
per share - basic and
diluted 21,543 21,650 21,492 21,635
SOURCE Nanogen, Inc.
David Ludvigson, Executive Vice President of Nanogen, Inc.,
+1-858-410-4600, dludvigson@nanogen.com; or Pam Lord of Atkins + Associates,
+1-858-527-3494, plord@irpr.com, for Nanogen, Inc.
http://www.nanogen.com
Danke Leute!
Tja, was soll man zu den Zahlen sagen?!
Ich bin nicht besonders begeistert. NGEN muß einfach
mehr Umsatz erzielen...
Na gut, wollen wir hoffen und warten auf News.
Ich bin persönlich trotzdem von NGEN überzeugt
Allen ein schönes, sonniges Wochenende
tst
Tja, was soll man zu den Zahlen sagen?!
Ich bin nicht besonders begeistert. NGEN muß einfach
mehr Umsatz erzielen...
Na gut, wollen wir hoffen und warten auf News.
Ich bin persönlich trotzdem von NGEN überzeugt
Allen ein schönes, sonniges Wochenende
tst
jepp tst, begeistert kann man da wohl wahrlich nicht sein...dennoch "the future will be better than the past"
was mich viel mehr interessieren würde (falls jemand den conference call gehört hat), was dort so von sich gegeben wurde. Gab es etwas neues?
grüsse und schönes wochenende, mamers
was mich viel mehr interessieren würde (falls jemand den conference call gehört hat), was dort so von sich gegeben wurde. Gab es etwas neues?
grüsse und schönes wochenende, mamers
okay, den conference call gibt´s noch auf der homepage von nanogen, habe aber leider kein windows und deren applikationen, also wenn jemand info´s daraus entnommen hat, würde ich mich sehr freuen, wenn es hier gepostet werden könnte.. thx
nach den zahlen sind wir ja einiges runtergerauscht...38 tage linie durchbrochen..kurzfristigen aufwärtstrend durchbrochen..
wie wird´s weitergehen? ohne positiven news glaube ich kaum, dass die 3$ halten können..
nach den zahlen sind wir ja einiges runtergerauscht...38 tage linie durchbrochen..kurzfristigen aufwärtstrend durchbrochen..
wie wird´s weitergehen? ohne positiven news glaube ich kaum, dass die 3$ halten können..
@mamers
kann leider den CC auch nicht abspielen. Wohl wg. meiner rasend schnellen I-net verbindung von fast 56k. Auf jeden Fall bricht er beim laden immer ab.
Wie es weiter geht?! Tja, ich denke nach dem Aufwärts des Gesamtmarktes gehts wohl nun doch langsam in die Sommerpause und das Sommerloch. Wir dürften sicher noch unter 2,50 kommen denke ich. Dann sollten wir auch den Herbst und einen Aufschwung hoffen...
viele Grüße
kann leider den CC auch nicht abspielen. Wohl wg. meiner rasend schnellen I-net verbindung von fast 56k. Auf jeden Fall bricht er beim laden immer ab.
Wie es weiter geht?! Tja, ich denke nach dem Aufwärts des Gesamtmarktes gehts wohl nun doch langsam in die Sommerpause und das Sommerloch. Wir dürften sicher noch unter 2,50 kommen denke ich. Dann sollten wir auch den Herbst und einen Aufschwung hoffen...
viele Grüße
Da fällt NGEN wohl auch drunter:
Overused, Misused Nano Becoming Pervasive Prefix
Sun August 3, 2003 01:35 PM ET
By Bill Berkrot
NEW YORK (Reuters) - Even though nanotechnology is still in its infancy, the nano prefix is quickly growing into one of the most over-used and misused phrases in the English language.
More than 1 million entries containing the word "nano" turned up using Google, the Internet search engine, while Hoovers.com lists dozens of companies with nano in the name.
The Institute of Nanotechnology Web site even has a section labeled: Nano Events.
"It`s kind of a fad word people use now to give the appearance of being high tech," said Jim Lowe, senior editor for Merriam-Webster Dictionary.
The dictionary defines nanotechnology as "the art of manipulating materials on an atomic or molecular scale, especially to build microscopic devices."
Nano comes from nanometer, a unit of measure equal to a billionth of a meter, or about the size of a single molecule. The thickness of a human hair, for example, measures about 50,000 nanometers.
Merriam-Webster currently has nine nano entries pertaining to various things of microscopic size. These don`t begin to explain the creative uses for nano that are popping up everywhere.
Presumably, Nano Seconds Convenience Store is not able to get you coffee and a newspaper and have you out the door in the billionths of seconds their name would suggest.
Start-up companies, looking to raise funds through excitement over the emerging technology that could yield breakthroughs in medicine, science, computers, communications and manufacturing have seized on nano names. Others have changed their names to emphasize their nanotech association.
"This is in the great tradition of picking up on the latest buzz prefix or suffix and attaching it to your company`s name to make it sound cool. And that can translate into more investment and better chance in the market place," said Mark Robinson, senior editor for Wired Magazine.
Nano-tex, which is majority owned by Burlington Industries Inc. BRLG.OB and aims to improve textiles at the molecular level, could have you outfitted in nanopants before long.
They have already listed trademarks such as nano-care and nano-pel for their stain- and wrinkle-resistant materials.
The environmental crusaders from Greenpeace may not be sure what nanotechnology is, but they are already against it.
Greenpeace has called for a moratorium on the release of nanoparticles in commercial products until studies of potential nano pollution can be completed.
Some resistance to nanotechnology could be inspired by the likes of Michael Crichton`s novel "Prey," which envisions a plague of deadly microscopic robots, Robinson suggests.
Such fears or negative associations have not stopped companies and Internet sites from jumping on the nano bandwagon -- even if nanotechnology has nothing to do with their products.
"What`s interesting is that technology-derived things often become the dominant metaphor and break out of the technology realm and start going into areas that you never would have thought they had any place. But people latch onto them because they resonate, and that`s definitely what`s happening with nano," Robinson said.
Nano-reef.com (http:www.nano-reef.com) deals with setting up and maintaining coral reef ecosystems in small home aquariums, but one does not need microscopes to enjoy them.
Enthusiasts are referred to as nano reefers, which apparently has nothing to do with minuscule marijuana cigarettes.
And then there is Nano Products of San Francisco, maker of The Nano Bag. The cozy sack for carrying babies is designed to secure them into car seats, strollers and high chairs "without removing baby from the Nano Bag."
All that`s missing is a nano flap for easy access to wiping nano bottoms.
Overused, Misused Nano Becoming Pervasive Prefix
Sun August 3, 2003 01:35 PM ET
By Bill Berkrot
NEW YORK (Reuters) - Even though nanotechnology is still in its infancy, the nano prefix is quickly growing into one of the most over-used and misused phrases in the English language.
More than 1 million entries containing the word "nano" turned up using Google, the Internet search engine, while Hoovers.com lists dozens of companies with nano in the name.
The Institute of Nanotechnology Web site even has a section labeled: Nano Events.
"It`s kind of a fad word people use now to give the appearance of being high tech," said Jim Lowe, senior editor for Merriam-Webster Dictionary.
The dictionary defines nanotechnology as "the art of manipulating materials on an atomic or molecular scale, especially to build microscopic devices."
Nano comes from nanometer, a unit of measure equal to a billionth of a meter, or about the size of a single molecule. The thickness of a human hair, for example, measures about 50,000 nanometers.
Merriam-Webster currently has nine nano entries pertaining to various things of microscopic size. These don`t begin to explain the creative uses for nano that are popping up everywhere.
Presumably, Nano Seconds Convenience Store is not able to get you coffee and a newspaper and have you out the door in the billionths of seconds their name would suggest.
Start-up companies, looking to raise funds through excitement over the emerging technology that could yield breakthroughs in medicine, science, computers, communications and manufacturing have seized on nano names. Others have changed their names to emphasize their nanotech association.
"This is in the great tradition of picking up on the latest buzz prefix or suffix and attaching it to your company`s name to make it sound cool. And that can translate into more investment and better chance in the market place," said Mark Robinson, senior editor for Wired Magazine.
Nano-tex, which is majority owned by Burlington Industries Inc. BRLG.OB and aims to improve textiles at the molecular level, could have you outfitted in nanopants before long.
They have already listed trademarks such as nano-care and nano-pel for their stain- and wrinkle-resistant materials.
The environmental crusaders from Greenpeace may not be sure what nanotechnology is, but they are already against it.
Greenpeace has called for a moratorium on the release of nanoparticles in commercial products until studies of potential nano pollution can be completed.
Some resistance to nanotechnology could be inspired by the likes of Michael Crichton`s novel "Prey," which envisions a plague of deadly microscopic robots, Robinson suggests.
Such fears or negative associations have not stopped companies and Internet sites from jumping on the nano bandwagon -- even if nanotechnology has nothing to do with their products.
"What`s interesting is that technology-derived things often become the dominant metaphor and break out of the technology realm and start going into areas that you never would have thought they had any place. But people latch onto them because they resonate, and that`s definitely what`s happening with nano," Robinson said.
Nano-reef.com (http:www.nano-reef.com) deals with setting up and maintaining coral reef ecosystems in small home aquariums, but one does not need microscopes to enjoy them.
Enthusiasts are referred to as nano reefers, which apparently has nothing to do with minuscule marijuana cigarettes.
And then there is Nano Products of San Francisco, maker of The Nano Bag. The cozy sack for carrying babies is designed to secure them into car seats, strollers and high chairs "without removing baby from the Nano Bag."
All that`s missing is a nano flap for easy access to wiping nano bottoms.
Vielleicht ganz gute News für Anleger die LONG orientiert sind:
WASHINGTON -- The Food and Drug Administration plans to shave 10% off the time it takes to review brand-new medical devices -- a move the agency said will get innovative, new implants, diagnostics and other products on the market sooner and ultimately reduce costs.
The FDA wants to invite medical-device makers to meet with it while the firms develop new products so the agency can tell the companies early in the process what will be necessary to sell the item in the U.S.
Early communication, the FDA said, will improve the quality of applications submitted and eliminate the need for the agency to ask for more information or reject submissions.
Groups representing device makers said the industry is eager to work closer with the agency`s device center.
Speedier reviews are needed to encourage companies to develop new types of devices, said Mark Leahey, executive director of the Medical Device Manufacturers Association, a group of about 160 device makers. "We hope this will reduce costs," he added. "Time will tell."
Pam Bailey, president of AdvaMed, an association of more than 1,100 medical- device makers, agreed. When medical products take longer to get to market, she said patients suffer and costs go up. "It is most important that review times come down," Ms. Bailey went on to say.
The FDA plans to reduce time it takes to review original premarket-approval applications, which companies submit when they want a brand-new type of product on the market. In fiscal 2002, the agency received 48 such applications, down 23 from a year earlier.
In fiscal 2002, it took an average 364 days from the time the FDA received a premarket application to the time a decision was made. That was down from the prior year`s 411-day average.
The FDA plans to further reduce the time by one month for applications submitted from fiscal 2005 to 2007. The benchmark will be how long it took to review devices that made it through the process the quickest in fiscal 1999 to 2001.
To help cut review times, the FDA said it will work with outside experts to create clear guidelines to steer device companies in the right direction when developing and testing in new fields.
-By Otesa Middleton; Dow Jones Newswires; 202-862-6654; otesa.middleton@ dowjones.com
WASHINGTON -- The Food and Drug Administration plans to shave 10% off the time it takes to review brand-new medical devices -- a move the agency said will get innovative, new implants, diagnostics and other products on the market sooner and ultimately reduce costs.
The FDA wants to invite medical-device makers to meet with it while the firms develop new products so the agency can tell the companies early in the process what will be necessary to sell the item in the U.S.
Early communication, the FDA said, will improve the quality of applications submitted and eliminate the need for the agency to ask for more information or reject submissions.
Groups representing device makers said the industry is eager to work closer with the agency`s device center.
Speedier reviews are needed to encourage companies to develop new types of devices, said Mark Leahey, executive director of the Medical Device Manufacturers Association, a group of about 160 device makers. "We hope this will reduce costs," he added. "Time will tell."
Pam Bailey, president of AdvaMed, an association of more than 1,100 medical- device makers, agreed. When medical products take longer to get to market, she said patients suffer and costs go up. "It is most important that review times come down," Ms. Bailey went on to say.
The FDA plans to reduce time it takes to review original premarket-approval applications, which companies submit when they want a brand-new type of product on the market. In fiscal 2002, the agency received 48 such applications, down 23 from a year earlier.
In fiscal 2002, it took an average 364 days from the time the FDA received a premarket application to the time a decision was made. That was down from the prior year`s 411-day average.
The FDA plans to further reduce the time by one month for applications submitted from fiscal 2005 to 2007. The benchmark will be how long it took to review devices that made it through the process the quickest in fiscal 1999 to 2001.
To help cut review times, the FDA said it will work with outside experts to create clear guidelines to steer device companies in the right direction when developing and testing in new fields.
-By Otesa Middleton; Dow Jones Newswires; 202-862-6654; otesa.middleton@ dowjones.com
http://www.metabion.com/specials/news9968.html
New modification is available: 5`Hydrazide modified oligonucleotides
Nanogen Recognomics’ technology gives metabion and its customer the chance to make broad use of this functional modification by offering and using hydrazide modified oligonucleotides for solution conjugation and surface attachment applications!
Full substitute for amino modified oligonucleotides!
Highly efficient reaction with aldehydes or active esters to form covalent linkages even under acidic conditions (pH 4)!
Superior immobilization efficiency of oligonucleotides on substrate surfaces (DNA-Biochips)!
Only covalent attachment system compatible with electronic addressing!
Exciting new possibilities for oligonucleotide bioconjugation!
3 Standard-scales including HPLC purification and Maldi-ToF check! Prices see here...
For technical information about hydrazide modified oligonucleotides, please check the techinfo and our FAQs.
New modification is available: 5`Hydrazide modified oligonucleotides
Nanogen Recognomics’ technology gives metabion and its customer the chance to make broad use of this functional modification by offering and using hydrazide modified oligonucleotides for solution conjugation and surface attachment applications!
Full substitute for amino modified oligonucleotides!
Highly efficient reaction with aldehydes or active esters to form covalent linkages even under acidic conditions (pH 4)!
Superior immobilization efficiency of oligonucleotides on substrate surfaces (DNA-Biochips)!
Only covalent attachment system compatible with electronic addressing!
Exciting new possibilities for oligonucleotide bioconjugation!
3 Standard-scales including HPLC purification and Maldi-ToF check! Prices see here...
For technical information about hydrazide modified oligonucleotides, please check the techinfo and our FAQs.
Hallo zusammen,
um ganz ehrlich zu sein, falls Ihr zur Zeit im Plus seid bei NGEN, würde ich zur Zeit Gewinne realisieren und unter 2$ wieder einsteigen.
Allen ein schönes Wochenende!
tst
um ganz ehrlich zu sein, falls Ihr zur Zeit im Plus seid bei NGEN, würde ich zur Zeit Gewinne realisieren und unter 2$ wieder einsteigen.
Allen ein schönes Wochenende!
tst
August 14, 2003
NANOGEN INC (NGEN)
Quarterly Report (SEC form 10-Q)
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This report includes forward-looking statements about our business and results of operations that are subject to risks and uncertainties that could cause our actual results to vary materially from those reflected in the forward-looking statements. These risks and uncertainties include possible delays in the introduction of new products, customer acceptance of existing products, price competition, the actions of competitors, infringement of intellectual property rights and licenses of the Company or others, the effects of government regulation, both foreign and domestic, availability of funded research and government contracts and grants, preservation of productive relationships with our manufacturer and collaborator Hitachi and our distributors, ability to manage our capital resources and other factors. Words such as “believes,” “anticipates,” “plans,” “estimates,” “future,” “could,” “may,” “should,” “expect,” “envision,” “potentially,” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements contained in this Form 10-Q may include, but are not limited to, statements about matters including the following: (i) the development of the markets and demand for our products and services; (ii) our product development plans and anticipated activities designed to pursue these plans, including collaborations and other corporate partnering arrangements; (iii) our ability to derive substantial revenues from sales of products and consumable cartridges and reagents and continuing revenues from reagent rental agreements; (iv) the ability of our product platform to affect the market and become an industry standard; (v) our ability to generate license and other fee revenue in the future; (vi) the amounts we invest in research and development activities in the future; (vii) future levels of selling, general and administrative expenses and other expenses associated with our business, including the related impact on these expenses as the result of our April 2003 restructuring; (viii) future levels of interest income; (ix) any amounts we may be able to realize from the liquidation of our investments, including our investments in short-term securities; (x) operating results of joint ventures and other corporate partnering arrangements; (xi) the amounts and timing of our contractual obligations and capital commitments and (xii) our future capital needs and our ability to fund those needs. Factors that could cause or contribute to these differences include those discussed below under the caption “Factors that May Affect Results” and elsewhere in this Quarterly Report on Form 10-Q and which are described in our Annual Report on Form 10-K for the year ended December 31, 2002. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We disclaim any intent or obligation to update these forward-looking statements.
Overview
It is our goal to become a leading provider of molecular diagnostic tests and services. We integrate advanced microelectronics and molecular biology into a core technology platform with potentially broad and diverse commercial applications. Our primary areas of focus have been in genomics and biomedical research, medical diagnostics, biodefense, forensics and drug discovery. The Company’s current commercially available products include (1) the NanoChip® Molecular Biology Workstation, an automated, multi-purpose instrument primarily used for DNA-based analyses, (2) the NanoChip® Cartridge, which incorporates the NanoChip® Electronic Microarray and provides a flexible tool for the rapid identification and precise analysis of biological test samples containing charged molecules, (3) various Analyte Specific Reagents (“ASRs”) for detecting gene mutations associated with diseases such as cystic fibrosis, Alzheimer’s disease and hereditary hemochromotosis and (4) Assay Toolbox™, a product designed to help customers develop their own assays on the NanoChip® System. The Company also has several other ASRs and applications of its proprietary technology under development including new instrumentation products. The Company provides technical support and field applications assistance to its customers.
Since commencing operations in 1993, we have applied substantially all of our resources to our research and development programs. We have incurred losses since inception and, as of June 30, 2003, had an accumulated deficit of $163.2 million. We expect to continue to incur significant losses over at least the next few years as we attempt to further commercialize our products as well as expand the menu of applications for our current products.
Table of Contents
We introduced our first two products into the marketplace in 2000. While we recognized revenue from product sales during the six months ended June 30, 2003 and the years ended December 31, 2002, 2001 and 2000, significant revenues during these periods were earned under our sponsored research agreements, contracts and grants and, in 2002, a license fee valued at $10.8 million received from a litigation settlement with CombiMatrix Corp. We believe that in future periods, however, our revenue base will shift to being more product driven as our research collaboration agreement with Hitachi is expected to be terminated and new products are introduced by us to the marketplace. We believe our future operating results may be subject to quarterly fluctuations due to a variety of factors, including, but not limited to; market acceptance of the NanoChip®System; other products currently being sold by the Company and potential products under development; the type of acquisition program our potential customers may choose; whether and when new products are successfully developed and introduced by us or our competitors; the achievement of milestones under our collaborative agreements with Hitachi and various government agencies; and whether Hitachi exercises its right to terminate the collaborative research agreement. The recognition of revenue under contracts, grants and sponsored research agreements will be subject to significant fluctuations in both timing and amount and therefore our results of operations for any period may not be comparable to the results of operations for any other period.
Critical Accounting Policies and Estimates
This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates and judgments, including those related to bad debts, inventories, investments, intangible assets, service obligations and contingencies. We base our estimates and judgments on historical experience and on various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
We believe the following critical accounting policies, among others, affect our more significant judgments and estimates used in the preparation of our consolidated financial statements:
Revenue recognition
We generate product revenue by the sale of our commercial products and services under various sales programs to the end user or through distribution channels. We recognize revenue in accordance with Staff Accounting Bulletin 101 “Revenue Recognition in Financial Statements” and record revenues as follows:
We offer our NanoChip® Molecular Biology Workstations under various commercial programs such as direct sales, lease arrangements, reagent rental programs and cost-per-test agreements. We also offer our Workstations to customers under development site programs that may result in one of the above commercial transactions. We sell our Workstations direct to the end user and to distributors. Revenue from the sale of consumables is recognized upon shipment and the transfer of title (f.o.b. shipping point), as we do not sell consumables with a right of return.
Revenue from the direct sale of NanoChip® Molecular Biology Workstations is recognized following receipt of a purchase order, shipment (f.o.b. shipping point) of product, and transfer of title when sold directly to the end user or to a distributor. In transactions where a right-of-return exists, revenue is deferred until acceptance has occurred and the period for the right-of-return has lapsed. The NanoChip® Molecular Biology Workstation is sold with a one-year warranty contract. The fair value of the warranty is recorded as deferred revenue and recognized ratably over the warranty period included in the customer contract. The fair value of the warranty is based on the renewal price paid by the same customer. This renewal price for the maintenance contract is consistent for all customers. We provide for the estimated cost of product warranty at the time revenue is recognized.
We also recognize revenue from the sale of our NanoChip® System under reagent rental and cost-per-test transactions whereby customers pay a premium for our consumable products (NanoChip® Cartridges or ASRs) over a number of years that is intended to cover the sales price of the NanoChip® Workstation, consumables and warranty. Under a reagent rental transaction, the customer commits to purchasing a fixed minimum number of
Table of Contents
consumable products on a periodic basis for a specified period of time (i.e. a certain number of cartridges for a certain number of years). Generally, these transactions require the customer to validate a test that they have developed utilizing our instrument and reagents. Recognition of revenue begins after the customer has completed validation. Revenue for the Workstation, consumables and warranty under reagent rental transactions is then recognized as consumable products are shipped, over a period of generally two to five years, depending on the specific customer arrangement as they may vary by customer. We reclassify the recorded value of the Workstation from inventory to fixed assets, recognizing the depreciation expense as cost of sales ratably over the period of the arrangement. Under a cost-per-test transaction, the customer agrees to purchase a certain number of consumable products on a periodic basis determined by the customer’s volume of reported test results (to third parties) from the use of our consumable products. We recognize revenue under this type of transaction at the time we receive evidence of the customer’s test results reported to third parties. Under these arrangements, we provide product warranty coverage for the Workstation over the period of the contract. Under both of these commercial transactions, the fair value of the warranty is recognized ratably over the warranty period included in the customer contract. The cost of sales related to the consumables is recorded in line with the revenue (i.e. as consumables are shipped or consumed, depending on the terms of the contract).
We also place our NanoChip® Molecular Biology Workstations at customer sites under programs, such as development site arrangements, where title of the NanoChip® Workstation does not transfer to the customer. No revenues are recognized at the time of placement under these agreements. These arrangements are for a period normally between six and twelve months for the purpose of developing content and optimizing assays that may result in the creation or enhancement of intellectual property that we may license in the future. In addition, a primary intent of the program is for the customer to purchase the NanoChip® Workstation during the period of the arrangement or at its expiration. We provide a warranty for these NanoChip® Workstations as well as insure them during the development site period. Warranty expense is recorded ratably over the period of the arrangement within selling, general, and administrative (SG&A) expenses. Development site customers are normally required to purchase any consumables to be used on the instrument from us during the development site period. We classify this inventory as consignment inventory and include this within finished goods. We record a reserve for the refurbishment costs, recorded within SG&A, for each unit included in consignment inventory for the purpose of resale in the event the unit is returned under this arrangement. This reserve totaled approximately $409,000 and $489,000 at June 30, 2003 and December 31, 2002, respectively, and is included in accrued liabilities. In addition, we have recorded a reserve related to the older production units that may be deemed obsolete or sold to the customer at a discount due to the age of the unit during the development site period. Transactions under these types of programs do not result in the recognition of revenue. However, if the customer opts to purchase the NanoChip® Workstation at any time, sales revenue is recognized upon receipt of a purchase order. Cost of sales for the Workstation is provided for at the time revenue is recognized. For the three and six months ended June 30, 2003, we converted two development site agreements to sales.
Workstations sold to distributors are sold outright with title transferring at point of shipment (i.e., f.o.b. shipping point) without a right of return. Workstations are sold at a discount to the standard sales price (but not below the cost of manufacturing the instrument) and without warranty coverage.
Sales revenue is subject to fluctuation due to the type of acquisition program our customers may choose. Sponsored research and contract and grant revenue are generally recorded as the costs and expenses to perform the research are incurred. Under certain arrangements revenue is recorded ratably over the term of the arrangement as funding is provided for contractually on a scheduled basis. Payments received in advance under these arrangements are recorded as deferred revenue until the expenses are incurred. Continuation of certain sponsored research and contracts and grants are dependent upon our achieving specific contractual milestones.
License fees include nonrefundable fees generated from the licensing of the Company’s technology. Revenue is recognized immediately when the Company has no further obligation to perform and collections are reasonably assured.
Bad debts
We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We record additions to our reserve based on specific analysis of each customer’s
Table of Contents
balance due us. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances would be required.
Inventory
We reduce the carrying value of our inventory, including NanoChip® Molecular Biology Workstations placed under development site arrangements, for estimated obsolescence or non-marketability after considering future purchase commitments, the potential impact of next generation instruments, and based upon assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than those projected by us, additional inventory write-downs may be required.
Intangible Assets
We have intangible assets related to acquired technology rights. The determination of related estimated useful lives and whether or not these assets are impaired involves significant judgments. Changes in strategy and/or market conditions could significantly impact these judgments and require adjustments to recorded asset balances.
Results of Operations
Revenues
Product Revenues. For the three and six months ended June 30, 2003, sales totaled $662,000 and $890,000, respectively, compared to $1.1 million and $1.9 million for the three and six months ended June 30, 2002, respectively. Product sales revenue during the three and six months ended June 30, 2003 included the sale of four and four and one half (a partial unit) NanoChip® Molecular Biology Workstations, respectively as well as sales of NanoChip® Cartridges, reagents and warranty revenue. The increased number of units sold during the second quarter of 2003 as compared to the first quarter of 2003 is the result of clinical laboratory customers beginning to evaluate and purchase the Company’s products subsequent to our launch of six new products during the first quarter that are targeted at the clinical reference laboratory customer. Sales revenue during the three months ended June 30, 2002 included the sale of eight NanoChip® Molecular Biology Workstations as well as sales of NanoChip® Cartridges. Sales revenue for the six months ended June 30, 2002 included the sale of thirteen NanoChip® Molecular Biology Workstations, royalty revenue earned in connection with two NanoChip® Workstations which were sold in Japan by our distributor, Hitachi, Ltd. and sales of NanoChip® Cartridges. The sale of instruments was the major source of product revenue in both of these periods. All revenue recorded related to sales of our NanoChip® Molecular Biology Workstation resulted from outright sales transactions where title of the instrument passed to the customer. We offer our products to customers under several different types of acquisition programs, some of which pass title of the instrument to the customer and some of which do not pass title to the customer. Our sales revenue may vary from year to year due to, among other things, the types of acquisition programs our potential customers may choose.
Sponsored Research. For the three and six months ended June 30, 2003, revenues from sponsored research totaled $375,000 and $750,000, respectively, compared to $313,000 and $626,000 for the three and six months ended June 30, 2002, respectively. Revenues are primarily recorded under these arrangements as expenses are incurred. Payments received in advance under these arrangements are recorded as deferred revenue until the expenses are incurred. Sponsored research revenue recognized during the three and six months ended June 30, 2003 and 2002 represents revenue earned in connection with our development agreement entered into in July 2000 with Hitachi. We are currently on schedule with project milestones and expect sponsored research revenues from the collaboration to continue at their current level through the first quarter of 2004. During July 2003, the Company received a verbal indication from Hitachi that Hitachi intends to terminate the research collaboration agreement in accordance with the terms of that agreement. Funding by Hitachi under the collaboration agreement is expected to terminate nine months after the Company receives a written notice of termination from Hitachi.
Contracts and Grants. We fund some of our research and development efforts through contracts and grants awarded by various federal and state agencies. Revenues are recognized under these contracts and grants as expenses are incurred, and totaled $657,000 and $1.3 million, respectively, and $534,000 and $942,000, respectively, for the three and six months ended June 30, 2003 and 2002.
Table of Contents
Cost of Product Sales and Gross Margins. Cost of product sales totaled $524,000 and $798,000 for the three and six months ended June 30, 2003, respectively, compared to $836,000 and $1.4 million for the three and six months ended June 30, 2002, respectively. Gross margins on product sales revenue were 21% and 10% for the three and six months ended June 30, 2003, respectively, compared to 24% and 27% for the three and six months ended June 30, 2002, respectively. Cost of product sales during the three months ended June 30, 2003 were adversely impacted by lower sales volume, underabsorbed overhead costs due to underutilized capacity, and manufacturing scrap as a result of lower yields on new products released into production. As we are still in the early stages of commercialization, we expect to continue to incur significant costs associated with excess production capacity within our manufacturing facility in 2003. In addition to underabsorbed overhead costs, cost of product sales for the three and six months ended June 30, 2003 included a reserve for obsolete inventory totaling $0 and $33,000, respectively. This reserve relates primarily to excess instrument parts and accessory items in our inventory that could potentially become obsolete prior to their consumption. If necessary, these parts will be used as replacement parts for Nanogen Systems located both internally and at customer sites. The improved gross margin for the three months ended June 30, 2003 of 21% compared to March 31, 2003 of negative 20% was primarily attributed to increased sales volume and a change in product mix. Gross margins during the three and six months ended June 30, 2002 were further impacted by sales of NanoChip® Workstations to certain customers under various discount programs, with discounts totaling approximately $145,000, and by sales to distributors that are at a discount. Gross margins in future periods may be further impaired by minimum product royalties or potential adjustments made to reflect the impairment of intangible assets related to products sold. The sale of NanoChip® Workstations is directly related to the successful validation of assays developed and implemented by clinical laboratories based on our ASRs. Should the successful validation or rate of adoption by clinical laboratories vary from our estimates, gross margins could be impacted by additional reserves for obsolete and slow moving inventory.
Research and Development Expenses. For the three and six months ended June 30, 2003, research and development expenses totaled $4.5 million and $9.2 million, respectively, compared to $5.0 million and $9.9 million for the three and six months ended June 30, 2002, respectively. During these periods, research and development expenses included the cost of salaries and benefits for scientific, engineering and operations personnel, costs associated with improving and refining our current products as well as development of potential new products and protocols, lab supplies, consulting, travel, facilities, and other expenditures associated with our research and product development activities. For the three and six months ended June 30, 2003 research and development activities primarily related to the development of new ASRs and new instrumentation products. Based on restructuring that occurred in April 2003, we anticipate research and product development costs to decline from amounts experienced during the six months ended June 30, 2003.
Selling, General and Administrative Expenses. For the three and six months ended June 30, 2003, selling, general and administrative expenses totaled $4.1 million and $8.2 million, respectively, compared to $5.3 million and $9.9 million for the three and six months ended June 30, 2002, respectively. Selling, general and administrative expenses include salaries, benefits, consulting, travel and other expenditures related to executive, legal, finance, human resources, sales and marketing personnel. In addition, these expenses include costs related to enhancing and maintaining our intellectual property portfolio. The decline in selling, general, and administrative expense for the three and six months ended June 30, 2003 as compared to the same period during the prior year is primarily the result of decreased expenditures associated with the launch of products and other cost reduction measures taken during the year. Based on restructuring that occurred in April 2003, we anticipate that selling, general and administrative expenses to decline from amounts experienced during the six months ended June 30, 2003.
Litigation and Settlement of Patent Matter, Net. For the three and six months ended June 30, 2002, litigation and settlement of patent matter totaled $428,000 and $798,000, respectively. The costs incurred in 2002 related to a dispute with CombiMatrix and Dr. Montgomery. As a settlement between all parties was reached in September 2002, there were no expenses related to this matter in 2003.
Interest Income, Net. For the three and six months ended June 30, 2003, net interest income totaled $113,000 and $308,000, respectively, compared to $586,000 and $1.3 million, respectively, for the three and six months ended June 30, 2002. The decrease in net interest income is a result of lower average cash and investment balances as well as lower yields on outstanding cash and investment balances during the three and six months ended June 30, 2003 when compared to the three and six months ended June 30, 2002. Based on the continued consumption of cash and
Table of Contents
short-term investments to augment operating activities, we expect net interest income to continue to decline during the remainder of 2003.
Minority Interest in Loss of Consolidated Subsidiary. We had losses relating to our majority-owned subsidiary, Nanogen Recognomics GmbH, for the three and six months ended June 30, 2003, of $558,000 and $1.1 million, respectively, compared to $422,000 and $983,000 for the three and six months ended June 30, 2002, respectively. Since this subsidiary is primarily engaged in research and does not generate any significant revenue, we expect to experience continued losses with the majority-owned subsidiary similar to levels incurred during 2002. These losses are funded by the investment from minority interest investors and are therefore offset against the minority interest balance in the respective balance sheet.
Liquidity and Capital Resources
At June 30, 2003, we had $28.5 million in cash, cash equivalents and short-term investments, compared to $52.7 million at December 31, 2002. The decrease is primarily due to cash used in operations during the six months ended June 30, 2003 totaling $15.5 million and realized and unrealized losses in short-term investments of approximately $7.8 million related primarily to CombiMatrix securities. While the CombiMatrix securities are included within short-term investments, we expect significant market value fluctuations in this investment that had a market value of approximately $2.4 million at June 30, 2003.
Net cash used in operating activities was $15.5 million and $13.6 million for the six months ended June 30, 2003 and 2002, respectively. Cash used for operations during the six months ended June 30, 2003 was primarily related to costs associated with commercializing our products, including the expansion, development and support of our sales and marketing organization; the procurement of inventory pursuant to our manufacturing arrangement with Hitachi, Ltd; support of our continuing research and development efforts including development of the ASRs which may be used by customers to develop tests for the detection of mutations in the CFTR gene associated with cystic fibrosis, the ASRs for mutations in the HFE gene associated with the hereditary hemochromotosis, and the other ASRs and other products recently introduced by Nanogen; and legal fees relating to establishing, maintaining and defending our intellectual property portfolio.
Net cash provided by investing activities was $11.9 million and $14.2 million for the six months ended June 30, 2003 and 2002, respectively. We purchase short-term investments in order to enhance the yield on our cash balances. These securities mature from time to time or are sold to fund operating expenses.
We fund some of our equipment acquisitions and leasehold improvements through capital leasing facilities. As of June 30, 2003, we had approximately $242,000 of available funding under our equipment lease lines which expires September 2003. We are in the process of seeking new equipment lease financing. If we are unable to obtain such financing, we will need to fund new equipment purchases from our existing cash resources which will further reduce cash available for other operating activities.
Our manufacturing agreement for the Molecular Biology Workstation with Hitachi, Ltd. requires that we provide annual purchase commitments to Hitachi for NanoChip Molecular Biology Workstations. As of June 30, 2003, we had commitments to purchase approximately $1.4 million in NanoChip Workstations from Hitachi for shipments of product through August 31, 2003. At June 30, 2003, the inventory under our purchase commitment with Hitachi is within our expected usage levels based upon current and estimated future demands.
We are a party to development site agreements with various entities and to license agreements under which we acquired rights to pay license fees, annual minimum royalties or product royalties for any customer owned or licensed intellectual property used to develop any Nanogen commercial products. None of these agreements individually are considered material.
We are also party to transactions known as reagent rentals and cost-per-test agreements. Under these types of transactions, we place a workstation at a customer site with no upfront cost to the customer. The value of the instrument is typically recaptured through a contracted stream of future reagent sales, sold at a premium to cover the cost of the system. Many of our reagent rentals and cost-per-test agreements entered into to date require customer acceptance of our CFTR ASRs as a pre-condition to this commitment. These reagent rentals and cost-per-test agreements might have an adverse impact on our short-term instrument sales revenue and cash flow as the revenues
Table of Contents
and cash received under these agreements are over the life of the contract, which is typically three to five years, as reagents are shipped to the customer.
We expect that our existing capital resources, combined with anticipated revenues from potential product sales, reagent rentals, leases or other types of acquisition programs for the NanoChip System, sponsored research agreements, contracts and grants will be sufficient to support our planned operations for at least one year from the date of this filing based on our reduced rate of expenditures as a result of cost reduction measures implemented during April 2003. This estimate of the period for which we expect our available sources of liquidity to be sufficient to meet our capital requirements is a forward-looking statement that involves risks and uncertainties, and actual results may differ materially. Our future liquidity and capital funding requirements will depend on numerous factors including, but not limited to, commercial success of our products, or lack thereof, of our current products, the extent to which our products under development are successfully developed and gain market acceptance, the timing of regulatory actions regarding our potential products, the costs and timing of expansion of sales, marketing and manufacturing activities, prosecution and enforcement of patents important to our business and any litigation related thereto, the results of clinical trials, competitive developments, and our ability to maintain existing collaborations, whether Hitachi exercises its right to terminate the collaborative agreement, and our ability to enter into additional collaborative arrangements. We have incurred negative cash flow from operations since inception and do not expect to generate positive cash flow to fund our operations for at least the next several years. We may need to raise additional capital to fund our research and development programs, to scale-up manufacturing activities and expand our sales and marketing efforts to support the commercialization of our products under development. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, we may be required to curtail our operations significantly or to obtain funds through entering into collaborative agreements or other arrangements on unfavorable terms. Our failure to raise capital on acceptable terms when needed could have a material adverse effect on our business, financial condition or results of operations.
NANOGEN INC (NGEN)
Quarterly Report (SEC form 10-Q)
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
This report includes forward-looking statements about our business and results of operations that are subject to risks and uncertainties that could cause our actual results to vary materially from those reflected in the forward-looking statements. These risks and uncertainties include possible delays in the introduction of new products, customer acceptance of existing products, price competition, the actions of competitors, infringement of intellectual property rights and licenses of the Company or others, the effects of government regulation, both foreign and domestic, availability of funded research and government contracts and grants, preservation of productive relationships with our manufacturer and collaborator Hitachi and our distributors, ability to manage our capital resources and other factors. Words such as “believes,” “anticipates,” “plans,” “estimates,” “future,” “could,” “may,” “should,” “expect,” “envision,” “potentially,” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements contained in this Form 10-Q may include, but are not limited to, statements about matters including the following: (i) the development of the markets and demand for our products and services; (ii) our product development plans and anticipated activities designed to pursue these plans, including collaborations and other corporate partnering arrangements; (iii) our ability to derive substantial revenues from sales of products and consumable cartridges and reagents and continuing revenues from reagent rental agreements; (iv) the ability of our product platform to affect the market and become an industry standard; (v) our ability to generate license and other fee revenue in the future; (vi) the amounts we invest in research and development activities in the future; (vii) future levels of selling, general and administrative expenses and other expenses associated with our business, including the related impact on these expenses as the result of our April 2003 restructuring; (viii) future levels of interest income; (ix) any amounts we may be able to realize from the liquidation of our investments, including our investments in short-term securities; (x) operating results of joint ventures and other corporate partnering arrangements; (xi) the amounts and timing of our contractual obligations and capital commitments and (xii) our future capital needs and our ability to fund those needs. Factors that could cause or contribute to these differences include those discussed below under the caption “Factors that May Affect Results” and elsewhere in this Quarterly Report on Form 10-Q and which are described in our Annual Report on Form 10-K for the year ended December 31, 2002. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We disclaim any intent or obligation to update these forward-looking statements.
Overview
It is our goal to become a leading provider of molecular diagnostic tests and services. We integrate advanced microelectronics and molecular biology into a core technology platform with potentially broad and diverse commercial applications. Our primary areas of focus have been in genomics and biomedical research, medical diagnostics, biodefense, forensics and drug discovery. The Company’s current commercially available products include (1) the NanoChip® Molecular Biology Workstation, an automated, multi-purpose instrument primarily used for DNA-based analyses, (2) the NanoChip® Cartridge, which incorporates the NanoChip® Electronic Microarray and provides a flexible tool for the rapid identification and precise analysis of biological test samples containing charged molecules, (3) various Analyte Specific Reagents (“ASRs”) for detecting gene mutations associated with diseases such as cystic fibrosis, Alzheimer’s disease and hereditary hemochromotosis and (4) Assay Toolbox™, a product designed to help customers develop their own assays on the NanoChip® System. The Company also has several other ASRs and applications of its proprietary technology under development including new instrumentation products. The Company provides technical support and field applications assistance to its customers.
Since commencing operations in 1993, we have applied substantially all of our resources to our research and development programs. We have incurred losses since inception and, as of June 30, 2003, had an accumulated deficit of $163.2 million. We expect to continue to incur significant losses over at least the next few years as we attempt to further commercialize our products as well as expand the menu of applications for our current products.
Table of Contents
We introduced our first two products into the marketplace in 2000. While we recognized revenue from product sales during the six months ended June 30, 2003 and the years ended December 31, 2002, 2001 and 2000, significant revenues during these periods were earned under our sponsored research agreements, contracts and grants and, in 2002, a license fee valued at $10.8 million received from a litigation settlement with CombiMatrix Corp. We believe that in future periods, however, our revenue base will shift to being more product driven as our research collaboration agreement with Hitachi is expected to be terminated and new products are introduced by us to the marketplace. We believe our future operating results may be subject to quarterly fluctuations due to a variety of factors, including, but not limited to; market acceptance of the NanoChip®System; other products currently being sold by the Company and potential products under development; the type of acquisition program our potential customers may choose; whether and when new products are successfully developed and introduced by us or our competitors; the achievement of milestones under our collaborative agreements with Hitachi and various government agencies; and whether Hitachi exercises its right to terminate the collaborative research agreement. The recognition of revenue under contracts, grants and sponsored research agreements will be subject to significant fluctuations in both timing and amount and therefore our results of operations for any period may not be comparable to the results of operations for any other period.
Critical Accounting Policies and Estimates
This Management’s Discussion and Analysis of Financial Condition and Results of Operations discusses our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an on-going basis, we evaluate our estimates and judgments, including those related to bad debts, inventories, investments, intangible assets, service obligations and contingencies. We base our estimates and judgments on historical experience and on various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions.
We believe the following critical accounting policies, among others, affect our more significant judgments and estimates used in the preparation of our consolidated financial statements:
Revenue recognition
We generate product revenue by the sale of our commercial products and services under various sales programs to the end user or through distribution channels. We recognize revenue in accordance with Staff Accounting Bulletin 101 “Revenue Recognition in Financial Statements” and record revenues as follows:
We offer our NanoChip® Molecular Biology Workstations under various commercial programs such as direct sales, lease arrangements, reagent rental programs and cost-per-test agreements. We also offer our Workstations to customers under development site programs that may result in one of the above commercial transactions. We sell our Workstations direct to the end user and to distributors. Revenue from the sale of consumables is recognized upon shipment and the transfer of title (f.o.b. shipping point), as we do not sell consumables with a right of return.
Revenue from the direct sale of NanoChip® Molecular Biology Workstations is recognized following receipt of a purchase order, shipment (f.o.b. shipping point) of product, and transfer of title when sold directly to the end user or to a distributor. In transactions where a right-of-return exists, revenue is deferred until acceptance has occurred and the period for the right-of-return has lapsed. The NanoChip® Molecular Biology Workstation is sold with a one-year warranty contract. The fair value of the warranty is recorded as deferred revenue and recognized ratably over the warranty period included in the customer contract. The fair value of the warranty is based on the renewal price paid by the same customer. This renewal price for the maintenance contract is consistent for all customers. We provide for the estimated cost of product warranty at the time revenue is recognized.
We also recognize revenue from the sale of our NanoChip® System under reagent rental and cost-per-test transactions whereby customers pay a premium for our consumable products (NanoChip® Cartridges or ASRs) over a number of years that is intended to cover the sales price of the NanoChip® Workstation, consumables and warranty. Under a reagent rental transaction, the customer commits to purchasing a fixed minimum number of
Table of Contents
consumable products on a periodic basis for a specified period of time (i.e. a certain number of cartridges for a certain number of years). Generally, these transactions require the customer to validate a test that they have developed utilizing our instrument and reagents. Recognition of revenue begins after the customer has completed validation. Revenue for the Workstation, consumables and warranty under reagent rental transactions is then recognized as consumable products are shipped, over a period of generally two to five years, depending on the specific customer arrangement as they may vary by customer. We reclassify the recorded value of the Workstation from inventory to fixed assets, recognizing the depreciation expense as cost of sales ratably over the period of the arrangement. Under a cost-per-test transaction, the customer agrees to purchase a certain number of consumable products on a periodic basis determined by the customer’s volume of reported test results (to third parties) from the use of our consumable products. We recognize revenue under this type of transaction at the time we receive evidence of the customer’s test results reported to third parties. Under these arrangements, we provide product warranty coverage for the Workstation over the period of the contract. Under both of these commercial transactions, the fair value of the warranty is recognized ratably over the warranty period included in the customer contract. The cost of sales related to the consumables is recorded in line with the revenue (i.e. as consumables are shipped or consumed, depending on the terms of the contract).
We also place our NanoChip® Molecular Biology Workstations at customer sites under programs, such as development site arrangements, where title of the NanoChip® Workstation does not transfer to the customer. No revenues are recognized at the time of placement under these agreements. These arrangements are for a period normally between six and twelve months for the purpose of developing content and optimizing assays that may result in the creation or enhancement of intellectual property that we may license in the future. In addition, a primary intent of the program is for the customer to purchase the NanoChip® Workstation during the period of the arrangement or at its expiration. We provide a warranty for these NanoChip® Workstations as well as insure them during the development site period. Warranty expense is recorded ratably over the period of the arrangement within selling, general, and administrative (SG&A) expenses. Development site customers are normally required to purchase any consumables to be used on the instrument from us during the development site period. We classify this inventory as consignment inventory and include this within finished goods. We record a reserve for the refurbishment costs, recorded within SG&A, for each unit included in consignment inventory for the purpose of resale in the event the unit is returned under this arrangement. This reserve totaled approximately $409,000 and $489,000 at June 30, 2003 and December 31, 2002, respectively, and is included in accrued liabilities. In addition, we have recorded a reserve related to the older production units that may be deemed obsolete or sold to the customer at a discount due to the age of the unit during the development site period. Transactions under these types of programs do not result in the recognition of revenue. However, if the customer opts to purchase the NanoChip® Workstation at any time, sales revenue is recognized upon receipt of a purchase order. Cost of sales for the Workstation is provided for at the time revenue is recognized. For the three and six months ended June 30, 2003, we converted two development site agreements to sales.
Workstations sold to distributors are sold outright with title transferring at point of shipment (i.e., f.o.b. shipping point) without a right of return. Workstations are sold at a discount to the standard sales price (but not below the cost of manufacturing the instrument) and without warranty coverage.
Sales revenue is subject to fluctuation due to the type of acquisition program our customers may choose. Sponsored research and contract and grant revenue are generally recorded as the costs and expenses to perform the research are incurred. Under certain arrangements revenue is recorded ratably over the term of the arrangement as funding is provided for contractually on a scheduled basis. Payments received in advance under these arrangements are recorded as deferred revenue until the expenses are incurred. Continuation of certain sponsored research and contracts and grants are dependent upon our achieving specific contractual milestones.
License fees include nonrefundable fees generated from the licensing of the Company’s technology. Revenue is recognized immediately when the Company has no further obligation to perform and collections are reasonably assured.
Bad debts
We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We record additions to our reserve based on specific analysis of each customer’s
Table of Contents
balance due us. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances would be required.
Inventory
We reduce the carrying value of our inventory, including NanoChip® Molecular Biology Workstations placed under development site arrangements, for estimated obsolescence or non-marketability after considering future purchase commitments, the potential impact of next generation instruments, and based upon assumptions about future demand and market conditions. If actual future demand or market conditions are less favorable than those projected by us, additional inventory write-downs may be required.
Intangible Assets
We have intangible assets related to acquired technology rights. The determination of related estimated useful lives and whether or not these assets are impaired involves significant judgments. Changes in strategy and/or market conditions could significantly impact these judgments and require adjustments to recorded asset balances.
Results of Operations
Revenues
Product Revenues. For the three and six months ended June 30, 2003, sales totaled $662,000 and $890,000, respectively, compared to $1.1 million and $1.9 million for the three and six months ended June 30, 2002, respectively. Product sales revenue during the three and six months ended June 30, 2003 included the sale of four and four and one half (a partial unit) NanoChip® Molecular Biology Workstations, respectively as well as sales of NanoChip® Cartridges, reagents and warranty revenue. The increased number of units sold during the second quarter of 2003 as compared to the first quarter of 2003 is the result of clinical laboratory customers beginning to evaluate and purchase the Company’s products subsequent to our launch of six new products during the first quarter that are targeted at the clinical reference laboratory customer. Sales revenue during the three months ended June 30, 2002 included the sale of eight NanoChip® Molecular Biology Workstations as well as sales of NanoChip® Cartridges. Sales revenue for the six months ended June 30, 2002 included the sale of thirteen NanoChip® Molecular Biology Workstations, royalty revenue earned in connection with two NanoChip® Workstations which were sold in Japan by our distributor, Hitachi, Ltd. and sales of NanoChip® Cartridges. The sale of instruments was the major source of product revenue in both of these periods. All revenue recorded related to sales of our NanoChip® Molecular Biology Workstation resulted from outright sales transactions where title of the instrument passed to the customer. We offer our products to customers under several different types of acquisition programs, some of which pass title of the instrument to the customer and some of which do not pass title to the customer. Our sales revenue may vary from year to year due to, among other things, the types of acquisition programs our potential customers may choose.
Sponsored Research. For the three and six months ended June 30, 2003, revenues from sponsored research totaled $375,000 and $750,000, respectively, compared to $313,000 and $626,000 for the three and six months ended June 30, 2002, respectively. Revenues are primarily recorded under these arrangements as expenses are incurred. Payments received in advance under these arrangements are recorded as deferred revenue until the expenses are incurred. Sponsored research revenue recognized during the three and six months ended June 30, 2003 and 2002 represents revenue earned in connection with our development agreement entered into in July 2000 with Hitachi. We are currently on schedule with project milestones and expect sponsored research revenues from the collaboration to continue at their current level through the first quarter of 2004. During July 2003, the Company received a verbal indication from Hitachi that Hitachi intends to terminate the research collaboration agreement in accordance with the terms of that agreement. Funding by Hitachi under the collaboration agreement is expected to terminate nine months after the Company receives a written notice of termination from Hitachi.
Contracts and Grants. We fund some of our research and development efforts through contracts and grants awarded by various federal and state agencies. Revenues are recognized under these contracts and grants as expenses are incurred, and totaled $657,000 and $1.3 million, respectively, and $534,000 and $942,000, respectively, for the three and six months ended June 30, 2003 and 2002.
Table of Contents
Cost of Product Sales and Gross Margins. Cost of product sales totaled $524,000 and $798,000 for the three and six months ended June 30, 2003, respectively, compared to $836,000 and $1.4 million for the three and six months ended June 30, 2002, respectively. Gross margins on product sales revenue were 21% and 10% for the three and six months ended June 30, 2003, respectively, compared to 24% and 27% for the three and six months ended June 30, 2002, respectively. Cost of product sales during the three months ended June 30, 2003 were adversely impacted by lower sales volume, underabsorbed overhead costs due to underutilized capacity, and manufacturing scrap as a result of lower yields on new products released into production. As we are still in the early stages of commercialization, we expect to continue to incur significant costs associated with excess production capacity within our manufacturing facility in 2003. In addition to underabsorbed overhead costs, cost of product sales for the three and six months ended June 30, 2003 included a reserve for obsolete inventory totaling $0 and $33,000, respectively. This reserve relates primarily to excess instrument parts and accessory items in our inventory that could potentially become obsolete prior to their consumption. If necessary, these parts will be used as replacement parts for Nanogen Systems located both internally and at customer sites. The improved gross margin for the three months ended June 30, 2003 of 21% compared to March 31, 2003 of negative 20% was primarily attributed to increased sales volume and a change in product mix. Gross margins during the three and six months ended June 30, 2002 were further impacted by sales of NanoChip® Workstations to certain customers under various discount programs, with discounts totaling approximately $145,000, and by sales to distributors that are at a discount. Gross margins in future periods may be further impaired by minimum product royalties or potential adjustments made to reflect the impairment of intangible assets related to products sold. The sale of NanoChip® Workstations is directly related to the successful validation of assays developed and implemented by clinical laboratories based on our ASRs. Should the successful validation or rate of adoption by clinical laboratories vary from our estimates, gross margins could be impacted by additional reserves for obsolete and slow moving inventory.
Research and Development Expenses. For the three and six months ended June 30, 2003, research and development expenses totaled $4.5 million and $9.2 million, respectively, compared to $5.0 million and $9.9 million for the three and six months ended June 30, 2002, respectively. During these periods, research and development expenses included the cost of salaries and benefits for scientific, engineering and operations personnel, costs associated with improving and refining our current products as well as development of potential new products and protocols, lab supplies, consulting, travel, facilities, and other expenditures associated with our research and product development activities. For the three and six months ended June 30, 2003 research and development activities primarily related to the development of new ASRs and new instrumentation products. Based on restructuring that occurred in April 2003, we anticipate research and product development costs to decline from amounts experienced during the six months ended June 30, 2003.
Selling, General and Administrative Expenses. For the three and six months ended June 30, 2003, selling, general and administrative expenses totaled $4.1 million and $8.2 million, respectively, compared to $5.3 million and $9.9 million for the three and six months ended June 30, 2002, respectively. Selling, general and administrative expenses include salaries, benefits, consulting, travel and other expenditures related to executive, legal, finance, human resources, sales and marketing personnel. In addition, these expenses include costs related to enhancing and maintaining our intellectual property portfolio. The decline in selling, general, and administrative expense for the three and six months ended June 30, 2003 as compared to the same period during the prior year is primarily the result of decreased expenditures associated with the launch of products and other cost reduction measures taken during the year. Based on restructuring that occurred in April 2003, we anticipate that selling, general and administrative expenses to decline from amounts experienced during the six months ended June 30, 2003.
Litigation and Settlement of Patent Matter, Net. For the three and six months ended June 30, 2002, litigation and settlement of patent matter totaled $428,000 and $798,000, respectively. The costs incurred in 2002 related to a dispute with CombiMatrix and Dr. Montgomery. As a settlement between all parties was reached in September 2002, there were no expenses related to this matter in 2003.
Interest Income, Net. For the three and six months ended June 30, 2003, net interest income totaled $113,000 and $308,000, respectively, compared to $586,000 and $1.3 million, respectively, for the three and six months ended June 30, 2002. The decrease in net interest income is a result of lower average cash and investment balances as well as lower yields on outstanding cash and investment balances during the three and six months ended June 30, 2003 when compared to the three and six months ended June 30, 2002. Based on the continued consumption of cash and
Table of Contents
short-term investments to augment operating activities, we expect net interest income to continue to decline during the remainder of 2003.
Minority Interest in Loss of Consolidated Subsidiary. We had losses relating to our majority-owned subsidiary, Nanogen Recognomics GmbH, for the three and six months ended June 30, 2003, of $558,000 and $1.1 million, respectively, compared to $422,000 and $983,000 for the three and six months ended June 30, 2002, respectively. Since this subsidiary is primarily engaged in research and does not generate any significant revenue, we expect to experience continued losses with the majority-owned subsidiary similar to levels incurred during 2002. These losses are funded by the investment from minority interest investors and are therefore offset against the minority interest balance in the respective balance sheet.
Liquidity and Capital Resources
At June 30, 2003, we had $28.5 million in cash, cash equivalents and short-term investments, compared to $52.7 million at December 31, 2002. The decrease is primarily due to cash used in operations during the six months ended June 30, 2003 totaling $15.5 million and realized and unrealized losses in short-term investments of approximately $7.8 million related primarily to CombiMatrix securities. While the CombiMatrix securities are included within short-term investments, we expect significant market value fluctuations in this investment that had a market value of approximately $2.4 million at June 30, 2003.
Net cash used in operating activities was $15.5 million and $13.6 million for the six months ended June 30, 2003 and 2002, respectively. Cash used for operations during the six months ended June 30, 2003 was primarily related to costs associated with commercializing our products, including the expansion, development and support of our sales and marketing organization; the procurement of inventory pursuant to our manufacturing arrangement with Hitachi, Ltd; support of our continuing research and development efforts including development of the ASRs which may be used by customers to develop tests for the detection of mutations in the CFTR gene associated with cystic fibrosis, the ASRs for mutations in the HFE gene associated with the hereditary hemochromotosis, and the other ASRs and other products recently introduced by Nanogen; and legal fees relating to establishing, maintaining and defending our intellectual property portfolio.
Net cash provided by investing activities was $11.9 million and $14.2 million for the six months ended June 30, 2003 and 2002, respectively. We purchase short-term investments in order to enhance the yield on our cash balances. These securities mature from time to time or are sold to fund operating expenses.
We fund some of our equipment acquisitions and leasehold improvements through capital leasing facilities. As of June 30, 2003, we had approximately $242,000 of available funding under our equipment lease lines which expires September 2003. We are in the process of seeking new equipment lease financing. If we are unable to obtain such financing, we will need to fund new equipment purchases from our existing cash resources which will further reduce cash available for other operating activities.
Our manufacturing agreement for the Molecular Biology Workstation with Hitachi, Ltd. requires that we provide annual purchase commitments to Hitachi for NanoChip Molecular Biology Workstations. As of June 30, 2003, we had commitments to purchase approximately $1.4 million in NanoChip Workstations from Hitachi for shipments of product through August 31, 2003. At June 30, 2003, the inventory under our purchase commitment with Hitachi is within our expected usage levels based upon current and estimated future demands.
We are a party to development site agreements with various entities and to license agreements under which we acquired rights to pay license fees, annual minimum royalties or product royalties for any customer owned or licensed intellectual property used to develop any Nanogen commercial products. None of these agreements individually are considered material.
We are also party to transactions known as reagent rentals and cost-per-test agreements. Under these types of transactions, we place a workstation at a customer site with no upfront cost to the customer. The value of the instrument is typically recaptured through a contracted stream of future reagent sales, sold at a premium to cover the cost of the system. Many of our reagent rentals and cost-per-test agreements entered into to date require customer acceptance of our CFTR ASRs as a pre-condition to this commitment. These reagent rentals and cost-per-test agreements might have an adverse impact on our short-term instrument sales revenue and cash flow as the revenues
Table of Contents
and cash received under these agreements are over the life of the contract, which is typically three to five years, as reagents are shipped to the customer.
We expect that our existing capital resources, combined with anticipated revenues from potential product sales, reagent rentals, leases or other types of acquisition programs for the NanoChip System, sponsored research agreements, contracts and grants will be sufficient to support our planned operations for at least one year from the date of this filing based on our reduced rate of expenditures as a result of cost reduction measures implemented during April 2003. This estimate of the period for which we expect our available sources of liquidity to be sufficient to meet our capital requirements is a forward-looking statement that involves risks and uncertainties, and actual results may differ materially. Our future liquidity and capital funding requirements will depend on numerous factors including, but not limited to, commercial success of our products, or lack thereof, of our current products, the extent to which our products under development are successfully developed and gain market acceptance, the timing of regulatory actions regarding our potential products, the costs and timing of expansion of sales, marketing and manufacturing activities, prosecution and enforcement of patents important to our business and any litigation related thereto, the results of clinical trials, competitive developments, and our ability to maintain existing collaborations, whether Hitachi exercises its right to terminate the collaborative agreement, and our ability to enter into additional collaborative arrangements. We have incurred negative cash flow from operations since inception and do not expect to generate positive cash flow to fund our operations for at least the next several years. We may need to raise additional capital to fund our research and development programs, to scale-up manufacturing activities and expand our sales and marketing efforts to support the commercialization of our products under development. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, we may be required to curtail our operations significantly or to obtain funds through entering into collaborative agreements or other arrangements on unfavorable terms. Our failure to raise capital on acceptable terms when needed could have a material adverse effect on our business, financial condition or results of operations.
@tst89 - bist du dir noch sicher, dass NGEN unter die 2.0 fällt? scheint sich nach knapp 1$ rückschlag wieder gefangen zu haben..vielleicht pendeln wir uns für die nächste zeit so um die 3$ ein..
nachrichten wären nicht schlecht....
gruss,mamers
nachrichten wären nicht schlecht....
gruss,mamers
@mamers
Sicher? Nein - nie. Aber irgendwie hatte ich damals das Gefühl und ich muß sagen ich bin momentan auch noch nicht sehr viel positiver gestimmt. Es fehlen einfach die News. Das Management sollte man mal die Ohren lang ziehen. Von PR haben die keine Ahnung.
Viele Grüße
tst
Sicher? Nein - nie. Aber irgendwie hatte ich damals das Gefühl und ich muß sagen ich bin momentan auch noch nicht sehr viel positiver gestimmt. Es fehlen einfach die News. Das Management sollte man mal die Ohren lang ziehen. Von PR haben die keine Ahnung.
Viele Grüße
tst
Hier muß ich Euch noch ein neues Patent nachliefern:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=… html%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=nanogen.AS.&OS=AN/n anogen&RS=AN/nanogen
Dr. Evans ist einer der Mitgründer von NGEN....
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=… html%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PG01&s1=nanogen.AS.&OS=AN/n anogen&RS=AN/nanogen
Dr. Evans ist einer der Mitgründer von NGEN....
bzw. natürlich noch kein Patent sondern eine Antragsstellung auf ein Patent...
Naja, der Kursverlauf heute ist ja gar nicht schlecht.
Mal sehen wie es weitergeht...
Mal sehen wie es weitergeht...
Hallo @ all
Man was geht denn auf einmal bei Nanogen ab? Da weiß wohl mal wieder jemand etwas mehr als wir..anders kann ich mir den Kursverlauf heute nicht erklären.
Man was geht denn auf einmal bei Nanogen ab? Da weiß wohl mal wieder jemand etwas mehr als wir..anders kann ich mir den Kursverlauf heute nicht erklären.
netter sprung heute...20% an der nasdaq...bin leider niht mehr drin (hatte bei 3.3 euro verkauft). würd mich schon interessieren warum die aktie jetzt schießt...die zahlen sind ja eher nicht gut...profitiert die firma vom namen, der ein bischen an nanotechnologien erinnert? (obwohl sie eigentlich nix damit zutun hat...).
wie auch immer. sie steigt.
wie auch immer. sie steigt.
Nanogen and Prodesse to Develop Infectious Disease Diagnostics
SAN DIEGO and MILWAUKEE, Sep 10, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) and Prodesse, Inc. announced today the signing of a collaboration agreement to develop automated, highly sensitive microarray- based products to detect a number of infectious disease agents, including influenza, pneumonia, adenovirus, herpes, West Nile Virus, and SARS. The Companies will integrate Prodesse`s proprietary multiplex amplification technology with the automated NanoChip(R) platform and jointly develop and market gene-based testing products to health care providers and clinical reference labs. Financial terms of the agreement and product availability dates were not disclosed.
Most infectious disease diagnostics are culture-based and labs often take a week or longer to produce results. Consequently, physicians frequently prescribe antibiotics or antivirals prior to determining the exact pathogen causing the infection. By combining Prodesse`s pathogen detecting products with the NanoChip(R) Molecular Biology Workstation, Nanogen and Prodesse expect to offer reagents for the development of an automated process for testing patient samples within hours, enabling physicians to obtain results and prescribe therapeutics in response to test results. This should help reduce inappropriate treatment with antibiotics, the overuse of which has resulted in an increase in antibiotic-resistant strains of bacteria and a decrease in the effectiveness of many commonly prescribed antibiotics.
"Our collaboration with Prodesse facilitates Nanogen`s entry into the large infectious disease marketplace and expands the capabilities of our molecular testing platform," said Bruce Huebner, president and chief operating officer of Nanogen, Inc. "Testing for infectious diseases on Nanogen workstations will become a cornerstone in our Platformation(TM) strategy of offering clinical reference labs a variety of analyte specific reagents and tests that can be performed on one versatile system."
"We believe the combination of Prodesse`s front-end multiplex amplification technology and Nanogen`s back-end rapid detection system is an ideal marriage of two technologies that will greatly improve the ability for health care providers and labs to detect infectious disease agents," said Tom Shannon, chief executive officer of Prodesse, Inc.
Prodesse currently offers six different multiplex products that can be used by laboratories to detect a total of 28 different pathogens, and it expects to release five more products with an additional 19 targets. The Company`s technology amplifies the sequences for many different pathogens simultaneously with virtually no loss of sensitivity or specificity, and with no cross-reactivity, which is important for obtaining precise test results. Nanogen`s open-architecture NanoChip(R) System allows detection of known, amplified sequences in a highly accurate and automated fashion, offering users increased speed, versatility and cost effectiveness over conventional detection methods.
About Prodesse, Inc.
Prodesse is a biotechnology company focused on developing analyte specific reagents that can be used by CLIA certified laboratories to detect infectious pathogens. The Company`s reagents incorporate proprietary technology that allow for the detection of multiple pathogens in a single test. Prodesse`s flagship product, Hexaplex(R), can be used to simultaneously test for the seven most common respiratory viruses in a single patient sample. The Company sells its reagents to laboratories throughout the US and the world, and also operates a CLIA certified laboratory for testing services in the Midwest area. For more information about Prodesse and its products, call 888-589-6974 or go to www.prodesse.com .
About Nanogen Inc.
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of various diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Our actual results may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, the value of our investment in CombiMatrix securities, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission. These forward-looking statements are based upon current expectations and speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.; Prodesse, Inc.
David Ludvigson, Executive Vice President & Chief Financial
Officer of Nanogen, Inc., +1-858-410-4608; or Andy Shrago, Vice President of
Sales and Marketing, Prodesse, Inc., +1-262-446-0700
http://www.prodesse.com
SAN DIEGO and MILWAUKEE, Sep 10, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) and Prodesse, Inc. announced today the signing of a collaboration agreement to develop automated, highly sensitive microarray- based products to detect a number of infectious disease agents, including influenza, pneumonia, adenovirus, herpes, West Nile Virus, and SARS. The Companies will integrate Prodesse`s proprietary multiplex amplification technology with the automated NanoChip(R) platform and jointly develop and market gene-based testing products to health care providers and clinical reference labs. Financial terms of the agreement and product availability dates were not disclosed.
Most infectious disease diagnostics are culture-based and labs often take a week or longer to produce results. Consequently, physicians frequently prescribe antibiotics or antivirals prior to determining the exact pathogen causing the infection. By combining Prodesse`s pathogen detecting products with the NanoChip(R) Molecular Biology Workstation, Nanogen and Prodesse expect to offer reagents for the development of an automated process for testing patient samples within hours, enabling physicians to obtain results and prescribe therapeutics in response to test results. This should help reduce inappropriate treatment with antibiotics, the overuse of which has resulted in an increase in antibiotic-resistant strains of bacteria and a decrease in the effectiveness of many commonly prescribed antibiotics.
"Our collaboration with Prodesse facilitates Nanogen`s entry into the large infectious disease marketplace and expands the capabilities of our molecular testing platform," said Bruce Huebner, president and chief operating officer of Nanogen, Inc. "Testing for infectious diseases on Nanogen workstations will become a cornerstone in our Platformation(TM) strategy of offering clinical reference labs a variety of analyte specific reagents and tests that can be performed on one versatile system."
"We believe the combination of Prodesse`s front-end multiplex amplification technology and Nanogen`s back-end rapid detection system is an ideal marriage of two technologies that will greatly improve the ability for health care providers and labs to detect infectious disease agents," said Tom Shannon, chief executive officer of Prodesse, Inc.
Prodesse currently offers six different multiplex products that can be used by laboratories to detect a total of 28 different pathogens, and it expects to release five more products with an additional 19 targets. The Company`s technology amplifies the sequences for many different pathogens simultaneously with virtually no loss of sensitivity or specificity, and with no cross-reactivity, which is important for obtaining precise test results. Nanogen`s open-architecture NanoChip(R) System allows detection of known, amplified sequences in a highly accurate and automated fashion, offering users increased speed, versatility and cost effectiveness over conventional detection methods.
About Prodesse, Inc.
Prodesse is a biotechnology company focused on developing analyte specific reagents that can be used by CLIA certified laboratories to detect infectious pathogens. The Company`s reagents incorporate proprietary technology that allow for the detection of multiple pathogens in a single test. Prodesse`s flagship product, Hexaplex(R), can be used to simultaneously test for the seven most common respiratory viruses in a single patient sample. The Company sells its reagents to laboratories throughout the US and the world, and also operates a CLIA certified laboratory for testing services in the Midwest area. For more information about Prodesse and its products, call 888-589-6974 or go to www.prodesse.com .
About Nanogen Inc.
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of various diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Our actual results may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, the value of our investment in CombiMatrix securities, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission. These forward-looking statements are based upon current expectations and speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.; Prodesse, Inc.
David Ludvigson, Executive Vice President & Chief Financial
Officer of Nanogen, Inc., +1-858-410-4608; or Andy Shrago, Vice President of
Sales and Marketing, Prodesse, Inc., +1-262-446-0700
http://www.prodesse.com
Wer hat um 15.00 Uhr Nanogen für 4.20 euro gekauft , herzliches Beileid ! Du könntes warten bis das 1-2 Stunden in New York läuft. Nach 5 Stunden ist es auf 3,50 gefallen. Nach der gestrigen Kursexplosion +25% in New York sollte man gleich um 9.00 in Frankfurt verkaufen und NICHT KAUFEN !Hoffentlich steigt es nach 6 Wochen im Oktober wieder auf die 4,20 euro. Nanogen ist unergründlich. Lieber Myriad !
Am liebsten Abgenix , Celgene , Medarex , Millennium Pharma
Press Release Source: Nanogen, Inc.
Nanogen to Present at UBS Global Life Sciences Conference on September 22
Wednesday September 17, 9:19 pm ET
SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), a leading provider of molecular diagnostics, today announced Howard Birndorf, Nanogen`s Chairman and CEO, will present an overview of the Company on Monday, September 22 at 10:00 a.m. EST during the UBS Global Life Sciences Conference. The conference will take place September 22-25 at The Plaza Hotel in New York City and will feature presentations by the life science industry`s leading public companies, as well as a select group of top privately held biotechnology companies.
Mr. Birndorf`s presentation will include an update on Nanogen`s strategy for capturing the highest potential revenues from its NanoChip® platform in molecular diagnostics, a fast-growing field within the clinical testing market. In the last ten months, the Company has launched seven new gene-based testing products currently being used by clinical labs to detect genetic mutations associated with diseases such as cystic fibrosis, Alzheimer`s disease and cardiovascular disease. In addition, Nanogen announced last week that it will enter the infectious disease market by jointly developing gene- based products with partner Prodesse for the detection of infectious disease pathogens on the NanoChip® Molecular Biology Workstation.
A live audio web cast of the presentation will be available online through Nanogen`s website at www.nanogen.com and will be archived for 30 days.
Nanogen to Present at UBS Global Life Sciences Conference on September 22
Wednesday September 17, 9:19 pm ET
SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), a leading provider of molecular diagnostics, today announced Howard Birndorf, Nanogen`s Chairman and CEO, will present an overview of the Company on Monday, September 22 at 10:00 a.m. EST during the UBS Global Life Sciences Conference. The conference will take place September 22-25 at The Plaza Hotel in New York City and will feature presentations by the life science industry`s leading public companies, as well as a select group of top privately held biotechnology companies.
Mr. Birndorf`s presentation will include an update on Nanogen`s strategy for capturing the highest potential revenues from its NanoChip® platform in molecular diagnostics, a fast-growing field within the clinical testing market. In the last ten months, the Company has launched seven new gene-based testing products currently being used by clinical labs to detect genetic mutations associated with diseases such as cystic fibrosis, Alzheimer`s disease and cardiovascular disease. In addition, Nanogen announced last week that it will enter the infectious disease market by jointly developing gene- based products with partner Prodesse for the detection of infectious disease pathogens on the NanoChip® Molecular Biology Workstation.
A live audio web cast of the presentation will be available online through Nanogen`s website at www.nanogen.com and will be archived for 30 days.
Ist schon im anderen Thread - der vollständigkeit halber
Press Release Source: Nanogen, Inc.
Nanogen Announces Private Placement of Common Stock and Warrants
Thursday September 18, 8:00 am ET
SAN DIEGO, Sept. 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), a leading provider of molecular diagnostics, announced today it has signed agreements to sell common stock and warrants to several accredited investors for aggregate potential gross proceeds of approximately $16 million. In the initial closing, Nanogen will receive $7 million in gross proceeds through the sale of 2,121,211 newly issued shares of its common stock at a price of $3.30 per share, which is based on a negotiated discount from the average of the closing prices for the five trading days ended September 16, 2003. The investors will also receive five-year warrants to purchase 424,243 shares of common stock at an exercise price of $4.75 per share, twelve-month warrants to purchase 530,305 shares of common stock at an exercise price of $4.75 per share, and six-month warrants to purchase 1,103,032 shares of common stock at an exercise price of $4.14 per share. Subject to customary closing conditions, the financing is scheduled to close on or about Friday, September 19, 2003. Seven Hills Partners LLC acted as exclusive placement agent to Nanogen for this financing.
ADVERTISEMENT
"This financing further strengthens our balance sheet and provides additional capital for the ongoing development of our technology and products for the molecular diagnostic market," said Howard Birndorf, chairman and CEO of Nanogen. "We are pleased to conclude a financing that also may provide significant additional capital over the next year."
The securities sold in this private placement have not been registered under the Securities Act of 1933 or any state securities laws and unless so registered may not be offered or sold in the United States (or to a U.S. person) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933 and applicable state securities laws. However, Nanogen has agreed to file a registration statement for the resale of the shares of the common stock, including all shares of common stock underlying the warrants. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities.
About Nanogen Inc.
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of various diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Our actual results may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including an inability to consummate the private placement, whether warrants sold in the private placement will be exercised in the future, whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA- approved molecular diagnostic test kits, whether the Company will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, the value of our investment in CombiMatrix securities, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission. These forward- looking statements are based upon current expectations and speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Source: Nanogen, Inc.
Press Release Source: Nanogen, Inc.
Nanogen Announces Private Placement of Common Stock and Warrants
Thursday September 18, 8:00 am ET
SAN DIEGO, Sept. 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), a leading provider of molecular diagnostics, announced today it has signed agreements to sell common stock and warrants to several accredited investors for aggregate potential gross proceeds of approximately $16 million. In the initial closing, Nanogen will receive $7 million in gross proceeds through the sale of 2,121,211 newly issued shares of its common stock at a price of $3.30 per share, which is based on a negotiated discount from the average of the closing prices for the five trading days ended September 16, 2003. The investors will also receive five-year warrants to purchase 424,243 shares of common stock at an exercise price of $4.75 per share, twelve-month warrants to purchase 530,305 shares of common stock at an exercise price of $4.75 per share, and six-month warrants to purchase 1,103,032 shares of common stock at an exercise price of $4.14 per share. Subject to customary closing conditions, the financing is scheduled to close on or about Friday, September 19, 2003. Seven Hills Partners LLC acted as exclusive placement agent to Nanogen for this financing.
ADVERTISEMENT
"This financing further strengthens our balance sheet and provides additional capital for the ongoing development of our technology and products for the molecular diagnostic market," said Howard Birndorf, chairman and CEO of Nanogen. "We are pleased to conclude a financing that also may provide significant additional capital over the next year."
The securities sold in this private placement have not been registered under the Securities Act of 1933 or any state securities laws and unless so registered may not be offered or sold in the United States (or to a U.S. person) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act of 1933 and applicable state securities laws. However, Nanogen has agreed to file a registration statement for the resale of the shares of the common stock, including all shares of common stock underlying the warrants. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities.
About Nanogen Inc.
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of various diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Our actual results may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including an inability to consummate the private placement, whether warrants sold in the private placement will be exercised in the future, whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip® System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA- approved molecular diagnostic test kits, whether the Company will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, the value of our investment in CombiMatrix securities, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission. These forward- looking statements are based upon current expectations and speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Source: Nanogen, Inc.
der chart sieht gut aus , erinnert mich an ein aufsteigendes dreieck, sieht aus als würde bald ein ausbruch anstehen
Title: Q3 2003 Nanogen, Inc. Earnings Conference Call
Date: Wednesday, October 29, 2003
Time: 4:30 PM ET
Duration: 1 hour
Date: Wednesday, October 29, 2003
Time: 4:30 PM ET
Duration: 1 hour
Nanogen Licenses Rights to Gene Linked to Hereditary Deafness
Company to Develop First Molecular Diagnostic Product Available in Europe
To Detect Hereditary Deafness
SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostics, today announced it signed a license agreement with Institut Pasteur that grants Nanogen exclusive rights in Europe to certain patents and patent applications relating to detection of mutations in the GJB2 gene for the diagnosis of hereditary deafness. The Company plans to develop a molecular diagnostic product that can be customized by European molecular testing labs to screen newborns for hereditary deafness. Financial terms of the license agreement were not disclosed.
"Early identification of deafness in infants is critical to providing clinical care and ensuring social development. Too often deafness is misdiagnosed as a learning or mental disability resulting in inappropriate therapy or educational approaches. If diagnosed early, infants can be given speech therapy essential to progress later in life," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer. "There is no genetic test available in Europe to identify whether infants have inherited deafness, and we`ve secured exclusive rights to intellectual property for this important gene from Institut Pasteur, a major pioneer in research into the genetics of deafness."
About one to three in 1,000 infants have profound hearing loss, making it one of the most common disabilities in newborns. Principal investigator Dr. Christine Petit`s team at the Sensory Deficit Genetics laboratory at Institut Pasteur identified many of the genes implicated in early-onset forms of deafness. The GJB2 gene that encodes a protein called connexin 26 was demonstrated to be associated with 25% to 50% of the cases of hereditary deafness in Western countries, as well as in countries around the Mediterranean Sea. Moreover, Dr. Petit`s group has recently shown that the vast majority of sporadic cases of deafness occurring in people from developed countries are of genetic origin. The identification of mutations in the GJB2 gene is then crucial for diagnosis of deafness.
Universal newborn screening for hearing loss using auditory or behavioral tests has been widely adopted, since it is known that early identification and management of deafness is important for the development of language and social skills. Genetic testing can help predict or identify the cause of hearing loss as well as whether it will deteriorate. Early detection of deafness can facilitate early interventions, such as personal amplification devices, cochlear implants, or speech therapy, which can significantly influence a child`s ability to communicate and learn. An additional benefit of early genetic testing is that it facilitates establishing a cause for hearing loss, obviating the need for more extensive medical evaluation and subsequently reducing medical costs. Genetic testing for hereditary deafness can also be offered for carrier detection during reproductive counseling.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
About The Institut Pasteur
The Institut Pasteur, Paris (France) is a world leading non-profit private foundation mainly dedicated to the prevention and treatment of infectious diseases through scientific and medical research, education and public health activities. Biomedical research is also focused on non-infectious diseases: genetic diseases, brain disorders and some cancers. Its main campus in Paris houses 130 research units and laboratories, with a total of 2500 people. Visit The Institut Pasteur`s website at www.pasteur.fr .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChi(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
For further information, please contact: David Ludvigson, Executive Vice President & Chief Financial Officer, +1-858-410-4600, dludvigson@nanogen.com ; or Pam Lord, Media Relations of Atkins + Associates, +1-858-527-3494, plord@irpr.com , for Nanogen, Inc.
SOURCE Nanogen, Inc.
-0- 10/28/2003
/CONTACT: David Ludvigson, Executive Vice President & Chief Financial
Officer, +1-858-410-4600, dludvigson@nanogen.com ; or Pam Lord, Media
Relations of Atkins + Associates, +1-858-527-3494, plord@irpr.com , for
Nanogen, Inc./
/Web site: http://www.pasteur.fr /
/Web site: http://www.nanogen.com /
(NGEN)
Company to Develop First Molecular Diagnostic Product Available in Europe
To Detect Hereditary Deafness
SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), a leading provider of molecular diagnostics, today announced it signed a license agreement with Institut Pasteur that grants Nanogen exclusive rights in Europe to certain patents and patent applications relating to detection of mutations in the GJB2 gene for the diagnosis of hereditary deafness. The Company plans to develop a molecular diagnostic product that can be customized by European molecular testing labs to screen newborns for hereditary deafness. Financial terms of the license agreement were not disclosed.
"Early identification of deafness in infants is critical to providing clinical care and ensuring social development. Too often deafness is misdiagnosed as a learning or mental disability resulting in inappropriate therapy or educational approaches. If diagnosed early, infants can be given speech therapy essential to progress later in life," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer. "There is no genetic test available in Europe to identify whether infants have inherited deafness, and we`ve secured exclusive rights to intellectual property for this important gene from Institut Pasteur, a major pioneer in research into the genetics of deafness."
About one to three in 1,000 infants have profound hearing loss, making it one of the most common disabilities in newborns. Principal investigator Dr. Christine Petit`s team at the Sensory Deficit Genetics laboratory at Institut Pasteur identified many of the genes implicated in early-onset forms of deafness. The GJB2 gene that encodes a protein called connexin 26 was demonstrated to be associated with 25% to 50% of the cases of hereditary deafness in Western countries, as well as in countries around the Mediterranean Sea. Moreover, Dr. Petit`s group has recently shown that the vast majority of sporadic cases of deafness occurring in people from developed countries are of genetic origin. The identification of mutations in the GJB2 gene is then crucial for diagnosis of deafness.
Universal newborn screening for hearing loss using auditory or behavioral tests has been widely adopted, since it is known that early identification and management of deafness is important for the development of language and social skills. Genetic testing can help predict or identify the cause of hearing loss as well as whether it will deteriorate. Early detection of deafness can facilitate early interventions, such as personal amplification devices, cochlear implants, or speech therapy, which can significantly influence a child`s ability to communicate and learn. An additional benefit of early genetic testing is that it facilitates establishing a cause for hearing loss, obviating the need for more extensive medical evaluation and subsequently reducing medical costs. Genetic testing for hereditary deafness can also be offered for carrier detection during reproductive counseling.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
About The Institut Pasteur
The Institut Pasteur, Paris (France) is a world leading non-profit private foundation mainly dedicated to the prevention and treatment of infectious diseases through scientific and medical research, education and public health activities. Biomedical research is also focused on non-infectious diseases: genetic diseases, brain disorders and some cancers. Its main campus in Paris houses 130 research units and laboratories, with a total of 2500 people. Visit The Institut Pasteur`s website at www.pasteur.fr .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChi(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
For further information, please contact: David Ludvigson, Executive Vice President & Chief Financial Officer, +1-858-410-4600, dludvigson@nanogen.com ; or Pam Lord, Media Relations of Atkins + Associates, +1-858-527-3494, plord@irpr.com , for Nanogen, Inc.
SOURCE Nanogen, Inc.
-0- 10/28/2003
/CONTACT: David Ludvigson, Executive Vice President & Chief Financial
Officer, +1-858-410-4600, dludvigson@nanogen.com ; or Pam Lord, Media
Relations of Atkins + Associates, +1-858-527-3494, plord@irpr.com , for
Nanogen, Inc./
/Web site: http://www.pasteur.fr /
/Web site: http://www.nanogen.com /
(NGEN)
Nanogen Reports 2003 Third Quarter Results
SAN DIEGO, Oct 29, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the third quarter ended September 30, 2003.
Total revenues for the third quarter of 2003 were $1.7 million, consistent with the $1.7 million recorded in the second quarter of 2003 and 12% higher than the $1.6 million reported for the third quarter of the prior year. Product revenues for the third quarter of 2003 were $752,000, 14% higher than the $662,000 recorded in the second quarter of 2003 and 21% lower than the third quarter of 2002. During the quarter, there were 10 commercial transactions for the NanoChip(R) Molecular Biology Workstation compared to six in the second quarter this year. Of the ten transactions, five were instrument sales, one was a reagent rental agreement, and four were development site agreements. In addition, one instrument was installed as part of a product collaboration.
The loss for the third quarter of 2003 was $7.1 million or $0.33 per share, an improvement of 14% from the loss of $8.2 million or $0.38 per share in the third quarter of 2002 and approximately the same as the loss of $6.9 million or $0.32 per share in the second quarter of this year. The third quarter loss included three significant charges: a $1,024,000 write-down of intangible assets; an increase of $829,000 in inventory reserves; and a realized gain on investments of $778,000 primarily related to the sale of shares of CombiMatrix stock received in 2002 as part of a litigation settlement. After deducting these charges, the third quarter loss would have improved by approximately $900,000 or $0.04 per share as compared to the second quarter of 2003.
The Company`s cash, cash equivalents and short-term investments balance at September 30, 2003 was $32.6 million, an increase of $4.1 million from the June 30, 2003 balance of $28.5 million. The increase was primarily the result of a private equity placement that was completed during the quarter resulting in $7.0 million in gross proceeds. In addition, additional gross proceeds of up to $9.0 million may result from the private equity placement if warrants associated with the financing are exercised.
"I am very pleased with our cash and expense management during the third quarter. We completed the first phase of a private equity placement that added $7.0 million in cash and has the potential to add an additional $9.0 million in the future. In addition, our net operating cash used during the quarter was $4.5 million, almost 50% better than in the second quarter. We also met our goals for continued operating expense improvement," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer. "During the quarter, we initiated a collaboration to develop infectious disease assays on the Nanogen platform. Our expanding menu of products will continue to target large market opportunities, such as infectious diseases, where there is a growing need for molecular diagnostic products."
Financial Guidance
For 2003, the expectation for instrument placements continues to be between 35 and 45 instruments. However, product revenue will be less than the $4 million lower level of prior guidance. The expectation for contract and sponsored research revenues continues to be approximately $4 million. The loss for 2003, including the charges discussed above, is expected to be at the high end of our guidance of $27 million to $29 million. Cash, cash equivalents and short-term investments at the end of the year are expected to be approximately $28 to $30 million.
For 2004, the Company anticipates a growth rate in total revenue of approximately 50% as compared to 2003, total operating expenses to run approximately 10% less than the 2003 fourth quarter run rate and an end of the year cash balance of approximately $15 million.
Webcast of the Conference Call
Nanogen management will host a conference call today to discuss the third quarter financial results at 4:30 p.m. Eastern Time. Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com . A telephone replay will be available approximately two hours following the conference call until 11:59 p.m. Eastern Time on October 31, 2003, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants. The conference ID is 3610320 and it will be required to listen to the playback. The webcast will also be archived on Nanogen`s website for 90 days.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Note Regarding Use of Non-GAAP Financial Information
To supplement our consolidated financial statements presented in accordance with GAAP, we used non-GAAP adjustments to exclude $1.9 million in reserves and non-cash impairment charges on assets, as well as an offsetting $778,000 gain on the sale of CombiMatrix stock from the loss for the third quarter of 2003. Non-GAAP adjustments are provided to enhance the user`s overall understanding of current financial performance and prospects for the future. Specifically, we believe that the non-GAAP adjustment provides useful information to both management and investors by excluding certain reserves, non-cash impairment charges and investment gains that we believe are not indicative of our operating results, thereby permitting a more meaningful comparison between the loss information for the second and third quarters of 2003. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.
Forward-Looking Statement
This press release contains forward-looking statements regarding future product revenues, contract and sponsored research revenues, estimates of operating expenses and estimates of future cash balances. These forward-looking statements are based upon current expectations and speak only as of the date hereof. Our actual results may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, the value of our investment in CombiMatrix securities, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
September 30, December 31,
2003 2002
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $12,767 $9,353
Short-term investments 19,787 43,376
Receivables, net 1,696 1,754
Inventories, net 4,972 4,717
Other current assets 1,309 1,781
Total current assets 40,531 60,981
Property and equipment, net 4,922 4,982
Acquired technology rights, net 2,761 4,544
Other assets, net 578 853
$48,792 $71,360
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $390 $753
Accrued liabilities 4,017 5,901
Deferred revenue 914 472
Current portion of capital lease obligations 835 805
Total current liabilities 6,156 7,931
Capital lease obligations, less current portion 675 1,134
Other long-term liabilities 3,841 3,085
Total long-term liabilities 4,516 4,219
Minority interest in consolidated subsidiary 223 1,817
Stockholders` equity:
Convertible preferred stock,
$0.001 par value, 5,000,000 shares
authorized; no shares issued and
outstanding at September 30, 2003
(unaudited) and December 31, 2002 -- --
Common stock, $0.001 par value,
50,000,000 shares authorized;
24,380,010 and 21,981,115 shares
issued and outstanding at
September 30, 2003 (unaudited) and
December 31, 2002, respectively 24 22
Additional paid-in capital 207,336 199,483
Accumulated other comprehensive income 1,904 4,926
Deferred compensation (134) (156)
Notes receivable from officers -- (513)
Accumulated deficit (170,311) (145,659)
Treasury stock, at cost, 500,189 and
366,857 shares at September 30, 2003
(unaudited) and December 31, 2002,
respectively (922) (710)
Total stockholders` equity 37,897 57,393
$48,792 $71,360
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Nine months ended
September 30, September 30,
2003 2002 2003 2002
Revenues:
Product sales $752 $957 $1,642 $2,873
License fees 46 -- 46 --
Sponsored research 375 354 1,125 980
Contracts and grant 568 240 1,822 1,182
Total revenues 1,741 1,551 4,635 5,035
Operating expenses:
Cost of product
sales 1,370 687 2,168 2,080
Research and
development 4,280 5,328 13,473 15,220
Selling, general
and administrative 3,336 5,428 11,532 15,346
Impairment of
acquired technology
rights 1,024 452 1,024 452
Litigation and
settlement of
patent matter 149 (963) 149 (165)
Total operating
expenses 10,159 10,932 28,346 32,933
Loss from operations (8,418) (9,381) (23,711) (27,898)
Interest income, net 97 488 405 1,834
Other income/(expense) (46) 18 (19) 153
Gain/(loss) on sale
of investments 778 -- (2,790) --
Gain/(loss) on sale
of fixed assets 22 -- (131) --
Minority interest in loss
of consolidated
subsidiary 488 651 1,594 1,634
Net loss $(7,079) $(8,224) $(24,652) $(24,277)
Net loss per share -
basic and diluted $(0.33) $(0.38) $(1.14) $(1.12)
Number of shares used in
computing net loss per share -
basic and diluted 21,781 21,923 21,652 21,732
SOURCE Nanogen, Inc.
David Ludvigson, Executive Vice President of Nanogen, Inc.,
+1-858-410-4600, dludvigson@nanogen.com ; or Pam Lord of Atkins + Associates,
+1-858-527-3494, plord@irpr.com , for Nanogen, Inc.
http://www.nanogen.com
SAN DIEGO, Oct 29, 2003 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced its financial results for the third quarter ended September 30, 2003.
Total revenues for the third quarter of 2003 were $1.7 million, consistent with the $1.7 million recorded in the second quarter of 2003 and 12% higher than the $1.6 million reported for the third quarter of the prior year. Product revenues for the third quarter of 2003 were $752,000, 14% higher than the $662,000 recorded in the second quarter of 2003 and 21% lower than the third quarter of 2002. During the quarter, there were 10 commercial transactions for the NanoChip(R) Molecular Biology Workstation compared to six in the second quarter this year. Of the ten transactions, five were instrument sales, one was a reagent rental agreement, and four were development site agreements. In addition, one instrument was installed as part of a product collaboration.
The loss for the third quarter of 2003 was $7.1 million or $0.33 per share, an improvement of 14% from the loss of $8.2 million or $0.38 per share in the third quarter of 2002 and approximately the same as the loss of $6.9 million or $0.32 per share in the second quarter of this year. The third quarter loss included three significant charges: a $1,024,000 write-down of intangible assets; an increase of $829,000 in inventory reserves; and a realized gain on investments of $778,000 primarily related to the sale of shares of CombiMatrix stock received in 2002 as part of a litigation settlement. After deducting these charges, the third quarter loss would have improved by approximately $900,000 or $0.04 per share as compared to the second quarter of 2003.
The Company`s cash, cash equivalents and short-term investments balance at September 30, 2003 was $32.6 million, an increase of $4.1 million from the June 30, 2003 balance of $28.5 million. The increase was primarily the result of a private equity placement that was completed during the quarter resulting in $7.0 million in gross proceeds. In addition, additional gross proceeds of up to $9.0 million may result from the private equity placement if warrants associated with the financing are exercised.
"I am very pleased with our cash and expense management during the third quarter. We completed the first phase of a private equity placement that added $7.0 million in cash and has the potential to add an additional $9.0 million in the future. In addition, our net operating cash used during the quarter was $4.5 million, almost 50% better than in the second quarter. We also met our goals for continued operating expense improvement," said Howard C. Birndorf, Nanogen`s chairman of the board and chief executive officer. "During the quarter, we initiated a collaboration to develop infectious disease assays on the Nanogen platform. Our expanding menu of products will continue to target large market opportunities, such as infectious diseases, where there is a growing need for molecular diagnostic products."
Financial Guidance
For 2003, the expectation for instrument placements continues to be between 35 and 45 instruments. However, product revenue will be less than the $4 million lower level of prior guidance. The expectation for contract and sponsored research revenues continues to be approximately $4 million. The loss for 2003, including the charges discussed above, is expected to be at the high end of our guidance of $27 million to $29 million. Cash, cash equivalents and short-term investments at the end of the year are expected to be approximately $28 to $30 million.
For 2004, the Company anticipates a growth rate in total revenue of approximately 50% as compared to 2003, total operating expenses to run approximately 10% less than the 2003 fourth quarter run rate and an end of the year cash balance of approximately $15 million.
Webcast of the Conference Call
Nanogen management will host a conference call today to discuss the third quarter financial results at 4:30 p.m. Eastern Time. Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com . A telephone replay will be available approximately two hours following the conference call until 11:59 p.m. Eastern Time on October 31, 2003, and can be accessed at (800) 642-1687 for US/Canada participants or (706) 645-9291 for international participants. The conference ID is 3610320 and it will be required to listen to the playback. The webcast will also be archived on Nanogen`s website for 90 days.
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Note Regarding Use of Non-GAAP Financial Information
To supplement our consolidated financial statements presented in accordance with GAAP, we used non-GAAP adjustments to exclude $1.9 million in reserves and non-cash impairment charges on assets, as well as an offsetting $778,000 gain on the sale of CombiMatrix stock from the loss for the third quarter of 2003. Non-GAAP adjustments are provided to enhance the user`s overall understanding of current financial performance and prospects for the future. Specifically, we believe that the non-GAAP adjustment provides useful information to both management and investors by excluding certain reserves, non-cash impairment charges and investment gains that we believe are not indicative of our operating results, thereby permitting a more meaningful comparison between the loss information for the second and third quarters of 2003. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.
Forward-Looking Statement
This press release contains forward-looking statements regarding future product revenues, contract and sponsored research revenues, estimates of operating expenses and estimates of future cash balances. These forward-looking statements are based upon current expectations and speak only as of the date hereof. Our actual results may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, the value of our investment in CombiMatrix securities, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002, filed with the Securities and Exchange Commission. The Company disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
September 30, December 31,
2003 2002
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $12,767 $9,353
Short-term investments 19,787 43,376
Receivables, net 1,696 1,754
Inventories, net 4,972 4,717
Other current assets 1,309 1,781
Total current assets 40,531 60,981
Property and equipment, net 4,922 4,982
Acquired technology rights, net 2,761 4,544
Other assets, net 578 853
$48,792 $71,360
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $390 $753
Accrued liabilities 4,017 5,901
Deferred revenue 914 472
Current portion of capital lease obligations 835 805
Total current liabilities 6,156 7,931
Capital lease obligations, less current portion 675 1,134
Other long-term liabilities 3,841 3,085
Total long-term liabilities 4,516 4,219
Minority interest in consolidated subsidiary 223 1,817
Stockholders` equity:
Convertible preferred stock,
$0.001 par value, 5,000,000 shares
authorized; no shares issued and
outstanding at September 30, 2003
(unaudited) and December 31, 2002 -- --
Common stock, $0.001 par value,
50,000,000 shares authorized;
24,380,010 and 21,981,115 shares
issued and outstanding at
September 30, 2003 (unaudited) and
December 31, 2002, respectively 24 22
Additional paid-in capital 207,336 199,483
Accumulated other comprehensive income 1,904 4,926
Deferred compensation (134) (156)
Notes receivable from officers -- (513)
Accumulated deficit (170,311) (145,659)
Treasury stock, at cost, 500,189 and
366,857 shares at September 30, 2003
(unaudited) and December 31, 2002,
respectively (922) (710)
Total stockholders` equity 37,897 57,393
$48,792 $71,360
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Nine months ended
September 30, September 30,
2003 2002 2003 2002
Revenues:
Product sales $752 $957 $1,642 $2,873
License fees 46 -- 46 --
Sponsored research 375 354 1,125 980
Contracts and grant 568 240 1,822 1,182
Total revenues 1,741 1,551 4,635 5,035
Operating expenses:
Cost of product
sales 1,370 687 2,168 2,080
Research and
development 4,280 5,328 13,473 15,220
Selling, general
and administrative 3,336 5,428 11,532 15,346
Impairment of
acquired technology
rights 1,024 452 1,024 452
Litigation and
settlement of
patent matter 149 (963) 149 (165)
Total operating
expenses 10,159 10,932 28,346 32,933
Loss from operations (8,418) (9,381) (23,711) (27,898)
Interest income, net 97 488 405 1,834
Other income/(expense) (46) 18 (19) 153
Gain/(loss) on sale
of investments 778 -- (2,790) --
Gain/(loss) on sale
of fixed assets 22 -- (131) --
Minority interest in loss
of consolidated
subsidiary 488 651 1,594 1,634
Net loss $(7,079) $(8,224) $(24,652) $(24,277)
Net loss per share -
basic and diluted $(0.33) $(0.38) $(1.14) $(1.12)
Number of shares used in
computing net loss per share -
basic and diluted 21,781 21,923 21,652 21,732
SOURCE Nanogen, Inc.
David Ludvigson, Executive Vice President of Nanogen, Inc.,
+1-858-410-4600, dludvigson@nanogen.com ; or Pam Lord of Atkins + Associates,
+1-858-527-3494, plord@irpr.com , for Nanogen, Inc.
http://www.nanogen.com
hier ein neues Patent:
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H… l/search-bool.html&r=1&f=G&l=50&co1=AND&d=ptxt&s1=nanogen.ASNM.&OS=AN/nanogen&RS =AN/nanogen
http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=H… l/search-bool.html&r=1&f=G&l=50&co1=AND&d=ptxt&s1=nanogen.ASNM.&OS=AN/nanogen&RS =AN/nanogen
Nach langer Durststrecke wieder mal News
Nanogen Issued Key Nanotechnology Patent
Newly Issued Patent Broadens Proprietary Position in Nanomanufacturing and
Nanotechnology
SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced that it has been issued U.S. Patent No. 6,652,808, "Methods for the Electronic Assembly and Fabrication of Devices," ("the `808 patent") by the U.S. Patent and Trademark Office. This patent is the parent of a series of pending patent applications that significantly broaden Nanogen`s proprietary position in the nanotechnology and nanomanufacturing areas. The Company has now been issued nine patents during 2003, bringing the total number of patents issued in the U.S. to 56.
"One of the challenges in producing new electronic and photonic devices using nanoscale components is the integration of these components into viable higher order devices. The new Nanogen patent describes a unique electric field `pick and place` process that facilitates the bringing together or integration of diverse DNA nanocomponents, thereby helping solve difficult scaling issues. Combining the top-down electric field process with the bottom-up DNA self-assembly process enables more selective and higher precision incorporation of nanoscale components into higher order devices and structures," said Dr. Michael J. Heller, co-founder of Nanogen, one of the inventors, and currently a Professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
"The technology described by Nanogen`s new patent may provide a technological foundation for the effective use of nanocomponents in many diverse applications," said Howard Birndorf, Nanogen chairman and CEO. "As we continue to increase and broaden our intellectual property portfolio, we intend to realize value from our nanotechnology patents through licensing or partnering opportunities. Congress` recent commitment to nanotechnology research and development underscores the potential our technologies may have for impacting several industries, including medicine."
The new nanotechnology patent relates to a nanofabrication technology that combines an electric field assisted manufacturing platform and programmable self-assembling nanostructures (for example, DNA building blocks) for the fabrication of a wide range of unique higher-order nano and microscale devices, structures, and materials. The nanofabrication platform and process would be used for: (1) producing new nanoscale electronic and photonic devices and structures, including high-density 2D and 3D data storage materials, 2D and 3D photonic crystal structures, hybrid electronic/photonic devices such as large area light emitting flat panel arrays and displays, and for the fabrication of highly integrated medical diagnostic and biosensor devices; (2) organization, assembly and interconnection of nanostructures and submicron components onto silicon wafers and other materials; (3) integration of nanostructures within preformed microelectronic and optoelectronic structures; (4) production of precision modified nanoparticles (for example, photonic crystals, nanospheres and quantum dots) which can then more efficiently self-assemble into 2D and 3D structures and materials (photonic band gap structures, nanocomposite materials and so forth); and (5) fabrication of selectively addressable DNA nanoarray substrates and materials.
The patent represents a unique nanofabrication technology which combines the best aspects of top-down microfabrication processes with bottom-up biological type self-assembly processes for producing novel nanodevices and nanostructures. The process is highly parallel and has an inherent hierarchical logic allowing one to control the organization, assembly and communication of components from the molecular and nanoscale into macroscale devices and structures.
The `808 patent is jointly owned by Nanotronics, Inc., a wholly owned subsidiary of Nanogen, and the Regents of the University of California. Nanogen has exclusively licensed the interests of the University of California where there is joint inventorship. Additionally, Nanogen disclosed the issuance over the last several months of three patents relating to electronic microarray technology. The three additional issued patents are U.S. Patent No. 6,582,660 "Control System for Active Programmable Electronic Microbiology System," U.S. Patent No. 6,589,742 "Multiplex Amplification and Separation of Nucleic Acid Sequences on a Bioelectronic Microchip Using Asymmetric Structures," and U.S. Patent No. 6,638,482 "Reconfigurable Detection and Analysis Apparatus and Method."
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
-0- 12/03/2003
/CONTACT: David Ludvigson, Executive Vice President & Chief Financial
Officer of Nanogen, Inc., +1-858-410-4600, dludvigson@nanogen.com; or Pam Lord
of Atkins + Associates, +1-858-527-3494, plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
CO: Nanogen, Inc.
ST: California
IN: BIO MTC HEA
SU: PDT
SE
-- LAW045 --
5073 12/03/2003 08:01 EST http://www.prnewswire.com
Nanogen Issued Key Nanotechnology Patent
Newly Issued Patent Broadens Proprietary Position in Nanomanufacturing and
Nanotechnology
SAN DIEGO, Dec. 3 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) today announced that it has been issued U.S. Patent No. 6,652,808, "Methods for the Electronic Assembly and Fabrication of Devices," ("the `808 patent") by the U.S. Patent and Trademark Office. This patent is the parent of a series of pending patent applications that significantly broaden Nanogen`s proprietary position in the nanotechnology and nanomanufacturing areas. The Company has now been issued nine patents during 2003, bringing the total number of patents issued in the U.S. to 56.
"One of the challenges in producing new electronic and photonic devices using nanoscale components is the integration of these components into viable higher order devices. The new Nanogen patent describes a unique electric field `pick and place` process that facilitates the bringing together or integration of diverse DNA nanocomponents, thereby helping solve difficult scaling issues. Combining the top-down electric field process with the bottom-up DNA self-assembly process enables more selective and higher precision incorporation of nanoscale components into higher order devices and structures," said Dr. Michael J. Heller, co-founder of Nanogen, one of the inventors, and currently a Professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
"The technology described by Nanogen`s new patent may provide a technological foundation for the effective use of nanocomponents in many diverse applications," said Howard Birndorf, Nanogen chairman and CEO. "As we continue to increase and broaden our intellectual property portfolio, we intend to realize value from our nanotechnology patents through licensing or partnering opportunities. Congress` recent commitment to nanotechnology research and development underscores the potential our technologies may have for impacting several industries, including medicine."
The new nanotechnology patent relates to a nanofabrication technology that combines an electric field assisted manufacturing platform and programmable self-assembling nanostructures (for example, DNA building blocks) for the fabrication of a wide range of unique higher-order nano and microscale devices, structures, and materials. The nanofabrication platform and process would be used for: (1) producing new nanoscale electronic and photonic devices and structures, including high-density 2D and 3D data storage materials, 2D and 3D photonic crystal structures, hybrid electronic/photonic devices such as large area light emitting flat panel arrays and displays, and for the fabrication of highly integrated medical diagnostic and biosensor devices; (2) organization, assembly and interconnection of nanostructures and submicron components onto silicon wafers and other materials; (3) integration of nanostructures within preformed microelectronic and optoelectronic structures; (4) production of precision modified nanoparticles (for example, photonic crystals, nanospheres and quantum dots) which can then more efficiently self-assemble into 2D and 3D structures and materials (photonic band gap structures, nanocomposite materials and so forth); and (5) fabrication of selectively addressable DNA nanoarray substrates and materials.
The patent represents a unique nanofabrication technology which combines the best aspects of top-down microfabrication processes with bottom-up biological type self-assembly processes for producing novel nanodevices and nanostructures. The process is highly parallel and has an inherent hierarchical logic allowing one to control the organization, assembly and communication of components from the molecular and nanoscale into macroscale devices and structures.
The `808 patent is jointly owned by Nanotronics, Inc., a wholly owned subsidiary of Nanogen, and the Regents of the University of California. Nanogen has exclusively licensed the interests of the University of California where there is joint inventorship. Additionally, Nanogen disclosed the issuance over the last several months of three patents relating to electronic microarray technology. The three additional issued patents are U.S. Patent No. 6,582,660 "Control System for Active Programmable Electronic Microbiology System," U.S. Patent No. 6,589,742 "Multiplex Amplification and Separation of Nucleic Acid Sequences on a Bioelectronic Microchip Using Asymmetric Structures," and U.S. Patent No. 6,638,482 "Reconfigurable Detection and Analysis Apparatus and Method."
About Nanogen
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip(R) System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip(R) System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by the Company will be developed into products, whether the Company`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
-0- 12/03/2003
/CONTACT: David Ludvigson, Executive Vice President & Chief Financial
Officer of Nanogen, Inc., +1-858-410-4600, dludvigson@nanogen.com; or Pam Lord
of Atkins + Associates, +1-858-527-3494, plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
CO: Nanogen, Inc.
ST: California
IN: BIO MTC HEA
SU: PDT
SE
-- LAW045 --
5073 12/03/2003 08:01 EST http://www.prnewswire.com
Auf einmal wird wieder über NGEN geschrieben - tja....stay long und have fun.....NGEN war nicht vor allzu langer Zeit nur knapp über 1$
Dow Jones Business News
Nanogen Shares Rise as Firm Obtains Another Patent
Wednesday December 3, 11:21 am ET
By Gretchen L. Wilson
NEW YORK -- Shares of Nanogen Inc. (NasdaqNM:NGEN - News) jumped Wednesday after the company was awarded a U.S. patent that it said "significantly" broadens its intellectual property in the nascent field of nanotechnology.
ADVERTISEMENT
Nanotechnology and nanomanufacturing combine physics and engineering to build materials from small numbers of atoms. According to Nanogen`s statement, the new patent relates to a technology that uses both an electric field-assisted manufacturing platform and self-assembling nanostructures such as DNA building blocks to make "higher-order" devices.
The provider of molecular-diagnostic products said the platform and process could be used in the production of such devices as light-emitting flat panel displays, 2D- and 3D data storage materials and silicon wafers.
"The technology described by Nanogen`s new patent may provide a technological foundation for the effective use of nanocomponents in many diverse applications, " said Nanogen Chairman and Chief Executive Howard Birndorf, adding that the company plans to pursue licensing and partnering opportunities.
While a company representative wasn`t available for comment on the release, Thomas Heinzen, vice president of Emergent Financial Group, said the patent represents an inroad into nanotechnology manufacturing.
"This patent is how you fabricate nanotechnology, which could be important going forward as nanotechnology becomes more pervasive, which may be why the market is so excited," he said.
Mr. Heinzen, whose clients have a position in the company and who owns Nanogen shares himself, pointed out that Nanogen`s most recent U.S. patent is the ninth the firm has secured this year.
"They are broadening the value of the company," he said. "If you believe nanotechnology is going to be important in the future, those patents are valuable."
At around 11 a.m. EST, shares of the San Diego-based company were up $1.75, or 46%, to $5.54 on the Nasdaq Stock Market (News - Websites) . The stock trounced its 52-week high of $4.98, set on June 2.
Emergent Financial`s Heinzen noted that in September Nanogen announced a private placement of stock and warrants. As part of the deal, the investors received five-year warrants to purchase 424,243 shares of stock at an exercise price of $4.75 a share, 12-month warrants to buy 530,305 shares at $4.75 a share and six-month warrants to buy 1.1 million shares at $4.14 a share.
With shares trading significantly higher than these prices Wednesday, Mr. Heinzen said investors may choose to exercise the warrants, which would "add more money to (Nanogen`s) coffers."
The executive pointed out that Nanogen isn`t profitable. "One of the worries about Nanogen was their cash-burn rate," he said.
Mr. Heinzen said he didn`t know how many more of the company`s pending patents are close to approval.
In May, Nanogen shares jumped after it announced another patent related to methods used to integrate micro and nanoscale components.
-Gretchen L. Wilson, Dow Jones Newswires; 201-938-5394
Dow Jones Business News
Nanogen Shares Rise as Firm Obtains Another Patent
Wednesday December 3, 11:21 am ET
By Gretchen L. Wilson
NEW YORK -- Shares of Nanogen Inc. (NasdaqNM:NGEN - News) jumped Wednesday after the company was awarded a U.S. patent that it said "significantly" broadens its intellectual property in the nascent field of nanotechnology.
ADVERTISEMENT
Nanotechnology and nanomanufacturing combine physics and engineering to build materials from small numbers of atoms. According to Nanogen`s statement, the new patent relates to a technology that uses both an electric field-assisted manufacturing platform and self-assembling nanostructures such as DNA building blocks to make "higher-order" devices.
The provider of molecular-diagnostic products said the platform and process could be used in the production of such devices as light-emitting flat panel displays, 2D- and 3D data storage materials and silicon wafers.
"The technology described by Nanogen`s new patent may provide a technological foundation for the effective use of nanocomponents in many diverse applications, " said Nanogen Chairman and Chief Executive Howard Birndorf, adding that the company plans to pursue licensing and partnering opportunities.
While a company representative wasn`t available for comment on the release, Thomas Heinzen, vice president of Emergent Financial Group, said the patent represents an inroad into nanotechnology manufacturing.
"This patent is how you fabricate nanotechnology, which could be important going forward as nanotechnology becomes more pervasive, which may be why the market is so excited," he said.
Mr. Heinzen, whose clients have a position in the company and who owns Nanogen shares himself, pointed out that Nanogen`s most recent U.S. patent is the ninth the firm has secured this year.
"They are broadening the value of the company," he said. "If you believe nanotechnology is going to be important in the future, those patents are valuable."
At around 11 a.m. EST, shares of the San Diego-based company were up $1.75, or 46%, to $5.54 on the Nasdaq Stock Market (News - Websites) . The stock trounced its 52-week high of $4.98, set on June 2.
Emergent Financial`s Heinzen noted that in September Nanogen announced a private placement of stock and warrants. As part of the deal, the investors received five-year warrants to purchase 424,243 shares of stock at an exercise price of $4.75 a share, 12-month warrants to buy 530,305 shares at $4.75 a share and six-month warrants to buy 1.1 million shares at $4.14 a share.
With shares trading significantly higher than these prices Wednesday, Mr. Heinzen said investors may choose to exercise the warrants, which would "add more money to (Nanogen`s) coffers."
The executive pointed out that Nanogen isn`t profitable. "One of the worries about Nanogen was their cash-burn rate," he said.
Mr. Heinzen said he didn`t know how many more of the company`s pending patents are close to approval.
In May, Nanogen shares jumped after it announced another patent related to methods used to integrate micro and nanoscale components.
-Gretchen L. Wilson, Dow Jones Newswires; 201-938-5394
Reuters
UPDATE - Nanogen shares soar 50 percent on nanotech patent
Wednesday December 3, 4:39 pm ET
(Updates with closing share price)
NEW YORK, Dec 3 (Reuters) - Shares of Nanogen Inc. (NasdaqNM:NGEN - News) jumped more than 50 percent to their highest level in nearly two years on Wednesday after the company received a U.S. patent related to the fledgling field of nanotechnology and nanomanufacturing.
ADVERTISEMENT
Nanogen, which develops diagnostic instruments for genetic testing, said the patent could lead to microscopic electronic and photonic devices for data storage or medical diagnostics.
The U.S. Congress last month passed a bill earmarking $3.7 billion over four years to fund research in nanotechnology -- the science of manipulating materials on the molecular level to create new machines or materials.
Howard Birndorf, Nanogen chairman and chief executive, said the company planned to capitalize on its nanotechnology patents through licensing or partnering.
Shares of San Diego-based Nanogen rose $1.95, or 51.5 percent, to close at $5.74 on the Nasdaq market, where it was the day`s top percentage gainer.
UPDATE - Nanogen shares soar 50 percent on nanotech patent
Wednesday December 3, 4:39 pm ET
(Updates with closing share price)
NEW YORK, Dec 3 (Reuters) - Shares of Nanogen Inc. (NasdaqNM:NGEN - News) jumped more than 50 percent to their highest level in nearly two years on Wednesday after the company received a U.S. patent related to the fledgling field of nanotechnology and nanomanufacturing.
ADVERTISEMENT
Nanogen, which develops diagnostic instruments for genetic testing, said the patent could lead to microscopic electronic and photonic devices for data storage or medical diagnostics.
The U.S. Congress last month passed a bill earmarking $3.7 billion over four years to fund research in nanotechnology -- the science of manipulating materials on the molecular level to create new machines or materials.
Howard Birndorf, Nanogen chairman and chief executive, said the company planned to capitalize on its nanotechnology patents through licensing or partnering.
Shares of San Diego-based Nanogen rose $1.95, or 51.5 percent, to close at $5.74 on the Nasdaq market, where it was the day`s top percentage gainer.
SmartMoney.com
A Tiny Triumph
Wednesday December 3, 6:10 pm ET
By Lawrence Carrel
Nanogen, Inc. (NASDAQ:NGEN - News)
Share price as of Tuesday`s close: $3.79
Share price now: $5.74
Change: 51.5%
Volume: 29.3 million shares, daily average 152,800 shares
Last time this high: Jan. 7, 2002
52-week high: $4.98
52-week low: $1.00
Forward P/E before announcement: n/a
Forward P/E after announcement: n/a
ADVERTISEMENT
WOULD YOU KNOW a "top-down electric field process" from "the bottom-up DNA self-assembly?"
If so, you`re unusually qualified to judge the value of the ninth patent obtained this year by suitably tiny nanotech pioneer Nanogen (NASDAQ:NGEN - News).
The rest of us will just have to live with the company`s assessment that it`s "key" and the market`s verdict that proprietary insights into "an electric field assisted manufacturing platform and programmable self-assembling nanostructures" were worthy of a 51% share-price surge to a two-year high of $5.74.
Nanotechnology, a blend of chemistry and engineering, creates tiny devices or systems that operate on atomic and molecular scales. A nanometer is a billionth of a meter. By comparison, a single human cell is between 5,000 and 10,000 nanometers long.
One day, nanotech might put a supercomputer on the head of the pin. For the moment, however, it`s hard pressed to turn a profit.
Still, the microscopic discipline is enjoying lots of buzz as The Next Big Thing. On Wednesday, President Bush signed the 21st Century Nanotechnology Research and Development Act, authorizing $3.7 billion in nanotech research funding over the next four years.
Also Wednesday, Merrill Lynch held a conference call on nanotechnology. Analyst John Roy tried to convince investors that "nanotechnology could become the next growth innovation." Roy foresees uses in the fields of enhanced materials, hard-disk drives, optical networking, memory chips, medical drugs and genomic testing. And while Merrill tech strategist Steve Milunovich said during the same call that "nanotech will be over-hyped," he added that "where there`s smoke there`s fire. Nanotech is real and the intellectual-property barriers are much higher than for the Internet."
Such helpful speculation has helped Nanogen shares gain 463% since its March lows, though they still fetch less than one-sixteenth of the all-time high set in March 2000.
The latest patent, the San Diego company`s 56th overall, is the first in a series of pending applications related to the same advance. "If you think nanotechnology will be valuable in the future, this patent could be very valuable," says Tom Heinzen, vice president of Emergent Financial Group, a Minneapolis brokerage.
The company seems to agree. "The patent is important because it pertains to fundamental methods of fabricating components," says Michael Heller, a professor of bioengineering and electrical engineering at the University of California, San Diego. He co-founded Nanogen and worked on the new technology. "It`s a microchip that produces electrical fields that can control the assembly of nanocomponents. It can manipulate the nanoparticles using the electric field device," he explains
According to Heller, nanocomponents can incorporate DNA sequences giving them specific binding affinity, in effect instructions for a process of self-assembly. He says the electric fields help guide and control the self-assembly process, and allow it to be replicated on a wide scale.
"The process will help create nanostructures that can be used to create things such as features on computer chips like transistors and memory elements," says Heller. "There is a lot of evolutionary progress in the field. There are a lot of pragmatic applications, but what you haven`t seen is anything revolutionary. We haven`t seen the paradigm change yet."
Nanoparticle materials are currently being used in some not-so-sexy applications, such as grinding and polishing agents.
What little revenue Nanogen currently has comes from the development of molecular diagnostic products. It currently sells two: the NanoChip Molecular Biology Workstation, a platform for detecting genetic mutations with forensic and biowarfare applications, and the disposable cartridges used by that platform. The products have been on the market less than two years, and the 10-year-old company remains unprofitable.
For the third quarter, it posted a net loss of $7.1 million, or 33 cents a share, a 14% improvement from the year-earlier period. Revenues jumped 12% year-over-year to $1.7 million, based on 10 sales or rentals of the workstation.
Heinzen is a fan of the company`s management. Howard Birndorf, Nanogen`s chairman and chief executive, founded six other companies, including Idec Pharmaceuticals, Ligand Pharmaceuticals (NASDAQ:LGND - News) and Gen-Probe (NASDAQ:GPRO - News). "He`s got a track record of success," says Heinzen. "He knows the bio industries and he`s the first reason we looked at it."
Others are also getting on board. The $32.6 million in cash Nanogen had at the end of the quarter represented a $4.1 million increase from the prior period, thanks to a private-equity placement that grossed $7 million in fresh capital. As part of the deal, investors received five-year warrants to purchase common stock at an exercise price of $4.75 a share, 12-month warrants at $4.75 a share and six-month warrants at $4.14 a share. If the stock stays at its current price, and investors exercise all their options, the company could receive an additional $9 million in cash.
At the end of the quarter, Nanogen forecast 2003 product revenue of less than $4 million and research revenue of $4 million. The loss for the year could approach $29 million, with cash holdings pegged at $28 million to $30 million. The company expects revenue to increase by 50% in 2004.
Quote:
"They know how to do things on a small scale and they are broadening their knowledge to get patents in other aspects in nanotechnology," says Heinzen of Emergent Financial Group. "We like the current workstation. We think it`s better, faster and will get cheaper. We think the platform will succeed. These patents are the cherry on the sundae. From the way I read it, it doesn`t deal with their day-to-day operations. But there are quite a few people out there that are looking for companies that have knowledge and patents in nanotechnology." (Heinzen owns shares of Nanogen; Emergent Financial Group doesn`t have an investment-banking relationship with the company.)
A Tiny Triumph
Wednesday December 3, 6:10 pm ET
By Lawrence Carrel
Nanogen, Inc. (NASDAQ:NGEN - News)
Share price as of Tuesday`s close: $3.79
Share price now: $5.74
Change: 51.5%
Volume: 29.3 million shares, daily average 152,800 shares
Last time this high: Jan. 7, 2002
52-week high: $4.98
52-week low: $1.00
Forward P/E before announcement: n/a
Forward P/E after announcement: n/a
ADVERTISEMENT
WOULD YOU KNOW a "top-down electric field process" from "the bottom-up DNA self-assembly?"
If so, you`re unusually qualified to judge the value of the ninth patent obtained this year by suitably tiny nanotech pioneer Nanogen (NASDAQ:NGEN - News).
The rest of us will just have to live with the company`s assessment that it`s "key" and the market`s verdict that proprietary insights into "an electric field assisted manufacturing platform and programmable self-assembling nanostructures" were worthy of a 51% share-price surge to a two-year high of $5.74.
Nanotechnology, a blend of chemistry and engineering, creates tiny devices or systems that operate on atomic and molecular scales. A nanometer is a billionth of a meter. By comparison, a single human cell is between 5,000 and 10,000 nanometers long.
One day, nanotech might put a supercomputer on the head of the pin. For the moment, however, it`s hard pressed to turn a profit.
Still, the microscopic discipline is enjoying lots of buzz as The Next Big Thing. On Wednesday, President Bush signed the 21st Century Nanotechnology Research and Development Act, authorizing $3.7 billion in nanotech research funding over the next four years.
Also Wednesday, Merrill Lynch held a conference call on nanotechnology. Analyst John Roy tried to convince investors that "nanotechnology could become the next growth innovation." Roy foresees uses in the fields of enhanced materials, hard-disk drives, optical networking, memory chips, medical drugs and genomic testing. And while Merrill tech strategist Steve Milunovich said during the same call that "nanotech will be over-hyped," he added that "where there`s smoke there`s fire. Nanotech is real and the intellectual-property barriers are much higher than for the Internet."
Such helpful speculation has helped Nanogen shares gain 463% since its March lows, though they still fetch less than one-sixteenth of the all-time high set in March 2000.
The latest patent, the San Diego company`s 56th overall, is the first in a series of pending applications related to the same advance. "If you think nanotechnology will be valuable in the future, this patent could be very valuable," says Tom Heinzen, vice president of Emergent Financial Group, a Minneapolis brokerage.
The company seems to agree. "The patent is important because it pertains to fundamental methods of fabricating components," says Michael Heller, a professor of bioengineering and electrical engineering at the University of California, San Diego. He co-founded Nanogen and worked on the new technology. "It`s a microchip that produces electrical fields that can control the assembly of nanocomponents. It can manipulate the nanoparticles using the electric field device," he explains
According to Heller, nanocomponents can incorporate DNA sequences giving them specific binding affinity, in effect instructions for a process of self-assembly. He says the electric fields help guide and control the self-assembly process, and allow it to be replicated on a wide scale.
"The process will help create nanostructures that can be used to create things such as features on computer chips like transistors and memory elements," says Heller. "There is a lot of evolutionary progress in the field. There are a lot of pragmatic applications, but what you haven`t seen is anything revolutionary. We haven`t seen the paradigm change yet."
Nanoparticle materials are currently being used in some not-so-sexy applications, such as grinding and polishing agents.
What little revenue Nanogen currently has comes from the development of molecular diagnostic products. It currently sells two: the NanoChip Molecular Biology Workstation, a platform for detecting genetic mutations with forensic and biowarfare applications, and the disposable cartridges used by that platform. The products have been on the market less than two years, and the 10-year-old company remains unprofitable.
For the third quarter, it posted a net loss of $7.1 million, or 33 cents a share, a 14% improvement from the year-earlier period. Revenues jumped 12% year-over-year to $1.7 million, based on 10 sales or rentals of the workstation.
Heinzen is a fan of the company`s management. Howard Birndorf, Nanogen`s chairman and chief executive, founded six other companies, including Idec Pharmaceuticals, Ligand Pharmaceuticals (NASDAQ:LGND - News) and Gen-Probe (NASDAQ:GPRO - News). "He`s got a track record of success," says Heinzen. "He knows the bio industries and he`s the first reason we looked at it."
Others are also getting on board. The $32.6 million in cash Nanogen had at the end of the quarter represented a $4.1 million increase from the prior period, thanks to a private-equity placement that grossed $7 million in fresh capital. As part of the deal, investors received five-year warrants to purchase common stock at an exercise price of $4.75 a share, 12-month warrants at $4.75 a share and six-month warrants at $4.14 a share. If the stock stays at its current price, and investors exercise all their options, the company could receive an additional $9 million in cash.
At the end of the quarter, Nanogen forecast 2003 product revenue of less than $4 million and research revenue of $4 million. The loss for the year could approach $29 million, with cash holdings pegged at $28 million to $30 million. The company expects revenue to increase by 50% in 2004.
Quote:
"They know how to do things on a small scale and they are broadening their knowledge to get patents in other aspects in nanotechnology," says Heinzen of Emergent Financial Group. "We like the current workstation. We think it`s better, faster and will get cheaper. We think the platform will succeed. These patents are the cherry on the sundae. From the way I read it, it doesn`t deal with their day-to-day operations. But there are quite a few people out there that are looking for companies that have knowledge and patents in nanotechnology." (Heinzen owns shares of Nanogen; Emergent Financial Group doesn`t have an investment-banking relationship with the company.)
www.boersenreport.de
Das Biotech-Unternehmen Nanogen (NGEN), mit Sitz in San Diego, hat ein weiteres Schlüssel-Patent im Rahmen seiner elektronischen Herstellungsprozesse für mikro- und nanotechnologische Bauteile erhalten. Die Meldung pushte die Aktie um 51,45 % auf 5,74 Dollar, nachbörslich legte sie um weitere 0,35 % oder 2 Cents zu.
Das Biotech-Unternehmen Nanogen (NGEN), mit Sitz in San Diego, hat ein weiteres Schlüssel-Patent im Rahmen seiner elektronischen Herstellungsprozesse für mikro- und nanotechnologische Bauteile erhalten. Die Meldung pushte die Aktie um 51,45 % auf 5,74 Dollar, nachbörslich legte sie um weitere 0,35 % oder 2 Cents zu.
http://yahoo.businessweek.com/technology/content/dec2003/tc2…
DECEMBER 8, 2003
STREET WISE
By Eric Wahlgren
Homeland Defense for Investors
Dawn Van Zant, founder of homelanddefensestocks.com, explains how you can "follow the money" in the anti-terrorism business
Protecting the U.S. against terrorism of all kinds -- bio, cyber, and general mayhem -- is a booming business. The homeland security industry should grow to more than $170 billion in 2006, from an expected $100 billion in 2003, says Homeland Security Research Corp., an industry research group.
The huge growth potential caught the attention of entrepreneur Dawn Van Zant, founder of ECON Investor Relations, a corporate-communications and investor-research firm in Point Roberts, Wash. Believing there was a need for a "one-stop shop" for information on companies big and small involved in the business, Van Zant launched investment portal homelanddefensestocks.com in 2002.
The Web site offers research conducted by Van Zant, a former trader for various boutique firms, as well as from other stock and homeland defense experts. Although the information is free for now, investors should be aware that the site receives compensation from the "Featured Companies" it profiles once a month. It doesn`t have ties to other companies mentioned on the site, Van Zant says.
In a recent chat with BusinessWeek Online Reporter Eric Wahlgren, Van Zant discussed trends in the homeland defense industry as well as certain companies that may stand to benefit from these trends. Edited excerpts of their conversation follow:
Q: How much is this industry expected to grow?
A: By 2006, it could grow to $170 billion. In talking to other analysts, fund managers, and homeland defense experts, everyone has the perception that this industry is very long-term. The ongoing war on terrorism is probably not going to end in our lifetimes.
Q: That`s a scary thought. What kind of companies are going to gain from this war?
A: It has changed since September 11, 2001, when companies involved in X-ray security and detection, in terms of airport security, saw gains. These days, the key emerging areas are biodefense and port and border security. In port and border security, there`s a move toward developing better ways to detect explosives and other dangerous materials.
Q: Before we talk specifics, you say investors should not view stocks that you mention here or on your site as recommendations for investment?
A: That`s right. We don`t make recommendations. We want to be an investment portal that investors can use as a starting point to do more research on particular firms.
Q: So any names that might benefit from the fight against bioterrorism?
A: One company that has gotten a lot of attention is Nanogen (NGEN ). In September, they announced that they were collaborating with another company to create products that would detect infectious diseases. What differentiates them from others is that they use nanotechnology to speed up the testing process. While a traditional lab might take a week to come back with results, one using Nanogen technology could process information much faster.
There`s also Avant Immunotherapeutics (AVAN ). They`re working on applications for the prevention and treatment of disease. Basically, they`re looking for vaccines for troops and civilians against biological warfare.
Q: What about companies involved in the business of boosting port and border defense?
A: Well, the one company that`s doing this is our client, Markland Technologies. It has a contract with the Homeland Security Dept. for a technology that basically uses acoustic waves to detect [hazardous] material. If the results are good, the technology would allow officials to determine what a particular material is, based on something akin to a DNA reading. This technology would enable border agents to better detect explosives and drugs. The company also has other products on the market right now for cargo screening and other uses.
Q: We`ve heard a lot about terrorists using the Web to send encoded messages, among other nefarious things. What companies that fight cyberterrorism might investors look at?
A: One company we follow here is Internet Security Systems (ISSX ). They probably are one of the bigger names in the industry. They make protection systems against a full spectrum of cyberterrorism threats.
Another one is Rainbow Technologies (RNBO ). They have secure-communication products for wireless transactions. They have commercial applications, but they also have applications for government defense and homeland security for securing classified information.
Q: How active are the big defense contractors in homeland defense?
A: One of the companies I`ve been watching is Honeywell International (HON ). A lot of the people I talk to also like Northrop Grumman (NOC ). We also watch Lockheed Martin (LMT ), but Honeywell looks like it`s trying to get more into homeland security than it was in the past.
It recently acquired a company called Silent Witness, which makes closed-circuit cameras used for surveillance. On the whole, I`m seeing more acquisitions like these by larger companies. I think homeland defense will be an area of growth for them.
Q: Are there any emerging technologies that are likely to have applications for homeland defense?
A: Again, nanotechnology is what a lot of people are looking at. It`s still emerging. There is one smaller company that is making bulletproof vests and doors using nanotechnology.What makes nanotechnology attractive in this application is that it is very lightweight.
Nanotechnology is also being used to develop explosives-detection devices. These are mostly smaller companies, so investors should keep watch on that area.
Q: Any other companies investors should know about?
A: TASER International (TASR ) has done really well. Their stock is up to more than $80 a share, from around $3 or so a year ago. They make what`s called less-lethal weapons for law-enforcement and corrections officers. Their product is a compressed nitrogen electrified probe. There`s a lot of interest in these less-lethal weapons. [TASER`S Web site says the electrical output from one of its probes "jams" the human body`s communication system, usually causing targets to fall to the ground.]
Overall, though, I would really recommend that investors look at sectors within the industry. They will see that money is going into biodefense, port and border security, and nanotechnology. Companies that benefit may change, so it may be more useful to start keeping tabs on these sectors.
For instance, when you look at the $29.4 billion 2004 budget for the Homeland Security Dept., over $9 billion of that was allocated to port and border security. Follow the money. Along with government spending, you always want to look at what the bigger companies in homeland defense are doing in terms of acquisitions. That will help tell you what technologies are likely to be at the forefront.
Q: The Bush Administration has made the war on terrorism one of its top priorities. Would the homeland defense industry be less successful if a Democrat were elected President in 2004?
A: Most people say no. There are still major gaps in security. That is not going to change. If we come out with new technologies, terrorists are going to be looking at those technologies as well. You always have to be at least one step ahead of them.
DECEMBER 8, 2003
STREET WISE
By Eric Wahlgren
Homeland Defense for Investors
Dawn Van Zant, founder of homelanddefensestocks.com, explains how you can "follow the money" in the anti-terrorism business
Protecting the U.S. against terrorism of all kinds -- bio, cyber, and general mayhem -- is a booming business. The homeland security industry should grow to more than $170 billion in 2006, from an expected $100 billion in 2003, says Homeland Security Research Corp., an industry research group.
The huge growth potential caught the attention of entrepreneur Dawn Van Zant, founder of ECON Investor Relations, a corporate-communications and investor-research firm in Point Roberts, Wash. Believing there was a need for a "one-stop shop" for information on companies big and small involved in the business, Van Zant launched investment portal homelanddefensestocks.com in 2002.
The Web site offers research conducted by Van Zant, a former trader for various boutique firms, as well as from other stock and homeland defense experts. Although the information is free for now, investors should be aware that the site receives compensation from the "Featured Companies" it profiles once a month. It doesn`t have ties to other companies mentioned on the site, Van Zant says.
In a recent chat with BusinessWeek Online Reporter Eric Wahlgren, Van Zant discussed trends in the homeland defense industry as well as certain companies that may stand to benefit from these trends. Edited excerpts of their conversation follow:
Q: How much is this industry expected to grow?
A: By 2006, it could grow to $170 billion. In talking to other analysts, fund managers, and homeland defense experts, everyone has the perception that this industry is very long-term. The ongoing war on terrorism is probably not going to end in our lifetimes.
Q: That`s a scary thought. What kind of companies are going to gain from this war?
A: It has changed since September 11, 2001, when companies involved in X-ray security and detection, in terms of airport security, saw gains. These days, the key emerging areas are biodefense and port and border security. In port and border security, there`s a move toward developing better ways to detect explosives and other dangerous materials.
Q: Before we talk specifics, you say investors should not view stocks that you mention here or on your site as recommendations for investment?
A: That`s right. We don`t make recommendations. We want to be an investment portal that investors can use as a starting point to do more research on particular firms.
Q: So any names that might benefit from the fight against bioterrorism?
A: One company that has gotten a lot of attention is Nanogen (NGEN ). In September, they announced that they were collaborating with another company to create products that would detect infectious diseases. What differentiates them from others is that they use nanotechnology to speed up the testing process. While a traditional lab might take a week to come back with results, one using Nanogen technology could process information much faster.
There`s also Avant Immunotherapeutics (AVAN ). They`re working on applications for the prevention and treatment of disease. Basically, they`re looking for vaccines for troops and civilians against biological warfare.
Q: What about companies involved in the business of boosting port and border defense?
A: Well, the one company that`s doing this is our client, Markland Technologies. It has a contract with the Homeland Security Dept. for a technology that basically uses acoustic waves to detect [hazardous] material. If the results are good, the technology would allow officials to determine what a particular material is, based on something akin to a DNA reading. This technology would enable border agents to better detect explosives and drugs. The company also has other products on the market right now for cargo screening and other uses.
Q: We`ve heard a lot about terrorists using the Web to send encoded messages, among other nefarious things. What companies that fight cyberterrorism might investors look at?
A: One company we follow here is Internet Security Systems (ISSX ). They probably are one of the bigger names in the industry. They make protection systems against a full spectrum of cyberterrorism threats.
Another one is Rainbow Technologies (RNBO ). They have secure-communication products for wireless transactions. They have commercial applications, but they also have applications for government defense and homeland security for securing classified information.
Q: How active are the big defense contractors in homeland defense?
A: One of the companies I`ve been watching is Honeywell International (HON ). A lot of the people I talk to also like Northrop Grumman (NOC ). We also watch Lockheed Martin (LMT ), but Honeywell looks like it`s trying to get more into homeland security than it was in the past.
It recently acquired a company called Silent Witness, which makes closed-circuit cameras used for surveillance. On the whole, I`m seeing more acquisitions like these by larger companies. I think homeland defense will be an area of growth for them.
Q: Are there any emerging technologies that are likely to have applications for homeland defense?
A: Again, nanotechnology is what a lot of people are looking at. It`s still emerging. There is one smaller company that is making bulletproof vests and doors using nanotechnology.What makes nanotechnology attractive in this application is that it is very lightweight.
Nanotechnology is also being used to develop explosives-detection devices. These are mostly smaller companies, so investors should keep watch on that area.
Q: Any other companies investors should know about?
A: TASER International (TASR ) has done really well. Their stock is up to more than $80 a share, from around $3 or so a year ago. They make what`s called less-lethal weapons for law-enforcement and corrections officers. Their product is a compressed nitrogen electrified probe. There`s a lot of interest in these less-lethal weapons. [TASER`S Web site says the electrical output from one of its probes "jams" the human body`s communication system, usually causing targets to fall to the ground.]
Overall, though, I would really recommend that investors look at sectors within the industry. They will see that money is going into biodefense, port and border security, and nanotechnology. Companies that benefit may change, so it may be more useful to start keeping tabs on these sectors.
For instance, when you look at the $29.4 billion 2004 budget for the Homeland Security Dept., over $9 billion of that was allocated to port and border security. Follow the money. Along with government spending, you always want to look at what the bigger companies in homeland defense are doing in terms of acquisitions. That will help tell you what technologies are likely to be at the forefront.
Q: The Bush Administration has made the war on terrorism one of its top priorities. Would the homeland defense industry be less successful if a Democrat were elected President in 2004?
A: Most people say no. There are still major gaps in security. That is not going to change. If we come out with new technologies, terrorists are going to be looking at those technologies as well. You always have to be at least one step ahead of them.
quo vadis ngen ?
hier ist ja der teufel los.
ich hoffe, es kommen ein paar einschätzungen von den superlspezis zu ngen.
wäre eine nettes weihnachtsgeschenk.
merci
rob
hier ist ja der teufel los.
ich hoffe, es kommen ein paar einschätzungen von den superlspezis zu ngen.
wäre eine nettes weihnachtsgeschenk.
merci
rob
ohne worte...
was hier abgeht
was hier abgeht
Da lässt man NGEN und die Aktien knapp einen Monat ruhen und dann folgt mit NGEN eine sehr positive Überraschung.
Es folgen einige Berichte über unsere Lieblingsaktie
Es folgen einige Berichte über unsere Lieblingsaktie
SmartMoney.com
Small Is Big
Friday December 19, 2:36 pm ET
By Monica Rivituso
NANOTECHNOLOGY, IN case you haven`t heard, is the biggest littlest thing around. Our advice for investors: Look before you leap.
Earlier this month, President Bush signed the 21st Century Nanotech Research and Development Act, a bill that creates the National Nanotechnology Coordination Office and devotes $3.7 billion to research over the next four years.
That news only added to the nanotech hype machine, which has been cranking full blast for months. Now, we`re beginning to see classic signs of speculative mania. For example, on Dec. 3 (coincidentally the same day as Bush`s bill signing), San Diego-based biotech outfit Nanogen (NASDAQ:NGEN - News) jumped 51% on news that it received a key nanotechnology patent. The euphoria spilled over to Milpitas, Calif.-based Nanometrics (NASDAQ:NANO - News), whose stock spiked 10% that day before closing with a 5% gain. The fact that Nanometrics is a 25-year-old metrology-equipment maker didn`t deter investors in the least. Such buzz might have prompted a tiny company last month to change its name from MicroSignal to NanoSignal (OTC:MSGL - News). Its shares trade on the over-the-counter bulletin board, fetching seven cents on Friday.
"This stock is at the tip of the iceberg," istockman81 wrote about Nanometrics on Yahoo`s message board Dec. 3. "Amazing potential, next MSFT right here." Does all this remind you of 1999? Us too.
As with all stock-market crazes, misconceptions and lofty ideas abound. The science of nanotechnology is nothing new — researchers have been studying it for about two decades now. Nanotechnology is often mischaracterized as a single technology; it`s actually a broad term for the manipulation of materials at the atomic or molecular level. (The prefix "nano" means one-billionth.) It also isn`t a process specific to one industry: Nanotechnology can be applied to a spectrum of disciplines, from biotech to semiconductors to manufacturing. Perhaps the most promising application is biotech. One day, some futurists say, little "nanobots" could enter our bloodstreams and move around our bodies, fixing problems as they go. Wouldn`t that be nice?
But that scenario isn`t exactly in the offing. Few analysts cover the industry, few publicly traded pure-play companies exist, and there are no market-share data available. Bottom line: While the nanotechnology concept is promising, the revolution hasn`t happened yet — and won`t happen for years.
Nevertheless, while the overenthusiastic market reactions and science-fictionesque fears of nanobots taking over the earth make it easy to dismiss this as a silly passing fad, doing so would be a big mistake. Nanoscale technology is indeed something that could have a profound impact on a broad spectrum of industries, says Rhondalee Donovan, director of research at Semico, a Phoenix-based research firm.
Just think what nanotech can make possible: Drugs that can be administered more effectively at the molecular level, semiconductors that are more powerful and smaller than ever before, and computers that are "instant on." And there are more far-reaching hopes: tiny probes capable of detecting cancer in the earliest of stages, and tiny nano particles that could be sprayed to immunize vast populations for bioterror agents.
Nanotechnology has already worked its way into our everyday lives. The recording industry uses giant magneto resistance recording heads, while CDs rely on laser technology — both of which employ nanoscale technology. Nanoscale enhancements have been made to tennis balls so they keep their bounce longer. Privately held Nano-Tex makes fabrics stain resistant with tiny fibers. Cosmetics companies are using nanotechnology in creams to optimize intake of ingredients. Sunscreen makers are using nanoscale methods to eliminate that pesky, cakey white buildup in lotions. The abrasives industry is honing its polishing techniques at the nanoscale level.
But the real promise for nanotechnology — the stuff that gets venture capitalists like Steve Jurvetson of Draper Fisher Jurvetson excited — are applications that are closely aligned with industrial markets such as semiconductors, medicine and energy. Ultimately, consumers will see products that are better, cheaper and faster, where nanotechnology is deeply embedded into a larger product or service. Industrial customers will stand up and take notice far sooner.
A number of tech heavyweights are forging the way with some substantial nanotech achievements. Take chip manufacturing. It`s well known that chip-circuit widths can only get so small with conventional lithography methods. Indeed, lithography-free chip making has long been considered the holy grail of the chip industry (it allows for more powerful, tinier chips), and IBM (NYSE:IBM - News) demonstrated the potential for just that last week. Researchers at Big Blue used what`s called a "molecular self-assembly" technique to create circuit patterns, using certain polymers that organize themselves at the nanoscale level. With self-assembly, IBM was able to achieve what traditional circuit-making processes couldn`t. And after its innovative nanotech step, the rest of the chip-making process proved to be compatible with existing tools.
That hybrid process — incorporating nanotech with existing manufacturing techniques — is critical, explains Dr. Chris Murray, manager of nanoscale materials and devices at IBM. While nanotechnology`s transformative potential is substantial, it`ll first have to be inserted into existing manufacturing processes. "I see nanotechnology as largely being an expansion of a tool set, of manipulating technology and giving us options as we move forth," says Murray.
Mind you, IBM won`t likely build chips using this groundbreaking process for another five or 10 years. But count on some nanotech impact before then. That`s how major technological shifts work. They don`t happen overnight, or in a linear fashion.
Which is why it`s important to remember that, despite the market`s buzz, the future isn`t here just yet. Nanoscale technology could have a substantial impact someday — but long-term investors will have to stay tuned.
Small Is Big
Friday December 19, 2:36 pm ET
By Monica Rivituso
NANOTECHNOLOGY, IN case you haven`t heard, is the biggest littlest thing around. Our advice for investors: Look before you leap.
Earlier this month, President Bush signed the 21st Century Nanotech Research and Development Act, a bill that creates the National Nanotechnology Coordination Office and devotes $3.7 billion to research over the next four years.
That news only added to the nanotech hype machine, which has been cranking full blast for months. Now, we`re beginning to see classic signs of speculative mania. For example, on Dec. 3 (coincidentally the same day as Bush`s bill signing), San Diego-based biotech outfit Nanogen (NASDAQ:NGEN - News) jumped 51% on news that it received a key nanotechnology patent. The euphoria spilled over to Milpitas, Calif.-based Nanometrics (NASDAQ:NANO - News), whose stock spiked 10% that day before closing with a 5% gain. The fact that Nanometrics is a 25-year-old metrology-equipment maker didn`t deter investors in the least. Such buzz might have prompted a tiny company last month to change its name from MicroSignal to NanoSignal (OTC:MSGL - News). Its shares trade on the over-the-counter bulletin board, fetching seven cents on Friday.
"This stock is at the tip of the iceberg," istockman81 wrote about Nanometrics on Yahoo`s message board Dec. 3. "Amazing potential, next MSFT right here." Does all this remind you of 1999? Us too.
As with all stock-market crazes, misconceptions and lofty ideas abound. The science of nanotechnology is nothing new — researchers have been studying it for about two decades now. Nanotechnology is often mischaracterized as a single technology; it`s actually a broad term for the manipulation of materials at the atomic or molecular level. (The prefix "nano" means one-billionth.) It also isn`t a process specific to one industry: Nanotechnology can be applied to a spectrum of disciplines, from biotech to semiconductors to manufacturing. Perhaps the most promising application is biotech. One day, some futurists say, little "nanobots" could enter our bloodstreams and move around our bodies, fixing problems as they go. Wouldn`t that be nice?
But that scenario isn`t exactly in the offing. Few analysts cover the industry, few publicly traded pure-play companies exist, and there are no market-share data available. Bottom line: While the nanotechnology concept is promising, the revolution hasn`t happened yet — and won`t happen for years.
Nevertheless, while the overenthusiastic market reactions and science-fictionesque fears of nanobots taking over the earth make it easy to dismiss this as a silly passing fad, doing so would be a big mistake. Nanoscale technology is indeed something that could have a profound impact on a broad spectrum of industries, says Rhondalee Donovan, director of research at Semico, a Phoenix-based research firm.
Just think what nanotech can make possible: Drugs that can be administered more effectively at the molecular level, semiconductors that are more powerful and smaller than ever before, and computers that are "instant on." And there are more far-reaching hopes: tiny probes capable of detecting cancer in the earliest of stages, and tiny nano particles that could be sprayed to immunize vast populations for bioterror agents.
Nanotechnology has already worked its way into our everyday lives. The recording industry uses giant magneto resistance recording heads, while CDs rely on laser technology — both of which employ nanoscale technology. Nanoscale enhancements have been made to tennis balls so they keep their bounce longer. Privately held Nano-Tex makes fabrics stain resistant with tiny fibers. Cosmetics companies are using nanotechnology in creams to optimize intake of ingredients. Sunscreen makers are using nanoscale methods to eliminate that pesky, cakey white buildup in lotions. The abrasives industry is honing its polishing techniques at the nanoscale level.
But the real promise for nanotechnology — the stuff that gets venture capitalists like Steve Jurvetson of Draper Fisher Jurvetson excited — are applications that are closely aligned with industrial markets such as semiconductors, medicine and energy. Ultimately, consumers will see products that are better, cheaper and faster, where nanotechnology is deeply embedded into a larger product or service. Industrial customers will stand up and take notice far sooner.
A number of tech heavyweights are forging the way with some substantial nanotech achievements. Take chip manufacturing. It`s well known that chip-circuit widths can only get so small with conventional lithography methods. Indeed, lithography-free chip making has long been considered the holy grail of the chip industry (it allows for more powerful, tinier chips), and IBM (NYSE:IBM - News) demonstrated the potential for just that last week. Researchers at Big Blue used what`s called a "molecular self-assembly" technique to create circuit patterns, using certain polymers that organize themselves at the nanoscale level. With self-assembly, IBM was able to achieve what traditional circuit-making processes couldn`t. And after its innovative nanotech step, the rest of the chip-making process proved to be compatible with existing tools.
That hybrid process — incorporating nanotech with existing manufacturing techniques — is critical, explains Dr. Chris Murray, manager of nanoscale materials and devices at IBM. While nanotechnology`s transformative potential is substantial, it`ll first have to be inserted into existing manufacturing processes. "I see nanotechnology as largely being an expansion of a tool set, of manipulating technology and giving us options as we move forth," says Murray.
Mind you, IBM won`t likely build chips using this groundbreaking process for another five or 10 years. But count on some nanotech impact before then. That`s how major technological shifts work. They don`t happen overnight, or in a linear fashion.
Which is why it`s important to remember that, despite the market`s buzz, the future isn`t here just yet. Nanoscale technology could have a substantial impact someday — but long-term investors will have to stay tuned.
http://www.marketwatch.com/news/yhoo/story.asp?source=blq/yh…
Taking out Nasdaq 2,000
Tuesday`s set ups: NGEN, NFLX, FLML, NABI, DRG
By Michael Ashbaugh, CBS.MarketWatch.com
Last Update: 10:55 AM ET Dec. 30, 2003
...
.
.
Originally profiled in The Technical Indicator last Tuesday, Nanogen (NGEN: news, chart, profile) has since returned as much as 63 percent. Monday, the shares posted a single-day gain of 20.6 percent. Though the longer-term outlook remains bullish, the short-term risk/reward profile is now considerably less favorable following the pronounced spike higher.
.
.
.
....
Taking out Nasdaq 2,000
Tuesday`s set ups: NGEN, NFLX, FLML, NABI, DRG
By Michael Ashbaugh, CBS.MarketWatch.com
Last Update: 10:55 AM ET Dec. 30, 2003
...
.
.
Originally profiled in The Technical Indicator last Tuesday, Nanogen (NGEN: news, chart, profile) has since returned as much as 63 percent. Monday, the shares posted a single-day gain of 20.6 percent. Though the longer-term outlook remains bullish, the short-term risk/reward profile is now considerably less favorable following the pronounced spike higher.
.
.
.
....
Tja.....dass erneute Interesse der amerikanischen Regierung an Nanotechnologie und der gut gewählte Name von Nanogen lassen die Aktie wieder in aller Munde sein.
Und nachdem auch mal ein hoch gebrochen worden ist, geht es einfach nur nach Norden!
Ich finds schöööööön.....das Jahrestief befindet sich bei 1,01$ jetzt sind wir bei 11,69$
NGEN....ein klarer Fall für MEEEEEGA-LONG
Und nachdem auch mal ein hoch gebrochen worden ist, geht es einfach nur nach Norden!
Ich finds schöööööön.....das Jahrestief befindet sich bei 1,01$ jetzt sind wir bei 11,69$
NGEN....ein klarer Fall für MEEEEEGA-LONG
Weils so schön ist......
Am Mo. könnte es in den Staaten auch noch richtig abgehen, wenn alle von den Ferien nach Hause kommen und auf den Zug aufspringen wollen. Denke am Mo. wären 14$ durchaus möglich....
Ich bleib dabei!
Ich bleib dabei!
Aktueller Wochenchart seit März 1999. (1 Kerze = 1 Woche)
Diagnose: Am 06.03.2000 erreichte die Aktie bei 101,9375 $ ihr Alltimehigh. März 2000 bis März 2003 fiel der Aktienkurs in einem sauber definierten Abwärtstrend nach unten ab. Am 07.03.2003 wurde das Alltimelow bei 1 $ erreicht. Am 14.05.2003 konnte Nanogen über seine Abwärtstrendlinie ausbrechen. Dieser erste große Ausbruch wurde vom 29.05.2003 bis 02.12.2003 in einem großen symmetrischen Konsolidierungsdreieck auskonsolidiert. Seit dem 03.12.2003 bricht die Aktie regelkonform aus dem Dreieck nach oben aus.
Prognose: In dieser Woche läuft die Aktie an einen sehr wichtigen Widerstand bei 9,75 $ heran. Hier ist die Aktie stark konsolidierungsanfällig! WENN die 9,75 $ nachhaltig überwunden werden können, dann ergibt sich ein absolutes Mindest-Kursziel von 14,5 $.
Für die langfristigen Aussichten ist diese 14,5 $ Marke sehr wichtig. Kann sie überwunden werden, gibt es nach oben hin keine nennenswerten Hürden mehr.
Achten Sie auf das Kursgeschehen im Bereich des 9,75er Widerstands. Es besteht hier die Gefahr, daß sie zunächst nur Stopps in diesem Bereich abgrasen ("Gunning the stops").
http://www.godmode-trader.de
Diagnose: Am 06.03.2000 erreichte die Aktie bei 101,9375 $ ihr Alltimehigh. März 2000 bis März 2003 fiel der Aktienkurs in einem sauber definierten Abwärtstrend nach unten ab. Am 07.03.2003 wurde das Alltimelow bei 1 $ erreicht. Am 14.05.2003 konnte Nanogen über seine Abwärtstrendlinie ausbrechen. Dieser erste große Ausbruch wurde vom 29.05.2003 bis 02.12.2003 in einem großen symmetrischen Konsolidierungsdreieck auskonsolidiert. Seit dem 03.12.2003 bricht die Aktie regelkonform aus dem Dreieck nach oben aus.
Prognose: In dieser Woche läuft die Aktie an einen sehr wichtigen Widerstand bei 9,75 $ heran. Hier ist die Aktie stark konsolidierungsanfällig! WENN die 9,75 $ nachhaltig überwunden werden können, dann ergibt sich ein absolutes Mindest-Kursziel von 14,5 $.
Für die langfristigen Aussichten ist diese 14,5 $ Marke sehr wichtig. Kann sie überwunden werden, gibt es nach oben hin keine nennenswerten Hürden mehr.
Achten Sie auf das Kursgeschehen im Bereich des 9,75er Widerstands. Es besteht hier die Gefahr, daß sie zunächst nur Stopps in diesem Bereich abgrasen ("Gunning the stops").
http://www.godmode-trader.de
Hier aucg noch eine Information die den starken Anstieg unterstützt
Zacks.com Announces That Gregory Spear Highlights the Following Stocks: Harris & Harris and Nanogen
CHICAGO--(BUSINESS WIRE)--Dec. 26, 2003--Gregory Spear is looking toward the future and sees nanotechnology as a major point of interest. Learn how to make an early play on this burgeoning technology with a pair of new additions to the A-List. Learn about Harris & Harris (NASDAQ:TINY) and Nanogen (NASDAQ:NGEN). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84
Here are the highlights from the Featured Expert column:
Nanotech. The name sounds sci-fi but the technology--which enables unprecedented opportunities for creating novel chemical and biological structures on the molecular level-- is real and it is already on the market in a variety of fairly mundane applications. As Federal nanotech research funding has increased dramatically in the past seven years, nanotech has quietly become the most significant U.S. government-funded research project since the Space Program.
If you remember the dot com craze, Harris & Harris (NASDAQ:TINY) is in some ways the "Internet Capital Group" of the nano universe. Although still small fry themselves, they are venture capitalists (i.e. part owners) for more than a dozen nanosized start-ups. The company Spear is particularly interested in for SSIA is Nanosys, which is crafting some of the most basic geometry in the nano-universe. By making nanometer-scale materials such as nanowires, nanotubes and nanodots (aka quantum dots), this company has positioned itself as the supplier of the "picks and shovels" of the nano enterprise.
Another company Spear likes, but which has been perhaps unfairly exploiting its moniker, is Nanogen (NASDAQ:NGEN). The 10-year-old company, one of the few nanotech start-ups to go public in the late 1990`s, has applied nanotechnology to genetic testing. Nanogen develops and commercializes molecular diagnostics products and tests for the gene-based testing market, including biodefense, forensics and drug discovery. Nanogen has received attention by collaborating with Prodresse, to develop automated, highly sensitive microarray- based products to detect a number of infectious disease agents, including influenza, pneumonia, adenovirus, herpes, West Nile virus, and SARS. The Companies will integrate Prodesse`s proprietary multiplex amplification technology with the automated NanoChip(R) platform and jointly develop and market gene-based testing products to health care providers and clinical reference labs.
Despite the recent hype, given the market capitalization of NGEN, Spear believes that the stock can move higher.
Read more about the above-mentioned companies, and don`t forget to view Gregory Spear`s complete commentary and A-List stocks by clicking: http://at.zacks.com/?id=85
About Zacks Featured Experts
To be a successful investor you need professional advice. Experts who know what they`re talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.
Recommendations from Featured Experts Highlighted in FREE Investment Newsletter
The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc.(NASDAQ-SMALL:RESEQ) , which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors.
tomhead
Zacks.com Announces That Gregory Spear Highlights the Following Stocks: Harris & Harris and Nanogen
CHICAGO--(BUSINESS WIRE)--Dec. 26, 2003--Gregory Spear is looking toward the future and sees nanotechnology as a major point of interest. Learn how to make an early play on this burgeoning technology with a pair of new additions to the A-List. Learn about Harris & Harris (NASDAQ:TINY) and Nanogen (NASDAQ:NGEN). Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84
Here are the highlights from the Featured Expert column:
Nanotech. The name sounds sci-fi but the technology--which enables unprecedented opportunities for creating novel chemical and biological structures on the molecular level-- is real and it is already on the market in a variety of fairly mundane applications. As Federal nanotech research funding has increased dramatically in the past seven years, nanotech has quietly become the most significant U.S. government-funded research project since the Space Program.
If you remember the dot com craze, Harris & Harris (NASDAQ:TINY) is in some ways the "Internet Capital Group" of the nano universe. Although still small fry themselves, they are venture capitalists (i.e. part owners) for more than a dozen nanosized start-ups. The company Spear is particularly interested in for SSIA is Nanosys, which is crafting some of the most basic geometry in the nano-universe. By making nanometer-scale materials such as nanowires, nanotubes and nanodots (aka quantum dots), this company has positioned itself as the supplier of the "picks and shovels" of the nano enterprise.
Another company Spear likes, but which has been perhaps unfairly exploiting its moniker, is Nanogen (NASDAQ:NGEN). The 10-year-old company, one of the few nanotech start-ups to go public in the late 1990`s, has applied nanotechnology to genetic testing. Nanogen develops and commercializes molecular diagnostics products and tests for the gene-based testing market, including biodefense, forensics and drug discovery. Nanogen has received attention by collaborating with Prodresse, to develop automated, highly sensitive microarray- based products to detect a number of infectious disease agents, including influenza, pneumonia, adenovirus, herpes, West Nile virus, and SARS. The Companies will integrate Prodesse`s proprietary multiplex amplification technology with the automated NanoChip(R) platform and jointly develop and market gene-based testing products to health care providers and clinical reference labs.
Despite the recent hype, given the market capitalization of NGEN, Spear believes that the stock can move higher.
Read more about the above-mentioned companies, and don`t forget to view Gregory Spear`s complete commentary and A-List stocks by clicking: http://at.zacks.com/?id=85
About Zacks Featured Experts
To be a successful investor you need professional advice. Experts who know what they`re talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.
Recommendations from Featured Experts Highlighted in FREE Investment Newsletter
The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc.(NASDAQ-SMALL:RESEQ) , which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors.
tomhead
Hallo,
ich konnte nicht anders und habe ein paar steuerfreie
Gewinne mitgenommen.
Obwohl ich von Nanogen überzeugt bin ging mir der
Anstieg der letzten Wochen doch etwas schnell.
Gruß
Viola
ich konnte nicht anders und habe ein paar steuerfreie
Gewinne mitgenommen.
Obwohl ich von Nanogen überzeugt bin ging mir der
Anstieg der letzten Wochen doch etwas schnell.
Gruß
Viola
In dieser Woche läuft die Aktie an einen sehr wichtigen Widerstand bei 9,75 $ heran. Hier ist die Aktie stark konsolidierungsanfällig! WENN die 9,75 $ nachhaltig überwunden werden können, dann ergibt sich ein absolutes Mindest-Kursziel von 14,5 $.
Für die langfristigen Aussichten ist diese 14,5 $ Marke sehr wichtig. Kann sie überwunden werden, gibt es nach oben hin keine nennenswerten Hürden mehr.
Aus Nanogen Analyse:
http://www.aktienboard.com/portal/modules.php?name=News&file…
Für die langfristigen Aussichten ist diese 14,5 $ Marke sehr wichtig. Kann sie überwunden werden, gibt es nach oben hin keine nennenswerten Hürden mehr.
Aus Nanogen Analyse:
http://www.aktienboard.com/portal/modules.php?name=News&file…
Der Wahnsinn "Nano..."
http://www.fool.com/news/mft/2004/mft04010507.htm?source=ept…
OUR TAKE
Gaga Over Nano
By Tom Taulli
January 5, 2004
What`s a day trader to do on a light day like last Friday? Roll the dice on nanotech stocks, of course. On the most actives list -- among the Ciscos (Nasdaq: CSCO) and Microsofts (Nasdaq: MSFT) -- were stocks like Altair Nanotechnologies (Nasdaq: ALTI), which traded 10.9 million shares and had a stock-price surge of 21.3%.
Investors are going gaga over nano, especially in light of President Bush`s signing of the 21st Century Nanotech Research and Development Act, which commits $3.7 billion to nanotechnology research. (Quick science lesson: Nano stands for one-billionth; thus, in scientific terms, nanotechnology means dealing with small things, at the atomic level.)
It`s also a breakthrough discovery for small-cap hypesters. According to the buzz, nanotechnology will lead to cost-effective (and healthy) foods, faster and more efficient microchips, medical fluids (perhaps to reverse the aging process), rebuilding of the ozone layer, clean up of oil spills, and on and on.
But is an obscure company, such as Altair Nanotechnologies, ready to revolutionize the world?
It hasn`t so far in its 25-year history. Based in the hotbed of nanotech (Reno, Nev.), the company was initially in the business of mineral properties exploration. Then it focused on the acquisition, development, and testing of mineral processing equipment.
It`s been a bust. For the first nine months of 2003, the company had revenues of $42,029 and a net loss of $3.9 million.
In December, the company announced wide-scale restructuring: dump the losers and focus on the Big Prize of nano. It was a smart move, as the company was having a near-death experience. Now, it has raised money through option and warrant exercises, and plans an issue of common stock.
Also, in December, Congress funded a $2 million grant to Altair (along with two universities) for the development of nanosensors in detecting chemical, biological, and radiological agents in the environment.
But this is for research -- which, in the world of science, is a dicey thing. Commercialization is likely to take several years, if at all. And will a mere $2 million revolutionize the world?
Many scientists believe that nanotech is likely to take several decades to make its mark. But, at least in the near term, nanotech has been able to suspend the laws of nature for its small public companies, including JMAR Technologies (Nasdaq: JMAR), Nanogen (Nasdaq: NGEN), Nanophase Technologies (Nasdaq: NANX), and Harris & Harris Group (Nasdaq: TINY).
Tom Taulli is the author of six books on investing, including The Complete M&A Handbook (Random House). You can reach him at tom@taulli.com.
http://www.fool.com/news/mft/2004/mft04010507.htm?source=ept…
OUR TAKE
Gaga Over Nano
By Tom Taulli
January 5, 2004
What`s a day trader to do on a light day like last Friday? Roll the dice on nanotech stocks, of course. On the most actives list -- among the Ciscos (Nasdaq: CSCO) and Microsofts (Nasdaq: MSFT) -- were stocks like Altair Nanotechnologies (Nasdaq: ALTI), which traded 10.9 million shares and had a stock-price surge of 21.3%.
Investors are going gaga over nano, especially in light of President Bush`s signing of the 21st Century Nanotech Research and Development Act, which commits $3.7 billion to nanotechnology research. (Quick science lesson: Nano stands for one-billionth; thus, in scientific terms, nanotechnology means dealing with small things, at the atomic level.)
It`s also a breakthrough discovery for small-cap hypesters. According to the buzz, nanotechnology will lead to cost-effective (and healthy) foods, faster and more efficient microchips, medical fluids (perhaps to reverse the aging process), rebuilding of the ozone layer, clean up of oil spills, and on and on.
But is an obscure company, such as Altair Nanotechnologies, ready to revolutionize the world?
It hasn`t so far in its 25-year history. Based in the hotbed of nanotech (Reno, Nev.), the company was initially in the business of mineral properties exploration. Then it focused on the acquisition, development, and testing of mineral processing equipment.
It`s been a bust. For the first nine months of 2003, the company had revenues of $42,029 and a net loss of $3.9 million.
In December, the company announced wide-scale restructuring: dump the losers and focus on the Big Prize of nano. It was a smart move, as the company was having a near-death experience. Now, it has raised money through option and warrant exercises, and plans an issue of common stock.
Also, in December, Congress funded a $2 million grant to Altair (along with two universities) for the development of nanosensors in detecting chemical, biological, and radiological agents in the environment.
But this is for research -- which, in the world of science, is a dicey thing. Commercialization is likely to take several years, if at all. And will a mere $2 million revolutionize the world?
Many scientists believe that nanotech is likely to take several decades to make its mark. But, at least in the near term, nanotech has been able to suspend the laws of nature for its small public companies, including JMAR Technologies (Nasdaq: JMAR), Nanogen (Nasdaq: NGEN), Nanophase Technologies (Nasdaq: NANX), and Harris & Harris Group (Nasdaq: TINY).
Tom Taulli is the author of six books on investing, including The Complete M&A Handbook (Random House). You can reach him at tom@taulli.com.
Klingt auch sehr vielversprechend.....mal sehen ob NGEN noch die 14$ knackt......stay long!
Press Release Source: St. Joseph`s Hospital and Medical Center
St. Joseph`s Among First in U.S. to Use New Technology in Genetic Testing for Alzheimer`s Disease
Tuesday January 6, 8:04 am ET
PHOENIX, Jan. 6 /PRNewswire/ -- Researchers at St. Joseph`s Hospital and Medical Center are among the first in the country to use a new molecular diagnostic tool to help develop genetic tests for Alzheimer`s disease. St. Joseph`s DNA Diagnostic Laboratories validated the test in collaboration with Nanogen, Inc. (Nasdaq: NGEN - News), a company that develops and commercializes molecular diagnostic products for the gene-based testing market.
Using the company`s NanoChip© Molecular Biology Workstation and analyte specific reagents, researchers can detect the specific genetic form, or allele, of the ApoE gene, which is associated with an increased risk for developing Alzheimer`s disease. Currently, this mutation is detected with more conventional technology that is not widely available. Nanogen licensed the detection of ApoE alleles for use with the NanoChip device in April 2003.
"The relationship between St. Joseph`s and Nanogen allows us to offer predisposition testing for Alzheimer`s disease to patients throughout Arizona in a timely, accurate and cost-effective manner. Currently, patients can wait up to six weeks for results," says Dr. John Stone, Laboratory Director. "We anticipate that this collaboration will soon lead to the development of similar tests."
The NanoChip® Molecular Biology Workstation is an automated multi-purpose instrument that uses a tiny silicon chip to test for genetic mutations. The system provides laboratories with a flexible platform to develop and validate tests to detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases.
St. Joseph`s DNA Diagnostic Laboratories offer a full service genetics program, including testing in the areas of cytogenetics and molecular genetics. For information on additional testing, call +1-602-406-3104.
Press Release Source: St. Joseph`s Hospital and Medical Center
St. Joseph`s Among First in U.S. to Use New Technology in Genetic Testing for Alzheimer`s Disease
Tuesday January 6, 8:04 am ET
PHOENIX, Jan. 6 /PRNewswire/ -- Researchers at St. Joseph`s Hospital and Medical Center are among the first in the country to use a new molecular diagnostic tool to help develop genetic tests for Alzheimer`s disease. St. Joseph`s DNA Diagnostic Laboratories validated the test in collaboration with Nanogen, Inc. (Nasdaq: NGEN - News), a company that develops and commercializes molecular diagnostic products for the gene-based testing market.
Using the company`s NanoChip© Molecular Biology Workstation and analyte specific reagents, researchers can detect the specific genetic form, or allele, of the ApoE gene, which is associated with an increased risk for developing Alzheimer`s disease. Currently, this mutation is detected with more conventional technology that is not widely available. Nanogen licensed the detection of ApoE alleles for use with the NanoChip device in April 2003.
"The relationship between St. Joseph`s and Nanogen allows us to offer predisposition testing for Alzheimer`s disease to patients throughout Arizona in a timely, accurate and cost-effective manner. Currently, patients can wait up to six weeks for results," says Dr. John Stone, Laboratory Director. "We anticipate that this collaboration will soon lead to the development of similar tests."
The NanoChip® Molecular Biology Workstation is an automated multi-purpose instrument that uses a tiny silicon chip to test for genetic mutations. The system provides laboratories with a flexible platform to develop and validate tests to detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases.
St. Joseph`s DNA Diagnostic Laboratories offer a full service genetics program, including testing in the areas of cytogenetics and molecular genetics. For information on additional testing, call +1-602-406-3104.
Hat keiner eine Meinung wie es bei Nanogen nächste Woche
weitergeht.
Bitte um Info.
Danke xxxyyy
weitergeht.
Bitte um Info.
Danke xxxyyy
Sämtliche Nanos auf meiner Watchlist haben am Freitag ca. 15% plus gemacht - denke mal, die Ralley wird am Montag noch weitergehen
Hi,
hat hier jemand schonmal den Nanotec Report der hier von wallstreet-online zum Kauf für 10,90 angeboten wird, gelesen? Mir gehts nicht um eine Kopie der pdf sondern um fachkundigen Rat, ob sich der Kauf lohnt.
Behandelt wird dort u.a. NGEN
Danke!
hat hier jemand schonmal den Nanotec Report der hier von wallstreet-online zum Kauf für 10,90 angeboten wird, gelesen? Mir gehts nicht um eine Kopie der pdf sondern um fachkundigen Rat, ob sich der Kauf lohnt.
Behandelt wird dort u.a. NGEN
Danke!
Press Release Source: American Stock Exchange
American Stock Exchange to Trade Options on Four Securities
Friday January 9, 1:19 pm ET
NEW YORK, Jan. 9 /PRNewswire/ -- The American Stock Exchange® (Amex®) will launch trading in options on Monday, January 12, 2004 on the following Nasdaq Stock Market and New York Stock Exchange listed stocks of:
-- BioLase Technology, Inc. (Option Symbol: BQF/Stock Symbol: BLTI)
-- Coeur D`Alene Mines Corporation (Symbol: CDE)
-- Nanogen, Inc. (Option Symbol: QEM/Stock Symbol: NGEN)
-- PetroChina Company Limited, American Depositary Shares (Symbol: PTR)
BioLase Technology, Inc. options open with position limits of 60,000 contracts. The options will trade on the March expiration cycle. The specialist will be LaBranche Structured Products, LLC. BioLase Technology, Inc. manufactures and markets laser dental, cosmetic, aesthetic and surgical systems.
Coeur D`Alene Mines Corporation options open with position limits of 75,000 contracts. The options will trade on the March expiration cycle. The specialist will be Charlton Specialist Partners LLC. Coeur D`Alene Mines Corporation, through its subsidiaries, explores, develops, operates and/or owns silver and gold mining properties and companies.
Nanogen, Inc. options open with position limits of 75,000 contracts. The options will trade on the March expiration cycle. The specialist will be Susquehanna Investment Group. Nanogen, Inc. integrates advanced microelectronics and molecular biology into a platform technology with commercial applications.
PetroChina Company Limited options open with position limits of 31,500 contracts. The options will trade on the March expiration cycle. The specialist will be Tanstaafl Research & Trading, LLC. PetroChina Company Limited explores, develops and produces crude oil and natural gas.
The American Stock Exchange® (Amex®) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 124 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks.
--------------------------------------------------------------------------------
Source: American Stock Exchange
American Stock Exchange to Trade Options on Four Securities
Friday January 9, 1:19 pm ET
NEW YORK, Jan. 9 /PRNewswire/ -- The American Stock Exchange® (Amex®) will launch trading in options on Monday, January 12, 2004 on the following Nasdaq Stock Market and New York Stock Exchange listed stocks of:
-- BioLase Technology, Inc. (Option Symbol: BQF/Stock Symbol: BLTI)
-- Coeur D`Alene Mines Corporation (Symbol: CDE)
-- Nanogen, Inc. (Option Symbol: QEM/Stock Symbol: NGEN)
-- PetroChina Company Limited, American Depositary Shares (Symbol: PTR)
BioLase Technology, Inc. options open with position limits of 60,000 contracts. The options will trade on the March expiration cycle. The specialist will be LaBranche Structured Products, LLC. BioLase Technology, Inc. manufactures and markets laser dental, cosmetic, aesthetic and surgical systems.
Coeur D`Alene Mines Corporation options open with position limits of 75,000 contracts. The options will trade on the March expiration cycle. The specialist will be Charlton Specialist Partners LLC. Coeur D`Alene Mines Corporation, through its subsidiaries, explores, develops, operates and/or owns silver and gold mining properties and companies.
Nanogen, Inc. options open with position limits of 75,000 contracts. The options will trade on the March expiration cycle. The specialist will be Susquehanna Investment Group. Nanogen, Inc. integrates advanced microelectronics and molecular biology into a platform technology with commercial applications.
PetroChina Company Limited options open with position limits of 31,500 contracts. The options will trade on the March expiration cycle. The specialist will be Tanstaafl Research & Trading, LLC. PetroChina Company Limited explores, develops and produces crude oil and natural gas.
The American Stock Exchange® (Amex®) is the only primary exchange that offers trading across a full range of equities, options and exchange traded funds (ETFs), including structured products and HOLDRS(SM). In addition to its role as a national equities market, the Amex is the pioneer of the ETF, responsible for bringing the first domestic product to market in 1993. Leading the industry in ETF listings, the Amex lists 124 ETFs to date. The Amex is also one of the largest options exchanges in the U.S., trading options on broad-based and sector indexes as well as domestic and foreign stocks.
--------------------------------------------------------------------------------
Source: American Stock Exchange
Dow Jones Business News
Nanogen And Transgenomic Enter Into Distribution Pact
Thursday January 15, 5:25 pm ET
SAN DIEGO and OMAHA, Neb. (Dow Jones)--Nanogen Inc. (NasdaqNM:NGEN - News) and Transgenomic Inc. (NasdaqNM:TBIO - News) will team up to bring Nanogen`s genetic testing equipment to Western Europe.
Transgenomic`s employees will sell the NanoChip Molecular Biology Workstation in selected Western European countries. The system complements Trangenomic`s own WAVE System, the companies said in a press release Thursday.
Both systems scan for genetic variations, but while Transgenomic`s system scans for any possible variation, known or unknown, Nanogen`s system seeks out known, low-abundance mutations such as those involved in cancer development.
Trangenomic shares traded in the after-hours session at $2.90, according to INET, up from their regular session of $2.30.
Neither company was immediately available to comment on financial terms of the deal.
Tiffany Kary; Dow Jones Newswires; 201-938-5285.
Order free Annual Report for Nanogen
Visit http://djnewswire.ar.wilink.com/?link=NGEN or call 1-888-301-0513
Order free Annual Report for Nanogen
Visit http://djnewswire.ar.wilink.com/?link=NGEN or call 1-888-301-0513
Nanogen And Transgenomic Enter Into Distribution Pact
Thursday January 15, 5:25 pm ET
SAN DIEGO and OMAHA, Neb. (Dow Jones)--Nanogen Inc. (NasdaqNM:NGEN - News) and Transgenomic Inc. (NasdaqNM:TBIO - News) will team up to bring Nanogen`s genetic testing equipment to Western Europe.
Transgenomic`s employees will sell the NanoChip Molecular Biology Workstation in selected Western European countries. The system complements Trangenomic`s own WAVE System, the companies said in a press release Thursday.
Both systems scan for genetic variations, but while Transgenomic`s system scans for any possible variation, known or unknown, Nanogen`s system seeks out known, low-abundance mutations such as those involved in cancer development.
Trangenomic shares traded in the after-hours session at $2.90, according to INET, up from their regular session of $2.30.
Neither company was immediately available to comment on financial terms of the deal.
Tiffany Kary; Dow Jones Newswires; 201-938-5285.
Order free Annual Report for Nanogen
Visit http://djnewswire.ar.wilink.com/?link=NGEN or call 1-888-301-0513
Order free Annual Report for Nanogen
Visit http://djnewswire.ar.wilink.com/?link=NGEN or call 1-888-301-0513
SEC FILINGS
MKS Instruments sued over contract
Also: Nanogen files to sell 5 million shares
By Leticia Williams, CBS.MarketWatch.com
Last Update: 5:33 PM ET Jan. 15, 2004
The company (MKSI: news, chart, profile) said a lawsuit was filed Monday by Gas Research Institute for alleged breach of contract and misappropriation of trade secrets.
The suit relates to certain analytical technology developed under a 1995 contract between the companies. Gas Research wants to prevent MKS from using the technology and seeks unspecified damages and attorney fees.
MKS is reviewing the merits of the claim and plans to "vigorously" defend against them, according to the filing.
The Andover, Mass.-based energy equipment maker`s shares closed at $26.43, down 99 cents.
Nanogen files to sell 5 million shares
Nanogen Inc. (NGEN: news, chart, profile) plans to offer up to 5 million shares of common stock, according to an SEC filing.
Proceeds from the sale of any shares are for general corporate purposes, the company said.
Shares of the San Diego-based research equipment maker gained 32 cents to close at $11.72.
Leticia Williams is a reporter for CBS.MarketWatch.com in Washington.
MKS Instruments sued over contract
Also: Nanogen files to sell 5 million shares
By Leticia Williams, CBS.MarketWatch.com
Last Update: 5:33 PM ET Jan. 15, 2004
The company (MKSI: news, chart, profile) said a lawsuit was filed Monday by Gas Research Institute for alleged breach of contract and misappropriation of trade secrets.
The suit relates to certain analytical technology developed under a 1995 contract between the companies. Gas Research wants to prevent MKS from using the technology and seeks unspecified damages and attorney fees.
MKS is reviewing the merits of the claim and plans to "vigorously" defend against them, according to the filing.
The Andover, Mass.-based energy equipment maker`s shares closed at $26.43, down 99 cents.
Nanogen files to sell 5 million shares
Nanogen Inc. (NGEN: news, chart, profile) plans to offer up to 5 million shares of common stock, according to an SEC filing.
Proceeds from the sale of any shares are for general corporate purposes, the company said.
Shares of the San Diego-based research equipment maker gained 32 cents to close at $11.72.
Leticia Williams is a reporter for CBS.MarketWatch.com in Washington.
Die Meldung nochmal in deutsch:
*vwd/PRN: Nanogen und Transgenomic schliessen Vertriebsvereinbar
*vwd/PRN: Nanogen und Transgenomic schliessen Vertriebsvereinbarung ab
Mitteilung uebermittelt von PR Newswire. Fuer den Inhalt ist
allein das berichtende Unternehmen verantwortlich.
PRNewswire
- Transgenomic vermarktet komplementäre Plattformen zur Genanalyse für
beide Unternehmen
SAN DIEGO, Kalifornien, und OMAHA, Nebraska
January 16
SAN DIEGO, Kalifornien, und OMAHA, Nebraska, January 16 /PRNewswire/ -- -
Transgenomic vermarktet komplementäre Plattformen zur Genanalyse für
beide Unternehmen
Die Nanogen Inc. (Nasdaq: NGEN) und die Transgenomic Inc. (Nasdaq: TBIO)
haben heute den Abschluss einer Vereinbarung bekannt gegeben, laut der
Transgenomic den Vertrieb von Nanogens NanoChip(R) Molecular Biology
Workstation in bestimmten westeuropäischen Ländern übernehmen wird.
Transgenomics europäische Marketing- und Vertriebsorganisation wird das
Instrument vermarkten, verkaufen und warten. Die NanoChip Workstation ist ein
automatisiertes Instrument in offener Architektur, das den routinemässigen
Nachweis bekannter genetischer Abweichungen ermöglicht und so die Fähigkeit
von Transgenomics WAVE(R)-System zum Scannen nach unbekannten genetischen
Abweichungen ergänzt.
Collin D`Silva, Transgenomics CEO, betonte, dass Transgenomic über einen
grossen, gut etablierten europäischen Kundenstamm verfügt. Laut D`Silva
"bildet diese Vereinbarung Teil einer Strategie, in deren Rahmen wir den
Märkten Genforschung und klinische Labors umfassende, komplementäre
Lösungen
bieten. Wir erwarten aus der Aufnahme der Nanogen-Plattform in unsere gut
etablierten europäischen Marketingbemühungen signifikante Synergien."
Howard Birndorf, Nanogens CEO, sieht die Vereinbarung als eine Chance zur
Erweiterung von Nanogens Marktpenetration auf extrem effiziente Weise.
Birndorf kommentierte, dass "Transgenomic bei den europäischen Kunden
des
Unternehmens einen Ruf für herausragenden Kundendienst und Support
geniesst."
Er schloss: "Durch die strategische Nutzung von Transgenomics Ressourcen
und
Expertise erreichen wir unmittelbare Abdeckung des westeuropäischen Markts,
was in unseren Augen eine Chance für signifikante Einnahmen darstellt."
Das Ziel von Forschern, genetische Abweichungen mit klinischen
Beobachtungen und Resultaten in Verbindung zu bringen, erfordert
möglicherweise, je nach spezifischer Situation, den Einsatz mehrerer
Technologien. Transgenomics WAVE-System bietet eine präzise, kosteneffektive
Lösung, wenn nach allen möglichen genetischen Abweichungen, bekannten wie
auch unbekannten, gesucht werden muss. Darüber hinaus hat sich die
WAVE-Technologie beim Nachweis seltener genetischer Abweichungen als äusserst
effektiv erwiesen, z. B. beim Nachweis somatischer Mutationen, die manchmal
während der Progression einer Krebserkrankung oder der Entwicklung von
Medikamentenresistenz auftreten können. Nanogens NanoChip Molecular Biology
Workstation ist eine extrem flexible Plattform, die anhand des NanoChip(R)
Electronic Microarray den routinemässigen Nachweis bekannter genetischer
Sequenzen ermöglicht, z. B. den Nachweis von SNPs und Mikrosatelliten (Short
Tandem Repeats/STRs). Die einzigartige Konzeption in offener Architektur
ermöglicht Forschern die Definition, Auswahl und Konstruktion ihrer eigenen
Test-Panels oder die Auswahl aus analytespezifischen, von Nanogen
entwickelten, auf den Nachweis von Mutationen im Zusammenhang mit
unterschiedlichen Erkrankungen ausgelegten Reagenzien.
Näheres über Transgenomic
Transgenomic bietet der Life-Sciences-Branche vielseitige, innovative
Forschungsinstrumente und verwandte Verbrauchsgüter für die Synthese,
Separation, Analyse und Reinigung von Nukleinsäuren und eine breite Palette
an Spezialchemikalien auf Nukleinsäurenbasis. Transgenomics
Unternehmensbereich Biosysteme vermarktet das WAVE-System und dazugehörige
Verbrauchsgüter. Diese Systeme sind spezifisch für die Verwendung beim
Nachweis genetischer Abweichungen sowie bei der Einzel- und
Doppelstrang-DNA/RNA-Analyse und bei Reinigungsverfahren konzipiert. Die
Systeme bieten breite Anwendungsmöglichkeiten in der Genforschung und
Molekulardiagnose. Bisher wurden in über 30 Ländern weltweit bereits etwa
eintausend Systeme installiert.
Über den Unternehmensbereich Nukleinsäuren bietet Transgenomic
Spezialchemikalien, darunter auch fortschrittliche Nukleinsäuren-Bausteine
und dazugehörige Reagenzien, die in Anwendungen wie Gendiagnostik und
-therapeutik Anwendung finden. Zu den Herstellungsbetrieben gehört eine
cGMP-Einrichtung für die Synthese von Oligonukleotiden.
*vwd/PRN: Nanogen und Transgenomic schliessen Vertriebsvereinbar /2
Weitere Informationen über die von Transgenomic entwickelten und
vermarkteten innovativen Genomik-Forschungsinstrumente erhalten Sie über den
Internetauftritt des Unternehmens unter www.transgenomic.com.
Warnhinweise von Seiten Transgenomics
Manche der in dieser Pressemitteilung enthaltenen Aussagen stellen
zukunftsgerichtete Aussagen von Transgenomic innerhalb der Begriffsbestimmung
des Private Securities Litigation Reform Act aus dem Jahr 1995 dar, die
bekannte und unbekannte Risiken, Unwägbarkeiten und andere Faktoren
beinhalten, aufgrund der die tatsächlichen Resultate wesentlich von in
solchen Aussagen explizit oder implizit enthaltenen zukünftigen Ergebnissen,
Leistungen oder Errungenschaften abweichen können. Zukunftsgerichtete
Aussagen schliessen Aussagen bezüglich gesteigerter Einnahmemöglichkeiten
aufgrund des Vertriebs des Nanogen-Instruments ein, sind aber nicht auf diese
beschränkt. Die bekannten Risiken, Unwägbarkeiten und weiteren Faktoren,
welche diese zukunftsgerichteten Aussagen beeinflussen können, werden von
Zeit zu Zeit in Transgenomics Berichten an die Securities and Exchange
Commission beschrieben. Etwaige Veränderungen dieser Faktoren, Risiken und
Unwägbarkeiten könnten dazu führen, dass die tatsächlichen Ergebnisse oder
Leistungen des Unternehmens wesentlich von den in den zukunftsgerichteten
Aussagen beschriebenen abweichen. Dementsprechend nimmt das Unternehmen
bezüglich aller in dieser Pressemitteilung enthaltener zukunftsorientierter
Aussagen den Schutz im Rahmen der Safe-Harbor-Bestimmungen des Private
Securities Litigation Reform Act aus dem Jahr 1995 in Anspruch. Alle in
dieser Pressemitteilung enthaltenen Informationen sind zum Datum der
Veröffentlichung aktuell. Transgenomic geht keinerlei Verpflichtung zur
Aktualisierung dieser Informationen, einschliesslich jeglicher
zukunftsorientierter Aussagen, ein, ausser solche Verpflichtungen bestehen
aufgrund gesetzlicher Bestimmungen.
Näheres über Nanogen
Die Nanogen, Inc., entwickelt molekulare Diagnostikprodukte für den
genbasierten Testmarkt und verwertet sie kommerziell. Das Unternehmen möchte
die NanoChip(R) Molecular Biology Workstation und die NanoChip(R) Cartridge
als Standardplattform für den Nachweis genetischer Mutationen etablieren. Es
entwickelt weiter seine Technologie für Anwendungen im Umfeld der
Kriminalmedizin und der biologischen Kriegsführung. Nanogen bietet
Forschungslabors und klinischen Referenzlabors analytespezifische Reagenzien
und verwandte Produkte für den Nachweis genetischer Mutationen im
Zusammenhang mit einer Reihe von Krankheiten, darunter zystische Fibrose,
Alzheimer, erbliche Hämochromatose, kardiovaskuläre Erkrankungen,
Beta-Thalassämie und Canavan-Syndrom. Die Konzeption des NanoChip(R)-Systems
des Unternehmens mit seiner einzigartigen offenen Architektur bietet Labors
eine flexible Plattform zur Entwicklung und Validierung von Tests zum
schnellen, präzisen und kosteneffektiven Nachweis von Mutationen im
Zusammenhang mit der Diagnose, der Prädiktion, dem Screening, der Behandlung
und der Kontrolle von Krankheiten. Das NanoChip(R)-System ist nur zum Einsatz
in Labors vorgesehen. Weitere Informationen finden Sie auf der
Nanogen-Website unter www.nanogen.com.
Warnhinweise von Seiten Nanogens
Diese Pressemitteilung enthält in die Zukunft gerichtete Aussagen, die
Risiken und Unwägbarkeiten unterliegen, aufgrund der tatsächliche Ergebnisse
von den in diesen Aussagen avisierten wesentlich abweichen könnten. Zu diesen
gehören die Fragen, ob sich das NanoChip(R)-System des Unternehmens
erfolgreich weiter kommerziell verwerten lässt, ob die Vereinbarung mit
Transgenomic die Umsatzerlöse für Produkte des Unternehmens in Europa
steigern wird, ob vom Unternehmen derzeit angebotene ASRs von der FDA
genehmigte molekulare Diagnostik-Testkits werden, ob Nanogen in der
Entwicklung weiterer ASRs und Protokolle anhand des NanoChip(R)-Systems
erfolgreich ist, sowie weitere Risiken und Unwägbarkeiten, die in den
Einreichungen des Unternehmens bei der Securities and Exchange Commission auf
Formular 10-K für das Jahr zum 31. Dezember 2002 unter der Überschrift
"Resultate potenziell beeinflussende Faktoren" dargestellt sind.
Diese
zukunftsgerichteten Aussagen sind nur zum Datum ihrer Veröffentlichung
aktuell. Das Unternehmen lehnt jegliche Absicht oder Verpflichtung zur
Aktualisierung dieser zukunftsgerichteten Aussagen ab.
PR Newswire (New York)
Investoren, Mitchell L. Murphy, +1-402-452-5418, mmurphy@transgenomic.com,
oder Robert J. Pogulis, Ph.D., +1-845-782-9617, rpogulis@transgenomic.com,
beide Transgenomic Inc.; oder David Ludvigson, Nanogen Inc., +1-858-410-4600,
dludvigson@nanogen.com , oder Pam Lord, Atkins + Associates, +1-858-527-3494,
plord@irpr.com, Website: http://www.transgenomic.com
*vwd/PRN: Nanogen und Transgenomic schliessen Vertriebsvereinbar
*vwd/PRN: Nanogen und Transgenomic schliessen Vertriebsvereinbarung ab
Mitteilung uebermittelt von PR Newswire. Fuer den Inhalt ist
allein das berichtende Unternehmen verantwortlich.
PRNewswire
- Transgenomic vermarktet komplementäre Plattformen zur Genanalyse für
beide Unternehmen
SAN DIEGO, Kalifornien, und OMAHA, Nebraska
January 16
SAN DIEGO, Kalifornien, und OMAHA, Nebraska, January 16 /PRNewswire/ -- -
Transgenomic vermarktet komplementäre Plattformen zur Genanalyse für
beide Unternehmen
Die Nanogen Inc. (Nasdaq: NGEN) und die Transgenomic Inc. (Nasdaq: TBIO)
haben heute den Abschluss einer Vereinbarung bekannt gegeben, laut der
Transgenomic den Vertrieb von Nanogens NanoChip(R) Molecular Biology
Workstation in bestimmten westeuropäischen Ländern übernehmen wird.
Transgenomics europäische Marketing- und Vertriebsorganisation wird das
Instrument vermarkten, verkaufen und warten. Die NanoChip Workstation ist ein
automatisiertes Instrument in offener Architektur, das den routinemässigen
Nachweis bekannter genetischer Abweichungen ermöglicht und so die Fähigkeit
von Transgenomics WAVE(R)-System zum Scannen nach unbekannten genetischen
Abweichungen ergänzt.
Collin D`Silva, Transgenomics CEO, betonte, dass Transgenomic über einen
grossen, gut etablierten europäischen Kundenstamm verfügt. Laut D`Silva
"bildet diese Vereinbarung Teil einer Strategie, in deren Rahmen wir den
Märkten Genforschung und klinische Labors umfassende, komplementäre
Lösungen
bieten. Wir erwarten aus der Aufnahme der Nanogen-Plattform in unsere gut
etablierten europäischen Marketingbemühungen signifikante Synergien."
Howard Birndorf, Nanogens CEO, sieht die Vereinbarung als eine Chance zur
Erweiterung von Nanogens Marktpenetration auf extrem effiziente Weise.
Birndorf kommentierte, dass "Transgenomic bei den europäischen Kunden
des
Unternehmens einen Ruf für herausragenden Kundendienst und Support
geniesst."
Er schloss: "Durch die strategische Nutzung von Transgenomics Ressourcen
und
Expertise erreichen wir unmittelbare Abdeckung des westeuropäischen Markts,
was in unseren Augen eine Chance für signifikante Einnahmen darstellt."
Das Ziel von Forschern, genetische Abweichungen mit klinischen
Beobachtungen und Resultaten in Verbindung zu bringen, erfordert
möglicherweise, je nach spezifischer Situation, den Einsatz mehrerer
Technologien. Transgenomics WAVE-System bietet eine präzise, kosteneffektive
Lösung, wenn nach allen möglichen genetischen Abweichungen, bekannten wie
auch unbekannten, gesucht werden muss. Darüber hinaus hat sich die
WAVE-Technologie beim Nachweis seltener genetischer Abweichungen als äusserst
effektiv erwiesen, z. B. beim Nachweis somatischer Mutationen, die manchmal
während der Progression einer Krebserkrankung oder der Entwicklung von
Medikamentenresistenz auftreten können. Nanogens NanoChip Molecular Biology
Workstation ist eine extrem flexible Plattform, die anhand des NanoChip(R)
Electronic Microarray den routinemässigen Nachweis bekannter genetischer
Sequenzen ermöglicht, z. B. den Nachweis von SNPs und Mikrosatelliten (Short
Tandem Repeats/STRs). Die einzigartige Konzeption in offener Architektur
ermöglicht Forschern die Definition, Auswahl und Konstruktion ihrer eigenen
Test-Panels oder die Auswahl aus analytespezifischen, von Nanogen
entwickelten, auf den Nachweis von Mutationen im Zusammenhang mit
unterschiedlichen Erkrankungen ausgelegten Reagenzien.
Näheres über Transgenomic
Transgenomic bietet der Life-Sciences-Branche vielseitige, innovative
Forschungsinstrumente und verwandte Verbrauchsgüter für die Synthese,
Separation, Analyse und Reinigung von Nukleinsäuren und eine breite Palette
an Spezialchemikalien auf Nukleinsäurenbasis. Transgenomics
Unternehmensbereich Biosysteme vermarktet das WAVE-System und dazugehörige
Verbrauchsgüter. Diese Systeme sind spezifisch für die Verwendung beim
Nachweis genetischer Abweichungen sowie bei der Einzel- und
Doppelstrang-DNA/RNA-Analyse und bei Reinigungsverfahren konzipiert. Die
Systeme bieten breite Anwendungsmöglichkeiten in der Genforschung und
Molekulardiagnose. Bisher wurden in über 30 Ländern weltweit bereits etwa
eintausend Systeme installiert.
Über den Unternehmensbereich Nukleinsäuren bietet Transgenomic
Spezialchemikalien, darunter auch fortschrittliche Nukleinsäuren-Bausteine
und dazugehörige Reagenzien, die in Anwendungen wie Gendiagnostik und
-therapeutik Anwendung finden. Zu den Herstellungsbetrieben gehört eine
cGMP-Einrichtung für die Synthese von Oligonukleotiden.
*vwd/PRN: Nanogen und Transgenomic schliessen Vertriebsvereinbar /2
Weitere Informationen über die von Transgenomic entwickelten und
vermarkteten innovativen Genomik-Forschungsinstrumente erhalten Sie über den
Internetauftritt des Unternehmens unter www.transgenomic.com.
Warnhinweise von Seiten Transgenomics
Manche der in dieser Pressemitteilung enthaltenen Aussagen stellen
zukunftsgerichtete Aussagen von Transgenomic innerhalb der Begriffsbestimmung
des Private Securities Litigation Reform Act aus dem Jahr 1995 dar, die
bekannte und unbekannte Risiken, Unwägbarkeiten und andere Faktoren
beinhalten, aufgrund der die tatsächlichen Resultate wesentlich von in
solchen Aussagen explizit oder implizit enthaltenen zukünftigen Ergebnissen,
Leistungen oder Errungenschaften abweichen können. Zukunftsgerichtete
Aussagen schliessen Aussagen bezüglich gesteigerter Einnahmemöglichkeiten
aufgrund des Vertriebs des Nanogen-Instruments ein, sind aber nicht auf diese
beschränkt. Die bekannten Risiken, Unwägbarkeiten und weiteren Faktoren,
welche diese zukunftsgerichteten Aussagen beeinflussen können, werden von
Zeit zu Zeit in Transgenomics Berichten an die Securities and Exchange
Commission beschrieben. Etwaige Veränderungen dieser Faktoren, Risiken und
Unwägbarkeiten könnten dazu führen, dass die tatsächlichen Ergebnisse oder
Leistungen des Unternehmens wesentlich von den in den zukunftsgerichteten
Aussagen beschriebenen abweichen. Dementsprechend nimmt das Unternehmen
bezüglich aller in dieser Pressemitteilung enthaltener zukunftsorientierter
Aussagen den Schutz im Rahmen der Safe-Harbor-Bestimmungen des Private
Securities Litigation Reform Act aus dem Jahr 1995 in Anspruch. Alle in
dieser Pressemitteilung enthaltenen Informationen sind zum Datum der
Veröffentlichung aktuell. Transgenomic geht keinerlei Verpflichtung zur
Aktualisierung dieser Informationen, einschliesslich jeglicher
zukunftsorientierter Aussagen, ein, ausser solche Verpflichtungen bestehen
aufgrund gesetzlicher Bestimmungen.
Näheres über Nanogen
Die Nanogen, Inc., entwickelt molekulare Diagnostikprodukte für den
genbasierten Testmarkt und verwertet sie kommerziell. Das Unternehmen möchte
die NanoChip(R) Molecular Biology Workstation und die NanoChip(R) Cartridge
als Standardplattform für den Nachweis genetischer Mutationen etablieren. Es
entwickelt weiter seine Technologie für Anwendungen im Umfeld der
Kriminalmedizin und der biologischen Kriegsführung. Nanogen bietet
Forschungslabors und klinischen Referenzlabors analytespezifische Reagenzien
und verwandte Produkte für den Nachweis genetischer Mutationen im
Zusammenhang mit einer Reihe von Krankheiten, darunter zystische Fibrose,
Alzheimer, erbliche Hämochromatose, kardiovaskuläre Erkrankungen,
Beta-Thalassämie und Canavan-Syndrom. Die Konzeption des NanoChip(R)-Systems
des Unternehmens mit seiner einzigartigen offenen Architektur bietet Labors
eine flexible Plattform zur Entwicklung und Validierung von Tests zum
schnellen, präzisen und kosteneffektiven Nachweis von Mutationen im
Zusammenhang mit der Diagnose, der Prädiktion, dem Screening, der Behandlung
und der Kontrolle von Krankheiten. Das NanoChip(R)-System ist nur zum Einsatz
in Labors vorgesehen. Weitere Informationen finden Sie auf der
Nanogen-Website unter www.nanogen.com.
Warnhinweise von Seiten Nanogens
Diese Pressemitteilung enthält in die Zukunft gerichtete Aussagen, die
Risiken und Unwägbarkeiten unterliegen, aufgrund der tatsächliche Ergebnisse
von den in diesen Aussagen avisierten wesentlich abweichen könnten. Zu diesen
gehören die Fragen, ob sich das NanoChip(R)-System des Unternehmens
erfolgreich weiter kommerziell verwerten lässt, ob die Vereinbarung mit
Transgenomic die Umsatzerlöse für Produkte des Unternehmens in Europa
steigern wird, ob vom Unternehmen derzeit angebotene ASRs von der FDA
genehmigte molekulare Diagnostik-Testkits werden, ob Nanogen in der
Entwicklung weiterer ASRs und Protokolle anhand des NanoChip(R)-Systems
erfolgreich ist, sowie weitere Risiken und Unwägbarkeiten, die in den
Einreichungen des Unternehmens bei der Securities and Exchange Commission auf
Formular 10-K für das Jahr zum 31. Dezember 2002 unter der Überschrift
"Resultate potenziell beeinflussende Faktoren" dargestellt sind.
Diese
zukunftsgerichteten Aussagen sind nur zum Datum ihrer Veröffentlichung
aktuell. Das Unternehmen lehnt jegliche Absicht oder Verpflichtung zur
Aktualisierung dieser zukunftsgerichteten Aussagen ab.
PR Newswire (New York)
Investoren, Mitchell L. Murphy, +1-402-452-5418, mmurphy@transgenomic.com,
oder Robert J. Pogulis, Ph.D., +1-845-782-9617, rpogulis@transgenomic.com,
beide Transgenomic Inc.; oder David Ludvigson, Nanogen Inc., +1-858-410-4600,
dludvigson@nanogen.com , oder Pam Lord, Atkins + Associates, +1-858-527-3494,
plord@irpr.com, Website: http://www.transgenomic.com
Vorbörslich tickern wir schon wieder bei 12$
Die ersten zu 12,15Dollar sind auch über den Tisch gegangen - da kommt Freude auf
12,25 bereits - die Amis haben es heute aber wieder eilig
So - vorbörslich gab es bereits schon 12,22$ - mal sehen, was da noch kommt
Die Analysten vom Anlegermagazin "Der Aktionär" empfehlen die Aktien von NANOGEN (/ ) zu halten. Bei einer Marktkapitalisierung von knapp 280 Mio. USD und hohen Verlusten (in Q3 2003 sei ein Minus von 7 Mio. USD angefallen) zähle der Wert zu den riskanteren Investments. Bei "Der Aktionär" spekuliere man, dass der Name des Unternehmens sicherlich eine Rolle beim Höhenflug des Kurses gespielt habe, denn immerhin denke bei NANOGEN wohl jeder gleich an Nanotechnologie. Die Analysten von "Der Aktionär" sind der Meinung, dass das Kurspotential bei NANOGEN kurzfristig ausgereizt ist und sehen die Aktie als Halteposition. Ein Stop-Loss werde bei 6 Euro empfohlen.
akat
akat
nanogen zur Zeit +5,2% Tageshöchstkurs waren bereits wieder Kurse über 12$ - 12,18$ um genau zu sein
@toolkit
danke für die Imformationen die Du hier rein stellst.
Gruss Mauserla
danke für die Imformationen die Du hier rein stellst.
Gruss Mauserla
Gern geschehen - Nanogen ist einer meiner Favoriten in meiner Nano-Sammlung und eines meiner wenigen Mittel/Langfrist-Investments. Bin sonst eher Daytrader bzw. Positiontrader
Upcoming Events
Event Date(s)
Q4 2003 Nanogen, Inc. Earnings Release Feb. 18, 2004
Q4 2003 Nanogen, Inc. Earnings Conference Call Feb. 18, 2004 4:30 PM
Da bin ich ja mal gespannt
Event Date(s)
Q4 2003 Nanogen, Inc. Earnings Release Feb. 18, 2004
Q4 2003 Nanogen, Inc. Earnings Conference Call Feb. 18, 2004 4:30 PM
Da bin ich ja mal gespannt
http://www.fool.com/news/commentary/2004/commentary040120df.…
Stocks at the Extremes
David Forrest uses a simple stock screen to identify a small handful of companies that may have come too far, too fast. Is there profit to be made by betting against these stocks?
By David Forrest (TMF Bogey)
January 20, 2004
If you`re like me, you spend most of your stock-sifting time searching for hidden gems or other similar growth investments. After all, we`re usually looking for the next big winner in the stock market, right? I mean, who wouldn`t want the 75% average returns that Tom Gardner`s Hidden Gems newsletter has achieved in the last seven months of stock picking?
We buy stocks we think are going to go up. Sometimes, however, it pays to look at the flip side and seek out businesses that might be on shaky ground. Today, we`ll look briefly at three companies whose stocks have been on fire lately. But are they about to crash and burn?
As I mentioned in my column last week, I enjoy using various stock screens as a way to generate new ideas and expose myself to new companies. I use both fundamental analysis and technical analysis screens to find ideas. This week, I`ll introduce you to a very simple technical screen I use to ferret out stocks that have risen abnormally fast.
200-Day Moving Average
Most people who analyze price movements in stocks will employ moving averages in their work. A stock`s moving average is simply the average of the closing prices for the stock in the last "x" number of days, plotted over time.
Perhaps the most oft-used is the 200-day moving average. Technicians will tell you that stocks trading above this average are doing OK, while stocks that trade below it are having a rough time. Indeed, many people will use that 200-day moving average as an inflection point, buying when a stock breaks through it to the upside and selling when a stock falls under it on the downside.
The logic beyond the voodoo is that if a company is doing reasonably well and growing its business, the price of the stock should reflect that growth and the stock should rise steadily over time. If a stock is rising steadily, the current price should always be somewhat higher than the 200-day moving average. Conversely, if investors lose confidence in a company`s ability to grow, they might sell the stock, causing it to drop below the 200-day moving average. Technicians consider this a bad sign and a "sell signal."
Irrespective of whether you buy into this or not (and the Fool generally eschews technical analysis), the 200-day moving average can be a useful tool to identify investor sentiment, in the extreme. For my technical screen, I look at companies whose stock price today is four times the 200-day moving average. In other words, something has happened in the recent past that has driven the stock up very fast, causing it to trade significantly higher than its 200-day moving average.
From looking at this screen over time, it is abnormal for a stock to trade at such a multiple. In my experience, after watching this screen for more than five years now, one of two things generally happens. The stock either drops pretty hard, bringing it back to earth, or the stock price stays about the same for a fairly long time, almost as if it were waiting for the moving average to catch up. Of course, this simply means that investors are less willing to buy at these lofty heights, or perhaps even wanting to take some profits off the table.
What almost never happens is that the stocks continue to race higher. Even in the bubble run of the late 1990s, it was rare to see a stock exceed four times its 200-day moving average.
The suspects
Out of almost 7,000 companies in the database I use for this screen, only nine stocks currently trade at more than four times their 200-day moving average. Four of these trade below $5, and are considered penny stocks. I`m not a big fan of looking at the pennies, so I generally disregard these companies. That leaves us with five:
Arrythmia Research (AMEX:HRT)
ChipMOS Technologies (Bermuda) (Nasdaq: IMOS)
Intelligroup (Nasdaq: ITIG)
Nanogen (Nasdaq: NGEN)
Taser International (Nasdaq: TASR)
The intriguing thing about this particular stock screen is that each of these companies has risen very far, very fast, but we don`t know why yet. Part of the fun of this kind of investigating is that after finding these stocks, it`s now time to turn toward the fundamentals to try to understand if something truly special is happening to explain the incredible rise in the prices, or if investors are simply building castles in the air. In some cases, with special companies, you identify a potential future investment. In other cases, you identify a stock you might be willing to short.
After a cursory look at each company, here`s my quick take on each one:
Taser International -- As fellow Fool Seth Jayson pointed out Friday, Taser has seen a dramatic rise in both revenue and net income, along with solid increases in profit margins. The company has new inroads at the Pentagon and has strong ties to the law-enforcement community. It seems like there is some fundamental justification for the incredible rise in its share price. Even if I thought the stock was too richly priced, I wouldn`t short it, largely because good things are happening at Taser.
Nanogen Inc. -- Nanotechnology is the hot buzzword in many technology circles and a number of small public companies (Altair Nanotechnologies (Nasdaq: ALTI) and Nanophase Technologies (Nasdaq: NANX) among them) are benefiting from all the attention. The big news for Nanogen is the patent it received on Nov. 25 that lets it play in the subatomic sandbox. The problem with shorting nanotechnology is that there are going to be a few massive winners along with the many losers and hype jobs. Right now, I`m not smart enough to differentiate. My inclination isn`t to short this group, but rather to buy very small dollar amounts in a handful of them, knowing that most will fail, but one or two will be absolute home runs.
ChipMOS Technologies (Bermuda) -- I know this isn`t fair, but don`t you get a little freaked out by the fact that it has "Bermuda" in the name? Kidding aside, this is a Taiwanese company incorporated in Bermuda. It does semiconductor testing and controller assembly. ChipMOS has also been working closely in the LCD market, which is red hot right now. With more than 1,700 employees and profitable, it may be expensive, but I wouldn`t be shorting it.
Intelligroup -- These folks are IT consultants and for the life of me I can`t understand how the business is worth $150 million when it can`t make any money. This stock was $1 in July and now it`s close to $10. The company showed a very small profit in the most recent quarter, which is probably what`s making people so excited, despite a sea of red ink prior. The only other thing to consider is that it pulled in more than $100 million in revenue. Perhaps the market believes Intelligroup`s customer base would be valuable to some other competitor. Still, I`m a bit suspect of this one and will likely dig in much deeper.
Arrhythmia Research Technologies -- This is the one that concerns me. The company traded at $3 in early 2003 and now trades at over $30. It has slightly declining revenue and is slightly profitable. It makes products designed to detect deadly heart arrhythmias. The odd thing is that there hasn`t been a significant piece of company news in over a year. No great new contracts to boast about, no nothing -- yet the stock is up over 1,000%? That makes absolutely no sense and is something I intend to look into in much greater detail. Of the five companies on the screen, this feels like a hype job and is my one solid short possibility. I`ll be digging around and try and provide an update next week.
As you can see, a simple technical stock screen like the 200-day moving average unveils a number of interesting companies, for both the short and long sides. Sometimes the key to successful investing is in looking to the extremes and asking yourself, "How long can this possibly continue?"
David Forrest does not own any of the companies discussed in this article.
Stocks at the Extremes
David Forrest uses a simple stock screen to identify a small handful of companies that may have come too far, too fast. Is there profit to be made by betting against these stocks?
By David Forrest (TMF Bogey)
January 20, 2004
If you`re like me, you spend most of your stock-sifting time searching for hidden gems or other similar growth investments. After all, we`re usually looking for the next big winner in the stock market, right? I mean, who wouldn`t want the 75% average returns that Tom Gardner`s Hidden Gems newsletter has achieved in the last seven months of stock picking?
We buy stocks we think are going to go up. Sometimes, however, it pays to look at the flip side and seek out businesses that might be on shaky ground. Today, we`ll look briefly at three companies whose stocks have been on fire lately. But are they about to crash and burn?
As I mentioned in my column last week, I enjoy using various stock screens as a way to generate new ideas and expose myself to new companies. I use both fundamental analysis and technical analysis screens to find ideas. This week, I`ll introduce you to a very simple technical screen I use to ferret out stocks that have risen abnormally fast.
200-Day Moving Average
Most people who analyze price movements in stocks will employ moving averages in their work. A stock`s moving average is simply the average of the closing prices for the stock in the last "x" number of days, plotted over time.
Perhaps the most oft-used is the 200-day moving average. Technicians will tell you that stocks trading above this average are doing OK, while stocks that trade below it are having a rough time. Indeed, many people will use that 200-day moving average as an inflection point, buying when a stock breaks through it to the upside and selling when a stock falls under it on the downside.
The logic beyond the voodoo is that if a company is doing reasonably well and growing its business, the price of the stock should reflect that growth and the stock should rise steadily over time. If a stock is rising steadily, the current price should always be somewhat higher than the 200-day moving average. Conversely, if investors lose confidence in a company`s ability to grow, they might sell the stock, causing it to drop below the 200-day moving average. Technicians consider this a bad sign and a "sell signal."
Irrespective of whether you buy into this or not (and the Fool generally eschews technical analysis), the 200-day moving average can be a useful tool to identify investor sentiment, in the extreme. For my technical screen, I look at companies whose stock price today is four times the 200-day moving average. In other words, something has happened in the recent past that has driven the stock up very fast, causing it to trade significantly higher than its 200-day moving average.
From looking at this screen over time, it is abnormal for a stock to trade at such a multiple. In my experience, after watching this screen for more than five years now, one of two things generally happens. The stock either drops pretty hard, bringing it back to earth, or the stock price stays about the same for a fairly long time, almost as if it were waiting for the moving average to catch up. Of course, this simply means that investors are less willing to buy at these lofty heights, or perhaps even wanting to take some profits off the table.
What almost never happens is that the stocks continue to race higher. Even in the bubble run of the late 1990s, it was rare to see a stock exceed four times its 200-day moving average.
The suspects
Out of almost 7,000 companies in the database I use for this screen, only nine stocks currently trade at more than four times their 200-day moving average. Four of these trade below $5, and are considered penny stocks. I`m not a big fan of looking at the pennies, so I generally disregard these companies. That leaves us with five:
Arrythmia Research (AMEX:HRT)
ChipMOS Technologies (Bermuda) (Nasdaq: IMOS)
Intelligroup (Nasdaq: ITIG)
Nanogen (Nasdaq: NGEN)
Taser International (Nasdaq: TASR)
The intriguing thing about this particular stock screen is that each of these companies has risen very far, very fast, but we don`t know why yet. Part of the fun of this kind of investigating is that after finding these stocks, it`s now time to turn toward the fundamentals to try to understand if something truly special is happening to explain the incredible rise in the prices, or if investors are simply building castles in the air. In some cases, with special companies, you identify a potential future investment. In other cases, you identify a stock you might be willing to short.
After a cursory look at each company, here`s my quick take on each one:
Taser International -- As fellow Fool Seth Jayson pointed out Friday, Taser has seen a dramatic rise in both revenue and net income, along with solid increases in profit margins. The company has new inroads at the Pentagon and has strong ties to the law-enforcement community. It seems like there is some fundamental justification for the incredible rise in its share price. Even if I thought the stock was too richly priced, I wouldn`t short it, largely because good things are happening at Taser.
Nanogen Inc. -- Nanotechnology is the hot buzzword in many technology circles and a number of small public companies (Altair Nanotechnologies (Nasdaq: ALTI) and Nanophase Technologies (Nasdaq: NANX) among them) are benefiting from all the attention. The big news for Nanogen is the patent it received on Nov. 25 that lets it play in the subatomic sandbox. The problem with shorting nanotechnology is that there are going to be a few massive winners along with the many losers and hype jobs. Right now, I`m not smart enough to differentiate. My inclination isn`t to short this group, but rather to buy very small dollar amounts in a handful of them, knowing that most will fail, but one or two will be absolute home runs.
ChipMOS Technologies (Bermuda) -- I know this isn`t fair, but don`t you get a little freaked out by the fact that it has "Bermuda" in the name? Kidding aside, this is a Taiwanese company incorporated in Bermuda. It does semiconductor testing and controller assembly. ChipMOS has also been working closely in the LCD market, which is red hot right now. With more than 1,700 employees and profitable, it may be expensive, but I wouldn`t be shorting it.
Intelligroup -- These folks are IT consultants and for the life of me I can`t understand how the business is worth $150 million when it can`t make any money. This stock was $1 in July and now it`s close to $10. The company showed a very small profit in the most recent quarter, which is probably what`s making people so excited, despite a sea of red ink prior. The only other thing to consider is that it pulled in more than $100 million in revenue. Perhaps the market believes Intelligroup`s customer base would be valuable to some other competitor. Still, I`m a bit suspect of this one and will likely dig in much deeper.
Arrhythmia Research Technologies -- This is the one that concerns me. The company traded at $3 in early 2003 and now trades at over $30. It has slightly declining revenue and is slightly profitable. It makes products designed to detect deadly heart arrhythmias. The odd thing is that there hasn`t been a significant piece of company news in over a year. No great new contracts to boast about, no nothing -- yet the stock is up over 1,000%? That makes absolutely no sense and is something I intend to look into in much greater detail. Of the five companies on the screen, this feels like a hype job and is my one solid short possibility. I`ll be digging around and try and provide an update next week.
As you can see, a simple technical stock screen like the 200-day moving average unveils a number of interesting companies, for both the short and long sides. Sometimes the key to successful investing is in looking to the extremes and asking yourself, "How long can this possibly continue?"
David Forrest does not own any of the companies discussed in this article.
Gestern wieder ein Versuch an der 12$-Marke zu kratzen - nicht ganz gelungen, aber saubere Up-Entwicklung über den gesamten Nachmittag. Mal sehen, wie das weitergeht.
Firmen: NANOGEN und TRANSGENOMIC: Vertriebskooperation
NANOGEN und TRANSGENOMIC (Nasdaq: TBIO) haben eine Vertriebskooperation vereinbart.
Im Rahmen der Zusammenarbeit wird TRANSGENOMIC das NanoChip®-System in Westeuropa vertreiben. Der Vertrag umfaßt das Marketing, den Verkauf und den Support für die Anlage.
Zeit: 23.01.2004.
Quelle: Nanogen.
NANOGEN und TRANSGENOMIC (Nasdaq: TBIO) haben eine Vertriebskooperation vereinbart.
Im Rahmen der Zusammenarbeit wird TRANSGENOMIC das NanoChip®-System in Westeuropa vertreiben. Der Vertrag umfaßt das Marketing, den Verkauf und den Support für die Anlage.
Zeit: 23.01.2004.
Quelle: Nanogen.
Yes - zurück im 12 Dollar Bereich - wenn wir die jetzt ein paar tage nachhaltig halten ist der weg zu de 14 Dollar frei
nanogen +10% - jetzt wollen wir es aber wissen. kommt heute doch noch 13 Dollar?
lt.Orderbuch in USA: 12,4980 Realtime
Soeben 10,80 in D.
Endlich bekommt Nanogen wieder die verdiente
Aufmerksamkeit ...
Gruß
Viola
Endlich bekommt Nanogen wieder die verdiente
Aufmerksamkeit ...
Gruß
Viola
soeben 14 $ in USA !!!!!
akat
akat
wenn wir die Tage 14,75$ überwinden, ist der Weg frei nach oben.
vielleicht schon heute!!
Jo, Nanogen geht ja heute wieder richtig ab. Amerika 14,58 $!
Die sind völlig irre die Amis - Höchstkurs über 14$ - das waren 8% im plus - jetzt runter auf 12,5 - das sind 6% Minus. Ein geiler Daytrader-Wert
Nanogen Nachbörslich bei 13,10 $, also wieder ein wenig weg von dem 12,47 $ Schlusskurs
Und hier der Grund
Wednesday January 28, 4:30 pm ET
SAN DIEGO, Jan. 28 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) announced today that it was issued U.S. Patent No. 6,682,936, "Addressable Biologic Electrode Array," by the U.S. Patent and Trademark Office. The `936 patent relates to electrode-based array devices and methods of operation in which individual electrodes contained within the array can be selectively addressed or manipulated. The technology enables high-density electrode arrays to be produced and has applications for the hybridization as well as combinatorial synthesis and self-assembly of biological molecules, such as nucleic acids and peptides. The technology also enables the production of smaller and more compact arrays, while at the same time minimizing the utilization of off-chip control circuitry, even for large numbers of electrodes. The technology described in the patent relates to Nanogen`s advanced chip designs, which can be used for biological applications and also for nanofabrication applications, such as those described in several other Nanogen patents including the Company`s recently issued U.S. Patent No. 6,652,808. With the addition of the `936 patent, Nanogen now has 57 issued patents in the United States.
"Customers using biomedical diagnostic applications -- and ultimately the patients they serve -- will require increasingly sophisticated capabilities at reasonable cost," said Howard Birndorf, Nanogen chairman and chief executive officer. "Application of the technology described in this patent allows for continually increasing array densities and capabilities, which simultaneously would reduce both array cost and instrument size."
"One of the challenges in producing biologic arrays of increasing density is the integration of electronic control circuitry with each electrode on the array. The new patent describes a semiconductor-based switching technology that helps solve these scaling issues," said Dr. Michael J. Heller, co-founder of Nanogen, and currently a professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
Wednesday January 28, 4:30 pm ET
SAN DIEGO, Jan. 28 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) announced today that it was issued U.S. Patent No. 6,682,936, "Addressable Biologic Electrode Array," by the U.S. Patent and Trademark Office. The `936 patent relates to electrode-based array devices and methods of operation in which individual electrodes contained within the array can be selectively addressed or manipulated. The technology enables high-density electrode arrays to be produced and has applications for the hybridization as well as combinatorial synthesis and self-assembly of biological molecules, such as nucleic acids and peptides. The technology also enables the production of smaller and more compact arrays, while at the same time minimizing the utilization of off-chip control circuitry, even for large numbers of electrodes. The technology described in the patent relates to Nanogen`s advanced chip designs, which can be used for biological applications and also for nanofabrication applications, such as those described in several other Nanogen patents including the Company`s recently issued U.S. Patent No. 6,652,808. With the addition of the `936 patent, Nanogen now has 57 issued patents in the United States.
"Customers using biomedical diagnostic applications -- and ultimately the patients they serve -- will require increasingly sophisticated capabilities at reasonable cost," said Howard Birndorf, Nanogen chairman and chief executive officer. "Application of the technology described in this patent allows for continually increasing array densities and capabilities, which simultaneously would reduce both array cost and instrument size."
"One of the challenges in producing biologic arrays of increasing density is the integration of electronic control circuitry with each electrode on the array. The new patent describes a semiconductor-based switching technology that helps solve these scaling issues," said Dr. Michael J. Heller, co-founder of Nanogen, and currently a professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
Nach dem Einbruch in USA habe ich gerade eine limitierte Order für 10,10 € in Frankfurt abgesetzt.
Ob ich welche bekomme ?
Bye
S.
Ob ich welche bekomme ?
Bye
S.
auf Deutsch
Übersetzungen schneller erhalten. Download der AltaVista Toolbar.
Startseite › Werkzeuge > Babel Fish-Übersetzung > Übersetzungsergebnisse
Babel Fish-Übersetzung Hilfe
Auf Deutsch:
Mittwoch Januar 28, 4:30 P.M. UND SAN DIEGO, Jan. 28 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - Nachrichten), daß es herausgegebenes VEREINIGTE STAATEN Patent Nr. 6.682.936, "war ansprechbare biologische Elektrode Reihe," durch das VEREINIGTE STAATEN Patent-und Warenzeichen-Büro heute verkündet. Das ` 936 Patent bezieht auf Elektrode-gegründeten Reihe Vorrichtungen und Operationsmethoden, in denen die einzelnen Elektroden, die innerhalb der Reihe enthalten werden, selektiv adressiert werden oder manipuliert werden können. Die Technologie ermöglicht mit hoher Dichte Elektrode Reihen produziert zu werden und hat Anwendungen für die Hybridation sowie kombinatorische Synthese und Selbst-Versammlung der biologischen Moleküle, wie Nukleinsäuren und Peptide. Die Technologie ermöglicht auch der Produktion von kleinerem und kompaktere Reihen, bei gleichzeitig der Minderung der Anwendung des off-chip Steuerschaltkreises, glätten für viele Elektroden. Die Technologie, die im Patent beschrieben wird, bezieht auf Nanogen`s vorgerückten Chip-Entwürfen, die für biologische Anwendungen und auch für nanofabrication Anwendungen verwendet werden können, wie die, die in einigen anderen Nanogen Patenten einschließlich das Company`s vor kurzem herausgegebene VEREINIGTE STAATEN Patent Nr. 6.652.808 beschrieben werden. Mit Hinzufügung von ` 936 Patent, hat Nanogen jetzt 57 herausgegebene Patente in den vereinigten Zuständen "Kunden, biomedizinische Diagnoseanwendungen zu verwenden -- und schließlich die Patienten, die sie dienen -- erfordert in zunehmendem Maße hoch entwickelte Fähigkeiten an den angemessenen Kosten," sagte Howard Birndorf, Nanogen Vorsitzender und Generaldirektor "Anwendung der Technologie, die in diesem Patent beschrieben wird, läßt fortwährend zunehmende Reihe Dichten und Fähigkeiten zu, die gleichzeitig würden verringern Reihe Kosten und Instrumentgröße." "eine der Herausforderungen, wenn es biologische Reihen der zunehmenden Dichte produziert, ist die Integration des elektronisches Steuerschaltkreises mit jeder Elektrode auf der Reihe. Das neue Patent beschreibt eine Halbleiter-gegründete zugeschaltete Technologie, der Hilfen diese Skalierungausgaben lösen, "sagte Dr. Michael J. Heller, Co-Gründer von Nanogen und z.Z. ein Professor in den Abteilungen von Biotechnik und von elektrischer und Computertechnik an der Universität von Kalifornien, San Diego.
Übersetzungen schneller erhalten. Download der AltaVista Toolbar.
Startseite › Werkzeuge > Babel Fish-Übersetzung > Übersetzungsergebnisse
Babel Fish-Übersetzung Hilfe
Auf Deutsch:
Mittwoch Januar 28, 4:30 P.M. UND SAN DIEGO, Jan. 28 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - Nachrichten), daß es herausgegebenes VEREINIGTE STAATEN Patent Nr. 6.682.936, "war ansprechbare biologische Elektrode Reihe," durch das VEREINIGTE STAATEN Patent-und Warenzeichen-Büro heute verkündet. Das ` 936 Patent bezieht auf Elektrode-gegründeten Reihe Vorrichtungen und Operationsmethoden, in denen die einzelnen Elektroden, die innerhalb der Reihe enthalten werden, selektiv adressiert werden oder manipuliert werden können. Die Technologie ermöglicht mit hoher Dichte Elektrode Reihen produziert zu werden und hat Anwendungen für die Hybridation sowie kombinatorische Synthese und Selbst-Versammlung der biologischen Moleküle, wie Nukleinsäuren und Peptide. Die Technologie ermöglicht auch der Produktion von kleinerem und kompaktere Reihen, bei gleichzeitig der Minderung der Anwendung des off-chip Steuerschaltkreises, glätten für viele Elektroden. Die Technologie, die im Patent beschrieben wird, bezieht auf Nanogen`s vorgerückten Chip-Entwürfen, die für biologische Anwendungen und auch für nanofabrication Anwendungen verwendet werden können, wie die, die in einigen anderen Nanogen Patenten einschließlich das Company`s vor kurzem herausgegebene VEREINIGTE STAATEN Patent Nr. 6.652.808 beschrieben werden. Mit Hinzufügung von ` 936 Patent, hat Nanogen jetzt 57 herausgegebene Patente in den vereinigten Zuständen "Kunden, biomedizinische Diagnoseanwendungen zu verwenden -- und schließlich die Patienten, die sie dienen -- erfordert in zunehmendem Maße hoch entwickelte Fähigkeiten an den angemessenen Kosten," sagte Howard Birndorf, Nanogen Vorsitzender und Generaldirektor "Anwendung der Technologie, die in diesem Patent beschrieben wird, läßt fortwährend zunehmende Reihe Dichten und Fähigkeiten zu, die gleichzeitig würden verringern Reihe Kosten und Instrumentgröße." "eine der Herausforderungen, wenn es biologische Reihen der zunehmenden Dichte produziert, ist die Integration des elektronisches Steuerschaltkreises mit jeder Elektrode auf der Reihe. Das neue Patent beschreibt eine Halbleiter-gegründete zugeschaltete Technologie, der Hilfen diese Skalierungausgaben lösen, "sagte Dr. Michael J. Heller, Co-Gründer von Nanogen und z.Z. ein Professor in den Abteilungen von Biotechnik und von elektrischer und Computertechnik an der Universität von Kalifornien, San Diego.
#256
Tut mir leid, aber es hat geklappt !
Bin wieder dabei !!!!
Auf nach Norden
S.
Tut mir leid, aber es hat geklappt !
Bin wieder dabei !!!!
Auf nach Norden
S.
Press Release Source: Nanogen, Inc.; SYN X Pharma, Inc.
Nanogen Announces Agreement to Acquire SYN X Pharma; Represents Entry Into Point-of-Care Diagnostics Market
Tuesday February 10, 8:00 am ET
SAN DIEGO and TORONTO, Feb. 10 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), developer of molecular diagnostic products for the gene-based testing market, and SYN X Pharma, Inc. (TSX: SYY - News), a point-of-care diagnostics company, announced today the signing of a definitive agreement whereby Nanogen will acquire SYN X in an all-stock transaction by way of a court-approved plan of arrangement. The acquisition will provide Nanogen with a pipeline of complementary products in order to expand its market share in the in vitro diagnostics market and augments its technology platform for developing advanced diagnostic products.
SYN X is preparing to commercialize a diagnostic product for congestive heart failure (CHF). As announced in July of 2003, SYN X obtained a worldwide license to the CHF marker NT-proBNP (N-terminal pro-hormone brain natriuretic peptide) from Roche Diagnostics to develop a test for the point-of-care market. SYN X`s new Nexus Dx(TM) product will offer substantial improvements over other CHF diagnostics, including stability at room temperature and quicker results, and will enable health professionals to provide an enhanced level of care. SYN X will seek European regulatory clearance by mid-2004 and U.S. Food and Drug Administration 510(k) clearance in the second half of 2004. Analysts predict the BNP market will have above-average growth and will reach approximately US $300 million by 2005 as use increases internationally.
SYN X currently markets point-of-care diagnostic tests for myocardial infarction in Europe and Canada, and infectious diseases and drugs of abuse in Canada. In addition to the CHF product, SYN X has been developing a pipeline of tests to be marketed under the brand name Nexus Dx(TM) for insulin resistance and traumatic brain injury. SYN X also intends to expand the CHF product line and obtain clearance for additional label indications. In addition, SYN X has developed diagnostic tests for Alzheimer`s disease and stroke, which, as previously announced, have been licensed to Ortho-Clinical Diagnostics Inc. (a Johnson & Johnson Company) and Genzyme Corporation, respectively.
"The acquisition of SYN X supports Nanogen`s long-term strategy to commercialize advanced diagnostics that enhance the level of medical care for the detection, diagnosis, monitoring and treatment of disease," said Howard Birndorf, Nanogen chairman and chief executive officer. "Nanogen has an established position in clinical reference labs, and this acquisition allows us to expand into a synergistic market, bringing diagnostics closer to the patients and physicians making critical treatment decisions. Nanogen welcomes the SYN X team and we look forward to joining efforts to commercialize our combined pipeline of genetic, infectious disease and point-of-care products," added Birndorf.
"This strategic union will deliver enhanced value for our shareholders, business partners and customers. It will provide the necessary resources to commercialize our rich Nexus Dx(TM) pipeline of products and enhance our abilities to respond to unmet medical diagnostic needs in areas like congestive heart failure, insulin resistance, type I diabetes and traumatic brain injury," said Dr. George Jackowski, SYN X chairman, chief executive officer and chief scientific officer.
"I believe the financial strength of the combined company positions us well for long-term leadership in diagnostics," said Rod Wilson, SYN X president and chief operation officer. "SYN X shareholders will have the opportunity to participate in the value created from an expanded and highly specialized diagnostics portfolio, U.S. listing and enhanced liquidity."
Upon closing the transaction, Nanogen intends to operate SYN X as a business unit with both Rod Wilson and Dr. George Jackowski joining the Nanogen management team. Nanogen will retain the SYN X brand name and the Toronto research facility.
SYN X recorded product revenues for the nine months ended September 30, 2003 of CDN $5.8 million and losses of CDN $5.3 million. Nanogen expects the SYN X business unit to be cash flow positive by the end of 2005.
Under the terms of the combination agreement, Nanogen will issue shares of Nanogen common stock in a stock-for-stock exchange to holders of SYN X common shares. The transaction is valued at approximately CDN $16.3 million. There are approximately 11.2 million SYN X shares and share equivalents outstanding. At closing, each SYN X common shareholder is expected to receive approximately CDN $1.45 per SYN X share in Nanogen common stock. Nanogen will also make available to SYN X a secured line of credit of CDN $2 million to fund working capital needs prior to closing. At closing, Nanogen will acquire the existing CDN $3.5 million principal amount subordinated secured debentures of SYN X in exchange for newly issued shares of Nanogen stock. Outstanding options and warrants to acquire SYN X common shares will convert into obligations of Nanogen at closing and will represent options and warrants to acquire shares of Nanogen common stock based on the transaction exchange ratio and the existing terms of the SYN X stock option plan and warrants.
The transaction is subject to the approval of holders of SYN X common shares and debentures, court approval and other customary closing conditions. The acquisition is expected to close in the second quarter of 2004. A joint special meeting of holders of SYN X common shares and debentures is expected to be held within 60 days. Further information will be contained in the management information circular that is expected to be mailed to shareholders and debenture holders in early March.
The transaction has the unanimous approval of the SYN X board of directors. In addition, Nanogen has entered into support agreements with all officers and directors and certain shareholders of SYN X common shares and with certain holders of SYN X debentures representing approximately 77% of the outstanding principal amount of SYN X debentures pursuant to which such security holders have agreed to vote in favor of the transaction.
Seven Hills Partners LLC acted as the financial advisor to Nanogen in this transaction. The Seidler Companies and Orenda Corporate Finance Ltd. acted as financial advisors to SYN X. First Associates Investments Inc. has rendered an opinion to the SYN X Board that the aggregate consideration payable pursuant to the arrangement is fair to SYN X shareholders.
A document addressing "Frequently Asked Questions" regarding this agreement can be found on Nanogen`s website at www.nanogen.com under "Press Releases."
About Nanogen
Nanogen develops and commercializes molecular diagnostic products for the gene-based testing market. The company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the acquisition of SYN X will be approved by holders of SYN X common shares and debentures, close as anticipated and achieve the synergies and other benefits anticipated, whether patents owned or licensed by Nanogen will be developed into products, whether the SYN X business unit will become cash flow positive as expected, whether Nanogen`s NanoChip® System can be successfully further commercialized, whether other products under development and point-of-care products can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
About SYN X Pharma Inc.
SYN X is a research driven, point-of-care diagnostic company dedicated to delivering innovative and quality products to its customers and value to its shareholders. The company leverages its proven Proteomics Discovery Platform(TM) to rapidly discover and develop innovative diagnostic products to detect disease in the earliest stages, thus facilitating more effective treatments. The company`s extensive line of products focuses on unmet medical needs in the areas of diabetes, cardiovascular and central nervous system diseases. For further information, please visit the SYN X website www.synxpharma.com .
Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors affecting SYN X`s operations, markets, products and prices and other factors.
--------------------------------------------------------------------------------
Source: Nanogen, Inc.; SYN X Pharma, Inc.
Nanogen Announces Agreement to Acquire SYN X Pharma; Represents Entry Into Point-of-Care Diagnostics Market
Tuesday February 10, 8:00 am ET
SAN DIEGO and TORONTO, Feb. 10 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), developer of molecular diagnostic products for the gene-based testing market, and SYN X Pharma, Inc. (TSX: SYY - News), a point-of-care diagnostics company, announced today the signing of a definitive agreement whereby Nanogen will acquire SYN X in an all-stock transaction by way of a court-approved plan of arrangement. The acquisition will provide Nanogen with a pipeline of complementary products in order to expand its market share in the in vitro diagnostics market and augments its technology platform for developing advanced diagnostic products.
SYN X is preparing to commercialize a diagnostic product for congestive heart failure (CHF). As announced in July of 2003, SYN X obtained a worldwide license to the CHF marker NT-proBNP (N-terminal pro-hormone brain natriuretic peptide) from Roche Diagnostics to develop a test for the point-of-care market. SYN X`s new Nexus Dx(TM) product will offer substantial improvements over other CHF diagnostics, including stability at room temperature and quicker results, and will enable health professionals to provide an enhanced level of care. SYN X will seek European regulatory clearance by mid-2004 and U.S. Food and Drug Administration 510(k) clearance in the second half of 2004. Analysts predict the BNP market will have above-average growth and will reach approximately US $300 million by 2005 as use increases internationally.
SYN X currently markets point-of-care diagnostic tests for myocardial infarction in Europe and Canada, and infectious diseases and drugs of abuse in Canada. In addition to the CHF product, SYN X has been developing a pipeline of tests to be marketed under the brand name Nexus Dx(TM) for insulin resistance and traumatic brain injury. SYN X also intends to expand the CHF product line and obtain clearance for additional label indications. In addition, SYN X has developed diagnostic tests for Alzheimer`s disease and stroke, which, as previously announced, have been licensed to Ortho-Clinical Diagnostics Inc. (a Johnson & Johnson Company) and Genzyme Corporation, respectively.
"The acquisition of SYN X supports Nanogen`s long-term strategy to commercialize advanced diagnostics that enhance the level of medical care for the detection, diagnosis, monitoring and treatment of disease," said Howard Birndorf, Nanogen chairman and chief executive officer. "Nanogen has an established position in clinical reference labs, and this acquisition allows us to expand into a synergistic market, bringing diagnostics closer to the patients and physicians making critical treatment decisions. Nanogen welcomes the SYN X team and we look forward to joining efforts to commercialize our combined pipeline of genetic, infectious disease and point-of-care products," added Birndorf.
"This strategic union will deliver enhanced value for our shareholders, business partners and customers. It will provide the necessary resources to commercialize our rich Nexus Dx(TM) pipeline of products and enhance our abilities to respond to unmet medical diagnostic needs in areas like congestive heart failure, insulin resistance, type I diabetes and traumatic brain injury," said Dr. George Jackowski, SYN X chairman, chief executive officer and chief scientific officer.
"I believe the financial strength of the combined company positions us well for long-term leadership in diagnostics," said Rod Wilson, SYN X president and chief operation officer. "SYN X shareholders will have the opportunity to participate in the value created from an expanded and highly specialized diagnostics portfolio, U.S. listing and enhanced liquidity."
Upon closing the transaction, Nanogen intends to operate SYN X as a business unit with both Rod Wilson and Dr. George Jackowski joining the Nanogen management team. Nanogen will retain the SYN X brand name and the Toronto research facility.
SYN X recorded product revenues for the nine months ended September 30, 2003 of CDN $5.8 million and losses of CDN $5.3 million. Nanogen expects the SYN X business unit to be cash flow positive by the end of 2005.
Under the terms of the combination agreement, Nanogen will issue shares of Nanogen common stock in a stock-for-stock exchange to holders of SYN X common shares. The transaction is valued at approximately CDN $16.3 million. There are approximately 11.2 million SYN X shares and share equivalents outstanding. At closing, each SYN X common shareholder is expected to receive approximately CDN $1.45 per SYN X share in Nanogen common stock. Nanogen will also make available to SYN X a secured line of credit of CDN $2 million to fund working capital needs prior to closing. At closing, Nanogen will acquire the existing CDN $3.5 million principal amount subordinated secured debentures of SYN X in exchange for newly issued shares of Nanogen stock. Outstanding options and warrants to acquire SYN X common shares will convert into obligations of Nanogen at closing and will represent options and warrants to acquire shares of Nanogen common stock based on the transaction exchange ratio and the existing terms of the SYN X stock option plan and warrants.
The transaction is subject to the approval of holders of SYN X common shares and debentures, court approval and other customary closing conditions. The acquisition is expected to close in the second quarter of 2004. A joint special meeting of holders of SYN X common shares and debentures is expected to be held within 60 days. Further information will be contained in the management information circular that is expected to be mailed to shareholders and debenture holders in early March.
The transaction has the unanimous approval of the SYN X board of directors. In addition, Nanogen has entered into support agreements with all officers and directors and certain shareholders of SYN X common shares and with certain holders of SYN X debentures representing approximately 77% of the outstanding principal amount of SYN X debentures pursuant to which such security holders have agreed to vote in favor of the transaction.
Seven Hills Partners LLC acted as the financial advisor to Nanogen in this transaction. The Seidler Companies and Orenda Corporate Finance Ltd. acted as financial advisors to SYN X. First Associates Investments Inc. has rendered an opinion to the SYN X Board that the aggregate consideration payable pursuant to the arrangement is fair to SYN X shareholders.
A document addressing "Frequently Asked Questions" regarding this agreement can be found on Nanogen`s website at www.nanogen.com under "Press Releases."
About Nanogen
Nanogen develops and commercializes molecular diagnostic products for the gene-based testing market. The company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the acquisition of SYN X will be approved by holders of SYN X common shares and debentures, close as anticipated and achieve the synergies and other benefits anticipated, whether patents owned or licensed by Nanogen will be developed into products, whether the SYN X business unit will become cash flow positive as expected, whether Nanogen`s NanoChip® System can be successfully further commercialized, whether other products under development and point-of-care products can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
About SYN X Pharma Inc.
SYN X is a research driven, point-of-care diagnostic company dedicated to delivering innovative and quality products to its customers and value to its shareholders. The company leverages its proven Proteomics Discovery Platform(TM) to rapidly discover and develop innovative diagnostic products to detect disease in the earliest stages, thus facilitating more effective treatments. The company`s extensive line of products focuses on unmet medical needs in the areas of diabetes, cardiovascular and central nervous system diseases. For further information, please visit the SYN X website www.synxpharma.com .
Except for historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including but not limited to economic, competitive, governmental and technological factors affecting SYN X`s operations, markets, products and prices and other factors.
--------------------------------------------------------------------------------
Source: Nanogen, Inc.; SYN X Pharma, Inc.
Reuters
Before-the-Bell: Nanogen, Blockbuster Off
Tuesday February 10, 9:10 am ET
CHICAGO (Reuters) - Nanogen Inc. (NasdaqNM:NGEN - News) shares fell in trade before Tuesday`s opening bell after the company said it agreed to acquire SYN X Pharma Inc. (Vancouver:SYN.V - News) for $16.3 million Canadian dollars ($12.3 million) to expand its presence in the diagnostics market.
Shares of Nanogen, which makes molecular diagnostic products for gene-based diagnostics, dropped to $11.00 on the electronic market INET from Monday`s Nasdaq close of $11.12.
Shares of Merrill Lynch & Co. (NYSE:MER - News), which runs the largest U.S. full-service brokerage, rose in trading before Tuesday`s open after the company announced a $2 billion share repurchase program.
Merrill said on Tuesday its board of directors authorized the company to buy back its common shares.
Merrill shares moved up to $58.28 on INET from Monday`s close of $57.73 on the New York Stock Exchange (News - Websites) .
Blockbuster Inc. (NYSE:BBI - News) fell before Tuesday`s open after it posted a quarterly loss, and said it may make a special payout to shareholders in connection with Viacom`s plan to spin off its majority stake in the company.
Shares of Blockbuster, the world`s top movie rental chain, fell to $15.47 on INET, down from their close of $16.41 on the New York Stock Exchange.
Early Tuesday morning, media conglomerate Viacom Inc. (NYSE:VIAb - News) said it would pursue a tax-free spin-off of its 81 percent stake in Blockbuster.
Blockbuster posted a fourth-quarter net loss of $1.19 billion, or $6.57 a share, compared with a year-ago profit of $30.7 million, or 17 a share.
Before-the-Bell: Nanogen, Blockbuster Off
Tuesday February 10, 9:10 am ET
CHICAGO (Reuters) - Nanogen Inc. (NasdaqNM:NGEN - News) shares fell in trade before Tuesday`s opening bell after the company said it agreed to acquire SYN X Pharma Inc. (Vancouver:SYN.V - News) for $16.3 million Canadian dollars ($12.3 million) to expand its presence in the diagnostics market.
Shares of Nanogen, which makes molecular diagnostic products for gene-based diagnostics, dropped to $11.00 on the electronic market INET from Monday`s Nasdaq close of $11.12.
Shares of Merrill Lynch & Co. (NYSE:MER - News), which runs the largest U.S. full-service brokerage, rose in trading before Tuesday`s open after the company announced a $2 billion share repurchase program.
Merrill said on Tuesday its board of directors authorized the company to buy back its common shares.
Merrill shares moved up to $58.28 on INET from Monday`s close of $57.73 on the New York Stock Exchange (News - Websites) .
Blockbuster Inc. (NYSE:BBI - News) fell before Tuesday`s open after it posted a quarterly loss, and said it may make a special payout to shareholders in connection with Viacom`s plan to spin off its majority stake in the company.
Shares of Blockbuster, the world`s top movie rental chain, fell to $15.47 on INET, down from their close of $16.41 on the New York Stock Exchange.
Early Tuesday morning, media conglomerate Viacom Inc. (NYSE:VIAb - News) said it would pursue a tax-free spin-off of its 81 percent stake in Blockbuster.
Blockbuster posted a fourth-quarter net loss of $1.19 billion, or $6.57 a share, compared with a year-ago profit of $30.7 million, or 17 a share.
Reuters
CORRECTED - Nanogen acquires SYN X for about $12.3 million
Tuesday February 10, 11:51 am ET
In NEW YORK story headlined "Nanogen acquires SYN X for about $12.3 million" in first paragraph please change SYN X ticker symbol to SYY.TO from SYN.TO. (Corrects symbol).
A corrected version follows.
NEW YORK, Feb 10 (Reuters) - Nanogen Inc. (NasdaqNM:NGEN - News), which makes molecular diagnostic products for gene-based diagnostics, on Tuesday said it agreed to acquire SYN X Pharma Inc. (Toronto:SYY.TO - News) for $16.3 million Canadian dollars ($12.3 million) to expand its presence in the diagnostics market.
Nanogen, based in San Diego, and SYN X, based in Toronto, said at the conclusion of the transaction, each SYN X common shareholder will receive about C$1.45 per SYN.X share of Nanogen common stock. Nanogen will also make available to SYN X a secured line of credit of C$2 million to fund working capital needs prior to closing.
At closing Nanogen will acquire the existing C$3.5 million principal amount of subordinated secured debentures of SYN X in exchange for newly issued shares of Nanogen stock.
SYN X is preparing to commercialize a diagnostic product for congestive heart failure. The company currently markets diagnostic tests for heart attacks in Europe and Canada and for infectious diseases and drug abuse in Canada. The company has also developed diagnostic tests for Alzheimer`s disease and stroke.
CORRECTED - Nanogen acquires SYN X for about $12.3 million
Tuesday February 10, 11:51 am ET
In NEW YORK story headlined "Nanogen acquires SYN X for about $12.3 million" in first paragraph please change SYN X ticker symbol to SYY.TO from SYN.TO. (Corrects symbol).
A corrected version follows.
NEW YORK, Feb 10 (Reuters) - Nanogen Inc. (NasdaqNM:NGEN - News), which makes molecular diagnostic products for gene-based diagnostics, on Tuesday said it agreed to acquire SYN X Pharma Inc. (Toronto:SYY.TO - News) for $16.3 million Canadian dollars ($12.3 million) to expand its presence in the diagnostics market.
Nanogen, based in San Diego, and SYN X, based in Toronto, said at the conclusion of the transaction, each SYN X common shareholder will receive about C$1.45 per SYN.X share of Nanogen common stock. Nanogen will also make available to SYN X a secured line of credit of C$2 million to fund working capital needs prior to closing.
At closing Nanogen will acquire the existing C$3.5 million principal amount of subordinated secured debentures of SYN X in exchange for newly issued shares of Nanogen stock.
SYN X is preparing to commercialize a diagnostic product for congestive heart failure. The company currently markets diagnostic tests for heart attacks in Europe and Canada and for infectious diseases and drug abuse in Canada. The company has also developed diagnostic tests for Alzheimer`s disease and stroke.
Hier mal einige neue Patente die NGEN mit der Übernahme von Synxpharma erhält:
http://www.synxpharma.com/
PAT. NO. Title
1 6,677,303 Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons
2 6,627,608 Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons
3 6,627,607 Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
4 6,627,606 Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons
5 6,620,787 Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons
6 6,620,786 Biopolymer marker indicative of disease state having molecular weight of 2937 daltons
7 6,617,308 Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
8 6,602,855 Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
9 6,599,877 Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons
10 6,593,298 Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
11 6,461,828 Conjunctive analysis of biological marker expression for diagnosing organ failure
12 6,451,547 Process for differential diagnosis of Alzheimer`s dementia and device therefor
13 6,235,489 Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
http://www.synxpharma.com/
PAT. NO. Title
1 6,677,303 Biopolymer marker indicative of disease state having a molecular weight of 1097 daltons
2 6,627,608 Biopolymer marker indicative of disease state having a molecular weight of 1206 daltons
3 6,627,607 Biopolymer marker indicative of disease state having a molecular weight of 1845 daltons
4 6,627,606 Biopolymer marker indicative of disease state having a molecular weight of 1465 daltons
5 6,620,787 Biopolymer marker indicative of disease state having a molecular weight of 2267 daltons
6 6,620,786 Biopolymer marker indicative of disease state having molecular weight of 2937 daltons
7 6,617,308 Biopolymer marker indicative of disease state having a molecular weight of 1865 daltons
8 6,602,855 Biopolymer marker indicative of disease state having a molecular weight of 1449 daltons
9 6,599,877 Biopolymer marker indicative of disease state having a molecular weight of 1020 daltons
10 6,593,298 Biopolymer marker indicative of disease state having a molecular weight of 1690 daltons
11 6,461,828 Conjunctive analysis of biological marker expression for diagnosing organ failure
12 6,451,547 Process for differential diagnosis of Alzheimer`s dementia and device therefor
13 6,235,489 Method for diagnosing and distinguishing stroke and diagnostic devices for use therein
Nanogen to Host Conference Call on 2003 Fourth Quarter and Year-End Financial Results
SAN DIEGO, Feb 11, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) will host a conference call on Wednesday, February 18, 2004 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2003 fourth quarter and year-end financial results. The financial results press release will be issued at close of market on February 18.
Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com , and will be archived for 90 days. A digital recording of the call will also be available two hours after the completion of the conference call on February 18 until midnight on February 20, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 5360247, will be required to listen to the playback.
SAN DIEGO, Feb 11, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) will host a conference call on Wednesday, February 18, 2004 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2003 fourth quarter and year-end financial results. The financial results press release will be issued at close of market on February 18.
Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com , and will be archived for 90 days. A digital recording of the call will also be available two hours after the completion of the conference call on February 18 until midnight on February 20, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 5360247, will be required to listen to the playback.
Die Zahlen heute scheinen nicht so gut auszufallen.
NGEN $ 10.32 -0.25 -2.37%
NGEN $ 10.32 -0.25 -2.37%
Press Release Source: Nanogen, Inc.
Nanogen Reports 2003 Fourth Quarter and Year-End Financial Results
Wednesday February 18, 4:01 pm ET
SAN DIEGO, Feb. 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), developer of molecular diagnostic products, today announced its financial results for the fourth quarter and year ended December 31, 2003.
Total revenues for the quarter ended December 31, 2003 were $2.1 million compared to $1.7 million in the third quarter of 2003 and $12.1 million in the fourth quarter of 2002. Fourth quarter product revenue increased by 45% over the prior quarter on the basis of eight new instrument sales and one reagent rental. Additionally, Nanogen signed two new strategic site agreements during the fourth quarter. For the year ended December 31, 2003, total revenues were $6.7 million, as compared to $17.2 million for 2002. Both the fourth quarter and annual revenues for 2002 include approximately $10.8 million in licensing revenue recognized as a result of the settlement agreement with CombiMatrix. Excluding the revenue recognized from this settlement, revenues for the fourth quarter and year ended December 31, 2002 were $1.3 million and $6.3 million, respectively.
Total operating expenses for the quarter ended December 31, 2003 were $9.2 million as compared to $10.9 million for the same period in 2002. For the year ended December 31, 2003, total operating expenses were $37.5 million as compared to $43.9 million for 2002. Excluding cost of product sales of $3.2 million for the year ended December 31, 2003 and $2.5 million for 2002, total operating expenses for 2003 were $34.4 million compared to $41.4 million for 2002, reflecting a 17% reduction. The reduction represents the benefits received from the reorganization and cost reduction measures that were implemented in April 2003 and ongoing improvements in operating efficiencies.
Nanogen`s consolidated cash, cash equivalents and short-term investments balance at the end of the fourth quarter of 2003 was $29.1 million, a decrease of $3.5 million from the $32.6 million at the end of the prior quarter. In the fourth quarter of 2003, Nanogen completed the sale of the remaining portion of the CombiMatrix stock received in late 2002 and recognized a related gain of $850,000 in the quarter.
For the quarter ended December 31, 2003, Nanogen reported a net loss of $5.9 million or $0.25 per share, compared to a loss of $7.1 million or $0.33 per share in the third quarter of 2003 and net income of $2.0 million or $0.09 per share for the fourth quarter of 2002. For the year ended December 31, 2003, the company reported a net loss of $30.6 million or $1.38 per share, compared to a net loss of $22.2 million or $1.02 per share for 2002. Excluding the impact of $10.8 million in licensing revenue recognized as a result of the CombiMatrix settlement agreement, the net loss for the year ended December 31, 2002 would have been $33.0 million or $1.52 per share.
"Last year was marked by steady progress. We made our initial entry into the clinical diagnostic laboratory market and increased revenue each quarter. We also made very good progress during the year in improving our cash flow and in reducing our spending levels," said Howard C. Birndorf, chairman of the board and chief executive officer. "The keystone accomplishments for the year were the collaborations and acquisitions that we initiated to help pave the way for Nanogen to enter new, synergistic markets in 2004. Our identification of promising technologies to accelerate our entry into the infectious disease and point-of-care markets illustrates our strategy to grow the business by increasing the number of products we offer for gene-based testing, as well as commercializing advanced diagnostics for both physicians and labs," Birndorf added.
2004 Outlook
In 2004, Nanogen plans to launch several important new products into fast growing in vitro diagnostic markets. Through its collaboration with Prodesse, Inc., Nanogen expects to begin offering highly sensitive microarray-based reagents for detection of a number of infectious disease agents. These reagents would be used by CLIA-certified laboratories to develop and validate assays on the automated NanoChip® platform.
Contingent upon closing the acquisition of SYN X Pharma, announced February 10, 2004, Nanogen plans to obtain European and United States regulatory approval for a point-of-care diagnostic product for congestive heart failure (CHF), also targeting a large, growing market. Priorities will be established for developing SYN X`s pipeline of diagnostics that address unmet needs. Nanogen expects the SYN X business unit will require investment during 2004 but should be cash flow positive by the end of 2005.
Last month, Nanogen established a distribution agreement with Transgenomic, Inc. to help penetrate new market opportunities. Nanogen expects to continue signing alliances with distributors in Europe, the United States, and other geographies in order to build its installed base of instruments and consumable product revenues.
Nanogen will commit additional resources to expanding the company`s nanotechnology intellectual property. The company anticipates utilizing the growing government interest in the area as a source of funding for its research and development efforts.
Nanogen will also continue to identify other business expansion opportunities, potentially including acquisitions or development collaborations.
Financial Guidance
For 2004, excluding the impact of the acquisition of SYN X, Nanogen anticipates a growth rate in total revenue of approximately 50% as compared to 2003. Total operating expenses, excluding cost of products sold, should run approximately 20% less than the 2003 total year spending. An end of the year cash balance of greater than $15 million is expected. Nanogen expects to invest approximately $6 - 8 million in SYN X, which includes costs to launch the CHF product. Additional financial guidance incorporating the impact of SYN X will be provided after the closing of the acquisition.
Webcast of the Conference Call
Nanogen management will host a conference call today to discuss the fourth quarter and year-end financial results at 4:30 p.m. Eastern Time. Audio of the presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived for 90 days. A telephone replay of the call will also be available two hours after the completion of the conference call on February 18 until midnight on February 20, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 5360247, will be required to listen to the playback.
Note Regarding Use of Non-GAAP Financial Information
To supplement consolidated financial statements presented in accordance with GAAP, Nanogen used a non-GAAP adjustment to exclude $10.8 million in license revenue recognized as part of a settlement agreement with CombiMatrix in the fourth quarter of 2002. Non-GAAP adjustments are provided to enhance the users` overall understanding of current financial performance and prospects for the future. Specifically, Nanogen believes that the non-GAAP adjustment provides useful information to both management and investors by excluding certain settlement proceeds that the company believes are not indicative of its operating results, thereby permitting a more meaningful comparison between the loss information for the fourth quarters and years ending December 31, 2002 and 2003. Additionally, Nanogen used a non-GAAP adjustment to exclude cost of sales from operating expenses for the fourth quarters and years ending December 31, 2002 and 2003. Nanogen believes that this non-GAAP adjustment is useful to management and investors because it enhances Nanogen`s comparability to other companies, many of which do not include cost of sales in their presentation of operating expenses. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.
About Nanogen
Nanogen develops and commercializes molecular diagnostic products for the gene-based testing market. The company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements regarding future product revenues, contract and sponsored research revenues, estimates of operating expenses and estimates of future cash balances. These forward-looking statements are based upon current expectations and speak only as of the date hereof. Nanogen`s actual results and cash balances may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether the acquisition of SYN X Pharma will be approved by holders of SYN X common shares and debentures, close as anticipated and achieve the synergies and other benefits anticipated, whether the SYN X business unit will become cash flow positive as expected, whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip® System can be successfully further commercialized, whether other products under development and point-of-care products can be successfully developed and commercialized, whether results reported by Nanogen`s customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s reports on Form 10-Q and Form 10-K filed with the Securities and Exchange Commission. Nanogen disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except par value and share data)
December 31 December 31,
2003 2002
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $8,550 $9,353
Short-term investments 20,564 43,376
Receivables, net 1,415 1,754
Inventories, net 4,774 4,717
Other current assets 1,590 1,781
Total current assets 36,893 60,981
Property and equipment, net 4,277 4,982
Acquired technology rights, net 2,508 4,544
Other assets, net 171 853
$43,849 $71,360
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $290 $753
Accrued liabilities 4,519 5,901
Deferred revenue 469 472
Current portion of capital lease obligations 743 805
Total current liabilities 6,021 7,931
Capital lease obligations, less current portion 586 1,134
Other long-term liabilities 4,419 3,085
Total long-term liabilities 5,005 4,219
Minority interest in consolidated subsidiary -- 1,817
Stockholders` equity:
Convertible preferred stock, $0.001 par value,
5,000,000 shares authorized; no shares issued
and outstanding at December 31, 2003
(unaudited) and December 31, 2002 -- --
Common stock, $0.001 par value, 50,000,000 shares
authorized; 24,867,325 and 21,981,115 shares
issued and outstanding at December 31, 2003
(unaudited) and December 31, 2002,
respectively 25 22
Additional paid-in capital 209,017 199,483
Accumulated other comprehensive income 1,132 4,926
Deferred compensation (175) (156)
Notes receivable from officers -- (513)
Accumulated deficit (176,254) (145,659)
Treasury stock, at cost, 500,189 and
366,857 shares at December 31, 2003
(unaudited) and December 31, 2002,
respectively (922) (710)
Total stockholders` equity 32,823 57,393
$43,849 $71,360
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Twelve months ended
December 31, December 31,
2003 2002 2003 2002
Revenues:
Product sales $1,090 $511 $2,732 $3,384
License fees 38 10,844 84 10,844
Sponsored research 375 375 1,500 1,355
Contracts and grant 575 414 2,397 1,596
Total revenues 2,078 12,144 6,713 17,179
Operating expenses:
Cost of product sales 1,008 386 3,176 2,466
Research and development 4,542 5,348 18,015 21,020
Selling, general and
administrative 3,582 5,194 15,114 20,540
Impairment of acquired
technology rights -- -- 1,024 --
Litigation and settlement
of patent matter 56 -- 205 (165)
Total operating expenses 9,188 10,928 37,534 43,861
Income (loss) from
operations (7,110) 1,216 (30,821) (26,682)
Interest income, net 85 285 490 2,119
Other income/(expense) (4) 8 (154) 161
Gain/(loss) on sale of
investments 865 -- (1,925) --
Minority interest in
loss of consolidated
subsidiary 221 522 1,815 2,156
Net income (loss) $(5,943) $2,031 $(30,595) $(22,246)
Net loss per share -
basic and diluted
$(0.25) $0.09 $(1.38) $(1.02)
Number of shares used in
computing net loss
per share - basic and
diluted 23,959 21,697 22,244 21,722
Nanogen Reports 2003 Fourth Quarter and Year-End Financial Results
Wednesday February 18, 4:01 pm ET
SAN DIEGO, Feb. 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News), developer of molecular diagnostic products, today announced its financial results for the fourth quarter and year ended December 31, 2003.
Total revenues for the quarter ended December 31, 2003 were $2.1 million compared to $1.7 million in the third quarter of 2003 and $12.1 million in the fourth quarter of 2002. Fourth quarter product revenue increased by 45% over the prior quarter on the basis of eight new instrument sales and one reagent rental. Additionally, Nanogen signed two new strategic site agreements during the fourth quarter. For the year ended December 31, 2003, total revenues were $6.7 million, as compared to $17.2 million for 2002. Both the fourth quarter and annual revenues for 2002 include approximately $10.8 million in licensing revenue recognized as a result of the settlement agreement with CombiMatrix. Excluding the revenue recognized from this settlement, revenues for the fourth quarter and year ended December 31, 2002 were $1.3 million and $6.3 million, respectively.
Total operating expenses for the quarter ended December 31, 2003 were $9.2 million as compared to $10.9 million for the same period in 2002. For the year ended December 31, 2003, total operating expenses were $37.5 million as compared to $43.9 million for 2002. Excluding cost of product sales of $3.2 million for the year ended December 31, 2003 and $2.5 million for 2002, total operating expenses for 2003 were $34.4 million compared to $41.4 million for 2002, reflecting a 17% reduction. The reduction represents the benefits received from the reorganization and cost reduction measures that were implemented in April 2003 and ongoing improvements in operating efficiencies.
Nanogen`s consolidated cash, cash equivalents and short-term investments balance at the end of the fourth quarter of 2003 was $29.1 million, a decrease of $3.5 million from the $32.6 million at the end of the prior quarter. In the fourth quarter of 2003, Nanogen completed the sale of the remaining portion of the CombiMatrix stock received in late 2002 and recognized a related gain of $850,000 in the quarter.
For the quarter ended December 31, 2003, Nanogen reported a net loss of $5.9 million or $0.25 per share, compared to a loss of $7.1 million or $0.33 per share in the third quarter of 2003 and net income of $2.0 million or $0.09 per share for the fourth quarter of 2002. For the year ended December 31, 2003, the company reported a net loss of $30.6 million or $1.38 per share, compared to a net loss of $22.2 million or $1.02 per share for 2002. Excluding the impact of $10.8 million in licensing revenue recognized as a result of the CombiMatrix settlement agreement, the net loss for the year ended December 31, 2002 would have been $33.0 million or $1.52 per share.
"Last year was marked by steady progress. We made our initial entry into the clinical diagnostic laboratory market and increased revenue each quarter. We also made very good progress during the year in improving our cash flow and in reducing our spending levels," said Howard C. Birndorf, chairman of the board and chief executive officer. "The keystone accomplishments for the year were the collaborations and acquisitions that we initiated to help pave the way for Nanogen to enter new, synergistic markets in 2004. Our identification of promising technologies to accelerate our entry into the infectious disease and point-of-care markets illustrates our strategy to grow the business by increasing the number of products we offer for gene-based testing, as well as commercializing advanced diagnostics for both physicians and labs," Birndorf added.
2004 Outlook
In 2004, Nanogen plans to launch several important new products into fast growing in vitro diagnostic markets. Through its collaboration with Prodesse, Inc., Nanogen expects to begin offering highly sensitive microarray-based reagents for detection of a number of infectious disease agents. These reagents would be used by CLIA-certified laboratories to develop and validate assays on the automated NanoChip® platform.
Contingent upon closing the acquisition of SYN X Pharma, announced February 10, 2004, Nanogen plans to obtain European and United States regulatory approval for a point-of-care diagnostic product for congestive heart failure (CHF), also targeting a large, growing market. Priorities will be established for developing SYN X`s pipeline of diagnostics that address unmet needs. Nanogen expects the SYN X business unit will require investment during 2004 but should be cash flow positive by the end of 2005.
Last month, Nanogen established a distribution agreement with Transgenomic, Inc. to help penetrate new market opportunities. Nanogen expects to continue signing alliances with distributors in Europe, the United States, and other geographies in order to build its installed base of instruments and consumable product revenues.
Nanogen will commit additional resources to expanding the company`s nanotechnology intellectual property. The company anticipates utilizing the growing government interest in the area as a source of funding for its research and development efforts.
Nanogen will also continue to identify other business expansion opportunities, potentially including acquisitions or development collaborations.
Financial Guidance
For 2004, excluding the impact of the acquisition of SYN X, Nanogen anticipates a growth rate in total revenue of approximately 50% as compared to 2003. Total operating expenses, excluding cost of products sold, should run approximately 20% less than the 2003 total year spending. An end of the year cash balance of greater than $15 million is expected. Nanogen expects to invest approximately $6 - 8 million in SYN X, which includes costs to launch the CHF product. Additional financial guidance incorporating the impact of SYN X will be provided after the closing of the acquisition.
Webcast of the Conference Call
Nanogen management will host a conference call today to discuss the fourth quarter and year-end financial results at 4:30 p.m. Eastern Time. Audio of the presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived for 90 days. A telephone replay of the call will also be available two hours after the completion of the conference call on February 18 until midnight on February 20, which may be accessed via telephone at (800) 642-1687 for US/Canada participants, and (706) 645-9291 for international participants. The conference ID, 5360247, will be required to listen to the playback.
Note Regarding Use of Non-GAAP Financial Information
To supplement consolidated financial statements presented in accordance with GAAP, Nanogen used a non-GAAP adjustment to exclude $10.8 million in license revenue recognized as part of a settlement agreement with CombiMatrix in the fourth quarter of 2002. Non-GAAP adjustments are provided to enhance the users` overall understanding of current financial performance and prospects for the future. Specifically, Nanogen believes that the non-GAAP adjustment provides useful information to both management and investors by excluding certain settlement proceeds that the company believes are not indicative of its operating results, thereby permitting a more meaningful comparison between the loss information for the fourth quarters and years ending December 31, 2002 and 2003. Additionally, Nanogen used a non-GAAP adjustment to exclude cost of sales from operating expenses for the fourth quarters and years ending December 31, 2002 and 2003. Nanogen believes that this non-GAAP adjustment is useful to management and investors because it enhances Nanogen`s comparability to other companies, many of which do not include cost of sales in their presentation of operating expenses. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.
About Nanogen
Nanogen develops and commercializes molecular diagnostic products for the gene-based testing market. The company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements regarding future product revenues, contract and sponsored research revenues, estimates of operating expenses and estimates of future cash balances. These forward-looking statements are based upon current expectations and speak only as of the date hereof. Nanogen`s actual results and cash balances may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether the acquisition of SYN X Pharma will be approved by holders of SYN X common shares and debentures, close as anticipated and achieve the synergies and other benefits anticipated, whether the SYN X business unit will become cash flow positive as expected, whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip® System can be successfully further commercialized, whether other products under development and point-of-care products can be successfully developed and commercialized, whether results reported by Nanogen`s customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip® System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s reports on Form 10-Q and Form 10-K filed with the Securities and Exchange Commission. Nanogen disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except par value and share data)
December 31 December 31,
2003 2002
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $8,550 $9,353
Short-term investments 20,564 43,376
Receivables, net 1,415 1,754
Inventories, net 4,774 4,717
Other current assets 1,590 1,781
Total current assets 36,893 60,981
Property and equipment, net 4,277 4,982
Acquired technology rights, net 2,508 4,544
Other assets, net 171 853
$43,849 $71,360
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $290 $753
Accrued liabilities 4,519 5,901
Deferred revenue 469 472
Current portion of capital lease obligations 743 805
Total current liabilities 6,021 7,931
Capital lease obligations, less current portion 586 1,134
Other long-term liabilities 4,419 3,085
Total long-term liabilities 5,005 4,219
Minority interest in consolidated subsidiary -- 1,817
Stockholders` equity:
Convertible preferred stock, $0.001 par value,
5,000,000 shares authorized; no shares issued
and outstanding at December 31, 2003
(unaudited) and December 31, 2002 -- --
Common stock, $0.001 par value, 50,000,000 shares
authorized; 24,867,325 and 21,981,115 shares
issued and outstanding at December 31, 2003
(unaudited) and December 31, 2002,
respectively 25 22
Additional paid-in capital 209,017 199,483
Accumulated other comprehensive income 1,132 4,926
Deferred compensation (175) (156)
Notes receivable from officers -- (513)
Accumulated deficit (176,254) (145,659)
Treasury stock, at cost, 500,189 and
366,857 shares at December 31, 2003
(unaudited) and December 31, 2002,
respectively (922) (710)
Total stockholders` equity 32,823 57,393
$43,849 $71,360
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Twelve months ended
December 31, December 31,
2003 2002 2003 2002
Revenues:
Product sales $1,090 $511 $2,732 $3,384
License fees 38 10,844 84 10,844
Sponsored research 375 375 1,500 1,355
Contracts and grant 575 414 2,397 1,596
Total revenues 2,078 12,144 6,713 17,179
Operating expenses:
Cost of product sales 1,008 386 3,176 2,466
Research and development 4,542 5,348 18,015 21,020
Selling, general and
administrative 3,582 5,194 15,114 20,540
Impairment of acquired
technology rights -- -- 1,024 --
Litigation and settlement
of patent matter 56 -- 205 (165)
Total operating expenses 9,188 10,928 37,534 43,861
Income (loss) from
operations (7,110) 1,216 (30,821) (26,682)
Interest income, net 85 285 490 2,119
Other income/(expense) (4) 8 (154) 161
Gain/(loss) on sale of
investments 865 -- (1,925) --
Minority interest in
loss of consolidated
subsidiary 221 522 1,815 2,156
Net income (loss) $(5,943) $2,031 $(30,595) $(22,246)
Net loss per share -
basic and diluted
$(0.25) $0.09 $(1.38) $(1.02)
Number of shares used in
computing net loss
per share - basic and
diluted 23,959 21,697 22,244 21,722
Reuters
UPDATE - Nanogen posts loss as revenue declines
Wednesday February 18, 5:24 pm ET
CHICAGO, Feb 18 (Reuters) - Molecular testing company Nanogen Inc. (NasdaqNM:NGEN - News) on Wednesday posted a quarterly net loss as revenue declined from a year earlier, when it benefited from a hefty licensing settlement.
The San Diego-based company posted a fourth-quarter net loss of $5.9 million, or 25 cents per share, compared with profit of $2 million, or 9 cents per share, for the fourth quarter of 2002.
The company, which is working to create a chip to detect gene mutations, said it sees 50 percent growth in 2004 revenue, excluding its pending acquisition of SYN X Pharma. The company predicts a year-end cash balance of more than $15 million.
Revenue in the fourth quarter fell to $2.1 million, from $12.1 million a year earlier.
But both the fourth quarter and yearly revenue for 2002 include about $10.8 million in licensing revenue recognized as a result of the settlement agreement with CombiMatrix.
Excluding that deal`s cash gain, revenue in the fourth quarter of 2002 was $1.3 million.
UPDATE - Nanogen posts loss as revenue declines
Wednesday February 18, 5:24 pm ET
CHICAGO, Feb 18 (Reuters) - Molecular testing company Nanogen Inc. (NasdaqNM:NGEN - News) on Wednesday posted a quarterly net loss as revenue declined from a year earlier, when it benefited from a hefty licensing settlement.
The San Diego-based company posted a fourth-quarter net loss of $5.9 million, or 25 cents per share, compared with profit of $2 million, or 9 cents per share, for the fourth quarter of 2002.
The company, which is working to create a chip to detect gene mutations, said it sees 50 percent growth in 2004 revenue, excluding its pending acquisition of SYN X Pharma. The company predicts a year-end cash balance of more than $15 million.
Revenue in the fourth quarter fell to $2.1 million, from $12.1 million a year earlier.
But both the fourth quarter and yearly revenue for 2002 include about $10.8 million in licensing revenue recognized as a result of the settlement agreement with CombiMatrix.
Excluding that deal`s cash gain, revenue in the fourth quarter of 2002 was $1.3 million.
UPDATE - Nanogen gibt Verlust bekannt, während Einkommen Mittwoch Februar 18, 5:24 P.M. sinkt UND CHICAGO, Feb 18 (Reuters) - molekulare prüfenfirma Nanogen Inc. (NasdaqNM:NGEN - Nachrichten) am Mittwoch gab einen vierteljährlichen Reinverlust bekannt, während Einkommen von ein Jahr früher sank, als es von einer hefty genehmigenden Regelung profitierte. Die San Diego-gegründete Firma gab einen Reinverlust des vierten Viertels von $5.9 Million oder 25 Cents pro den Anteil bekannt, verglichen mit Profit von $2 Million oder 9 Cents pro Anteil, für das vierte Viertel von 2002. Die Firma, die arbeitet, um einen Span herzustellen, um Genveränderungen zu ermitteln, sagte, daß sie 50 Prozent Wachstum Einkommen 2004, ausschließlich seines schwebenden Erwerbs von SYN X Pharma sieht. Die Firma sagt ein year-end Barguthaben von mehr als $15 Million voraus. Einkommen im vierten Viertel fiel bis $2.1 Million, von $12.1 Million ein das Jahr früher. Aber beide das vierte Viertel und das jährliche Einkommen für 2002 schließen ungefähr $10.8 Million im genehmigenden Einkommen mit ein, das resultierend aus dem Abfindungsvertrag mit CombiMatrix erkannt wird. Ausschließlich dessen war deal`s Bargeldgewinn, Einkommen im vierten Viertel von 2002 $1.3 Million.
wie gehts weiter nach diesen zahlen.
hat jemand einschätzungen?
bei schlechten nachrichten soll man kaufen !!
alte matrosen regel ??
akat
alte matrosen regel ??
akat
Nach den News haben sich viele Leute andere Zahlen
ausgemahlt, doch bis sich die Patente und die restlichen Errungenschaften bemerkbar machen vergeht ein wenig Zeit.
Deswegen bleibe ich ganz ruhig und bleibe looooong.
Wir werden die Früchte ernten
ausgemahlt, doch bis sich die Patente und die restlichen Errungenschaften bemerkbar machen vergeht ein wenig Zeit.
Deswegen bleibe ich ganz ruhig und bleibe looooong.
Wir werden die Früchte ernten
Ich glaube die Nano-Gemeinde hat etwas wichtiges aus den Augen verloren. NANOGEN ist eines der besten Werte überhaupt...
folgende AdHoc auch nicht vergessen:
Tuesday, 3. February 2004 | 14:16 Uhr
Nanogen-Patent Grundlage für Nanoroboter?
Zweites wichtiges US-Patent innerhalb weniger Wochen
Erst vor wenigen Wochen hatte Nanogen, Inc. (Nasdaq: NGEN) die Ausgabe eines wichtigen US-Patentes, das eine ganz neue Technologie zur Herstellung von Nanobauteilen unter Schutz stellt, bekannt gegeben und war daraufhin um 50 Prozent geklettert. Und erst vor wenigen Tagen konnte Nanogen erneut einen Erfolg bei der U.S. Patent and Trademark Office bekannt geben. Das neue Patent mit der Nummer 6,682,936 trägt den Titel “Addressable Biologic Electrode Array” und stellt Elektrodenbasierte Arrays sowie Methoden, die ein selektives Ansprechen von Elektroden auf dem Chip ermöglichen, unter Schutz.
Wie bereits das erste Patent, so lässt sich auch das neue Patent zur Produktion von Arrays mit einer hohen Dichte an Elektroden nutzen. Unter Anwendung der patentierten Technologie lassen sich diese Arrays dann durch das gezielte Ansprechen der verschiedenen Elektroden zu elektrochemischen Veränderungen bestimmter Moleküle wie beispielsweise Erbgutsequenzen nutzen. Damit ließen sich nicht nur ganz gezielt Wirkstoffe aus verschiedenen chemischen Verbindungen sehr viel einfacher als bisher synthetisieren, sondern die Technik dürfte sich auch zum selbständigen Zusammenbau verschiedener biologischer Moleküle zu ersten Nanomaschinen eignen.
Die patentierte Technologie eignet sich aber auch zur Produktion wesentlich kompakterer Chips, die trotz ihrer geringeren Abmessungen eine deutlich größere Menge an Daten verarbeiten und speichern könnten als alle bisher bekannten Chips und Datenspeicher. Damit dürfte die patentierte Nanogen Technologie auch für Hersteller von Computern und Datenspeichern von Interesse sein. Nanogen spricht mit seiner nun unter Patentschutz stehenden Technologie also nicht nur potenzielle Lizenznehmer in der Biotechindustrie, sondern auch Interessenten in der Computerindustrie an.
Erst im Dezember hat Präsident Bush mit der Unterzeichnung des „21st Century Nanotechnology Research and Development Act“, der den im Bereich der Nanotechnologie forschenden Unternehmen in den nächsten vier Jahren Finanzhilfen in Höhe von $3,7 Milliarden zusichert, eine kleine Rallye unter den Nanotech-Unternehmen ausgelöst. Nun scheinen also auch die ersten Großinvestoren auf die „winzige“ Technologie aufmerksam geworden zu sein. Von diesem Aufwärtstrend konnte auch Nanogen profitieren und die jüngsten Patente lassen darauf schließen, dass Nanogen beabsichtigt auch in Zukunft ein Wörtchen mitzureden, wenn es darum geht, die Grundlage für die ersten Nanoroboter zu legen.
Wie bereits das erst kürzlich erhaltene Patent mit der Nummer 6,652,808 will Nanogen auch das jüngste Patent sowohl zum eigenen Nutzen einsetzen, als auch in Form von nicht-exklusiven Lizenzvergaben daraus Kapital schlagen. Mit dem letzten Patent besitzt Nanogen nun ein wirklich beachtliches US-Patentportfolio von 57 Patenten und damit die Voraussetzung in Zukunft in der Nanotechnologie ein wichtiges Wörtchen mitzureden.
Von der Ausgabe des neuen Patentes konnte Nanogen immerhin zweistellig profitieren, doch der Rückschlag des Gesamtmarktes, ausgelöst durch die Rede von Notenbankchef Alan Greenspan am Tag der Patentausgabe, ließ auch den stattlichen Gewinn bei Nanogen bis zum Handelsschluss dahin schmelzen. Im nachbörslichen Handel konnte die Aktie von Nanogen aber erneut ein Plus von 5,9% verzeichnen.
folgende AdHoc auch nicht vergessen:
Tuesday, 3. February 2004 | 14:16 Uhr
Nanogen-Patent Grundlage für Nanoroboter?
Zweites wichtiges US-Patent innerhalb weniger Wochen
Erst vor wenigen Wochen hatte Nanogen, Inc. (Nasdaq: NGEN) die Ausgabe eines wichtigen US-Patentes, das eine ganz neue Technologie zur Herstellung von Nanobauteilen unter Schutz stellt, bekannt gegeben und war daraufhin um 50 Prozent geklettert. Und erst vor wenigen Tagen konnte Nanogen erneut einen Erfolg bei der U.S. Patent and Trademark Office bekannt geben. Das neue Patent mit der Nummer 6,682,936 trägt den Titel “Addressable Biologic Electrode Array” und stellt Elektrodenbasierte Arrays sowie Methoden, die ein selektives Ansprechen von Elektroden auf dem Chip ermöglichen, unter Schutz.
Wie bereits das erste Patent, so lässt sich auch das neue Patent zur Produktion von Arrays mit einer hohen Dichte an Elektroden nutzen. Unter Anwendung der patentierten Technologie lassen sich diese Arrays dann durch das gezielte Ansprechen der verschiedenen Elektroden zu elektrochemischen Veränderungen bestimmter Moleküle wie beispielsweise Erbgutsequenzen nutzen. Damit ließen sich nicht nur ganz gezielt Wirkstoffe aus verschiedenen chemischen Verbindungen sehr viel einfacher als bisher synthetisieren, sondern die Technik dürfte sich auch zum selbständigen Zusammenbau verschiedener biologischer Moleküle zu ersten Nanomaschinen eignen.
Die patentierte Technologie eignet sich aber auch zur Produktion wesentlich kompakterer Chips, die trotz ihrer geringeren Abmessungen eine deutlich größere Menge an Daten verarbeiten und speichern könnten als alle bisher bekannten Chips und Datenspeicher. Damit dürfte die patentierte Nanogen Technologie auch für Hersteller von Computern und Datenspeichern von Interesse sein. Nanogen spricht mit seiner nun unter Patentschutz stehenden Technologie also nicht nur potenzielle Lizenznehmer in der Biotechindustrie, sondern auch Interessenten in der Computerindustrie an.
Erst im Dezember hat Präsident Bush mit der Unterzeichnung des „21st Century Nanotechnology Research and Development Act“, der den im Bereich der Nanotechnologie forschenden Unternehmen in den nächsten vier Jahren Finanzhilfen in Höhe von $3,7 Milliarden zusichert, eine kleine Rallye unter den Nanotech-Unternehmen ausgelöst. Nun scheinen also auch die ersten Großinvestoren auf die „winzige“ Technologie aufmerksam geworden zu sein. Von diesem Aufwärtstrend konnte auch Nanogen profitieren und die jüngsten Patente lassen darauf schließen, dass Nanogen beabsichtigt auch in Zukunft ein Wörtchen mitzureden, wenn es darum geht, die Grundlage für die ersten Nanoroboter zu legen.
Wie bereits das erst kürzlich erhaltene Patent mit der Nummer 6,652,808 will Nanogen auch das jüngste Patent sowohl zum eigenen Nutzen einsetzen, als auch in Form von nicht-exklusiven Lizenzvergaben daraus Kapital schlagen. Mit dem letzten Patent besitzt Nanogen nun ein wirklich beachtliches US-Patentportfolio von 57 Patenten und damit die Voraussetzung in Zukunft in der Nanotechnologie ein wichtiges Wörtchen mitzureden.
Von der Ausgabe des neuen Patentes konnte Nanogen immerhin zweistellig profitieren, doch der Rückschlag des Gesamtmarktes, ausgelöst durch die Rede von Notenbankchef Alan Greenspan am Tag der Patentausgabe, ließ auch den stattlichen Gewinn bei Nanogen bis zum Handelsschluss dahin schmelzen. Im nachbörslichen Handel konnte die Aktie von Nanogen aber erneut ein Plus von 5,9% verzeichnen.
Nanogen scheint sich um ein neues Patent zu bemühen:
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=…
http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=…
Wie tief noch ?
Press Release Source: Nanogen, Inc.
Nanogen Announces $34 Million Common Stock Sale
Friday March 5, 11:10 am ET
SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) announced today that it has sold 4.25 million shares of its common stock to institutional investors at a price of $7.94 per share, for gross proceeds of approximately $33.7 million. After deducting fees and expenses, Nanogen will receive approximately $31.5 million from the sale, which is being conducted pursuant to Nanogen`s shelf registration statement filed in January 2004. The sale is expected to close on or about Friday, March 5, 2004. Nanogen plans to use the net proceeds for working capital, including the pending SYN X Pharma acquisition, and other general corporate purposes. Seven Hills Partners LLC acted as exclusive placement agent to Nanogen for this financing.
ADVERTISEMENT
"This financing further strengthens our balance sheet and provides additional capital to accelerate our entry into the point-of-care diagnostics market, which began with our recent agreement to acquire SYN X Pharma," said Howard C. Birndorf, chairman and CEO of Nanogen. "The financing will also support our long-term strategy to commercialize advanced medical diagnostics and help pave the way for Nanogen to enter new, synergistic markets."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Nanogen Inc.
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of various diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Nanogen Announces $34 Million Common Stock Sale
Friday March 5, 11:10 am ET
SAN DIEGO, March 5 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) announced today that it has sold 4.25 million shares of its common stock to institutional investors at a price of $7.94 per share, for gross proceeds of approximately $33.7 million. After deducting fees and expenses, Nanogen will receive approximately $31.5 million from the sale, which is being conducted pursuant to Nanogen`s shelf registration statement filed in January 2004. The sale is expected to close on or about Friday, March 5, 2004. Nanogen plans to use the net proceeds for working capital, including the pending SYN X Pharma acquisition, and other general corporate purposes. Seven Hills Partners LLC acted as exclusive placement agent to Nanogen for this financing.
ADVERTISEMENT
"This financing further strengthens our balance sheet and provides additional capital to accelerate our entry into the point-of-care diagnostics market, which began with our recent agreement to acquire SYN X Pharma," said Howard C. Birndorf, chairman and CEO of Nanogen. "The financing will also support our long-term strategy to commercialize advanced medical diagnostics and help pave the way for Nanogen to enter new, synergistic markets."
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Nanogen Inc.
Nanogen, Inc. develops and commercializes molecular diagnostic products for the gene-based testing market. The Company seeks to establish the NanoChip® Molecular Biology Workstation and NanoChip® Cartridge as the standard platform for the detection of genetic mutations and is also developing its technology for forensic and biowarfare applications. Nanogen offers Analyte Specific Reagents and related products to research laboratories and clinical reference labs for the detection of genetic mutations associated with a variety of diseases, including cystic fibrosis, Alzheimer`s disease, hereditary hemochromatosis, cardiovascular disease, beta thalassemia and Canavan disease. The unique, open-architecture design of its NanoChip® System provides laboratories with a flexible platform to develop and validate tests to quickly, accurately, and cost effectively detect mutations associated with the diagnoses, prediction, screening, treatment and monitoring of various diseases. The NanoChip® System is intended for laboratory use only. For additional information please visit Nanogen`s website at www.nanogen.com .
Reuters
Nanogen sells $34 mln of shares at $7.94 a share
Friday March 5, 11:22 am ET
NEW YORK, March 5 (Reuters) - Nanogen Inc. (NasdaqNM:NGEN - News), which makes molecular diagnostic products, on Friday said it had sold 4.25 million shares of stock for nearly $34 million.
Nanogen sold the shares to institutional investors for $7.94 a share. The company said it expects the sale to close around March 5. It plans to use the funds for working capital and for an acquisition.
The San Diego, California-based company`s products aim to detect genetic mutations.
Nanogen sells $34 mln of shares at $7.94 a share
Friday March 5, 11:22 am ET
NEW YORK, March 5 (Reuters) - Nanogen Inc. (NasdaqNM:NGEN - News), which makes molecular diagnostic products, on Friday said it had sold 4.25 million shares of stock for nearly $34 million.
Nanogen sold the shares to institutional investors for $7.94 a share. The company said it expects the sale to close around March 5. It plans to use the funds for working capital and for an acquisition.
The San Diego, California-based company`s products aim to detect genetic mutations.
Nanogen Issued Nanotechnology Patent for Photonic Driven Assembly and Hybridization
SAN DIEGO, March 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that it was issued U.S. Patent No. 6,706,473, "Systems and Devices for Photoelectrophoretic Transport and Hybridization of Oligonucleotides," by the U.S. Patent and Trademark Office. The `473 patent relates to new devices for nanofabrication that enable the photoelectric transport and positioning of self-assembling DNA nanostructures (and microstructures) on a semiconductor substrate material. These devices use directed light beams to create precise electric fields on the substrate material. Charged nanostructures (such as DNA derivatized nanoparticles) are transported to the electric field site where they become attached and can then lead to the further self-organization of higher-order nanoscale or microscale structures and devices. With the addition of the `473 patent, Nanogen now has 58 issued patents in the United States.
"The `473 patent builds upon our previous nanotechnology patents by describing nanofabrication and assembly approaches using photonics to create guiding electronic fields," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "This technology would allow us or others to create very small scale electronic arrays where the addressable fields are independent of preset platform designs and could greatly increase the flexibility of manufacturing and use of electronic arrays."
"More broadly, the `473 patent represents a potential manufacturing technology that combines the best aspects of self-assembly and microfabrication processes for the nanofabrication of 2D and 3D structures and devices. This highly parallel process has the inherent hierarchical logic to control the organization, assembly and communication of structures and components ranging in size from the molecular scale through macroscale systems," said Dr. Michael J. Heller, co-founder of Nanogen, and currently a professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
In addition to the creation of selectively addressable DNA electronic array substrates and materials, the technology described in the `473 patent could have numerous applications including:
(1) Creation of molecular-based electronic and photonic mechanisms,
materials and devices;
(2) Organization, assembly and interconnection of multiple scale
components (from nanostructures to microcomponents) onto silicon
materials and also, potentially, within the perimeters of
microelectronic and optoelectronic structures on the silicon
substrate;
(3) Production of multiple layer nanocomposite materials;
(4) Creation and manufacturing of novel photonic and electronic devices
such as high-density 2D and 3D data storage materials and devices or
photonic crystal structures;
(5) Development of low density optical memory for applications in
authentication, anti-counterfeiting, and encryption of information
in document or goods; and
(6) Heterogeneous integration of hybrid devices such as large area light
emitting flat panel arrays, displays and medical diagnostic devices
with the fabrication platform itself becoming the final product
(such as a flat panel array or display screen).
About Nanogen
Nanogen, Inc. develops and commercializes products for the in vitro diagnostics market. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen also offers Analyte Specific Reagents and related products to research and clinical reference labs for the detection of a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company is advancing its nanotechnology research to further its mission of delivering advanced diagnostic products to physicians and patients. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
-0- 03/18/2004
/CONTACT: David Ludvigson, Executive Vice President & Chief Financial
Officer of Nanogen, Inc., +1-858-410-4600, dludvigson@nanogen.com; or Pam Lord
of Atkins + Associates, +1-858-527-3494, plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
CO: Nanogen, Inc.
ST: California
IN: HEA MTC BIO
SU:
BM-CM
-- LATH012 --
2357 03/18/2004 08:00 EST http://www.prnewswire.com
SAN DIEGO, March 18 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that it was issued U.S. Patent No. 6,706,473, "Systems and Devices for Photoelectrophoretic Transport and Hybridization of Oligonucleotides," by the U.S. Patent and Trademark Office. The `473 patent relates to new devices for nanofabrication that enable the photoelectric transport and positioning of self-assembling DNA nanostructures (and microstructures) on a semiconductor substrate material. These devices use directed light beams to create precise electric fields on the substrate material. Charged nanostructures (such as DNA derivatized nanoparticles) are transported to the electric field site where they become attached and can then lead to the further self-organization of higher-order nanoscale or microscale structures and devices. With the addition of the `473 patent, Nanogen now has 58 issued patents in the United States.
"The `473 patent builds upon our previous nanotechnology patents by describing nanofabrication and assembly approaches using photonics to create guiding electronic fields," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "This technology would allow us or others to create very small scale electronic arrays where the addressable fields are independent of preset platform designs and could greatly increase the flexibility of manufacturing and use of electronic arrays."
"More broadly, the `473 patent represents a potential manufacturing technology that combines the best aspects of self-assembly and microfabrication processes for the nanofabrication of 2D and 3D structures and devices. This highly parallel process has the inherent hierarchical logic to control the organization, assembly and communication of structures and components ranging in size from the molecular scale through macroscale systems," said Dr. Michael J. Heller, co-founder of Nanogen, and currently a professor in the Departments of Bioengineering and Electrical and Computer Engineering at the University of California, San Diego.
In addition to the creation of selectively addressable DNA electronic array substrates and materials, the technology described in the `473 patent could have numerous applications including:
(1) Creation of molecular-based electronic and photonic mechanisms,
materials and devices;
(2) Organization, assembly and interconnection of multiple scale
components (from nanostructures to microcomponents) onto silicon
materials and also, potentially, within the perimeters of
microelectronic and optoelectronic structures on the silicon
substrate;
(3) Production of multiple layer nanocomposite materials;
(4) Creation and manufacturing of novel photonic and electronic devices
such as high-density 2D and 3D data storage materials and devices or
photonic crystal structures;
(5) Development of low density optical memory for applications in
authentication, anti-counterfeiting, and encryption of information
in document or goods; and
(6) Heterogeneous integration of hybrid devices such as large area light
emitting flat panel arrays, displays and medical diagnostic devices
with the fabrication platform itself becoming the final product
(such as a flat panel array or display screen).
About Nanogen
Nanogen, Inc. develops and commercializes products for the in vitro diagnostics market. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen also offers Analyte Specific Reagents and related products to research and clinical reference labs for the detection of a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company is advancing its nanotechnology research to further its mission of delivering advanced diagnostic products to physicians and patients. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2002 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
-0- 03/18/2004
/CONTACT: David Ludvigson, Executive Vice President & Chief Financial
Officer of Nanogen, Inc., +1-858-410-4600, dludvigson@nanogen.com; or Pam Lord
of Atkins + Associates, +1-858-527-3494, plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
CO: Nanogen, Inc.
ST: California
IN: HEA MTC BIO
SU:
BM-CM
-- LATH012 --
2357 03/18/2004 08:00 EST http://www.prnewswire.com
Hallo!
was meint ihr denn wann nanogen den nächsten kursausbruch von über 50-70% haben wird??? laut chart is es ja schon wiedemal soweit würd ich sagen. bei den nächsten guten konjukturdaten könnte der kurs wieder explodieren.
was meint ihr???
gruß
balboa
was meint ihr denn wann nanogen den nächsten kursausbruch von über 50-70% haben wird??? laut chart is es ja schon wiedemal soweit würd ich sagen. bei den nächsten guten konjukturdaten könnte der kurs wieder explodieren.
was meint ihr???
gruß
balboa
Kann jemand kurz zusammenfassen und sagen ob die Zahlen gut oder schlecht sind und wie ist der Ausblick. Danke und hoffentlich bessere Kurse
an #278 Strait1
Was soll der Schwachsinn "3.Quartal vom 30 März 2004" ?????
UUUUUralt
Was soll der Schwachsinn "3.Quartal vom 30 März 2004" ?????
UUUUUralt
Der Kurs im Amiland z.Zt. auf 8,70 $ !!
Kann keine Meldung finden für den Anstieg. Weiß jemand was ??
Kann keine Meldung finden für den Anstieg. Weiß jemand was ??
Könnte vielleicht mit der Auflage eines neuen Nanotechfonds von Merrill Lynch von zusammenhängen
http://www.cwes01.com/9093/24013/ds/4351_747.pdf
http://www.cwes01.com/9093/24013/ds/4351_747.pdf
Könnte sein. Aber dann wäre doch der Anstieg nicht so plötzlich ! Sieht eher nach ner guten News aus, die hier noch nicht bekannt ist. Egal, Nanogen und wir könnens gebrauchen.
Tachchen zusammen,
scheint heute eine Tag der Nano-Technologie zu werden.
Man beachte auch Arquel 903396 + 17%.
Ich weiss gehört eigentlich nicht hierher, aber ich konnte nicht wiederstehen.
Gruß
lova
scheint heute eine Tag der Nano-Technologie zu werden.
Man beachte auch Arquel 903396 + 17%.
Ich weiss gehört eigentlich nicht hierher, aber ich konnte nicht wiederstehen.
Gruß
lova
#280
Sorry, aber ich bekam halt diese Mail von Nanogen:
Event: 3rd Quarter Earnings Release for 2003
Date(s): 3/30/2004 12:00:00 PM
und heute :
Nanogen, Inc. has posted a new financial report to its Investor Relations website.
Event: Form 10-K 2003
Date(s): 4/1/2004
Sorry, aber ich bekam halt diese Mail von Nanogen:
Event: 3rd Quarter Earnings Release for 2003
Date(s): 3/30/2004 12:00:00 PM
und heute :
Nanogen, Inc. has posted a new financial report to its Investor Relations website.
Event: Form 10-K 2003
Date(s): 4/1/2004
Nanogen Receives Court Approval to Acquire SynX Pharma
SAN DIEGO and TORONTO, Apr 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) and SynX Pharma Inc. (TSX: SYY) announced today that the Ontario Superior Court of Justice has approved the plan of arrangement for Nanogen to acquire SynX in an all-stock transaction.
SynX shareholders and debentureholders met in Toronto on April 15, where they overwhelmingly approved the transaction by 99.8% and 100% of the votes respectively.
The total consideration for the SynX common shares is fixed at approximately CDN$16.3 million. With approximately 11.4 million SynX shares and share equivalents outstanding, it is expected that each SynX common shareholder will be entitled to receive approximately CDN$1.426 per SynX share in Nanogen common stock. The exchange ratio will be determined on the closing date. At closing, Nanogen will acquire the existing CDN$3.5 million principal amount of subordinated secured debentures of SynX in exchange for shares of Nanogen common stock.
The closing of the transaction, which is currently scheduled for April 21, 2004, is subject to other regulatory approvals and other customary closing conditions.
About Nanogen
Nanogen, Inc. develops and commercializes products for the in vitro diagnostics market. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip System can be successfully further commercialized, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip System, whether patents owned or licensed by Nanogen will be developed into products and other risks and uncertainties discussed under the caption, "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.; SynX Pharma Inc.
David Ludvigson, Executive Vice President & Chief Financial
Officer of Nanogen, Inc., +1-858-410-4608, dludvigson@nanogen.com; or Michael
Moore of Atkins + Associates, +1-858-860-0266, mmoore@irpr.com, for Nanogen,
Inc.
http://www.nanogen.com
SAN DIEGO and TORONTO, Apr 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN) and SynX Pharma Inc. (TSX: SYY) announced today that the Ontario Superior Court of Justice has approved the plan of arrangement for Nanogen to acquire SynX in an all-stock transaction.
SynX shareholders and debentureholders met in Toronto on April 15, where they overwhelmingly approved the transaction by 99.8% and 100% of the votes respectively.
The total consideration for the SynX common shares is fixed at approximately CDN$16.3 million. With approximately 11.4 million SynX shares and share equivalents outstanding, it is expected that each SynX common shareholder will be entitled to receive approximately CDN$1.426 per SynX share in Nanogen common stock. The exchange ratio will be determined on the closing date. At closing, Nanogen will acquire the existing CDN$3.5 million principal amount of subordinated secured debentures of SynX in exchange for shares of Nanogen common stock.
The closing of the transaction, which is currently scheduled for April 21, 2004, is subject to other regulatory approvals and other customary closing conditions.
About Nanogen
Nanogen, Inc. develops and commercializes products for the in vitro diagnostics market. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip System can be successfully further commercialized, whether ASRs currently sold by the Company will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip System, whether patents owned or licensed by Nanogen will be developed into products and other risks and uncertainties discussed under the caption, "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.; SynX Pharma Inc.
David Ludvigson, Executive Vice President & Chief Financial
Officer of Nanogen, Inc., +1-858-410-4608, dludvigson@nanogen.com; or Michael
Moore of Atkins + Associates, +1-858-860-0266, mmoore@irpr.com, for Nanogen,
Inc.
http://www.nanogen.com
Nanogen Completes Acquisition of SynX Pharma Inc.
SAN DIEGO and TORONTO, April 21 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) and SynX Pharma Inc. (TSX: SYY) announced today that Nanogen completed its acquisition of all of the common shares and debentures of SynX, pursuant to a plan of arrangement, in exchange for shares of Nanogen common stock. SynX is now a wholly-owned subsidiary of Nanogen.
Pursuant to the plan of arrangement, each SynX shareholder is entitled to receive 0.123 shares (the "Exchange Ratio") of Nanogen common stock per SynX common share. Accordingly, approximately 1.6 million shares of Nanogen common stock are issuable to former SynX shareholders and to holders of replacement warrants and options. In addition, the CDN$3.5 million principal amount of subordinated secured debentures of SynX (together with unpaid interest) were acquired in exchange for approximately 300,000 shares of Nanogen common stock.
The acquisition will provide Nanogen with a pipeline of complementary products in order to expand its market share in the in vitro diagnostics market and augments its technology platform for developing advanced diagnostic products. As announced in July 2003, SynX obtained a worldwide license to the Congestive Heart Failure (CHF) marker NT-proBNP (N-terminal pro-hormone brain natriuretic peptide) from Roche Diagnostics to develop a test for the point-of-care market. Nanogen plans to seek European regulatory clearance for its CHF product in mid-2004 and U.S. Food and Drug Administration 510(k) clearance in the second half of 2004. Analysts predict the BNP market will have above-average growth and will reach approximately US $300 million by 2005 as use increases internationally.
As a Nanogen subsidiary, SynX will continue to market point-of-care diagnostic tests for myocardial infarction in Europe and Canada, and for infectious diseases and drugs of abuse in Canada. In addition to the CHF product, SynX has been developing a pipeline of tests to be marketed under the brand name Nexus Dx(TM) for insulin resistance, traumatic brain injury and Alzheimer`s disease. SynX has also developed diagnostic tests for stroke, which as previously announced, have been licensed to Genzyme Corporation.
"The acquisition of SynX furthers our strategy to commercialize advanced diagnostics that enhance the level of medical care for the detection, diagnosis, monitoring and treatment of disease," said Howard Birndorf, Nanogen chairman and chief executive officer. "We welcome the SynX team and look forward to joining efforts to commercialize our combined pipeline of genetic, infectious disease and point-of-care products," added Birndorf.
Seven Hills Partners, LLC acted as the financial advisor to Nanogen in this transaction. The Seidler Companies, Orenda Corporate Finance Ltd. and First Associates Investments Inc. acted as financial advisors to SynX on this transaction.
About Nanogen
Nanogen, Inc. develops and commercializes products for the in vitro diagnostics market. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen`s website at www.nanogen.com.
SAN DIEGO and TORONTO, April 21 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) and SynX Pharma Inc. (TSX: SYY) announced today that Nanogen completed its acquisition of all of the common shares and debentures of SynX, pursuant to a plan of arrangement, in exchange for shares of Nanogen common stock. SynX is now a wholly-owned subsidiary of Nanogen.
Pursuant to the plan of arrangement, each SynX shareholder is entitled to receive 0.123 shares (the "Exchange Ratio") of Nanogen common stock per SynX common share. Accordingly, approximately 1.6 million shares of Nanogen common stock are issuable to former SynX shareholders and to holders of replacement warrants and options. In addition, the CDN$3.5 million principal amount of subordinated secured debentures of SynX (together with unpaid interest) were acquired in exchange for approximately 300,000 shares of Nanogen common stock.
The acquisition will provide Nanogen with a pipeline of complementary products in order to expand its market share in the in vitro diagnostics market and augments its technology platform for developing advanced diagnostic products. As announced in July 2003, SynX obtained a worldwide license to the Congestive Heart Failure (CHF) marker NT-proBNP (N-terminal pro-hormone brain natriuretic peptide) from Roche Diagnostics to develop a test for the point-of-care market. Nanogen plans to seek European regulatory clearance for its CHF product in mid-2004 and U.S. Food and Drug Administration 510(k) clearance in the second half of 2004. Analysts predict the BNP market will have above-average growth and will reach approximately US $300 million by 2005 as use increases internationally.
As a Nanogen subsidiary, SynX will continue to market point-of-care diagnostic tests for myocardial infarction in Europe and Canada, and for infectious diseases and drugs of abuse in Canada. In addition to the CHF product, SynX has been developing a pipeline of tests to be marketed under the brand name Nexus Dx(TM) for insulin resistance, traumatic brain injury and Alzheimer`s disease. SynX has also developed diagnostic tests for stroke, which as previously announced, have been licensed to Genzyme Corporation.
"The acquisition of SynX furthers our strategy to commercialize advanced diagnostics that enhance the level of medical care for the detection, diagnosis, monitoring and treatment of disease," said Howard Birndorf, Nanogen chairman and chief executive officer. "We welcome the SynX team and look forward to joining efforts to commercialize our combined pipeline of genetic, infectious disease and point-of-care products," added Birndorf.
Seven Hills Partners, LLC acted as the financial advisor to Nanogen in this transaction. The Seidler Companies, Orenda Corporate Finance Ltd. and First Associates Investments Inc. acted as financial advisors to SynX on this transaction.
About Nanogen
Nanogen, Inc. develops and commercializes products for the in vitro diagnostics market. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen`s website at www.nanogen.com.
Einen Tag vor den 1st Quarter Zahlen solch ein Abverkauf.
Da wissen wieder einige früher als wir was kommt !
Da wissen wieder einige früher als wir was kommt !
Die Zahlen waren doch wohl super !!!!!!!!!!
Nanogen Reports 2004 First Quarter Results
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, today announced its financial results for the first quarter ended March 31, 2004.
Total revenues for the first quarter of 2004 were $2.2 million compared to $1.2 million for the same period in 2003 and $2.1 million in the fourth quarter of 2003. Product revenues for the first quarter were $1.1 million versus $228,000 for the same period in 2003 and were approximately equal to the prior quarter.
Nanogen`s consolidated cash, cash equivalents and short-term investments balance at the end of the first quarter of 2004 was $63.0 million, an increase of approximately $34.0 million from the final quarter of 2003. This compares to the company`s cash, cash equivalents and short-term investments balance of $36.9 million at the close of the first quarter of 2003. In March this year, Nanogen sold 4.25 million shares of common stock in a direct placement for gross proceeds of approximately $33.7 million. Subsequently, in April, Nanogen again augmented its cash position when it closed a second direct placement of stock to generate additional gross proceeds of approximately $7.7 million.
Nanogen`s total costs and expenses for the first quarter of 2004 were $8.8 million, as compared to $9.1 million in the first quarter of 2003 and $9.2 million in the fourth quarter of 2003. Total costs and expenses, excluding cost of product sales in the amount of $914,000, for the first quarter of 2004 were $7.9 million, compared to $8.8 million, excluding cost of product sales in the amount of $274,000, in the same quarter in 2003. This reflects a 10% reduction made possible by continued cost management and improved operating efficiency. Total costs and expenses, excluding the cost of product sales in the amount of $1.0 million, for the fourth quarter of 2003 were $8.2 million. During the first quarter of 2004, Nanogen also reached the decision to conclude operations of Recognomics, its joint venture with Aventis. Nanogen and Aventis will retain rights to intellectual property that each contributed to the collaboration in addition to any intellectual property that was developed during the venture. Accordingly, $870,000 in expenses associated with the closure of Recognomics was recorded in costs and expenses during the first quarter.
For the first quarter of 2004, Nanogen reported a net loss of $5.4 million, or $.20 per share, which compares with a net loss of $10.7 million, or $.50 per share, for the prior year`s first quarter. The 2004 first quarter loss included a $1.2 million foreign currency gain, which was recognized in conjunction with the closure of Recognomics. The 2003 first quarter net loss included a $3.6 million loss recorded on the sale of stock Nanogen held of CombiMatrix Corporation. The net loss for the fourth quarter of last year was $5.9 million or $.25 per share.
"As demonstrated by our first quarter balance sheet and initiatives for early 2004, Nanogen`s focus has been on improving our cash position and taking advantage of opportunities to expand our business into new and growing markets in the U.S. and abroad," said Howard C. Birndorf, chairman of the board and chief executive officer of Nanogen. "The decision to dissolve Recognomics will allow us to redirect resources to product development efforts that are more closely aligned with our mission to provide advanced in vitro diagnostics to enhance individual healthcare." Continuing, Mr. Birndorf said, "Completing the SynX Pharma acquisition provides us with new market opportunities and we are eager to hit the ground running to launch new point-of-care products this year."
Financial Guidance
Nanogen completed the acquisition of point-of-care diagnostic developer SynX Pharma on April 21, 2004. As previously stated, Nanogen expects to invest approximately $6-8 million in SynX, including costs to launch the congestive heart failure product.
Nanogen affirms its previous guidance for this year (excluding the impact of the SynX acquisition), which anticipates a growth rate in total revenue of approximately 50% as compared to 2003 and total costs and expenses, excluding cost of products sold, of approximately 20% less than the 2003 total year spending. Nanogen expects its cash position at the end of the year will be approximately $50 million. The company plans to revise this guidance in the future to include the estimated impact of the SynX acquisition.
Webcast of Conference Call
Nanogen management will host a conference call to discuss first quarter 2004 financial results today at 4:30 p.m. Eastern (1:30 p.m. Pacific). Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s website at www.nanogen.com. A telephone replay will also be available for 48 hours, beginning approximately two hours after the completion of today`s call, and can be accessed via (800) 642-1687 for U.S./Canada participants, and (706) 645-9291 for international participants. The conference ID, 6874714, will be required to listen to the playback.
Note Regarding Use of Non-GAAP Financial Information
Nanogen used a non-GAAP adjustment to exclude cost of product sales from costs and expenses for the periods presented. Nanogen believes that this non- GAAP adjustment is useful to management and investors because it enhances Nanogen`s comparability to other companies, many of which do not include cost of product sales in their presentation of costs and expenses. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements regarding future product revenues, contract and sponsored research revenues, estimates of costs and expenses and estimates of future cash balances. These forward-looking statements are based upon current expectations and speak only as of the date hereof. Nanogen`s actual results and cash balances may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether the acquisition of SynX will achieve the synergies and other benefits anticipated, whether SynX and Nanogen will receive regulatory clearances for the congestive heart failure product on the planned schedule, if at all, whether patents owned or licensed by Nanogen will be developed into products, whether the SynX business unit will become cash flow positive as expected, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. Nanogen disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
March 31, December 31,
2004 2003
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $32,030 $8,550
Short-term investments 30,947 20,564
Receivables, net 2,333 1,415
Inventories, net 4,145 4,774
Other current assets 849 1,590
Total current assets 70,304 36,893
Property and equipment, net 3,898 4,276
Acquired technology rights, net 2,232 2,508
Other assets, net 1,513 172
$77,947 $43,849
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $170 $290
Accrued liabilities 4,323 4,519
Deferred revenue 411 469
Current portion of capital lease obligations 580 743
Total current liabilities 5,484 6,021
Capital lease obligations, less current portion 530 586
Other long-term liabilities 4,304 4,419
Total long-term liabilities 4,834 5,005
Stockholders` equity:
Convertible preferred stock, $0.001 par value,
5,000,000 shares authorized; no shares issued
and outstanding at March 31, 2004 (unaudited)
and December 31, 2003 -- --
Common stock, $0.001 par value, 50,000,000
shares authorized; 31,209,615 (unaudited)
and 24,867,325 shares issued and outstanding
at March 31, 2004 (unaudited) and
December 31, 2003, respectively 31 25
Additional paid-in capital 250,296 209,014
Accumulated other comprehensive income 11 1,136
Deferred compensation (158) (175)
Accumulated deficit (181,629) (176,255)
Treasury stock, at cost, 500,189 shares
at March 31, 2004 (unaudited) and
December 31, 2003 (922) (922)
Total stockholders` equity 67,629 32,823
$77,947 $43,849
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended
March 31,
2004 2003
Revenues:
Product sales $1,132 $228
License revenue 152 --
Sponsored research 375 375
Contracts and grant 500 597
Total revenues 2,159 1,200
Costs and expenses:
Cost of product sales 914 274
Research and development 4,348 4,710
Selling, general and administrative 3,575 4,066
Total costs and expenses 8,837 9,050
Loss from operations (6,678) (7,850)
Interest income, net 102 195
Other income/(expense) (20) 27
Loss on sale of investments -- (3,600)
Gain on foreign currency translation 1,221 --
Minority interest in loss of
consolidated subsidiary -- 548
Net loss $(5,375) $(10,680)
Net loss per share -
basic and diluted $(.20) $(0.50)
Number of shares used in computing
net loss per share - basic and diluted 26,936 21,540
SOURCE Nanogen, Inc.
SAN DIEGO, May 3 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, today announced its financial results for the first quarter ended March 31, 2004.
Total revenues for the first quarter of 2004 were $2.2 million compared to $1.2 million for the same period in 2003 and $2.1 million in the fourth quarter of 2003. Product revenues for the first quarter were $1.1 million versus $228,000 for the same period in 2003 and were approximately equal to the prior quarter.
Nanogen`s consolidated cash, cash equivalents and short-term investments balance at the end of the first quarter of 2004 was $63.0 million, an increase of approximately $34.0 million from the final quarter of 2003. This compares to the company`s cash, cash equivalents and short-term investments balance of $36.9 million at the close of the first quarter of 2003. In March this year, Nanogen sold 4.25 million shares of common stock in a direct placement for gross proceeds of approximately $33.7 million. Subsequently, in April, Nanogen again augmented its cash position when it closed a second direct placement of stock to generate additional gross proceeds of approximately $7.7 million.
Nanogen`s total costs and expenses for the first quarter of 2004 were $8.8 million, as compared to $9.1 million in the first quarter of 2003 and $9.2 million in the fourth quarter of 2003. Total costs and expenses, excluding cost of product sales in the amount of $914,000, for the first quarter of 2004 were $7.9 million, compared to $8.8 million, excluding cost of product sales in the amount of $274,000, in the same quarter in 2003. This reflects a 10% reduction made possible by continued cost management and improved operating efficiency. Total costs and expenses, excluding the cost of product sales in the amount of $1.0 million, for the fourth quarter of 2003 were $8.2 million. During the first quarter of 2004, Nanogen also reached the decision to conclude operations of Recognomics, its joint venture with Aventis. Nanogen and Aventis will retain rights to intellectual property that each contributed to the collaboration in addition to any intellectual property that was developed during the venture. Accordingly, $870,000 in expenses associated with the closure of Recognomics was recorded in costs and expenses during the first quarter.
For the first quarter of 2004, Nanogen reported a net loss of $5.4 million, or $.20 per share, which compares with a net loss of $10.7 million, or $.50 per share, for the prior year`s first quarter. The 2004 first quarter loss included a $1.2 million foreign currency gain, which was recognized in conjunction with the closure of Recognomics. The 2003 first quarter net loss included a $3.6 million loss recorded on the sale of stock Nanogen held of CombiMatrix Corporation. The net loss for the fourth quarter of last year was $5.9 million or $.25 per share.
"As demonstrated by our first quarter balance sheet and initiatives for early 2004, Nanogen`s focus has been on improving our cash position and taking advantage of opportunities to expand our business into new and growing markets in the U.S. and abroad," said Howard C. Birndorf, chairman of the board and chief executive officer of Nanogen. "The decision to dissolve Recognomics will allow us to redirect resources to product development efforts that are more closely aligned with our mission to provide advanced in vitro diagnostics to enhance individual healthcare." Continuing, Mr. Birndorf said, "Completing the SynX Pharma acquisition provides us with new market opportunities and we are eager to hit the ground running to launch new point-of-care products this year."
Financial Guidance
Nanogen completed the acquisition of point-of-care diagnostic developer SynX Pharma on April 21, 2004. As previously stated, Nanogen expects to invest approximately $6-8 million in SynX, including costs to launch the congestive heart failure product.
Nanogen affirms its previous guidance for this year (excluding the impact of the SynX acquisition), which anticipates a growth rate in total revenue of approximately 50% as compared to 2003 and total costs and expenses, excluding cost of products sold, of approximately 20% less than the 2003 total year spending. Nanogen expects its cash position at the end of the year will be approximately $50 million. The company plans to revise this guidance in the future to include the estimated impact of the SynX acquisition.
Webcast of Conference Call
Nanogen management will host a conference call to discuss first quarter 2004 financial results today at 4:30 p.m. Eastern (1:30 p.m. Pacific). Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s website at www.nanogen.com. A telephone replay will also be available for 48 hours, beginning approximately two hours after the completion of today`s call, and can be accessed via (800) 642-1687 for U.S./Canada participants, and (706) 645-9291 for international participants. The conference ID, 6874714, will be required to listen to the playback.
Note Regarding Use of Non-GAAP Financial Information
Nanogen used a non-GAAP adjustment to exclude cost of product sales from costs and expenses for the periods presented. Nanogen believes that this non- GAAP adjustment is useful to management and investors because it enhances Nanogen`s comparability to other companies, many of which do not include cost of product sales in their presentation of costs and expenses. The presentation of this additional information is not meant to be considered in isolation or as a substitute for results prepared in accordance with accounting principles generally accepted in the United States.
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements regarding future product revenues, contract and sponsored research revenues, estimates of costs and expenses and estimates of future cash balances. These forward-looking statements are based upon current expectations and speak only as of the date hereof. Nanogen`s actual results and cash balances may differ materially from those set forth in the forward-looking statements as a result of various factors and uncertainties, including whether the acquisition of SynX will achieve the synergies and other benefits anticipated, whether SynX and Nanogen will receive regulatory clearances for the congestive heart failure product on the planned schedule, if at all, whether patents owned or licensed by Nanogen will be developed into products, whether the SynX business unit will become cash flow positive as expected, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether current trends in product revenue will continue in the future, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. Nanogen disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
March 31, December 31,
2004 2003
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $32,030 $8,550
Short-term investments 30,947 20,564
Receivables, net 2,333 1,415
Inventories, net 4,145 4,774
Other current assets 849 1,590
Total current assets 70,304 36,893
Property and equipment, net 3,898 4,276
Acquired technology rights, net 2,232 2,508
Other assets, net 1,513 172
$77,947 $43,849
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $170 $290
Accrued liabilities 4,323 4,519
Deferred revenue 411 469
Current portion of capital lease obligations 580 743
Total current liabilities 5,484 6,021
Capital lease obligations, less current portion 530 586
Other long-term liabilities 4,304 4,419
Total long-term liabilities 4,834 5,005
Stockholders` equity:
Convertible preferred stock, $0.001 par value,
5,000,000 shares authorized; no shares issued
and outstanding at March 31, 2004 (unaudited)
and December 31, 2003 -- --
Common stock, $0.001 par value, 50,000,000
shares authorized; 31,209,615 (unaudited)
and 24,867,325 shares issued and outstanding
at March 31, 2004 (unaudited) and
December 31, 2003, respectively 31 25
Additional paid-in capital 250,296 209,014
Accumulated other comprehensive income 11 1,136
Deferred compensation (158) (175)
Accumulated deficit (181,629) (176,255)
Treasury stock, at cost, 500,189 shares
at March 31, 2004 (unaudited) and
December 31, 2003 (922) (922)
Total stockholders` equity 67,629 32,823
$77,947 $43,849
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended
March 31,
2004 2003
Revenues:
Product sales $1,132 $228
License revenue 152 --
Sponsored research 375 375
Contracts and grant 500 597
Total revenues 2,159 1,200
Costs and expenses:
Cost of product sales 914 274
Research and development 4,348 4,710
Selling, general and administrative 3,575 4,066
Total costs and expenses 8,837 9,050
Loss from operations (6,678) (7,850)
Interest income, net 102 195
Other income/(expense) (20) 27
Loss on sale of investments -- (3,600)
Gain on foreign currency translation 1,221 --
Minority interest in loss of
consolidated subsidiary -- 548
Net loss $(5,375) $(10,680)
Net loss per share -
basic and diluted $(.20) $(0.50)
Number of shares used in computing
net loss per share - basic and diluted 26,936 21,540
SOURCE Nanogen, Inc.
Nanogen Issued Patent for Electronic Devices for Active Biological Operations
SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, announced today that it was issued U.S. Patent No. 6,726,880, "Electronic Devices for Performing Active Biological Operations and Method of Using Same," by the U.S. Patent and Trademark Office. The `880 patent relates to new devices that enable increased sensitivity of active, programmable electronic matrix (APEX) devices and perform actions such as concentration and assembly of biological materials on a substrate.
DNA, RNA, proteins and other biologics can be electronically concentrated at collection electrodes and then re-distributed to reaction or detection electrodes. With alternating manipulation of the collection and reactive electrodes, molecular nanostructures can be assembled for more sensitive detection or used to manufacture molecular structures such as DNA hybrids or Protein/Protein complexes. With the addition of the `880 patent, Nanogen now has 59 issued patents in the United States.
"The `880 patent builds upon and extends our previous programmable electronic matrix patents by describing approaches to the collection and concentration of biological materials that can then be manipulated in an organized manner," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "Nanogen continues to add to its intellectual property position in order to retain the value of our novel technologies and their potential applications."
SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, announced today that it was issued U.S. Patent No. 6,726,880, "Electronic Devices for Performing Active Biological Operations and Method of Using Same," by the U.S. Patent and Trademark Office. The `880 patent relates to new devices that enable increased sensitivity of active, programmable electronic matrix (APEX) devices and perform actions such as concentration and assembly of biological materials on a substrate.
DNA, RNA, proteins and other biologics can be electronically concentrated at collection electrodes and then re-distributed to reaction or detection electrodes. With alternating manipulation of the collection and reactive electrodes, molecular nanostructures can be assembled for more sensitive detection or used to manufacture molecular structures such as DNA hybrids or Protein/Protein complexes. With the addition of the `880 patent, Nanogen now has 59 issued patents in the United States.
"The `880 patent builds upon and extends our previous programmable electronic matrix patents by describing approaches to the collection and concentration of biological materials that can then be manipulated in an organized manner," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "Nanogen continues to add to its intellectual property position in order to retain the value of our novel technologies and their potential applications."
Hallo tst89,
zusammengefasst was kann man aus den ganzen neuen News zu nanogen entnehmen?
Gruße
zusammengefasst was kann man aus den ganzen neuen News zu nanogen entnehmen?
Gruße
Ich würde die Zahlen etwas vorsichtiger rannehmen als
die Börse, da ich persönlich die +21% von vor ein paar Tagen als ziemlich überzogen halte.
Bin aber sehr positiv bei long....
die Börse, da ich persönlich die +21% von vor ein paar Tagen als ziemlich überzogen halte.
Bin aber sehr positiv bei long....
Bei http://www.Nano-Invests.de
Die 4Investors-Studie:
http://www.4investors.de/Partner/nano/4investorsnano.html
Die 4Investors-Studie:
http://www.4investors.de/Partner/nano/4investorsnano.html
Das Chartbild hat sich nun doch wieder deutlich gebessert.
Sollte der Ausbruch über 6,5 gelingen ist weiteres Potential vorhanden.
Sollte der Ausbruch über 6,5 gelingen ist weiteres Potential vorhanden.
Nett, 6.6$
Nanogen Appoints New President
SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that it has appointed David Ludvigson as its president and chief operating officer replacing Bruce Huebner. Mr. Ludvigson is currently executive vice president and chief financial officer. Mr. Huebner has resigned to pursue other interests and will remain at Nanogen for several months in a transition capacity.
"David Ludvigson has been associated with Nanogen since 1996 as either an executive or as a board member. His familiarity with our business, operations and people will facilitate the management transition," said Howard C. Birndorf, chairman and CEO of Nanogen. "I thank Bruce for his contributions to our business over the last two years."
After serving on Nanogen`s board for seven years, Mr. Ludvigson was named executive vice president in May 2003. Over the last 20 years, he has held executive positions at leading biotechnology and high-technology companies, including Black Pearl, InterTrust Technologies, Matrix Pharmaceuticals, and IDEC Pharmaceuticals (now Biogen Idec). Mr. Ludvigson is a director for Argonaut Technologies and holds B.S. and M.S. degrees from the University of Illinois, Champaign-Urbana.
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward- looking statements.
SOURCE Nanogen, Inc.
-0- 06/02/2004
/CONTACT: Pam Lord of Atkins + Associates, +1-858-527-3494,
plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
CO: Nanogen, Inc.
ST: California
IN: BIO HEA MTC
SU: PER
MV
-- LAW118 --
5421 06/02/2004 19:18 EDT http://www.prnewswire.com
SAN DIEGO, June 2 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN) announced today that it has appointed David Ludvigson as its president and chief operating officer replacing Bruce Huebner. Mr. Ludvigson is currently executive vice president and chief financial officer. Mr. Huebner has resigned to pursue other interests and will remain at Nanogen for several months in a transition capacity.
"David Ludvigson has been associated with Nanogen since 1996 as either an executive or as a board member. His familiarity with our business, operations and people will facilitate the management transition," said Howard C. Birndorf, chairman and CEO of Nanogen. "I thank Bruce for his contributions to our business over the last two years."
After serving on Nanogen`s board for seven years, Mr. Ludvigson was named executive vice president in May 2003. Over the last 20 years, he has held executive positions at leading biotechnology and high-technology companies, including Black Pearl, InterTrust Technologies, Matrix Pharmaceuticals, and IDEC Pharmaceuticals (now Biogen Idec). Mr. Ludvigson is a director for Argonaut Technologies and holds B.S. and M.S. degrees from the University of Illinois, Champaign-Urbana.
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward- looking statements.
SOURCE Nanogen, Inc.
-0- 06/02/2004
/CONTACT: Pam Lord of Atkins + Associates, +1-858-527-3494,
plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
CO: Nanogen, Inc.
ST: California
IN: BIO HEA MTC
SU: PER
MV
-- LAW118 --
5421 06/02/2004 19:18 EDT http://www.prnewswire.com
....nur mal so zur info:
Nanogen ist jetzt auch auf n-tv-teletext, Seite 256,
zu sehen. Kurs in € FSE.
dedecol
Nanogen ist jetzt auch auf n-tv-teletext, Seite 256,
zu sehen. Kurs in € FSE.
dedecol
Was ist los an der NASDAQ ?
Vorbörslich bereits über 7 $ !
Bye
S.
Vorbörslich bereits über 7 $ !
Bye
S.
Nanogen Issued Patent for Detecting Genetic Variants Utilizing Base Stacking
SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, announced today that it was issued U.S. Patent No. 6,753,148, "Methods and Apparatus for Detecting Variants Utilizing Base Stacking," by the U.S. Patent and Trademark Office. The `148 patent is a continuation of patents issued to Nanogen that cover methods and apparatus that are particularly useful for detecting varying lengths of genetic variants. The patent covers the application of base stacking technologies that use specific types of oligonucleotides, both capture and probe oligonucleotides, to bind and discriminate nucleic acid sequences of differing lengths. Historically, variations in nucleic acid sequences had to be detected by using electrophoresis, a tedious and multi-step process, to determine fragment sizes. With this new and novel approach, the nucleic acid sequence variants can be detected by hybridization and be included in DNA/RNA array panels. The issuance of patent `148 expands Nanogen`s intellectual property portfolio to 59 patents issued within the United States.
The new patent describes methods and apparatus whereby capture and probe oligonucleotides are used to bind to a target nucleic acid sequence resulting in differing possible positions of the terminal nucleotides for both the capture and probe oligonucleotides. The positions of these terminal nucleotides are controlled by the length of the target sequence. When the terminal nucleotides are adjacent, the internal energy of base stacking increases, thereby increasing the stability of the complex as compared to complexes formed with lower stability, either because the sequences are mismatched or the terminal nucleotides of the capture and probe oligonucleotides are not adjacent.
"The use of technologies in this patent address the need for a novel approach to discriminate between differences in length of genetic variants, a requirement for broad application of microarrays," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "We continue our strategy of building Nanogen`s intellectual property position in order to preserve the value of our novel technologies and their potential applications."
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
-0- 06/25/2004
/CONTACT: David Ludvigson, President & Chief Operating Officer of
Nanogen, Inc., +1-858-410-4600, dludvigson@nanogen.com; or Pam Lord of Atkins
+ Associates, +1-858-527-3494, plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
CO: Nanogen, Inc.
ST: California
IN: HEA BIO MTC
SU:
AI-MV
-- LAF013 --
6605 06/25/2004 08:00 EDT http://www.prnewswire.com
SAN DIEGO, June 25 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, announced today that it was issued U.S. Patent No. 6,753,148, "Methods and Apparatus for Detecting Variants Utilizing Base Stacking," by the U.S. Patent and Trademark Office. The `148 patent is a continuation of patents issued to Nanogen that cover methods and apparatus that are particularly useful for detecting varying lengths of genetic variants. The patent covers the application of base stacking technologies that use specific types of oligonucleotides, both capture and probe oligonucleotides, to bind and discriminate nucleic acid sequences of differing lengths. Historically, variations in nucleic acid sequences had to be detected by using electrophoresis, a tedious and multi-step process, to determine fragment sizes. With this new and novel approach, the nucleic acid sequence variants can be detected by hybridization and be included in DNA/RNA array panels. The issuance of patent `148 expands Nanogen`s intellectual property portfolio to 59 patents issued within the United States.
The new patent describes methods and apparatus whereby capture and probe oligonucleotides are used to bind to a target nucleic acid sequence resulting in differing possible positions of the terminal nucleotides for both the capture and probe oligonucleotides. The positions of these terminal nucleotides are controlled by the length of the target sequence. When the terminal nucleotides are adjacent, the internal energy of base stacking increases, thereby increasing the stability of the complex as compared to complexes formed with lower stability, either because the sequences are mismatched or the terminal nucleotides of the capture and probe oligonucleotides are not adjacent.
"The use of technologies in this patent address the need for a novel approach to discriminate between differences in length of genetic variants, a requirement for broad application of microarrays," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "We continue our strategy of building Nanogen`s intellectual property position in order to preserve the value of our novel technologies and their potential applications."
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
SOURCE Nanogen, Inc.
-0- 06/25/2004
/CONTACT: David Ludvigson, President & Chief Operating Officer of
Nanogen, Inc., +1-858-410-4600, dludvigson@nanogen.com; or Pam Lord of Atkins
+ Associates, +1-858-527-3494, plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com /
(NGEN)
CO: Nanogen, Inc.
ST: California
IN: HEA BIO MTC
SU:
AI-MV
-- LAF013 --
6605 06/25/2004 08:00 EDT http://www.prnewswire.com
Nach einer kleinen Zwischenkonslidierung stehen wir nun an einer nächsten Hürde, der 7,2.
Aktuell wird mit hohem Volumen gekämpft. Sollte Nanogen die 7,2 überwinden,hat die Aktie viel Luft nach oben.
Aktuell wird mit hohem Volumen gekämpft. Sollte Nanogen die 7,2 überwinden,hat die Aktie viel Luft nach oben.
Hohes Volumen heute und gegen den Markt 7%. :O
Die Marke 7.2 ist geschafft.
Potential aus meiner Sicht erst mal bis 8.2.
Die Marke 7.2 ist geschafft.
Potential aus meiner Sicht erst mal bis 8.2.
Nanogen, Inc. Second Quarter 2004 Financial Results Conference Call
SAN DIEGO--(BUSINESS WIRE)--July 27, 2004--Nanogen, Inc. (Nasdaq:NGEN) will host a conference call on Tuesday, August 3, 2004 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2004 second quarter financial results. The financial results press release will be issued at close of market on August 3rd.
Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on August 3, and can be accessed via telephone at (877) 519-4471 for US/Canada participants, and (973) 341-3080 for international participants. The conference ID, 4974258, will be required to listen to the playback.
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open- architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Nanogen, Inc.
David Ludvigson, 858-410-4600
dludvigson@nanogen.com
or
Atkins + Associates
Michael Moore, 858-527-3497
mmoore@irpr.com
SOURCE: Nanogen, Inc.
SAN DIEGO--(BUSINESS WIRE)--July 27, 2004--Nanogen, Inc. (Nasdaq:NGEN) will host a conference call on Tuesday, August 3, 2004 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2004 second quarter financial results. The financial results press release will be issued at close of market on August 3rd.
Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on August 3, and can be accessed via telephone at (877) 519-4471 for US/Canada participants, and (973) 341-3080 for international participants. The conference ID, 4974258, will be required to listen to the playback.
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open- architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
CONTACT: Nanogen, Inc.
David Ludvigson, 858-410-4600
dludvigson@nanogen.com
or
Atkins + Associates
Michael Moore, 858-527-3497
mmoore@irpr.com
SOURCE: Nanogen, Inc.
Nanogen Reports 2004 Second Quarter Results
SAN DIEGO, Aug 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, today announced its financial results for the second quarter ended June 30, 2004. Nanogen`s second quarter results include approximately two months of activity related to SynX Pharma Inc., which was acquired on April 21, 2004.
Total revenues for the second quarter of 2004 were $1.1 million compared to $1.7 million for the same period in 2003 and $2.2 million in the first quarter of 2004. Product revenues for the second quarter were $477,000 versus $662,000 for the same period in 2003 and were $1.1 million in the first quarter of 2004.
Nanogen`s consolidated cash, cash equivalents and short-term investments balance at the end of the second quarter of 2004 was $60.3 million, approximately $2.7 million less than the previous quarter of $63.0 million. This compares to the company`s cash, cash equivalents and short-term investments balance of $29.1 million at December 31, 2003. During the second quarter of 2004, Nanogen received approximately $7.4 million in net proceeds from the sale of common stock.
Nanogen`s research and development, and selling, general and administrative operating expenses for the second quarter of 2004 were $7.7 million, as compared to $8.6 million in the second quarter of 2003 and $7.9 million in the first quarter of 2004.
For the second quarter of 2004, Nanogen reported a net loss of $12.3 million, or $0.38 per share, which compares with a net loss of $6.9 million, or $0.32 per share, for the prior year`s second quarter. The net loss for the first quarter of 2004 was $5.4 million, or $0.20 per share. The second quarter loss includes an acquired in-process R&D write off of $3.8 million related to the SynX acquisition and inventory reserve charges of $1.5 million reflecting reduced product revenues anticipated from clinical laboratories. The 2004 first quarter loss included a $1.2 million foreign currency gain, which was recognized in conjunction with the closure of Recognomics, Nanogen`s joint venture with Aventis, which concluded operations.
"We are continuing to put the foundation in place to become a leader in advanced diagnostics. Our SynX acquisition, our new product development efforts and our capital raising activities are all directed at accomplishing that objective," said Howard C. Birndorf, chairman of the board and chief executive officer of Nanogen. "Going forward, we will continue to identify and develop opportunities to increase our critical mass of products and resources."
Financial Guidance
Based on the second quarter results and on the expectation of reduced revenues from clinical laboratories, Nanogen does not expect a significant revenue increase in 2004 versus 2003. Estimated revenue growth rates are dependent on a number of factors including the timing and success of new product introductions, the schedules for which continue to be difficult to estimate. The company continues to expect total costs and expenses, excluding cost of products sold and acquisition related expenses, to run approximately 20% less than the 2003 total year spending. Nanogen expects its cash position at the end of the year will be approximately $50 million.
Webcast of Conference Call
Nanogen management will host a conference call today at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2004 second quarter financial results. Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call, and can be accessed via telephone at (877) 519-4471 for US/Canada participants, and (973) 341-3080 for international participants. The conference ID, 4974258, will be required to listen to the playback.
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether the acquisition of SynX will achieve the synergies and other benefits anticipated, whether SynX and Nanogen will receive regulatory approval for the Congestive Heart Failure product on the planned schedule, if at all, whether the SynX business unit will become cash flow positive as expected, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
June 30, December 31,
2004 2003
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $8,543 $8,550
Short-term investments 51,777 20,564
Receivables, net 1,860 1,415
Inventories, net 2,706 4,774
Other current assets 1,673 1,590
Total current assets 66,559 36,893
Property and equipment, net 7,372 4,277
Acquired technology rights, net 2,277 2,508
Restricted cash 753 14
Other assets, net 796 157
Goodwill 13,071 --
$90,828 $43,849
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $1,889 $290
Accrued liabilities 3,240 4,519
Deferred revenue 404 469
Current portion of capital lease obligations 552 743
Total current liabilities 6,085 6,021
Capital lease obligations, less current portion 545 586
Other long-term liabilities 5,451 4,419
Total long-term liabilities 5,996 5,005
Stockholders` equity:
Convertible preferred stock, $0.001
par value, 5,000,000 shares authorized;
no shares issued and outstanding at
June 30, 2004 (unaudited) and
December 31, 2003 -- --
Common stock, $0.001 par value, 50,000,000
shares authorized; 33,846,250 and
24,867,325 shares issued and
outstanding at June 30, 2004
(unaudited) and December 31, 2003,
respectively 34 25
Additional paid-in capital 274,003 209,014
Accumulated other comprehensive income (226) 1,136
Deferred compensation (170) (175)
Accumulated deficit (193,972) (176,255)
Treasury stock, at cost, 500,189 shares
at June 30, 2004
(unaudited) and December 31, 2003 (922) (922)
Total stockholders` equity 78,747 32,823
$90,828 $43,849
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Six months ended
June 30, June 30,
2004 2003 2004 2003
Revenues:
Product sales $477 $662 $1,609 $890
License 38 -- 190 --
Sponsored research 125 375 500 750
Contracts and grant 478 657 978 1,254
Total revenues 1,118 1,694 3,277 2,894
Costs and expenses:
Cost of product sales 1,940 524 2,854 798
Research and development 3,495 4,483 7,843 9,193
Selling, general and
administrative 4,234 4,130 7,809 8,196
Charge for acquired
in-process research
and development 3,758 -- 3,758 --
Total costs and expenses 13,427 9,137 22,264 18,187
Loss from operations (12,309) (7,443) (18,987) (15,293)
Interest income, net 129 113 231 308
Other income (loss) (100) 11 (120) 43
Gain/(loss) on sale of
investments (6) 32 (6) (3,568)
Gain/(loss) on foreign
currency translations (17) (11) 1,204 (16)
Loss on sale of fixed
assets (41) (153) (41) (153)
Minority interest in
loss of consolidated
subsidiary -- 558 -- 1,106
Net loss $(12,344) $(6,893) $(17,719) $(17,573)
Net loss per share --
basic and diluted $(0.38) $(0.32) $(0.59) $(0.82)
Number of shares used
in computing net loss
per share -- basic
and diluted 32,798 21,543 29,870 21,492
SOURCE Nanogen, Inc.
David Ludvigson, President and Chief Operating Officer of Nanogen, Inc., +1-858-410-4600, dludvigson@nanogen.com;
or Pam Lord of Atkins + Associates, +1-858-527-3494, plord@irpr.com, for Nanogen, Inc.
http://www.nanogen.com
SAN DIEGO, Aug 3, 2004 /PRNewswire-FirstCall via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN), developer of molecular and point-of-care diagnostic products, today announced its financial results for the second quarter ended June 30, 2004. Nanogen`s second quarter results include approximately two months of activity related to SynX Pharma Inc., which was acquired on April 21, 2004.
Total revenues for the second quarter of 2004 were $1.1 million compared to $1.7 million for the same period in 2003 and $2.2 million in the first quarter of 2004. Product revenues for the second quarter were $477,000 versus $662,000 for the same period in 2003 and were $1.1 million in the first quarter of 2004.
Nanogen`s consolidated cash, cash equivalents and short-term investments balance at the end of the second quarter of 2004 was $60.3 million, approximately $2.7 million less than the previous quarter of $63.0 million. This compares to the company`s cash, cash equivalents and short-term investments balance of $29.1 million at December 31, 2003. During the second quarter of 2004, Nanogen received approximately $7.4 million in net proceeds from the sale of common stock.
Nanogen`s research and development, and selling, general and administrative operating expenses for the second quarter of 2004 were $7.7 million, as compared to $8.6 million in the second quarter of 2003 and $7.9 million in the first quarter of 2004.
For the second quarter of 2004, Nanogen reported a net loss of $12.3 million, or $0.38 per share, which compares with a net loss of $6.9 million, or $0.32 per share, for the prior year`s second quarter. The net loss for the first quarter of 2004 was $5.4 million, or $0.20 per share. The second quarter loss includes an acquired in-process R&D write off of $3.8 million related to the SynX acquisition and inventory reserve charges of $1.5 million reflecting reduced product revenues anticipated from clinical laboratories. The 2004 first quarter loss included a $1.2 million foreign currency gain, which was recognized in conjunction with the closure of Recognomics, Nanogen`s joint venture with Aventis, which concluded operations.
"We are continuing to put the foundation in place to become a leader in advanced diagnostics. Our SynX acquisition, our new product development efforts and our capital raising activities are all directed at accomplishing that objective," said Howard C. Birndorf, chairman of the board and chief executive officer of Nanogen. "Going forward, we will continue to identify and develop opportunities to increase our critical mass of products and resources."
Financial Guidance
Based on the second quarter results and on the expectation of reduced revenues from clinical laboratories, Nanogen does not expect a significant revenue increase in 2004 versus 2003. Estimated revenue growth rates are dependent on a number of factors including the timing and success of new product introductions, the schedules for which continue to be difficult to estimate. The company continues to expect total costs and expenses, excluding cost of products sold and acquisition related expenses, to run approximately 20% less than the 2003 total year spending. Nanogen expects its cash position at the end of the year will be approximately $50 million.
Webcast of Conference Call
Nanogen management will host a conference call today at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2004 second quarter financial results. Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call, and can be accessed via telephone at (877) 519-4471 for US/Canada participants, and (973) 341-3080 for international participants. The conference ID, 4974258, will be required to listen to the playback.
About Nanogen
Nanogen, Inc. develops and commercializes products for the molecular and point-of-care diagnostics markets. The company seeks to establish the unique, open-architecture NanoChip(R) Molecular Biology Workstation and NanoChip(R) Cartridge as the standard platform for the prediction, diagnosis and treatment of genetic and infectious diseases. Nanogen offers Analyte Specific Reagents and related products to research and clinical reference labs for the development of tests for the detection of genetic mutations associated with a variety of diseases, such as cystic fibrosis, Alzheimer`s disease, and cardiovascular disease. The company`s ten years of research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. Nanogen`s business unit, SynX Pharma, leverages proteomic and biomarker research to offer a line of point-of-care diagnostic tests. For additional information please visit Nanogen`s website at www.nanogen.com.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether Nanogen`s NanoChip(R) System can be successfully further commercialized, whether other products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, whether ASRs currently sold by Nanogen will become FDA-approved molecular diagnostic test kits, whether Nanogen will be successful in developing additional ASRs and protocols utilizing the NanoChip(R) System, whether the acquisition of SynX will achieve the synergies and other benefits anticipated, whether SynX and Nanogen will receive regulatory approval for the Congestive Heart Failure product on the planned schedule, if at all, whether the SynX business unit will become cash flow positive as expected, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December 31, 2003 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
NANOGEN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)
June 30, December 31,
2004 2003
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents $8,543 $8,550
Short-term investments 51,777 20,564
Receivables, net 1,860 1,415
Inventories, net 2,706 4,774
Other current assets 1,673 1,590
Total current assets 66,559 36,893
Property and equipment, net 7,372 4,277
Acquired technology rights, net 2,277 2,508
Restricted cash 753 14
Other assets, net 796 157
Goodwill 13,071 --
$90,828 $43,849
LIABILITIES AND STOCKHOLDERS` EQUITY
Current liabilities:
Accounts payable $1,889 $290
Accrued liabilities 3,240 4,519
Deferred revenue 404 469
Current portion of capital lease obligations 552 743
Total current liabilities 6,085 6,021
Capital lease obligations, less current portion 545 586
Other long-term liabilities 5,451 4,419
Total long-term liabilities 5,996 5,005
Stockholders` equity:
Convertible preferred stock, $0.001
par value, 5,000,000 shares authorized;
no shares issued and outstanding at
June 30, 2004 (unaudited) and
December 31, 2003 -- --
Common stock, $0.001 par value, 50,000,000
shares authorized; 33,846,250 and
24,867,325 shares issued and
outstanding at June 30, 2004
(unaudited) and December 31, 2003,
respectively 34 25
Additional paid-in capital 274,003 209,014
Accumulated other comprehensive income (226) 1,136
Deferred compensation (170) (175)
Accumulated deficit (193,972) (176,255)
Treasury stock, at cost, 500,189 shares
at June 30, 2004
(unaudited) and December 31, 2003 (922) (922)
Total stockholders` equity 78,747 32,823
$90,828 $43,849
NANOGEN, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)
Three months ended Six months ended
June 30, June 30,
2004 2003 2004 2003
Revenues:
Product sales $477 $662 $1,609 $890
License 38 -- 190 --
Sponsored research 125 375 500 750
Contracts and grant 478 657 978 1,254
Total revenues 1,118 1,694 3,277 2,894
Costs and expenses:
Cost of product sales 1,940 524 2,854 798
Research and development 3,495 4,483 7,843 9,193
Selling, general and
administrative 4,234 4,130 7,809 8,196
Charge for acquired
in-process research
and development 3,758 -- 3,758 --
Total costs and expenses 13,427 9,137 22,264 18,187
Loss from operations (12,309) (7,443) (18,987) (15,293)
Interest income, net 129 113 231 308
Other income (loss) (100) 11 (120) 43
Gain/(loss) on sale of
investments (6) 32 (6) (3,568)
Gain/(loss) on foreign
currency translations (17) (11) 1,204 (16)
Loss on sale of fixed
assets (41) (153) (41) (153)
Minority interest in
loss of consolidated
subsidiary -- 558 -- 1,106
Net loss $(12,344) $(6,893) $(17,719) $(17,573)
Net loss per share --
basic and diluted $(0.38) $(0.32) $(0.59) $(0.82)
Number of shares used
in computing net loss
per share -- basic
and diluted 32,798 21,543 29,870 21,492
SOURCE Nanogen, Inc.
David Ludvigson, President and Chief Operating Officer of Nanogen, Inc., +1-858-410-4600, dludvigson@nanogen.com;
or Pam Lord of Atkins + Associates, +1-858-527-3494, plord@irpr.com, for Nanogen, Inc.
http://www.nanogen.com
Eeeyo - ab in den Süden / den Kursen hinterher, eeyo was geht, den Kursen hinterher, eeyo was geht..
Rette sich wer kann.
Aber eigentlich ist es jetzt eh schon alles für`n Arsch:
3,60 US-Dollar letzte Notierung, schon wieder über 5% im Minus - und das nach über -20% gestern.
Danke, ich bin bedient.
Aber eigentlich ist es jetzt eh schon alles für`n Arsch:
3,60 US-Dollar letzte Notierung, schon wieder über 5% im Minus - und das nach über -20% gestern.
Danke, ich bin bedient.
25.08.2004 14:15:
Nanogen Issued Patent for Enhancing Molecular Biological Reactions
SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Nanogen (Nachrichten), developer of molecular and point-of-care diagnostic products, announced today that it was issued U.S. Patent No. 6,780,584, "Electronic Systems and Component Devices for Macroscopic and Microscopic Molecular Biological Reactions, Analyses and Diagnostics," by the U.S. Patent and Trademark Office. The `584 patent covers the design, development, and capability of an electronic system to carry out and control multi-step and multiplex reactions in macroscopic or microscopic formats. The system described in the patent is at the core of Nanogen`s electronic microarray technology, which uses electricity to move and concentrate biological samples in miniature formats for diagnostic applications.
The `584 patent covers technology that controls biological reactions by managing the localized concentration of two or more reaction-dependant molecules and their reaction environment. This approach greatly enhances the rate and specificity of the molecular biological reaction, as evidenced by the Nanogen microarray`s ability to accelerate molecular binding up to 1,000 times faster than traditional passive methods. The technology described in this broad patent enables control over a wide range of molecular reactions involved in molecular analyses and diagnostics, including nucleic acid hybridizations and amplification, antibody and antigen reactions, and more.
"Nanogen`s unique approach of integrating sophisticated microelectronics and molecular biology made the NanoChip(R) Electronic Microarray the first to be used in developing fast and accurate molecular diagnostic tests," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "With the issuance of patent `584, Nanogen increases its intellectual property portfolio enabling the continued development and commercialization of advanced diagnostics that provide physicians and patients valuable healthcare information."
Nanogen, Inc.
Nanogen Issued Patent for Enhancing Molecular Biological Reactions
SAN DIEGO, Aug. 25 /PRNewswire-FirstCall/ -- Nanogen (Nachrichten), developer of molecular and point-of-care diagnostic products, announced today that it was issued U.S. Patent No. 6,780,584, "Electronic Systems and Component Devices for Macroscopic and Microscopic Molecular Biological Reactions, Analyses and Diagnostics," by the U.S. Patent and Trademark Office. The `584 patent covers the design, development, and capability of an electronic system to carry out and control multi-step and multiplex reactions in macroscopic or microscopic formats. The system described in the patent is at the core of Nanogen`s electronic microarray technology, which uses electricity to move and concentrate biological samples in miniature formats for diagnostic applications.
The `584 patent covers technology that controls biological reactions by managing the localized concentration of two or more reaction-dependant molecules and their reaction environment. This approach greatly enhances the rate and specificity of the molecular biological reaction, as evidenced by the Nanogen microarray`s ability to accelerate molecular binding up to 1,000 times faster than traditional passive methods. The technology described in this broad patent enables control over a wide range of molecular reactions involved in molecular analyses and diagnostics, including nucleic acid hybridizations and amplification, antibody and antigen reactions, and more.
"Nanogen`s unique approach of integrating sophisticated microelectronics and molecular biology made the NanoChip(R) Electronic Microarray the first to be used in developing fast and accurate molecular diagnostic tests," said Howard C. Birndorf, Nanogen chairman and chief executive officer. "With the issuance of patent `584, Nanogen increases its intellectual property portfolio enabling the continued development and commercialization of advanced diagnostics that provide physicians and patients valuable healthcare information."
Nanogen, Inc.
Ist Nanogen wieder ein Kauf wert? Was meint ihr?
Leute, servus!
die zeit von nanogen wird noch kommen.
aber erst nach den us-wahlen wird man wieder mit steigenden kursen rechnen können.
dieser momentane kurs ist ein optimal um einzusteigen.
dennoch würde ich noch die us-wahlen abwarten. danach geht es in breiter front nach norden. werdet ihr alle sehen.
nanogen, ist auf jedenfall in meinem depor drinnen.
da rechne ich locker mit 9-10 € bis zum jahresende.
leute, das wird ein spaß!
gruß
bal
die zeit von nanogen wird noch kommen.
aber erst nach den us-wahlen wird man wieder mit steigenden kursen rechnen können.
dieser momentane kurs ist ein optimal um einzusteigen.
dennoch würde ich noch die us-wahlen abwarten. danach geht es in breiter front nach norden. werdet ihr alle sehen.
nanogen, ist auf jedenfall in meinem depor drinnen.
da rechne ich locker mit 9-10 € bis zum jahresende.
leute, das wird ein spaß!
gruß
bal
Bin vor kurzem auch eingestiegen. Am 3. 11 kommen ja die Zahlen!
9 - 10€ bis zum Jahresende wäre echt super! Mal schaun!
9 - 10€ bis zum Jahresende wäre echt super! Mal schaun!
9 - 10 € so ein Blödsinn !
Aber aufwärts geht es wieder.
http://www.nasdaq.com/asp/quotes_news.asp?selected=NGEN&text…
Aber aufwärts geht es wieder.
http://www.nasdaq.com/asp/quotes_news.asp?selected=NGEN&text…
Neues europäisches Patent.
Aktuell +20% in USA !
http://www.nasdaq.com/asp/quotes_news.asp?selected=NGEN&text…
Bye
S.
Aktuell +20% in USA !
http://www.nasdaq.com/asp/quotes_news.asp?selected=NGEN&text…
Bye
S.
geht doch
Hi Heike,
nur zu Deiner Unfo,
habe 09/03 1300 NGEN für 3.8€ gekauft und in 02/04 für 10,8€ wieder verkauft. Dann abgewartet bis jetzt und nun 2400 Stck zum Durchschnittspreis von 3,49€ wieder eingekauft. Bin Mediziner und verstehe etwas von dem Potenzial der Firma.
nur zu Deiner Unfo,
habe 09/03 1300 NGEN für 3.8€ gekauft und in 02/04 für 10,8€ wieder verkauft. Dann abgewartet bis jetzt und nun 2400 Stck zum Durchschnittspreis von 3,49€ wieder eingekauft. Bin Mediziner und verstehe etwas von dem Potenzial der Firma.
Schon wieder +25% in USA !
-------------
#315 selten solch einen selbstverliebten Angeber gehört.
Bye
S.
-------------
#315 selten solch einen selbstverliebten Angeber gehört.
Bye
S.
Hallo confidential!
Bin zwar kein mediziner, bin gestern aber mit 400 Stück eingestiegen .( Beruf: Vogelhändler,insbes.Kukuck)
Mail mal , wenn Du neuen Tip hast oder bei nanogen wieder tätig wirst)
Gruß Theo
Bin zwar kein mediziner, bin gestern aber mit 400 Stück eingestiegen .( Beruf: Vogelhändler,insbes.Kukuck)
Mail mal , wenn Du neuen Tip hast oder bei nanogen wieder tätig wirst)
Gruß Theo
Will ja nicht pessimistisch sein und zynisch gleich gar nicht.Aber der Anstieg hat seine Ursachen und kann sich schnell wieder abkühlen.Anbei einige Informationen.29.11.2004 20:51:
Nanogen nach Patenterhalt +18%
Die Aktien der auf Nanotechnologie spezialisierten Nanogen (Nachrichten) können von der Meldung über den Erhalt eines neuen Patents deutlich profitieren. Wie Nanogen am Montag mitteilte, hat die Sparte Synx ein europäisches Patent zur Diagnose von Schlaganfällen erhalten. Die Bausatz würde indizieren ob der Patient einen Schlaganfall erlitten hat. Im Falle eines Schlaganfalls könne das Gerät zudem diagnostizieren ob der Schlaganfall aufgrund mangelnder Durchblutung oder durch eine Blutung im Gehirn ausgelöst worden ist.
Nanogen legen zur Zeit an der NASDAQ um 17,71% auf 4,65 USD zu
Hi Theo,
kann Dir leider nicht versprechen, Dich bei meinen Nano-Aktionen zu benachrichtigen. Ich sag Dir aber gerne, wonach ich mich richten werde.
Schnelle Kursanstiege, insbesondere wenn sich dabei Gaps zeigen, werden sehr häufig wieder nach unten korrigiert.
Ausserdem: Kurse halten sich nur sehr selten lange über dem ca. dreifachen der zugehörigen 200 Tagelinie auf.
Weiterhin zeigt sich das Ende einer (raschen) Aufwärtsbewegung oft darin, dass es zu einem besonders steilen Kursanstieg kommt.
All das traf im Jan./Feb. auf Nano zu, deshalb habe ich da verkauft.
Zeigt sich das Bild wieder, werde ich erneut verkaufen. Kommt es allerdings nur zu einem kontinuierlichen, dabei immer wieder von Kursrücksetzern gekennzeichneten Verlauf, bleibe ich investiert. Ein solcher Verlauf wäre mir lieber, aber was derzeit abläuft, spricht nicht dafür, dass sich die Aktie so entwickeln wird.
Typischerweise kommen die Kurse auch wieder zurück auf die 200 Tagelinie, wenn diese von unten nach oben durchstossen wird (s. Nano 08-11.2003). Das würde mich auch jetzt nicht beunruhigen. Ganz im Gegenteil: Ich würde erwarten, dass es erst danach richtig weitergehen wird, ob kontin. oder steil.
Im Gegenteil zu 2003 ist nach meiner Ansicht fundamental eine neue Situation eingetreten: Die Nanotechnologie hat ihren Einzug in die Medizin gefunden, ist also hier aus der Zukunft in der Gegenwart angekommen. Das mag viell. der Grund sein, warum der Markt bei Nano nun wieder so euphorisch reagiert.
Als ich jetzt die erste Position bei genau 3E aufbaute, hatte ich mich nur vom Chartbild leiten lassen. Am Tag danach erfuhr ich von dem neuen Patent in Europa und habe dann sofort auf 2400 Stck aufgestockt. Ein Kursziel habe ich aber nicht, ich werde nur auf das Chartbild (s. oben) reagieren.
kann Dir leider nicht versprechen, Dich bei meinen Nano-Aktionen zu benachrichtigen. Ich sag Dir aber gerne, wonach ich mich richten werde.
Schnelle Kursanstiege, insbesondere wenn sich dabei Gaps zeigen, werden sehr häufig wieder nach unten korrigiert.
Ausserdem: Kurse halten sich nur sehr selten lange über dem ca. dreifachen der zugehörigen 200 Tagelinie auf.
Weiterhin zeigt sich das Ende einer (raschen) Aufwärtsbewegung oft darin, dass es zu einem besonders steilen Kursanstieg kommt.
All das traf im Jan./Feb. auf Nano zu, deshalb habe ich da verkauft.
Zeigt sich das Bild wieder, werde ich erneut verkaufen. Kommt es allerdings nur zu einem kontinuierlichen, dabei immer wieder von Kursrücksetzern gekennzeichneten Verlauf, bleibe ich investiert. Ein solcher Verlauf wäre mir lieber, aber was derzeit abläuft, spricht nicht dafür, dass sich die Aktie so entwickeln wird.
Typischerweise kommen die Kurse auch wieder zurück auf die 200 Tagelinie, wenn diese von unten nach oben durchstossen wird (s. Nano 08-11.2003). Das würde mich auch jetzt nicht beunruhigen. Ganz im Gegenteil: Ich würde erwarten, dass es erst danach richtig weitergehen wird, ob kontin. oder steil.
Im Gegenteil zu 2003 ist nach meiner Ansicht fundamental eine neue Situation eingetreten: Die Nanotechnologie hat ihren Einzug in die Medizin gefunden, ist also hier aus der Zukunft in der Gegenwart angekommen. Das mag viell. der Grund sein, warum der Markt bei Nano nun wieder so euphorisch reagiert.
Als ich jetzt die erste Position bei genau 3E aufbaute, hatte ich mich nur vom Chartbild leiten lassen. Am Tag danach erfuhr ich von dem neuen Patent in Europa und habe dann sofort auf 2400 Stck aufgestockt. Ein Kursziel habe ich aber nicht, ich werde nur auf das Chartbild (s. oben) reagieren.
confidential
bin keine Medizinerin, hat nur zur Architektin gereicht.
Nanogen ist mir seit Jahren ein Begriff. Habe in der Vergangenheit immer gezögert mit dem Einstieg. In der letzten Woche konnte ich nicht anfers und bin rein. Meine Stückzahlen dürften hier jedoch keinen interessieren, und es gehört auch nicht zu meiner Art, diese einzustellen.
Kann aber sagen, das bis dato der Gewinn in ordnung geht.
Ich denke das das Kaufinteresse in USA mehr als gut zu bezeichnen ist. Jodoch bleibt festzustellen das nanogen immer zu den Werten gehört die sehr volatil in beide Richtungen gehen können.
Dem Anleger den kurzfristige Rückschläge nicht soviel ausmachen, der kann/darf und sollte ruhig über mehrere Monate invetsiert sein. Für Kurzfristig Orientierte eine Aktie um sich in Nervenkribbeln zu üben.
Ich für meinen Teil werde diesen Wert halten. Potential ist hier auf jeden Fall drin.
Zum Abschluß:
Mich wundert das Naogen so wenig im Board besprochen wird. Den meisten müsste dieser Wert eigentlich ein Begriff sein.
bin keine Medizinerin, hat nur zur Architektin gereicht.
Nanogen ist mir seit Jahren ein Begriff. Habe in der Vergangenheit immer gezögert mit dem Einstieg. In der letzten Woche konnte ich nicht anfers und bin rein. Meine Stückzahlen dürften hier jedoch keinen interessieren, und es gehört auch nicht zu meiner Art, diese einzustellen.
Kann aber sagen, das bis dato der Gewinn in ordnung geht.
Ich denke das das Kaufinteresse in USA mehr als gut zu bezeichnen ist. Jodoch bleibt festzustellen das nanogen immer zu den Werten gehört die sehr volatil in beide Richtungen gehen können.
Dem Anleger den kurzfristige Rückschläge nicht soviel ausmachen, der kann/darf und sollte ruhig über mehrere Monate invetsiert sein. Für Kurzfristig Orientierte eine Aktie um sich in Nervenkribbeln zu üben.
Ich für meinen Teil werde diesen Wert halten. Potential ist hier auf jeden Fall drin.
Zum Abschluß:
Mich wundert das Naogen so wenig im Board besprochen wird. Den meisten müsste dieser Wert eigentlich ein Begriff sein.
Hallo
Auf island-com konnte man heute wesentlich mehr Käufer
sehen gegenüber gestern, wo der Kurs auch schon anzog.
Confidential-danke für dein Posting!
Theo
Auf island-com konnte man heute wesentlich mehr Käufer
sehen gegenüber gestern, wo der Kurs auch schon anzog.
Confidential-danke für dein Posting!
Theo
und die 7$ sind uach das erste Mal seit langem aufgetaucht. Auch, wenn Sie vorerst nur auf der ASK-Seite stehen. Man wird sehen...
Viel Glück allen Investierten
Viel Glück allen Investierten
heikekarina,
"nur zur Architektin gereicht"? Architekten bauen auf, Mediziner können allenfalls verhindern, dass zu schnell abgebaut wird!! Das nur zum Thema Beruf.
Nano ist ein Nasdaq-Wert. Vergleicht man deren Index-Entwicklung mit Nano hat diese Aktie meist eine höhere Steigerungsrate als der Index. D.h. natürlich nicht, dass sie von einem Abschwung der Nasdaq unberührt bleiben würde.
Stückzahlen: Im Thread sollen doch wohl Meinungen und Info`s ausgetauscht werden und wir alle wollen doch hier die (hoffentlich ehrliche) Ansicht des anderen hören. Wenn ich also Stck.-Zahlen nenne (1300 in 2003, jetzt 2400), dann will ich damit auch auf diese Weise nur mein persönl. gesteigertes Vertrauen in die Entwicklung von Nano ausdrücken.
Grüsse aus Freiburg!
"nur zur Architektin gereicht"? Architekten bauen auf, Mediziner können allenfalls verhindern, dass zu schnell abgebaut wird!! Das nur zum Thema Beruf.
Nano ist ein Nasdaq-Wert. Vergleicht man deren Index-Entwicklung mit Nano hat diese Aktie meist eine höhere Steigerungsrate als der Index. D.h. natürlich nicht, dass sie von einem Abschwung der Nasdaq unberührt bleiben würde.
Stückzahlen: Im Thread sollen doch wohl Meinungen und Info`s ausgetauscht werden und wir alle wollen doch hier die (hoffentlich ehrliche) Ansicht des anderen hören. Wenn ich also Stck.-Zahlen nenne (1300 in 2003, jetzt 2400), dann will ich damit auch auf diese Weise nur mein persönl. gesteigertes Vertrauen in die Entwicklung von Nano ausdrücken.
Grüsse aus Freiburg!
confidential
diese Ansicht teile ich gerne mit Dir.
Meine Stückzahl 2000 aufgeteilt zu 2,37 und 2,52
Nachbörslich im BID 6,27
Grüße aus Essen
diese Ansicht teile ich gerne mit Dir.
Meine Stückzahl 2000 aufgeteilt zu 2,37 und 2,52
Nachbörslich im BID 6,27
Grüße aus Essen
To whom it may concern,
bin auf ein kleines Phänomen gestossen:
vor einem Jahr, d.h. genau am 30.11., setzte Nano zu seinem letzten Höhenflug an. Dieses Jahr passierte dies an genau dem gleichem Datum. In beiden Fällen startete der Kurs knapp unter 4 USD und erreichte in beiden Fällen in drei Tagen den fast gleichen Wert, d.h. knapp über 6 USD.
Konnte das jemand ahnen? Ist das jemand schon einmal bei einer anderen Aktie begegnet?
Bin nun gespannt, ob sich der weitere Verlauf ebenfalls gleichen wird.
bin auf ein kleines Phänomen gestossen:
vor einem Jahr, d.h. genau am 30.11., setzte Nano zu seinem letzten Höhenflug an. Dieses Jahr passierte dies an genau dem gleichem Datum. In beiden Fällen startete der Kurs knapp unter 4 USD und erreichte in beiden Fällen in drei Tagen den fast gleichen Wert, d.h. knapp über 6 USD.
Konnte das jemand ahnen? Ist das jemand schon einmal bei einer anderen Aktie begegnet?
Bin nun gespannt, ob sich der weitere Verlauf ebenfalls gleichen wird.
To whom it may concern (TWIMC),
sieht man sich (z.B. bei comdirect.de) den 10 Tageschart (Balken-, Candelstickdarstellung) von Nano an, dann sind seit dem 22.11. zwei gaps enstanden: Ein sehr kleines (22./23.) und ein sicher signifikantes (01./02.12.). Wenn das zweite jetzt in der Korrektur geschlossen würde (Kursrückgang auf rund 5 USD), wäre das sehr gut, weshalb ich nun für diesen Level eine weitere Kauforder in den Markt geben werde.
Bleibt das gap jedoch offen, werde ich es für später im Auge behalten.
PS In mein letztes Posting hat sich ein kleiner Fehler eingeschlichen, er ist aber nicht relevant für die Aussage.
sieht man sich (z.B. bei comdirect.de) den 10 Tageschart (Balken-, Candelstickdarstellung) von Nano an, dann sind seit dem 22.11. zwei gaps enstanden: Ein sehr kleines (22./23.) und ein sicher signifikantes (01./02.12.). Wenn das zweite jetzt in der Korrektur geschlossen würde (Kursrückgang auf rund 5 USD), wäre das sehr gut, weshalb ich nun für diesen Level eine weitere Kauforder in den Markt geben werde.
Bleibt das gap jedoch offen, werde ich es für später im Auge behalten.
PS In mein letztes Posting hat sich ein kleiner Fehler eingeschlichen, er ist aber nicht relevant für die Aussage.
Moin, moin
Nanogen Issued Patent for Apparatus for Active Biological Sample Preparation
December 06, 2004 08:01:00 AM ET
SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- Nanogen, Inc. NGEN, developer of advanced diagnostic products, announced today that it was issued U.S. Patent No. 6,824,740, "Apparatus for Active Biological Sample Preparation," by the U.S. Patent and Trademark Office. The `740 patent relates to methods and devices for performing active, multi-step molecular and biological sample preparation and diagnostic analyses, whereby electrocharged molecules such as nucleic acids are isolated from blood cells to be enriched and analyzed. This new patent expands Nanogen`s intellectual property portfolio covering technologies involved in development of sample-to-answer molecular diagnostics and is the company`s 81st patent issued in the U.S.
The patent allows for an integrated system in which some or all of the processes involved in sample preparation are performed together. These include receipt of biological materials, cell lysing, sample purification, sample concentration, buffer exchange, complexity reduction, diagnosis and analysis. Claims of the `740 patent also cover the design of an apparatus intended to improve sensitivity, specificity and reproducibility of general sample preparation and handling.
Gruß,
OJS (dem diese Aktie immer mehr Spaß bereitet)
Nanogen Issued Patent for Apparatus for Active Biological Sample Preparation
December 06, 2004 08:01:00 AM ET
SAN DIEGO, Dec. 6 /PRNewswire-FirstCall/ -- Nanogen, Inc. NGEN, developer of advanced diagnostic products, announced today that it was issued U.S. Patent No. 6,824,740, "Apparatus for Active Biological Sample Preparation," by the U.S. Patent and Trademark Office. The `740 patent relates to methods and devices for performing active, multi-step molecular and biological sample preparation and diagnostic analyses, whereby electrocharged molecules such as nucleic acids are isolated from blood cells to be enriched and analyzed. This new patent expands Nanogen`s intellectual property portfolio covering technologies involved in development of sample-to-answer molecular diagnostics and is the company`s 81st patent issued in the U.S.
The patent allows for an integrated system in which some or all of the processes involved in sample preparation are performed together. These include receipt of biological materials, cell lysing, sample purification, sample concentration, buffer exchange, complexity reduction, diagnosis and analysis. Claims of the `740 patent also cover the design of an apparatus intended to improve sensitivity, specificity and reproducibility of general sample preparation and handling.
Gruß,
OJS (dem diese Aktie immer mehr Spaß bereitet)
LAST MATCH
Price 6.4100
Time 8:17:04.083
TODAY`S ACTIVITY
Orders 182
Volume 14,715
--------------------------------------------------------------------------------
BUY ORDERS
SHARES PRICE
500 6.4000
1,350 6.4000
1,200 6.3600
1,000 6.3500
500 6.3000
2,800 6.3000
10,000 6.1800
1,000 6.1400
200 5.5300
1,000 5.5100
240 5.4900
200 5.4600
500 5.4500
100 5.4400
100 5.4300
(34 more)
SELL ORDERS
SHARES PRICE
400 6.4800
100 6.4900
5,000 6.4900
100 6.5000
100 6.5000
770 6.5000
500 6.5500
200 6.6000
2,000 6.6700
80 6.8000
1,000 6.9900
100 6.9900
200 6.9900
5,000 6.9900
100 7.0000
(37 more)
Price 6.4100
Time 8:17:04.083
TODAY`S ACTIVITY
Orders 182
Volume 14,715
--------------------------------------------------------------------------------
BUY ORDERS
SHARES PRICE
500 6.4000
1,350 6.4000
1,200 6.3600
1,000 6.3500
500 6.3000
2,800 6.3000
10,000 6.1800
1,000 6.1400
200 5.5300
1,000 5.5100
240 5.4900
200 5.4600
500 5.4500
100 5.4400
100 5.4300
(34 more)
SELL ORDERS
SHARES PRICE
400 6.4800
100 6.4900
5,000 6.4900
100 6.5000
100 6.5000
770 6.5000
500 6.5500
200 6.6000
2,000 6.6700
80 6.8000
1,000 6.9900
100 6.9900
200 6.9900
5,000 6.9900
100 7.0000
(37 more)
Hobby: Patente sammeln !
Egal weiter so !
Bye
S.
Egal weiter so !
Bye
S.
Ich lasse Sie weiterhin liegen....es wird die Zeit wieder kommen.....
und wer long investiert bleibt sahnt ab
und wer long investiert bleibt sahnt ab
die aktie kommt runter bis 4 €.
werdet sehen.
danach dasselbe spielchen wieder wie letzes jahr.
grüße
bal
werdet sehen.
danach dasselbe spielchen wieder wie letzes jahr.
grüße
bal
bis jetzt +10% in USA!
14,49- USA
+17,21% in USA
Was geht denn zur Zeit bei Nanogen ab? Weiss da etwa wieder jemand mehr als wir?Ich finde es ja gut wenn die so steigen..
MfG..W
MfG..W
alle nanoplays sind heute zwischen 20-30 % gestiegen. Vermutlich irgend ne politische Aussage in USA zur Förderung o.ä. Anders kann ich mir das nicht erklären.
Außer Biophan, und genau das gibt mir zu denken.
Cyberworker
Cyberworker
+27,6% sind es geworden !
wahnsinn was da abgeht. aber gut dass einer das stopbuy erfunden hat sonst hätte ich innerhalb von paar std. keine 1500€ gemacht.
mit dieser aktie werden wir noch viel spaß haben jungs.
nicht die köpfe hängen lassen.
allen ein großen dicken
grüße
bal
mit dieser aktie werden wir noch viel spaß haben jungs.
nicht die köpfe hängen lassen.
allen ein großen dicken
grüße
bal
17.12.2004 14:07:
Nanogen and Epoch Biosciences Complete Merger
SAN DIEGO and BOTHELL, Wash., Dec. 17 /PRNewswire-FirstCall/ -- Nanogen (Nachrichten) and Epoch Biosciences (Nachrichten) announced today that they have completed their merger transaction, creating an advanced diagnostics company with the ability to address customer needs spanning the research, clinical reference laboratory and point-of-care markets. The molecular diagnostic products of the combined company address customer needs ranging from single, real-time tests to complex molecular tests performed on Nanogen`s advanced microarray systems. The merger enlarges the company`s existing product line with the addition of 25 real-time analyte specific reagent products and other technologies for genetic analysis from Epoch Biosciences.
The combined company is expected to enjoy the benefit of having strong operating synergies in sales and marketing due to the shared customers and common customer base. The enlarged product portfolio will provide Nanogen`s direct sales force with more solutions to meet customer needs and the ability to develop deeper customer relationships, permitting a better utilization of the company`s existing infrastructure. Additional benefits are expected through the elimination of duplicate general and administrative activities.
The merger follows Nanogen`s acquisition of SynX in April 2004. In each case, Nanogen is seeking to build its product line in order to differentiate itself as a leading provider of both molecular and proteomic diagnostic products. The SynX acquisition offered Nanogen access to the point-of-care market with its pipeline of complementary products that are initially focused on cardiac related health conditions. The Epoch merger enhances the molecular diagnostic product offerings and adds numerous large customers. The Epoch merger will result in an immediate increase in revenue for Nanogen. During the first nine months of 2004, Epoch had revenues of approximately $6.3 million.
"The combination of Epoch and Nanogen is a continuation of our strategy to build critical mass," said Howard Birndorf, chairman and chief executive officer of Nanogen. "This merger will allow us to better leverage our infrastructure, will offer immediate benefits to our customer base and will immediately contribute to revenue growth."
William Gerber, president and chief executive officer of Epoch Biosciences stated, "The addition of Nanogen`s direct sales force should accelerate the adoption of Epoch products by clinical and research laboratories, and the combined organization`s broad product line can better address the growing demands of the molecular diagnostics market."
Nanogen has a market capitalization of approximately $350 million at current market prices and is expected to have approximately $50 million in cash at the end of the fourth quarter 2004. Approximately 13.6 million shares of Nanogen stock were issued to complete the merger, the lower end of the previously negotiated exchange ratio.
Seven Hills Partners LLC acted as the financial advisor to Nanogen in this transaction. Molecular Securities Inc. acted as the financial advisor to Epoch Biosciences on this transaction.
About Nanogen, Inc.
Nanogen`s advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen`s subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen`s ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen`s website at http://www.nanogen.com/.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the acquisition of Epoch Biosciences will achieve the synergies and other benefits anticipated, whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Nanogen, Inc.; Epoch Biosciences, Inc.
Gruß
Glimmerman
Nanogen and Epoch Biosciences Complete Merger
SAN DIEGO and BOTHELL, Wash., Dec. 17 /PRNewswire-FirstCall/ -- Nanogen (Nachrichten) and Epoch Biosciences (Nachrichten) announced today that they have completed their merger transaction, creating an advanced diagnostics company with the ability to address customer needs spanning the research, clinical reference laboratory and point-of-care markets. The molecular diagnostic products of the combined company address customer needs ranging from single, real-time tests to complex molecular tests performed on Nanogen`s advanced microarray systems. The merger enlarges the company`s existing product line with the addition of 25 real-time analyte specific reagent products and other technologies for genetic analysis from Epoch Biosciences.
The combined company is expected to enjoy the benefit of having strong operating synergies in sales and marketing due to the shared customers and common customer base. The enlarged product portfolio will provide Nanogen`s direct sales force with more solutions to meet customer needs and the ability to develop deeper customer relationships, permitting a better utilization of the company`s existing infrastructure. Additional benefits are expected through the elimination of duplicate general and administrative activities.
The merger follows Nanogen`s acquisition of SynX in April 2004. In each case, Nanogen is seeking to build its product line in order to differentiate itself as a leading provider of both molecular and proteomic diagnostic products. The SynX acquisition offered Nanogen access to the point-of-care market with its pipeline of complementary products that are initially focused on cardiac related health conditions. The Epoch merger enhances the molecular diagnostic product offerings and adds numerous large customers. The Epoch merger will result in an immediate increase in revenue for Nanogen. During the first nine months of 2004, Epoch had revenues of approximately $6.3 million.
"The combination of Epoch and Nanogen is a continuation of our strategy to build critical mass," said Howard Birndorf, chairman and chief executive officer of Nanogen. "This merger will allow us to better leverage our infrastructure, will offer immediate benefits to our customer base and will immediately contribute to revenue growth."
William Gerber, president and chief executive officer of Epoch Biosciences stated, "The addition of Nanogen`s direct sales force should accelerate the adoption of Epoch products by clinical and research laboratories, and the combined organization`s broad product line can better address the growing demands of the molecular diagnostics market."
Nanogen has a market capitalization of approximately $350 million at current market prices and is expected to have approximately $50 million in cash at the end of the fourth quarter 2004. Approximately 13.6 million shares of Nanogen stock were issued to complete the merger, the lower end of the previously negotiated exchange ratio.
Seven Hills Partners LLC acted as the financial advisor to Nanogen in this transaction. Molecular Securities Inc. acted as the financial advisor to Epoch Biosciences on this transaction.
About Nanogen, Inc.
Nanogen`s advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen`s subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen`s ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen`s website at http://www.nanogen.com/.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the acquisition of Epoch Biosciences will achieve the synergies and other benefits anticipated, whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen`s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
Nanogen, Inc.; Epoch Biosciences, Inc.
Gruß
Glimmerman
Hallo!
Was meint ihr? Ist noch viel Potenzial in der Aktie? Oder sollte man die Gewinne mitnehmen?
Habt ihr ein Kursziel für die Aktie?
Was meint ihr? Ist noch viel Potenzial in der Aktie? Oder sollte man die Gewinne mitnehmen?
Habt ihr ein Kursziel für die Aktie?
servus!
auf keinen fall verkaufen.
ich halte auch noch paar tausende von nanogen.
ich sags dir, war haben anfang januar 7€.
da lass i a wette mitlaufen!
frohes fest dann euch allen hier.
ende februar sinds dann um die 11euro...
auf keinen fall verkaufen.
ich halte auch noch paar tausende von nanogen.
ich sags dir, war haben anfang januar 7€.
da lass i a wette mitlaufen!
frohes fest dann euch allen hier.
ende februar sinds dann um die 11euro...
Gut, dann verkaufe ich erst bei 11€! :-)
@lugano!
na klaro. wirst sehen im neuen jahr geht die nanogen-rakete ab. nur der starke euro bremst uns ein wenig aus. naja,. was solls. das juckt ja keinen mehr so richtig.
wir machen unseren weg. wirst sehen. wenn wir glück haben gehts am donnerstag auch nochmal nen schub nach oben.
gruß und nen guten rutsch luga
na klaro. wirst sehen im neuen jahr geht die nanogen-rakete ab. nur der starke euro bremst uns ein wenig aus. naja,. was solls. das juckt ja keinen mehr so richtig.
wir machen unseren weg. wirst sehen. wenn wir glück haben gehts am donnerstag auch nochmal nen schub nach oben.
gruß und nen guten rutsch luga
Hat jemand eine Idee warum NGEN seit Jänner fällt und fällt
und fällt???
und fällt???
Ich halte NGEN für nichts weiter als heiße Luft. Man kann damit ein wenig zocken, aber wer sein Geld anlegen möchte, sollte es woanders probieren.
NGEN hat zwar einige Nanotech-Patente, aber daraus macht die Firma scheinbar nix und wie es aussieht hat wohl auch niemand Interesse daran Lizenzen zu erwerben.
Falls mal wieder eine Nanotech-Hype ausbricht wird NGEN als Nanotech-Pretender wohl davon profitieren, schließlich hat man zumindest Nano im Namen, aber das war es auch schon wieder.
NGEN hat zwar einige Nanotech-Patente, aber daraus macht die Firma scheinbar nix und wie es aussieht hat wohl auch niemand Interesse daran Lizenzen zu erwerben.
Falls mal wieder eine Nanotech-Hype ausbricht wird NGEN als Nanotech-Pretender wohl davon profitieren, schließlich hat man zumindest Nano im Namen, aber das war es auch schon wieder.
hallo ennox!
Danke für die Info.Ngen soll doch einen Supertest
für die Diagnose von Schlaganfällen auf den Markt gebracht haben. Müsste doch ein gutes Geschäft sein!?
Danke für die Info.Ngen soll doch einen Supertest
für die Diagnose von Schlaganfällen auf den Markt gebracht haben. Müsste doch ein gutes Geschäft sein!?
hallo ennox!
Danke für die Info.Ngen soll doch einen Supertest
für die Diagnose von Schlaganfällen auf den Markt gebracht haben. Müsste doch ein gutes Geschäft sein!?
Danke für die Info.Ngen soll doch einen Supertest
für die Diagnose von Schlaganfällen auf den Markt gebracht haben. Müsste doch ein gutes Geschäft sein!?
hallo leute.
schön dass mal nach längerer zeit wieder welche auferwacht sind.
ich sehe den chart von nanogen ganz gut.
macd geht an die 0...da bedeutet erholung.
wird die nächste zeit wieder nach oben gehen.
werdet sehen.
mfg
bal
schön dass mal nach längerer zeit wieder welche auferwacht sind.
ich sehe den chart von nanogen ganz gut.
macd geht an die 0...da bedeutet erholung.
wird die nächste zeit wieder nach oben gehen.
werdet sehen.
mfg
bal
ja das denke ich auch. Bodenbildung sollte schon erreicht sein. Wenn es nächste Woche nicht wieder runtergeht, werde ich investieren. Der Ausbruch kann dann kommen.
hi!
ja der ausbruch steht vor der tür.
würde jetzt mal schön die ersten posten investieren.
der boden ist gut fest für die nächste rakete.
die aktie ist extrem überVerkauft.
deswegen an alle die dabei sein wollen.
den ersten posten ins depot...und dann bei 4,40 ein stopbuy. meine empfehlung. dann gibts ein stopbuyfeuerwerk in richtung 7€ marke!
ich habs erwähnt...sagt ja nicht, ich habs euch verschwiegen.
hatte letztes jahr sehr viel spaß mit der aktie.
und die kommt wieder!
gruß an alle!
bal
ja der ausbruch steht vor der tür.
würde jetzt mal schön die ersten posten investieren.
der boden ist gut fest für die nächste rakete.
die aktie ist extrem überVerkauft.
deswegen an alle die dabei sein wollen.
den ersten posten ins depot...und dann bei 4,40 ein stopbuy. meine empfehlung. dann gibts ein stopbuyfeuerwerk in richtung 7€ marke!
ich habs erwähnt...sagt ja nicht, ich habs euch verschwiegen.
hatte letztes jahr sehr viel spaß mit der aktie.
und die kommt wieder!
gruß an alle!
bal
huhu balboa
hier steht bald ein gewaltiger ausbruch an, habe mich vorsichtshalber nun doch positioniert, da könnte heute einiges gehen
hier steht bald ein gewaltiger ausbruch an, habe mich vorsichtshalber nun doch positioniert, da könnte heute einiges gehen
7 bis 8$ könnten es locker werden, €uro kommt nebenbei auch etwas zurück und schwupp die wups haben wir hier eine astreine Gewinchance von mehr als 50%
Strong Buy!
www.wallst.net
bis 7$ ist der weg noch relativ offen, was darüber kommt weiß ich nicht..
Strong Buy!
www.wallst.net
bis 7$ ist der weg noch relativ offen, was darüber kommt weiß ich nicht..
hallo kerncodex mein freund!
hast dich doch entschieden bei nanogen einzusteigen!!!
freut mich.
habe heute mit primacom schon 20% gemacht.
biomira hoffe ich geht heut auch nochmal ab.
und wenn nanogen auch wieder kommt...
na denn...
hoffe es klappt heute...aber ich denke eher zum wochenschluss hin könnte der ausbruch kommen.
charttechnisch noch nicht so weit.
was jetzt macd und rsi anbelangt.
aber ich lass mich gern eines besseren belehren....
hast dich doch entschieden bei nanogen einzusteigen!!!
freut mich.
habe heute mit primacom schon 20% gemacht.
biomira hoffe ich geht heut auch nochmal ab.
und wenn nanogen auch wieder kommt...
na denn...
hoffe es klappt heute...aber ich denke eher zum wochenschluss hin könnte der ausbruch kommen.
charttechnisch noch nicht so weit.
was jetzt macd und rsi anbelangt.
aber ich lass mich gern eines besseren belehren....
huhu
=> Wenn das Momentum und die Stochastic ins PLUS dreht kauf ich nochmal dick nach und lass mich treiben
NGEN sieht gut aus, aber bei BIOM ist der Verkaufsdruck heute zu hoch, aber du bist ja noch im PLUS
Ja bei PRC geht echt die POST ab
=> Wenn das Momentum und die Stochastic ins PLUS dreht kauf ich nochmal dick nach und lass mich treiben
NGEN sieht gut aus, aber bei BIOM ist der Verkaufsdruck heute zu hoch, aber du bist ja noch im PLUS
Ja bei PRC geht echt die POST ab
Hi, weiß jemand wann die Zahlen kommen??
Hier gibt es bald eine gewaltige charttechnische Entladung!
07.01.2005 14:08:
Nanogen Names Robert Saltmarsh Chief Financial Officer
SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Nanogen (Nachrichten), developer of advanced diagnostic products, announced today the appointment of Robert Saltmarsh as Chief Financial Officer. Mr. Saltmarsh joined Nanogen as Vice President of Corporate Development last September. In addition to participating in business development initiatives, he assumed oversight of all financial operations and investor relations for the company.
Mr. Saltmarsh has over 25 years of experience in the high tech industry including public and private equity financing transactions, financial operations, and the building of successful finance functions. He worked for Apple Computer, Inc. and Silicon Graphics, Inc. during times of tremendous growth. At both companies, he was the Vice President of Finance and Treasurer. Mr. Saltmarsh has also been Chief Financial Officer of Radius and Riffage.com. For the three years prior to joining Nanogen, he consulted for a series of start-up companies and taught entrepreneurial finance at the University of California at Riverside. He received a B.A. in Economics and an M.B.A. in Finance from the University of Michigan.
"Robert brings broad treasury and financial management skills to Nanogen, having successfully directed financings, M&A activity and administrative functions for evolving companies. We`re pleased he`ll join Nanogen`s executive team during a time marked by exciting growth," said Howard C. Birndorf, Nanogen Chairman and Chief Executive Officer.
Falls es nochmal 5% runtergeht sollte man im Bereich von 4,5$ massiv kaufen!
gruß codex
Nanogen Names Robert Saltmarsh Chief Financial Officer
SAN DIEGO, Jan. 7 /PRNewswire-FirstCall/ -- Nanogen (Nachrichten), developer of advanced diagnostic products, announced today the appointment of Robert Saltmarsh as Chief Financial Officer. Mr. Saltmarsh joined Nanogen as Vice President of Corporate Development last September. In addition to participating in business development initiatives, he assumed oversight of all financial operations and investor relations for the company.
Mr. Saltmarsh has over 25 years of experience in the high tech industry including public and private equity financing transactions, financial operations, and the building of successful finance functions.
He worked for Apple Computer, Inc. and Silicon Graphics, Inc. during times of tremendous growth. At both companies, he was the Vice President of Finance and Treasurer. Mr. Saltmarsh has also been Chief Financial Officer of Radius and Riffage.com. For the three years prior to joining Nanogen, he consulted for a series of start-up companies and taught entrepreneurial finance at the University of California at Riverside. He received a B.A. in Economics and an M.B.A. in Finance from the University of Michigan."Robert brings broad treasury and financial management skills to Nanogen, having successfully directed financings, M&A activity and administrative functions for evolving companies. We`re pleased he`ll join Nanogen`s executive team during a time marked by exciting growth," said Howard C. Birndorf, Nanogen Chairman and Chief Executive Officer.
Falls es nochmal 5% runtergeht sollte man im Bereich von 4,5$ massiv kaufen!
gruß codex
Achja morgen ist ein Event:
Title: Revolutionizing Real Time PCR
Analysis: Technology overview and Applications with Nanogen, Inc. MGB EclipseTM Probes and Superbases Seminar
Date: Thursday, February 10, 2005
Time: 1:00 PM ET / 10:00 AM PT
Duration: 2 hours
For webcast click here:
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=NGEN&…
Title: Revolutionizing Real Time PCR
Analysis: Technology overview and Applications with Nanogen, Inc. MGB EclipseTM Probes and Superbases Seminar
Date: Thursday, February 10, 2005
Time: 1:00 PM ET / 10:00 AM PT
Duration: 2 hours
For webcast click here:
http://www.corporate-ir.net/ireye/ir_site.zhtml?ticker=NGEN&…
kerni!
sauber die news!
heute vielleicht noch nicht!
aber morgen geht die post ab!
mir sicher bin!
sauber die news!
heute vielleicht noch nicht!
aber morgen geht die post ab!
mir sicher bin!
huhu
Wenn ich dazu komme höre ich mir das Event nachher auf jeden Fall mit an, registriert habe ich mich bereits
Muss eigentlich nur noch meine ISDN Leitung mitspielen
Wenn ich dazu komme höre ich mir das Event nachher auf jeden Fall mit an, registriert habe ich mich bereits
Muss eigentlich nur noch meine ISDN Leitung mitspielen
Noch 100 Minuten
Der Kurs springt an
habs gesehen!
haben voll ins plus gedreht die säcke!
denke morgen gehts rund!
was meinst zu primacom kerni?
aussteigen und bei nanogen rein oder nicht?
haben voll ins plus gedreht die säcke!
denke morgen gehts rund!
was meinst zu primacom kerni?
aussteigen und bei nanogen rein oder nicht?
Beides halten
Kaufen bevor das Momentum ein Kaufsignal generiert und der Stochastic ins plus dreht
gruß codex
p.s.bei prc werden morgen shortis gegrillt
Kaufen bevor das Momentum ein Kaufsignal generiert und der Stochastic ins plus dreht
gruß codex
p.s.bei prc werden morgen shortis gegrillt
mir gehts darum dass der macd in den norden geht.
der geht schon wieder seitwärts dahin!
rsi ist schon durch über die 30!
mal schauen! hoffe mal dass die 6€ morgen geknackt werden bei primacom!!!!
der geht schon wieder seitwärts dahin!
rsi ist schon durch über die 30!
mal schauen! hoffe mal dass die 6€ morgen geknackt werden bei primacom!!!!
NGEN 5,05$ +8,6%
Es ist immer gut zu streuen
gruß codex
p.s.Hier sind keine Charts mehr zu sehen weil freerealtime.com anscheinend probleme hat Naja man kann ja auf stockcharts.com ausweichen..
Es ist immer gut zu streuen
gruß codex
p.s.Hier sind keine Charts mehr zu sehen weil freerealtime.com anscheinend probleme hat
Naja man kann ja auf stockcharts.com ausweichen..
huhu, die Entwicklung bei NGEN freut mich sehr
Last Price 4.940
Last Trade 4:03
Change 0.290
% Change 6.24%
Volume 1.99 m
Open 5.059
High 5.110
Low 4.838
Ich glaube es geht noch ein paar Tage seitwärts bevor es richtig losgeht
gn8 codex
Last Price 4.940
Last Trade 4:03
Change 0.290
% Change 6.24%
Volume 1.99 m
Open 5.059
High 5.110
Low 4.838
Ich glaube es geht noch ein paar Tage seitwärts bevor es richtig losgeht
gn8 codex
So nun gehe ich aber wirklich ins Bett
Nächste Woche knacken wir die 5$ nachhaltig
Nächste Woche knacken wir die 5$ nachhaltig
@kerni!
theta??
was isn das für ne firma?
warum stellst das hier rein?
gruß
ps: glaube du hast ne BM von mir bzgl. altair.
theta??
was isn das für ne firma?
warum stellst das hier rein?
gruß
ps: glaube du hast ne BM von mir bzgl. altair.
Title: Revolutionizing Real Time PCR Analysis: Technology overview and Applications with Nanogen, Inc. MGB EclipseTM Probes and Superbases Seminar
Date: Thursday, February 17, 2005
Time: 11:00 AM PT / 2:00 PM ET
Duration: 2 hours
:tup:
Date: Thursday, February 17, 2005
Time: 11:00 AM PT / 2:00 PM ET
Duration: 2 hours
:tup:
Weiß jemand wann es Earnings gibt, Gerüchten zu Folge nächste Woche.. sagen zumindest einige aus
den AMI Boards, aber denen kann man eh nix glauben (!)
Vorbörslich auf 4,6
bid 4,6 1000
ask 4,73 100
den AMI Boards, aber denen kann man eh nix glauben (!)
Vorbörslich auf 4,6
bid 4,6 1000
ask 4,73 100
In den USA füllt sich das BID zunehmend, Kurs bei 4,74$
morgen rakete! wirst sehen!
macd ist durch!
da könnten wir morgen und freitag nen hype landen!
macd ist durch!
da könnten wir morgen und freitag nen hype landen!
haben die 4,76$ geknackt.
dass war die decke!
morgen kommts ganz fett raus!
dass war die decke!
morgen kommts ganz fett raus!
Nanogen to Release Fourth Quarter Financial Results and Host Webcast on Wednesday, February 23, 2005
Wednesday February 16, 4:30 pm ET
SAN DIEGO, Feb. 16 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) will host a conference call on Wednesday, February 23, 2005 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2004 fourth quarter and year-end financial results. The financial results press release will be issued at close of market on February 23rd. (!)
Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at http://www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on February 23, and can be accessed via telephone at (877) 519-4471 for US/Canada participants, and (973) 341-3080 for international participants. The conference ID, 5663809, will be required to listen to the playback.
About Nanogen, Inc.
Nanogen`s advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen`s subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen`s ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries.
Wednesday February 16, 4:30 pm ET
SAN DIEGO, Feb. 16 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN - News) will host a conference call on Wednesday, February 23, 2005 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2004 fourth quarter and year-end financial results. The financial results press release will be issued at close of market on February 23rd. (!)
Audio of management`s presentation will be available via live webcast on the investor relations section of Nanogen`s corporate website at http://www.nanogen.com, and will be archived for 90 days. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on February 23, and can be accessed via telephone at (877) 519-4471 for US/Canada participants, and (973) 341-3080 for international participants. The conference ID, 5663809, will be required to listen to the playback.
About Nanogen, Inc.
Nanogen`s advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen`s subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen`s ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries.
Hier nochmal die letzten Key Developments:
+++
Nanogen, Inc. Names Robert Saltmarsh as Chief Financial Officer
2005 Jan 7 8:03 AM
Nanogen, Inc. announced that Robert Saltmarsh has been appointed as Chief Financial Officer.
+++
Nanogen, Inc. and Epoch Biosciences Complete Merger
2004 Dec 17 8:00 AM
Nanogen, Inc. and Epoch Biosciences, Inc. announced that they have completed their merger transaction.
+++
Nanogen, Inc. and Epoch Biosciences Stockholders Vote in Favor of Merger
2004 Dec 15 6:00 PM
Nanogen, Inc. announced that stockholders approved the merger agreement with Epoch Biosciences. Nanogen stockholders also approved an amendment to the company`s certificate of incorporation increasing the number of authorized shares of Nanogen common stock to 135 million shares. Nanogen and Epoch expect to close the merger on December 16, 2004. Epoch stock is expected to cease trading on NASDAQ at the close of trading on December 16, 2004.
+++
Nanogen, Inc. Funding Advances Nanotech Research at University of California, San Diego
2004 Dec 2 8:04 AM
Nanogen, Inc. announced that it has agreed to provide $300,000 of funding over a two-year period to support the nanotechnology research of Michael Heller, Ph.D., professor in the Department of Bioengineering at Jacobs School of Engineering, University of California, San Diego (UCSD) and cofounder of Nanogen. Dr. Heller`s research under this grant will focus on exploring further use of electric field-based technology for nanofabrication and assembly of nanostructures as well as the integration of nanostructures with other devices. The funding will be used to advance nanotechnology and nanofabrication applications that are related to the intellectual property position held by Nanogen and UCSD while the company focuses its internal efforts on commercial products for medical diagnostics.
+++
Nanogen, Inc. Granted Key European Patent for Stroke Diagnostic
2004 Nov 29 1:39 PM
Nanogen, Inc. announced its SynX subsidiary was issued European Patent No. 1155325, "Method for Diagnosing and Distinguishing Stroke," by the European Patent Office. The `325 patent relates to a diagnostic kit and method of measuring the presence of both an ischemic marker and a brain endothelial cell membrane protein to indicate that a patient has suffered a stroke and, if so, whether it was an ischemic or hemorrhagic cerebral event. The patent covers both a method and a diagnostic kit for analyzing the levels of proteins released from the brain during a stroke. In October, the U.S. Patent and Trademark Office granted SynX a patent for similar claims related to the rapid, point-of-care stoke diagnostic test that the Company is developing for emergency medicine.
+++
powered by reuters.com
+++
Nanogen, Inc. Names Robert Saltmarsh as Chief Financial Officer
2005 Jan 7 8:03 AM
Nanogen, Inc. announced that Robert Saltmarsh has been appointed as Chief Financial Officer.
+++
Nanogen, Inc. and Epoch Biosciences Complete Merger
2004 Dec 17 8:00 AM
Nanogen, Inc. and Epoch Biosciences, Inc. announced that they have completed their merger transaction.
+++
Nanogen, Inc. and Epoch Biosciences Stockholders Vote in Favor of Merger
2004 Dec 15 6:00 PM
Nanogen, Inc. announced that stockholders approved the merger agreement with Epoch Biosciences. Nanogen stockholders also approved an amendment to the company`s certificate of incorporation increasing the number of authorized shares of Nanogen common stock to 135 million shares. Nanogen and Epoch expect to close the merger on December 16, 2004. Epoch stock is expected to cease trading on NASDAQ at the close of trading on December 16, 2004.
+++
Nanogen, Inc. Funding Advances Nanotech Research at University of California, San Diego
2004 Dec 2 8:04 AM
Nanogen, Inc. announced that it has agreed to provide $300,000 of funding over a two-year period to support the nanotechnology research of Michael Heller, Ph.D., professor in the Department of Bioengineering at Jacobs School of Engineering, University of California, San Diego (UCSD) and cofounder of Nanogen. Dr. Heller`s research under this grant will focus on exploring further use of electric field-based technology for nanofabrication and assembly of nanostructures as well as the integration of nanostructures with other devices. The funding will be used to advance nanotechnology and nanofabrication applications that are related to the intellectual property position held by Nanogen and UCSD while the company focuses its internal efforts on commercial products for medical diagnostics.
+++
Nanogen, Inc. Granted Key European Patent for Stroke Diagnostic
2004 Nov 29 1:39 PM
Nanogen, Inc. announced its SynX subsidiary was issued European Patent No. 1155325, "Method for Diagnosing and Distinguishing Stroke," by the European Patent Office. The `325 patent relates to a diagnostic kit and method of measuring the presence of both an ischemic marker and a brain endothelial cell membrane protein to indicate that a patient has suffered a stroke and, if so, whether it was an ischemic or hemorrhagic cerebral event. The patent covers both a method and a diagnostic kit for analyzing the levels of proteins released from the brain during a stroke. In October, the U.S. Patent and Trademark Office granted SynX a patent for similar claims related to the rapid, point-of-care stoke diagnostic test that the Company is developing for emergency medicine.
+++
powered by reuters.com
Top Holders - 12/31/2004
SMITH BARNEY ASSET MANAGEMENT 2,902,283 $21,360.80 8.54% 12/31/2004
BARCLAYS GLOBAL INVESTORS INTL 1,118,835 $8,234.63 3.29% 12/31/2004
DIMENSIONAL FUND ADVISORS 821,922 $6,049.35 2.42% 12/31/2004
PERKINS CAPITAL MANAGEMENT 564,072 $4,151.57 1.66% 12/31/2004
VANGUARD GROUP 539,820 $3,973.08 1.59% 12/31/2004
BRIDGEWAY CAPITAL MGMT 448,811 $3,303.25 1.32% 12/31/2004
STATE STREET GLOBAL ADVISORS 399,698 $2,941.78 1.18% 12/31/2004
TIAA CREF INVESTMENT MANAGEMENT INC 287,932 $2,119.18 0.85% 12/31/2004
HUSSMAN ECONOMETRICS ADVISORS INC 250,000 $1,840.00 0.74% 12/31/2004
NORTHERN TRUST CO 353,511 $1,353.95 1.04% 9/30/2004
AVENIR CORP 130,002 $956.81 0.38% 12/31/2004
SHAW (DE) & CO 125,832 $926.12 0.37% 12/31/2004
CREDIT SUISSE FIRST BOSTON INC 112,605 $828.77 0.33% 12/31/2004
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 100,710 $741.23 0.30% 12/31/2004
UBS FINANCIAL SERVICES (STAMFORD) 88,554 $651.76 0.26% 12/31/2004
Recent Buyers - 12/31/2004
BARCLAYS GLOBAL INVESTORS INTL 172,739 $4,611.08 1,118,835 12/31/2004
DIMENSIONAL FUND ADVISORS 51,320 $3,097.94 821,922 12/31/2004
VANGUARD GROUP 116,578 $2,352.06 539,820 12/31/2004
STATE STREET GLOBAL ADVISORS 8,826 $1,444.74 399,698 12/31/2004
TIAA CREF INVESTMENT MANAGEMENT INC 4,250 $1,032.68 287,932 12/31/2004
SHAW (DE) & CO + 125,832 $926.12 125,832 12/31/2004
UBS FINANCIAL SERVICES (STAMFORD) 32,644 $437.62 88,554 12/31/2004
MERRILL LYNCH & CO INC 47,511 $425.13 68,884 12/31/2004
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 10,138 $394.33 100,710 12/31/2004
FLORIDA STATE BOARD OF ADMIN 16,800 $338.98 77,800 12/31/2004
CITADEL INVESTMENT MGMT + 41,769 $307.42 41,769 12/31/2004
GEODE CAPITAL MANAGEMENT LLC 27,204 $243.59 39,490 12/31/2004
OHIO PUBLIC EMPLOYEES RETIREMENT SYSTEM 3,509 $216.88 57,633 12/31/2004
ELLIOTT MGMT CORP + 27,000 $198.72 27,000 12/31/2004
NEUBERGER BERMAN + 23,100 $170.02 23,100 12/31/2004
SMITH BARNEY ASSET MANAGEMENT 2,902,283 $21,360.80 8.54% 12/31/2004
BARCLAYS GLOBAL INVESTORS INTL 1,118,835 $8,234.63 3.29% 12/31/2004
DIMENSIONAL FUND ADVISORS 821,922 $6,049.35 2.42% 12/31/2004
PERKINS CAPITAL MANAGEMENT 564,072 $4,151.57 1.66% 12/31/2004
VANGUARD GROUP 539,820 $3,973.08 1.59% 12/31/2004
BRIDGEWAY CAPITAL MGMT 448,811 $3,303.25 1.32% 12/31/2004
STATE STREET GLOBAL ADVISORS 399,698 $2,941.78 1.18% 12/31/2004
TIAA CREF INVESTMENT MANAGEMENT INC 287,932 $2,119.18 0.85% 12/31/2004
HUSSMAN ECONOMETRICS ADVISORS INC 250,000 $1,840.00 0.74% 12/31/2004
NORTHERN TRUST CO 353,511 $1,353.95 1.04% 9/30/2004
AVENIR CORP 130,002 $956.81 0.38% 12/31/2004
SHAW (DE) & CO 125,832 $926.12 0.37% 12/31/2004
CREDIT SUISSE FIRST BOSTON INC 112,605 $828.77 0.33% 12/31/2004
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 100,710 $741.23 0.30% 12/31/2004
UBS FINANCIAL SERVICES (STAMFORD) 88,554 $651.76 0.26% 12/31/2004
Recent Buyers - 12/31/2004
BARCLAYS GLOBAL INVESTORS INTL 172,739 $4,611.08 1,118,835 12/31/2004
DIMENSIONAL FUND ADVISORS 51,320 $3,097.94 821,922 12/31/2004
VANGUARD GROUP 116,578 $2,352.06 539,820 12/31/2004
STATE STREET GLOBAL ADVISORS 8,826 $1,444.74 399,698 12/31/2004
TIAA CREF INVESTMENT MANAGEMENT INC 4,250 $1,032.68 287,932 12/31/2004
SHAW (DE) & CO + 125,832 $926.12 125,832 12/31/2004
UBS FINANCIAL SERVICES (STAMFORD) 32,644 $437.62 88,554 12/31/2004
MERRILL LYNCH & CO INC 47,511 $425.13 68,884 12/31/2004
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 10,138 $394.33 100,710 12/31/2004
FLORIDA STATE BOARD OF ADMIN 16,800 $338.98 77,800 12/31/2004
CITADEL INVESTMENT MGMT + 41,769 $307.42 41,769 12/31/2004
GEODE CAPITAL MANAGEMENT LLC 27,204 $243.59 39,490 12/31/2004
OHIO PUBLIC EMPLOYEES RETIREMENT SYSTEM 3,509 $216.88 57,633 12/31/2004
ELLIOTT MGMT CORP + 27,000 $198.72 27,000 12/31/2004
NEUBERGER BERMAN + 23,100 $170.02 23,100 12/31/2004
Naja wie schon gesagt gibt es Heute folgendes zu hören:
Title: Revolutionizing Real Time PCR Analysis: Technology overview and Applications with Nanogen, Inc. MGB EclipseTM Probes and Superbases Seminar
Date: Thursday, February 17, 2005
Time: 11:00 AM PT / 2:00 PM ET
Duration: 2 hours
Und Earnings nächste Woche..
Title: Revolutionizing Real Time PCR Analysis: Technology overview and Applications with Nanogen, Inc. MGB EclipseTM Probes and Superbases Seminar
Date: Thursday, February 17, 2005
Time: 11:00 AM PT / 2:00 PM ET
Duration: 2 hours
Und Earnings nächste Woche..
scheint wohl noch ein bisschen zu dauern mit nanogen!
aber der macd ist noch nicht ganz durch...
zwar nach oben hin durch aber läuft oberhalb des triggers weider seitwärts.
aber der macd ist noch nicht ganz durch...
zwar nach oben hin durch aber läuft oberhalb des triggers weider seitwärts.
=> Aufpassen wenn der Stochastic über 40 geht.. (!)
AfterHours island.com Last 4,85$
Financial Guidance
Nanogen expects revenue in the fourth quarter to be consistent with third quarter levels. As a result of the pending merger with Epoch Biosciences and the anticipated introduction of new products, the company expects significant revenue growth in 2005. Nanogen continues to emphasize expense control and expects total research and development, and selling, general and administrative operating expenses for 2004, to be approximately 15% less than the 2003 total year spending before consideration of SynX and Epoch businesses. Including the estimated impact of the pending merger with Epoch and related transaction costs, Nanogen expects its cash position at December 31, 2004 will be approximately $50 million.
Alle die Vorhaben in NGEN zu investieren sollten bis nach den Earnings warten und danach ggbf. kaufen..
gruß codex
Nanogen expects revenue in the fourth quarter to be consistent with third quarter levels. As a result of the pending merger with Epoch Biosciences and the anticipated introduction of new products, the company expects significant revenue growth in 2005. Nanogen continues to emphasize expense control and expects total research and development, and selling, general and administrative operating expenses for 2004, to be approximately 15% less than the 2003 total year spending before consideration of SynX and Epoch businesses. Including the estimated impact of the pending merger with Epoch and related transaction costs, Nanogen expects its cash position at December 31, 2004 will be approximately $50 million.
Alle die Vorhaben in NGEN zu investieren sollten bis nach den Earnings warten und danach ggbf. kaufen..
gruß codex
Hab mich gestern vorsichtshalber von meiner Position verabschiedet Ich warte jetzt die Earnings und den Outlook ab bevor ich evtl. wieder investiere
Ich warte jetzt die Earnings und den Outlook ab bevor ich evtl. wieder investiere
habe mich schon freitag davon verabschiedet.
nur, ist die aktie noch nicht vergessen...
tipp an alle:
kauft nanogen mitte august....da sind sie meistens am billigsten...
ich grantiere 100% und mehr bis dezember!!!
war bisher immer so!!!
nur, ist die aktie noch nicht vergessen...
tipp an alle:
kauft nanogen mitte august....da sind sie meistens am billigsten...
ich grantiere 100% und mehr bis dezember!!!
war bisher immer so!!!
Der Outlook den NGEN gibt kann einem schon fast egal sein. Anfang des letzten Jahres prognostizierte man, daß die Einnahmen um 50% wachsen sollen.
Was ist passiert ? Im Endeffekt sind die Einnahmen gefallen. War wohl nix.
NGEN ist und bleibt meiner Meinung nach Schrott, wer es spekulativer mag kauft sich eher eine Aktie wie Medarex, die Zukunft hat.
NGEN ist nix, hat nix und wird auch meiner Meinung nach nie was werden. Daran ändern auch kurzfristige Kurssprünge nichts, die darauf zurückzuführen sind, daß man wieder ein (vermutlich) nutzloses Patent bekommen hat.
Ich erinnere mich an dieses "tolle" Nanotech-Patent, das man vor einem Jahr bekam und seit dem wohl nur in der Schublade rumliegt. Keiner nutzt es, nicht einmal NGEN selber.
Fazit: Wer zuviel Geld hat, kann es besser mir geben.
Was ist passiert ? Im Endeffekt sind die Einnahmen gefallen. War wohl nix.
NGEN ist und bleibt meiner Meinung nach Schrott, wer es spekulativer mag kauft sich eher eine Aktie wie Medarex, die Zukunft hat.
NGEN ist nix, hat nix und wird auch meiner Meinung nach nie was werden. Daran ändern auch kurzfristige Kurssprünge nichts, die darauf zurückzuführen sind, daß man wieder ein (vermutlich) nutzloses Patent bekommen hat.
Ich erinnere mich an dieses "tolle" Nanotech-Patent, das man vor einem Jahr bekam und seit dem wohl nur in der Schublade rumliegt. Keiner nutzt es, nicht einmal NGEN selber.
Fazit: Wer zuviel Geld hat, kann es besser mir geben.
Puh, gerad nochmal rechtzeitig verabschiedet
nanogen als NICHTS zu sehen ist ein schmarrn.
die zeit dieser aktie liegt anfang dez bis ende januar.
die aktie ist aber nichts für longinvestments.
ich finde, eine besser zockeraktie nicht mehr und nicht weniger. wer in nanotech investieren möchte, sollte sich biophan anschauen.
als 2. altair.
biophan wird der highflyer 2005.
habe leider selber keine, weil ich schon ausreichend investiert habe...
gruß
balboa
die zeit dieser aktie liegt anfang dez bis ende januar.
die aktie ist aber nichts für longinvestments.
ich finde, eine besser zockeraktie nicht mehr und nicht weniger. wer in nanotech investieren möchte, sollte sich biophan anschauen.
als 2. altair.
biophan wird der highflyer 2005.
habe leider selber keine, weil ich schon ausreichend investiert habe...
gruß
balboa
lese gerade das ihr euch alle von der aktie
verabschiedet habt...
charttechnisch ist doch um die 3€ eigentlich
eine stützung zu erwarten...und die stoch ist
auch ziemlich weit unten.
denkt ihr es geht richtung 2,50 ATL ? oder tiefer?
wollte an für sich jetzt um die 3,00€ einsteigen.
gruss ivan..
verabschiedet habt...
charttechnisch ist doch um die 3€ eigentlich
eine stützung zu erwarten...und die stoch ist
auch ziemlich weit unten.
denkt ihr es geht richtung 2,50 ATL ? oder tiefer?
wollte an für sich jetzt um die 3,00€ einsteigen.
gruss ivan..
ob die aktie bald wir nen norden geht...
weiss nur gott...
aber 3€ als einstiegskurs...sind optimal...
nur langfristig betrachtet...
würde, wenn ich nicht in lipro und cbb voll investiert hätte (tipp: schaut sie euch an! noch absolute schnäppchenkurse) dann würde ich mir jetzt schon nen teil für 3€ ins depot legen und bei rücksetzern wieder welche ins depot holen.
bis herbst hast aber dann locker deine 100% mit ngen.
würde aber wenn du mehr willst wirklich mal LIPRO UND CBB
anschauen...
weiss nur gott...
aber 3€ als einstiegskurs...sind optimal...
nur langfristig betrachtet...
würde, wenn ich nicht in lipro und cbb voll investiert hätte (tipp: schaut sie euch an! noch absolute schnäppchenkurse) dann würde ich mir jetzt schon nen teil für 3€ ins depot legen und bei rücksetzern wieder welche ins depot holen.
bis herbst hast aber dann locker deine 100% mit ngen.
würde aber wenn du mehr willst wirklich mal LIPRO UND CBB
anschauen...
hi balboa,
danke für deine einschätzung!..
zu lipro und cbb...
beides pennys die sich schon ca.verfünffacht haben.
potenzial ja....aber ich steige nicht auf einen zug
der schon so angelaufen ist...trotzdem danke!
gruss ivan
danke für deine einschätzung!..
zu lipro und cbb...
beides pennys die sich schon ca.verfünffacht haben.
potenzial ja....aber ich steige nicht auf einen zug
der schon so angelaufen ist...trotzdem danke!
gruss ivan
Ich warte bis sich bei NGEN ein Boden bildet oder News kommen, im Moment kann keiner genau sagen wo NGEN halt macht..
!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de!
Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an feedback@wallstreet-online.de
Neuigkeiten bei NANOGEN:
Keiner mehr Interesse hier am Board ???
11.03.2005 14:11:
Nanogen Issued Patent for Ligation-Based Strand Displacement Amplification Technologies for DNA Analysis
SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Nanogen (Nachrichten), developer of advanced diagnostic products, announced today that it was issued U.S. Patent No. 6,864,071, `Multiplex amplification and separation of nucleic acid sequences using ligation-dependent strand displacement amplification and bioelectronic chip technology,` by the U.S. Patent and Trademark Office. The `071 patent relates to amplifying and analyzing multiple samples of nucleic acid using ligation-based strand displacement amplification (SDA) technologies. The intellectual property pertains to research Nanogen conducted in collaboration with Becton Dickinson and increases Nanogen`s portfolio of technologies for multiplex amplification on a chip.
The combination of SDA and Nanogen chip technologies makes it possible to conduct multiplex amplification, detection and analysis of multiple samples within a single electronic microarray. Unlike techniques that rely on thermal cycling, SDA is an isothermal amplification process that utilizes a series of primers, DNA polymerase and a restriction enzyme to exponentially amplify the target nucleic acid sequence. The devices and methods of Nanogen`s invention may be useful in a variety of applications, including disease diagnostics, genetic analyses, drug discovery, pharmacogenomics, and agricultural and environmental applications.
This new patent expands Nanogen`s intellectual property portfolio to include 113 patents issued in the U.S.
About Nanogen, Inc.
Nanogen`s advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen`s subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen`s ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen`s website at http://www.nanogen.com/.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption `Factors That May Affect Results` and elsewhere in Nanogen`s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
gruß
kurttilly
Keiner mehr Interesse hier am Board ???
11.03.2005 14:11:
Nanogen Issued Patent for Ligation-Based Strand Displacement Amplification Technologies for DNA Analysis
SAN DIEGO, March 11 /PRNewswire-FirstCall/ -- Nanogen (Nachrichten), developer of advanced diagnostic products, announced today that it was issued U.S. Patent No. 6,864,071, `Multiplex amplification and separation of nucleic acid sequences using ligation-dependent strand displacement amplification and bioelectronic chip technology,` by the U.S. Patent and Trademark Office. The `071 patent relates to amplifying and analyzing multiple samples of nucleic acid using ligation-based strand displacement amplification (SDA) technologies. The intellectual property pertains to research Nanogen conducted in collaboration with Becton Dickinson and increases Nanogen`s portfolio of technologies for multiplex amplification on a chip.
The combination of SDA and Nanogen chip technologies makes it possible to conduct multiplex amplification, detection and analysis of multiple samples within a single electronic microarray. Unlike techniques that rely on thermal cycling, SDA is an isothermal amplification process that utilizes a series of primers, DNA polymerase and a restriction enzyme to exponentially amplify the target nucleic acid sequence. The devices and methods of Nanogen`s invention may be useful in a variety of applications, including disease diagnostics, genetic analyses, drug discovery, pharmacogenomics, and agricultural and environmental applications.
This new patent expands Nanogen`s intellectual property portfolio to include 113 patents issued in the U.S.
About Nanogen, Inc.
Nanogen`s advanced diagnostics provide physicians and patients worldwide with sophisticated information to predict, diagnose and treat disease. Research and clinical reference labs use the highly accurate and reliable NanoChip(R) Molecular Biology Workstation, NanoChip(R) Electronic Microarray and broad suite of analyte specific reagents to develop tests to detect infectious diseases, drug toxicity and mutations associated with cancer, cardiovascular and genetic diseases. The next generation instrument system, the NanoChip(R) 400, is expected to be available in 2005. Nanogen`s subsidiary SynX offers a line of point-of-care diagnostic tests and is building expertise in cardiac related health conditions. Nanogen`s ten years of pioneering research involving nanotechnology may also have future applications in medical diagnostics, biowarfare and other industries. For additional information please visit Nanogen`s website at http://www.nanogen.com/.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption `Factors That May Affect Results` and elsewhere in Nanogen`s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
gruß
kurttilly
Der eine sammelt Briefmarken, der andere Patente.
Selten ist jedoch eine blaue Mauritius dabei.
Bye
S.
Selten ist jedoch eine blaue Mauritius dabei.
Bye
S.
16.03.05 / 09:36
Nanogen interessantes Investment
Die Analysten von Jaindl & Mautz erachten die Aktie von Nanogen (ISIN US6300751095/ WKN 911841) als sehr interessantes Investment.
Das Unternehmen Nanogen habe sich auf die Entwicklung und Verkauf von molekularen Diagnostikprodukten und Gentests insbesondere in den Staaten und Europa spezialisiert. Zur Zeit erwirtschafte das Nanotechunternehmen so gut wie keine Umsätze und dementsprechend auch keine Gewinne.
Durch die Fusion Ende 2004 mit Epoch Bioscienses Inc. habe sich jedoch andererseits die Chance auf zukünftige Gewinne und erfolgreicher Kommerzialisierung der entwickelten Produkte erheblich gebessert, weshalb die Analysten auch gerade bei Nanogen, auch unter Berücksichtigung der immens guten finanziellen Lage des Unternehmens, einen erfolgreichen Kandidaten im Bereich Nanotechnologie für die nächsten Jahre sehen.
Durch die Fusion und der Zulassung eines neuen Patents in den Staaten habe der Kurs von Nanogen im Dezember ein Kursplus von über 100 Prozent aufweisen können. Am 11. März 2005 habe das Unternehmen eine weitere Zulassung für den Einsatz von Nanotechnologie im Bereich der DNA Analyse in Europa erhalten, wodurch die Annahme eines weiteren Kurssprung nach Erachten der Analysten durchaus gerechtfertigt sei.
Mit einem Risiko von nicht einmal 10 Prozent (Stopp bei 3,65 USD) und einer Chance von über 50 Prozent ist diese Nanogen-Aktie zur Zeit ein sehr interessantes Investment, so die Analysten von Jaindl & Mautz.
Nanogen interessantes Investment
Die Analysten von Jaindl & Mautz erachten die Aktie von Nanogen (ISIN US6300751095/ WKN 911841) als sehr interessantes Investment.
Das Unternehmen Nanogen habe sich auf die Entwicklung und Verkauf von molekularen Diagnostikprodukten und Gentests insbesondere in den Staaten und Europa spezialisiert. Zur Zeit erwirtschafte das Nanotechunternehmen so gut wie keine Umsätze und dementsprechend auch keine Gewinne.
Durch die Fusion Ende 2004 mit Epoch Bioscienses Inc. habe sich jedoch andererseits die Chance auf zukünftige Gewinne und erfolgreicher Kommerzialisierung der entwickelten Produkte erheblich gebessert, weshalb die Analysten auch gerade bei Nanogen, auch unter Berücksichtigung der immens guten finanziellen Lage des Unternehmens, einen erfolgreichen Kandidaten im Bereich Nanotechnologie für die nächsten Jahre sehen.
Durch die Fusion und der Zulassung eines neuen Patents in den Staaten habe der Kurs von Nanogen im Dezember ein Kursplus von über 100 Prozent aufweisen können. Am 11. März 2005 habe das Unternehmen eine weitere Zulassung für den Einsatz von Nanotechnologie im Bereich der DNA Analyse in Europa erhalten, wodurch die Annahme eines weiteren Kurssprung nach Erachten der Analysten durchaus gerechtfertigt sei.
Mit einem Risiko von nicht einmal 10 Prozent (Stopp bei 3,65 USD) und einer Chance von über 50 Prozent ist diese Nanogen-Aktie zur Zeit ein sehr interessantes Investment, so die Analysten von Jaindl & Mautz.
Der CEO verkauft seit Anfang des Jahres wieder kräftig, also machen wir uns nichts vor...
Date Name Transaction Num Shares Price(s) Value
03/01/05 BIRNDORF HOWARD C Sold 25,000 $4.02 100,375.00
02/01/05 BIRNDORF HOWARD C Sold 25,000 $5.07 126,750.01
01/03/05 BIRNDORF HOWARD C Sold 25,000 $7.23 180,750.00
Date Name Transaction Num Shares Price(s) Value
03/01/05 BIRNDORF HOWARD C Sold 25,000 $4.02 100,375.00
02/01/05 BIRNDORF HOWARD C Sold 25,000 $5.07 126,750.01
01/03/05 BIRNDORF HOWARD C Sold 25,000 $7.23 180,750.00
Nun gehts aber rasant runter
Nanogen and Pathway to help personalize drug prescribing
Nanogen and Pathway Diagnostics have entered into a nonexclusive, worldwide license agreement to develop products that detect genetic variations associated with responses to antidepressant and antipsychotic therapeutics.
23 Mar 2005, 15:41 GMT - The companies have begun work on developing a product that could be used to select the most appropriate drug and dosage for patients treated for psychiatric diseases.
Although many therapeutic options are available for patients suffering from schizophrenia and depression, for some patients the side effects of drug therapy can range from unpleasant to life-threatening. Determining optimal drug regimens and dosing strategies are challenges that are currently addressed by trial-and-error prescribing practices.
Side effects may be caused by a variety of factors, including variations in genes that are targets of the drugs or are involved in drug response. In addition to the negative effect on an individual`s health, significant direct and indirect costs are associated with these adverse drug responses.
"We are optimistic that Nanogen`s partnership with Pathway Diagnostics will result in exciting products that will contribute to more personalized medical treatments," said Howard Birndorf, Nanogen`s chairman of the board and CEO. "Because our NanoChip platform can simultaneously analyze multiple genetic markers, we have the capability to develop a diagnostic panel to detect these newly licensed genetic variations, along with genes in the cytochrome P450 family that are related to drug metabolism, in order to allow the physician to prescribe the right drug at the right dosage."
Source: Datamonitor Newswire
Nanogen and Pathway Diagnostics have entered into a nonexclusive, worldwide license agreement to develop products that detect genetic variations associated with responses to antidepressant and antipsychotic therapeutics.
23 Mar 2005, 15:41 GMT - The companies have begun work on developing a product that could be used to select the most appropriate drug and dosage for patients treated for psychiatric diseases.
Although many therapeutic options are available for patients suffering from schizophrenia and depression, for some patients the side effects of drug therapy can range from unpleasant to life-threatening. Determining optimal drug regimens and dosing strategies are challenges that are currently addressed by trial-and-error prescribing practices.
Side effects may be caused by a variety of factors, including variations in genes that are targets of the drugs or are involved in drug response. In addition to the negative effect on an individual`s health, significant direct and indirect costs are associated with these adverse drug responses.
"We are optimistic that Nanogen`s partnership with Pathway Diagnostics will result in exciting products that will contribute to more personalized medical treatments," said Howard Birndorf, Nanogen`s chairman of the board and CEO. "Because our NanoChip platform can simultaneously analyze multiple genetic markers, we have the capability to develop a diagnostic panel to detect these newly licensed genetic variations, along with genes in the cytochrome P450 family that are related to drug metabolism, in order to allow the physician to prescribe the right drug at the right dosage."
Source: Datamonitor Newswire
Hey, mal was Neues --> ein Patent !
Nanogen Issued Patent for Electronic Microarray With Memory
24.03.05
Nanogen Issued Patent for Electronic Microarray With Memory
24.03.05
Nanogen: Mein Kauftipp heute.
Umsatz 1st Quarter 05 + 47% zum Vorjahreszeitraum.
Quelle: NASDAQ
Quelle: NASDAQ
Total revenues for the first quarter of this year increased by 47 percent to $3.2 million from $2.2 million in the same period in 2004, and $1.0 million in the fourth quarter of 2004. Product revenues for the first quarter of 2005 were $1.2 million compared to $1.1 million for the first quarter of 2004 and $0.4 million in the fourth quarter of 2004. This is the first complete quarter of financial results that reflect operations of Epoch Biosciences which was acquired on December 16, 2004.
Aktuell +17,6% in USA
In Frankfurt wieder ganz gut im plus.
Nach Bestätigung des zieles von Nanogen gehts jetzt
wohl wieder aufwärts. Von der Grafik her könnte es wieder
schnell zu 5 Dollar gehen.
Nach Bestätigung des zieles von Nanogen gehts jetzt
wohl wieder aufwärts. Von der Grafik her könnte es wieder
schnell zu 5 Dollar gehen.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Investoren beobachten auch:
| Wertpapier | Perf. % |
|---|---|
| +0,06 | |
| +0,05 | |
| 0,00 | |
| +0,16 | |
| +0,06 | |
| +8,41 | |
| 0,00 | |
| -1,02 | |
| 0,00 | |
| +0,05 |
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 194 | ||
| 188 | ||
| 143 | ||
| 72 | ||
| 31 | ||
| 29 | ||
| 29 | ||
| 26 | ||
| 25 | ||
| 25 |
